<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006992.pub2" GROUP_ID="ENDOC" ID="946007032912213304" MERGED_FROM="" MODIFIED="2016-09-07 10:12:06 +0100" MODIFIED_BY="Gudrun Paletta" REVIEW_NO="P_I_08_1" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2016-09-07 10:09:44 +0100" MODIFIED_BY="Gudrun Paletta">
<TITLE MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control</TITLE>
<CONTACT MODIFIED="2016-09-07 10:09:44 +0100" MODIFIED_BY="Gudrun Paletta"><PERSON ID="z1403190852216667610031917439809" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rimke</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Vos</LAST_NAME><EMAIL_1>R.C.Vos-3@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 AB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-09-07 10:09:44 +0100" MODIFIED_BY="Gudrun Paletta"><PERSON ID="z1403190852216667610031917439809" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rimke</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Vos</LAST_NAME><EMAIL_1>R.C.Vos-3@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 AB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="9CC7866682E26AA2007D5B6E627A96AE" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mariëlle</FIRST_NAME><MIDDLE_INITIALS>JP</MIDDLE_INITIALS><LAST_NAME>van Avendonk</LAST_NAME><POSITION>Epidemiologist</POSITION><EMAIL_1>m.vanavendonk@nhg.org</EMAIL_1><EMAIL_2>mvanavendonk@chello.nl</EMAIL_2><ADDRESS><DEPARTMENT>Dutch College of General Practitioners</DEPARTMENT><ORGANISATION>Guideline Development and Research</ORGANISATION><ADDRESS_1>PO Box 3231</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3502 GE</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 302823500</PHONE_1><PHONE_2>+31 616088531</PHONE_2></ADDRESS></PERSON><PERSON ID="308BCBC882E26AA200DA2AF322DBF9E5" ROLE="AUTHOR"><FIRST_NAME>Hanneke</FIRST_NAME><LAST_NAME>Jansen</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>hannekejansen@gmail.com</EMAIL_1><EMAIL_2>hannekejansen@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>P.O.Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 AB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+ 31 8875 53513</PHONE_1></ADDRESS></PERSON><PERSON ID="14677" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Alexander</FIRST_NAME><MIDDLE_INITIALS>N</MIDDLE_INITIALS><LAST_NAME>Goudswaard</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>General Practioner</POSITION><EMAIL_1>lex@goudswaard.com</EMAIL_1><EMAIL_2>goudswaard@molenzoom.nl</EMAIL_2><MOBILE_PHONE>+31652553383</MOBILE_PHONE><ADDRESS><ORGANISATION/><ADDRESS_1>Koperslagersgilde 5</ADDRESS_1><CITY>Houten</CITY><ZIP>3994CH</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31652553383</PHONE_1></ADDRESS></PERSON><PERSON ID="9CD2E4AD82E26AA2007D5B6E8A8EDB52" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Maureen</FIRST_NAME><LAST_NAME>van den Donk</LAST_NAME><POSITION>Epidemiologist</POSITION><EMAIL_1>m.vandendonk@nhg.org</EMAIL_1><EMAIL_2>m.vandendonk@umcutrecht.nl</EMAIL_2><ADDRESS><DEPARTMENT>Dutch College of General Practitioners</DEPARTMENT><ORGANISATION>Guideline Development and Research</ORGANISATION><ADDRESS_1>PO Box 3231</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3502 GE</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 302823500</PHONE_1><PHONE_2>+31 616512081</PHONE_2></ADDRESS></PERSON><PERSON ID="9D2F38E882E26AA2007D5B6E959500B1" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Kees</FIRST_NAME><LAST_NAME>Gorter</LAST_NAME><POSITION>Senior Researcher and GP</POSITION><EMAIL_1>gorterkj@telfort.nl</EMAIL_1><EMAIL_2>k.j.gorter@umcutrecht.nl</EMAIL_2><ADDRESS><ORGANISATION/><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="393B8A7D82E26AA2001AB0E3C16F2EC7" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anneloes</FIRST_NAME><LAST_NAME>Kerssen</LAST_NAME><EMAIL_1>a.kerssen@umcutrecht.nl</EMAIL_1><EMAIL_2>anneloeskerssen@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="14739" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Guy</FIRST_NAME><MIDDLE_INITIALS>EHM</MIDDLE_INITIALS><LAST_NAME>Rutten</LAST_NAME><POSITION>Professor of Diabetology in Primary Care and GP</POSITION><EMAIL_1>G.E.H.M.Rutten@UmcUtrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Julius Center for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 AB</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 88 756 8154</PHONE_1><FAX_1>+31 30 2539028</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-11-12 12:25:11 +0100" MODIFIED_BY="Bernd Richter">
<UP_TO_DATE>
<DATE DAY="17" MONTH="11" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="11" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="17" MONTH="11" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="9" YEAR="2016"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-26 13:27:33 +0100" MODIFIED_BY="Gudrun Paletta"/>
<HISTORY/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University Medical Center Utrecht</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-08-30 07:46:57 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<TITLE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">Combinations of insulin and oral glucose-lowering drugs for people with type 2 diabetes on insulin treatment</TITLE>
<SUMMARY_BODY MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Introduction</B>
</P>
<P>Many guidelines on type 2 diabetes recommend a glycosylated haemoglobin A1c (HbA1c) level below 7%. HbA1c levels in the blood express glucose or glycaemic control over a longer time period (two to three months). During the course of type 2 diabetes it will get more difficult to reach these levels with 'lifestyle' modification (diet, exercise or both) and oral glucose-lowering agents alone. Finally, a substantial number of people will need insulin therapy for better glycaemic control. Insulin therapy can be initiated as insulin alone, called monotherapy (which means that oral glucose-lowering medication will be stopped) or in combination with oral glucose-lowering agents. In the former case, oral blood glucose-lowering agents can be added at a later stage, if insulin monotherapy fails to achieve a good HbA1c level. Hypoglycaemia and weight gain are the most common and well known side effects of insulin therapy. Adding oral agents to insulin could reduce the required insulin dose and thus decrease these insulin-related side effects. However, there could be other side effects specific to the various oral blood glucose-lowering drugs.</P>
<P>
<B>Review question</B>
</P>
<P>To assess the effects of insulin monotherapy and the addition of an oral antidiabetic drug in people with type 2 diabetes already treated with insulin but not having good glycaemic control.</P>
<P>
<B>Background</B>
</P>
<P>It is unclear whether people with type 2 diabetes mellitus on insulin alone who do not achieve good glucose levels should continue with insulin alone or can benefit from adding an oral antidiabetic drug to their insulin therapy.</P>
<P>
<B>Study characteristics</B>
</P>
<P>All 37 included studies were randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups). Their duration ranged from 2 to 12 months. The total number of participants was 3227. Several types of insulin monotherapy (once-daily long- or intermediate-acting insulin, twice-daily premixed insulin, multiple injection therapy with short-acting insulin) were compared with different types of additional antidiabetic tablets: sulphonylureas (such as glibenclamide/glyburide), metformin, alpha-glucosidase inhibitors (such as acarbose), pioglitazone and DPP-4 inhibitors (such as saxagliptin).</P>
<P>
<B>Key results</B>
</P>
<P>The addition of oral agents to insulin monotherapy reduced HbA1c by 0.4% to 1%. Most combinations of oral antidiabetic agents with insulin resulted in a reduction in the necessary insulin dose per day whereas the insulin dose per day had to be increased or remained stable in participants with insulin monotherapy. In studies reporting hypoglycaemic episodes severe events were rare and mild to moderate hypoglycaemia was observed in similar numbers when comparing insulin monotherapy to the addition of oral antidiabetic agents to insulin. However, most studies adding sulphonylureas to insulin reported more hypoglycaemic episodes. Moreover, the addition of sulphonylureas to insulin resulted in an additional weight gain of 0.4 kg to 1.9 kg compared with -0.8 kg to 2.1 kg in the insulin monotherapy groups. Pioglitazone insulin combination therapy caused on average an increase in weight of 3.8 kg compared with insulin monotherapy. The difference in average weight gain with metformin insulin combination therapy compared with insulin monotherapy was 2.1 kg less in favour of the combination therapy. Gastro-intestinal side effects such as flatulence and diarrhoea were mostly reported with metformin and alpha-glucosidase inhibitors. Addition of pioglitazone to insulin compared with insulin monotherapy resulted in more cases of oedema (fluid retention in the body) and heart failure. Only one study assessed participants' treatment satisfaction and showed no substantial differences between the addition of glimepiride or metformin and glimepiride to insulin compared with insulin monotherapy. No study assessed all-cause mortality, diabetes-related morbidity or health-related quality of life.</P>
<P>This evidence is up to date as of November 2015.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>Almost a third of the studies had 30 or fewer participants. A lot of studies seemed to be underpowered and thus were probably not able to answer their own research question. This could mean that potentially important differences between intervention and control groups were not detected. Only five studies had a follow-up of 12 months.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<ABS_BACKGROUND MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>It is unclear whether people with type 2 diabetes mellitus on insulin monotherapy who do not achieve adequate glycaemic control should continue insulin as monotherapy or can benefit from adding oral glucose-lowering agents to the insulin therapy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>To assess the effects of insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin monotherapy for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, ClinicalTrials.gov, the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) and reference lists of articles. The date of the last search was November 2015 for all databases.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Randomised controlled clinical trials of at least two months' duration comparing insulin monotherapy with combinations of insulin with one or more oral glucose-lowering agent in people with type 2 diabetes.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Two review authors independently selected trials, assessed risk of bias, extracted data and evaluated overall quality of the evidence using GRADE. We summarised data statistically if they were available, sufficiently similar and of sufficient quality. We performed statistical analyses according to the statistical guidelines in the <I>Cochrane Handbook for Systematic Reviews of Interventions.</I>
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We included 37 trials with 40 treatment comparisons involving 3227 participants. The duration of the interventions ranged from 2 to 12 months for parallel trials and two to four months for cross-over trials.</P>
<P>The majority of trials had an unclear risk of bias in several risk of bias domains. Fourteen trials showed a high risk of bias, mainly for performance and detection bias. Insulin monotherapy, including once-daily long-acting, once-daily intermediate-acting, twice-daily premixed insulin, and basal-bolus regimens (multiple injections), was compared to insulin in combination with sulphonylureas (17 comparisons: glibenclamide = 11, glipizide = 2, tolazamide = 2, gliclazide = 1, glimepiride = 1), metformin (11 comparisons), pioglitazone (four comparisons), alpha-glucosidase inhibitors (four comparisons: acarbose = 3, miglitol = 1), dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) (three comparisons: vildagliptin = 1, sitagliptin = 1, saxagliptin = 1) and the combination of metformin and glimepiride (one comparison). No trials assessed all-cause mortality, diabetes-related morbidity or health-related quality of life. Only one trial assessed patients' treatment satisfaction and showed no substantial differences between the addition of either glimepiride or metformin and glimepiride to insulin compared with insulin monotherapy.</P>
<P>Insulin-sulphonylurea combination therapy (CT) compared with insulin monotherapy (IM) showed a MD in glycosylated haemoglobin A1c (HbA1c) of -1% (95% confidence interval (CI) -1.6 to -0.5); P &lt; 0.01; 316 participants; 9 trials; low-quality evidence. Insulin-metformin CT compared with IM showed a MD in HbA1c of -0.9% (95% CI -1.2 to -0.5); P &lt; 0.01; 698 participants; 9 trials; low-quality evidence. We could not pool the results of adding pioglitazone to insulin. Insulin combined with alpha-glucosidase inhibitors compared with IM showed a MD in HbA1c of -0.4% (95% CI -0.5 to -0.2); P &lt; 0.01; 448 participants; 3 trials; low-quality evidence). Insulin combined with DPP-4 inhibitors compared with IM showed a MD in HbA1c of -0.4% (95% CI -0.5 to -0.4); P &lt; 0.01; 265 participants; 2 trials; low quality evidence. In most trials the participants with CT needed less insulin, whereas insulin requirements increased or remained stable in participants with IM.</P>
<P>We did not perform a meta-analysis for hypoglycaemic events because the included studies used different definitions.. In most trials the insulin-sulphonylurea combination resulted in a higher number of mild episodes of hypoglycaemia, compared to the IM group (range: 2.2 to 6.1 episodes per participant in CT versus 2.0 to 2.6 episodes per participant in IM; low-quality evidence). Pioglitazone CT also resulted in more mild to moderate hypoglycaemic episodes compared with IM (range 15 to 90 episodes versus 9 to 75 episodes, respectively; low-quality evidence. The trials that reported hypoglycaemic episodes in the other combinations found comparable numbers of mild to moderate hypoglycaemic events (low-quality evidence).</P>
<P>The addition of sulphonylureas resulted in an additional weight gain of 0.4 kg to 1.9 kg versus -0.8 kg to 2.1 kg in the IM group (220 participants; 7 trials; low-quality evidence). Pioglitazone CT caused more weight gain compared to IM: MD 3.8 kg (95% CI 3.0 to 4.6); P &lt; 0.01; 288 participants; 2 trials; low-quality evidence. Metformin CT was associated with weight loss: MD -2.1 kg (95% CI -3.2 to -1.1), P &lt; 0.01; 615 participants; 7 trials; low-quality evidence). DPP-4 inhibitors CT showed weight gain of -0.7 to 1.3 kg versus 0.6 to 1.1 kg in the IM group (362 participants; 2 trials; low-quality evidence). Alpha-glucosidase CT compared to IM showed a MD of -0.5 kg (95% CI -1.2 to 0.3); P = 0.26; 241 participants; 2 trials; low-quality evidence.</P>
<P>Users of metformin CT (range 7% to 67% versus 5% to 16%), and alpha-glucosidase inhibitors CT (14% to 75% versus 4% to 35%) experienced more gastro-intestinal adverse effects compared to participants on IM. Two trials reported a higher frequency of oedema with the use of pioglitazone CT (range: 16% to 18% versus 4% to 7% IM).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>The addition of all oral glucose-lowering agents in people with type 2 diabetes and inadequate glycaemic control who are on insulin therapy has positive effects on glycaemic control and insulin requirements. The addition of sulphonylureas results in more hypoglycaemic events. Additional weight gain can only be avoided by adding metformin to insulin. Other well-known adverse effects of oral glucose-lowering agents have to be taken into account when prescribing oral glucose-lowering agents in addition to insulin therapy.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<BACKGROUND MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<CONDITION MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Diabetes mellitus is a metabolic disorder resulting from a defect in insulin secretion, insulin action, or both. A consequence of these defects is chronic hyperglycaemia and disturbances of carbohydrate, fat and protein metabolism. Long-term complications of diabetes mellitus include retinopathy, nephropathy and neuropathy. The risk of cardiovascular disease is increased.</P>
<P>The United Kingdom Prospective Diabetes Study (UKPDS) and its 10-year follow-up afterwards showed that tight glycaemic control can significantly reduce the development and progression of microvascular complications (<LINK REF="REF-Holman-2008" TYPE="REFERENCE">Holman 2008</LINK>; <LINK REF="REF-UKPDS-33" TYPE="REFERENCE">UKPDS 33</LINK>; <LINK REF="REF-UKPDS-34" TYPE="REFERENCE">UKPDS 34</LINK>). There is some inconsistency in the evidence of the effects of intensive treatment on macrovascular outcomes and mortality. Several large long-term clinical trials comparing standard with intensive therapy did not show a significant reduction of cardiovascular outcomes and mortality (<LINK REF="REF-ACCORD-2008" TYPE="REFERENCE">ACCORD 2008</LINK>; <LINK REF="REF-ADVANCE-2008" TYPE="REFERENCE">ADVANCE 2008</LINK>; <LINK REF="REF-Duckworth-2009" TYPE="REFERENCE">Duckworth 2009</LINK>; <LINK REF="REF-Kooy-2009" TYPE="REFERENCE">Kooy 2009</LINK>). Intensive glycaemic control reduced the risk of microvascular complications but increased the risk of hypoglycaemia. Many guidelines on type 2 diabetes recommend a glycosylated haemoglobin A1c (HbA1c) below 7% for the majority of people with type 2 diabetes, however, a patient-centred approach is more and more advocated, with the intent to encourage an appreciation of the variable and progressive nature of type 2 diabetes, the specific role of each drug, the patient and disease factors that drive clinical decision making and the constraints imposed by age and comorbidity (<LINK REF="REF-Inzucchi-2012" TYPE="REFERENCE">Inzucchi 2012</LINK>). During the course of type 2 diabetes it will get more difficult to reach the HbA1c target levels with 'lifestyle' modification (diet, exercise or both) and oral glucose-lowering agents alone. Finally, a substantial number of individuals will need insulin therapy for better glycaemic control (<LINK REF="REF-Turner-1999" TYPE="REFERENCE">Turner 1999</LINK>; <LINK REF="STD-Wright-2002" TYPE="STUDY">Wright 2002</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Since the natural course of type 2 diabetes causes progressive decline of the pancreatic ß-cell function, finally oral glucose-lowering agents may not suffice and exogenous insulin will be required in a substantial number of people. At that stage insulin therapy can be initiated as insulin alone, that is monotherapy (which means that oral glucose-lowering medication will be stopped) or in combination with oral glucose-lowering agents. In the former category of people, oral blood glucose-lowering agents can be added at a later stage, if monotherapy fails to achieve a sufficient HbA1c level. The latter intervention is the intervention under study in this review.</P>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects of the intervention</HEADING>
<P>Hypoglycaemia, injection site reactions and weight gain are the most common and well known adverse effects of insulin therapy. Experimental and observational trials have shown that exogenous insulin may lead to increased atherosclerosis (<LINK REF="REF-Muis-2005" TYPE="REFERENCE">Muis 2005</LINK>; <LINK REF="REF-Ruige-1998" TYPE="REFERENCE">Ruige 1998</LINK>; <LINK REF="REF-Stout-1990" TYPE="REFERENCE">Stout 1990</LINK>). Weight gain is another frequently reported adverse effect of insulin, with weight gain ranges from 0.3 kg to 3.8 kg. Several Dutch trials reported no effect or no negative effects on health-related quality of life after starting insulin treatment (<LINK REF="REF-De-Grauw-2001" TYPE="REFERENCE">De Grauw 2001</LINK>; <LINK REF="REF-De-Sonnaville-1998" TYPE="REFERENCE">De Sonnaville 1998</LINK>; <LINK REF="REF-Goddijn-1999" TYPE="REFERENCE">Goddijn 1999</LINK>; <LINK REF="STD-Goudswaard-2004a" TYPE="STUDY">Goudswaard 2004a</LINK>). On the other hand, many people with type 2 diabetes (and healthcare providers) are reluctant to initiate insulin therapy. People with type 2 diabetes may be afraid of hypoglycaemia and weight gain, they may be uncomfortable with daily injections, they might experience restrictions in lifestyle and feelings of guilt and failure (<LINK REF="REF-Brunton-2005" TYPE="REFERENCE">Brunton 2005</LINK>; <LINK REF="REF-Hunt-1997" TYPE="REFERENCE">Hunt 1997</LINK>; <LINK REF="REF-Korytkowski-2002" TYPE="REFERENCE">Korytkowski 2002</LINK>; <LINK REF="REF-Snoek-2002" TYPE="REFERENCE">Snoek 2002</LINK>). In addition, primary care patients treated with insulin reported higher diabetes-related distress compared with oral- or diet-treated patients, which is stable over time and might be difficult to alter (<LINK REF="REF-Delahanty-2007" TYPE="REFERENCE">Delahanty 2007</LINK>; <LINK REF="REF-Karlsen-2014" TYPE="REFERENCE">Karlsen 2014</LINK>).
</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>In the 1990s three reviews were executed comparing insulin monotherapy with insulin-oral glucose-lowering agents combination therapy (<LINK REF="REF-Johnson-1996" TYPE="REFERENCE">Johnson 1996</LINK>; <LINK REF="REF-Peters-1991" TYPE="REFERENCE">Peters 1991</LINK>; <LINK REF="REF-Pugh-1992" TYPE="REFERENCE">Pugh 1992</LINK>). The reviews did not distinguish between insulin-treated and insulin-naive participants. Besides, they only focused on sulphonylureas in combination with insulin therapy and excluded trials with other oral agents. Their conclusions differed. <LINK REF="REF-Peters-1991" TYPE="REFERENCE">Peters 1991</LINK> concluded that combination therapy has no additional value for insulin-treated people with type 2 diabetes, since it improved glycaemic control only slightly and it did not produce normal blood glucose concentrations. But <LINK REF="REF-Pugh-1992" TYPE="REFERENCE">Pugh 1992</LINK> and <LINK REF="REF-Johnson-1996" TYPE="REFERENCE">Johnson 1996</LINK> concluded that insulin combination therapy with sulphonylureas was more appropriate than insulin monotherapy because it was more efficacious and may be more cost-effective. A more comprehensive review on the combination of insulin and oral glucose-lowering agents in insulin-naive and insulin-treated patients did not meet Cochrane criteria (<LINK REF="REF-Yki_x002d_Jarvinen-2001" TYPE="REFERENCE">Yki-Jarvinen 2001</LINK>). It showed that in most trials glycaemic control was better and less insulin was required with the combination of insulin and oral glucose-lowering agents compared with insulin alone. Notably, the difference in the required insulin dose between insulin monotherapy and the combination therapy was smaller in participants who were already being treated with insulin than in insulin-naive participants.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>In 2004 a Cochrane Review was published on the comparison of insulin monotherapy versus combinations of insulin and oral glucose-lowering agents in insulin-naive people with type 2 diabetes with poor glycaemic control despite maximal dosages of oral glucose-lowering agents (<LINK REF="REF-Goudswaard-2004b" TYPE="REFERENCE">Goudswaard 2004b</LINK>). The authors concluded that bedtime Neutral Protamine Hagedorn (NPH) insulin combined with oral glucose-lowering agents provides comparable glycaemic control to insulin monotherapy, but with less weight gain if metformin was used. </P>
<P>Up to now, no definitive answer has been available with regard to the comparison of insulin monotherapy versus combinations of insulin and oral glucose-lowering agents in people with type 2 diabetes already on insulin therapy. In other words: is the adding of an oral glucose-lowering agent to insulin beneficial with regard to outcomes such as glycaemic control, weight gain, hypoglycaemia, insulin dosage, health-related quality of life and other outcome parameters? This systematic review will try to clarify the benefits of adding an oral blood glucose-lowering agent to insulin monotherapy in people already on insulin therapy.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>To assess the effects of insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin monotherapy for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<SELECTION_CRITERIA MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<CRIT_STUDIES MODIFIED="2014-10-17 11:11:48 +0200" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials (RCTs) with a minimal follow-up period of two months.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Participants with type 2 diabetes mellitus (according to the appropriate diagnostic criteria at the time) already on insulin therapy and inadequate glycaemic control. To be consistent with changes in classification and diagnostic criteria of type 2 diabetes mellitus through the years, the diagnosis should have been established using the standard criteria valid at the time of the beginning of the trial (for example <LINK REF="REF-ADA-1997" TYPE="REFERENCE">ADA 1997</LINK>; <LINK REF="REF-ADA-1999" TYPE="REFERENCE">ADA 1999</LINK>; <LINK REF="REF-WHO-1980" TYPE="REFERENCE">WHO 1980</LINK>; <LINK REF="REF-WHO-1985" TYPE="REFERENCE">WHO 1985</LINK>; <LINK REF="REF-WHO-1998" TYPE="REFERENCE">WHO 1998</LINK>). Ideally, diagnostic criteria should have been described. If necessary, we used the study authors' definition of diabetes mellitus.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<SUBSECTION>
<HEADING LEVEL="5">Intervention</HEADING>
<P>Combinations of insulin with one or more oral glucose-lowering agent(s).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Control</HEADING>
<P>Insulin monotherapy.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-12-03 16:18:55 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>All-cause mortality</LI>
<LI>Diabetes-related morbidity</LI>
<LI>Adverse events</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<UL>
<LI>Health-related quality of life</LI>
<LI>Patient satisfaction</LI>
<LI>Glycosylated haemoglobin A1c (HbA1c)</LI>
<LI>Fasting glucose</LI>
<LI>Lipids</LI>
<LI>Insulin dose</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="5">Method and timing of outcome measurement</HEADING>
<UL>
<LI>Mortality: defined as all-cause and diabetes-related (cardiovascular mortality, mortality due to end-stage renal disease or due to amputation) and measured at baseline and follow-up with a minimum duration of two months.</LI>
<LI>Diabetes-related morbidity: defined as myocardial infarction, angina, heart failure, stroke, renal failure, amputation (of at least one digit), vitreous haemorrhage, retinal photocoagulation, blindness in at least one eye, or cataract extraction and measured at baseline and follow-up with a minimum duration of two months.</LI>
<LI>Adverse events such as hypoglycaemic episodes, weight gain, gastrointestinal symptoms, heart failure and measured at baseline and follow-up with a minimum duration of two months.</LI>
<LI>Health-related quality of life: evaluated by a validated instrument and measured at baseline and follow-up with a minimum duration of two months.</LI>
<LI>Patient satisfaction: evaluated by a validated instrument and measured at baseline and follow-up with a minimum duration of two months.</LI>
<LI>HbA1c: measured at baseline and follow-up with a minimum duration of two months.</LI>
<LI>Fasting glucose: defined as after a period of eight hours of not eating or drinking with the exception of water and measured at baseline and follow-up with a minimum duration of two months.</LI>
<LI>Lipids: defined as total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, triglycerides and measured at baseline and follow-up with a minimum duration of two months.</LI>
<LI>Insulin dose: defined as once-daily long-acting, once-daily intermediate-acting, twice-daily premixed insulin, and basal-bolus regimen (multiple injections) and measured at baseline and follow-up with a minimum duration of two months.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Summary of findings</HEADING>
<P>We present a 'Summary of findings' table to report the following outcomes, listed according to priority.</P>
<UL>
<LI>All-cause mortality.</LI>
<LI>Diabetes-related mortality.</LI>
<LI>Diabetes-related morbidity.</LI>
<LI>Health-related quality of life.</LI>
<LI>Patient satisfaction.</LI>
<LI>Adverse events.</LI>
<LI>HbA1c.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<ELECTRONIC_SEARCHES MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We searched the following sources from inception of each database to the specified date and placed no restrictions on the language of publication.<BR/>
</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL issue 10, October 2015, 18.11.2015)</LI>
<LI>Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present (18.11.2015)</LI>
<LI>Embase 1974 to 2015 November 17 (18.11.2015)</LI>
<LI>
<A HREF="http://ClinicalTrials.gov">ClinicalTrials.gov</A> (18.11.2015)</LI>
<LI>World Health Organization (WHO) ICTRP (International Clinical Trials Registry Platform - <A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>) (18.11.2015), including:</LI>
<UL>
<LI>Australian New Zealand Clinical Trials Registry (2 November 2015)</LI>
<LI>Chinese Clinical Trial Registry (2 November 2015)</LI>
<LI>ClinicalTrials.gov (2 November 2015)</LI>
<LI>EU Clinical Trials Register (EU-CTR) (2 November 2015)</LI>
<LI>ISRCTN (2 November 2015)</LI>
<LI>The Netherlands National Trial Register (3 November 2015)</LI>
<LI>Brazilian Clinical Trials Registry (ReBec) (13 October 2015)</LI>
<LI>Clinical Trials Registry - India (13 October 2015)</LI>
<LI>Clinical Research Information Service - Republic of Korea (13 October 2015)</LI>
<LI>Cuban Public Registry of Clinical Trials (13 October 2015)</LI>
<LI>German Clinical Trials Register (13 October 2015)</LI>
<LI>Iranian Registry of Clinical Trials (4 August 2015)</LI>
<LI>Japan Primary Registries Network (19 October 2015)</LI>
<LI>Pan African Clinical Trial Registry (13 October 2015)</LI>
<LI>Sri Lanka Clinical Trials Registry (13 October 2015)</LI>
<LI>Thai Clinical Trials Register (TCTR) (13 October 2015)</LI>
</UL>
</UL>
<P>We also searched the excluded trials from the Cochrane Review with the same objective as ours except in insulin-naive people with type 2 diabetes (<LINK REF="REF-Goudswaard-2004b" TYPE="REFERENCE">Goudswaard 2004b</LINK>).</P>
<P>If we had detected additional relevant key words during any of the electronic or other searches, we would have modified the electronic search strategies to incorporate these terms and document the changes.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-12-03 16:18:55 +0100" MODIFIED_BY="[Empty name]">
<P>We tried to identify additional trials by searching the reference lists of included trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<STUDY_SELECTION MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>One review author (MA) first screened titles and abstracts to remove duplicates and obviously irrelevant records. Then two review authors (MA, AG or RV) independently scanned the abstract, title, or both, of the retriever records, to determine which trials should be assessed further. We investigated all potentially-relevant articles as full text. Full articles were retrieved for further assessment if the information given suggested that the trial included participants with type 2 diabetes mellitus, compared insulin with a combination of insulin with oral glucose lowering agent(s), assessed one or more relevant clinical outcome measure(s), and used random allocation to the comparison groups. We resolved any discrepancies through consensus or recourse to a third review author (KG or GR). If resolution of a disagreement was not possible, we added the article to those 'awaiting assessment' and we contacted trial authors for clarification. We present an adapted Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram showing the process of trial selection (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) (<LINK REF="REF-Liberati-2009" TYPE="REFERENCE">Liberati 2009</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Dealing with duplicate and companion publications</HEADING>
<P>In the event of duplicate publications, companion documents or multiple reports of a primary trial, we maximised yield of information by collating all available data and used the most complete data set aggregated across all known publications. In case of doubt, we prioritised the publication reporting the longest follow-up associated with our primary or secondary outcomes.</P>
</SUBSECTION>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>For trials that fulfilled inclusion criteria, two review authors (MA and AK or MD or AG or RV) independently abstracted relevant population and intervention characteristics using standard data extraction templates (for details see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>; <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>; <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>; <LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>) with any disagreements to be resolved by discussion, or, if required, by a third party (KG).</P>
<P>We provide information including trial identifier about potentially relevant ongoing trials in the table '<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>'.</P>
<P>We sent an email request to authors of included trials to enquire whether they were willing to answer questions regarding their trials. Thereafter, we sought relevant missing information on the trial from the authors of the article, if required.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Two review authors (MA and AK or MD or AG) assessed each trial independently. Possible disagreement was resolved by consensus, or with consultation with a third party in case of disagreement. We explored the influence of individual bias criteria in a sensitivity analysis (see <LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>). In case of disagreement, we consulted the rest of the group and made a judgement based on consensus. We investigated risk of bias due to carry-over effect in cross-over trials during data-extraction.</P>
<P>We used the Cochrane 'risk of bias' assessment tool (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>; <LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>) and investigated the following risk of bias criteria.</P>
<UL>
<LI>Random sequence generation (selection bias).</LI>
<LI>Allocation concealment (selection bias).</LI>
<LI>Blinding of participants and personnel (performance bias).</LI>
<LI>Blinding of outcome assessment (detection bias).</LI>
<LI>Incomplete outcome data (attrition bias).</LI>
<LI>Selective reporting (reporting bias).</LI>
<LI>Other potential sources of bias.</LI>
</UL>
<P>We judged 'risk of bias' criteria as 'low risk', 'high risk' or 'unclear risk' and evaluated individual bias items as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> <I>(</I>
<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). We present a 'Risk of bias' graph (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) and a 'Risk of bias summary' figure (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). We assessed the impact of individual risk of bias domains on trial results at the endpoint and trial levels. In case of high risk of selection bias, all endpoints investigated in the associated trial were marked as 'high risk'.</P>
<P>For performance bias (blinding of participants and personnel) and detection bias (blinding of outcome assessors) we evaluated the risk of bias separately for each outcome (<LINK REF="REF-Hr_x00f3_bjartsson-2013" TYPE="REFERENCE">Hróbjartsson 2013</LINK>). We noted whether outcomes were measured subjectively or objectively, for example if body weight was measured by participants or trial personnel.</P>
<P>We considered the implications of missing outcome data from individual participants per outcome such as high dropout rates (e.g. above 15%) or disparate attrition rates (e.g. difference of 10% or more between trial arms).</P>
<P>We defined the following endpoints as subjective outcomes.</P>
<UL>
<LI>Health-related quality of life.</LI>
<LI>Patient satisfaction.</LI>
</UL>
<P>We defined the following endpoints as objective outcomes.</P>
<UL>
<LI>All-cause mortality.</LI>
<LI>Diabetes-related morbidity.</LI>
<LI>Adverse events.</LI>
<LI>HbA1c.</LI>
<LI>Fasting glucose.</LI>
<LI>Lipids.</LI>
<LI>Insulin dose.</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<SUBSECTION>
<HEADING LEVEL="5">Continuous data</HEADING>
<P>The results are expressed as mean differences (MD) with 95% confidence intervals (CIs).</P>
<P>For trials that did not provide HbA1c change-from-baseline values, we computed these data from baseline and post-treatment values, if necessary extracted from graphs. When standard deviations of mean differences from the main outcome HbA1c were not provided in 11 publications (<LINK REF="STD-Barnett-2013" TYPE="STUDY">Barnett 2013</LINK>; <LINK REF="STD-Casner-1988" TYPE="STUDY">Casner 1988</LINK>; <LINK REF="STD-Fonseca-2007" TYPE="STUDY">Fonseca 2007</LINK>; <LINK REF="STD-Giugliano-1993" TYPE="STUDY">Giugliano 1993</LINK>; <LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>; <LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK>; <LINK REF="STD-Osei-1984" TYPE="STUDY">Osei 1984</LINK>; <LINK REF="STD-Quatraro-1986" TYPE="STUDY">Quatraro 1986</LINK>; <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>), we computed these data assuming a general correlation coefficient that was derived from baseline and post-treatment outcomes for HbA1c in trials that presented accompanying standard deviations. We computed matching standard deviations in SPSS 15.0 with a formula (formula 1), which included a general correlation coefficient of 0.5. This figure was 0.1 point lower than the correlation coefficient that was calculated from trials that provided information on change scores including standard deviations, and which appeared to be 0.6 in most trials (formula 2) (<LINK REF="REF-Armitage-2002" TYPE="REFERENCE">Armitage 2002</LINK>). We used the same method and formula for assessing the standard deviation of the differences of fasting glucose for seven trials (<LINK REF="STD-Avil_x00e9_s-1999" TYPE="STUDY">Avilés 1999</LINK>; <LINK REF="STD-Casner-1988" TYPE="STUDY">Casner 1988</LINK>; <LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK>; <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK>; <LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>), weight for six trials (<LINK REF="STD-Barnett-2013" TYPE="STUDY">Barnett 2013</LINK>; <LINK REF="STD-Casner-1988" TYPE="STUDY">Casner 1988</LINK>; <LINK REF="STD-Krawczyk-2005" TYPE="STUDY">Krawczyk 2005</LINK>; <LINK REF="STD-Mauerhoff-1986" TYPE="STUDY">Mauerhoff 1986</LINK>; <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>), total cholesterol for five trials (<LINK REF="STD-Giugliano-1993" TYPE="STUDY">Giugliano 1993</LINK>; <LINK REF="STD-Osei-1984" TYPE="STUDY">Osei 1984</LINK>; <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>), HDL-cholesterol for six trials (<LINK REF="STD-Giugliano-1993" TYPE="STUDY">Giugliano 1993</LINK>; <LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK>; <LINK REF="STD-Osei-1984" TYPE="STUDY">Osei 1984</LINK>; <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>) and triglycerides for six trials (<LINK REF="STD-Fonseca-2007" TYPE="STUDY">Fonseca 2007</LINK>; <LINK REF="STD-Giugliano-1993" TYPE="STUDY">Giugliano 1993</LINK>; <LINK REF="STD-Osei-1984" TYPE="STUDY">Osei 1984</LINK>; <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>). We included a correlation coefficient of 0.3 for fasting glucose, 0.9 for weight gain, 0.8 for HDL-cholesterol and 0.6 for total cholesterol and triglycerides.</P>
<P>
<I>Formula 1: SPSS syntax for <U>computing standard deviations of changes</U> from baseline values of HbA1c:<BR/>
</I>SD = sqrt (sd_tr_b<SUP>2</SUP> + sd_tr_p<SUP>2</SUP> - (2 x corr x sd_tr_b x sd_tr_p)).</P>
<P>Abbreviations:</P>
<P>sd = standard deviation</P>
<P>sqrt = square root</P>
<P>sd_tr_b = standard deviation of mean baseline HbA1c</P>
<P>sd_tr_p = standard deviation of mean post-treatment HbA1c</P>
<P>corr = correlation coefficient between baseline and post-treatment values of HbA1c</P>
<P>
<I>Formula 2: SPSS syntax for <U>computing correlation coefficient between baseline and post-treatment values</U> of HbA1c: </I>
</P>
<P>corr_tr = (hba1cbsd<SUP>2</SUP> + hba1cptsd<SUP>2</SUP> - sddiff_tr<SUP>2</SUP>) / (2 x hba1cbsd x hba1cptsd).</P>
<P>Abbreviations:</P>
<P>corr_tr = correlation coefficient between baseline and post-treatment values of HbA1c</P>
<P>hba1cbsd = standard deviation of mean baseline HbA1c</P>
<P>hba1cptsd = standard deviation of mean post-treatment HbA1c</P>
<P>sddiff_tr = standard deviation of change from baseline HbA1c</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We pooled the results of mean difference and standard error of the parallel group and the cross-over trials using the generic inverse variance (GIV) method. In addition, we also used the non-GIV method in order to give insight into the number of participants included in each trial and the range of mean values. For the cross-over trials we calculated the correlation coefficient for within-participants difference based on the trial results of <LINK REF="STD-Robinson-1998" TYPE="STUDY">Robinson 1998</LINK>, and estimated the standard error as described in chapter 16 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> <I>(</I>
<LINK REF="REF-Higgins-2011c" TYPE="REFERENCE">Higgins 2011c</LINK>). We then imputed this correlation coefficient in the other trials. When standard deviations of mean differences were not provided in the publications, we computed these data assuming a correlation coefficient that was derived from intervention and control outcomes in trials that presented accompanying standard deviations (HbA1c: <LINK REF="STD-Fritsche-2000" TYPE="STUDY">Fritsche 2000</LINK>; <LINK REF="STD-Kitabchi-1987" TYPE="STUDY">Kitabchi 1987</LINK>; <LINK REF="STD-Kyllastinen-1985" TYPE="STUDY">Kyllastinen 1985</LINK>; <LINK REF="STD-Lewitt-1989" TYPE="STUDY">Lewitt 1989</LINK>; <LINK REF="STD-Schade-1987" TYPE="STUDY">Schade 1987</LINK>; <LINK REF="STD-Stenman-1988" TYPE="STUDY">Stenman 1988</LINK>; fasting glucose: <LINK REF="STD-Fritsche-2000" TYPE="STUDY">Fritsche 2000</LINK>; <LINK REF="STD-Kyllastinen-1985" TYPE="STUDY">Kyllastinen 1985</LINK>; <LINK REF="STD-Lewitt-1989" TYPE="STUDY">Lewitt 1989</LINK>; <LINK REF="STD-Longnecker-1986" TYPE="STUDY">Longnecker 1986</LINK>; <LINK REF="STD-Robinson-1998" TYPE="STUDY">Robinson 1998</LINK>; <LINK REF="STD-Stenman-1988" TYPE="STUDY">Stenman 1988</LINK>; weight: <LINK REF="STD-Kitabchi-1987" TYPE="STUDY">Kitabchi 1987</LINK>; <LINK REF="STD-Kyllastinen-1985" TYPE="STUDY">Kyllastinen 1985</LINK>; <LINK REF="STD-Lindstrom-1999" TYPE="STUDY">Lindstrom 1999</LINK>; <LINK REF="STD-Robinson-1998" TYPE="STUDY">Robinson 1998</LINK>; <LINK REF="STD-Schade-1987" TYPE="STUDY">Schade 1987</LINK>; <LINK REF="STD-Stenman-1988" TYPE="STUDY">Stenman 1988</LINK>; total cholesterol: <LINK REF="STD-Groop-1985" TYPE="STUDY">Groop 1985</LINK>; <LINK REF="STD-Kitabchi-1987" TYPE="STUDY">Kitabchi 1987</LINK>; <LINK REF="STD-Lindstrom-1999" TYPE="STUDY">Lindstrom 1999</LINK>; <LINK REF="STD-Stenman-1988" TYPE="STUDY">Stenman 1988</LINK>; HDL-cholesterol: <LINK REF="STD-Groop-1985" TYPE="STUDY">Groop 1985</LINK>; <LINK REF="STD-Lindstrom-1999" TYPE="STUDY">Lindstrom 1999</LINK>; <LINK REF="STD-Stenman-1988" TYPE="STUDY">Stenman 1988</LINK>; triglycerides: <LINK REF="STD-Groop-1985" TYPE="STUDY">Groop 1985</LINK>; <LINK REF="STD-Kitabchi-1987" TYPE="STUDY">Kitabchi 1987</LINK>; <LINK REF="STD-Lindstrom-1999" TYPE="STUDY">Lindstrom 1999</LINK>; <LINK REF="STD-Stenman-1988" TYPE="STUDY">Stenman 1988</LINK>).</P>
<P>
<I>Formula 3: SPSS syntax for <U>computing correlation coefficient</U> in cross-over trials</I>
</P>
<P>corr_tr = (sd_tr_pa<SUP>2</SUP> + sd_tr_pb<SUP>2</SUP> - sddiff_tr<SUP>2</SUP>) / (2 x sd_tr_pa x sd_tr_pb).<BR/>
</P>
<P>Abbreviations:</P>
<P>corr_tr = correlation coefficient between intervention and control values</P>
<P>sd_tr_pa = standard deviation of mean value after intervention</P>
<P>sd_tr_pb = standard deviation of mean value after control</P>
<P>sddiff_tr = standard deviation of within-participant difference between intervention and control measurements</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We carefully evaluated important numerical data such as screened, eligible and randomised participants, as well as intention-to-treat (ITT) and per-protocol (PP) population. We investigated attrition rates, for example dropouts, losses to follow-up and withdrawals. We critically appraised issues of missing data, ITT and PP and compared them to specification of primary outcome parameters and power calculation.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We assessed clinical heterogeneity by comparing the trials with regard to different clinical parameters: patient characteristics, duration of disease, interventions and outcome. In the event of substantial clinical or methodological heterogeneity, we did not combine trial results by means of meta-analysis. We identified statistical heterogeneity by visual inspection of the forest plots, by using a standard Chi² test and a significance level of &#945; = 0.1, in view of the low power of such tests. Heterogeneity was specifically examined with the I² statistic (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>), where I² values of 75% and more indicate a considerable level of heterogeneity (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). When heterogeneity was found, we attempted to determine potential reasons for it by examining individual trial characteristics and those of subgroups of the main body of evidence. We did not report the results of meta-analysis with a considerable level of statistical heterogeneity (I² greater than 75%).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>If we included 10 trials or more investigating a particular outcome, we used funnel plots to assess small trial effects. Several explanations can be offered for the asymmetry of a funnel plot, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials) and publication bias. We therefore interpreted results carefully <LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We summarised data statistically if they were available, sufficiently similar and of sufficient quality. We performed statistical analyses according to the statistical guidelines referenced in the latest version of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>).</P>
<P>Unless there was good evidence for homogeneous effects across trials, we primarily summarised low risk of bias data using a random-effects model (<LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>). We interpreted random-effects meta-analyses with due consideration of the whole distribution of effects, ideally by presenting a prediction interval (<LINK REF="REF-Higgins-2009" TYPE="REFERENCE">Higgins 2009</LINK>). A prediction interval specifies a predicted range for the true treatment effect in an individual trial (<LINK REF="REF-Riley-2011" TYPE="REFERENCE">Riley 2011</LINK>). In addition, we performed statistical analyses according to the statistical guidelines contained in the <I>Cochrane Handbook for Systematic Reviews of Interventions (</I>
<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>.</P>
<P>
<B>Quality of evidence</B>
</P>
<P>We present the overall quality of the evidence for each outcome as specified in types of outcome measures under 'Summary of findings' according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach which takes into account issues not only related to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity such as directness of results<I>. </I>Two review authors (MA and AK or MD or AG) independently rated the quality for each outcome. We present a summary of the evidence in a 'Summary of findings' table, which provides key information about the best estimate of the magnitude of the effect, in relative terms and absolute differences for each relevant comparison of alternative management strategies, numbers of participants and trials addressing each important outcome, and the rating of the overall confidence in effect estimates for each outcome. We created the 'Summary of findings' table based on the methods described the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>). We present results on the outcomes as described in the <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK> section. If meta-analysis was not possible, we presented results in a narrative format in the 'Summary of findings' table.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We performed subgroup analyses if one of the primary outcome parameters demonstrated statistically significant differences between intervention groups. In any other case, subgroup analyses would have been clearly marked as a hypothesis-generating exercise.</P>
<P>We planned to carry out the following subgroup analyses.<BR/>
</P>
<UL>
<LI>Different oral glucose-lowering agent(s) and different types of insulin.</LI>
<LI>Timing and frequency of insulin injections.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We planned to perform sensitivity analyses in order to explore the influence of very long trials (defined as equal to or greater than 24 weeks or six months) and the influence of trials with high risk of bias (defined as high risk of performance bias and detection bias because of not blinding researchers, or high risk of attrition bias because of incomplete outcome data, or both) on the effect size, to establish how much they dominated the results. Moreover, we compared the results of trials with a parallel design with the results of trials with a cross-over design. We also planned to perform sensitivity analyses by restricting the analysis to published trials or restricting the analysis to trials using the following filters: diagnostic criteria; imputation; language of publication; source of funding (industry versus other); and country.</P>
<P>We also tested the robustness of the results by repeating the analysis using different measures of effect size (RR, odds ratio (OR), etc.) and different statistical models (fixed-effect and random-effects models).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<STUDY_DESCRIPTION MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> and <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>The search strategy provided 10,048 citations. After exclusion of duplicates and trials not related to the objective of the review, two review authors (MA, AG or RV) independently assessed the remaining abstracts. One of the authors of this review (AG) has conducted a similar Cochrane Review, that also compares insulin monotherapy to insulin combined with oral glucose-lowering agents, though in insulin-naive type 2 diabetes patients (<LINK REF="REF-Goudswaard-2004b" TYPE="REFERENCE">Goudswaard 2004b</LINK>). One author (MA) scanned the title, abstract and text of the excluded trials of that review. Seven excluded trials were related to the objective of the current review and did not appear in the search. We found two additional records in the references of included articles. We obtained the full text of 151 potentially relevant trials, of which 37 (39 publications) fulfilled the inclusion criteria (for details see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>All 37 included trials were randomised controlled trials, of which 26 had a parallel design and 11 a cross-over design (<LINK REF="STD-Feinglos-1998" TYPE="STUDY">Feinglos 1998</LINK>; <LINK REF="STD-Fritsche-2000" TYPE="STUDY">Fritsche 2000</LINK>; <LINK REF="STD-Groop-1985" TYPE="STUDY">Groop 1985</LINK>; <LINK REF="STD-Kitabchi-1987" TYPE="STUDY">Kitabchi 1987</LINK>; <LINK REF="STD-Kyllastinen-1985" TYPE="STUDY">Kyllastinen 1985</LINK>; <LINK REF="STD-Lewitt-1989" TYPE="STUDY">Lewitt 1989</LINK>; <LINK REF="STD-Lindstrom-1999" TYPE="STUDY">Lindstrom 1999</LINK>; <LINK REF="STD-Longnecker-1986" TYPE="STUDY">Longnecker 1986</LINK>; <LINK REF="STD-Robinson-1998" TYPE="STUDY">Robinson 1998</LINK>; <LINK REF="STD-Schade-1987" TYPE="STUDY">Schade 1987</LINK>; <LINK REF="STD-Stenman-1988" TYPE="STUDY">Stenman 1988</LINK>). Thirteen trials were conducted in the United States of America, three were conducted in Finland, two each in the United Kingdom, Sweden, Germany and Italy, and one each in Canada, Poland, Turkey, Australia, Belgium, Spain, Korea, Japan and the Netherlands. Another four trials were conducted in two or more countries. All trials were, if stated, conducted in secondary care. All were published in English, except one in Polish (<LINK REF="STD-Krawczyk-2005" TYPE="STUDY">Krawczyk 2005</LINK>). More than 80% of the trials were sponsored by pharmaceutical companies.</P>
<P>The total number of participants was 3227 (range 9 to 566), with 0% to 100% men. Gender was not reported in four trials (<LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK>; <LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>; <LINK REF="STD-Mezitis-1992" TYPE="STUDY">Mezitis 1992</LINK>; <LINK REF="STD-Quatraro-1986" TYPE="STUDY">Quatraro 1986</LINK>). Participants ranged from 29 to 83 years of age and the duration of diabetes ranged from less than 1 to 31 years.</P>
<P>We evaluated 37 trials providing 40 comparisons between insulin monotherapy and insulin-oral glucose-lowering agents combination therapy. Insulin monotherapy was compared to insulin therapy in combination with:</P>
<UL>
<LI>sulphonylureas; n = 17 comparisons (glibenclamide = 11, glipizide = 2, tolazamide = 2, gliclazide = 1, glimepiride = 1);</LI>
<LI>metformin; n = 11 comparisons;</LI>
<LI>combination of metformin and sulphonylureas; n = 1 comparison;</LI>
<LI>pioglitazone; n = 4 comparisons;</LI>
<LI>alpha-glucosidase inhibitors; n = 4 comparisons (acarbose n = 3, miglitol n = 1);</LI>
<LI>dipeptidyl peptidase-4 inhibitors (DPP 4-inhibitors); n = 3 comparisons (vildagliptin n = 1, sitagliptin n = 1, saxagliptin n = 1).</LI>
</UL>
<P>One trial on pioglitazone (<LINK REF="STD-Rosenstock-2002" TYPE="STUDY">Rosenstock 2002</LINK>) compared the combination of insulin therapy with pioglitazone 15 mg as well as pioglitazone 30 mg to placebo. Insulin therapy was applied as a once-daily, twice-daily, and/or a multiple-daily injection regimen. In almost all trials that reported the insulin regimens, participants received a different number of injections per day. Nine trials included participants who used a once-daily insulin regimen (<LINK REF="STD-Barnett-2013" TYPE="STUDY">Barnett 2013</LINK>; <LINK REF="STD-Longnecker-1986" TYPE="STUDY">Longnecker 1986</LINK>; <LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK>; <LINK REF="STD-Mudaliar-2010" TYPE="STUDY">Mudaliar 2010</LINK>; <LINK REF="STD-Osei-1984" TYPE="STUDY">Osei 1984</LINK>; <LINK REF="STD-Quatraro-1986" TYPE="STUDY">Quatraro 1986</LINK>; <LINK REF="STD-Reich-1987" TYPE="STUDY">Reich 1987</LINK>; <LINK REF="STD-Simpson-1990" TYPE="STUDY">Simpson 1990</LINK>; <LINK REF="STD-Stenman-1988" TYPE="STUDY">Stenman 1988</LINK>), in the other trials all participants received two or more injections per day. The total trial duration of all trials ranged from 2 to 12 months. The mean follow-up of an intervention period of the cross-over trials varied from two to four months.</P>
<P>All except one trial (<LINK REF="STD-Mauerhoff-1986" TYPE="STUDY">Mauerhoff 1986</LINK>) reported glycaemic control as mean values of glycosylated haemoglobin A1c (HbA1c). Ten trials provided change-from-baseline values for HbA1c with standard deviations or errors (<LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK>; <LINK REF="STD-Fonseca-2007" TYPE="STUDY">Fonseca 2007</LINK>; <LINK REF="STD-Fritsche-2000" TYPE="STUDY">Fritsche 2000</LINK>; <LINK REF="STD-Hong-2012" TYPE="STUDY">Hong 2012</LINK>; <LINK REF="STD-Nemoto-2011" TYPE="STUDY">Nemoto 2011</LINK>; <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK>; <LINK REF="STD-Robinson-1998" TYPE="STUDY">Robinson 1998</LINK>; <LINK REF="STD-Rosenstock-2002" TYPE="STUDY">Rosenstock 2002</LINK>; <LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK>; <LINK REF="STD-Wulffel_x00e9_-2002" TYPE="STUDY">Wulffelé 2002</LINK>;). Fasting blood glucose values were not reported in two trials (<LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK>; <LINK REF="STD-Mezitis-1992" TYPE="STUDY">Mezitis 1992</LINK>). Eleven trials provided change-from-baseline values for body weight with standard deviations or errors (<LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK>; <LINK REF="STD-Fonseca-2007" TYPE="STUDY">Fonseca 2007</LINK>; <LINK REF="STD-Fritsche-2000" TYPE="STUDY">Fritsche 2000</LINK>; <LINK REF="STD-Hong-2012" TYPE="STUDY">Hong 2012</LINK>; <LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK>; <LINK REF="STD-Mudaliar-2010" TYPE="STUDY">Mudaliar 2010</LINK>; <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK>; <LINK REF="STD-Robinson-1998" TYPE="STUDY">Robinson 1998</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>; <LINK REF="STD-Wulffel_x00e9_-2002" TYPE="STUDY">Wulffelé 2002</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>). Change in insulin requirement was reported in all trials, except one (<LINK REF="STD-Chiasson-1994" TYPE="STUDY">Chiasson 1994</LINK>). No trial assessed patient-reported outcomes like general well-being or health-related quality of life. Only one trial assessed patient treatment satisfaction (<LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK>). Eight trials reported data on total cholesterol, HDL-cholesterol and/or triglycerides. All but 13 trials (<LINK REF="STD-Fritsche-2000" TYPE="STUDY">Fritsche 2000</LINK>; <LINK REF="STD-Giugliano-1993" TYPE="STUDY">Giugliano 1993</LINK>; <LINK REF="STD-Groop-1985" TYPE="STUDY">Groop 1985</LINK>; <LINK REF="STD-Kitabchi-1987" TYPE="STUDY">Kitabchi 1987</LINK>; <LINK REF="STD-Krawczyk-2005" TYPE="STUDY">Krawczyk 2005</LINK>; <LINK REF="STD-Kyllastinen-1985" TYPE="STUDY">Kyllastinen 1985</LINK>; <LINK REF="STD-Lewitt-1989" TYPE="STUDY">Lewitt 1989</LINK>; <LINK REF="STD-Lindstrom-1999" TYPE="STUDY">Lindstrom 1999</LINK>; <LINK REF="STD-Longnecker-1986" TYPE="STUDY">Longnecker 1986</LINK>; <LINK REF="STD-Mezitis-1992" TYPE="STUDY">Mezitis 1992</LINK>; <LINK REF="STD-Mudaliar-2010" TYPE="STUDY">Mudaliar 2010</LINK>; <LINK REF="STD-Osei-1984" TYPE="STUDY">Osei 1984</LINK>; <LINK REF="STD-Quatraro-1986" TYPE="STUDY">Quatraro 1986</LINK>) in some way provided information on hypoglycaemic events. Almost half of the trials reported information on other adverse effects.</P>
<P>Further details are listed in the Table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Reasons for exclusion of trials are given in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. Main reasons for exclusion were that participants were insulin-naive, trials used a non-appropriate trial design, and non-oral agents were added to insulin therapy.</P>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>We found seven ongoing trials, four with a subgroup for the combination insulin-DPP IV inhibitor (sitagliptin = 1, vildagliptin = 1, saxagliptin = 2) versus insulin monotherapy, one with a thiazolidinedione (rosiglitazone) combined therapy and one with the combination insulin-ipragliflozin (approved in Japan). More details of these trials are given in <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>All trials included in this review had some methodological weaknesses according to the criteria set out in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>), and thus showed unclear or high risk of bias in several risk of bias domains (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<ALLOCATION MODIFIED="2016-07-25 11:40:17 +0200" MODIFIED_BY="[Empty name]">
<P>Only six trials (<LINK REF="STD-Barnett-2013" TYPE="STUDY">Barnett 2013</LINK>; <LINK REF="STD-Hermann-2001" TYPE="STUDY">Hermann 2001</LINK>; <LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK>; <LINK REF="STD-Reich-1987" TYPE="STUDY">Reich 1987</LINK>; <LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>) fully reported the method of randomisation and allocation concealment. For the remaining trials it was not possible to judge whether the sequence generation was adequate and if the allocation to the intervention and control groups was concealed.</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-07-26 17:08:26 +0200" MODIFIED_BY="Gudrun Paletta">
<P>The method of blinding was stated as open in four trials (<LINK REF="STD-Hong-2012" TYPE="STUDY">Hong 2012</LINK>; <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK>; <LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>). The majority of the trials were double-blinded. Mostly, it was unclear whether the researcher or the outcome assessor was blinded in addition to the participant. Risk of performance and detection bias was high for some outcomes in five trials (<LINK REF="STD-Casner-1988" TYPE="STUDY">Casner 1988</LINK>; <LINK REF="STD-Hong-2012" TYPE="STUDY">Hong 2012</LINK>; <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK>; <LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-07-25 11:40:17 +0200" MODIFIED_BY="[Empty name]">
<P>Eleven trials (<LINK REF="STD-Feinglos-1998" TYPE="STUDY">Feinglos 1998</LINK>; <LINK REF="STD-Fritsche-2000" TYPE="STUDY">Fritsche 2000</LINK>; <LINK REF="STD-Giugliano-1993" TYPE="STUDY">Giugliano 1993</LINK>; <LINK REF="STD-Kitabchi-1987" TYPE="STUDY">Kitabchi 1987</LINK>; <LINK REF="STD-Krawczyk-2005" TYPE="STUDY">Krawczyk 2005</LINK>; <LINK REF="STD-Lindstrom-1999" TYPE="STUDY">Lindstrom 1999</LINK>; <LINK REF="STD-Mauerhoff-1986" TYPE="STUDY">Mauerhoff 1986</LINK>; <LINK REF="STD-Mezitis-1992" TYPE="STUDY">Mezitis 1992</LINK>; <LINK REF="STD-Mudaliar-2010" TYPE="STUDY">Mudaliar 2010</LINK>; <LINK REF="STD-Quatraro-1986" TYPE="STUDY">Quatraro 1986</LINK>; <LINK REF="STD-Simpson-1990" TYPE="STUDY">Simpson 1990</LINK>), with rather small trial populations ranging from 12 to 50 participants, did not mention whether there were dropouts or whether there was excessive loss to follow-up. In thirteen trials (<LINK REF="STD-Avil_x00e9_s-1999" TYPE="STUDY">Avilés 1999</LINK>; <LINK REF="STD-Barnett-2013" TYPE="STUDY">Barnett 2013</LINK>; <LINK REF="STD-Casner-1988" TYPE="STUDY">Casner 1988</LINK>; <LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK>; <LINK REF="STD-Groop-1985" TYPE="STUDY">Groop 1985</LINK>; <LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>; <LINK REF="STD-Kyllastinen-1985" TYPE="STUDY">Kyllastinen 1985</LINK>; <LINK REF="STD-Lewitt-1989" TYPE="STUDY">Lewitt 1989</LINK>; <LINK REF="STD-Longnecker-1986" TYPE="STUDY">Longnecker 1986</LINK>; <LINK REF="STD-Osei-1984" TYPE="STUDY">Osei 1984</LINK>; <LINK REF="STD-Robinson-1998" TYPE="STUDY">Robinson 1998</LINK>; <LINK REF="STD-Stenman-1988" TYPE="STUDY">Stenman 1988</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>), dropouts were reported but no intention-to-treat analysis was executed or it was unclear whether it was done. In thirteen trials (<LINK REF="STD-Chiasson-1994" TYPE="STUDY">Chiasson 1994</LINK>; <LINK REF="STD-Fonseca-2007" TYPE="STUDY">Fonseca 2007</LINK>; <LINK REF="STD-Hermann-2001" TYPE="STUDY">Hermann 2001</LINK>; <LINK REF="STD-Hong-2012" TYPE="STUDY">Hong 2012</LINK>; <LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK>; <LINK REF="STD-Nemoto-2011" TYPE="STUDY">Nemoto 2011</LINK>; <LINK REF="STD-Reich-1987" TYPE="STUDY">Reich 1987</LINK>; <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK>; <LINK REF="STD-Rosenstock-2002" TYPE="STUDY">Rosenstock 2002</LINK>; <LINK REF="STD-Schade-1987" TYPE="STUDY">Schade 1987</LINK>; <LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK>; <LINK REF="STD-Wulffel_x00e9_-2002" TYPE="STUDY">Wulffelé 2002</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007)</LINK> dropouts were reported and intention-to-treat analysis was performed.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We judged five trials (<LINK REF="STD-Barnett-2013" TYPE="STUDY">Barnett 2013</LINK>; <LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK>; <LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>; <LINK REF="STD-Longnecker-1986" TYPE="STUDY">Longnecker 1986</LINK>; <LINK REF="STD-Mezitis-1992" TYPE="STUDY">Mezitis 1992</LINK>) to be at a high risk of bias for selective reporting, because some predefined outcomes were not reported. These outcomes (like level of liver enzymes or hormones) were often unimportant for the objective of this review.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>The sample size of trials ranged from 9 to 566 participants. Thirteen of the 37 trials had 30 or fewer participants. Only eight trials (<LINK REF="STD-Casner-1988" TYPE="STUDY">Casner 1988</LINK>; <LINK REF="STD-Chiasson-1994" TYPE="STUDY">Chiasson 1994</LINK>; <LINK REF="STD-Hermann-2001" TYPE="STUDY">Hermann 2001</LINK>; <LINK REF="STD-Hong-2012" TYPE="STUDY">Hong 2012</LINK>; <LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK>; <LINK REF="STD-Schade-1987" TYPE="STUDY">Schade 1987</LINK>; <LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK>; <LINK REF="STD-Wulffel_x00e9_-2002" TYPE="STUDY">Wulffelé 2002</LINK>) discussed power calculations. This might mean that potential significant differences across groups were difficult to detect. Follow-up periods differed between trials, ranging from 2 to 12 months. The outcome values of the trials with a short follow-up might have been different if the trial had been continued for a longer period. In all cross-over trials a cross-over design was suitable and no risks of a carry-over effect were found. Most trials were funded by pharmaceutical companies and often the overall outcome was in favour of the product of the sponsoring company.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We categorised comparisons according to the oral glucose-lowering agent that was added to insulin therapy. In the included trials we distinguished five groups of oral glucose-lowering agents: sulphonylureas, metformin, pioglitazone, alpha-glucosidase inhibitors and dipeptidyl-peptidase (DPP) 4-inhibitors. Categorisation regarding mode of insulin therapy (once-daily, twice-daily, or multiple daily injections) was not possible due to the often mixed use of number of insulin injections in participants in a trial or due to lack of reporting. We used a random-effects model for the meta-analyses.</P>
<P>None of the included trials assessed the primary outcomes of all-cause mortality, diabetes-related mortality or diabetes-related morbidity.</P>
<P>None of the included trials assessed the secondary outcome, health-related quality of life. Only one trial assessed patient satisfaction.</P>
<SUBSECTION>
<HEADING LEVEL="3">Insulin monotherapy versus insulin plus sulphonylurea</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events: hypoglycaemia</HEADING>
<P>Heterogeneity in the definitions used between trials, and the quality of reporting of hypoglycaemia precluded the pooling of data.</P>
<P>Eight trials reported hypoglycaemic events, quantitatively or qualitatively (<LINK REF="STD-Casner-1988" TYPE="STUDY">Casner 1988</LINK>; <LINK REF="STD-Feinglos-1998" TYPE="STUDY">Feinglos 1998</LINK>; <LINK REF="STD-Mauerhoff-1986" TYPE="STUDY">Mauerhoff 1986</LINK>; <LINK REF="STD-Reich-1987" TYPE="STUDY">Reich 1987</LINK>; <LINK REF="STD-Schade-1987" TYPE="STUDY">Schade 1987</LINK>; <LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK>; <LINK REF="STD-Simpson-1990" TYPE="STUDY">Simpson 1990</LINK>; <LINK REF="STD-Stenman-1988" TYPE="STUDY">Stenman 1988</LINK>). <LINK REF="STD-Feinglos-1998" TYPE="STUDY">Feinglos 1998</LINK> only reported the number of hypoglycaemic events for the total group: 69 mild events, six moderate events (glucose ranging from 1.2 to 3.0 mmol/L) and one severe event requiring assistance from another individual. <LINK REF="STD-Simpson-1990" TYPE="STUDY">Simpson 1990</LINK> reported that four out of nine participants on combination therapy had to reduce their treatment drug because of hypoglycaemic symptoms. <LINK REF="STD-Stenman-1988" TYPE="STUDY">Stenman 1988</LINK> reported more mild hypoglycaemic events with combination therapy (6.1 ± 1.0 events per participant; n = 13) than with insulin monotherapy (2.6 ± 1.0 events per patient; n = 8; P &lt; 0.01). No severe hypoglycaemic reactions requiring medical treatment occurred in this trial. <LINK REF="STD-Mauerhoff-1986" TYPE="STUDY">Mauerhoff 1986</LINK> and <LINK REF="STD-Schade-1987" TYPE="STUDY">Schade 1987</LINK> also counted more hypoglycaemic events with combination therapy than with insulin monotherapy (107 versus 25 and 6 versus 1, respectively). However, <LINK REF="STD-Reich-1987" TYPE="STUDY">Reich 1987</LINK> counted more events in insulin monotherapy than with combination therapy (10 versus 5 (of which three were biochemically confirmed)). <LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK> reported a similar number of mild hypoglycaemic episodes per participant (glimepiride 2.2 (37 episodes) versus insulin monotherapy 2.0 (34 episodes)). No episodes of severe hypoglycaemia (i.e. the need for intravenous glucose or glucagon injection) were reported in this trial. <LINK REF="STD-Casner-1988" TYPE="STUDY">Casner 1988</LINK> qualitatively reported similar rates of mild hypoglycaemia for both regimens.</P>
<P>We rated this as low-quality evidence, because of indirectness and risk of bias. In most trials randomisation and allocation concealment were unclear, in all trials blinding of the outcome assessor was unclear, and four of the eight trials were funded by a pharmaceutical company. In addition, heterogeneity in the definitions used between trials precluded pooling of data. Serious hypoglycaemic episodes were rare.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other adverse events</HEADING>
<P>One trial investigating the addition of sulphonylurea to insulin therapy reported one myocardial infarction during the insulin-sulphonylurea combination period (<LINK REF="STD-Schade-1987" TYPE="STUDY">Schade 1987</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events: weight gain</HEADING>
<P>Seven trials (intervention period ranging from two months to one year) reported data on weight change. In six comparisons (<LINK REF="STD-Casner-1988" TYPE="STUDY">Casner 1988</LINK>; <LINK REF="STD-Kyllastinen-1985" TYPE="STUDY">Kyllastinen 1985</LINK>; <LINK REF="STD-Lindstrom-1999" TYPE="STUDY">Lindstrom 1999</LINK>; <LINK REF="STD-Mauerhoff-1986" TYPE="STUDY">Mauerhoff 1986</LINK>; <LINK REF="STD-Schade-1987" TYPE="STUDY">Schade 1987</LINK>; <LINK REF="STD-Stenman-1988" TYPE="STUDY">Stenman 1988</LINK>) the addition of glibenclamide was compared with insulin monotherapy and in one trial tolazamide was added (<LINK REF="STD-Kitabchi-1987" TYPE="STUDY">Kitabchi 1987</LINK>). The addition of sulphonylureas to insulin resulted in an additional weight gain of 0.4 kg to 1.9 kg compared to -0.8 kg to 2.1 kg in the insulin monotherapy group (220 participants; 7 trials; low-quality evidence; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The mean difference (MD) in weight change from baseline for the insulin-sulphonylurea combination therapy compared to insulin monotherapy of the trials with a parallel design (1.1 kg (95% CI -3.1 to 5.3; P = 0.60; 86 participants; 2 trials) showed a weight gain, whereas the MD in weight change from baseline of the trials with a cross-over design ranged between -1 kg to 0.4 kg (134 participants; 5 trials; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>The sensitivity analysis for the effect of trial duration indicated that, after excluding the only long-term trial (<LINK REF="STD-Casner-1988" TYPE="STUDY">Casner 1988</LINK>), the effect on weight remained largely the same. Also, the sensitivity analysis excluding trials with high risk of bias (<LINK REF="STD-Casner-1988" TYPE="STUDY">Casner 1988</LINK>; <LINK REF="STD-Kitabchi-1987" TYPE="STUDY">Kitabchi 1987</LINK>; <LINK REF="STD-Kyllastinen-1985" TYPE="STUDY">Kyllastinen 1985</LINK>; <LINK REF="STD-Stenman-1988" TYPE="STUDY">Stenman 1988</LINK>) indicated that these trials had only very modest effects on the association between insulin-sulphonylurea combination therapy and change in weight.</P>
<P>We rated this as low-quality evidence, because of indirectness and risk of bias. In most trials randomisation and allocation concealment were unclear, in all trials blinding of the outcome assessor was unclear, and four of the six trials were funded by a pharmaceutical company.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c and fasting glucose</HEADING>
<P>In 12 comparisons the addition of glibenclamide to insulin therapy was compared to insulin monotherapy. In two comparisons (<LINK REF="STD-Feinglos-1998" TYPE="STUDY">Feinglos 1998</LINK>; <LINK REF="STD-Simpson-1990" TYPE="STUDY">Simpson 1990</LINK>) glipizide was added, in two comparisons tolazamide was added (<LINK REF="STD-Kitabchi-1987" TYPE="STUDY">Kitabchi 1987</LINK>; <LINK REF="STD-Longnecker-1986" TYPE="STUDY">Longnecker 1986</LINK>), in one comparison glimepiride was added (<LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK>) and in one comparison gliclazide was added (<LINK REF="STD-Quatraro-1986" TYPE="STUDY">Quatraro 1986</LINK>). We pooled data in a meta-analysis on HbA1c from nine comparisons (glibenclamide n = 6, gliclazide n = 1, glimepiride n = 1, tolazamide n = 1), with the intervention period ranging from 2 to 12 months (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Insulin-sulfphonylurea combination therapy compared with insulin monotherapy was associated with a pooled MD in lowering of HbA1c of -1.0% (95% CI -1.6 to -0.5; P = 0.0003; participants = 316 participants; 9 trials; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> and <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). In one trial (<LINK REF="STD-Casner-1988" TYPE="STUDY">Casner 1988</LINK>) metabolic control (glycohaemoglobin) increased less in the intervention than in the control group after a follow-up of one year. In addition, it was not clear whether glycohaemoglobin referred to HbA or HbA1c. After exclusion of this trial the MD did not change substantially.</P>
<P>Insulin-sulphonylurea combination was also associated with a MD in lowering of fasting glucose of -2.29 mmol/L (95% CI -3.23 to -1.35; P &lt; 0.00001; 205 participants; 6 trials; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK> and <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). This was calculated with pooled data from three different sulphonylurea compounds (glibenclamide, glimepiride, tolazamide).</P>
<P>The sensitivity analysis excluding long-term trials (<LINK REF="STD-Casner-1988" TYPE="STUDY">Casner 1988</LINK>; <LINK REF="STD-Quatraro-1986" TYPE="STUDY">Quatraro 1986</LINK>) indicated that there was some impact of long-term trials on the effect on HbA1c. Without these trials, insulin-sulphonylurea combination therapy was associated with a MD in lowering of HbA1c of -0.8% (95% CI -1.2 to -0.3; P = 0.001) compared to insulin monotherapy. There was no impact of the long-term trial (<LINK REF="STD-Casner-1988" TYPE="STUDY">Casner 1988</LINK>) on the effect on fasting glucose; the MD in lowering of fasting glucose was -2.41 mmol/L (95% CI -3.44 to -1.37; P &lt; 0.00001).</P>
<P>All trials pooled in the meta-analysis on HbA1c and fasting glucose, except <LINK REF="STD-Schade-1987" TYPE="STUDY">Schade 1987</LINK>, had a high risk of bias in some domain. The MD in HbA1c of the trials with a parallel design was higher compared to the MD in HbA1c of the trials with a cross-over design (-1.3% (95% CI -2.6 to 0.1; P = 0.06; 150 participants; 4 trials) versus -1% (95% CI -1.4 to -0.5; P &lt; 0.00001; 166 participants; 5 trials) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). We had to impute SDs for all cross-over trials.</P>
<P>In contrast, for fasting glucose, the pooled effect of trials with a parallel design was substantially lower -1.02 mmol/L (95% CI -2.48 to 0.44; P = 0.17; 71 participants; 2 trials) compared to the pooled effect of the trials with a cross-over design -2.73 mmol/L (95% CI -3.70 to -1.75; P &lt; 0.00001; 134 participants; 4 trials; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK> and <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>We rated this as low-quality evidence, because of indirectness and risk of bias. In most trials randomisation and allocation concealment were unclear, in all trials blinding of the outcome assessor was unclear, and four of the nine trials were funded by a pharmaceutical company.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lipids</HEADING>
<P>We pooled data from five trials in a meta-analysis on total cholesterol (<LINK REF="STD-Groop-1985" TYPE="STUDY">Groop 1985</LINK>; <LINK REF="STD-Kitabchi-1987" TYPE="STUDY">Kitabchi 1987</LINK>; <LINK REF="STD-Lindstrom-1999" TYPE="STUDY">Lindstrom 1999</LINK>; <LINK REF="STD-Osei-1984" TYPE="STUDY">Osei 1984</LINK>; <LINK REF="STD-Stenman-1988" TYPE="STUDY">Stenman 1988</LINK>). Insulin-sulphonylurea combination therapy compared to insulin monotherapy was associated with a MD in change from baseline in total cholesterol of -0.04 mmol/L (95% CI -0.2 to 0.1; P = 0.52, 132 participants; 5 trials; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK> and <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). The same trials showed comparable results for HDL-cholesterol and triglycerides: the MD was -0.1 mmol/L (95% CI -0.2 to 0.1; P = 0.31; 108 participants; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK> and <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>) and 0.04 mmol/L (95% CI -0.2 to 0.3; P = 0.76; 132 participants; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK> and <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>), respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Insulin dose</HEADING>
<P>Heterogeneity in type of insulin (short-, intermediate- and long-acting), units of quantification and the quality of reporting precluded the pooling of data.</P>
<P>
<LINK REF="STD-Kyllastinen-1985" TYPE="STUDY">Kyllastinen 1985</LINK>; <LINK REF="STD-Longnecker-1986" TYPE="STUDY">Longnecker 1986</LINK>; <LINK REF="STD-Osei-1984" TYPE="STUDY">Osei 1984</LINK> reported a fixed insulin dose during the trial period. <LINK REF="STD-Casner-1988" TYPE="STUDY">Casner 1988</LINK> reported a decreased mean insulin dose over the trial period in the insulin-sulphonylurea therapy group of -4 U and an increase in the insulin dose in the placebo group of 12 U. Almost no change in mean insulin amount was reported by <LINK REF="STD-Mauerhoff-1986" TYPE="STUDY">Mauerhoff 1986</LINK>: -0.04 difference in insulin dose in the insulin-sulphonylurea-treated participants versus 0.02 in the placebo-treated participants. <LINK REF="STD-Kitabchi-1987" TYPE="STUDY">Kitabchi 1987</LINK> reported a mean (SD) insulin amount of 0.7 (0.01) U/kg body weight in the insulin-sulphonylurea therapy group versus 0.9 (0.08) U/kg body weight in the placebo group at six months. In case of unexplained hypoglycaemia, insulin dose was changed in the trial by <LINK REF="STD-Lewitt-1989" TYPE="STUDY">Lewitt 1989</LINK> and <LINK REF="STD-Stenman-1988" TYPE="STUDY">Stenman 1988</LINK>. <LINK REF="STD-Lewitt-1989" TYPE="STUDY">Lewitt 1989</LINK> reported a mean decrease in insulin amount of -4 U after the insulin-sulphonylurea period versus -1 U after the placebo period. <LINK REF="STD-Stenman-1988" TYPE="STUDY">Stenman 1988</LINK> reported a 2 U to 4 U/visit increase by reported hypoglycaemia or if fasting glucose was less than 6.0 mmol/L, after the insulin-sulphonylurea period a mean (SD) of 24 (3) U was found compared with 32 (4) U after the placebo period. <LINK REF="STD-Lindstrom-1999" TYPE="STUDY">Lindstrom 1999</LINK> reported a mean (SD) of 54 (7) U at the end of the run-in period, which decreased to 45 (8) U after the insulin-sulphonylurea therapy period versus an increase to 61 (6) after the placebo period. <LINK REF="STD-Quatraro-1986" TYPE="STUDY">Quatraro 1986</LINK> reported a mean decrease of 33 U (mean (SD): 57 (4) U) after insulin-SU therapy versus a mean decrease of 3 U (mean (SD): 85 (6) U) after placebo treatment. <LINK REF="STD-Schade-1987" TYPE="STUDY">Schade 1987</LINK> reported comparable mean (SD) insulin dose after the insulin-sulphonylurea period (54 (6) U) and the placebo period (55 (6) U). <LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK> reported a mean (95%CI) decrease in insulin dose in the insulin-sulphonylurea therapy group from 36 (10 to 62) to 26 (10 to 54) compared with no change in the placebo group from 31 (14 to112) U at both measurements.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Insulin monotherapy versus insulin plus metformin</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events: hypoglycaemia</HEADING>
<P>Heterogeneity in the definitions used between trials, and the quality of reporting of hypoglycaemia precluded the pooling of data.</P>
<P>All but three trials (<LINK REF="STD-Fritsche-2000" TYPE="STUDY">Fritsche 2000</LINK>; <LINK REF="STD-Giugliano-1993" TYPE="STUDY">Giugliano 1993</LINK>; <LINK REF="STD-Krawczyk-2005" TYPE="STUDY">Krawczyk 2005</LINK>) reported hypoglycaemic events, quantitatively or qualitatively. <LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK> and <LINK REF="STD-Robinson-1998" TYPE="STUDY">Robinson 1998</LINK> only reported that no severe hypoglycaemia occurred. <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK> reported qualitatively that some minor hypoglycaemic events took place in both groups. <LINK REF="STD-Avil_x00e9_s-1999" TYPE="STUDY">Avilés 1999</LINK> reported three hypoglycaemic events in the insulin-metformin group (with blood glucose levels ranging from 3.1 to 3.9 mmol/L). <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK> reported a similar occurrence of hypoglycaemic events (n = 2 in both groups). None of the participants experienced severe hypoglycaemia in this trial. <LINK REF="STD-Hermann-2001" TYPE="STUDY">Hermann 2001</LINK> reported two versus zero hypoglycaemic events in the combination therapy group compared with the insulin monotherapy group. Also, <LINK REF="STD-Wulffel_x00e9_-2002" TYPE="STUDY">Wulffelé 2002</LINK> reported comparable occurrences of hypoglycaemic events per person per month in both treatment groups (P = 0.477). Eight events in the metformin group and four in the control group required partner assistance, and none required medical assistance. <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK> reported less mild hypoglycaemia with insulin plus metformin compared to insulin alone (0.6 versus two episodes per participant per month; P &lt; 0.01). In this trial, one participant taking insulin alone experienced six episodes of hypoglycaemia severe enough to require assistance, including emergency medical treatment.</P>
<P>We rated this as low-quality evidence, because of indirectness and risk of bias. In most trials randomisation and allocation concealment were unclear, in all trials blinding of the outcome assessor was unclear, five of the eight included trials were funded by a pharmaceutical company, and in one trial funding was unclear. In addition, heterogeneity in the definitions used between trials precluded pooling; serious hypoglycaemic episodes were rare. In the largest trial (n = 353; <LINK REF="STD-Wulffel_x00e9_-2002" TYPE="STUDY">Wulffelé 2002</LINK>) no substantial difference in hypoglycaemic episodes between groups was found.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other adverse events</HEADING>
<P>Seven trials regarding the addition of metformin reported the number of gastro-intestinal symptoms. The percentage of participants treated with insulin-metformin combination therapy having gastro-intestinal complaints ranged from 7% to 67%, and was mostly higher than in the insulin monotherapy group (<LINK REF="STD-Avil_x00e9_s-1999" TYPE="STUDY">Avilés 1999</LINK>; <LINK REF="STD-Giugliano-1993" TYPE="STUDY">Giugliano 1993</LINK>; <LINK REF="STD-Hermann-2001" TYPE="STUDY">Hermann 2001</LINK>; <LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>; <LINK REF="STD-Wulffel_x00e9_-2002" TYPE="STUDY">Wulffelé 2002</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>). Some trials mentioned that gastro-intestinal complaints resolved spontaneously. <LINK REF="STD-Hermann-2001" TYPE="STUDY">Hermann 2001</LINK> reported one myocardial infarction in the metformin-treated group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events: weight gain</HEADING>
<P>Data from seven trials (intervention period ranging from three to six months) were pooled in a meta-analysis on weight (<LINK REF="STD-Avil_x00e9_s-1999" TYPE="STUDY">Avilés 1999</LINK>; <LINK REF="STD-Krawczyk-2005" TYPE="STUDY">Krawczyk 2005</LINK>; <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK>; <LINK REF="STD-Robinson-1998" TYPE="STUDY">Robinson 1998</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>; <LINK REF="STD-Wulffel_x00e9_-2002" TYPE="STUDY">Wulffelé 2002</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>). Insulin-metformin combination therapy compared to insulin monotherapy was associated with a MD of 2.1 kg less weight gain (95% CI -3.2 to -1.1 kg; P = 0.0001; 615 participants; 7 trials; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> and <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>A sensitivity analysis for the effect of trial duration indicated that after excluding long-term trials (<LINK REF="STD-Avil_x00e9_s-1999" TYPE="STUDY">Avilés 1999</LINK>; <LINK REF="STD-Krawczyk-2005" TYPE="STUDY">Krawczyk 2005</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>) there was still less weight gain in the intervention group (-1.7 kg (95% CI -2.9 to -0.4); P = 0.009; 496 participants; 4 trials). All trials pooled in the meta-analysis on weight, except <LINK REF="STD-Wulffel_x00e9_-2002" TYPE="STUDY">Wulffelé 2002</LINK>, had some high or unclear risk of bias. The only cross-over trial that was used for pooling in the meta-analysis (<LINK REF="STD-Robinson-1998" TYPE="STUDY">Robinson 1998</LINK>) had a similar result on weight gain compared to the trials with a parallel design.</P>
<P>We rated this as low-quality evidence, because of indirectness and risk of bias. In most trials randomisation and allocation concealment were unclear, in all trials blinding of the outcome assessor was unclear, five of the seven included trials were funded by a pharmaceutical company, and in one trial funding was unclear.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c and fasting glucose</HEADING>
<P>Eleven trials compared the addition of metformin to insulin therapy with insulin monotherapy. We pooled data from nine comparisons in a meta-analysis, with the intervention period ranging from two to six months (<LINK REF="STD-Avil_x00e9_s-1999" TYPE="STUDY">Avilés 1999</LINK>; <LINK REF="STD-Fritsche-2000" TYPE="STUDY">Fritsche 2000</LINK>; <LINK REF="STD-Giugliano-1993" TYPE="STUDY">Giugliano 1993</LINK>; <LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>; <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK>; <LINK REF="STD-Robinson-1998" TYPE="STUDY">Robinson 1998</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>; <LINK REF="STD-Wulffel_x00e9_-2002" TYPE="STUDY">Wulffelé 2002</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>). Insulin-metformin combination therapy compared to insulin monotherapy was associated with a MD in lowering of HbA1c of -0.9% (95% CI -1.2 to -0.5); P &lt; 0.00001; 698 participants; 9 trials; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK> and <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
<P>Because of considerable heterogeneity it was not possible to pool the results of insulin-metformin combination therapy on fasting glucose. However, the MD in fasting glucose (insulin-metformin combination therapy compared with insulin monotherapy; n = 6 trials) ranged from -5.7 to 1.1 mmol/L. The sensitivity analysis excluding long-term trials (<LINK REF="STD-Avil_x00e9_s-1999" TYPE="STUDY">Avilés 1999</LINK>; <LINK REF="STD-Giugliano-1993" TYPE="STUDY">Giugliano 1993</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>) indicated that these trials had hardly any impact on the association between insulin-metformin combination therapy and lowering of HbA1c (MD -0.8% (95% CI -1.3 to -0.3); P = 0.001).The sensitivity analysis excluding trials with high risk of bias (<LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>; <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>) indicated that these trials also had almost no impact on the effect of insulin-metformin combination therapy on HbA1c (MD -1.0% (95% CI -1.3 to -0.6); P &lt; 0.0001; 546 participants; 6 trials). The MD in HbA1c of the trials with a parallel design was smaller compared to the MD in HbA1c of the trials with a cross-over design (-0.8%, 95% CI -1.1 to -0.4; P &lt; 0.0001; 634 participants; 7 trials; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK> versus -1.2%, 95% CI -2.1 to -0.2; P = 0.02; 64 participants; 2 trials; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK> and <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
<P>We rated this as low-quality evidence, because of indirectness and risk of bias. In most trials randomisation and allocation concealment were unclear, in all trials blinding of the outcome assessor was unclear, five of the nine included trials were funded by a pharmaceutical company, and in one trial funding was unclear.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lipids</HEADING>
<P>We pooled data from eight trials in a meta-analysis on total cholesterol (<LINK REF="STD-Avil_x00e9_s-1999" TYPE="STUDY">Avilés 1999</LINK>; <LINK REF="STD-Fritsche-2000" TYPE="STUDY">Fritsche 2000</LINK>; <LINK REF="STD-Giugliano-1993" TYPE="STUDY">Giugliano 1993</LINK>; <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK>; <LINK REF="STD-Robinson-1998" TYPE="STUDY">Robinson 1998</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>; <LINK REF="STD-Wulffel_x00e9_-2002" TYPE="STUDY">Wulffelé 2002</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>). Insulin-metformin combination therapy compared to insulin monotherapy was associated with a MD in decrease of total cholesterol of -0.3 mmol/L (95% CI -0.5 to -0.1; P = 0.01; 651 participants; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK> and <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). The same pooled trials showed the following MDs for differences in HDL-cholesterol and triglycerides: MD for HDL-cholesterol 0.0 mmol/L (95% CI -0.1 to 0.0); P = 0.65; 651 participants; <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK> and <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK> and MD for triglycerides -0.2 mmol/L (95% CI -0.4 to 0.1); P = 0.26; 651 participants; <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK> and <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Insulin dose</HEADING>
<P>Heterogeneity in type of insulin (short-, intermediate- and long-acting), units of quantification and the quality of reporting precluded the pooling of data.</P>
<P>Ten
 
of the 11 trials provided information about insulin requirements. One trial did not report the numbers of insulin doses, it only mentioned that there were no differences in insulin requirements (<LINK REF="STD-Hirsch-1999" TYPE="STUDY">Hirsch 1999</LINK>). Insulin doses were titrated to predetermined glycaemic targets based on fasting, postprandial or both glucose values in five trials (<LINK REF="STD-Avil_x00e9_s-1999" TYPE="STUDY">Avilés 1999</LINK>; <LINK REF="STD-Fritsche-2000" TYPE="STUDY">Fritsche 2000</LINK>; <LINK REF="STD-Hermann-2001" TYPE="STUDY">Hermann 2001</LINK>; <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK>; <LINK REF="STD-Wulffel_x00e9_-2002" TYPE="STUDY">Wulffelé 2002</LINK>). <LINK REF="STD-Avil_x00e9_s-1999" TYPE="STUDY">Avilés 1999</LINK> reported a decrease in insulin dose in participants treated with metformin of 5 U/d (95% CI -17 to 8; P &gt; 0.2) and an increase in insulin dose of 23 U/d (95% CI 11 to 35; P &lt; 0.001) in participants treated with placebo. Also, <LINK REF="STD-Strowig-2002" TYPE="STUDY">Strowig 2002</LINK> and <LINK REF="STD-Wulffel_x00e9_-2002" TYPE="STUDY">Wulffelé 2002</LINK> reported a decrease in mean total daily insulin dose in the insulin plus metformin group (from 83 U at baseline to 82 U at week 16 and a change of 7 U (95% CI -6 to -9), respectively) and an increase in total daily insulin dosage in the group treated with insulin alone (from 80 U to 135 U and a change of 1 U (95% CI 0.3 to 3), respectively). <LINK REF="STD-Fritsche-2000" TYPE="STUDY">Fritsche 2000</LINK> (cross-over trial) reported that total insulin requirements decreased by one-third during the metformin treatment (from 53 U (SD 10) to 35 U (SD 7); P = 0.006), while insulin requirements were unchanged during the placebo phase (metformin versus placebo; P = 0.02). In contrast, <LINK REF="STD-Hermann-2001" TYPE="STUDY">Hermann 2001</LINK> reported no change in mean daily insulin dose after treatment, neither after metformin treatment (0.8 U/kg/day at baseline versus 0.8 U/kg/day after treatment) nor after treatment with placebo (0.7 U/kg/day at baseline versus 0.8 U/kg/day after treatment). In two trials insulin doses were titrated if hypoglycaemia occurred (<LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>). <LINK REF="STD-Relimpio-1998" TYPE="STUDY">Relimpio 1998</LINK> reported a small reduction in insulin dose during the trial in the insulin plus metformin group (from 0.63 U/kg (SD 0.1) at baseline to 0.6 U/kg (SD 0.2) at the end of trial), while in participants assigned to insulin there was an increase in insulin dose from 0.7 U/kg (SD 0.1) at baseline to 0.8 U/kg (SD 0.14) at the end of trial. Also, <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK> reported a decrease in participants treated with insulin in combination with metformin (4.2/day; P &lt; 0.001) and an increase in total daily insulin dose in participants treated with insulin alone (12.8 U/day; P &lt; 0.001). Three trials did not report any targets to which insulin doses were titrated (<LINK REF="STD-Giugliano-1993" TYPE="STUDY">Giugliano 1993</LINK>; <LINK REF="STD-Krawczyk-2005" TYPE="STUDY">Krawczyk 2005</LINK>; <LINK REF="STD-Robinson-1998" TYPE="STUDY">Robinson 1998</LINK>). <LINK REF="STD-Giugliano-1993" TYPE="STUDY">Giugliano 1993</LINK> reported a decrease in daily insulin dose in participants treated with insulin in combination with metformin (from 90 U (SD 9) at baseline to 68 U (SD 18) at six months' follow-up) while the daily insulin dose remained constant in the participants treated with insulin and placebo (from 88 U (SD 9) at baseline to 86 U(SD 9) at six months' follow-up). <LINK REF="STD-Krawczyk-2005" TYPE="STUDY">Krawczyk 2005</LINK> also reported a decrease in insulin requirement in participants treated with insulin and metformin (from 0.6 U/kg (SD 0.1) at baseline to 0.6 U/kg (SD 0.2) at follow-up; P &lt; 0.05). But in this trial, insulin requirements significantly increased from 0.6 U/kg (SD .0.1) at baseline to 0.6 U/kg (SD 0.2) at follow-up (P &lt; 0.05) in the control group. <LINK REF="STD-Robinson-1998" TYPE="STUDY">Robinson 1998</LINK> (cross-over trial) reported a relatively constant daily insulin dosage in the insulin plus metformin phase as well as the insulin plus placebo phase (mean change during metformin -2 U; mean change during placebo +0.6 U).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Insulin monotherapy versus insulin plus glimepiride versus insulin plus metformin and glimepiride</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events: hypoglycaemia</HEADING>
<P>
<LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK> reported a comparable number of mild hypoglycaemic events with the addition of glimepiride and metformin to insulin (2.3 episodes per participant) and with insulin monotherapy (2.0 episodes per participant). No episodes of severe hypoglycaemia (that is, the need for intravenous glucose of glucagon injection) were reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events: weight gain</HEADING>
<P>
<LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK> reported minor differences regarding weight gain between the addition of glimepiride and metformin to insulin and insulin monotherapy.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Patient satisfaction</HEADING>
<P>
<LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK> assessed patients' treatment satisfaction with the 'Diabetes Treatment Satisfaction Questionnaire'. They found no statistically significant differences between the addition of glimepiride to insulin, the addition of both metformin and glimepiride to insulin or insulin monotherapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c and fasting glucose</HEADING>
<P>Insulin plus metformin and glimepiride (<LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK>) showed a greater reduction of HbA1c (-0.7% (SD 0.9)) than the addition of glimepiride to insulin alone (-0.4% (SD 0.5)) or compared with insulin monotherapy (-0.3% (SD 1.0)). The same applied to fasting glucose levels.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lipids</HEADING>
<P>Data on lipids were not collected.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Insulin dose</HEADING>
<P>
<LINK REF="STD-Schiel-2007" TYPE="STUDY">Schiel 2007</LINK> reported a decrease in insulin requirements in the insulin plus glimepiride and metformin group (from 65 U/day (SD 32) to 54 U/day (SD 37); P = 0.009), whereas there was an increase in the insulin monotherapy group (65 U/day (SD 34) to 71 U/day (SD 35); P = 0.009).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Insulin monotherapy versus insulin plus pioglitazone</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events: hypoglycaemia</HEADING>
<P>Heterogeneity in the definitions used between trials, and the quality of reporting of hypoglycaemia precluded the pooling of data.</P>
<P>Two trials reported, quantitatively, hypoglycaemic events. <LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK> reported more subjective hypoglycaemia with insulin plus pioglitazone than with insulin monotherapy (90 events (63%) versus 75 (51%); P &lt; 0.05). They reported that they found no differences in the number of clinical hypoglycaemic episodes (blood glucose &lt; 2.8 mmol/L), but numbers were not reported. <LINK REF="STD-Rosenstock-2002" TYPE="STUDY">Rosenstock 2002</LINK> reported that 29 participants (15%) in the 30 mg pioglitazone group, 15 participants (8%) in the 15 mg pioglitazone group, and nine participants (5%) in the placebo group reported hypoglycaemia. All hypoglycaemic episodes were considered mild or moderate.</P>
<P>We rated this as low-quality evidence, because of serious risk of bias. Only one trial reported adequate randomisation and allocation concealment, blinding of the outcome assessor was unclear in all of the trials, and all of the trials were funded by a pharmaceutical company.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other adverse events</HEADING>
<P>Two trials regarding the addition of pioglitazone reported a higher frequency of oedema with the use of pioglitazone, which increased with dose. <LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK> reported percentages of 16% versus 4% (pioglitazone 30 mg versus placebo) and <LINK REF="STD-Rosenstock-2002" TYPE="STUDY">Rosenstock 2002</LINK> reported 18% and 13% versus 7% (pioglitazone 30 mg and 15 mg versus placebo). In addition, <LINK REF="STD-Rosenstock-2002" TYPE="STUDY">Rosenstock 2002</LINK> reported congestive heart failure for two participants receiving 15 mg pioglitazone and two participants receiving 30 mg pioglitazone.</P>
<P>We rated this as low quality evidence, because of indirectness, imprecision and risk of bias; only one from the two included trials reported adequate randomisation and allocation concealment, in all trials blinding of the outcome assessor was unclear and all trials were funded by a pharmaceutical company.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events: weight gain</HEADING>
<P>We pooled data from two trials (intervention period ranging from three to six months) in a meta-analysis on weight (<LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK>; <LINK REF="STD-Mudaliar-2010" TYPE="STUDY">Mudaliar 2010</LINK>). Insulin-pioglitazone combination compared to insulin monotherapy was associated with more weight gain (MD 3.8 kg (95% CI 3.0 to 4.6); P &lt; 0.00001; 288 participants; 2 trials; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). The multi-intervention trial (<LINK REF="STD-Rosenstock-2002" TYPE="STUDY">Rosenstock 2002</LINK>) showed a greater increase in weight (1.9 kg to 5.3 kg) with combination therapy than with insulin monotherapy (-0.04 kg to 0.9 kg). Weight increased with increasing dosage of pioglitazone.</P>
<P>We rated this as low-quality evidence, because of indirectness, imprecision and risk of bias. Only one of the three trials reported adequate randomisation and allocation concealment, in all trials blinding of the outcome assessor was unclear, and all trials were funded by a pharmaceutical company. Although the number of included participants in the meta analysis was low, the minimum of 1.9 kg weight gain is clinically relevant, because it may be partially caused by oedema.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c and fasting glucose</HEADING>
<P>Three trials (<LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK>; <LINK REF="STD-Mudaliar-2010" TYPE="STUDY">Mudaliar 2010</LINK>; <LINK REF="STD-Rosenstock-2002" TYPE="STUDY">Rosenstock 2002</LINK>) compared the addition of pioglitazone to insulin therapy with insulin monotherapy. Because of missing SDs we could not perform a meta-analysis. The mean difference in HbA1c for insulin-pioglitazone combination therapy ranged from -0.5% to -1.0% and for insulin monotherapy from -0.6% to 0% (785 participants; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>We pooled data from three comparisons, with the intervention period ranging from three to six months, in a meta-analysis to investigate the effect on fasting glucose (<LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK>; <LINK REF="STD-Mudaliar-2010" TYPE="STUDY">Mudaliar 2010</LINK>; <LINK REF="STD-Rosenstock-2002" TYPE="STUDY">Rosenstock 2002</LINK>). We only included the results of the comparison pioglitazone 30 mg versus placebo from <LINK REF="STD-Rosenstock-2002" TYPE="STUDY">Rosenstock 2002</LINK>. We did not use the results of the comparison between the addition of pioglitazone 15 mg versus placebo in the meta-analysis because it comprised the same placebo group. Insulin-pioglitazone combination therapy showed a greater variation in change in fasting glucose (-1.5 mmol/L to 2.7 mmol/L) compared to insulin monotherapy (-0.6 mmol/L to 0.7 mmol/L) (624 participants; 3 trials; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
<P>The sensitivity analysis excluding the long-term trial (<LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK>) indicated that this trial had only a small impact on the association between insulin-pioglitazone combination therapy and lowering of fasting glucose (-2.1 mmol/L (95% CI -3.8 to -0.4); P = 0.02).</P>
<P>We rated this as low-quality evidence, because of indirectness, imprecision and risk of bias. Only one of the three trials reported adequate randomisation and allocation concealment, in all trials blinding of the outcome assessor was unclear, and all trials were funded by a pharmaceutical company.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lipids</HEADING>
<P>Two trials reported data on HDL-cholesterol and LDL-cholesterol (<LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK>; <LINK REF="STD-Rosenstock-2002" TYPE="STUDY">Rosenstock 2002</LINK>), <LINK REF="STD-Rosenstock-2002" TYPE="STUDY">Rosenstock 2002</LINK> also reported data on total cholesterol and triglycerides.</P>
<P>
<LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK> reported a small mean (SE) increase in HDL-cholesterol in participants treated with insulin-pioglitazone combination therapy (from 1.2 (0.03) to 1.4 (0.02) mmol/L) and a small mean (SE) decrease in the placebo group (from 1.2 (0.03) to 1.2 (0.02) mmol/L). For LDL-cholesterol a small mean (SE) reduction in both groups was found (from 3.2 (0.1) to 3.2 (0.1) mmol/L in the insulin-pioglitazone combination therapy group versus 3.2 (0.1) to 3.1 (0.1) mmol/L in the placebo groups.</P>
<P>
<LINK REF="STD-Rosenstock-2002" TYPE="STUDY">Rosenstock 2002</LINK> investigated two different doses of pioglitazone (15 mg and 30 mg). In this trial a mean change (SD) in total cholesterol of 1.4 (1.1) mg/dL in the 15 mg pioglitazone group and of 0.4 (1.1) mg/dL in the 30 mg pioglitazone group versus -0.7 (1.1) mg/dL in the placebo group was found. For HDL-cholesterol mean change (SD) of 7.1 (1.6) mg/dL in the 15 mg pioglitazone group and of 9.1 (1.6) mg/dL in the 30 mg pioglitazone group versus -0.2 (1.6) mg/dL in the placebo group was found. For LDL-cholesterol a mean change (SD) of 5.1 (1.7) mg/dL in the 15 mg pioglitazone group and of 2.8 (1.8) mg/dL in the 30 mg pioglitazone group versus -1.4 (1.7) mg/dL in the placebo group was found. For triglycerides a mean (SD) change of 5.4 (6.6) mg/dL in the 15 mg pioglitazone group and of -10.4 (6.5) mg/dL in the 30 mg pioglitazone group versus 13.3 (6.6) mg/dL in the placebo group was found.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Insulin dose</HEADING>
<P>Heterogeneity in type of insulin (short, intermediate and long acting), units of quantification and the quality of reporting precluded the pooling of data.</P>
<P>All trials provided information about insulin requirements. Insulin doses were titrated to predetermined glycaemic targets based on fasting, postprandial or both glucose values in two trials (<LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK>; <LINK REF="STD-Mudaliar-2010" TYPE="STUDY">Mudaliar 2010</LINK>). <LINK REF="STD-Mattoo-2005" TYPE="STUDY">Mattoo 2005</LINK> reported a mean (SE) reduction in insulin dose in participants treated with insulin in combination with pioglitazone of -0.2 U/d/kg (0.02) - P &lt; 0.002; in participants treated with insulin in combination with placebo they found no change in insulin dose (from 0.9 U/d/kg (0.03) at baseline to 0.9 U/d/kg (0.02) at trial end point). <LINK REF="STD-Mudaliar-2010" TYPE="STUDY">Mudaliar 2010</LINK> also reported a decrease in insulin dose in the insulin plus pioglitazone group (from 105 U (SD 22) to 92 U (SD19)) but they found an increase in insulin dose in the insulin plus placebo group (from 114 U (SD 11) to 127 U (SD 16). <LINK REF="STD-Rosenstock-2002" TYPE="STUDY">Rosenstock 2002</LINK> investigated two different doses of pioglitazone (15 mg and 30 mg). In this trial insulin doses were only titrated if hypoglycaemia occurred. Total daily insulin dose remained stable in participants with insulin monotherapy (71 U (SD 34) at screening versus 70 U (SD 34) at the end of treatment), but decreased in participants with insulin-pioglitazone combination therapy (pioglitazone 15 mg: 70 U (SD 34) at screening versus 67 U (SD 34) at the end of treatment; pioglitazone 30 mg: 72 U(SD 39) at screening versus 64 U (SD33) at the end of treatment.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Insulin monotherapy versus insulin plus alpha-glucosidase inhibitor</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events: hypoglycaemia</HEADING>
<P>Heterogeneity in the definitions used between trials, and the quality of reporting of hypoglycaemia precluded the pooling of data.</P>
<P>All trials reported, quantitatively, hypoglycaemic events. <LINK REF="STD-Chiasson-1994" TYPE="STUDY">Chiasson 1994</LINK> reported one severe hypoglycaemic event in the insulin-acarbose group against three episodes in the insulin monotherapy group. <LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK> and <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK> reported that hypoglycaemic episodes were not statistically significantly different between the treatment groups, both trials reported no severe hypoglycaemic events. <LINK REF="STD-Nemoto-2011" TYPE="STUDY">Nemoto 2011</LINK> also reported no statistically significant difference in the incidence of hypoglycaemia between the insulin-miglitol group and the insulin monotherapy group (39% versus 35%); all hypoglycaemic events in this trial were mild.</P>
<P>We rated this as low-quality evidence, because of indirectness, imprecision and risk of bias. In most trials randomisation and allocation concealment were unclear, in all trials blinding of the outcome assessor was unclear, three of the four trials were funded by a pharmaceutical company, in one trial there was a high risk of bias because of selective reporting (<LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK>), and in another because of incomplete outcome data (<LINK REF="STD-Chiasson-1994" TYPE="STUDY">Chiasson 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other adverse events</HEADING>
<P>All trials regarding the addition of alpha-glucosidase inhibitors reported higher frequencies of gastro-intestinal complaints in the alpha-glucosidase inhibitor group than under insulin monotherapy (<LINK REF="STD-Chiasson-1994" TYPE="STUDY">Chiasson 1994</LINK>; <LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK>; <LINK REF="STD-Nemoto-2011" TYPE="STUDY">Nemoto 2011</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>). <LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK> and <LINK REF="STD-Nemoto-2011" TYPE="STUDY">Nemoto 2011</LINK> reported percentages: flatulence 75% versus 35% and 21% versus 12%, diarrhoea 33% versus 13% and 14% versus 4%, respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events: weight gain</HEADING>
<P>Data from two trials were pooled in a meta-analysis on weight (<LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>). Insulin-acarbose combination therapy compared to insulin monotherapy showed a MD of -0.5 kg weight change (95% CI -1.2 to 0.3); P = 0.26; 241 participants; 2 trials; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
<P>We rated this as low-quality evidence, because of indirectness, imprecision and risk of bias. In most trials randomisation and allocation concealment were unclear, in all trials blinding of the outcome assessor was unclear, both trials were funded by a pharmaceutical company, and in one trial there was bias because of selective reporting (<LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c and fasting glucose</HEADING>
<P>Three trials compared (<LINK REF="STD-Chiasson-1994" TYPE="STUDY">Chiasson 1994</LINK>; <LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>) the addition of acarbose to insulin therapy and one trial compared the addition of miglitol (<LINK REF="STD-Nemoto-2011" TYPE="STUDY">Nemoto 2011</LINK>) to insulin therapy with insulin monotherapy. We pooled data from three comparisons, with an intervention period of three to six months, in a meta-analysis (<LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK>; <LINK REF="STD-Nemoto-2011" TYPE="STUDY">Nemoto 2011</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>). Insulin-alpha-glucosidase inhibitor combination therapy was associated with a MD in lowering of HbA1c of -0.4% (95% CI -0.5 to -0.2); P &lt; 0.00001; 448 participants; 3 trials; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
<P>
<LINK REF="STD-Chiasson-1994" TYPE="STUDY">Chiasson 1994</LINK> and <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>, when comparing combination-therapy with insulin monotherapy, showed a MD of fasting glucose levels of 0.3 mmol/L (95% CI -0.7 to 1.4); P = 0.55; 113 participants; 2 trials; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P>
<P>We rated this as low-quality evidence, because of indirectness, imprecision and risk of bias. In most trials randomisation and allocation concealment were unclear, in all trials blinding of the outcome assessor was unclear, all included trials were funded by a pharmaceutical company, and in one trial there was bias because of selective reporting (<LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lipids</HEADING>
<P>
<LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK> assessed total cholesterol, HDL-cholesterol and triglycerides at baseline and at the trial end point (six months). In this trial the mean (SD) total cholesterol decreased more in the insulin-only group (from 5.4 mmol/L (1.8) to 5.1 mmol/L (1.2)) compared to the insulin-acarbose combination therapy group (from 5.1 mmol/L (1.5) to 5.0 mmol/L (1.1)).</P>
<P>HDL-cholesterol did not change substantially in both groups after six months (in the insulin-only group from 1.3 mmol/L (0.2) to 1.3 mmol/L (0.2) and in the insulin-acarbose combination therapy group from 1.2 mmol/L (0.3) to 1.1 mmol/L (0.3).</P>
<P>Triglycerides were reduced in both groups at the trial end (in the insulin only group from 2.5 mmol/L (2.4) to 1.8 mmol/L (0.8) and in the insulin-acarbose combination therapy group from 2.1 mmol/L (1.4) to 1.8 mmol/L (0.9).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Insulin dose</HEADING>
<P>Heterogeneity in type of insulin (short-, intermediate- and long-acting), units of quantification and the quality of reporting precluded the pooling of data.</P>
<P>Three of the four trials provided information about insulin requirements (<LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK>; <LINK REF="STD-Nemoto-2011" TYPE="STUDY">Nemoto 2011</LINK>; <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK>). Insulin doses were titrated if hypoglycaemia occurred. <LINK REF="STD-Coniff-1995" TYPE="STUDY">Coniff 1995</LINK> reported a decrease in total daily insulin dose of 7 U (SD 2) in the insulin plus acarbose group (at baseline 57 U (SD 3)), whereas total daily insulin remained constant in the insulin plus placebo group (baseline: 62 U (SD3); change: 1 U (SD 2). In <LINK REF="STD-Nemoto-2011" TYPE="STUDY">Nemoto 2011</LINK> the mean reduction of insulin dosage to avoid hypoglycaemia was 5 U in participants treated with insulin and miglitol and 2 U in participants treated with insulin and placebo. <LINK REF="STD-Yilmaz-2007" TYPE="STUDY">Yilmaz 2007</LINK> reported a decrease in participants treated with insulin in combination with acarbose (3 U/day; P = 0.035) and an increase in total daily insulin dose in participants treated with insulin alone (13 U/day; P &lt; 0.001).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Insulin monotherapy versus insulin plus dipeptidyl peptidase 4 (DPP-4) inhibitor</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events: hypoglycaemia</HEADING>
<P>Heterogeneity in the definitions used between trials, and the quality of reporting of hypoglycaemia precluded the pooling of data.</P>
<P>
<LINK REF="STD-Barnett-2013" TYPE="STUDY">Barnett 2013</LINK> reported lower rates of confirmed hypoglycaemia in the insulin-saxagliptin group compared to the placebo group (8 versus 5) and no severe episodes. <LINK REF="STD-Hong-2012" TYPE="STUDY">Hong 2012</LINK> reported a higher percentage of hypoglycaemia in the insulin increase group compared to the insulin-sitagliptin combination group (18% versus 8%; severe 5% versus 2%). <LINK REF="STD-Fonseca-2007" TYPE="STUDY">Fonseca 2007</LINK> reported highest rates of confirmed hypoglycaemia (2 versus 3 events per patient-year; P &lt; 0.001; 23% versus 30% of the participants) and severe hypoglycaemia (0 versus 0.1 events per patient-year; P = 0.032; absolute number of events n = 6) with insulin-vildagliptin therapy compared to insulin monotherapy.</P>
<P>We rated this as low-quality evidence, because of indirectness, imprecision and risk of bias. Randomisation and allocation concealment were unclear in these trials, in two trials, blinding of the outcome assessor was unclear and one trial was without blinding, and two trials were funded by a pharmaceutical company.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events: weight gain</HEADING>
<P>Two trials reported data on body weight change with conflicting results. <LINK REF="STD-Hong-2012" TYPE="STUDY">Hong 2012</LINK> reported a weight loss for participants in the insulin-sitagliptin group of 0.7 kg (0.1 SD) versus a weight gain of 1.1 kg (0.4 SD) in the insulin monotherapy group. In contrast, in the trial of <LINK REF="STD-Fonseca-2007" TYPE="STUDY">Fonseca 2007</LINK> the body weight of participants in both groups increased during the intervention period (insulin-vildagliptin: 1.3 kg (0.3 SD) versus insulin-placebo: 0.6 kg (0.3 SD) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
<P>We rated this as low-quality evidence, because of indirectness, imprecision and risk of bias. Randomisation and allocation concealment was unclear, in one trial, blinding of the outcome assessor was unclear, and another trial was without blinding and funded by a pharmaceutical company.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">HbA1c and fasting glucose</HEADING>
<P>The pooled effect of insulin and DPP-4 inhibitor combination therapy compared to insulin monotherapy on HbA1c showed a MD of -0.4% (95% CI -0.5 to -0.4; 265 participants; 2 trials; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>) (<LINK REF="STD-Barnett-2013" TYPE="STUDY">Barnett 2013</LINK>; <LINK REF="STD-Hong-2012" TYPE="STUDY">Hong 2012</LINK>).</P>
<P>
<LINK REF="STD-Fonseca-2007" TYPE="STUDY">Fonseca 2007</LINK> was the only trial with data on fasting plasma glucose. In this trial with 238 participants the MD was -0.6 mmol/L (95% CI -1.6 to 0.4) for insulin-vildagliptin therapy compared to insulin monotherapy.</P>
<P>We rated this as low-quality evidence, because of indirectness, imprecision and risk of bias. Randomisation and allocation concealment was unclear, in one trial blinding of the outcome assessor was unclear and the other was without blinding, and both were funded by a pharmaceutical company.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Lipids</HEADING>
<P>No trials assessed change in lipids.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Insulin dose</HEADING>
<P>Heterogeneity in type of insulin (short-, intermediate- and long-acting), units of quantification and the quality of reporting precluded the pooling of data.</P>
<P>
<LINK REF="STD-Barnett-2013" TYPE="STUDY">Barnett 2013</LINK> reported a similar increase in mean (95% CI) insulin dose for participants treated with saxagliptin (6 U (4 to 7)) and those treated with placebo (7 U (5 to 9)). <LINK REF="STD-Fonseca-2007" TYPE="STUDY">Fonseca 2007</LINK> reported an adjusted mean change from baseline to endpoint of 1 U/day (SD 2) in vildagliptin treated participants and 4 U/day (SD 2) in participants receiving placebo (between-group difference P = 0.315). <LINK REF="STD-Hong-2012" TYPE="STUDY">Hong 2012</LINK> reported an overall mean decrease (95% CI) in insulin dose from baseline of 3 U (1 to 5) in the sitagliptin group versus an increase of 10 U (5 to 15) in the insulin increase group.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<P>Repeating all meta-analyses with a fixed-effect model only yielded small differences compared to the results of the random-effects model. The results of the sensitivity analyses investigating the impact of very long trials and trials with high risk of bias are reported in the relevant paragraphs. Also, the results of the comparisons between trials with a parallel design and trials with a cross-over design are reported in the relevant paragraphs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analyses</HEADING>
<P>We planned two subgroup analyses: </P>
<UL>
<LI>different oral glucose lowering agent(s) and different types of insulin; and</LI>
<LI>timing and frequency of insulin injections.</LI>
</UL>
<P>We divided our results into groups of the added oral glucose-lowering agents. Subgroup analyses regarding the diverse types, timing and frequency of insulin were not feasible. The required information was often not reported or the participant groups used different insulin types and regimens in one trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Reporting bias</HEADING>
<P>We did not create funnel plots, because we were not able to include 10 trials or more for a given outcome.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<SUMMARY_OF_RESULTS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>We included 37 RCTs with 3227 participants in this review. The addition of an oral glucose-lowering agent to the treatment of people with type 2 diabetes, who were already on insulin therapy, had a beneficial effect on glycosylated haemoglobin A1c (HbA1c) levels . Sulphonylureas had a positive effect on fasting glucose levels. Combination therapy also led to a reduction of the insulin requirements in most trials on insulin-sulphonylurea, insulin-metformin, insulin-pioglitazone, as well as insulin-alpha-glucosidase inhibitor combination therapy. Besides the benefits of an improved glycaemic control and lower required insulin doses, the addition of oral glucose-lowering agents had some unwanted effects. Insulin therapy in combination with pioglitazone resulted in a higher frequency of hypoglycaemic events compared to insulin monotherapy. The combination with pioglitazone caused more weight gain compared to insulin monotherapy. On the other hand, weight gain appeared less when metformin was added. A substantial proportion of participants using metformin experienced gastrointestinal adverse effects. These adverse effects partly resolved spontaneously, however. Alpha-glucosidase inhibitor-users also experienced some gastro-intestinal adverse effects. A substantial proportion of the pioglitazone-users developed oedema, in a few cases combined with heart failure.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>The included trials shared an outcome measure of glycaemic control, often accompanied by some other diverse outcome measures. None of the included trials reported the effects on the primary outcomes, diabetes-related morbidity and all-cause mortality, as well as on health-related quality of life and only one reported patient satisfaction. Although the trials were of overall low quality, they could answer questions regarding some outcome measures. One of our objectives was to distinguish the effects between the different oral glucose-lowering agents and insulin regimens. The categorisation in insulin schemes was not possible, since most trials included participants with several kinds of insulin regimens without discriminating between them or without specification of the insulin regimens. In 11 of the 17 trials that investigated sulphonylureas, glibenclamide was added. Glibenclamide is associated with an increased risk of hypoglycaemic events compared to other sulphonylureas (<LINK REF="REF-Gangji-2007" TYPE="REFERENCE">Gangji 2007</LINK>). So, the number of hypoglycaemic events in this review might be higher than expected with the use of other sulphonylureas.</P>
<P>There are some general barriers for the applicability of the evidence from this review. Abnormal liver and renal function limits the use of many oral agents. Therefore, in most trials participants with renal or liver failure were excluded. In the included trials, patient care reflected trial circumstances instead of routine daily care. This could mean that the participants received a more structured care which may have resulted in more educated and compliant participants. These features may have contributed to the reaching of better glycaemic control and other positive consequences, such as less weight gain and less hypoglycaemia.</P>
<P>The participants ranged in age from 29 to 83 years, and the duration of diabetes ranged from less than 1 to 31 years. These numbers are fairly comparable to the numbers of the type 2 diabetes patients with insufficient glycaemic control on insulin therapy that are currently treated for diabetes in daily practice.</P>
<P>The addition of alpha-glucosidase inhibitors had a small effect on HbA1c (-0.4%), but resulted in a reduction of insulin requirement ranging from 3 to 7 units per day. The baseline HbA1c was approximately 7.6% in the group of alpha-glucosidase inhibitors, compared to 10.7% in the sulphonylurea, 9.0% in the metformin and DPP-4, and 8.3% in the pioglitazone group. Apparently, the participants receiving alpha-glucosidase inhibitors had a better glycaemic control at baseline than the other groups. It is not likely that a pronounced lowering of HbA1c would still be possible in these participants. This indicates the importance of perceiving features of a trial population when interpreting results.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>All included trials were RCTs, of which 26 had a parallel design and 11 had a cross-over design. The total number of participants was 3227 (range 9 to 566), with 0% to 100% men. A third of the trials had 30 or fewer participants, partly due to the number of participants in the cross-over trials (mean n = 18 (range 9 to 33)). A lot of trials seemed to have been underpowered and only eight trials discussed power calculations. This might mean that potential significant differences across groups were not detected.</P>
<P>Follow-up periods differed between trials, ranging from 2 to 12 months. Only five trials had a follow-up of 12 months. The outcome values of the trials with a short follow-up might have been different if the trial had continued for longer. We performed sensitivity analyses in which we explored the influence of very long trials on the effect size, to establish how much they dominated the results. These analyses showed that a longer follow-up somewhat strengthened the effects, but that it did not change the direction. Long-term effects on diabetes-related morbidity and all-cause mortality particularly remained unclear.</P>
<P>Many trials had a serious risk of bias in some risk of bias domains, in addition randomisation, allocation concealment and blinding of the outcome assessor was often unclear. Most trials were funded by pharmaceutical companies and often the overall outcome was in favour of the product of the sponsoring company. Some argue that systematic bias favours products which are made by the company funding the research. Explanations include the selection of an inappropriate comparator to the product being investigated and publication bias (<LINK REF="REF-Lexchin-2003" TYPE="REFERENCE">Lexchin 2003</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-05-31 22:07:11 +0200" MODIFIED_BY="[Empty name]">
<P>It is possible that trials concerning our objective were not published. Only one author did the first rough selection of possible appropriate trials in the references obtained by the searches. This approach might have caused some selection bias.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<LINK REF="REF-Yki_x002d_Jarvinen-2001" TYPE="REFERENCE">Yki-Jarvinen 2001</LINK> draws some similar conclusions in a non-systematic review with 25 comparisons in previously insulin-treated type 2 diabetes patients. She showed better glycaemic control with the addition of metformin, sulphonylurea and thiazolidinediones compared to the treatment of insulin-treated type 2 diabetes patients. Metformin was associated with less weight gain, whereas the addition of sulphonylureas showed no difference and the combination with thiazolidinediones caused more weight gain than insulin alone. The occurrence of hypoglycaemia was sparsely described in the trials included in <LINK REF="REF-Yki_x002d_Jarvinen-2001" TYPE="REFERENCE">Yki-Jarvinen 2001</LINK>. The trials reported more hypoglycaemic events with sulphonylurea (one trial) and thiazolidinediones (three trials) and fewer with metformin (one trial). There was no definite conclusion in favour of one treatment over the other with respect to the effects on lipids.</P>
<P>
<LINK REF="REF-Goudswaard-2004b" TYPE="REFERENCE">Goudswaard 2004b</LINK> executed a Cochrane Review in insulin-naive patients with the same objectives as ours. They did not include trials that observed combination therapy with thiazolidinediones. In contrast to our finding that combination therapy gives better glycaemic control, they found similar glycaemic control in combination therapy and insulin monotherapy. They demonstrated, as we did, a beneficial effect of metformin and no effect of sulphonylurea on weight gain. An explanation of the difference between <LINK REF="REF-Goudswaard-2004b" TYPE="REFERENCE">Goudswaard 2004b</LINK> and our review could be the difference in the history of insulin therapy of the included participants. The participants in our review experienced a period of failing oral agents after which insulin monotherapy was started and the majority was included at the moment they did not reach the aimed glycaemic control with insulin monotherapy. Unfortunately we did not have enough data about the duration of insulin therapy at the moment of inclusion. Goudswaard concluded that the start of insulin treatment with or without the continuation of oral agents had positive effects on glycaemic control. However, the additional effect of the combination of insulin with oral glucose-lowering agents on glycaemic control in insulin-naive patients was small. To conclude: the effectiveness of adding oral glucose-lowering agents to insulin therapy is differential depending on whether they are administered in insulin-naive patients or in patients who are already on insulin therapy.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<IMPLICATIONS_PRACTICE MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Adding oral glucose-lowering agents to insulin therapy in people with type 2 diabetes with inadequate glycaemic control reduces glycosylated haemoglobin A1c (HbA1; range: -0.4% to -1.0%; low quality evidence). In most trials the participants with combination therapy needed less insulin, whereas insulin requirements increased or remained stable in participants with insulin monotherapy. Because adding an oral glucose-lowering agent may also lead to weight gain, more hypoglycaemic events and other adverse effects like gastro-intestinal complaints, oedema and heart failure (all low quality evidence), it is important that clinicians meticulously weight the advantages of combination therapy against possible negative effects in every individual patient. The evidence presented in this review is of &#8216;low quality&#8217;, therefore there is still uncertainty about the estimate of effect presented, and further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>As the majority of the included trials seemed to be underpowered and follow-up was often short (&lt; 12 months in all but five of the trials). Multi-centre trials with a long follow-up focusing on diabetes-related morbidity and mortality and all-cause mortality as outcome measures are needed.</P>
<P>None of the included trials assessed health-related quality of life. Future trials investigating the effects on patient-reported outcomes, like health-related quality of life, health status, wellbeing and treatment satisfaction are also needed. We have found seven ongoing trials, four with a subgroup for the combination insulin-DPP IV inhibitor versus insulin monotherapy, one with a thiazolidinedione combined therapy and one with the combination insulin-ipragliflozin (approved in Japan).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>The authors gratefully acknowledge the contribution of Gudrun Paletta, Karla Bergerhoff and Bernd Richter of Cochrane Metabolic and Endocrine Disorders for their valuable assistance in the preparation of the protocol and this review. We also acknowledge the assistance of Rob Scholten of Cochrane Netherlands for his help with performing the generic inverse variance analysis.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-08-30 07:46:38 +0200" MODIFIED_BY="[Empty name]">
<P>RV: an unrestricted grant for a study in type 2 diabetes patients on insulin therapy (support of self-managment by triggers) is received by Sanofi. An unrestricted grant is received for a study on the long term effects of a self management education course for patients with type 2 diabetes by the European Foundation for the Study of Diabetes.</P>
<P>MA: received a reimbursement from Sanofi-Aventis for attending a congress and printing her thesis (2010) and she received royalties from publisher Bohn Stafleu van Loghum for authorship of a book: "Leven met diabetes mellitus type 2".</P>
<P>HJ: has no conflict of interest.</P>
<P>AG: received an unrestricted research grant from Novo Nordisk in 1999.</P>
<P>MD: has no conflict of interest.</P>
<P>KG: has no conflict of interest.</P>
<P>AK: has no conflict of interest.</P>
<P>GR: received a grant for a study project from Sanofi-aventis. Besides he received honoraria from Novo Nordisk for lecturing and attending (inter-) national board meetings. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-07-26 12:01:47 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Rimke C Vos (RV): methodology, statistical analysis and review development.</P>
<P>Marielle JP van Avendonk (MA): protocol development, searching for trials, trial selection, quality assessment of trials, data extraction, methodology, statistics and review development.</P>
<P>Hanneke Jansen (HJ): quality assessment of trials, data extraction and review development.</P>
<P>Alex N Goudswaard (AG): protocol development, trial selection, quality assessment, data extraction and review development.</P>
<P>Maureen Van den Donk (MD): methodology, statistics, data extraction and review development.</P>
<P>Kees Gorter (KG): data extraction and review development.</P>
<P>Anneloes Kerssen (AK): data extraction and review development.</P>
<P>Guy EHM Rutten (GR): review development.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-08-30 07:46:57 +0200" MODIFIED_BY="[Empty name]">
<P>Terminology was changed from 'oral hypoglycaemic agents' to 'oral glucose-lowering agents'.</P>
<SUBSECTION>
<HEADING LEVEL="5">Type of outcome measures</HEADING>
<P>We deleted from secondary outcome measures 'the percentage of participants achieving good glycaemic control (HbA1c less than 7%) without hypoglycaemic events', blood pressure and body-mass index, because reporting about these outcomes was rare.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Data collection and analysis</HEADING>
<P>We changed second reviewer from AG to AK for data extraction, assessment of risk of bias and data entry. Dichotomous data were not identified, therefore this part was omitted. RV and MA, contributed equally to the data analyses and the review development.</P>
<P>Analyses of cross-over trials were specified.</P>
<P>We changed the sensitivity analyses. We did not repeat the analysis excluding unpublished trials, because only published trials were included. We did not repeat the analysis excluding trials using different filters i.e. diagnostic criteria, language of publication, source of funding (industry versus other) and country. Not all trials reported diagnostic criteria and only one trial was not published in English. Almost all trials were funded by a pharmaceutical company. The trials were mainly performed in Western-European countries and the United States. We did not expect large differences in the results between these countries.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Declarations of interest</HEADING>
<P>Changed from 'None known' to 'GR has received research grants from Sanofi-Aventis and honoraria form Novo Nordisk for lecturing and attending (inter-)national board meetings. In 1999, AG has received an unrestricted research grant from Novo Nordisk. MA received a reimbursement from Sanofi-Aventis for attending a congress and printing her thesis' and royalties from publisher Bohn Stafleu van Loghum for authorship of a book: "Leven met diabetes mellitus type 2".</P>
</SUBSECTION>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Part of the background, the methods section, appendices, additional tables and figures 1 to 3 of this review are based on a standard template established by Cochrane Metabolic and Endocrine Disorders.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-09-07 10:12:06 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDIES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<INCLUDED_STUDIES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<STUDY DATA_SOURCE="PUB" ID="STD-Avil_x00e9_s-1999" MODIFIED="2011-10-18 18:17:38 +0200" MODIFIED_BY="[Empty name]" NAME="Avilés 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-10-18 18:17:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Avilés-Santa L, Sinding J, Raskin P</AU>
<TI>Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1999</YR>
<VL>131</VL>
<PG>182-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363017"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363016"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barnett-2013" MODIFIED="2016-07-25 11:40:17 +0200" MODIFIED_BY="[Empty name]" NAME="Barnett 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-11-03 13:08:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barnett AH, Charbonnel B, Li J, Donovan M, Fleming D, Iqbal N</AU>
<TI>Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy</TI>
<SO>Clinical drug investigation</SO>
<YR>2013</YR>
<VL>33</VL>
<NO>10</NO>
<PG>707-17</PG>
<IDENTIFIERS MODIFIED="2014-11-03 13:08:44 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363019"/><IDENTIFIER TYPE="PUBMED" VALUE="23949898"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363018"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casner-1988" MODIFIED="2016-04-28 17:07:08 +0200" MODIFIED_BY="[Empty name]" NAME="Casner 1988" YEAR="1988">
<REFERENCE MODIFIED="2016-04-28 17:07:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Casner PR</AU>
<TI>Insulin-glyburide combination therapy for non-insulin-dependent diabetes mellitus: a long-term double-blind, placebo-controlled trial</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1988</YR>
<VL>44</VL>
<PG>594-603</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363021"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363020"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chiasson-1994" MODIFIED="2016-04-28 17:07:17 +0200" MODIFIED_BY="[Empty name]" NAME="Chiasson 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-04-28 17:07:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiasson J-L, Josse R, Hunt J, Palmason C, Rodger W, Ross S, et al</AU>
<TI>The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1994</YR>
<VL>121</VL>
<PG>928-35</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363023"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363022"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coniff-1995" MODIFIED="2011-10-18 18:19:05 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Coniff 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-10-18 18:19:05 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA</AU>
<TI>A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>7</NO>
<PG>928-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363025"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-06-03 11:54:19 +0200" MODIFIED_BY="Marielle van Avendonk"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363024"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feinglos-1998" MODIFIED="2016-04-28 17:07:32 +0200" MODIFIED_BY="[Empty name]" NAME="Feinglos 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-04-28 17:07:32 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feinglos MN, Thacker CR, Lobaugh B, DeAtkine DD, McNeill DB, English JS, et al</AU>
<TI>Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus</TI>
<SO>Diabetes Research and Clinical Practice</SO>
<YR>1998</YR>
<VL>39</VL>
<PG>193-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363027"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363026"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fonseca-2007" MODIFIED="2010-06-03 11:56:14 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Fonseca 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-06-03 11:56:14 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S</AU>
<TI>Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes</TI>
<SO>Diabetologia</SO>
<YR>2007</YR>
<VL>50</VL>
<PG>1148-55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363029"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363028"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fritsche-2000" MODIFIED="2011-10-18 18:20:12 +0200" MODIFIED_BY="[Empty name]" NAME="Fritsche 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-10-18 18:20:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fritsche A, Schmulling RM, Haring HU, Stumvoll M</AU>
<TI>Intensive insulin therapy combined with metformin in obese type 2 diabetic patients</TI>
<SO>Acta Diabetologica</SO>
<YR>2000</YR>
<VL>37</VL>
<PG>13-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363031"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363030"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giugliano-1993" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Giugliano 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, et al</AU>
<TI>Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1993</YR>
<VL>44</VL>
<PG>107-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363033"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363032"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groop-1985" MODIFIED="2011-10-18 18:20:56 +0200" MODIFIED_BY="[Empty name]" NAME="Groop 1985" YEAR="1985">
<REFERENCE MODIFIED="2011-10-18 18:20:56 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groop L, Harno K, Nikkila EA, Pelkonen R, Tolppannen EM</AU>
<TI>Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin dependent diabetics poorly controlled on insulin alone</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1985</YR>
<VL>217</VL>
<PG>33-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363035"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363034"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hermann-2001" MODIFIED="2016-04-28 17:07:56 +0200" MODIFIED_BY="[Empty name]" NAME="Hermann 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-04-28 17:07:56 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hermann LS, Kalén J, Katzman P, Lager I, Nilsson A, Norrhamn O, et al</AU>
<TI>Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2001</YR>
<VL>3</VL>
<PG>428-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363037"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363036"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hirsch-1999" MODIFIED="2009-05-10 20:10:36 +0200" MODIFIED_BY="[Empty name]" NAME="Hirsch 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-05-10 20:10:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hirsch IB</AU>
<TI>Metformin added to insulin therapy in poorly controlled type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>5</NO>
<PG>854</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363039"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363038"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hong-2012" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Hong 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hong ES, Khang AR, Yoon JW, Kang SM, Choi SH, Park KS, et al</AU>
<TI>Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study</TI>
<SO>Diabetes, Obesity &amp; Metabolism</SO>
<YR>2012</YR>
<VL>14</VL>
<NO>9</NO>
<PG>795-802</PG>
<IDENTIFIERS MODIFIED="2014-11-03 12:56:20 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363041"/><IDENTIFIER TYPE="PUBMED" VALUE="22443183"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363040"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kitabchi-1987" MODIFIED="2016-07-25 11:47:33 +0200" MODIFIED_BY="[Empty name]" NAME="Kitabchi 1987" YEAR="1987">
<REFERENCE MODIFIED="2016-07-25 11:47:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kitabchi AE, Soria AG, Radparvar A, Lawson-Grant V</AU>
<TI>Combined therapy of insulin and tolazamide decreases insulin requirement and serum triglycerides in obese patients with non-insulin-dependent diabetes mellitus</TI>
<SO>American Journal Medical Science</SO>
<YR>1987</YR>
<VL>294</VL>
<NO>1</NO>
<PG>10-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363043"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363042"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krawczyk-2005" MODIFIED="2016-04-28 17:08:12 +0200" MODIFIED_BY="[Empty name]" NAME="Krawczyk 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-04-28 17:08:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krawczyk A, Gajer G, Greszczak W, Strojek K</AU>
<TI>The impact of metformin on metabolic control in obese type 2 diabetes patients treated with insulin. Preliminary observation</TI>
<TO>Wplyw metforminy na wyrównanie metaboliczne u otylych chorych na cukrzyce typu 2 leczonych insulina. Obserwacja wstepna</TO>
<SO>Diabetologia Doswiadczalna i Kliniczna</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>1</NO>
<PG>47-51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363045"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363044"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kyllastinen-1985" MODIFIED="2011-10-18 18:22:10 +0200" MODIFIED_BY="[Empty name]" NAME="Kyllastinen 1985" YEAR="1985">
<REFERENCE MODIFIED="2011-10-18 18:22:10 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kyllastinen M, Groop L</AU>
<TI>Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients</TI>
<SO>Annals of Clinical Research</SO>
<YR>1985</YR>
<VL>17</VL>
<PG>100-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363047"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363046"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewitt-1989" MODIFIED="2016-04-28 17:08:31 +0200" MODIFIED_BY="[Empty name]" NAME="Lewitt 1989" YEAR="1989">
<REFERENCE MODIFIED="2016-04-28 17:08:31 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewitt MS, Yu VKF, Rennie GC, Carter JN, Marel GM, Yue DKS, et al</AU>
<TI>Effects of combined insulin-sulfonylurea therapy in type II patients</TI>
<SO>Diabetes Care</SO>
<YR>1989</YR>
<VL>12</VL>
<NO>6</NO>
<PG>379-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363049"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363048"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindstrom-1999" MODIFIED="2011-10-18 18:22:38 +0200" MODIFIED_BY="[Empty name]" NAME="Lindstrom 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-10-18 18:22:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindstrom T, Nystrom FH, Olsson AG, Ottoson AM, Arnqvist HJ</AU>
<TI>The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylurea in patients with type 2 diabetes mellitus</TI>
<SO>Diabetic Medicine</SO>
<YR>1999</YR>
<VL>16</VL>
<PG>820-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363051"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363050"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Longnecker-1986" MODIFIED="2011-10-18 18:23:18 +0200" MODIFIED_BY="[Empty name]" NAME="Longnecker 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-10-18 18:23:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Longnecker MP, Elsenhans VD, Leiman SM, Owen OE, Boden G</AU>
<TI>Insulin and a sulfonylurea agent in non-insulin-dependent diabetes mellitus</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1986</YR>
<VL>146</VL>
<PG>673-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363053"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363052"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattoo-2005" MODIFIED="2016-04-28 17:08:40 +0200" MODIFIED_BY="[Empty name]" NAME="Mattoo 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-04-28 17:08:40 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, et al</AU>
<TI>Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2005</YR>
<VL>27</VL>
<NO>5</NO>
<PG>554-67</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363055"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363054"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mauerhoff-1986" MODIFIED="2011-10-18 18:23:37 +0200" MODIFIED_BY="[Empty name]" NAME="Mauerhoff 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-10-18 18:23:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mauerhoff T, Ketelslegers JM, Lambert AE</AU>
<TI>Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin secretion</TI>
<SO>Diabete &amp; Metabolisme</SO>
<YR>1986</YR>
<VL>12</VL>
<PG>34-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363057"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363056"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mezitis-1992" MODIFIED="2011-10-18 18:23:54 +0200" MODIFIED_BY="[Empty name]" NAME="Mezitis 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-10-18 18:23:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mezitis NHE, Heshka S, Saitas V, Bailey T, Costa R, Pi-Sunyer FX</AU>
<TI>Combination therapy for NIDDM with biosynthetic human insulin and glyburide</TI>
<SO>Diabetes Care</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>2</NO>
<PG>265-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363059"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363058"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mudaliar-2010" MODIFIED="2015-12-15 19:49:47 +0100" MODIFIED_BY="[Empty name]" NAME="Mudaliar 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-12-15 19:49:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mudaliar S, Chang AR, Aroda VR, Chao E, Burke P, Baxi et al</AU>
<TI>Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 diabetes</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2010</YR>
<VL>12</VL>
<PG>133-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363061"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-15 19:48:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shah PK, Mudaliar S, Chang AR, Aroda V, Andre M, Burke P, et al</AU>
<TI>Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2011</YR>
<VL>13</VL>
<PG>505-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363062"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363060"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nemoto-2011" MODIFIED="2011-11-01 14:56:53 +0100" MODIFIED_BY="Marielle JP van Avendonk" NAME="Nemoto 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-11-01 14:56:53 +0100" MODIFIED_BY="Marielle JP van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nemoto M, Tajima N, Kawamori R</AU>
<TI>Efficacy of combined use of miglitol in type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study</TI>
<SO>Acta Diabetologica</SO>
<YR>2011</YR>
<VL>48</VL>
<PG>15-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363064"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363063"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Osei-1984" MODIFIED="2015-12-15 19:51:33 +0100" MODIFIED_BY="[Empty name]" NAME="Osei 1984" YEAR="1984">
<REFERENCE MODIFIED="2015-12-15 19:51:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falko JM, Osei K</AU>
<TI>Combination insulin/glyburide therapy in type II diabetes mellitus. Effects on lipoprotein metabolism and glucoregulation</TI>
<SO>American Journal of Medicine</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>Suppl 3B</NO>
<PG>92-101</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363066"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-15 19:51:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Osei K, O'Dorisio TM, Falko JM</AU>
<TI>Concomitant insulin and sulfonylurea therapy in patients with type II diabetes</TI>
<SO>American Journal of Medicine</SO>
<YR>1984</YR>
<VL>77</VL>
<PG>1002-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363067"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363065"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quatraro-1986" MODIFIED="2011-10-18 18:24:25 +0200" MODIFIED_BY="[Empty name]" NAME="Quatraro 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-10-18 18:24:25 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quatraro A, Consoli G, Ceriello A, Giugliano D</AU>
<TI>Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up</TI>
<SO>Diabete &amp; Metabolisme</SO>
<YR>1986</YR>
<VL>12</VL>
<PG>315-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363069"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363068"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reich-1987" MODIFIED="2009-05-12 11:42:33 +0200" MODIFIED_BY="[Empty name]" NAME="Reich 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-05-12 11:42:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reich A, Abraira C, Lawrence AM</AU>
<TI>Combined glyburide and insulin therapy in type II diabetes</TI>
<SO>Diabetes Research</SO>
<YR>1987</YR>
<VL>6</VL>
<PG>99-104</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363071"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363070"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Relimpio-1998" MODIFIED="2009-05-12 11:47:55 +0200" MODIFIED_BY="[Empty name]" NAME="Relimpio 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-05-12 11:47:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Relimpio F, Pumar A, Losada F, Mangas MA, Acosta D, Astorga R</AU>
<TI>Adding metformin versus insulin dose increase in insulin-treated but poorly controlled type 2 diabetes mellitus: an open-label randomized trial</TI>
<SO>Diabetic Medicine</SO>
<YR>1998</YR>
<VL>15</VL>
<PG>997-1002</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363073"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363072"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-1998" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Robinson 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS</AU>
<TI>The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>5</NO>
<PG>701-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363075"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363074"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenstock-2002" MODIFIED="2016-07-25 12:29:11 +0200" MODIFIED_BY="[Empty name]" NAME="Rosenstock 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-07-25 12:29:11 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S; Pioglitazone 014 Study Group</AU>
<TI>Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2002</YR>
<VL>56</VL>
<NO>4</NO>
<PG>251-57</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363077"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363076"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schade-1987" MODIFIED="2011-10-18 18:25:35 +0200" MODIFIED_BY="[Empty name]" NAME="Schade 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-10-18 18:25:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schade DS, Mitchell WJ, Griego G</AU>
<TI>Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1987</YR>
<VL>257</VL>
<NO>18</NO>
<PG>2441-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363079"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363078"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiel-2007" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Schiel 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiel R, Muller UA</AU>
<TI>Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: The Switch pilot study</TI>
<SO>Experimental and Clinical Endocrinology &amp; Diabetes</SO>
<YR>2007</YR>
<VL>115</VL>
<PG>627-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363081"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363080"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simpson-1990" MODIFIED="2011-10-18 18:26:44 +0200" MODIFIED_BY="[Empty name]" NAME="Simpson 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-10-18 18:26:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simpson HCR, Sturley R, Stirling CA, Reckless JPD</AU>
<TI>Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients</TI>
<SO>Diabetic Medicine</SO>
<YR>1990</YR>
<VL>7</VL>
<PG>143-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363083"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363082"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stenman-1988" MODIFIED="2009-12-10 10:57:31 +0100" MODIFIED_BY="[Empty name]" NAME="Stenman 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-12-10 10:57:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stenman S, Gropp PH, Saloranta C, Totterman KJ, Fyhrqvist F, Groop L</AU>
<TI>Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral glucose lowering agents</TI>
<SO>Diabetologia</SO>
<YR>1988</YR>
<VL>31</VL>
<PG>206-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363085"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363084"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strowig-2002" MODIFIED="2011-10-18 18:26:54 +0200" MODIFIED_BY="[Empty name]" NAME="Strowig 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-10-18 18:26:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strowig S, Avilés-Santa ML, Raskin P</AU>
<TI>Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>10</NO>
<PG>1691-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363087"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363086"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wulffel_x00e9_-2002" MODIFIED="2016-04-28 17:09:19 +0200" MODIFIED_BY="[Empty name]" NAME="Wulffelé 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-04-28 17:09:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wulffelé MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, et al</AU>
<TI>Combination of insulin and metformin in the treatment of type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2002</YR>
<VL>25</VL>
<PG>2133-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363089"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363088"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yilmaz-2007" MODIFIED="2011-10-18 18:27:17 +0200" MODIFIED_BY="[Empty name]" NAME="Yilmaz 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-10-18 18:27:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yilmaz H, Gursoy A, Sahin M, Guvener Demirag N</AU>
<TI>Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes</TI>
<SO>Acta Diabetologica</SO>
<YR>2007</YR>
<VL>44</VL>
<PG>187-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363091"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363090"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<STUDY DATA_SOURCE="PUB" ID="STD-Abraira-1998" MODIFIED="2016-04-28 17:06:52 +0200" MODIFIED_BY="[Empty name]" NAME="Abraira 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-04-28 17:06:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, et al</AU>
<TI>Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>4</NO>
<PG>574-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363093"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363092"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Al_x002d_Shaikh-2006" MODIFIED="2011-10-18 18:27:42 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Al-Shaikh 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-10-18 18:27:42 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al-Shaikh AR</AU>
<TI>Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes</TI>
<SO>Pakistan Journal of Medical Science</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>1</NO>
<PG>14-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363095"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363094"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Altuntas-2003" MODIFIED="2011-10-18 18:27:53 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Altuntas 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-10-18 18:27:53 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altuntas Y, Ozen B, Ozturk B, Sengul A, Ucak S, Ersoy O et al</AU>
<TI>Comparison of additional metformin or NPH insulin to mealtime insulin lispro with mealtime human insulin therapy in secondary OAD failure</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2003</YR>
<VL>5</VL>
<PG>371-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363097"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363096"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bachman-1988" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Bachman 1988" YEAR="1988">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bachmann W, Lotz N, Mehnert H, Rosak C, Schoffling K</AU>
<TI>Effectiviness of combined glibenclamide and insulin treatment of patients with secondary sulphonylurea failure: a controlled multi-center double-blind trial</TI>
<TO>Wirksamheit der kombinationsbehandlung mit glibenclamid und insulin bei sulfonylharnstoff-sekundarversagen</TO>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1988</YR>
<VL>113</VL>
<PG>631-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363099"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363098"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barranco-2006" MODIFIED="2011-10-18 18:28:27 +0200" MODIFIED_BY="[Empty name]" NAME="Barranco 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-10-18 18:28:27 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barranco C</AU>
<TI>Early use of combination therapy improves outcome of patients with type 2 diabetes</TI>
<SO>Endocrinology &amp; Metabolism</SO>
<YR>2006</YR>
<VL>2</VL>
<NO>4</NO>
<PG>186-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363101"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363100"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berhanu-2007" MODIFIED="2011-10-18 18:28:39 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Berhanu 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-10-18 18:28:39 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berhanu P, Perez A, Yu S</AU>
<TI>Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy</TI>
<SO>Diabetes, Obesity &amp; Metabolism</SO>
<YR>2007</YR>
<VL>9</VL>
<PG>512-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363103"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363102"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bianchi-1996" MODIFIED="2011-10-18 18:29:51 +0200" MODIFIED_BY="[Empty name]" NAME="Bianchi 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-10-18 18:29:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bianchi R, De Vries DE, Bravenboer B, Erkelens DW</AU>
<TI>Effect of benfluorex in addition to insulin therapy in obese type II diabetic patients with secondary failure to conventional oral treatment</TI>
<SO>Diabetes Nutrition Metabolism.</SO>
<YR>1996</YR>
<VL>9</VL>
<PG>81-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363105"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363104"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buse-1998" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Buse 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buse JB, Gumbiner BG, Mathias NP, Nelson DM, Faja BW, Whitcomb RW, Troglitazone Insulin study group</AU>
<TI>Troglitazone use in insulin-treated type 2 diabetic patients</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<PG>1455-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363107"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363106"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carta-1984" MODIFIED="2011-10-18 18:34:40 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Carta 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-10-18 18:34:40 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carta Q, Trovati M, Dani F, Caselle MT, Vitali S, Cavalot F et al</AU>
<TI>Insulin or insulin + oral agents in the treatment of type II diabetics after oral agents failure.</TI>
<TO>Insulina o insulina + farmaci ipoglicemizzanti orali nella terapia del diabete di tipo II di difficile compenso metabolico</TO>
<SO>Minerva Endocrinologia</SO>
<YR>1984</YR>
<VL>9</VL>
<PG>241-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363109"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363108"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castillo-1987" MODIFIED="2009-05-07 14:09:19 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Castillo 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-05-07 14:09:19 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castillo M, Scheen AJ, Paolisso G, Lefebvre PJ</AU>
<TI>The addition of glipizide to insulin therapy in type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion</TI>
<SO>Acta Endocrinologica</SO>
<YR>1987</YR>
<VL>116</VL>
<PG>364-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363111"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363110"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Charbonnel-2010" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Charbonnel 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Charbonnel B, DeFronzo R, Davidson J, Schmitz O, Birkeland K, Pirags V, et al</AU>
<TI>Pioglitazone use in combination with insulin in the prospective Pioglitazone Clinical Trial in Macrovascular Events Study (PROactive19)</TI>
<SO>Journal of Clinical Endocrinology &amp; Metabolism</SO>
<YR>2010</YR>
<VL>95</VL>
<PG>2163-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363113"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-07-25 12:01:40 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363112"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chazan-2001" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Chazan 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chazan ACS, Gomes MB</AU>
<TI>Glicazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure</TI>
<SO>Brazilian Journal of Medical and Biological Research</SO>
<YR>2001</YR>
<VL>34</VL>
<PG>49-56</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363115"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363114"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chow1995" MODIFIED="2009-05-07 14:08:54 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Chow1995" YEAR="1995">
<REFERENCE MODIFIED="2009-05-07 14:08:54 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chow C, Tsang LWW, Sorensen JP, Cockram CS</AU>
<TI>Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients</TI>
<SO>Diabetes Care</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>3</NO>
<PG>307-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363117"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363116"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clauson-1995" MODIFIED="2011-10-18 18:35:17 +0200" MODIFIED_BY="[Empty name]" NAME="Clauson 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-10-18 18:35:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clauson P, Karlander S, Steen L, Efendic S</AU>
<TI>Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up</TI>
<SO>Diabetic Medicine</SO>
<YR>1996</YR>
<VL>13</VL>
<PG>471-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363119"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363118"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cortes-1993" MODIFIED="2011-10-18 18:35:33 +0200" MODIFIED_BY="[Empty name]" NAME="Cortes 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-10-18 18:35:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cortes Aguirre H, Espinosa Lopez FR, Angluo Ververa JA, Diaz Torres J</AU>
<TI>A comparative study of insulin and glyburide versus glyburide or insulin in the chronic control of patients with type-2 diabetes</TI>
<TO>Estudio comparativo de insulina y glyburida contra gliburia o insulina, en el control crónico de pacientes con diabetes tipo II</TO>
<SO>Gaceta Medica de Mexico</SO>
<YR>1993</YR>
<VL>129</VL>
<NO>6</NO>
<PG>383-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363121"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363120"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dashora-2007" MODIFIED="2015-01-12 18:33:09 +0100" MODIFIED_BY="[Empty name]" NAME="Dashora 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-01-12 18:33:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dashora UK, Sibal L, Ashwell SG, Home PD</AU>
<TI>Insulin glargine in combination with nateglinide in people with type 2 diabetes: a randomized placebo-controlled trial</TI>
<SO>Diabetic Medicine</SO>
<YR>2007</YR>
<VL>24</VL>
<PG>344-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363123"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363122"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-2006" MODIFIED="2011-10-18 18:35:49 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Davidson 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-10-18 18:35:49 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson J, Perez A, Zhang J and The Pioglitazone 343 Study group</AU>
<TI>Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multi-centre, randomized study</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2006</YR>
<VL>8</VL>
<PG>164-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363125"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363124"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Luis-2001" MODIFIED="2011-10-18 18:35:57 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="De Luis 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-10-18 18:35:57 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Luis DA, Aller R, Cuellar L, Terroba C, Ovalle H, Izaola O et al</AU>
<TI>Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2001</YR>
<VL>24</VL>
<PG>1844-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363127"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363126"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Douek-2005" MODIFIED="2009-05-07 14:08:03 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Douek 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-07 14:08:03 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Douek IF, Allen SE, Ewings P, Gale EAM, Bingley PJ for the Metformin Trial Group</AU>
<TI>Continuing metformin when starting insulin in patients with type 2 diabetes: a double-blind randomized placebo-controlled trial</TI>
<SO>Diabetic Medicine</SO>
<YR>2005</YR>
<VL>22</VL>
<PG>634-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363129"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363128"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fonseca-2006" MODIFIED="2009-05-07 14:15:18 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Fonseca 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-05-07 14:15:18 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fonseca VA, Theuma P, Mundaliar S, Leissinger CA, Clejan S, Henry RR</AU>
<TI>Diabetes treatments have differential effects on nontraditional cardiovascular risk factors</TI>
<SO>Journal of Diabetes and Its Complications</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>14-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363131"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363130"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fonseca-2008" MODIFIED="2011-10-18 18:37:09 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Fonseca 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-10-18 18:37:09 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fonseca V, Baron M, Shao Q, Dejager S</AU>
<TI>Sustained efficacy and reduced hypoglycaemia during one year of treatment with vildagliptine added to insulin in patients with type 2 diabetes mellitus</TI>
<SO>Hormone and Metabolic Research</SO>
<YR>2008</YR>
<VL>40</VL>
<PG>427-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363133"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363132"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garg-2007" MODIFIED="2011-10-18 18:37:28 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Garg 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-10-18 18:37:28 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garg R, Gopal J, Jones GR</AU>
<TI>Rosiglitazone: safety and efficacy in combination with insulin in poorly controlled type2 diabetes mellitus patients treated with insulin alone</TI>
<SO>Journal of Diabetes and its Complications</SO>
<YR>2007</YR>
<VL>21</VL>
<PG>1-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363135"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363134"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerstein-2006" MODIFIED="2010-02-06 11:25:20 +0100" MODIFIED_BY="[Empty name]" NAME="Gerstein 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-02-06 11:25:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E</AU>
<TI>A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes in either no oral glucose-lowering agents or submaximal doses of metformin and/or sulfonylureas. The Canadian INSIGHT (Implementing new Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study</TI>
<SO>Diabetic Medicine</SO>
<YR>2006</YR>
<VL>23</VL>
<PG>736-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363137"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363136"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goudswaard-2004a" MODIFIED="2011-10-18 18:37:53 +0200" MODIFIED_BY="[Empty name]" NAME="Goudswaard 2004a" YEAR="2004">
<REFERENCE MODIFIED="2011-10-18 18:37:53 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goudswaard AN, Stolk RP, Zuithoff P, De Valk HW, Rutten GE</AU>
<TI>Starting insulin in type 2 diabetes: continue oral glucose lowering agents? A randomized trial in primary care</TI>
<SO>Journal of Family Practice</SO>
<YR>2004</YR>
<VL>53</VL>
<NO>5</NO>
<PG>393-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363139"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363138"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greco-1998" MODIFIED="2010-06-03 12:04:31 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Greco 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-06-03 12:04:31 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greco D, Taravella V, Sinagra D, Galluzzo A</AU>
<TI>Considerations on combined use of insulin and oral antidiabetic agents in the treatment of type 2 diabetes mellitus</TI>
<TO>Considerazioni sull'uso della "terapia combinata" insulina + antidiabetici orali nel trattamento del diabete mellito di tipo 2</TO>
<SO>L'Internista</SO>
<YR>1998</YR>
<VL>6</VL>
<PG>95-100</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363141"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363140"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groop-1984" MODIFIED="2009-05-10 15:02:56 +0200" MODIFIED_BY="[Empty name]" NAME="Groop 1984" YEAR="1984">
<REFERENCE MODIFIED="2009-05-10 15:02:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groop L, Harno K, Tolppanen E</AU>
<TI>The combination of insulin and sulphonylurea in the treatment of secondary drug failure in patients with type II diabetes</TI>
<SO>Acta Endocrinologica</SO>
<YR>1984</YR>
<VL>106</VL>
<PG>97-101</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363143"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363142"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groop-1991" MODIFIED="2009-05-10 15:05:12 +0200" MODIFIED_BY="[Empty name]" NAME="Groop 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-05-10 15:05:09 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groop L, Widén E</AU>
<TI>Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there place for intermittent insulin therapy?</TI>
<SO>Diabete &amp; Metabolisme</SO>
<YR>1991</YR>
<VL>17</VL>
<PG>218-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363145"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363144"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gutniak-1987" MODIFIED="2009-05-07 13:42:08 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Gutniak 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-05-07 13:41:34 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gutniak M, Karlander S, Efendic S</AU>
<TI>Glyburide decreases insulin requirement, increases beta-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea</TI>
<SO>Diabetes Care</SO>
<YR>1987</YR>
<VL>10</VL>
<NO>5</NO>
<PG>545-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363147"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363146"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamelbeck-1982" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Hamelbeck 1982" YEAR="1982">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamelbeck H, Klein W, Zoltobrocki M, Schoffling K</AU>
<TI>Glibenclamide-insulin combination in the management of secondary failure of sulfonylurea medication</TI>
<TO>Glibenclamid-Insulin-Kombinationsbehandlung beim Sekundarversagen der Sulfonylharnstoff-Therapie</TO>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1982</YR>
<VL>107</VL>
<PG>1581-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363149"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363148"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hermanns-2004" MODIFIED="2011-10-18 18:40:15 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Hermanns 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-10-18 18:40:15 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hermanns N, Burkert A, Haak T</AU>
<TI>The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type 2 diabetes</TI>
<SO>Experimental and Clinical Endocrinology and Diabetes</SO>
<YR>2004</YR>
<VL>112</VL>
<PG>310-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363151"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363150"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollander-2003" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Hollander 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollander P, Ratner R, Fineman M, Strobel S, Shen L, Maggs D, et al</AU>
<TI>Addition of pramlintide to insulin therapy lowers hbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2003</YR>
<VL>5</VL>
<PG>408-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363153"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363152"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollander-2003a" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Hollander 2003a" YEAR="2003">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, et al</AU>
<TI>Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>3</NO>
<PG>784-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363155"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363154"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollander-2004" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Hollander 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, et al</AU>
<TI>Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients</TI>
<SO>Obesity Research</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>4</NO>
<PG>661-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363157"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363156"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollander-2007" MODIFIED="2011-11-08 13:47:50 +0100" MODIFIED_BY="Marielle JP van Avendonk" NAME="Hollander 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-11-08 13:47:50 +0100" MODIFIED_BY="Marielle JP van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollander P, Dahong Y, Chou HS</AU>
<TI>Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2007</YR>
<VL>167</VL>
<PG>1284-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363159"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363158"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holman-1987" MODIFIED="2009-12-09 22:03:57 +0100" MODIFIED_BY="[Empty name]" NAME="Holman 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-12-09 22:03:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holman RR, Steemson J, Turner RC</AU>
<TI>Sulfonylurea failure in type 2 diabetes: treatment with a basal insulin supplement</TI>
<SO>Diabetic Medicine</SO>
<YR>1987</YR>
<VL>4</VL>
<PG>457-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363161"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363160"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Home-2007" MODIFIED="2009-05-07 14:43:21 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Home 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-05-07 14:43:15 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Home PD, Bailey CJ, Donaldson J, Chen H, Stewart MW</AU>
<TI>A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes</TI>
<SO>Diabetic Medicine</SO>
<YR>2007</YR>
<VL>24</VL>
<PG>618-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363163"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363162"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inoue1998" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Inoue1998" YEAR="1998">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inoue M, Satou T, Shimizu T, Tumagari K, Ishihara H, Chino T, et al</AU>
<TI>Efficacy of sulfonylureas plus &#945;-glucosidase inhibitor plus bedtime NPH insulin combination therapy in type II diabetes patients with secondary failure using sulfonylureas</TI>
<SO>Journal of the Japan Diabetes Society</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>8</NO>
<PG>683-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363165"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363164"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacob-2007" MODIFIED="2011-10-18 18:43:15 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Jacob 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-10-18 18:43:15 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacob AN, Salinas K, Adams-Huet B, Raskin P</AU>
<TI>Weight gain in type 2 diabetes mellitus</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2007</YR>
<VL>9</VL>
<PG>386-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363167"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363166"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacober-2006" MODIFIED="2010-02-06 11:24:38 +0100" MODIFIED_BY="[Empty name]" NAME="Jacober 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-02-06 11:24:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacober SJ, Scism-Bacon JL, Zagar AJ</AU>
<TI>A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2006</YR>
<VL>8</VL>
<PG>448-55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363169"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363168"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janka-2005" MODIFIED="2011-10-18 18:43:33 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Janka 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-10-18 18:43:33 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H</AU>
<TI>Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy or type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2005</YR>
<VL>28</VL>
<PG>254-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363171"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363170"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janka-2007" MODIFIED="2011-10-18 18:44:38 +0200" MODIFIED_BY="[Empty name]" NAME="Janka 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-10-18 18:44:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janka HU, Plewe G, Busch K</AU>
<TI>Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus</TI>
<SO>Journal of American Geriatrics Society</SO>
<YR>2007</YR>
<VL>55</VL>
<PG>182-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363173"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363172"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Juurinen-2008" MODIFIED="2011-10-18 18:44:52 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Juurinen 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-10-18 18:44:52 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Juurinen L, Kotronen A, Granér M, Yki-Jarvinen H</AU>
<TI>Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2008</YR>
<VL>93</VL>
<NO>1</NO>
<PG>118-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363175"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363174"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Juurinen-2009" MODIFIED="2015-01-12 18:33:44 +0100" MODIFIED_BY="[Empty name]" NAME="Juurinen 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-01-12 18:33:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Juurinen L, Tiikkainen M, Saltevot J, Nikkila K, Lanki H, Leppavuori E</AU>
<TI>Nateglinide combination therapy with basal insulin and metformin in patients with type 2 diabetes</TI>
<SO>Diabetic Medicine</SO>
<YR>2009</YR>
<VL>26</VL>
<PG>409-15</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363177"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363176"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kabadi-2003" MODIFIED="2011-10-18 18:45:07 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Kabadi 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-10-18 18:45:07 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kabadi MU, Kabadi UM</AU>
<TI>Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus</TI>
<SO>The Annals of Pharmacotherapy</SO>
<YR>2003</YR>
<VL>37</VL>
<PG>1572-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363179"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363178"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanda-1996" MODIFIED="2011-10-18 18:45:28 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Kanda 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-10-18 18:45:28 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanda T, Imano E, Matsushima H, Wada M, Kubota M, Yamasaki Y et al</AU>
<TI>The usefulness of combination therapy with preprandial rapid-acting insulin injections and &#945;-glucosidase inhibitor in non-obese NIDDM patients with secondary failure on oral hypoglycemic agents</TI>
<SO>Journal of Japanese Diabetes Association</SO>
<YR>1996</YR>
<VL>39</VL>
<NO>3</NO>
<PG>183-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363181"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363180"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kandalintseva-2008" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Kandalintseva 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kandalintseva OA, Ametov AS</AU>
<TI>Effects of combined treatment with rosiglitazone and NPH insulin on carbohydrate metabolism in patients with type 2 diabetes mellitus</TI>
<SO>Terapevticeskij Arhiv</SO>
<YR>2008</YR>
<VL>80</VL>
<NO>12</NO>
<PG>40-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363183"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-12-15 19:19:13 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363182"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karlander-1991" MODIFIED="2011-10-18 18:45:52 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Karlander 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-10-18 18:45:52 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karlander SG, Gutniak MKM, Efendic S</AU>
<TI>Effects of combination therapy with glyburide and insulin on serum lipid levels in NIDDM patients with secondary sulfonylurea failure</TI>
<SO>Diabetes Care</SO>
<YR>1991</YR>
<VL>14</VL>
<PG>963-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363185"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363184"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kilo-2003" MODIFIED="2009-05-07 16:48:42 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Kilo 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-07 16:48:42 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P</AU>
<TI>Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin</TI>
<SO>Journal of Diabetes and Its Complications</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>307-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363187"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363186"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kokic-2003" MODIFIED="2011-10-18 18:46:14 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Kokic 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-10-18 18:46:14 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kokic S, Bukovic D, Radman M, Capkun V, Gabric N, Lesko V et al</AU>
<TI>Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure</TI>
<SO>Collegium Antropologicum</SO>
<YR>2003</YR>
<VL>27</VL>
<PG>181-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363189"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363188"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kothny-2013" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Kothny 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V</AU>
<TI>Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus</TI>
<SO>Diabetes, Obesity &amp; Metabolism</SO>
<YR>2013</YR>
<VL>15</VL>
<NO>3</NO>
<PG>252-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363191"/><IDENTIFIER TYPE="PUBMED" VALUE="23039321"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363190"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kvapil-2006" MODIFIED="2009-05-07 16:55:28 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Kvapil 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-05-07 16:55:25 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kvapil M, Swatko A, Hilberg C, Shestakova M</AU>
<TI>Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2006</YR>
<VL>8</VL>
<PG>39-48</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363193"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363192"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LAPToP-2004" MODIFIED="2009-05-10 15:00:21 +0200" MODIFIED_BY="[Empty name]" NAME="LAPToP 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-05-10 15:00:21 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>LAPToP Studie</AU>
<TO>Lantus in der BOT ist dem Standard-Mischinsulin uberlegen</TO>
<SO>Krankenpflege</SO>
<YR>2004</YR>
<VL>42</VL>
<PG>172</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363195"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363194"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lins-1988" MODIFIED="2011-10-18 18:46:34 +0200" MODIFIED_BY="[Empty name]" NAME="Lins 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-10-18 18:46:34 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lins P, Lundland S, Persson-Trotzig E, Adamson U</AU>
<TI>Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1988</YR>
<VL>223</VL>
<PG>171-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363197"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363196"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2003" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Liu 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu HX, Qin AP, He BX</AU>
<TI>Clinical observation of efficacy of rosiglitazone combined with insulin in treatment of elderly type 2 diabetes mellitus</TI>
<SO>Journal of Chinese Physician</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>11</NO>
<PG>1502-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363199"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363198"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lotz-1988" MODIFIED="2009-12-09 22:03:42 +0100" MODIFIED_BY="[Empty name]" NAME="Lotz 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-12-09 22:03:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lotz N, Bachmann W, Ladik T, Mehnert H</AU>
<TI>The combination of insulin and sulfonylureas in the treatment of type 2 diabetes with 'secondary failure of sulfonylurea therapy' - long term results</TI>
<TO>Die Kombinationstherapie Insulin/Sulfonylharnstoff in der Langzeittherapie des type-II-Diabetes nach 'Sekundarversagen'</TO>
<SO>Klinische Wochenschrift</SO>
<YR>1988</YR>
<VL>66</VL>
<PG>1079-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363201"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363200"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lund-2009" MODIFIED="2010-06-03 12:09:18 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Lund 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-06-03 12:09:18 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O et al</AU>
<TI>Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blinded trial</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>339</VL>
<NO>b4324</NO>
<PG>DOI:10.1136/bmj.b4324</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363203"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363202"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundershausen-1987" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Lundershausen 1987" YEAR="1987">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lundershausen R, Orban S, Pissarek D, Panzram G</AU>
<TI>Long-term effect of glibenclamide-insulin combination therapy in the management of secondary drug failure - results of a double-blind one-year follow-up study</TI>
<TO>Langzeiteffekt der glibenclamid-insulin-kombinationsbehandlung beim sekundarversagen der sulfonylharnstofftherapie - ergebnisse einer einjahrigen doppelblindstudie</TO>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1987</YR>
<VL>99</VL>
<PG>603-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363205"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363204"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Makimattila-1999" MODIFIED="2009-05-07 17:06:30 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Makimattila 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-05-07 17:06:28 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Makimatilla S, Nikkila K, Yki-Jarvinen H</AU>
<TI>Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus</TI>
<SO>Diabetologia</SO>
<YR>1999</YR>
<VL>42</VL>
<PG>406-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363207"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363206"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohan-1990" MODIFIED="2011-10-18 18:48:37 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Mohan 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-10-18 18:48:37 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohan V, Snehalatha C, Ramachandran A, Viswanathan M</AU>
<TI>Combination therapy of glibenclamide and insulin in NIDDM patients with secondary failure to oral drugs</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>1990</YR>
<VL>38</VL>
<PG>537-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363209"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363208"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morrow-2011" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Morrow 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morrow L, Hompesch M, Guthrie H, Chang D, Chatterjee DJ</AU>
<TI>Co-administration of liraglutide with insulin detetmir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2011</YR>
<VL>13</VL>
<PG>75</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363211"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363210"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olsson-2002" MODIFIED="2011-10-18 18:48:49 +0200" MODIFIED_BY="[Empty name]" NAME="Olsson 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-10-18 18:48:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olsson PO, Lindstrom T</AU>
<TI>Combination-therapy with bedtime NPH insulin and sulphonylurea gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes</TI>
<SO>Diabetes and Metabolism</SO>
<YR>2002</YR>
<VL>28</VL>
<PG>272-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363213"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363212"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ose-2005" MODIFIED="2011-10-18 18:49:00 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Ose 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-10-18 18:49:00 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ose H, Fukui M, Kitagawa Y, Hirata C, Ichio N, Kadono M et al</AU>
<TI>Efficacy of glimepiride in patients with poorly controlled insulin-treated type 2 diabetes mellitus</TI>
<SO>Endocrine Journal</SO>
<YR>2005</YR>
<VL>52</VL>
<NO>5</NO>
<PG>563-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363215"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363214"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozbek-2006" MODIFIED="2010-06-03 12:10:20 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Ozbek 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-03 12:10:20 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ozbek M, Erdogan M, Karadeniz M, Cetinkalp S, Ozgen AG, Saygili F et al</AU>
<TI>Preprandial repaglinide decreases exogenous insulin requirements and HbA1c levels in type 2 diabetic patients taking intensive insulin treatment</TI>
<SO>Acta Diabetologica</SO>
<YR>2006</YR>
<VL>43</VL>
<PG>148-51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363217"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363216"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pan-2007" MODIFIED="2011-10-18 18:49:18 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Pan 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-10-18 18:49:18 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pan C, Sinnassamy P, Chung K, Kim K, on behalf of the LEAD Study Investigators Group</AU>
<TI>Insulin glargine versus NPH insulin therapy ins Asian type 2 diabetes patients</TI>
<SO>Diabetes Research and Clinical Practice</SO>
<YR>2007</YR>
<VL>76</VL>
<PG>111-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363219"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363218"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peacock-1984" MODIFIED="2011-10-18 18:49:47 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Peacock 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-10-18 18:49:47 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peacock I, Tattersall RB</AU>
<TI>The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin?</TI>
<SO>British Medical Journal</SO>
<YR>1984</YR>
<VL>288</VL>
<PG>1956-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363221"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363220"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peyrot-2008" MODIFIED="2011-10-18 18:49:58 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Peyrot 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-10-18 18:49:58 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peyrot M, Rubin RR, Polonsky WH</AU>
<TI>Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy</TI>
<SO>Diabetes Technology &amp; Therapeutics</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>6</NO>
<PG>461-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363223"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363222"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ponssen-2000" MODIFIED="2009-05-10 14:42:43 +0200" MODIFIED_BY="[Empty name]" NAME="Ponssen 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-05-10 14:42:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponssen HH, Elte JWF, Lehert P, Schouten JP, Bets D</AU>
<TI>Combined metformin and insulin therapy for patients with type 2 diabetes mellitus</TI>
<SO>Clinical Therapeutics</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>6</NO>
<PG>709-18</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363225"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363224"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pontiroli-1990" MODIFIED="2011-10-18 18:50:13 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Pontiroli 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-10-18 18:50:13 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pontiroli AE, Dino G, Capra F, Pozza G</AU>
<TI>Combined therapy with glibenclamide and ultralente insulin in lean patients with NIDDM with secondary failure of sulfonylureas. Follow up at two years</TI>
<SO>Diabete &amp; Metabolisme</SO>
<YR>1990</YR>
<VL>16</VL>
<PG>323-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363227"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363226"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poulsen-2003" MODIFIED="2011-10-18 18:50:19 +0200" MODIFIED_BY="[Empty name]" NAME="Poulsen 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-10-18 18:50:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poulsen MK, Henriksen JE, Hother-Nielsen O, Beck-Nielsen H</AU>
<TI>The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients</TI>
<SO>Diabetes Care</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>12</NO>
<PG>3273-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363229"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363228"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raskin-2001" MODIFIED="2011-11-08 13:48:05 +0100" MODIFIED_BY="Marielle JP van Avendonk" NAME="Raskin 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-11-08 13:48:05 +0100" MODIFIED_BY="Marielle JP van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J, for the Rosiglitazone Clinical Trials Study Group</AU>
<TI>A randomized trial of rosiglitazone therapy inpatients with inadequately controlled insulin-treated type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2001</YR>
<VL>24</VL>
<PG>1226-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363231"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363230"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ravnik-1989" MODIFIED="2011-10-18 18:50:29 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Ravnik 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-10-18 18:50:29 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ravnik-Oblak M</AU>
<TI>The rationality and effectiveness of insulin therapy in elderly patients with type II diabetes</TI>
<SO>Diabetologia Croatica</SO>
<YR>1989</YR>
<VL>18</VL>
<PG>163-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363233"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363232"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ravnik-1995" MODIFIED="2009-05-07 17:46:10 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Ravnik 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-05-07 17:46:07 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ravnik-Oblak M, Mrevlje F</AU>
<TI>insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure</TI>
<SO>Diabetes Research and Clinical Practice</SO>
<YR>1995</YR>
<VL>30</VL>
<PG>27-35</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363235"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363234"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raz-2005" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Raz 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raz I, Stranks S, Filipczak R, Joshi P, Lertoft B, Rastam J, et al</AU>
<TI>Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week randomized, open-label study</TI>
<SO>Clinical Therapeutics</SO>
<YR>2005</YR>
<VL>27</VL>
<NO>9</NO>
<PG>1432-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363237"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363236"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riddle-1989" MODIFIED="2011-10-18 18:50:47 +0200" MODIFIED_BY="[Empty name]" NAME="Riddle 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-10-18 18:50:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riddle MC, Hart JS, Bouma DJ, Phillipson BE, Youker G</AU>
<TI>Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects</TI>
<SO>Diabetes Care</SO>
<YR>1989</YR>
<VL>12</VL>
<NO>9</NO>
<PG>623-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363239"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363238"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riddle-1992" MODIFIED="2011-10-18 18:51:03 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Riddle 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-10-18 18:51:03 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riddle M, Hart J, Bingham P, Garrison C, McDaniel P</AU>
<TI>Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea</TI>
<SO>American Journal of Medical Sciences</SO>
<YR>1992</YR>
<VL>303</VL>
<NO>3</NO>
<PG>151-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363241"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363240"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riddle-1998" MODIFIED="2011-10-18 18:51:09 +0200" MODIFIED_BY="[Empty name]" NAME="Riddle 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-10-18 18:51:09 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riddle MC, Schneider J, The Glimepiride Combination Group</AU>
<TI>Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>7</NO>
<PG>1052-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363243"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363242"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riddle-2007" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Riddle 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, et al</AU>
<TI>Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin</TI>
<SO>Diabetes care</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>11</NO>
<PG>2794-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363245"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363244"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosak-1985" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Rosak 1985" YEAR="1985">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosak C, Schwarz O, Althoff PH, Schoffling K, Schmidt FH</AU>
<TI>Combination treatment of type II diabetics with insulin and glibenclamide following secondary failure</TI>
<TO>Kombinierte behandlung von typ-II-diabetikern mit insulin und glibenclamid nach tablettensekundarversagen</TO>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1985</YR>
<VL>110</VL>
<PG>1975-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363247"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363246"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sachse-1984" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Sachse 1984" YEAR="1984">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sachse G, Maser E, Federlin K</AU>
<TI>Combination of insulin and glibenclamide in secondary failure of sulphonylurea treatment?</TI>
<TO>Kombinationstherapie mit insulin und sulfonylharnstoffen bei sekundarversagen der sulfonylharnstofftherapie?</TO>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>1984</YR>
<VL>109</VL>
<PG>419-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363249"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363248"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sangiorgio-2000" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Sangiorgio 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sangiorgio L, Attardo T, Condorelli L, Lunetta M</AU>
<TI>Effects of the treatment with acarbose in elderly overweight type 2 diabetic patients in poor glycemic control with oral hypoglycemic agents or insulin</TI>
<SO>Archives Gerontology and Geriatrics</SO>
<YR>2000</YR>
<VL>31</VL>
<PG>27-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363251"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363250"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-1986" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Schmidt 1986" YEAR="1986">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt FH, Klujko J, Kuhnle HF, Reiter J</AU>
<TI>The mode of action of the combination glibenclamide/insulin in type-II-diabetics</TI>
<TO>Untersuchungen zum wirkungsmechanismus de kombinierten gabe von glibenclamid und insulin bei type-II-diabetikern mit sekundarversagen auf die orale behandlung</TO>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1986</YR>
<VL>64</VL>
<PG>1021-28</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363253"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363252"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schnell-2006" MODIFIED="2011-10-18 18:52:59 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Schnell 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-10-18 18:52:59 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schnell O, Mertes G, Standl E, on behalf of the Acarbose-Insulin Combination Study Group</AU>
<TI>Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2007</YR>
<VL>9</VL>
<PG>853-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363255"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363254"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwartz-1998" MODIFIED="2011-10-18 18:52:45 +0200" MODIFIED_BY="[Empty name]" NAME="Schwartz 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-10-18 18:52:45 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwartz S, Raskin P, Fonseca V, Graveline JF; Troglitazone and Exogenous Insulin Study Group</AU>
<TI>Effect of troglitazone in insulin-treated patients with type II diabetes mellitus</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<PG>861-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363257"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363256"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-1995" MODIFIED="2011-10-18 18:53:12 +0200" MODIFIED_BY="Marielle van Avendonk" NAME="Sun 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-10-18 18:53:12 +0200" MODIFIED_BY="Marielle van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun Y, Xiong Y, Yang J et al</AU>
<TI>The effectiveness of combined insulin and sulfonylurea in treating non-insulin dependent diabetic patients</TI>
<SO>Zhonghua Nei Ke Za Zhi</SO>
<YR>1995</YR>
<VL>34</VL>
<NO>4</NO>
<PG>246-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363259"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363258"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tamemoto-2007" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Tamemoto 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tamemoto H, Ikoma A, Saitoh T, Ishikawa A, Kawakami M</AU>
<TI>Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naive Japanese patients with diabetes</TI>
<SO>Diabetes Technology &amp; Therapeutics</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>3</NO>
<PG>246-53</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363261"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363260"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vilsboll-2010" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Vilsboll 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vilsboll T, Rosenstock J, Yki-Jarvinen H, Cefalu WT, Chen Y, Luo E, et al</AU>
<TI>Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2010</YR>
<VL>12</VL>
<PG>167-77</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363263"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363262"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Willey-1994" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Willey 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Willey KA, Molyneaux LM, Yue DK</AU>
<TI>Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexflenfluramine therapy on glycaemic control</TI>
<SO>Diabetic Medicine</SO>
<YR>1994</YR>
<VL>11</VL>
<PG>701-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363265"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363264"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolffenbuttel-1991" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Wolffenbuttel 1991" YEAR="1991">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolffenbuttel BHR, Rondas-Colbers GJWM, Menheere PPCA, Sels JPJE, Nieuwenhuijzen Kruseman AC</AU>
<TI>The effects of insulin in combination with glibenclamide on glucose and lipid metabolism in patients with type II diabetes mellitus</TI>
<TO>De effecten van insuline in combinatie met glibenclamide op glucose- en vetstofwisseling bij patiënten met diabetes mellitus type II</TO>
<SO>Nederlands Tijdschrift Voor Geneeskunde</SO>
<YR>1991</YR>
<VL>135</VL>
<NO>24</NO>
<PG>1080-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363267"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363266"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolffenbuttel-1999" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Wolffenbuttel 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolffenbuttel BHR, Sels JPJE, Rondas-Colbers JWM, Menheere PPCA</AU>
<TI>Prognostic factors for successful insulin therapy in subjects with type 2 diabetes</TI>
<SO>Netherlands Journal of Medicine</SO>
<YR>1999</YR>
<VL>54</VL>
<PG>63-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363269"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363268"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-2005" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Wong 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong TY, Szeto C, Chow K, Leung C, Lam CW, Li PK</AU>
<TI>Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>4</NO>
<PG>713-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363271"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363270"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wright-2002" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Wright 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR for the UK Prospective Diabetes Study group</AU>
<TI>Sulfonylurea inadequacy. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)</TI>
<SO>Diabetes Care</SO>
<YR>2002</YR>
<VL>25</VL>
<PG>330-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363273"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363272"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamada-2007" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Yamada 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamada S, Watanabe M, Funae O, Atsumi Y, Suzuki R, Yajima K, et al</AU>
<TI>Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus</TI>
<SO>Internal Medicine</SO>
<YR>2007</YR>
<VL>46.0415</VL>
<PG>1893-7</PG>
<IDENTIFIERS MODIFIED="2016-07-25 12:47:51 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363275"/><IDENTIFIER MODIFIED="2016-07-25 12:47:51 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.2169"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363274"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yki_x002d_Jarvinen-1992" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Yki-Jarvinen 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, et al</AU>
<TI>Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>327</VL>
<PG>1426-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363277"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363276"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yki_x002d_Jarvinen-1999" MODIFIED="2009-05-10 13:19:07 +0200" MODIFIED_BY="[Empty name]" NAME="Yki-Jarvinen 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-05-10 13:19:05 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M</AU>
<TI>Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1999</YR>
<VL>130</VL>
<NO>5</NO>
<PG>389-96</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363279"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363278"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yki_x002d_Jarvinen-2013" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Yki-Jarvinen 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yki-Jarvinen H, Duran-Garcia S, Pinnetti S, Bhattacharya S, Thiemann S, Patel S, et al</AU>
<TI>Efficacy and safety of linagliptin as add-on therapy to basal insulin in patients with type 2 diabetes</TI>
<SO>Canadian Journal of Diabetes</SO>
<YR>2012</YR>
<VL>1</VL>
<PG>S39</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363281"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-07-25 12:50:24 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yki-Jarvinen H, Rosenstock J, Duran-Garcia S, Pinnetti S, Bhattacharya S, Thiemann S, et al</AU>
<TI>Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a &gt;/=52-week randomized, double-blind study</TI>
<SO>Diabetes care</SO>
<YR>2013</YR>
<VL>36</VL>
<NO>12</NO>
<PG>3875-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363282"/><IDENTIFIER TYPE="PUBMED" VALUE="24062327"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363280"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yokoyama-2011" MODIFIED="2011-11-01 15:15:15 +0100" MODIFIED_BY="Marielle JP van Avendonk" NAME="Yokoyama 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-11-01 15:15:13 +0100" MODIFIED_BY="Marielle JP van Avendonk" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yokoyama H, Sone H, Yamada D, Honjo J, Haneda M</AU>
<TI>Contribution of glimepiride to basal-prandial insulin therapy in patients with type 2 diabetes</TI>
<SO>Diabetes Research and Clinical Practice</SO>
<YR>2011</YR>
<VL>91</VL>
<PG>148-53</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363284"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363283"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zargar-2002" MODIFIED="2011-10-18 18:57:33 +0200" MODIFIED_BY="[Empty name]" NAME="Zargar 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-10-18 18:57:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zargar AH, Masoodi SR, Laway BA, Wani AI, Bashir MI</AU>
<TI>Response to regimens of insulin therapy in type 2 diabetes mellitus subjects with secondary failure</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>2002</YR>
<VL>50</VL>
<PG>641-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363286"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363285"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<STUDY DATA_SOURCE="PUB" ID="STD-Fargren-2014" MODIFIED="2016-04-28 16:48:39 +0200" MODIFIED_BY="[Empty name]" NAME="Fargren 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-04-28 16:48:39 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farngren J, Persson M, Schweizer A, Foley J, Ahren B</AU>
<TI>Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes</TI>
<SO>Diabetes, Obesity &amp; Metabolism</SO>
<YR>2014</YR>
<VL>16</VL>
<PG>812-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363288"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363287"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaku-2014" MODIFIED="2016-04-28 16:49:09 +0200" MODIFIED_BY="[Empty name]" NAME="Kaku 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-04-28 16:49:09 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaku K, Mori M, Kanoo T, Katou M, Seino Y</AU>
<TI>Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2014</YR>
<VL>15</VL>
<PG>2121-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363290"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363289"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mathieu-2015" MODIFIED="2016-04-28 16:49:56 +0200" MODIFIED_BY="[Empty name]" NAME="Mathieu 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-04-28 16:49:56 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathieu C, Shankar R, Lorber D, Umpierrez G, Wu F, Xu L, et al</AU>
<TI>A randomized clinical trial to evaluate the efficacy and safety of co-administration of sitagliptin with intensively titrated insulin glargine</TI>
<SO>Diabetes Therapy</SO>
<YR>2015</YR>
<VL>6</VL>
<PG>127-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363292"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363291"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGill-2015" MODIFIED="2016-07-25 12:52:58 +0200" MODIFIED_BY="[Empty name]" NAME="McGill 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-07-25 12:52:58 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McGill J, Yki-Jarvinen H, Crowe S, Woerle HJ, Eynatten M</AU>
<TI>Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease</TI>
<SO>Diabetes &amp; Vascular Disease Research</SO>
<YR>2015</YR>
<VL>12</VL>
<PG>249-57</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363294"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-28 16:50:29 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGill JB, Yki-Jarvinen H, Duran-Garcia S, Thiemann S, Hehnke U, Pinnetti S, et al</AU>
<TI>Efficacy and safety of linagliptin as add-on to basal insulin in patients with type 2 diabetes and renal impairment</TI>
<SO>Diabetes</SO>
<YR>2014</YR>
<VL>63</VL>
<PG>A264</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363295"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363293"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ning-2014" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Ning 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-04-28 16:51:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ning G, Li L, Ma J, Lv X, Yang M, Wang W, et al</AU>
<TI>Vildagliptin as add-on to insulin improves glycaemic control without increased risk of hypoglycaemia in Asian (predominantly Chinese) patients with type 2 diabetes mellitus</TI>
<SO>Diabetologia</SO>
<YR>2014</YR>
<VL>57</VL>
<PG>S330</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363297"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ning G, Wang W, Li L, Ma J, Lv X, Yang M, et al</AU>
<TI>Vildagliptin as an add-on therapy to insulin improves glycemic control without an increased risk of hypoglycemia: a dedicated Asian study, in a predominantly Chinese population</TI>
<SO>Diabetes</SO>
<YR>2014</YR>
<VL>63</VL>
<PG>A274</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363298"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363296"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenstock-2009" MODIFIED="2015-12-15 19:45:13 +0100" MODIFIED_BY="[Empty name]" NAME="Rosenstock 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-12-15 19:45:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q</AU>
<TI>Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia</TI>
<SO>Diabetes, Obesity and Metabolism</SO>
<YR>2009</YR>
<VL>11</VL>
<PG>1145-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363300"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363299"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sato-2015" MODIFIED="2016-04-28 16:47:56 +0200" MODIFIED_BY="[Empty name]" NAME="Sato 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-04-28 16:47:56 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sato S, Saisho Y, Kou K, Meguro S, Tanaka M, Irie J, et al</AU>
<TI>Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial</TI>
<SO>PLoS ONE</SO>
<YR>2015</YR>
<VL>10</VL>
<PG>e0121988</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363302"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363301"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheu-2015" MODIFIED="2016-04-28 16:52:46 +0200" MODIFIED_BY="[Empty name]" NAME="Sheu 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-04-28 16:52:46 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheu WH, Park S, Gong Y, Pinnetti S, Bhattacharya S, Patel S, et al</AU>
<TI>Linagliptin improves glycaemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2015</YR>
<VL>31</VL>
<PG>503-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363304"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363303"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Srivanichakorn-2015" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Srivanichakorn 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Srivanichakorn W, Sriwijitkamol A, Kongchoo A, Sriussadaporn S, Plengvidhya N, Lertwattanarak R, et al</AU>
<TI>Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial</TI>
<SO>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</SO>
<YR>2015</YR>
<VL>8</VL>
<PG>137-45</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363306"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363305"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takahashi-2015" MODIFIED="2016-04-28 16:53:57 +0200" MODIFIED_BY="[Empty name]" NAME="Takahashi 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-04-28 16:53:57 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takahashi H, Sakai K, Kawanishi K, Suzuki J, Igawa K, Sankoda K, et al</AU>
<TI>Efficacy of switching from premix analog insulin twice daily injection to insulin glargine once daily injection with sitagliptin</TI>
<SO>Diabetology International</SO>
<YR>2015</YR>
<VL>6</VL>
<PG>33-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363308"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363307"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<STUDY DATA_SOURCE="PUB" ID="STD-EUCTR2011_x002d_004622_x002d_96_x002d_ES" MODIFIED="2016-04-28 16:59:20 +0200" MODIFIED_BY="[Empty name]" NAME="EUCTR2011-004622-96-ES" YEAR="2011">
<REFERENCE MODIFIED="2016-04-28 16:59:20 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>EUCTR2011-004622-96-ES</AU>
<TI>Study to test the safety, tolerability, and effectiveness of sitagliptin when compared to placebo in reducing the amount of insulin (with or without metformin) needed per day, to control blood sugar, over a 24-week period</TI>
<SO>http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011-004622-96-ES</SO>
<YR>(accessed 28 April 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363310"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363309"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IRCT201204229536N1" MODIFIED="2016-04-28 17:00:08 +0200" MODIFIED_BY="[Empty name]" NAME="IRCT201204229536N1" YEAR="2012">
<REFERENCE MODIFIED="2016-04-28 17:00:06 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>IRCT201204229536N1</AU>
<TI>The comparison glycemic control in two group patient treated with insulin alone and insulin plus sulfunyl urea</TI>
<SO>http://apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT201204229536N1</SO>
<YR>(accessed 28 April 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363312"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363311"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-JPRN_x002d_UMIN000011851" MODIFIED="2016-04-28 16:58:21 +0200" MODIFIED_BY="[Empty name]" NAME="JPRN-UMIN000011851" YEAR="2013">
<REFERENCE MODIFIED="2016-04-28 16:58:21 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>JPRN-UMIN000011851</AU>
<TI>The efficacy of vildagliptin on type 2 diabetic patients with basal-bolus insulin therapy in the short-term hospitalization (single-center, randomized, open-label, controlled study)</TI>
<SO>http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000011851</SO>
<YR>(accessed 28 April 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363314"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363313"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-JPRN_x002d_UMIN000018784" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="JPRN-UMIN000018784" YEAR="2015">
<REFERENCE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" PRIMARY="NO" TYPE="OTHER">
<AU>JPRN-UMIN000018784</AU>
<TI>Comparison of the effects of insulin monotherapy and combination therapy with ipragliflozin and insulin on glucose toxicity in type 2 diabetes mellitus : a randomized controlled trial</TI>
<SO>http://apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000018784</SO>
<YR>(accessed 28 April 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363316"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363315"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00329225" MODIFIED="2016-04-28 17:02:19 +0200" MODIFIED_BY="[Empty name]" NAME="NCT00329225" YEAR="">
<REFERENCE MODIFIED="2016-04-28 17:02:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00329225</AU>
<TI>Rosiglitazone in subjects with type 2 diabetes mellitus who are inadequately controlled on insulin</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT00329225</SO>
<YR>(accessed 28 April 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363318"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363317"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00757588" MODIFIED="2016-04-28 17:03:24 +0200" MODIFIED_BY="[Empty name]" NAME="NCT00757588" YEAR="">
<REFERENCE MODIFIED="2016-04-28 17:03:24 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00757588</AU>
<TI>Safety and efficacy of saxagliptin plus insulin with or without metformin</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT00757588</SO>
<YR>(accessed 28 April 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363320"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363319"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02104804" MODIFIED="2016-04-28 17:04:52 +0200" MODIFIED_BY="[Empty name]" NAME="NCT02104804" YEAR="">
<REFERENCE MODIFIED="2016-04-28 17:04:52 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02104804</AU>
<TI>Evaluate the efficacy and safety of saxagliptin added to insulin monotherapy or to insulin combined with metformin in Chinese subjects with type 2 diabetes who have inadequate glycaemic control</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT02104804</SO>
<YR>(accessed 28 April 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4363322"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4363321"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<ADDITIONAL_REFERENCES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<REFERENCE ID="REF-ACCORD-2008" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="ACCORD 2008" TYPE="JOURNAL_ARTICLE">
<AU>The Action to Control Cardiovascular Risk in Diabetes Study Group</AU>
<TI>Effects of intensive glucose lowering in type 2 diabetes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>358</VL>
<NO>24</NO>
<PG>2545-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-1997" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="ADA 1997" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetes Association</AU>
<TI>Report on the Expert Committee on the diagnosis and classification of diabetes mellitus</TI>
<SO>Diabetes Care</SO>
<YR>1997</YR>
<VL>20 Suppl 1</VL>
<PG>S5-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADA-1999" NAME="ADA 1999" TYPE="JOURNAL_ARTICLE">
<AU>The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus</AU>
<TI>Report of the Expert Committee on the diagnosis and classification of diabetes mellitus</TI>
<SO>Diabetes Care</SO>
<YR>1999</YR>
<VL>22 Suppl 1</VL>
<PG>S5-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ADVANCE-2008" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="ADVANCE 2008" TYPE="JOURNAL_ARTICLE">
<AU>The ADVANCE Collaborative Group</AU>
<TI>Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>358</VL>
<NO>24</NO>
<PG>2560-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Armitage-2002" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Armitage 2002" TYPE="BOOK_SECTION">
<AU>Armitage P, Berry G, Matthews JNS</AU>
<TI>Paragraph 5.3</TI>
<SO>Statistical Methods in Medical Research</SO>
<YR>2002</YR>
<EN>4th</EN>
<PB>Blackwell Science</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brunton-2005" MODIFIED="2011-10-18 18:59:01 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Brunton 2005" TYPE="JOURNAL_ARTICLE">
<AU>Brunton S, Carmichael B, Funnell M, Lorber D, Rakel R, Rubin R</AU>
<TI>Type 2 diabetes: the role of insulin</TI>
<SO>The Journal of Family Practice</SO>
<YR>2005</YR>
<VL>54</VL>
<NO>5</NO>
<PG>445-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Grauw-2001" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="De Grauw 2001" TYPE="JOURNAL_ARTICLE">
<AU>De Grauw WJ, Van de Lisdonk EH, Van Gerwen WH, Van den Hoogen HJ, Van Weel C</AU>
<TI>Insulin therapy in poorly controlled type 2 diabetic patients: does it affect quality of life?</TI>
<SO>British Journal of General Practice</SO>
<YR>2001</YR>
<VL>51</VL>
<NO>468</NO>
<PG>527-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Sonnaville-1998" NAME="De Sonnaville 1998" TYPE="JOURNAL_ARTICLE">
<AU>De Sonnaville JJ, Snoek FJ, Colly LP, Deville W, Wijkel D, Heine RJ</AU>
<TI>Well-being and symptoms in relation to insulin therapy in type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>6</NO>
<PG>919-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Delahanty-2007" MODIFIED="2016-05-02 12:47:15 +0200" MODIFIED_BY="Bernd Richter" NAME="Delahanty 2007" TYPE="JOURNAL_ARTICLE">
<AU>Delahanty LM, Grant RW, Wittenberg E, Bosch JL, Wexler DJ, Cagliero E, et al</AU>
<TI>Association of diabetes-related emotional distress with diabetes treatment in primary care patients with type 2 diabetes</TI>
<SO>Diabetic Medicine</SO>
<YR>2007</YR>
<VL>24</VL>
<NO>1</NO>
<PG>48&#8211;54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duckworth-2009" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Duckworth 2009" TYPE="JOURNAL_ARTICLE">
<AU>Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al</AU>
<TI>Glucose control and vascular complications in veterans with type 2 diabetes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>2</NO>
<PG>129-39</PG>
<IDENTIFIERS MODIFIED="2016-07-25 13:10:18 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gangji-2007" MODIFIED="2012-01-04 18:08:22 +0100" MODIFIED_BY="Marielle JP van Avendonk" NAME="Gangji 2007" TYPE="JOURNAL_ARTICLE">
<AU>Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM</AU>
<TI>A systematic review and meta-analysis of hypoglycaemia and cardiovascular events</TI>
<SO>Diabetes Care</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>2</NO>
<PG>389-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goddijn-1999" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Goddijn 1999" TYPE="JOURNAL_ARTICLE">
<AU>Goddijn PP, Bilo HJ, Feskens EJ, Groeniert KH, Van der Zee KI, Meyboom-de Jong B</AU>
<TI>Longitudinal study on glycaemic control and quality of life in patients with type 2 diabetes mellitus referred for intensified control</TI>
<SO>Diabetes Medicine</SO>
<YR>1999</YR>
<VL>16</VL>
<NO>1</NO>
<PG>23-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goudswaard-2004b" MODIFIED="2016-07-25 12:09:48 +0200" MODIFIED_BY="[Empty name]" NAME="Goudswaard 2004b" TYPE="COCHRANE_REVIEW">
<AU>Goudswaard AN, Furlong NJ, Rutten GE, Stolk RP, Valk GD</AU>
<TI>Insulin monotherapy versus combinations of insulin with oral glucose lowering agents in patients with type 2 diabetes mellitus</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<PG>CD003418</PG>
<IDENTIFIERS MODIFIED="2008-11-26 13:22:14 +0100" MODIFIED_BY="Gudrun Paletta"><IDENTIFIER MODIFIED="2008-11-26 13:22:10 +0100" MODIFIED_BY="Gudrun Paletta" TYPE="DOI" VALUE="10.1002/14651858.CD003418.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2011-10-18 19:00:16 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2016-07-26 12:37:31 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2009" MODIFIED="2014-10-16 16:49:21 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Higgins 2009" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Spiegelhalter DJ</AU>
<TI>A re-evaluation of random-effects meta-analysis</TI>
<SO>Journal of the Royal Statistical Society. Series A, (Statistics in Society)</SO>
<YR>2009</YR>
<VL>172</VL>
<NO>1</NO>
<PG>137-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2016-07-26 12:45:09 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Higgins 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al</AU>
<TI>The Cochrane Collaboration's tool for assessing risk of bias in randomised trials</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d5928</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011c" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Higgins 2011c" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ, Altman DG (editors)</AU>
<TI>Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holman-2008" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Holman 2008" TYPE="JOURNAL_ARTICLE">
<AU>Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA</AU>
<TI>10-year follow-up of intensive glucose control in type 2 diabetes</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>359</VL>
<NO>15</NO>
<PG>1577-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hr_x00f3_bjartsson-2013" MODIFIED="2014-10-16 16:49:21 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Hróbjartsson 2013" TYPE="JOURNAL_ARTICLE">
<AU>Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al</AU>
<TI>Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2013</YR>
<VL>185</VL>
<NO>4</NO>
<PG>E201-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunt-1997" MODIFIED="2008-11-11 19:59:09 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Hunt 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hunt LM, Valenzuela MA, Pugh JA</AU>
<TI>NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance</TI>
<SO>Diabetes Care</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>3</NO>
<PG>292-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Inzucchi-2012" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Inzucchi 2012" TYPE="JOURNAL_ARTICLE">
<AU>Inzucchi SE, Bergenstal RM, Buse JB</AU>
<TI>Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA)and the European Association for the study of Diabetes (EASD)</TI>
<SO>Diabetes Care</SO>
<YR>2012</YR>
<VL>35</VL>
<PG>1364-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-1996" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Johnson 1996" TYPE="JOURNAL_ARTICLE">
<AU>Johnson JL, Wolf SL, Kabadi UM</AU>
<TI>Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1996</YR>
<VL>156</VL>
<NO>3</NO>
<PG>259-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karlsen-2014" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Karlsen 2014" TYPE="JOURNAL_ARTICLE">
<AU>Karlsen B, Bru E</AU>
<TI>The relationship between diabetes-related distress and clinical variables and perceived support among adults with type 2 diabetes: a prospective study</TI>
<SO>International Journal of Nursing Studies</SO>
<YR>2014</YR>
<VL>51</VL>
<PG>438-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kooy-2009" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Kooy 2009" TYPE="JOURNAL_ARTICLE">
<AU>Kooy A, de Jager J, Lehert P, Bets D, Wulffele MG, Donker AJM, et al</AU>
<TI>Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients With type 2 diabetes mellitus</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2009</YR>
<VL>169</VL>
<NO>9</NO>
<PG>616-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Korytkowski-2002" MODIFIED="2011-10-18 19:02:00 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Korytkowski 2002" TYPE="JOURNAL_ARTICLE">
<AU>Korytkowski M</AU>
<TI>When oral agents fail: practical barriers to starting insulin</TI>
<SO>International Journal of Obesity Related Metabolic Disorders</SO>
<YR>2002</YR>
<VL>26 Suppl 3</VL>
<PG>S18-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lexchin-2003" MODIFIED="2016-07-26 13:42:28 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Lexchin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lexchin J, Bero LA, Djulbegovic B, Clark O</AU>
<TI>Pharmaceutical industry sponsorship and research outcome and quality: systematic review</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>326</VL>
<PG>1167-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liberati-2009" MODIFIED="2014-10-16 16:49:21 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Liberati 2009" TYPE="JOURNAL_ARTICLE">
<AU>Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al</AU>
<TI>The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration</TI>
<SO>PLoS Medicine</SO>
<YR>2009</YR>
<VL>6</VL>
<NO>7</NO>
<PG>1-28</PG>
<IDENTIFIERS><IDENTIFIER TYPE="DOI" VALUE="10.1371/journal.pmed.1000100"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Muis-2005" MODIFIED="2008-11-11 19:59:17 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Muis 2005" TYPE="JOURNAL_ARTICLE">
<AU>Muis MJ, Bots ML, Bilo HJ, Hoogma RP, Hoekstra JB, Grobbee DE</AU>
<TI>High cumulative insulin exposure: a risk factor of atherosclerosis in type 1 diabetes?</TI>
<SO>Atherosclerosis</SO>
<YR>2005</YR>
<VL>181</VL>
<NO>1</NO>
<PG>185-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peters-1991" MODIFIED="2011-10-18 19:03:16 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Peters 1991" TYPE="JOURNAL_ARTICLE">
<AU>Peters AL, Davidson MB</AU>
<TI>Insulin plus a sulfonylurea agent for treating type 2 diabetes</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1991</YR>
<VL>115</VL>
<NO>1</NO>
<PG>45-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pugh-1992" MODIFIED="2008-11-11 19:59:20 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Pugh 1992" TYPE="JOURNAL_ARTICLE">
<AU>Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ</AU>
<TI>Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A meta analysis</TI>
<SO>Diabetes Care</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>8</NO>
<PG>953-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riley-2011" MODIFIED="2014-10-16 16:49:21 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Riley 2011" TYPE="JOURNAL_ARTICLE">
<AU>Riley RD, Higgins JP, Deeks JJ</AU>
<TI>Interpretation of random effects meta-analyses</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>342</VL>
<PG>d549</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ruige-1998" NAME="Ruige 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM</AU>
<TI>Insulin and risk of cardiovascular disease: a meta-analysis</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>97</VL>
<NO>10</NO>
<PG>996-1001</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011" MODIFIED="2016-07-26 12:49:48 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Schünemann 2011" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH</AU>
<TI>Chapter 11: Presenting results and &#8216;Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Snoek-2002" MODIFIED="2008-11-11 19:59:43 +0100" MODIFIED_BY="Gudrun Paletta" NAME="Snoek 2002" TYPE="JOURNAL_ARTICLE">
<AU>Snoek FJ</AU>
<TI>Breaking the barriers to optimal glycaemic control--what physicians need to know from patients' perspectives</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2002</YR>
<VL>129</VL>
<NO>Supplement</NO>
<PG>80-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2014-10-16 16:49:21 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Sterne 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J et al</AU>
<TI>Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d4002</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stout-1990" NAME="Stout 1990" TYPE="JOURNAL_ARTICLE">
<AU>Stout RW</AU>
<TI>Insulin and atheroma. 20-yr perspective</TI>
<SO>Diabetes Care</SO>
<YR>1990</YR>
<VL>13</VL>
<NO>6</NO>
<PG>631-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turner-1999" MODIFIED="2011-10-18 19:04:22 +0200" MODIFIED_BY="[Empty name]" NAME="Turner 1999" TYPE="JOURNAL_ARTICLE">
<AU>Turner RC, Cull CA, Frighi V, Holman RR</AU>
<TI>Glycaemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group</TI>
<SO>Journal of American Medical Association</SO>
<YR>1999</YR>
<VL>281</VL>
<NO>21</NO>
<PG>2005-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UKPDS-33" MODIFIED="2011-10-18 19:04:41 +0200" MODIFIED_BY="[Empty name]" NAME="UKPDS 33" TYPE="JOURNAL_ARTICLE">
<AU>UK Prospective Diabetes Study</AU>
<TI>Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>837-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-UKPDS-34" MODIFIED="2009-12-22 12:29:26 +0100" MODIFIED_BY="[Empty name]" NAME="UKPDS 34" TYPE="JOURNAL_ARTICLE">
<AU>UK Prospective Diabetes Study (UKPDS)</AU>
<TI>Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9131</NO>
<PG>854-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1980" MODIFIED="2016-07-26 12:55:32 +0200" MODIFIED_BY="Gudrun Paletta" NAME="WHO 1980" TYPE="OTHER">
<AU>World Health Organization (WHO) Expert Committee on Diabetes Mellitus</AU>
<TI>Second report. Technical Report Series 646</TI>
<SO>World Health Organization, Geneva</SO>
<YR>1980</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1985" MODIFIED="2016-07-26 12:55:53 +0200" MODIFIED_BY="Gudrun Paletta" NAME="WHO 1985" TYPE="OTHER">
<AU>World Health Organization (WHO) Expert Committee on Diabetes Mellitus</AU>
<TI>Technical Report Series 727</TI>
<SO>World Health Organization, Geneva</SO>
<YR>1985</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1998" MODIFIED="2010-02-06 11:28:45 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1998" TYPE="JOURNAL_ARTICLE">
<AU>Alberti KM, Zimmet PZ</AU>
<TI>Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation</TI>
<SO>Diabetic Medicine</SO>
<YR>1998</YR>
<VL>15</VL>
<PG>539-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman D,G et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yki_x002d_Jarvinen-2001" NAME="Yki-Jarvinen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Yki-Jarvinen H</AU>
<TI>Combination therapies with insulin in type 2 diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>4</NO>
<PG>758-67</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<REFERENCE ID="REF-Van-Avendonk-2008" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NAME="Van Avendonk 2008" TYPE="COCHRANE_PROTOCOL">
<AU>Van Avendonk MJ, Gorter K, Goudswaard AN, Rutten GEHM, Van den Donk M</AU>
<TI>Combinations of insulin and oral hypoglycaemic agents for people with type 2 diabetes mellitus on insulin treatment</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2016-07-25 18:28:12 +0200" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-07-25 18:28:12 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006992"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-09-07 09:43:41 +0200" MODIFIED_BY="Gudrun Paletta">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-09-07 09:43:41 +0200" MODIFIED_BY="Gudrun Paletta" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Study details" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Publication details" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Stated aim of study">
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Avil_x00e9_s-1999">
<CHAR_METHODS MODIFIED="2016-07-22 16:20:47 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio:</B> 1:1</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: type 2 diabetes diagnosed after 30 years of age and treated for at least 2 years with at least 50 units of insulin per day, age at enrolment younger than 70 years and HbA1c level &#8805; 8%.</P>
<P>
<B>Exclusion criteria</B>: pregnant women; women trying to become pregnant; patients with a serum creatinine concentration greater than 132.6 mmol/L (1.5 mg/dL) or hepatic enzyme levels greater than twice the upper limit of normal; and patients with medical conditions that could promote lactic acidoses such as renal or hepatic disease, congestive heart failure or chronic obstructive pulmonary disease.</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 00:20:12 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: insulin: intervention 96.2 ± 44.9 U/day, control 96.9 ± 43.3 U/day</P>
<P>
<B>Titration period</B>: 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-10-17 00:20:35 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Outcomes reported in <U>abstract</U> of publication</B>:</P>
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (HbA1c, fasting plasma glucose), C-peptide, body weight, lipids, insulin dose, adverse events (hypoglycaemia)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Run-in period</B>: 8 weeks to titrate metformin in maximal dosage</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Bristol-Myers-Squibb</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-07-22 15:30:35 +0200" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To evaluate the efficacy of metformin in combination with insulin in patients with type 2 diabetes mellitus poorly controlled with insulin therapy alone".</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-10-17 10:11:52 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:31:20 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Barnett-2013">
<CHAR_METHODS MODIFIED="2016-07-22 15:55:46 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 2:1</B>
</P>
<P>
<B>Equivalence design</B>
</P>
<P>
<B>Controlled clinical trial (CCT): a Phase IIIb, extension of RCT</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: Men and women aged 18&#8211;78 years with T2DM, fasting<BR/>C-peptide C 0.8 ng/mL, body mass index (BMI) B45 kg/m2, and inadequate glycaemic control (HbA1c 7.5%&#8211;11.0%) on a stable regimen of insulin (30&#8211;150 U/day, with B 20% variation in total daily dose for C 8 weeks before screening).</P>
<P>
<B>Exclusion criteria</B>: poorly controlled diabetes (e.g. marked polyuria and polydipsia with 10% weight loss during the 3 months before screening); history of diabetic ketoacidosis or hyperosmolar nonketotic coma; history of significant cardiovascular disease or haemoglobinopathy; contraindications to DPP-4 inhibitors, metformin,<BR/>or insulin; or pregnancy, breast feeding, or not using an acceptable method of birth control</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres</B>: unclear</P>
<P>
<B>Treatment before study</B>: intermediate-acting insulin, long-acting (basal) insulin, or a premixed formulation in which rapid- or short-acting insulin constituted one component was permitted. Participants could also be taking metformin if the daily dose was stable for C 8 weeks before screening.</P>
<P>
<B>Titration period</B>: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:31:20 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): mean change from baseline to 52 weeks in HbA1c</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 56 weeks</P>
<P>
<B>Run-in period</B>: 4 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Bristol-Myers-Squibb and AstraZeneca</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>To evaluate the safety and efficacy of the DPP4 inhibitor saxagliptin vs placebo as add-on therapy in type 2 diabetes inadequately controlled with insulin with or without metformin</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-11-03 13:10:46 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Casner-1988">
<CHAR_METHODS MODIFIED="2016-03-23 13:52:28 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with non-insulin-dependent diabetes previously treated with an oral hypoglycaemic agent, currently receiving at least 25 U insulin/day with a fasting blood glucose value of 140 mg/dL or greater.</P>
<P>
<B>Exclusion criteria</B>: history of allergic reactions to sulphonylurea therapy or a serious debilitating disease that would limit ability to participate in the study</P>
<P>
<B>Diagnostic criteria</B>: NDDG 1979</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 08:05:17 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: insulin: intervention 65.9 U/day and control 66.9 U/day</P>
<P>
<B>Titration period</B>: variable<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-29 18:53:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (HbA1c, oral glucose tolerance test, fasting blood glucose), side effects, C-peptide, insulin dose, weight</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 1 year</P>
<P>
<B>Run-in period</B>: variable</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Upjohn Company and an intramural grant from Texas Tech Health Sciences Center</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-01-07 12:13:37 +0100" MODIFIED_BY="Bernd Richter">
<P>Can the combination of a sulphonylurea and insulin improve glycaemic control? If this is true, can it be done with lower doses of exogenous insulin? Can the effect be maintained over a long period of time?</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:38:52 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 09:38:04 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Chiasson-1994">
<CHAR_METHODS MODIFIED="2016-03-23 13:52:22 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with non-insulin-dependent diabetes of at least 6 months, HbA1c &gt; 7%, normal renal and hepatic function</P>
<P>
<B>Exclusion criteria</B>: poor controlled hypertension, documented gastrointestinal disease, taking medication likely to alter gut motility or absorption, taking medications to lower lipid levels</P>
<P>
<B>Diagnostic criteria</B>: WHO 1985</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-04 15:18:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 7</P>
<P>
<B>Treatment before study</B>: insulin, dose is not stated in the publication</P>
<P>
<B>Titration period</B>: 6 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-12 21:07:44 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (HbA1c, oral glucose tolerance test, fasting blood glucose), side effects, hypoglycaemia, C-peptide, lipids, blood count, biochemistry, vitamins, minerals</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 12 months</P>
<P>
<B>Run-in period</B>: 6 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Miles Canada</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-09-07 09:38:04 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "to evaluate the long-term efficacy of acarbose, an alpha-glucosidase inhibitor, in improving glycaemic control in patients with non-insulin-dependent diabetes mellitus"</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:38:54 +0200" MODIFIED_BY="Marielle van Avendonk"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 09:38:10 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Coniff-1995">
<CHAR_METHODS MODIFIED="2016-03-23 13:51:13 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes of at least 6 months, stable body weight, not receiving sulphonylurea for at least 2 months</P>
<P>
<B>Exclusion criteria</B>: not stated</P>
<P>
<B>Diagnostic criteria</B>: WHO 1985<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres</B>: multicentre, number of centres not mentioned, 4 centres are mentioned in the acknowledgements</P>
<P>
<B>Treatment before study</B>: insulin: 56.8 (SE3.4) IU/day (intervention), 62.2 (SE3.3) IU/day</P>
<P>
<B>Titration period</B>: 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-29 18:53:26 +0100" MODIFIED_BY="Marielle van Avendonk">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (HbA1c, glucose tolerance tests, fasting blood glucose), insulin requirements</P>
<P>
<B>Secondary outcomes</B> (as stated in the publication): lipids, hypoglycaemic episodes</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 6 weeks pretreatment, 24 weeks double-blind, 6 weeks follow-up (discontinuation acarbose)</P>
<P>
<B>Run-in period</B>: 6 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Miles pharmaceutical division</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-09-07 09:38:10 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "To determine whether a forced titration of acarbose (from 50 to 300 mg three times daily) administered over a 24-week period, in conjunction with diet and insulin therapy, improves glycaemic control and reduce daily insulin requirements in insulin-requiring type II diabetes."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:38:56 +0200" MODIFIED_BY="Marielle van Avendonk"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 09:38:19 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Feinglos-1998">
<CHAR_METHODS MODIFIED="2016-03-23 13:51:07 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Cross-over randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: insulin-requiring type 2 diabetes, total daily insulin dose &#8805; 40 units, insulin monotherapy &#8805; 1 year prior to the study</P>
<P>
<B>Exclusion criteria</B>: not stated</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 08:19:10 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: insulin NPH and regular 80.8 (range 40-210) U/day</P>
<P>
<B>Titration period</B>: 1 week<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-23 13:06:59 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (plasma glucose, HbA1c), C-peptide, plasma free insulin levels, lipoprotein (TC, TG, HDL, LDL, VLDL), insulin dose, BMI</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 8 months</P>
<P>
<B>Run-in period</B>: 1 week</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Pfizer Pharmaceuticals, Lifescan, National Center for Research Resources</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-09-07 09:38:19 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "To determine the effect(s) on glucose control, insulin dose and circulating insulin levels of the addition of a sulphonylurea (glipizide) to the treatment regimen of patients with insulin-requiring type 2 diabetes mellitus."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:38:58 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Fonseca-2007">
<CHAR_METHODS MODIFIED="2016-03-23 13:51:03 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: participants had to have received only injectable insulin for at least 3 months, at a dose of at least 30 U/day for a minimum of 4 weeks prior to enrolment. Age 18-80 years, HbA1c 7.5-11.0%, fasting plasma glucose &lt; 15 mmol/L and BMI 22-45 kg/m²</P>
<P>
<B>Exclusion criteria</B>: people with type 1 diabetes, diabetes resulting from pancreatic injury or secondary forms of diabetes. People with acute metabolic diabetic complications within the past 6 months, serious cardiac conditions or clinically significant liver disease. Any of the following laboratory abnormalities: alanine transaminase &gt; 3 x the upper limit of normal; direct bilirubin &gt; 1.3 x the upper limit of normal; serum creatinine &gt; 220 &#956;mol/L; fasting triacylglycerol &gt; 7.9 mmol/L</P>
<P>
<B>Diagnostic criteria</B>: based on the investigator's diagnosis and on the patient's medical record</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 08:19:55 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 68</P>
<P>
<B>Treatment before study</B>: insulin: intervention 81.2 ± 44.8 U/day and control 81.9 ± 49.4 U/day</P>
<P>
<B>Titration period</B>: 4 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (HbA1c, fasting plasma glucose), insulin dose and number of injections, fasting lipids, bodyweight</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 24 weeks</P>
<P>
<B>Run-in period</B>: 4 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Novartis</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-17 10:14:22 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To assess the efficacy and tolerability of vildagliptin added to added to insulin therapy in patients with type 2 diabetes."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:38:59 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Fritsche-2000">
<CHAR_METHODS MODIFIED="2016-03-23 13:50:57 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Cross-over randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: not clearly defined: severe obesity, moderate glycaemic control, intensive insulin therapy with regular specialist consultations for regimen adaptation for at least 6 months prior to inclusion</P>
<P>
<B>Exclusion criteria</B>: not stated</P>
<P>
<B>Diagnostic criteria</B>: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: intervention: insulin: NPH 26 ± 6 U/day and regular 27 ± 5 U/day</P>
<P>control: insulin: NPH 20 ± 4 U/day and regular 26 ± 4 U/day</P>
<P>
<B>Titration period</B>: 6 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-23 13:07:33 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (HbA1c, blood glucose levels, OGTT), insulin dose, lipids, C-peptide, lactate</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 24 weeks</P>
<P>
<B>Run-in period</B>: 6 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Lipha Pharmaceuticals (medication)</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "To examine the effect of adjunct metformin in 13 severely obese type 2 diabetes patients in sub optimal glucaemic control pretreated with intensified insulin therapy" on glycaemic control, insulin dosage, lipid profile and bodyweight</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:00 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Giugliano-1993">
<CHAR_METHODS MODIFIED="2016-03-23 13:50:48 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: age at diagnosis &gt; 40 years, duration of disease &gt; 3 years, duration of previous response to oral drugs &gt; 1 year, inadequate metabolic control even when on maximal doses of sulphonylurea</P>
<P>
<B>Exclusion criteria</B>: age &gt; 70 years, creatinine &gt; 1.2 mg/dL, ischaemic of wasting disease, acute severe diseases</P>
<P>
<B>Diagnostic criteria</B>: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres</B>: 1?</P>
<P>
<B>Treatment before study</B>: intervention: insulin: lente + regular 2 dd 90 ± 9 U/day; control: insulin lente + regular 2 dd 88 ± 9.4 U/day</P>
<P>
<B>Titration period</B>: 4 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (HbA1c, daily glucose levels), lipids, blood pressure, body weight, insulin dose, beta-cell function (C-peptide, insulin)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 7 months</P>
<P>
<B>Run-in period</B>: 4 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: not reported</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-17 10:52:47 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To evaluate the effectiveness and safety of metformin in obese type 2 diabetic patients poorly controlled by conventional insulin therapy."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:01 +0200" MODIFIED_BY="Marielle van Avendonk"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Groop-1985">
<CHAR_METHODS MODIFIED="2016-03-23 13:50:43 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Cross-over randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-17 08:26:56 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>: onset of non-ketotic diabetes after the age of 35 years, treated with oral antidiabetic drugs for at least 1 year before insulin therapy was started due to secondary drug failure.</P>
<P>
<B>Exclusion criteria</B>: not stated</P>
<P>
<B>Diagnostic criteria</B>: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 08:26:47 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: insulin 0.75 ± 0.11 IU/kg per day</P>
<P>
<B>Titration period</B>: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-23 13:08:15 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): insulin dose and bodyweight, glycaemic control (HbA1c, FBG, blood glucose profile), serum insulin levels, C-peptide, lipids</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 24 weeks (2 x 8 = 16 weeks intervention)</P>
<P>
<B>Run in period: </B>8 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-01-30 11:18:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: none</P>
<P>
<B>Publication status</B>: peer review journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-17 11:11:49 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To investigate the metabolic effects of the combination of insulin and sulphonylurea (glibenclamide) during controlled long-term therapy in NIDDM patients whose hyperglycaemia could not be controlled by insulin alone."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:06 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Hermann-2001">
<CHAR_METHODS MODIFIED="2016-03-23 13:50:39 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes with insulin therapy &gt; 1 year. BMI &gt; 27 kg/m2 for men and &gt; 25 kg/m2 for women. HbA1c value higher than the upper reference limit + 2%. Insulin dose 0.4-1.0 U/kg/day. C-peptide after 1 mg glucagon intravenously &gt; 0.6 nmol/L</P>
<P>
<B>Exclusion criteria</B>: treatment with oral antidiabetic agents within the last 6 months. Presence of any of the usual contraindications for metformin. Abnormal serum creatinine concentration. Transaminases &gt; 2 x the upper reference limit. Overconsumption of alcohol</P>
<P>
<B>Diagnostic criteria</B>: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 08:30:57 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 3</P>
<P>
<B>Treatment before study</B>: insulin: intervention 0.75 ± 0.28 U/kg/day and control 0.73 ± 0.23 U/kg/day</P>
<P>
<B>Titration period</B>: 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (HbA1c, FBG), bodyweight and BMI, insulin dose, lipids</P>
<P>
<B>Secondary outcomes</B> (as stated in the publication): waist-hip ratio, blood pressure, fibrinogen, C-peptide, serum B12, compliance</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 15 months</P>
<P>
<B>Run-in period: </B>12 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: none</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-17 11:55:42 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To assess the adjunct effect of metformin to insulin in type 2 diabetes."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:09 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Hirsch-1999">
<CHAR_METHODS MODIFIED="2016-03-23 13:50:35 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes with less than optimal control on insulin therapy alone.</P>
<P>
<B>Exclusion criteria</B>: not stated</P>
<P>
<B>Diagnostic criteria</B>: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 08:42:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: insulin: dose not stated</P>
<P>
<B>Titration period</B>: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-29 18:54:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (HbA1c, FPG), bodyweight, blood pressure, insulin dose, fasting insulin levels, fasting C-peptide, hypoglycaemia</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 5 months</P>
<P>
<B>Run-in period: </B>no</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Bristol-Myers-Squibb</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "To prospectively evaluate the efficacy of metformin added to insulin for patients with type 2 diabetes with less than optimal glycaemic control on insulin alone."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-01-29 13:11:56 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Publication is a letter</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Hong-2012">
<CHAR_METHODS MODIFIED="2016-07-23 09:36:47 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: type 2 diabetes mellitus; age 30&#8211;70 years; HbA1c 7.5%&#8211;11.0%; fasting plasma glucose (FPG) &lt; 15 mmol/L (270 mg/dL) and body mass index (BMI) 18&#8211;35 kg/m2. Female participants had to be non-fertile or of childbearing potential using a medically approved birth control method.</P>
<P>
<B>Exclusion criteria</B>: type 1 diabetes, gestational diabetes or diabetes with identifiable secondary causes, significant renal impairment (estimated creatinine clearance &lt; 50 ml/min) or elevated (&gt; 100) alanine or aspartate aminotransferase (ALT or AST). Participants who were taking medications, aside from antidiabetic medications, known to affect glycaemic control, such as glucocorticoids were also excluded.</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-12 21:12:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 2</P>
<P>
<B>Treatment before study</B>: insulin injections for at least 3 months; at a dose of at least 10 U/day and for a minimum of 4 weeks prior to enrolment.</P>
<P>
<B>Titration period</B>: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): change in HbA1c (from baseline to 24 weeks)</P>
<P>
<B>Secondary outcomes</B> (as stated in the publication): proportion of participants achieving HbA1c &lt; 7%, body weight, waist circumference, change in insulin dose, change in C-peptide, safety (AE, SAE, hypoglycaemia, liver/renal function)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 24 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: non commercial; National Research Foundation</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-03 15:16:04 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "This study compared the efficacy and tolerability of adding sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, and an up to 20% increase in insulin dose in patients with uncontrolled type 2 diabetes on insulin therapy."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-11-03 15:08:21 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 09:38:54 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Kitabchi-1987">
<CHAR_METHODS MODIFIED="2016-03-23 13:50:26 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Cross-over randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: obese (130%-200% IBW) women with type 2 diabetes mellitus on prior insulin therapy who were poorly controlled but without severe diabetic complications.</P>
<P>
<B>Exclusion criteria</B>: history of diabetic ketoacidosis</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 08:45:14 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: insulin 0.89 ± 0.07 U/kg/BW</P>
<P>
<B>Titration period</B>: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-29 18:55:03 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (HbA1c, FBG, 2-hour post prandial glucose), bodyweight, insulin requirement, total cholesterol, triglyceride, C-peptide</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 6 months</P>
<P>
<B>Run-in period:</B> no</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: NIH, Abe Goodman Fund for Diabetes Research, Eli Lilly, Upjohn Company</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-09-07 09:38:54 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "To assess the efficacy of combined NPH and tolazamide in enhancing insulin secretion and tissue sensitivity in obese patients with type 2 diabetes mellitus who were maintained at the same weight and glycaemic index during both phases of the study."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Several young participants with long-term insulin use and without severe obesity</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Krawczyk-2005">
<CHAR_METHODS MODIFIED="2016-03-23 13:50:22 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: type 2 diabetes patients, diabetes duration of at least 5 years, BMI &gt; 30, Insulin &gt; 40 IU/day</P>
<P>
<B>Exclusion criteria</B>: contraindication for metformin, body weight change &gt; 5 kg last year</P>
<P>
<B>Diagnostic criteria</B>: age &gt; 35 years at diagnosis and at least 1 year of effective treatment with oral glucose-lowering agents</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 08:45:46 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: insulin 2dd, 59.5 (15.4) IU/day intervention, 55.6 (16.3) IU/day control</P>
<P>
<B>Titration period</B>: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-29 18:55:11 +0100" MODIFIED_BY="Marielle van Avendonk">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (HbA1c, glucose), bodyweight, insulin dose, WHR</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 6 months</P>
<P>
<B>Run-in period</B>: none</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-01-30 11:18:46 +0100" MODIFIED_BY="Marielle van Avendonk">
<P>
<B>Language of publication</B>: Polish</P>
<P>
<B>Funding source</B>: not reported</P>
<P>
<B>Publication status</B>: unknown</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-17 13:56:37 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To assess the influence of adding metformin to insulin monotherapy on metabolic control in type 2 diabetes patients."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-02-18 14:40:00 +0100" MODIFIED_BY="Marielle van Avendonk">
<P>Statistical methods not described</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Kyllastinen-1985">
<CHAR_METHODS MODIFIED="2016-03-23 13:50:17 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Cross-over randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: elderly patients, type 2 diabetes inadequately controlled by insulin</P>
<P>
<B>Exclusion criteria</B>: surgical operation; lack of co-operation</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 08:49:52 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: insulin 58 ± 3 IU/day (n = 1 once daily, n = 8 twice daily)</P>
<P>
<B>Titration period</B>: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-23 13:11:56 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (HbA1c, FPG), daily insulin dose, C-peptide, bodyweight, triglyceride, total cholesterol, HDL-cholesterol, Na, K, creatinine, chloride</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 4 months</P>
<P>
<B>Run-in period: none</B>
</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: none</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-01-12 21:13:56 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To determine whether glibenclamide could improve glycaemic control in patients not adequately controlled by insulin."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:14 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Lewitt-1989">
<CHAR_METHODS MODIFIED="2016-03-23 13:50:13 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Cross-over randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: insulin treated participants who were not ketosis prone and had previous primary or secondary oral hypoglycaemic failure.</P>
<P>
<B>Exclusion criteria</B>: combined insulin-sulphonylurea therapy</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 08:50:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: insulin 47.3 ± 21.3 U/day. Insulin regimen: once or twice daily</P>
<P>
<B>Titration period</B>: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (HbA1c, self-monitored fasting and postprandial glucose), BMI, C-peptide, insulin dosage</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 6 months</P>
<P>
<B>Run-in period: none</B>
</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: none</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-01-12 21:14:25 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To determine which patient characteristics best predict a beneficial response to combined Insulin-gliburide therapy."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:16 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Lindstrom-1999">
<CHAR_METHODS MODIFIED="2016-03-23 13:50:08 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Cross-over randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: participants with type 2 diabetes with insulin monotherapy for 6-36 months.</P>
<P>
<B>Exclusion criteria</B>: not stated</P>
<P>
<B>Diagnostic criteria</B>: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres</B>: unclear</P>
<P>
<B>Treatment before study</B>: insulin 54.5 ± 6.9 U/day (at the end of the run-in period) Insulin regimen: four times daily, regular plus intermediate insulin</P>
<P>
<B>Titration period</B>: 4-8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-29 18:55:33 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (blood glucose, HbA1c), insulin dose, C-peptide, lipoproteins, IGF-1, SHBG, serum testosterone</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 7-8 months</P>
<P>
<B>Run-in period: </B>4-8 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Swedish Medical Research Council, Swedish Diabetes Association, County Council of Östergötland, Novo Nordisk Insulin Fund</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-17 14:44:47 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To study whether changes in endogenous insulin secretion at the same glycaemic control affect the plasma concentration of lipoproteins in patients with type 2 diabetes mellitus."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:24 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Longnecker-1986">
<CHAR_METHODS MODIFIED="2016-03-23 13:50:02 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Cross-over randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: severely hyperglycaemic patients with type 2 diabetes with insulin monotherapy failed to sulphonylurea therapy</P>
<P>Controls were nondiabetic women comparable with patients in age and weight.</P>
<P>
<B>Exclusion criteria</B>: not stated</P>
<P>
<B>Diagnostic criteria</B>: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 08:51:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: insulin 64 ± 5.6 U/day (insulin regimen: once or twice daily, regular and/or isophane insulin)</P>
<P>
<B>Titration period</B>: 1 week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (HbA1c, fasting blood glucose), plasma glucose and C-peptide before and after standardised meal, weight, C-peptide, drug compliance, side effects</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 20 weeks</P>
<P>
<B>Run-in period: </B>1 week</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Public Health Service Grant, ADA, Upjohn</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-17 14:56:19 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To evaluate the efficacy of adding tolazamide, an oral agent, to insulin in a group of severely hyperglycaemic patients with NIDDM, all of whom had previously failed to respond to therapy with oral sulfonylurea agent alone."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2011-05-31 14:04:32 +0200" MODIFIED_BY="[Empty name]">
<P>Carry-over effect not described</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Mattoo-2005">
<CHAR_METHODS MODIFIED="2016-03-23 13:49:58 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes with insulin therapy with or without oral antihyperglycaemic agents for &#8805; 3 months, HbA1c &#8805; 7,5% and &#8805; 30 years at the time of diagnosis</P>
<P>
<B>Exclusion criteria</B>: type 1 DM, signs or symptoms of any chronic condition or drug or alcohol abuse, previous TZD, glucocorticoid, nicotinic acid or therapy for a malignancy (except basal cell or squamous cell cancer), breastfeeding, pregnancy, women of childbearing potential</P>
<P>
<B>Diagnostic criteria</B>: WHO</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 08:52:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 39</P>
<P>
<B>Treatment before study</B>: intervention: insulin 0.96 (0.03) U/day/kg, control insulin 0.92 (0.03) U/day/kg. Insulin regimen: once, twice, thrice or four times a day.</P>
<P>
<B>Titration period</B>: 2 weeks lead-in (at the end oral agents were stopped) and 3 months insulin intensification period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-23 13:12:26 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glycaemic control (HbA1c, fasting blood glucose), lipids, hs-CRP, PAI-1, hypoglycaemia, bodyweight, insulin dose</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 6 months</P>
<P>
<B>Run-in period: </B>2 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Eli Lilly, Takeda Europe</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-12-03 16:18:57 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To determine the effect of pioglitazone 30 mg plus insulin versus placebo plus insulin on glycaemic control, the serum lipid profile, and selected cardiovascular risk factors in patients with type 2 diabetes mellitus whose disease was inadequately controlled with insulin therapy alone despite efforts to intensify such treatment."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Some participants also used oral antihyperglycaemic agents before study. Users and non-users were separated in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Mauerhoff-1986">
<CHAR_METHODS MODIFIED="2016-03-23 13:49:52 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes with insulin therapy for &#8805; 1 year.</P>
<P>
<B>Exclusion criteria</B>: abnormal renal and hepatic functions, C-peptide &gt; 0.2 pmol/mL</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 08:53:31 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: intervention: insulin 0.50 (0.07) U/day/kg, control insulin 0.44 (0.05) U/day/kg</P>
<P>
<B>Titration period</B>: 3 weeks lead-in</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): plasma glucose and C-peptide after standardised breakfast, HbA1c (no assessment for technical reasons), fasting cholesterol and triglyceride, hypoglycaemia, insulin requirements</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 16 weeks</P>
<P>
<B>Run-in period: </B>3 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Hoechst Belgium</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "We have studied the effect of the combination of a sulphonylurea (Hb 420 or glibenclamide) with insulin in 22 type 2 diabetic patients, treated with insulin and with residual insulin secretion."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-07-15 11:36:46 +0200" MODIFIED_BY="[Empty name]">
<P>Use of intervention medication Hb420 (galenic form of glibenclamide)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 09:39:30 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Mezitis-1992">
<CHAR_METHODS MODIFIED="2016-03-23 13:49:47 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1 </B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>HbA1c</B> before randomisation (% (SD)): intervention 8.7, control 8.6</P>
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes with insulin therapy for &#8805; 1 year.</P>
<P>
<B>Exclusion criteria</B>: endocrinologic disease other than diabetes mellitus, history of allergies to sulphonamides and/or insulin, history of impaired gastric emptying, active hepatic disease, renal disease significantly impairing creatinine clearance, current treatment with steroids, oestrogens, progestogens, beta-blockers, Ca-channel antagonists, diuretics, monoamine oxidase inhibitors, clonidine, probenecid, anticoagulants, NSAID</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 08:53:57 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: insulin monotherapy, dosages not stated</P>
<P>
<B>Titration period</B>: yes, duration not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): urinary C-peptide, HbA1c, lipids, insulin requirement, glycaemic profiles in response to test meals</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 20 weeks</P>
<P>
<B>Run-in period: </B>unclear</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: UpJohn, Boehringer Mannheim, Becton Dickinson</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-09-07 09:39:30 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "To investigate the effects of addition of glibenclamide to the regimen of insulin-treated non-insulin-dependent diabetes mellitus (NIDDM) patients with regard to their overall insulin requirements and dosage schedule and to assess persistence of these effects."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>A lot of data were missing: dose of glibenclamide, incomplete study design and baseline data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Mudaliar-2010">
<CHAR_METHODS MODIFIED="2016-03-23 13:49:42 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: obese people with type 2 diabetes on insulin therapy alone and with HbA1c between 7.5% and 10%.</P>
<P>
<B>Exclusion criteria</B>: history of peripheral oedema, cardiac, hepatic or renal problems, or had been treated with NSAIDs or diuretics within 21 days of screening</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 08:54:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: insulin monotherapy (IU/day (SD)): intervention: 105 (22), control 114 (11)</P>
<P>
<B>Titration period</B>: 4 weeks: weight maintenance, carbohydrate diet</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-29 18:56:09 +0100" MODIFIED_BY="Marielle JP van Avendonk">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): HbA1c, fasting plasma glucose, insulin dose, weight, total body water, extracellular fluid, renal measures, hormonal measures</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 16-20 weeks</P>
<P>
<B>Run-in period: </B>4 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Takeda pharmaceuticals, Veterans Medical Research Foundation, Department of Veterans Affairs and the VA San Diego Healthcare System, University of California San Diego Clin Res. Centre NIH Grant</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-12-12 12:09:11 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To evaluate the effects of intensive insulin therapy alone or with added pioglitazone on renal salt/water balance and body fluid compartment shifts in type 2 diabetes."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Funded by pharmaceutical company</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Nemoto-2011">
<CHAR_METHODS MODIFIED="2016-03-23 13:49:36 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes on insulin therapy alone, HbA1c &#8805; 6.5%, outpatients, age at least 20 years</P>
<P>
<B>Exclusion criteria</B>: not stated</P>
<P>
<B>Diagnostic criteria</B>: plasma glucose level at either 1 or 2 h after meal was 180 mg/dL or higher; HbA1c &#8805; 6.5%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-23 16:58:46 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: not stated</P>
<P>
<B>Treatment before study</B>: insulin monotherapy (U/day (SD)): 31.7 (17.6)</P>
<P>
<B>Titration period</B>: 4-10 weeks observation period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-29 18:56:14 +0100" MODIFIED_BY="Marielle JP van Avendonk">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): meal tolerance test, plasma glucose AUC</P>
<P>
<B>Secondary outcomes</B> (as stated in the publication): HbA1c, 1,5 AG, glycoalbumin, hypoglycaemic symptoms</P>
<P>
<B>ADDITIONAL OUTCOMES</B>: safety</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 16-22 weeks (4-10 weeks observation + 12 weeks treatment)</P>
<P>
<B>Run-in period: </B>4-10 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Sanwa Kagaku Kenkyusyo Co Ltd</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "To investigate the efficacy of combination therapy with miglitol and insulin" in people with type 2 diabetes receiving insulin therapy</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:27 +0200" MODIFIED_BY="Marielle JP van Avendonk"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Osei-1984">
<CHAR_METHODS MODIFIED="2016-03-23 13:49:31 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial </B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes with serum glucose levels &gt; 200 mg/dL and daily insulin requirement &gt; 30 IU</P>
<P>
<B>Exclusion criteria</B>: renal and hepatic disease, allergies to sulphonylurea</P>
<P>
<B>Diagnostic criteria</B>: NDDG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 08:54:54 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Control (route, total dose/day, frequency)</B>: placebo, oral</P>
<P>
<B>Treatment before study</B>: intervention: insulin 60.3 (7.1) U/day, control insulin 50.27 (5.0) U/day</P>
<P>(insulin regimen: once or twice daily, short-acting and/or intermediate insulin)</P>
<P>
<B>Titration period</B>: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): fasting glucose, HbA1c and C-peptide, after OGTT serum glucose and C-peptide, lipids, lipoproteins, weight, dietary intake, compliance</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 16 weeks</P>
<P>
<B>Run-in period: </B>4 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: UpJohn, Core Laboratory, Central Ohio Diabetes Association</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-12-01 11:00:14 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To evaluate, in a double-blind, placebo-controlled manner, glucose and lipoprotein responses after long-term use of combination therapy in the management of insulin-treated patients with poorly controlled type 2 diabetes mellitus." </P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:29 +0200" MODIFIED_BY="Bernd Richter"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Quatraro-1986">
<CHAR_METHODS MODIFIED="2016-03-23 13:49:27 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes on insulin therapy</P>
<P>
<B>Exclusion criteria</B>: not stated</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-23 16:59:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: intervention: insulin 90 (6) U/day, control insulin 88 (5) U/day</P>
<P>Insulin regimen: twice or thrice daily, porcine lente and/or rapid-acting insulin</P>
<P>
<B>Titration period</B>: 2 months + 1-2 weeks inpatient period</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): diurnal glucose profile, HbA1c, C-peptide, glucagon stimulated C-peptide, insulin dose, weight</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 14 months</P>
<P>
<B>Run-in period: </B>2 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events): </B>no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: none</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-01-12 21:18:04 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "We studied the influence of chronic sulphonylurea treatment on glucose metabolism and beta-cell secretory activity in diabetic patients requiring insulin after secondary failure to oral drugs."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:30 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Reich-1987">
<CHAR_METHODS MODIFIED="2016-03-23 13:49:21 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes on insulin therapy</P>
<P>
<B>Exclusion criteria</B>: significant surgery within 3 months before entry into the study, major organ or system disease, medication use affecting glucose metabolism or sulphonylurea activity</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres</B>: 2</P>
<P>
<B>Treatment before study</B>: intervention: 36.5 (6.3) insulin, placebo: insulin 48.2 (4.0) U/day. Insulin regimen: only intermediate insulin</P>
<P>
<B>Titration period</B>: 12 days hospitalisation (after 6 weeks optimisation glycaemic control with insulin)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): serum and urinary glucoses, HbA1c, urinary C-peptide, insulin dose, number of tablets prescribed, compliance</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 5.5 months</P>
<P>
<B>Run-in period: </B>12 days</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Upjohn</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "To test the effect of combined glibenclamide-insulin therapy over 4 months in 20 patients after achieving good control of fasting glucose with diet and intermediate insulin alone."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Participants had adequate glycaemic control</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Relimpio-1998">
<CHAR_METHODS MODIFIED="2016-03-23 13:49:14 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel open-label randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: poorly controlled (HbA1c &gt; 8%) people with type 2 diabetes on insulin therapy (&#8805; 0.5 IU/kg body weight in 2 or more daily doses))</P>
<P>
<B>Exclusion criteria</B>: life-threatening condition, contraindication for biguanides, serum creatinine &lt; 132.6 &#956;mol/L</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: intervention: 47.9 (10) insulin, control: insulin 51.8 (9.6) U/day. Insulin regimen: twice or more daily, premixed soluble and NPH insulin or NPH insulin alone</P>
<P>
<B>Titration period</B>: 4 weeks increase metformin dose (1,275 g -&gt; 2,550 g)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-29 18:56:50 +0100" MODIFIED_BY="Marielle van Avendonk">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): HbA1c, glucose, lipids, blood pressure, height, weight, BMI, insulin dose, serum creatinine, albumin excretion rate, uric acid, compliance</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 4 months</P>
<P>
<B>Run-in period: </B>4 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Novo Nordisk</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-17 17:56:56 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To compare the effect of adding metformin to insulin therapy with a moderate increase in insulin dose alone in insulin-treated, poorly controlled type 2 diabetes."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:32 +0200" MODIFIED_BY="Marielle van Avendonk"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Robinson-1998">
<CHAR_METHODS MODIFIED="2016-03-23 13:48:57 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Two cross-over randomised controlled clinical trials</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-10-17 09:04:56 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>: study I: DM2 patients with insulin monotherapy for at least 1 year after secondary failure of maximum dose oral antihyperglycaemic agents; study II: see study I plus taking metformin (100-2550 mg/day as the sole oral antihyperglycaemic agent for at least 1 year</P>
<P>
<B>Exclusion criteria</B>: women of childbearing age, unable to give informed consent</P>
<P>
<B>Diagnostic criteria</B>: fasting plasma glucose &gt; 7.8 mmol/L on 2 occasions</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 09:05:04 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 2</P>
<P>
<B>Treatment before study</B>: study I: insulin 71 (47) U/day, study II : insulin 41 (16) U/day + metformin 1000-2550</P>
<P>
<B>Titration period</B>: 6 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-29 18:56:56 +0100" MODIFIED_BY="Marielle van Avendonk">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): HbA1c, glucose, lipids, blood pressure, insulin dose, hypoglycaemia</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 12 weeks (intervention period study I)</P>
<P>
<B>Run-in period: </B>6 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Lipha Pharmaceuticals</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2015-01-12 21:19:05 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To test the hypothesis that metformin therapy, given as an adjunct to insulin therapy, improves metabolic control in insulin-treated type 2 diabetes mellitus patients with sub optimal glycaemic control."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-04-04 16:55:42 +0200" MODIFIED_BY="[Empty name]">
<P>2 studies, only study I fulfilled our inclusion criteria</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 09:40:23 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Rosenstock-2002">
<CHAR_METHODS MODIFIED="2016-03-23 13:48:26 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes on insulin therapy (&#8805; 30 IU/day) for 4 months, 30-75 years, HbA1c &#8805; 8.0%, fasting C-peptide &gt; 0.7&#956;g/l</P>
<P>
<B>Exclusion criteria</B>: history of ketoacidosis; unstable retinopathy, nephropathy or neuropathy; impaired hepatic and renal function; anaemia; unstable cardiovascular or cerebrovascular condition; concomitant lipid lowering medication must be taken for a stable dose &gt; 60 days</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres</B>: 79</P>
<P>
<B>Treatment before study</B>: pioglitazone 15: 70.2 (34.0) insulin, pioglitazone 30: insulin 72.3 (38.5), placebo: insulin 70.7 (33.5) U/day (insulin regimen: 88% monotherapy)</P>
<P>
<B>Titration period</B>: insulin monotherapy: 2 weeks screening + 1 week single-blind placebo</P>
<P>insulin with oral anti-diabetic (OAD) medication: 2 weeks screening + 4 weeks single-blind placebo (= washout)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): HbA1c, glucose, C-peptide, lipids, insulin dose, safety profile: chemistry, haematology, urine analysis, vital signs, ECG, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 16 weeks</P>
<P>
<B>Run-in period: </B>3 weeks for insulin users and 6 weeks for insulin + OAD users (last group discontinued oral agent at the beginning of the screening period</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Takeda Pharmaceuticals</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-09-07 09:40:23 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "To evaluate the ability of two doses of pioglitazone in combination with a stable insulin regimen to improve glycaemic control in patient whose type 2 diabetes remained poorly controlled despite current insulin therapy."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:33 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 09:40:39 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Schade-1987">
<CHAR_METHODS MODIFIED="2016-03-23 13:48:19 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Cross-over randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes on insulin therapy (&#8805; 28 IU/day &#8805; 3 months), C-peptide-positive on stimulation of endogenous insulin secretion (OGTT)</P>
<P>
<B>Exclusion criteria</B>: hepatic or renal disease or other major diseases that might impair participation, use of sulphonylurea or other drugs that alter glucose control within 1 month of the study</P>
<P>
<B>Diagnostic criteria</B>: NDDG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres</B>: &gt; 1?</P>
<P>
<B>Treatment before study</B>: 55.4 (6.0) IU/day (insulin regimen: 10/16 twice daily)</P>
<P>
<B>Titration period</B>: 4 weeks (washout)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-25 16:33:04 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): OGTT, insulin- C-peptide, fasting blood glucose, HbA1c, ery-glu binding capacity, compliance, insulin dose, weight</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 32 weeks</P>
<P>
<B>Run-in period: </B>4 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Upjohn, NIH</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-09-07 09:40:39 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "To examine the potential beneficial effect of the addition of a second-generation sulphonylurea to insulin therapy for poorly controlled type 2 diabetes."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:34 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Schiel-2007">
<CHAR_METHODS MODIFIED="2016-03-23 13:48:13 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes with inadequate glycaemic control (HbA1c &#8805; 8.0% or FBG &#8805; 6.6 mmol/L) on premix insulin therapy (&#8804; 5 years), diabetes duration &gt; 5 years, BMI 27-35</P>
<P>
<B>Exclusion criteria</B>: impaired hepatic or renal function, pregnancy, unable to understand the study, to cope or attend follow-up visits</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 09:48:06 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: mix insulin 75/25 or 70/30 A: 77.6 (32.1) , B: 64.9 (32.1), C: 65.2 (34.2) IU/day</P>
<P>
<B>Titration period</B>: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-29 18:57:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): fasting blood glucose, HbA1c, treatment satisfaction, hypoglycaemia, adverse events, blood pressure, creatinine, liver enzymes</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 20 weeks (4 + 16 wks)</P>
<P>
<B>Run-in period: </B>4 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-01-30 11:19:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Sanofi-Aventis</P>
<P>
<B>Publication status</B>: peer review journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "To establish whether insulin plus OADs is effective in type 2 diabetes patients previously poorly controlled on premixed insulin therapy."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:35 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Simpson-1990">
<CHAR_METHODS MODIFIED="2016-03-23 13:48:08 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes on insulin therapy, inadequate controlled (fasting glucose &gt; 8.0 mmol/L</P>
<P>
<B>Exclusion criteria</B>: not stated</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: intervention: 36 (10-62) insulin , placebo: insulin 31 (14-112) U/day. Insulin regimen: once (n = 5) or twice daily (n = 15)</P>
<P>
<B>Titration period</B>: 2 months minimum run-in period in which oral medication was stopped</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): serum and urinary glucoses, HbA1c, urinary C-peptide, insulin dose, number of tablets prescribed, compliance</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 2 months run-in and 8 weeks intervention</P>
<P>
<B>Run-in period: </B>2 months</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Farmaitalia</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-19 15:05:39 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To assess the relative contribution of endogenous insulin secretion and peripheral insulin sensitivity when SU was given in combination with insulin to 'secondary failure' type 2 diabetes patients."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:36 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 09:41:05 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Stenman-1988">
<CHAR_METHODS MODIFIED="2016-03-23 13:48:03 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Cross-over randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes failing on oral antidiabetic agents</P>
<P>
<B>Exclusion criteria</B>: hepatic, renal or pulmonary dysfunction; secondary diabetes</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: intervention: 34 (4) insulin, placebo: insulin 26 (3) U/day. Insulin regimen: once or twice daily intermediate or intermediate mixed with short-acting insulin</P>
<P>
<B>Titration period</B>: 4 months (2 weeks in hospital) initiation insulin therapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): HbA1c, fasting glucose, urinary glucose, C-peptide after glucagon, insulin dose, lipids, body weight, free insulin</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 8 months: 4 months run-in and 4 months intervention</P>
<P>
<B>Run-in period: </B>2 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Sigrid Juselius Foundation, Finnish Medical Association, Signe and Ane Gyllenberg foundation</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-09-07 09:41:05 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "To examine the effect of the addition of glibenclamide to insulin therapy on glycaemic control and beta cell function."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:37 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 09:41:17 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Strowig-2002">
<CHAR_METHODS MODIFIED="2016-03-23 13:47:59 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes on insulin therapy (&#8805; 30 IU/day), 24-70 years, HbA1c &#8805; 7.0%, normal renal and hepatic function</P>
<P>
<B>Exclusion criteria</B>: not stated</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: metformin insulin 82.9 U/day, troglitazone insulin 96.5 U/day, control insulin 80.3 U/day. Insulin regimen: 2 or more daily, 70/30 mix insulin or intermediate and short-acting insulin</P>
<P>
<B>Titration period</B>: 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-29 18:57:38 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): insulin dose, lipids, HbA1c, glucose, C-peptide, body weight, Alat, Asat, medical history, physical exam, waist-hip measurement, 3-day food record, serum chemistry</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 4 weeks run-in and 12 weeks intervention</P>
<P>
<B>Run-in period: </B>4 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Bristol Myers Squibb</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-09-07 09:41:17 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "To evaluate the safety and efficacy of treatment with insulin alone, insulin plus metformin, or insulin plus troglitazone for 4 months in type 2 DM."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:39 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-09-07 09:41:31 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Wulffel_x00e9_-2002">
<CHAR_METHODS MODIFIED="2016-03-23 13:47:53 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with type 2 diabetes on insulin therapy</P>
<P>
<B>Exclusion criteria</B>: significant surgery within 3 months before entry into the study, major organ or system disease, medication use affecting glucose metabolism or sulphonylurea activity</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Number of study centres</B>: 3</P>
<P>
<B>Treatment before study</B>: intervention: 71 (33) insulin, placebo: insulin 70 (33) U/day. Insulin regimen: 4 times daily intermediate plus short-acting insulin or twice daily mix-insulin</P>
<P>
<B>Titration period</B>: 12 weeks (optimisation of insulin therapy, cessation of metformin, cessation of antihypertensive and lipid-lowering medication)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-29 18:58:10 +0100" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): glucose, HbA1c, lipids, insulin dose, blood pressure, weight, BMI, waist-hip-ratio</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 16 weeks</P>
<P>
<B>Run-in period: </B>12 weeks</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no (results of the interim analysis)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: Byk, Lifescan, Merck Lipha, MSD, Novo Nordsik</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-09-07 09:41:31 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Quote from publication: "To investigate the metabolic effects of metformin, as compared with placebo, in type 2 diabetes patients intensively treated with insulin."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:40 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Yilmaz-2007">
<CHAR_METHODS MODIFIED="2016-03-23 13:47:48 +0100" MODIFIED_BY="Bernd Richter">
<P>
<B>Parallel randomised controlled clinical trial</B>
</P>
<P>
<B>Randomisation ratio: 1:1:1</B>
</P>
<P>
<B>Superiority design</B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Inclusion criteria</B>: people with poorly controlled type 2 diabetes on insulin monotherapy</P>
<P>
<B>Exclusion criteria</B>: severe hypertension, repeated hypoglycaemic episodes, severe cardiovascular and cerebrovascular disease, renal or hepatic failure, acute diabetic complications, incipient heart failure, pregnancy, breastfeeding</P>
<P>
<B>Diagnostic criteria</B>: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-10-17 09:57:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Number of study centres</B>: 1</P>
<P>
<B>Treatment before study</B>: insulin MIX 30/70 aspart/NPH</P>
<P>
<B>Titration period</B>: not stated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Primary outcome(s)</B> (as stated in the publication): change in HbA1c</P>
<P>
<B>Secondary outcomes</B> (as stated in the publication): changes in insulin dosage, body weight, waist-to-hip ratio, lipids</P>
<P>
<B>ADDITIONAL OUTCOMES</B>: incidence of hypoglycaemia and side effects</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Total study duration</B>: 6 months</P>
<P>
<B>Run-in period</B>: unclear</P>
<P>
<B>Study terminated early (for benefit/because of adverse events):</B> no</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>
<B>Language of publication</B>: English</P>
<P>
<B>Funding source</B>: not stated</P>
<P>
<B>Publication status</B>: peer-reviewed journal</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-12-01 10:46:12 +0100" MODIFIED_BY="[Empty name]">
<P>Quote from publication: "To investigate the glucose lowering effects of insulin alone, insulin plus metformin, insulin plus rosiglitazone, or insulin plus acarbose in subjects with type 2 diabetes mellitus and determine the type of treatment that would influence the serum level of total cholesterol, LDL-C, HDL-C, CRP and fibrinogen in these patients."</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-04-01 15:39:41 +0200" MODIFIED_BY="Marielle van Avendonk"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Note: where the judgement is 'Unclear' and the description is blank, the study did not report that particular outcome.</P>
<P>NPH: Neutral Protamine Hagedorn</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Abraira-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Mixed population: insulin-naive and previously insulin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:39:14 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Al_x002d_Shaikh-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:39:14 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:39:29 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Altuntas-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:39:29 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:39:34 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Bachman-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:39:34 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:39:38 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Barranco-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:39:38 +0100" MODIFIED_BY="Bernd Richter">
<P>No insulin therapy arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:39:42 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Berhanu-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:39:42 +0100" MODIFIED_BY="Bernd Richter">
<P>Impossible to analyse subgroup of insulin-users separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:39:49 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Bianchi-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:39:49 +0100" MODIFIED_BY="Bernd Richter">
<P>Trial on combination of benfluorex with insulin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:42:20 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Buse-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:42:20 +0100" MODIFIED_BY="Bernd Richter">
<P>Use of troglitazone (off the market)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:39:58 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Carta-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:39:58 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:40:02 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Castillo-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:40:02 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:40:07 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Charbonnel-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:40:07 +0100" MODIFIED_BY="Bernd Richter">
<P>Impossible to analyse subgroup of insulin-users separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:40:11 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Chazan-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:40:11 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:40:14 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Chow1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:40:14 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:40:18 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Clauson-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:40:18 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-31 10:37:53 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Cortes-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-31 10:37:53 +0200" MODIFIED_BY="Bernd Richter">
<P>Well-controlled population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:40:30 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Dashora-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:40:30 +0100" MODIFIED_BY="Bernd Richter">
<P>Impossible to analyse subgroup of insulin-users separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:40:41 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Davidson-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:40:41 +0100" MODIFIED_BY="Bernd Richter">
<P>No arm without oral agent or placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:40:44 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-De-Luis-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:40:44 +0100" MODIFIED_BY="Bernd Richter">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:40:48 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Douek-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:40:48 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:40:51 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Fonseca-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:40:51 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:40:55 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Fonseca-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:40:55 +0100" MODIFIED_BY="Bernd Richter">
<P>Observational phase of RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:41:00 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Garg-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:41:00 +0100" MODIFIED_BY="Bernd Richter">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:41:05 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Gerstein-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:41:05 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:41:09 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Goudswaard-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:41:09 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:41:12 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Greco-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:41:12 +0100" MODIFIED_BY="Bernd Richter">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:41:17 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Groop-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:41:17 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:41:21 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Groop-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:41:21 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:41:25 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Gutniak-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:41:25 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:41:28 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Hamelbeck-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:41:28 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:41:32 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Hermanns-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:41:32 +0100" MODIFIED_BY="Bernd Richter">
<P>Follow-up less than 2 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:41:38 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Hollander-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:41:38 +0100" MODIFIED_BY="Bernd Richter">
<P>Adding of non-oral agent pramlintide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:41:44 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Hollander-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:41:44 +0100" MODIFIED_BY="Bernd Richter">
<P>Adding of non-oral agent pramlintide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:41:49 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Hollander-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:41:49 +0100" MODIFIED_BY="Bernd Richter">
<P>Adding of non-oral agent pramlintide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:41:56 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Hollander-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:41:56 +0100" MODIFIED_BY="Bernd Richter">
<P>Adding of rosiglitazone (off the market)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:42:33 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Holman-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:42:33 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:42:36 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Home-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:42:36 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:42:39 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Inoue1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:42:39 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:42:43 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Jacob-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:42:43 +0100" MODIFIED_BY="Bernd Richter">
<P>Impossible to analyse subgroup of insulin-users separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:42:47 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Jacober-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:42:47 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:42:51 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Janka-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:42:51 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:42:54 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Janka-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:42:54 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:42:59 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Juurinen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:42:59 +0100" MODIFIED_BY="Bernd Richter">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:43:02 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Juurinen-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:43:02 +0100" MODIFIED_BY="Bernd Richter">
<P>Impossible to analyse subgroup of insulin-users separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:43:09 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Kabadi-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:43:09 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:43:12 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Kanda-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:43:12 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:43:22 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Kandalintseva-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:43:22 +0100" MODIFIED_BY="Bernd Richter">
<P>Rosiglitazone combination therapy (off the market)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:43:26 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Karlander-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:43:26 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:43:29 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Kilo-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:43:29 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:43:32 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Kokic-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:43:32 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:43:36 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Kothny-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:43:36 +0100" MODIFIED_BY="Bernd Richter">
<P>Impossible to analyse subgroup of insulin-users separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:43:39 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Kvapil-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:43:39 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:43:42 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-LAPToP-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:43:42 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:43:49 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Lins-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:43:49 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:43:58 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Liu-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:43:58 +0100" MODIFIED_BY="Bernd Richter">
<P>Rosiglitazone combination therapy (off the market)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:44:01 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Lotz-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:44:01 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:44:06 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Lund-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:44:06 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:44:09 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Lundershausen-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:44:09 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:44:12 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Makimattila-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:44:12 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:44:16 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Mohan-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:44:16 +0100" MODIFIED_BY="Bernd Richter">
<P>No RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:44:19 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Morrow-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:44:19 +0100" MODIFIED_BY="Bernd Richter">
<P>Combination with ligarglutide (non-oral agent)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:44:22 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Olsson-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:44:22 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Ose-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-31 10:44:10 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Ozbek-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-31 10:44:10 +0200" MODIFIED_BY="Bernd Richter">
<P>Well-controlled population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:44:35 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Pan-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:44:35 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:44:38 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Peacock-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:44:38 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:44:42 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Peyrot-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:44:42 +0100" MODIFIED_BY="Bernd Richter">
<P>Addition of a non-oral agent pramlintide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:44:57 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Ponssen-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:44:57 +0100" MODIFIED_BY="Bernd Richter">
<P>Mixed group: insulin-naive and previously insulin-treated participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:44:51 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Pontiroli-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:44:51 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Poulsen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Control group mixed: insulin- and insulin + metformin-treated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:45:07 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Raskin-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:45:07 +0100" MODIFIED_BY="Bernd Richter">
<P>Addition of rosiglitazone (off the market)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:45:13 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Ravnik-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:45:13 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:45:15 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Ravnik-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:45:15 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:45:20 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Raz-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:45:20 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:45:27 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Riddle-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:45:27 +0100" MODIFIED_BY="Bernd Richter">
<P>Mixed group: insulin-naive and previously insulin-treated participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:45:31 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Riddle-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:45:31 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:45:34 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Riddle-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:45:34 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:45:37 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Riddle-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:45:37 +0100" MODIFIED_BY="Bernd Richter">
<P>Adding of a non-oral agent pramlintide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:45:40 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Rosak-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:45:40 +0100" MODIFIED_BY="Bernd Richter">
<P>Follow-up less than 2 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:45:43 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Sachse-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:45:43 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Sangiorgio-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:45:49 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Schmidt-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:45:49 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:45:52 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Schnell-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:45:52 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:46:00 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Schwartz-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:46:00 +0100" MODIFIED_BY="Bernd Richter">
<P>Use of troglitazone (off the market)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:46:03 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Sun-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:46:03 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:46:06 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Tamemoto-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:46:06 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:46:09 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Vilsboll-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:46:09 +0100" MODIFIED_BY="Bernd Richter">
<P>Impossible to analyse subgroup of insulin-users separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Willey-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Mixed group: insulin- and insulin + metformin-treated participants; trial on combination of insulin and dexfenfluramine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:46:23 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Wolffenbuttel-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:46:23 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:46:28 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Wolffenbuttel-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:46:28 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:46:42 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Wong-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:46:42 +0100" MODIFIED_BY="Bernd Richter">
<P>Special population: type 2 diabetes participants with peritoneal dialysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:46:46 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Wright-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:46:46 +0100" MODIFIED_BY="Bernd Richter">
<P>Newly diagnosed type 2 diabetes participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:46:50 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Yamada-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:46:50 +0100" MODIFIED_BY="Bernd Richter">
<P>No arm without oral agent or placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:46:53 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Yki_x002d_Jarvinen-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:46:53 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:46:58 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Yki_x002d_Jarvinen-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:46:58 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:47:05 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Yki_x002d_Jarvinen-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:47:05 +0100" MODIFIED_BY="Bernd Richter">
<P>Impossible to analyse subgroup of insulin-users separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:47:09 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Yokoyama-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:47:09 +0100" MODIFIED_BY="Bernd Richter">
<P>Two arms: continuation and discontinuation of glimepiride</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-23 13:47:12 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Zargar-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-23 13:47:12 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin-naive participants</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Fargren-2014">
<CHAR_METHODS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>A single-centre, double-blind, randomised, placebo-controlled cross-over study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Participants with type 2 diabetes, mean age 59 + 6 (SD) years and mean HbA1c 7.7% + 0.8%, treated with exogenous insulin with or without oral antihyperglycaemic agents</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Participants received vildagliptin (50 mg twice a day) or placebo as add-on to insulin for 4 weeks in random order with a 4-week washout in between</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 12:07:28 +0100" MODIFIED_BY="Bernd Richter">
<P>Glucose, glucagon</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-24 12:07:31 +0100" MODIFIED_BY="Bernd Richter">
<P>-</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-05-02 14:14:01 +0200" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-Kaku-2014">
<CHAR_METHODS MODIFIED="2016-03-24 12:07:38 +0100" MODIFIED_BY="Bernd Richter">
<P>Randomised, double-blind, 12-week comparative trial, followed by a 40-week, open-label phase</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-05-02 14:14:01 +0200" MODIFIED_BY="Bernd Richter">
<P>179 participants with type 2 diabetes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-24 12:07:54 +0100" MODIFIED_BY="Bernd Richter">
<P>Alogliptin and insulin versus placebo and insulin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-17 16:05:50 +0100" MODIFIED_BY="[Empty name]">
<P>HbA1c, body weight, hypoglycaemia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-24 12:08:06 +0100" MODIFIED_BY="Bernd Richter">
<P>-</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Mathieu-2015">
<CHAR_METHODS MODIFIED="2016-03-24 12:08:37 +0100" MODIFIED_BY="Bernd Richter">
<P>Multicenter, randomised, double-blind, placebo-controlled, 24-week clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>660 participants with type 2 diabetes and inadequate glycaemic control on insulin, with or without metformin (&gt; 1500 mg/day) or sulfonylurea, for &gt; 10 weeks. Participants could remain on metformin but not sulphonylurea after randomisation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-24 12:09:06 +0100" MODIFIED_BY="Bernd Richter">
<P>Sitagliptin 100 mg/day or placebo was administered concurrently with insulin glargine titration, targeting a fasting glucose of 4.0-5.6 mmol/L (72-100 mg/dL)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 12:09:18 +0100" MODIFIED_BY="Bernd Richter">
<P>Insulin dose, HbA1c, hypoglycaemia, adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-24 12:09:25 +0100" MODIFIED_BY="Bernd Richter">
<P>Subgroup analysis with insulin monotherapy needs to be checked</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-03-24 12:09:55 +0100" MODIFIED_BY="Bernd Richter" STUDY_ID="STD-McGill-2015">
<CHAR_METHODS MODIFIED="2016-03-24 12:09:35 +0100" MODIFIED_BY="Bernd Richter">
<P>Data for participants in two phase 3 trials with linagliptin who were receiving insulin were analysed separately (n = 811)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 12:09:42 +0100" MODIFIED_BY="Bernd Richter">
<P>Type 2 diabetes mellitus participants with chronic kidney disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-24 12:09:47 +0100" MODIFIED_BY="Bernd Richter">
<P>Linagliptin + insulin vs placebo + insulin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-17 16:06:14 +0100" MODIFIED_BY="[Empty name]">
<P>HbA1c, (severe) hypoglycaemia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-24 12:09:55 +0100" MODIFIED_BY="Bernd Richter">
<P>Inadequate control needs to be checked</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Ning-2014">
<CHAR_METHODS MODIFIED="2016-03-24 12:09:59 +0100" MODIFIED_BY="Bernd Richter">
<P>Multicentre, double-blind, placebo-controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 12:10:18 +0100" MODIFIED_BY="Bernd Richter">
<P>Participants with type 2 diabetes inadequately controlled (HbA1c 7.5%-11.0%) on stable therapy with long-acting, intermediate-acting or premixed insulin, with or without concomitant metformin</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-24 12:10:37 +0100" MODIFIED_BY="Bernd Richter">
<P>Vildagliptin 50 mg twice a day (n = 146) or placebo (n = 147)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-17 08:19:11 +0100" MODIFIED_BY="[Empty name]">
<P>HbA1c, fasting blood glucose, BMI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Need to determine if subgroup analysis with insulin monotherapy is possible</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Rosenstock-2009">
<CHAR_METHODS MODIFIED="2015-12-17 15:36:48 +0100" MODIFIED_BY="[Empty name]">
<P>26-week, double-blind, placebo-controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>People with type 2 diabetes inadequately controlled with insulin alone or combined with metformin</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Participants received alogliptin 12.5 mg (n = 131), alogliptin 25 mg (n = 129) or placebo (n = 130) once daily, as add-on to stable insulin therapy with or without metformin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>HbA1c, body weight, hypoglycaemia, incidences of overall adverse events, and of gastrointestinal, dermatological and infection-related events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Need to determine whether subgroup analysis for insulin monotherapy group is possible</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Sato-2015">
<CHAR_METHODS MODIFIED="2016-03-24 12:11:03 +0100" MODIFIED_BY="Bernd Richter">
<P>24-week, prospective, randomised, open-labelled, controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Participants with type 2 diabetes who were suboptimally controlled despite receiving at least twice-daily injections of insulin were enrolled in the trial</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<P>The participants were randomised to continuation of insulin treatment (insulin group) or addition of sitagliptin 50 mg-100 mg daily to insulin treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 12:12:05 +0100" MODIFIED_BY="Bernd Richter">
<P>HbA1c, body weight, hypoglycaemia, treatment satisfaction</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-24 12:12:07 +0100" MODIFIED_BY="Bernd Richter">
<P>-</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Sheu-2015">
<CHAR_METHODS MODIFIED="2016-03-24 12:12:03 +0100" MODIFIED_BY="Bernd Richter">
<P>Randomised double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 12:12:22 +0100" MODIFIED_BY="Bernd Richter">
<P>Asian participants with type 2 diabetes mellitus inadequately controlled by basal insulin with/without oral agents</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Treatment with linagliptin 5 mg once daily or placebo. Basal insulin dose remained stable for 24 weeks, after which adjustments could be made according to the investigator's discretion to improve glycaemic control</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-17 13:23:16 +0100" MODIFIED_BY="[Empty name]">
<P>HbA1c, adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Need to determine if subgroup analysis with insulin monotherapy is possible</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Srivanichakorn-2015">
<CHAR_METHODS MODIFIED="2016-03-24 12:12:44 +0100" MODIFIED_BY="Bernd Richter">
<P>8-week randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 12:12:59 +0100" MODIFIED_BY="Bernd Richter">
<P>Participants with type 2 diabetes who had been treated with insulin for at least 3 years plus moderate to high doses of sulphonylureas</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-24 12:13:26 +0100" MODIFIED_BY="Bernd Richter">
<P>Withdrawal of sulphonylureas (insulin monotherapy) (n = 16) or continuation (n = 16) of sulphonylureas</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-17 13:36:42 +0100" MODIFIED_BY="[Empty name]">
<P>HbA1c, insulin secretion </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Need to determine whether participants were adequately controlled</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-Takahashi-2015">
<CHAR_METHODS MODIFIED="2016-03-24 12:13:41 +0100" MODIFIED_BY="Bernd Richter">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Type 2 diabetes participants receiving twice-daily injections of premix analog insulin</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Group A, in which participants were switched to long-acting insulin glargine at 80% of the insulin dose in the previous treatment regimen (23 participants), or group B (21 participants), given 50% of the previous dose, concurrently with the oral dipeptidyl-peptidase 4 inhibitor sitagliptin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-17 16:06:26 +0100" MODIFIED_BY="[Empty name]">
<P>HbA1c, lipids, hyperglycaemia and nocturnal hypoglycaemia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Need to determine if participants were adequately controlled before randomisation</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>BMI: body mass index; HbA1c: glycosylated haemoglobin A1c</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-EUCTR2011_x002d_004622_x002d_96_x002d_ES">
<CHAR_STUDY_NAME MODIFIED="2016-03-24 13:02:57 +0100" MODIFIED_BY="Bernd Richter">
<P>Study to test the safety, tolerability, and effectiveness of sitagliptin when compared to placebo in reducing the amount of insulin (with or without metformin) needed per day, to control blood sugar, over a 24-week period</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>A phase III, multicenter, randomised, double-blind, placebo-controlled clinical trial to study the safety and insulin-sparing efficacy of the addition of sitagliptin in - Study to test the safety, tolerability, and effectiveness of sitagliptin when compared to placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Participants with type 2 diabetes mellitus who have inadequate glycaemic control on insulin alone or in combination with metformin</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Sitagliptin compared with placebo on the change in insulin dose in IU per day in people with type 2 diabetes mellitus (T2DM) with inadequate glycaemic control on insulin with or without metformin, who titrate insulin glargine (treat-to-target)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 13:03:32 +0100" MODIFIED_BY="Bernd Richter">
<P>Daily insulin dose, HbA1c, fasting plasma glucose, body weight</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-12-17 14:46:31 +0100" MODIFIED_BY="[Empty name]">
<P>23 December 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2016-07-23 12:44:27 +0200" MODIFIED_BY="[Empty name]">
<P>Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-IRCT201204229536N1">
<CHAR_STUDY_NAME MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>The comparison glycaemic control in two group patient treated with insulin alone and insulin plus sulfonylurea [<I>title as provided by study investigators]</I>
</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-12-15 21:32:54 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_PARTICIPANTS MODIFIED="2015-12-15 21:32:45 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Insulin 0.2 U/kg /day and sulphonylurea with previous dose vs insulin 0.3 U/kg /day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 13:08:27 +0100" MODIFIED_BY="Bernd Richter">
<P>Blood glucose, body weight, hypoglycaemic events</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-JPRN_x002d_UMIN000011851">
<CHAR_STUDY_NAME MODIFIED="2015-12-17 16:06:42 +0100" MODIFIED_BY="[Empty name]">
<P>The efficacy of vildagliptin on type 2 diabetic patients with basal-bolus insulin therapy in the short-term hospitalisation (single-center, randomised, open-label, controlled study)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-03-24 13:04:27 +0100" MODIFIED_BY="Bernd Richter">
<P>Single-center, randomised, open-label, controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 13:08:35 +0100" MODIFIED_BY="Bernd Richter">
<P>Type 2 diabetes participants</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Insulin + vildagliptin vs insulin alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 13:04:40 +0100" MODIFIED_BY="Bernd Richter">
<P>Blood glucose, lipids</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-JPRN_x002d_UMIN000018784">
<CHAR_STUDY_NAME MODIFIED="2016-07-23 12:48:39 +0200" MODIFIED_BY="[Empty name]">
<P>Comparison of the effects of insulin monotherapy and combination therapy with ipragliflozin and insulin on glucose toxicity in type 2 diabetes mellitus : a randomised controlled trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-03-24 13:04:49 +0100" MODIFIED_BY="Bernd Richter">
<P>Not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Combination therapy with ipragliflozin and insulin group. Oral administration of 50 mg ipragliflozin once a day, after breakfast. Multiple injection of rapid-acting insulin and long-acting insulin. Insulin monotherapy group: multiple injection of rapid-acting insulin and long-acting insulin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 13:05:24 +0100" MODIFIED_BY="Bernd Richter">
<P>Glucose, insulin dose, lipids, body weight</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-12-17 14:59:43 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-NCT00329225">
<CHAR_STUDY_NAME MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Rosiglitazone in subjects with type 2 diabetes mellitus who are inadequately controlled on insulin</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-03-24 13:09:43 +0100" MODIFIED_BY="Bernd Richter">
<P>A multicenter, randomised, double-blind, parallel-group, placebo-controlled clinical evaluation of insulin plus rosiglitazone (2 mg and 4 mg) compared to insulin plus placebo for 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 13:10:09 +0100" MODIFIED_BY="Bernd Richter">
<P>Participants with type 2 diabetes mellitus who are inadequately controlled on insulin</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-17 14:50:02 +0100" MODIFIED_BY="[Empty name]">
<P>Rosiglitazone + insulin vs insulin + placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-17 14:51:16 +0100" MODIFIED_BY="[Empty name]">
<P>HbA1c, fasting plasma glucose, lipids</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-12-17 14:52:43 +0100" MODIFIED_BY="[Empty name]">
<P>22 May 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2015-12-17 14:51:49 +0100" MODIFIED_BY="[Empty name]">
<P>GlaxoSmithKline</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-NCT00757588">
<CHAR_STUDY_NAME MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Safety and efficacy of saxagliptin plus insulin with or without metformin</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Multicenter double-blind parallel-group randomised controlled trial, phase 3 trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 13:05:59 +0100" MODIFIED_BY="Bernd Richter">
<P>Type 2 diabetes with inadequate glycaemic control</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Saxagliptin (5 mg) + insulin vs placebo for saxagliptin + insulin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-01 17:40:24 +0200" MODIFIED_BY="[Empty name]">
<P>HbA1c, fasting glucose, insulin dose, blood pressure, (serious) adverse events (hypoglycaemia)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-12-17 14:44:44 +0100" MODIFIED_BY="[Empty name]">
<P>22 September 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2015-12-15 21:06:14 +0100" MODIFIED_BY="[Empty name]">
<P>AstraZeneca</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-NCT02104804">
<CHAR_STUDY_NAME MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Evaluate the efficacy and aafety of aaxagliptin added to insulin monotherapy or to insulin combined with metformin in Chinese subjects with type 2 diabetes who have inadequate glycaemic control</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Double-blind parallel-group randomised controlled trial, phase 3 trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 13:11:13 +0100" MODIFIED_BY="Bernd Richter">
<P>Type 2 diabetes participants who have inadequate glycaemic control on insulin alone or on insulin in combination with metformin<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<P>Saxagliptin (5 mg) + insulin vs placebo for saxagliptin + insulin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-05-01 17:40:27 +0200" MODIFIED_BY="[Empty name]">
<P>HbA1c, fasting glucose, insulin dose, (serious) adverse events (hypoglycaemia)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-12-17 14:43:20 +0100" MODIFIED_BY="[Empty name]">
<P>2 April 2014</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES MODIFIED="2015-12-15 21:06:21 +0100" MODIFIED_BY="[Empty name]">
<P>AstraZeneca</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>HbA1c: glycosylated haemoglobin A1c</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-09-07 09:43:41 +0200" MODIFIED_BY="Gudrun Paletta">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-09-07 09:41:45 +0200" MODIFIED_BY="Gudrun Paletta" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:29:13 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:37:43 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Patients were stratified based on metformin use at enrolment and randomised 2:1 via an interactive voice response system using a blocked randomisation schedule to receive saxagliptin 5 mg (Onglyza, Bristol-Myers Squibb Company, Princeton, NJ, USA, and AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA) or placebo once daily as add-on to baseline therapy with insulin or insulin plus metformin."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:08 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Casner-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:16 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:24 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:32 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:38 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:38:28 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Patients were randomly assigned to either metformin or placebo treatment (double-blind)...."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:38:31 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Phase II (double-blind) patients were randomly assigned to continue to receive placebo or to treatment with metformin for six months"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:38:35 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Groop-1985">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...the patients were randomly allocated to 8 weeks of treatment with ....."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:38:39 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...the patients entered a 12-month double-blind treatment phase randomly allocated to metformin or placebo in parallel groups and as adjunct to their current insulin therapy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:31:28 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:31:56 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2012">
<DESCRIPTION>
<P>
<B>Comment</B>: not mentioned in the publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:32:24 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:32:43 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: randomisations in two groups of 20 participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:32:51 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:03 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:12 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:25 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:39:20 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "randomised"</P>
<P>
<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:50 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:39:42 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "random assignment to equal-sized parallel-groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:39:49 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "After the completion of the baseline studies, subjects were randomised (in a double-blind manner) to..."</P>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:39:55 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "The enrolled patients were randomised to groups treated with miglitol or with placebo"</P>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:39:59 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Osei-1984">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Patients were randomly assigned in a double-blind manner to receive either glyburide or placebo..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:40:04 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "They were allocated at random into two groups, each consisting of 15 subjects..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:40:07 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Reich-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "randomised"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:40:11 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "... and were subsequently randomised (31 to insulin + metformin and 29 to insulin dose increase)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:40:18 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "patients were randomised..."</P>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:56 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:40:42 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Schade-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "The order of the two treatment regimens was randomised..."</P>
<P>
<B>Comment</B>: not possible to judge whether the sequence generation was adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:40:49 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Randomization was performed..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:41:00 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "patients were randomised to receive either glipizide 10 mg twice daily or placebo, in addition to usual insulin"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:41:07 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...the patients were randomised to a double-blind treatment with insulin in combination with glibenclamide or insulin and placebo for four months"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:41:20 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Subjects ... were randomly assigned ..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:41:39 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...all subject were randomly assigned..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:41:45 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "After the initial assessment, subjects were randomly assigned to continue insulin therapy alone, or add acarbose (300 mg/day), or metformin (1,700 mg/day), or rosiglitazone (8 mg/day) to insulin therapy."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-09-07 09:41:21 +0200" MODIFIED_BY="Gudrun Paletta" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:29:21 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:37:47 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "To maintain blinding to patients and physicians, saxagliptin and placebo tablets were identical in appearance, and bottles were printed with a blinded label."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:09 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Casner-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:16 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:25 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:33 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:39 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:47 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:55 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:31:00 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Groop-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:38:40 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Randomization was performed by center in block of four."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:31:29 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:31:57 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2012">
<DESCRIPTION>
<P>
<B>Comment</B>: not mentioned in the publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:32:30 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:32:43 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: randomisations in blocks of 4 (20 participants per group)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:32:52 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:04 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:13 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:25 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:39:21 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "randomised with equal probability.... according to a central randomisation table generated by the study sponsor and administered by an automated interactive voice response system at all sites"</P>
<P>
<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:51 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:58 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:34:04 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:34:27 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:15 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Osei-1984">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:22 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:40:07 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Reich-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "randomised by the hospital pharmacy"<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-12 21:18:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION>
<P>"patients were randomised into two study groups following an experimental design of open-label randomisation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:46 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:57 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:36:23 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Schade-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:40:50 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Randomization was performed by a central computer and patients were assigned (1:1:1) to one of the three treatment groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:36:35 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:36:40 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:41:21 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Random assignment was determined by the sponsor who provided sealed sequentially numbered envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:36:51 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:37:12 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: not possible to judge whether the allocation to the intervention and control group was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-09-07 09:41:43 +0200" MODIFIED_BY="Gudrun Paletta" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.06" NO="6">
<NAME>HbA1c, FPG, lipids</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.05" NO="5">
<NAME>Health-related quality of life, patient satisfaction</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>Mortality, morbidity</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.07" NO="7" REF_IDS="CMP-001.03 CMP-001.05 CMP-001.01 CMP-001.07 CMP-001.09 CMP-001.12 CMP-002.03 CMP-002.01 CMP-002.05 CMP-002.07 CMP-002.09 CMP-003.02 CMP-003.03 CMP-004.02 CMP-004.03 CMP-004.01 CMP-005.03 CMP-005.01">
<NAME>Insulin dose</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.04" NO="4">
<NAME>Adverse events</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:19:28 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:37:32 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Patients who met the inclusion criteria were randomly assigned in a double-blind fashion to receive metformin or placebo in addition to their current insulin therapy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:19:28 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:37:41 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Patients who met the inclusion criteria were randomly assigned in a double-blind fashion to receive metformin or placebo in addition to their current insulin therapy"</P>
<P/>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:37:42 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Patients who met the inclusion criteria were randomly assigned in a double-blind fashion to receive metformin or placebo in addition to their current insulin therapy"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:19:32 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:37:51 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "To maintain blinding to patients and physicians, saxagliptin and placebo tablets were identical in appearance, and bottles were printed with a blinded label."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:19:32 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:29:34 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION>
<P>
<B>Comment</B>: FGP and lipids not assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:37:52 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "To maintain blinding to patients and physicians, saxagliptin and placebo tablets were identical in appearance, and bottles were printed with a blinded label."</P>
<P/>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:19:37 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Casner-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:37:53 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Casner-1988">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Patients and physicians were blinded regarding laboratory results and study medication but not on insulin"</P>
<P>
<B>Comment</B>: so patients were not blinded for their weight gain (this is the only adverse event mentioned)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:19:37 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Casner-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:37:54 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Casner-1988">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Patients and physicians were blinded regarding laboratory results and study medication but not on insulin"</P>
<P>
<B>Comment</B>:</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:37:54 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Casner-1988">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Patients and physicians were blinded regarding laboratory results and study medication but not on insulin"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:19:42 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:30:17 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION>
<P>
<B>Comment</B>: it is not clear whether the physician or the outcome assessor is besides the participants blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:19:46 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:38:06 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: (from the abstract) " Design: a 1-year, multicenter, randomised, double-blind, placebo-controlled study" (from the main text) "Acarbose or placebo was taken with the first sip of the liquid meal"</P>
<P>
<B>Comment</B>: it is not clear whether the physician or the outcome assessor is besides the participants blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:38:07 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: (from the abstract) " Design: a 1-year, multicenter, randomised, double-blind, placebo-controlled study" (from the main text) "Acarbose or placebo was taken with the first sip of the liquid meal"</P>
<P>
<B>Comment</B>: it is not clear whether the physician or the outcome assessor is besides the participants blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:19:47 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:38:12 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: (abstract and main text): "This double-blind, randomised, multicenter, placebo-controlled study..." (main text) "The double-blind endpoint was defined as last visit observation for each patients"</P>
<P>
<B>Comment</B>: at all measurement occasions the efficacy and safety tests were assessed. However it is not clear whether the physician or the outcome assessor was blinded in addition to the participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:19:51 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:38:13 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: (abstract and main text): "This double-blind, randomised, multicenter, placebo-controlled study..." (main text)"The double-blind endpoint was defined as last visit observation for each patients"</P>
<P>
<B>Comment</B>: at all measurement occasions the efficacy and safety tests were assessed. However it is not clear whether the physician or the outcome assessor was blinded in addition to the participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:30:26 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION>
<P>
<B>Comment</B>: data are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:20:01 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2015-01-07 12:20:05 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:20:06 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:38:21 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "This study was a double-blind crossover comparison of insulin and placebo vs. insulin and glipizide."</P>
<P>
<B>Comment</B>: probably the participant and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:38:22 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "This study was a double-blind crossover comparison of insulin and placebo vs. insulin and glipizide."</P>
<P>
<B>Comment</B>: probably the participant and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:20:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:38:25 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "This was a 24-week, randomised, double-blind, placebo-controlled, parallel-group study...."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:20:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:38:25 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "All assessments were made by central laboratories."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:38:26 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "This was a 24-week, randomised, double-blind, placebo-controlled, parallel-group study...."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:20:17 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2015-01-07 12:20:17 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:20:17 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:38:29 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "patients were randomised in a double-blind fashion..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:38:30 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "patients were randomised in a double-blind fashion..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:20:22 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2015-01-07 12:20:22 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:20:22 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:38:32 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Phase II (double-blind) patients were randomly assigned to continue to receive placebo or to treatment with metformin for six months</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:38:33 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Phase II (double-blind) patients were randomly assigned to continue to receive placebo or to treatment with metformin fro six months"</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:20:27 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Groop-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:38:36 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Groop-1985">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a double-blind cross-over study we compared the effect of...."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:20:28 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Groop-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:38:37 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Groop-1985">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a double-blind cross-over study we compared the effect of...."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:38:38 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Groop-1985">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a double-blind cross-over study we compared the effect of...."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:20:33 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:38:41 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "The study was a 12-month double-blind placebo-controlled trial..."</P>
<P>
<B>Comment</B>: probably the participants and personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:20:33 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:38:41 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "The study was a 12-month double-blind placebo-controlled trial..."</P>
<P>
<B>Comment</B>: probably the participants and personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:38:42 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "The study was a 12-month double-blind placebo-controlled trial..."</P>
<P>
<B>Comment</B>: probably the participants and personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:20:38 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:38:44 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "... a 5-month single-center prospective double-blind placebo-controlled study"</P>
<P>
<B>Comment</B>: probably the participants and personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:20:38 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:38:45 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "... a 5-month single-center prospective double-blind placebo-controlled study"</P>
<P>
<B>Comment</B>: probably the participants and personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:38:46 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "... a 5-month single-center prospective double-blind placebo-controlled study"</P>
<P>
<B>Comment</B>: probably the participants and personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:20:43 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:31:57 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Hong-2012">
<DESCRIPTION>
<P>
<B>Comment</B>: participants and personnel were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:20:43 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:31:58 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Hong-2012">
<DESCRIPTION>
<P>
<B>Comment</B>: participants and personnel were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:31:59 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Hong-2012">
<DESCRIPTION>
<P>
<B>Comment</B>: participants and personnel were not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:20:54 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:38:56 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a randomised cross-over trial, ..."</P>
<P>
<B>Comment</B>: unclear if it was a blinded trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:20:54 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:38:57 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a randomised cross-over trial, ..."</P>
<P>
<B>Comment</B>: unclear if it was a blinded trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:38:58 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a randomised cross-over trial, ..."</P>
<P>
<B>Comment</B>:unclear if it was a blinded trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:21:05 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:32:44 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: it is unclear if the study was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:21:05 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:32:44 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: it is unclear if the study was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:32:45 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: it is unclear if the study was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:39:05 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "A double blind, cross over trial was assigned ...after randomisation patients were given either glibenclamide or placebo....5 patients started with glibenclamide and 4 with placebo"</P>
<P>
<B>Comment</B>: probably the participants and personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:39:05 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "A double blind, cross over trial was assigned...after randomisation patients were given either glibenclamide or placebo....5 patients started with glibenclamide and 4 with placebo"</P>
<P>
<B>Comment</B>: probably the participants and personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:39:08 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Glyburide was compared with placebo in a double-blind crossover design"</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:39:09 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Glyburide was compared with placebo in a double-blind crossover design"</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:39:10 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Glyburide was compared with placebo in a double-blind crossover design"</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:39:13 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...in this randomised double-blind crossover study."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:39:14 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...in this randomised double-blind crossover study."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:39:14 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...in this randomised double-blind crossover study."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:39:17 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: (from the abstract) "Using a double-blind crossover design, ..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:39:18 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: (from the abstract) "Using a double-blind crossover design, ..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 12:04:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:39:22 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "this 6-month, randomised, double blind, prospective, multicenter, placebo-controlled, parallel-group study was ...."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 12:04:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:39:23 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "this 6-month, randomised, double blind, prospective, multicenter, placebo-controlled, parallel-group study was ...."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:39:24 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "this 6-month, randomised, double blind, prospective, multicenter, placebo-controlled, parallel-group study was ...."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 12:05:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:39:26 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "The study was carried out double-blind......"</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 12:05:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:39:27 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "The study was carried out double-blind......"</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:39:27 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "The study was carried out double-blind......"</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 12:06:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2014-12-12 12:06:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 12:06:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:39:46 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "The study was double-blinded with random assignment to equal-sized parallel-groups..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:39:48 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "The study was double-blinded with random assignment to equal-sized parallel-groups..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 12:12:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:39:50 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "After the completion of the baseline studies, subjects were randomised (in a double-blind manner) to..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 12:14:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:39:51 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "After the completion of the baseline studies, subjects were randomised (in a double-blind manner) to..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:39:52 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "After the completion of the baseline studies, subjects were randomised (in a double-blind manner) to..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 12:25:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:39:55 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "We conducted a placebo-controlled double-blind comparative study..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 12:27:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:39:56 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "We conducted a placebo-controlled double-blind comparative study..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:39:57 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "We conducted a placebo-controlled double-blind comparative study..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 12:33:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Osei-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:40:00 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Osei-1984">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Patients were randomly assigned in a double-blind manner..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 12:33:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Osei-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:40:01 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Osei-1984">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Patients were randomly assigned in a double-blind manner..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:40:02 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Osei-1984">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Patients were randomly assigned in a double-blind manner..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 12:37:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:35:23 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the study was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 12:38:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:35:23 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the study was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:35:24 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the study was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 12:38:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reich-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2014-12-12 12:38:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reich-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 12:38:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reich-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:40:08 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Reich-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: (from abstract) "A placebo-controlled, double-blinded design..."</P>
<P>
<B>Comment</B>: Probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:40:09 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Reich-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: (from abstract) "A placebo-controlled, double-blinded design..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 12:39:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:40:12 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "open-label randomisation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 12:39:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:40:13 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "open-label randomisation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:40:14 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "open-label randomisation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 12:39:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:40:19 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: (from abstract) "Two randomised double-blind placebo-controlled crossover studies were run."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 12:39:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:40:20 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: (from abstract) "Two randomised double-blind placebo-controlled crossover studies were run."</P>
<P>
<B>Comment</B>:probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:40:21 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: (from abstract) "Two randomised double-blind placebo-controlled crossover studies were run."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 12:40:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:40:26 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "... the 16-weeks double-blind treatment period"</P>
<P>
<B>Comment</B>: Probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 12:40:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:40:29 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "... the16-weeks double-blind treatment period"</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:40:31 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "During the single-blinded period, patients received their stable insulin regimens"</P>
<P>
<B>Quote from publication</B>: "... the16-weeks double-blind treatment period"</P>
<P>
<B>Comment</B>: the single-blind period refers to the run-in period and the 16-weeks to the treatment period. Probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 12:40:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schade-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:40:43 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Schade-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...neither the patient nor the investigators knew until the completion of the study which treatment regimen the patients were receiving during each 16-weeks period."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 12:40:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schade-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:40:43 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Schade-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...neither the patient nor the investigators knew until the completion of the study which treatment regimen the patients were receiving during each 16-weeks period."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:40:44 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Schade-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...neither the patient nor the investigators knew until the completion of the study which treatment regimen the patients were receiving during each 16-weeks period."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 12:41:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:40:51 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a open, controlled, randomised, parallel-group, single-centre, 16-weeks pilot study..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2016-09-07 09:40:52 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a open, controlled, randomised, parallel-group, single-centre, 16-weeks pilot study..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:40:53 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a open, controlled, randomised, parallel-group, single-centre, 16-weeks pilot study..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:40:54 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a open, controlled, randomised, parallel-group, single-centre, 16-weeks pilot study..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 12:41:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:41:01 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "The treatment was blind to both the patient and investigators"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 12:41:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:41:02 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "The treatment was blind to both the patient and investigators"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:41:03 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "The treatment was blind to both the patient and investigators"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 12:42:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:41:07 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "....the patients were randomised to a four-months double-blind cross-over treatment...."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 12:42:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:41:08 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "....the patients were randomised to a four-months double-blind cross-over treatment...."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:41:09 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "....the patients were randomised to a four-months double-blind cross-over treatment...."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 12:42:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:41:22 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...were randomly assigned in an unmasked fashion..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 12:42:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:41:23 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...were randomly assigned in an unmasked fashion..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:41:25 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...were randomly assigned in an unmasked fashion..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 13:36:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:41:41 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...all subjects were randomly assigned in a double-blind fashion..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 13:36:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:41:42 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...all subjects were randomly assigned in a double-blind fashion..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:41:43 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...all subjects were randomly assigned in a double-blind fashion..."</P>
<P>
<B>Comment</B>: probably the participants and the personnel were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2014-12-12 13:36:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.04" MODIFIED="2016-09-07 09:37:13 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear, not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.05" MODIFIED="2014-12-12 13:37:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.06" MODIFIED="2016-09-07 09:37:14 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear, not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.07" MODIFIED="2016-09-07 09:37:14 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear, not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-09-07 09:41:28 +0200" MODIFIED_BY="Gudrun Paletta" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.05" NO="5">
<NAME>Health-related quality of life, patient satisfaction</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1" REF_IDS="CMP-001.03 CMP-001.05 CMP-001.01 CMP-001.07 CMP-001.09 CMP-001.12 CMP-002.03 CMP-002.01 CMP-002.05 CMP-002.07 CMP-002.09 CMP-003.02 CMP-003.03 CMP-004.02 CMP-004.03 CMP-004.01 CMP-005.03 CMP-005.01">
<NAME>Mortality, morbidity</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.07" NO="7">
<NAME>Insulin dose</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.04" NO="4">
<NAME>Adverse events</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.06" NO="6">
<NAME>HbA1c, FPG, lipids</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:19:28 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:29:25 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: it is unclear if the outcome assessor were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:19:28 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:29:28 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: it is unclear if the outcome assessor were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:29:29 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: it is unclear if the outcome assessor were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:19:32 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:30:02 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:19:33 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2015-12-04 11:45:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2015-12-04 11:45:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:19:37 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Casner-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:30:11 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Casner-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: it is unclear if the outcome assessment was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:19:37 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Casner-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:30:11 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Casner-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: it is unclear if the outcome assessment was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:30:12 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Casner-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: it is unclear if the outcome assessment was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:19:46 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:30:19 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION>
<P>
<B>Comment</B>: it is not clear whether the physician or the outcome assessor is besides the participants blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:19:47 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:30:19 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION>
<P>
<B>Comment</B>: it is not clear whether the physician or the outcome assessor is besides the participants blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:30:20 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION>
<P>
<B>Comment</B>: it is not clear whether the physician or the outcome assessor is besides the participants blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:19:51 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:38:14 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: (abstract and main text): "This double-blind, randomised, multicenter, placebo-controlled study..." (main text) "The double-blind endpoint was defined as last visit observation for each patient"</P>
<P>
<B>Comment</B>: at all measurement occasions the efficacy and safety tests were assessed. However it is not clear whether the physician or the outcome assessor was blinded in addition to the participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:19:51 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:38:15 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: (abstract and main text): "This double-blind, randomised, multicenter, placebo-controlled study..." (main text) "The double-blind endpoint was defined as last visit observation for each patient"</P>
<P>
<B>Comment</B>: at all measurement occasions the efficacy and safety tests were assessed. However it is not clear whether the physician or the outcome assessor was blinded in addition to the participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:38:16 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: (abstract and main text): "This double-blind, randomised, multicenter, placebo-controlled study..." (main text)"The double-blind endpoint was defined as last visit observation for each patients"</P>
<P>
<B>Comment</B>: at all measurement occasions the efficacy and safety tests were assessed. However it is not clear whether the physician or the outcome assessor was blinded in addition to the participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:20:06 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2015-01-07 12:20:06 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:20:06 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:30:34 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: it is unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:30:35 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: it is unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:20:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:30:41 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:20:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:30:42 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:30:43 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:20:17 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2015-01-07 12:20:18 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:20:18 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:30:50 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:30:50 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:20:22 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2015-01-07 12:20:23 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:20:23 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:30:57 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:30:57 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:20:28 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Groop-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:31:03 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Groop-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:20:28 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Groop-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:31:03 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Groop-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:31:04 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Groop-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:20:33 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:31:10 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:20:37 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:31:13 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:31:18 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:20:38 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2015-12-04 11:46:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:20:38 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:31:43 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:31:46 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:20:43 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:31:59 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Hong-2012">
<DESCRIPTION>
<P>
<B>Comment</B>: the outcome assessor was not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:20:43 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:31:59 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Hong-2012">
<DESCRIPTION>
<P>
<B>Comment</B>: the outcome assessor was not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:32:01 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Hong-2012">
<DESCRIPTION>
<P>
<B>Comment</B>: the outcome assessor was not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:20:54 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:38:59 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a randomised cross-over trial, ..."</P>
<P>
<B>Comment</B>: unclear if it was a blinded trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:20:54 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:39:00 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a randomised cross-over trial, ..."</P>
<P>
<B>Comment</B>: unclear if it was a blinded trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:39:01 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a randomised cross-over trial, ..."</P>
<P>
<B>Comment</B>: unclear if it was a blinded trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:21:05 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:32:46 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: it is unclear if the study was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:21:05 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:32:47 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: it is unclear if the study was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:32:48 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: it is unclear if the study was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:32:54 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:32:54 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:33:06 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:33:07 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:33:08 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:33:16 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:33:17 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:33:17 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:33:27 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:33:28 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 12:04:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:33:45 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 12:05:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:33:46 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:33:47 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 12:05:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:33:53 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 12:05:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:33:54 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:33:54 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 12:06:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2014-12-12 12:06:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 12:06:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:34:00 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:34:01 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 12:14:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:34:07 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 12:15:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:34:07 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:34:09 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 12:27:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:34:29 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 12:28:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:34:30 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:34:30 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 12:33:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Osei-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:35:17 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Osei-1984">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 12:33:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Osei-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:35:17 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Osei-1984">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:35:18 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Osei-1984">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 12:38:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:35:24 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the study was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 12:38:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:35:25 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the study was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:35:25 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the study was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 12:38:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reich-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2014-12-12 12:38:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reich-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 12:38:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reich-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:35:34 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Reich-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:35:35 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Reich-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 12:39:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:40:15 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "open-label randomisation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 12:39:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:40:15 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "open-label randomisation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:40:17 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "open-label randomisation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 12:39:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:35:49 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 12:40:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:35:51 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:35:51 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 12:40:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:36:00 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 12:40:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:36:01 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:36:01 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 12:40:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schade-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:40:45 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Schade-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...neither the patient nor the investigators knew until the completion of the study which treatment regimen the patients were receiving during each 16-weeks period."</P>
<P>
<B>Comment</B>: unclear if "end of the study" meant the end of the treatment period or after outcome analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 12:41:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schade-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:40:46 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Schade-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...neither the patient nor the investigators knew until the completion of the study which treatment regimen the patients were receiving during each 16-weeks period."</P>
<P>
<B>Comment</B>: unclear if "end of the study" meant the end of the treatment period or after outcome analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:40:47 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Schade-1987">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...neither the patient nor the investigators knew until the completion of the study which treatment regimen the patients were receiving during each 16-weeks period."</P>
<P>
<B>Comment</B>: unclear if "end of the study" meant the end of the treatment period or after outcome analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 12:41:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:40:55 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a open, controlled, randomised, parallel-group, single-centre, 16-weeks pilot study..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2016-09-07 09:40:56 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a open, controlled, randomised, parallel-group, single-centre, 16-weeks pilot study..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:40:57 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a open, controlled, randomised, parallel-group, single-centre, 16-weeks pilot study..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:40:58 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "In a open, controlled, randomised, parallel-group, single-centre, 16-weeks pilot study..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 12:41:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:36:35 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 12:41:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:36:36 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:36:37 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 12:42:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:36:43 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 12:42:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:36:43 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:36:44 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 12:42:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:41:27 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...were randomly assigned in an unmasked fashion..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 12:42:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:41:27 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...were randomly assigned in an unmasked fashion..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:41:28 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "...were randomly assigned in an unmasked fashion..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 13:36:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:37:05 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 13:36:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:37:07 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:37:08 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear if the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-12-12 13:37:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.04" MODIFIED="2016-09-07 09:37:14 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear, not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.05" MODIFIED="2014-12-12 13:37:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.06" MODIFIED="2016-09-07 09:37:15 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear, not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.07" MODIFIED="2016-09-07 09:37:16 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear, not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-09-07 09:40:05 +0200" MODIFIED_BY="Gudrun Paletta" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.05" NO="5">
<NAME>Health-related quality of life, patient satisfaction</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.04" NO="4">
<NAME>Adverse events</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Mortality, morbidity</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.07" NO="7" REF_IDS="CMP-001.03 CMP-001.05 CMP-001.01 CMP-001.07 CMP-001.09 CMP-001.12 CMP-002.03 CMP-002.01 CMP-002.05 CMP-002.07 CMP-002.09 CMP-003.02 CMP-003.03 CMP-004.02 CMP-004.03 CMP-004.01 CMP-005.03 CMP-005.01">
<NAME>Insulin dose</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.06" NO="6">
<NAME>HbA1c, FPG, lipids</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:19:28 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:29:30 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: in table 3 of the article the incidence of adverse events is listed for both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:19:29 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:29:31 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: data were collected, analysed and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:29:32 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: was reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:19:33 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:30:03 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION>
<P>
<B>Comment</B>: no exact SDs are reported as text only in the figures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:19:33 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:30:05 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION>
<P>
<B>Comment</B>: no exact SDs are reported as text only in the figures</P>
<P>
<B>Comment</B>: incomplete for FPG and lipids</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:30:06 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION>
<P>
<B>Comment</B>: available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:19:37 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Casner-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:30:13 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Casner-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: data on weight gain was reported for both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:19:37 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Casner-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:30:13 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Casner-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: data were reported for both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:30:14 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Casner-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: data were reported for both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:19:47 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:30:21 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION>
<P>
<B>Comment</B>: none</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:19:47 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:30:21 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION>
<P>
<B>Comment</B>: data on lipids is only mentioned, no analyses is performed or shown</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:30:22 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION>
<P>
<B>Comment</B>: data were presented for both groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:19:51 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:38:17 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "Most adverse events involved.....There were no significant differences between treatment groups in the incidence of adverse events related to other body systems "</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:19:52 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:30:29 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION>
<P>
<B>Comment</B>: data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:30:30 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION>
<P>
<B>Comment</B>: data were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:20:06 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2015-01-07 12:20:06 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:20:06 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:30:36 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:30:36 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:20:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:30:43 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: data on weight gain and hypoglycaemia were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:20:12 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:30:44 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: data on all outcome measures were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:30:45 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose was collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:20:18 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2014-12-12 11:53:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:20:22 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:30:52 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:30:52 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:20:23 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2015-01-07 12:20:27 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:20:27 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:30:58 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:30:58 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:20:32 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Groop-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:31:05 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Groop-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: data of adverse events (myocardial infarct, weight gain) were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:20:32 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Groop-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:31:05 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Groop-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:31:06 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Groop-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: all data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:20:38 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:31:19 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION>
<P>
<B>Comment</B>: data on adverse events were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:20:38 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:31:24 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:31:25 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:20:43 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:31:48 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: data on adverse events were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:20:43 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:31:50 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: the outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:31:52 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:20:43 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:32:03 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hong-2012">
<DESCRIPTION>
<P>
<B>Comment</B>: all end points shown</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:20:48 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:32:08 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hong-2012">
<DESCRIPTION>
<P>
<B>Comment</B>: all end points shown</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:32:10 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hong-2012">
<DESCRIPTION>
<P>
<B>Comment</B>: all end points shown</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:20:59 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:32:39 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: data on weight gain were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:20:59 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:32:40 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:32:40 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:32:48 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: weight gain was reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:32:48 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:32:49 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:33:00 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: data on weight gain were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:32:55 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2014-12-12 12:02:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:41:26 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:33:08 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION>
<P>
<B>Comment</B>: data on weight gain were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:33:09 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:33:10 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:33:18 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: data on weight gain were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:33:19 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:33:19 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:33:28 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: the effects on weight and side effects were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:33:29 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome date were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2015-01-07 12:21:11 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-12 12:05:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:33:47 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: data on adverse events and weight gain were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 12:05:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:33:48 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:33:48 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:42:42 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:33:55 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: data on number of hypoglycaemia were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 12:05:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:33:55 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: HbA1c analyses not performed for technical reasons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:33:56 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-12 12:06:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2014-12-12 12:06:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 12:06:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:34:01 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION>
<P>
<B>Comment</B>: outcomes of C-peptide, lipids and HbA1c assays were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:34:02 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION>
<P>
<B>Comment</B>: missing data on dose of glibenclamide</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-12 12:15:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:34:09 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION>
<P>
<B>Comment</B>: data on weight gain were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 12:16:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:34:10 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:34:10 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-07 12:43:19 +0100" MODIFIED_BY="Bernd Richter" RESULT="UNKNOWN" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:34:31 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION>
<P>
<B>Comment</B>: adverse events were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 12:30:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:35:12 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION>
<P>
<B>Comment</B>: data on HbA1c were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:35:13 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION>
<P>
<B>Comment</B>: part of the results only described in figures, not in numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-12 12:33:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Osei-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:35:18 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Osei-1984">
<DESCRIPTION>
<P>
<B>Comment</B>: data on weight gain were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 12:33:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Osei-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:35:19 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Osei-1984">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:35:20 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Osei-1984">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-12 12:38:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:40:05 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION>
<P>
<B>Quote from publication</B>: "weight remained stable throughout the study period."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 12:38:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:35:26 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:35:27 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-12 12:39:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reich-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2014-12-12 12:39:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reich-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 12:39:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reich-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:35:36 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Reich-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: not all outcome values were reported, only graphical</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:35:36 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Reich-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: insulin dose was collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-12 12:39:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:35:39 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: data on weight gain were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 12:39:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:35:39 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:35:40 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-23 16:58:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:35:52 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: data on weight gain were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 12:40:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:35:52 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:35:54 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-12 12:40:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:36:02 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: data on weight gain and drug-related adverse events were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 12:40:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:36:02 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:36:04 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-12 12:41:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schade-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:36:27 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Schade-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: data on weight gain were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 12:41:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schade-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:36:27 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Schade-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:36:28 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Schade-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-12 12:41:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:36:30 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: data on weight gain and hypoglycaemia were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2016-09-07 09:36:31 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: data on patient satisfaction were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:36:31 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:36:32 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-12 12:41:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:36:37 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION>
<P>
<B>Comment</B>: data on weight gain were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 12:42:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:36:38 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:36:38 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-12 12:42:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:36:45 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: data on weight gain and hypoglycaemia were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 12:42:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:36:45 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:36:46 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-12 12:42:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:36:47 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: data on adverse events were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 12:43:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:36:48 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:36:49 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-12 13:36:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:37:09 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: data on adverse events were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 13:36:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:37:10 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:37:10 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-12 13:37:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2016-09-07 09:37:16 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: data on weight gain were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.05" MODIFIED="2014-12-12 13:37:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.06" MODIFIED="2016-09-07 09:37:17 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: outcome data were collected and reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.07" MODIFIED="2016-09-07 09:37:18 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: data on insulin dose were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-09-07 09:43:37 +0200" MODIFIED_BY="Gudrun Paletta" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:29:33 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: data on blood pressure, medical history and the physical examination is not reported. However this is not likely to bias the results of the other outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:07 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION>
<P>
<B>Comment</B>: no exact SDs are reported as text only in the figures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:14 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Casner-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: data which was collected was also reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:23 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION>
<P>
<B>Comment</B>: more figures than tables, that causes unclear reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:30 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION>
<P>
<B>Comment</B>: serum lipids and SGOT and SGPT values were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:37 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:45 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: post-treatment BMI not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:53 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:59 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION>
<P>
<B>Comment</B>: no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:31:06 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Groop-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: unclear graphical reporting of data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:31:26 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION>
<P>
<B>Comment</B>: data were reported graphically, unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:31:54 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: short report of the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:43:37 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hong-2012">
<DESCRIPTION>
<P>
<B>Comment</B>: none</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:32:41 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:32:50 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:02 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:11 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:20 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:30 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: the effects on weight and side effects were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:49 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:57 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: HbA1c analyses not performed for technical reasons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:34:02 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION>
<P>
<B>Comment</B>: outcomes of C-peptide, lipids and HbA1c assays were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:34:11 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:14 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION>
<P>
<B>Comment</B>: part of the results only described in figures, not in numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:21 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Osei-1984">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:27 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:38 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Reich-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: not all outcome values were reported, only graphical</P>
<P>
<B>Comment</B>: dropouts were described; intention-to-treat</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:44 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:54 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:36:05 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:36:29 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Schade-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:36:32 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:36:39 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:36:46 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: some data were only reported graphically</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:36:49 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: medical history and physical exam were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:37:11 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:37:19 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: all outcomes of interest were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-09-07 09:43:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:29:33 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Avil_x00e9_s-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: no incomplete outcome data (attrition bias) Diabetes-related mortality</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:07 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Barnett-2013">
<DESCRIPTION>
<P>
<B>Comment</B>: sponsoring by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:15 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Casner-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: no other concerns</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:23 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Chiasson-1994">
<DESCRIPTION>
<P>
<B>Comment</B>: funded in part by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:31 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Coniff-1995">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:38 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Feinglos-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:46 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Fonseca-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:30:54 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Fritsche-2000">
<DESCRIPTION>
<P>
<B>Comment</B>: funding by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:31:00 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Giugliano-1993">
<DESCRIPTION>
<P>
<B>Comment</B>: no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:42:55 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Groop-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: none</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:31:26 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Hermann-2001">
<DESCRIPTION>
<P>
<B>Comment</B>: medication was funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:31:55 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Hirsch-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:43:41 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Hong-2012">
<DESCRIPTION>
<P>
<B>Comment</B>: none</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:32:42 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Kitabchi-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:32:50 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Krawczyk-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: statistical methods were not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:03 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Kyllastinen-1985">
<DESCRIPTION>
<P>
<B>Comment</B>: only 9 participants included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:11 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Lewitt-1989">
<DESCRIPTION>
<P>
<B>Comment</B>: none</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:22 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Lindstrom-1999">
<DESCRIPTION>
<P>
<B>Comment</B>: also funded by pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:30 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Longnecker-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: only 12 participants were included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:50 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mattoo-2005">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by pharmaceutical companies</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:33:57 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mauerhoff-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:34:03 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Mezitis-1992">
<DESCRIPTION>
<P>
<B>Comment</B>: no data on adverse events and population size; funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:34:12 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Mudaliar-2010">
<DESCRIPTION>
<P>
<B>Comment</B>: funding by pharmaceutical company; performed in clinical research centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:14 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Nemoto-2011">
<DESCRIPTION>
<P>
<B>Comment</B>: funding unclear, possibly commercial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:21 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Osei-1984">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:28 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="NO" STUDY_ID="STD-Quatraro-1986">
<DESCRIPTION>
<P>
<B>Comment</B>: different participant groups reported in figure and table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:38 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Reich-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:41 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Relimpio-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:35:55 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1998">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:36:06 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Rosenstock-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:36:30 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Schade-1987">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:36:34 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Schiel-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:36:40 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Simpson-1990">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:36:47 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="YES" STUDY_ID="STD-Stenman-1988">
<DESCRIPTION>
<P>
<B>Comment</B>: none</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:36:51 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Strowig-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:37:11 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Wulffel_x00e9_-2002">
<DESCRIPTION>
<P>
<B>Comment</B>: funded by a pharmaceutical company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-07 09:37:19 +0200" MODIFIED_BY="Gudrun Paletta" RESULT="UNKNOWN" STUDY_ID="STD-Yilmaz-2007">
<DESCRIPTION>
<P>
<B>Comment</B>: funding not disclosed; differences in baseline data between groups; people with heart failure excluded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-01-06 13:57:29 +0100" MODIFIED_BY="Gudrun Paletta" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-09-07 09:37:19 +0200" MODIFIED_BY="Gudrun Paletta">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-09-07 09:37:19 +0200" MODIFIED_BY="Gudrun Paletta" NO="1">
<TITLE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">Summary of findings: sulphonylureas</TITLE>
<TABLE COLS="6" ROWS="12">
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>Combinations of insulin and sulphonylureas compared with insulin monotherapy for diabetes mellitus</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>Patient: </B>participants with type 2 diabetes mellitus</P>
<P>
<B>Settings: </B>mostly secondary care outpatients and secondary care inpatients</P>
<P>
<B>Intervention: </B>sulphonylureas plus insulin</P>
<P>
<B>Comparison: </B>insulin monotherapy</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH VALIGN="TOP">
<P>Insulin monotherapy</P>
</TH>
<TH VALIGN="TOP">
<P>Insulin plus sulphonylureas</P>
</TH>
<TH VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Comment</B>s</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>All-cause mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Diabetes-related mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Diabetes-related morbidity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Health-related quality of life</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Patient satisfaction</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events: </B>
</P>
<P>
<B>a. mild hypoglycaemia </B>(<B>episodes per participant</B>)<BR/>Follow-up: 12 weeks to 12 months</P>
<P>
<B>b.</B> <B>weight gain </B>(<B>kg</B>)<BR/>Follow-up: 8 weeks to 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>a. range 2.0-2.6</P>
<P/>
<P>b. the mean weight gain across control groups ranged from -0.8 kg to 2.1 kg</P>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>a. range 2.2-6.1</P>
<P/>
<P>b. the mean weight gain across intervention groups ranged from 0.4 kg to 1.9 kg</P>
</TD>
<TD VALIGN="TOP">
<P>a. 239 (8)</P>
<P/>
<P>b. 220 (7)</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>a. &#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>a</SUP>
</B>
</P>
<P>b. &#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>a</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>a. Serious hypoglycaemic episodes were rare</P>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>HbA1c, change from baseline </B>(<B>%</B>)</P>
<P>Follow-up: 2 to 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>The mean change in HbA1c ranged across control groups from -1.5% to 3%</P>
</TD>
<TD VALIGN="TOP">
<P>The mean change in HbA1c in the intervention groups was <B>1% lower </B>(1.6% lower to 0.5% lower)</P>
</TD>
<TD VALIGN="TOP">
<P>316 (9)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>b</SUP>
</B>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>CI:</B> confidence interval; <B>HbA1c:</B> glycosylated haemoglobin A1c</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded by two levels because of risk of performance and detection bias and indirectness<BR/>
<SUP>b</SUP>Downgraded by two levels because of risk of performance bias and indirectness<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NO="2">
<TITLE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">Summary of findings: metformin</TITLE>
<TABLE COLS="6" ROWS="12">
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>Combinations of insulin and metformin compared with insulin monotherapy for diabetes mellitus</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>Patient: </B>participants with type 2 diabetes mellitus</P>
<P>
<B>Settings: </B>mostly secondary care outpatients and secondary care inpatients</P>
<P>
<B>Intervention: </B>metformin plus insulin</P>
<P>
<B>Comparison: </B>insulin monotherapy</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH VALIGN="TOP">
<P>Insulin monotherapy</P>
</TH>
<TH VALIGN="TOP">
<P>Insulin plus metformin</P>
</TH>
<TH VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>All-cause mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Diabetes-related mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Diabetes-related morbidity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Health-related quality of life</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Patient satisfaction</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events: </B>
</P>
<P>
<B>a. mild hypoglycaemia </B>(<B>episodes per participant</B>)</P>
<P>Follow-up: 12 weeks to 12 months</P>
<P>
<B>b.</B> <B>weight gain </B>(<B>kg</B>)</P>
<P>Follow-up: 12 weeks to 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>a. see comment</P>
<P/>
<P>b. the mean weight gain across control groups ranged from 0 kg to 4.4 kg</P>
</TD>
<TD VALIGN="TOP">
<P>a. see comment</P>
<P/>
<P>b. the mean weight gain across intervention groups was <B>2.1 kg lower</B> (3.2 kg lower to 1.1 kg lower)</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>a. 590 (8)</P>
<P/>
<P>b. 615 (7)</P>
</TD>
<TD VALIGN="TOP">
<P>a. &#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>a</SUP>
</B>
</P>
<P>
<B>
<SUP>b.</SUP>
</B>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>a</SUP>
</B>
</P>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>a. comparable occurrences of hypoglycaemic events, severe hypoglycaemic episodes were rare</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>HbA1c, change from baseline </B>(<B>%</B>)</P>
<P>Follow-up: 3.5 to 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>The mean change in HbA1c across control groups ranged from -1.6% to 0.5%</P>
</TD>
<TD VALIGN="TOP">
<P>The mean change in HbA1c in the intervention groups was <B>0.9% lower </B>(1.2% lower to 0.5% lower)</P>
</TD>
<TD VALIGN="TOP">
<P>698 (9)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>b</SUP>
</B>
<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>CI:</B> confidence interval; <B>HbA1c:</B> glycosylated haemoglobin A1c</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded by two levels because of risk of performance and detection bias and indirectness<BR/>
<SUP>b</SUP>Downgraded by two levels because of risk of performance bias and indirectness<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NO="3">
<TITLE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">Summary of findings: pioglitazone</TITLE>
<TABLE COLS="6" ROWS="12">
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>Combinations of insulin and pioglitazone compared with insulin monotherapy for diabetes mellitus</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>Patient: </B>participants with type 2 diabetes mellitus</P>
<P>
<B>Settings: </B>mostly secondary care outpatients and clinical research centre</P>
<P>
<B>Intervention: </B>pioglitazone plus insulin</P>
<P>
<B>Comparison: </B>insulin monotherapy</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH VALIGN="TOP">
<P>Insulin monotherapy</P>
</TH>
<TH VALIGN="TOP">
<P>Insulin plus pioglitazone</P>
</TH>
<TH VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>All-cause mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Diabetes-related mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Diabetes-related morbidity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Health-related quality of life</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Patient satisfaction</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events: </B>
</P>
<P>
<B>a. mild to moderate hypoglycaemia </B>(<B>episodes per participant</B>)<BR/>Follow-up: 16 weeks to 6 months</P>
<P>
<B>b.</B> <B>weight gain </B>(<B>kg</B>)</P>
<P>Follow-up: 16 weeks to 6 months</P>
<P>
<B>c. oedema </B>(<B>%</B>)<BR/>Follow-up: 16 weeks to 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>a. range 9-75</P>
<P/>
<P>b. the mean weight gain across control groups ranged from 0.2 kg to 1.7 kg</P>
<P/>
<P>c. range 4%-7%</P>
</TD>
<TD VALIGN="TOP">
<P>a. range 15-90</P>
<P/>
<P>b. the mean weight gain in the intervention groups was<B> 3.8 kg higher </B>(3.0 kg higher to 4.6 kg higher)</P>
<P/>
<P>c. range 16%-18%</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>a. 760 (2)</P>
<P/>
<P>b. 288 (2)</P>
<P/>
<P>c. 760 (2)</P>
</TD>
<TD VALIGN="TOP">
<P>a. &#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>a</SUP>
</B>
</P>
<P>b.
 
&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>b</SUP>
</B>
</P>
<P>c.
 
&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>b</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>a. the proportion of all hypoglycaemic episodes was higher in the pioglitazone-insulin combination group compared to insulin monotherapy; serious hypoglycaemic episodes were rare</P>
<P/>
<P>b. the minimum of 1.9 kg weight gain is clinically relevant, because it may have been partially caused by oedema</P>
<P/>
<P>c. pioglitazone was associated with a higher frequency of oedema which increased with dose. In addition, <LINK REF="STD-Rosenstock-2002" TYPE="STUDY">Rosenstock 2002</LINK> reported congestive heart failure for two participants receiving 15 mg pioglitazone and two participants receiving 30 mg pioglitazone.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>HbA1c, change from baseline </B>(<B>%</B>)<BR/>Follow-up: 12 weeks to 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>785 (3)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>c</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The mean difference in HbA1c for insulin-pioglitazone combination therapy ranged from -0.5% to -1.0% and for insulin monotherapy from -0.6% to 0%</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>CI:</B> confidence interval; <B>HbA1c:</B> glycosylated haemoglobin A1c</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded by two levels because of risk of performance bias, indirectness and imprecision<BR/>
<SUP>b</SUP>Downgraded by two levels because of unclear risk of bias in several risk of bias domains, indirectness and imprecision<BR/>
<SUP>c</SUP>Downgraded by two levels because of unclear risk of bias in several risk of bias domains, indirectness and imprecision<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NO="4">
<TITLE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">Summary of findings: alpha-glucosidase inhibitors</TITLE>
<TABLE COLS="6" ROWS="12">
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>Combinations of insulin and alpha-glucosidase inhibitors compared with insulin monotherapy for diabetes mellitus</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>Patient: </B>participants with type 2 diabetes mellitus</P>
<P>
<B>Settings: </B>mostly secondary care outpatients</P>
<P>
<B>Intervention: </B>alpha-glucosidase inhibitors plus insulin</P>
<P>
<B>Comparison: </B>insulin monotherapy</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH VALIGN="TOP">
<P>Insulin monotherapy</P>
</TH>
<TH VALIGN="TOP">
<P>Insulin plus alpha-glucosidase inhibitors</P>
</TH>
<TH VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>All-cause mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Diabetes-related mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Diabetes-related morbidity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Health-related quality of life</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Patient satisfaction</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events: </B>
</P>
<P>
<B>a. mild hypoglycaemia </B>(<B>% of participants</B>)</P>
<P>Follow-up: 24 weeks to 12 months<BR/>
</P>
<P>
<B>b. weight gain </B>(<B>kg</B>)</P>
<P>Follow-up: 24 weeks to 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>a. range 0%-35%</P>
<P/>
<P>b. The mean weight gain across control groups ranged from +0.7 kg to +3.6 kg</P>
</TD>
<TD VALIGN="TOP">
<P>a. range 0%-39%</P>
<P/>
<P>b. the mean weight gain in the intervention groups was<B> 0.5 kg lower </B>(1.2 kg lower to 0.3 kg higher)</P>
</TD>
<TD VALIGN="TOP">
<P>a. 583 (4)</P>
<P/>
<P>b. 241 (2)</P>
</TD>
<TD VALIGN="TOP">
<P>a) &#8853;&#8861;&#8861;&#8861;<B> low<SUP>a</SUP>
</B>
</P>
<P>b) &#8853;&#8861;&#8861;&#8861;<B> low<SUP>a</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>a. serious hypoglycaemic episodes were rare</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>HbA1c, change from baseline </B>(<B>%</B>)</P>
<P>Follow-up: 3 to 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>The mean change in HbA1c across control groups ranged from -1.1% to 0.04%</P>
</TD>
<TD VALIGN="TOP">
<P>The mean change in HbA1c in the intervention groups was <B>0.4% lower </B>(0.5% lower to 0.2% lower)</P>
</TD>
<TD VALIGN="TOP">
<P>448 (3)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<B> low<SUP>a</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>
<B>CI:</B> confidence interval; <B>HbA1c:</B> glycosylated haemoglobin A1c</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6" VALIGN="TOP">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded by two levels because of unclear or high risk of bias in several risk of bias domains, indirectness and imprecision<BR/>
<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NO="5">
<TITLE MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">Summary of findings: DPP-4 inhibitors</TITLE>
<TABLE COLS="6" ROWS="12">
<TR>
<TD COLSPAN="6">
<P>
<B>Combinations of insulin and dipeptidyl peptidase 4 inhibitors compared with insulin monotherapy for diabetes mellitus</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient: </B>participants with type 2 diabetes mellitus</P>
<P>
<B>Settings: </B>mostly secondary care outpatients</P>
<P>
<B>Intervention: </B>dipeptidyl peptidase 4 (DPP-4) inhibitors plus insulin</P>
<P>
<B>Comparison: </B>insulin monotherapy</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH VALIGN="TOP">
<P>Insulin monotherapy</P>
</TH>
<TH VALIGN="TOP">
<P>Insulin + DPP4-inhibitor</P>
</TH>
<TH VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>All-cause mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Diabetes-related mortality</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Diabetes-related morbidity</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Health-related quality of life</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>See comment</P>
</TD>
<TD VALIGN="TOP">
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Patient satisfaction</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not investigated</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events:</B>
</P>
<P>
<B>a. hypoglycaemia </B>(% of participants)</P>
<P>Follow-up: 24 weeks to 52 weeks</P>
<P>
<B>b. weight gain </B>(kg)</P>
<P>Follow-up: 24 weeks to 52 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>a. range 5%-30% (0%-5% severe)<BR/>
</P>
<P>b. the mean weight gain across control groups ranged from 0.6 kg to 1.1 kg</P>
<P/>
<P/>
</TD>
<TD VALIGN="TOP">
<P>a. range 8%-23% (0%-2% severe)</P>
<P/>
<P>b. the mean weight gain in the intervention groups ranged from -0.7 kg to 1.3 kg compared to 0.6 kg to 1.1 kg in the insulin (+ placebo) monotherapy group</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>a. 503 (3)</P>
<P/>
<P>b. 362 (2)</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>a) &#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>a</SUP>
</B>
</P>
<P>b) &#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>a</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>HbA1c, change from baseline </B>(<B>%</B>)</P>
<P>Follow-up: 24 weeks to 52 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>The mean change in HbA1c across control groups ranged from -0.2% to -0.3%</P>
</TD>
<TD VALIGN="TOP">
<P>The mean change in HbA1c in the intervention groups was<BR/>
<B>0.4% lower </B>(0.5% lower to 0.4% lower)</P>
</TD>
<TD VALIGN="TOP">
<P>265 (2)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low<SUP>a</SUP>
</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>CI:</B> confidence interval; <B>DPP-4: </B>dipeptidyl peptidase 4; <B>HbA1c:</B> glycosylated haemoglobin A1c</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Downgraded by two levels because of unclear or high risk of bias in several risk of bias domains, indirectness and imprecision<BR/>
<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-09-07 10:12:48 +0200" MODIFIED_BY="Gudrun Paletta">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-09-07 10:12:48 +0200" MODIFIED_BY="Gudrun Paletta" NO="1">
<TITLE MODIFIED="2014-10-14 14:32:17 +0200" MODIFIED_BY="Gudrun Paletta">Overview of study populations</TITLE>
<TABLE COLS="10" ROWS="120">
<TR>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>Intervention(s) and comparator(s)</P>
</TH>
<TH VALIGN="TOP">
<P>Sample size<SUP>a</SUP>
</P>
</TH>
<TH VALIGN="TOP">
<P>Screened/eligible<BR/>(N)</P>
</TH>
<TH VALIGN="TOP">
<P>Randomised<BR/>(N)</P>
</TH>
<TH VALIGN="TOP">
<P>Safety<BR/>(N)</P>
</TH>
<TH VALIGN="TOP">
<P>ITT<BR/>(N)</P>
</TH>
<TH VALIGN="TOP">
<P>Finishing study<BR/>(N)</P>
</TH>
<TH VALIGN="TOP">
<P>Randomised finishing study<BR/>(%)</P>
</TH>
<TH VALIGN="TOP">
<P>Follow-up time<SUP>b</SUP>
</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(1) Avilés 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>54</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>95</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>24 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>96</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>45</P>
</TH>
<TH VALIGN="TOP">
<P>45</P>
</TH>
<TH VALIGN="TOP">
<P>-</P>
</TH>
<TH VALIGN="TOP">
<P>43</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(2) Barnett 2013</P>
</TH>
<TD VALIGN="TOP">
<P>I:saxagliptin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>141</P>
</TD>
<TD VALIGN="TOP">
<P>95</P>
</TD>
<TD VALIGN="TOP">
<P>95</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>89</P>
</TD>
<TD VALIGN="TOP">
<P>94</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>52 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C:placebo</P>
</TD>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>98</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>141</P>
</TH>
<TH VALIGN="TOP">
<P>141</P>
</TH>
<TH VALIGN="TOP">
<P>-</P>
</TH>
<TH VALIGN="TOP">
<P>134</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(3) Casner 1988</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>42 needed, 50 recruitment goal</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>83</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>1 year</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>64</P>
</TH>
<TH VALIGN="TOP">
<P>64</P>
</TH>
<TH VALIGN="TOP">
<P>64</P>
</TH>
<TH VALIGN="TOP">
<P>64</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(4) Chiasson 1994<SUP>c</SUP>
</P>
</TH>
<TD VALIGN="TOP">
<P>I: acarbose</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>76 total, 38 per group</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>91</P>
</TD>
<TD VALIGN="TOP">
<P>41</P>
</TD>
<TD VALIGN="TOP">
<P>41</P>
</TD>
<TD VALIGN="TOP">
<P>40</P>
</TD>
<TD VALIGN="TOP">
<P>35</P>
</TD>
<TD VALIGN="TOP">
<P>85</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>1 year</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>42</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>88</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>91</P>
</TH>
<TH VALIGN="TOP">
<P>91</P>
</TH>
<TH VALIGN="TOP">
<P>82</P>
</TH>
<TH VALIGN="TOP">
<P>79</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(5) Coniff 1995</P>
</TH>
<TD VALIGN="TOP">
<P>I: acarbose</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>103</P>
</TD>
<TD VALIGN="TOP">
<P>103</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>103</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>24 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>104</P>
</TD>
<TD VALIGN="TOP">
<P>104</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>104</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>207</P>
</TH>
<TH VALIGN="TOP">
<P>207</P>
</TH>
<TH VALIGN="TOP">
<P>-</P>
</TH>
<TH VALIGN="TOP">
<P>207</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(6) Feinglos 1998<SUP>d</SUP>
</P>
</TH>
<TD VALIGN="TOP">
<P>I: glipizide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>37</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>7 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>29</P>
</TH>
<TH VALIGN="TOP">
<P>29</P>
</TH>
<TH VALIGN="TOP">
<P>-</P>
</TH>
<TH VALIGN="TOP">
<P>29</P>
</TH>
<TH VALIGN="TOP">
<P>100</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(7) Fonseca 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I: vildagliptin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>461</P>
</TD>
<TD VALIGN="TOP">
<P>144</P>
</TD>
<TD VALIGN="TOP">
<P>144</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>114</P>
</TD>
<TD VALIGN="TOP">
<P>79</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>24 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>152</P>
</TD>
<TD VALIGN="TOP">
<P>152</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>124</P>
</TD>
<TD VALIGN="TOP">
<P>82</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>296</P>
</TH>
<TH VALIGN="TOP">
<P>296</P>
</TH>
<TH VALIGN="TOP">
<P>290</P>
</TH>
<TH VALIGN="TOP">
<P>238</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(8) Fritsche 2000<SUP>d</SUP>
</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>24 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>13</P>
</TH>
<TH VALIGN="TOP">
<P>13</P>
</TH>
<TH VALIGN="TOP">
<P>-</P>
</TH>
<TH VALIGN="TOP">
<P>13</P>
</TH>
<TH VALIGN="TOP">
<P>100</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(9) Giugliano 1993</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>7 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>50</P>
</TH>
<TH VALIGN="TOP">
<P>50</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>50</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(10) Groop 1985<SUP>d</SUP>
</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>16 weeks (after 8 weeks run-in)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>14</P>
</TH>
<TH VALIGN="TOP">
<P>14</P>
</TH>
<TH VALIGN="TOP">
<P>-</P>
</TH>
<TH VALIGN="TOP">
<P>13</P>
</TH>
<TH VALIGN="TOP">
<P>93</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(11) Hermann 2001</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>30, 15 in each group</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>37</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>75</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>12 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>95</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>35</P>
</TH>
<TH VALIGN="TOP">
<P>35</P>
</TH>
<TH VALIGN="TOP">
<P>35</P>
</TH>
<TH VALIGN="TOP">
<P>30</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(12) Hong 2012</P>
</TH>
<TD VALIGN="TOP">
<P>I: sitagliptin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>140</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>70</P>
</TD>
<TD VALIGN="TOP">
<P>61</P>
</TD>
<TD VALIGN="TOP">
<P>61</P>
</TD>
<TD VALIGN="TOP">
<P>61</P>
</TD>
<TD VALIGN="TOP">
<P>87</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>24 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin increase</P>
</TD>
<TD VALIGN="TOP">
<P>70</P>
</TD>
<TD VALIGN="TOP">
<P>63</P>
</TD>
<TD VALIGN="TOP">
<P>63</P>
</TD>
<TD VALIGN="TOP">
<P>63</P>
</TD>
<TD VALIGN="TOP">
<P>90</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>140</P>
</TH>
<TH VALIGN="TOP">
<P>124</P>
</TH>
<TH VALIGN="TOP">
<P>124</P>
</TH>
<TH VALIGN="TOP">
<P>124</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(13) Hirsch 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>88</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>5 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>50</P>
</TH>
<TH VALIGN="TOP">
<P>50</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>47</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(14) Kitabchi 1987<SUP>d</SUP>
</P>
</TH>
<TD VALIGN="TOP">
<P>I: tolazamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>6 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>12</P>
</TH>
<TH VALIGN="TOP">
<P>12</P>
</TH>
<TH VALIGN="TOP">
<P>-</P>
</TH>
<TH VALIGN="TOP">
<P>12</P>
</TH>
<TH VALIGN="TOP">
<P>100</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(15) Krawczyk 2005</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>6 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>40</P>
</TH>
<TH VALIGN="TOP">
<P>40</P>
</TH>
<TH VALIGN="TOP">
<P>40</P>
</TH>
<TH VALIGN="TOP">
<P>40</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(16) Kyllastinen 1985<SUP>d</SUP>
</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>4 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>9</P>
</TH>
<TH VALIGN="TOP">
<P>9</P>
</TH>
<TH VALIGN="TOP">
<P>-</P>
</TH>
<TH VALIGN="TOP">
<P>9</P>
</TH>
<TH VALIGN="TOP">
<P>100</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(17) Lewitt 1989<SUP>d</SUP>
</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>6 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>31</P>
</TH>
<TH VALIGN="TOP">
<P>31</P>
</TH>
<TH VALIGN="TOP">
<P>-</P>
</TH>
<TH VALIGN="TOP">
<P>31</P>
</TH>
<TH VALIGN="TOP">
<P>100</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(18) Lindstrom 1999<SUP>d</SUP>
</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>6 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>15</P>
</TH>
<TH VALIGN="TOP">
<P>15</P>
</TH>
<TH VALIGN="TOP">
<P>-</P>
</TH>
<TH VALIGN="TOP">
<P>15</P>
</TH>
<TH VALIGN="TOP">
<P>100</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(19) Longnecker 1986<SUP>d</SUP>
</P>
</TH>
<TD VALIGN="TOP">
<P>I: tolazamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>20 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>12</P>
</TH>
<TH VALIGN="TOP">
<P>12</P>
</TH>
<TH VALIGN="TOP">
<P>-</P>
</TH>
<TH VALIGN="TOP">
<P>11</P>
</TH>
<TH VALIGN="TOP">
<P>92</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(20) Mattoo 2005</P>
</TH>
<TD VALIGN="TOP">
<P>I: pioglitazone</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>250 (125 per treatment)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>385</P>
</TD>
<TD VALIGN="TOP">
<P>142</P>
</TD>
<TD VALIGN="TOP">
<P>142</P>
</TD>
<TD VALIGN="TOP">
<P>142</P>
</TD>
<TD VALIGN="TOP">
<P>128</P>
</TD>
<TD VALIGN="TOP">
<P>90</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>6 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>147</P>
</TD>
<TD VALIGN="TOP">
<P>147</P>
</TD>
<TD VALIGN="TOP">
<P>147</P>
</TD>
<TD VALIGN="TOP">
<P>135</P>
</TD>
<TD VALIGN="TOP">
<P>92</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>289</P>
</TH>
<TH VALIGN="TOP">
<P>289</P>
</TH>
<TH VALIGN="TOP">
<P>289</P>
</TH>
<TH VALIGN="TOP">
<P>263</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(21) Mauerhoff 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>19 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>22</P>
</TH>
<TH VALIGN="TOP">
<P>22</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>22</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(22) Mezitis 1992</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>20 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>20</P>
</TH>
<TH VALIGN="TOP">
<P>20</P>
</TH>
<TH VALIGN="TOP">
<P>-</P>
</TH>
<TH VALIGN="TOP">
<P>20</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(23) Mudaliar 2010</P>
</TH>
<TD VALIGN="TOP">
<P>I: pioglitazone</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>12-16 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>25</P>
</TH>
<TH VALIGN="TOP">
<P>25</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>25</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(24) Nemoto 2011</P>
</TH>
<TD VALIGN="TOP">
<P>I: miglitol</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>276</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>93</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>16-22 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>97</P>
</TD>
<TD VALIGN="TOP">
<P>97</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>207</P>
</TH>
<TH VALIGN="TOP">
<P>207</P>
</TH>
<TH VALIGN="TOP">
<P>207</P>
</TH>
<TH VALIGN="TOP">
<P>197</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(25) Osei 1984</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>60</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>16 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>92</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>22</P>
</TH>
<TH VALIGN="TOP">
<P>22</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>17</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(26) Quartraro 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: gliclazide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>40</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>12 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>30</P>
</TH>
<TH VALIGN="TOP">
<P>30</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>30</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(27) Reich 1987<SUP>e</SUP>
</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>90</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>4 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>20</P>
</TH>
<TH VALIGN="TOP">
<P>20</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>19</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(28) Relimpio 1998</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>60</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>77</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>4 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin dose increase</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>29</P>
</TD>
<TD VALIGN="TOP">
<P>29</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>79</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>60</P>
</TH>
<TH VALIGN="TOP">
<P>60</P>
</TH>
<TH VALIGN="TOP">
<P>60</P>
</TH>
<TH VALIGN="TOP">
<P>47</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(29) Robinson 1998<SUP>d</SUP>
</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>30 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>20</P>
</TH>
<TH VALIGN="TOP">
<P>20</P>
</TH>
<TH VALIGN="TOP">
<P>-</P>
</TH>
<TH VALIGN="TOP">
<P>19</P>
</TH>
<TH VALIGN="TOP">
<P>95</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="4" VALIGN="TOP">
<P>(30) Rosenstock 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I1: pioglitazone 15 mg</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>161</P>
</TD>
<TD VALIGN="TOP">
<P>89</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>16 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: pioglitazone 30 mg</P>
</TD>
<TD VALIGN="TOP">
<P>188</P>
</TD>
<TD VALIGN="TOP">
<P>188</P>
</TD>
<TD VALIGN="TOP">
<P>188</P>
</TD>
<TD VALIGN="TOP">
<P>172</P>
</TD>
<TD VALIGN="TOP">
<P>92</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>187</P>
</TD>
<TD VALIGN="TOP">
<P>187</P>
</TD>
<TD VALIGN="TOP">
<P>187</P>
</TD>
<TD VALIGN="TOP">
<P>164</P>
</TD>
<TD VALIGN="TOP">
<P>88</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>566</P>
</TH>
<TH VALIGN="TOP">
<P>566</P>
</TH>
<TH VALIGN="TOP">
<P>566</P>
</TH>
<TH VALIGN="TOP">
<P>497</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(31) Schade 1987<SUP>d</SUP>
</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>16</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>32 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>16</P>
</TH>
<TH VALIGN="TOP">
<P>16</P>
</TH>
<TH VALIGN="TOP">
<P>16</P>
</TH>
<TH VALIGN="TOP">
<P>15</P>
</TH>
<TH VALIGN="TOP">
<P>94</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="4" VALIGN="TOP">
<P>(32) Schiel 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I1: glimepiride</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>60 (20 participants in each group)</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>54</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>20 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: glimepiride + metformin</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>89</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>52</P>
</TH>
<TH VALIGN="TOP">
<P>52</P>
</TH>
<TH VALIGN="TOP">
<P>50</P>
</TH>
<TH VALIGN="TOP">
<P>50</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(33) Simpson 1990</P>
</TH>
<TD VALIGN="TOP">
<P>I: glipizide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>20</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>4 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>20</P>
</TH>
<TH VALIGN="TOP">
<P>20</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>19</P>
</TH>
<TH VALIGN="TOP">
<P>95</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(34) Stenman 1988<SUP>d</SUP>
</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>16</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>5 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>16</P>
</TH>
<TH VALIGN="TOP">
<P>16</P>
</TH>
<TH VALIGN="TOP">
<P>-</P>
</TH>
<TH VALIGN="TOP">
<P>15</P>
</TH>
<TH VALIGN="TOP">
<P>94</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="4" VALIGN="TOP">
<P>(35) Strowig 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I1: metformin</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>92</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>90</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>4 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: troglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>97</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>92</P>
</TH>
<TH VALIGN="TOP">
<P>92</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>88</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>(36) Wulffelé 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>390</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>745</P>
</TD>
<TD VALIGN="TOP">
<P>196</P>
</TD>
<TD VALIGN="TOP">
<P>195</P>
</TD>
<TD VALIGN="TOP">
<P>196</P>
</TD>
<TD VALIGN="TOP">
<P>171</P>
</TD>
<TD VALIGN="TOP">
<P>87</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>16 weeks</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>194</P>
</TD>
<TD VALIGN="TOP">
<P>193</P>
</TD>
<TD VALIGN="TOP">
<P>194</P>
</TD>
<TD VALIGN="TOP">
<P>182</P>
</TD>
<TD VALIGN="TOP">
<P>94</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>390</P>
</TH>
<TH VALIGN="TOP">
<P>388</P>
</TH>
<TH VALIGN="TOP">
<P>390</P>
</TH>
<TH VALIGN="TOP">
<P>353</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="5" VALIGN="TOP">
<P>(37) Yilmaz 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I1: acarbose</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD ROWSPAN="5" VALIGN="TOP">
<P>6 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: metformin</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I3: rosiglitazone</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
</TR>
<TR>
<TH ALIGN="RIGHT" COLSPAN="3" VALIGN="TOP">
<P>total:</P>
</TH>
<TH VALIGN="TOP">
<P>66</P>
</TH>
<TH VALIGN="TOP">
<P>66</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>66</P>
</TH>
<TH VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>
<I>Grand total</I>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<I>
<B>All interventions</B>
</I>
</P>
</TH>
<TD COLSPAN="2" ROWSPAN="3" VALIGN="TOP">
<P/>
</TD>
<TH VALIGN="TOP">
<P>
<I>1856<SUP>f</SUP>
</I>
</P>
</TH>
<TD COLSPAN="2" ROWSPAN="3" VALIGN="TOP">
<P/>
</TD>
<TH VALIGN="TOP">
<P>
<I>1677<SUP>f</SUP>
</I>
</P>
</TH>
<TD COLSPAN="2" ROWSPAN="3" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<I>
<B>All c</B>omparator<B>s</B>
</I>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<I>1558<SUP>f</SUP>
</I>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<I>1460<SUP>f</SUP>
</I>
</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>
<I>
<B>All interventions and c</B>omparator<B>s</B>
</I>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<I>3227</I>
</P>
</TH>
<TH VALIGN="TOP">
<P>
<I>2951</I>
</P>
</TH>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>According to power calculation in study publication or report<BR/>
<SUP>b</SUP>Duration of intervention and/or follow-up under randomised conditions until end of study<BR/>
<SUP>c</SUP>Subgroup of participants using insulin<BR/>
<SUP>d</SUP>Cross-over study<BR/>
<SUP>e</SUP>Three participants in the intervention group discontinued insulin<BR/>
<SUP>f</SUP>Participants in cross-over trials were counted both in the intervention and comparator groups<BR/>
</P>
<P>- denotes not reported</P>
<P>C: comparator; I: intervention; ITT: intention-to-treat; N/A: not applicable</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta">
<COMPARISON ID="CMP-001" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NO="1">
<NAME>Insulin monotherapy versus insulin plus sulphonylurea</NAME>
<CONT_OUTCOME CHI2="0.23025561970546704" CI_END="3.667090555388263" CI_START="-2.5207540887409343" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5731682333236642" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2016-07-14 11:34:06 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.9997666550099074" P_Q="0.7052416324516502" P_Z="0.7165335897770783" Q="0.1430765037137693" RANDOM="YES" SCALE="27.76" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="111" UNITS="kg" WEIGHT="100.0" Z="0.363095442437348">
<NAME>Weight (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin+sulphonylurea</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+sulphonylureas</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.06148029107738642" CI_END="5.316038340469161" CI_START="-3.075727674007661" DF="1" EFFECT_SIZE="1.12015533323075" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" MODIFIED="2016-03-29 11:52:04 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.8041713975799613" P_Z="0.6008055452938617" STUDIES="2" TAU2="0.0" TOTAL_1="42" TOTAL_2="44" WEIGHT="54.37159470510261" Z="0.5232424513351037">
<NAME>Parallel-group trials</NAME>
<CONT_DATA CI_END="13.352276377822557" CI_START="-8.552276377822556" EFFECT_SIZE="2.4000000000000004" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="-0.8" MODIFIED="2016-03-29 11:52:04 +0200" MODIFIED_BY="Bernd Richter" ORDER="77" SD_1="20.16" SD_2="24.45" SE="5.587998791923074" STUDY_ID="STD-Casner-1988" TOTAL_1="31" TOTAL_2="33" WEIGHT="7.9801310337260976"/>
<CONT_DATA CI_END="5.442452225402571" CI_START="-3.6424522254025704" EFFECT_SIZE="0.9" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="0.4" MODIFIED="2010-04-06 14:56:37 +0200" MODIFIED_BY="[Empty name]" ORDER="32" SD_1="5.67" SD_2="5.19" SE="2.3176202528377328" STUDY_ID="STD-Mauerhoff-1986" TOTAL_1="11" TOTAL_2="11" WEIGHT="46.39146367137651"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.025698824914311302" CI_END="4.501646151314792" CI_START="-4.658908209001313" DF="4" EFFECT_SIZE="-0.07863102884326117" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" MODIFIED="2013-02-06 17:54:38 +0100" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.9999181500844252" P_Z="0.9731583994354481" STUDIES="5" TAU2="0.0" TOTAL_1="67" TOTAL_2="67" WEIGHT="45.62840529489739" Z="0.03364730529142432">
<NAME>Cross-over trials</NAME>
<CONT_DATA CI_END="12.858631705745662" CI_START="-14.858631705745662" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="2.0" MODIFIED="2013-02-06 17:54:38 +0100" MODIFIED_BY="Bernd Richter" ORDER="78" SD_1="17.32" SD_2="17.32" SE="7.070860390834107" STUDY_ID="STD-Kitabchi-1987" TOTAL_1="12" TOTAL_2="12" WEIGHT="4.984000814756796"/>
<CONT_DATA CI_END="11.087230594797424" CI_START="-11.087230594797424" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.0" MODIFIED="2013-02-06 17:54:37 +0100" MODIFIED_BY="Bernd Richter" ORDER="79" SD_1="12.0" SD_2="12.0" SE="5.656854249492381" STUDY_ID="STD-Kyllastinen-1985" TOTAL_1="9" TOTAL_2="9" WEIGHT="7.78704440631614"/>
<CONT_DATA CI_END="8.552153134919852" CI_START="-8.352153134919853" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.6" MODIFIED="2012-06-04 12:11:00 +0200" MODIFIED_BY="Bernd Richter" ORDER="76" SD_1="11.81" SD_2="11.81" SE="4.312402269424008" STUDY_ID="STD-Lindstrom-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="13.399361306459483"/>
<CONT_DATA CI_END="12.46158495957456" CI_START="-11.66158495957456" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.0" MODIFIED="2012-06-04 12:11:00 +0200" MODIFIED_BY="Bernd Richter" ORDER="37" SD_1="17.6" SD_2="17.21" SE="6.153982958214948" STUDY_ID="STD-Schade-1987" TOTAL_1="16" TOTAL_2="16" WEIGHT="6.579759974614593"/>
<CONT_DATA CI_END="8.421466975962367" CI_START="-8.821466975962366" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="2.1" MODIFIED="2013-02-06 17:54:38 +0100" MODIFIED_BY="Bernd Richter" ORDER="39" SD_1="12.24" SD_2="11.85" SE="4.398788469567501" STUDY_ID="STD-Stenman-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="12.878238792750373"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="114.37550063769224" CI_END="0.3154719875821893" CI_START="-0.5748712319387221" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="-0.12969962217826642" ESTIMABLE="YES" I2="94.75412132270684" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.5010391980001623" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 13:43:52 +0200" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="1.1102230246251565E-15" P_Q="0.5572926279478294" P_Z="0.5679789384402016" Q="0.34441391594288895" RANDOM="YES" SCALE="16.11" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.240312244856847" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.00000000000001" Z="0.5710305480051653">
<NAME>Weight (change from baseline) [kg] GIV</NAME>
<GROUP_LABEL_1>Insulin+sulphonylureas</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+sulphonylureas</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.06148042610130165" CI_END="5.316003824574708" CI_START="-3.07569988650826" DF="1" EFFECT_SIZE="1.1201519690332242" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.7255852847219912" LOG_CI_START="NaN" LOG_EFFECT_SIZE="0.04927694663030846" MODIFIED="2016-07-26 13:43:31 +0200" MODIFIED_BY="Gudrun Paletta" NO="1" P_CHI2="0.8041711869101931" P_Z="0.6008039356973294" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="1.0832861043493636" Z="0.5232447646160798">
<NAME>Parallel-group</NAME>
<IV_DATA CI_END="13.352278745609825" CI_START="-8.552278745609824" EFFECT_SIZE="2.4" ESTIMABLE="YES" ESTIMATE="2.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-03-29 11:51:56 +0200" MODIFIED_BY="Bernd Richter" ORDER="124" SE="5.588" STUDY_ID="STD-Casner-1988" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.16395188842227043"/>
<IV_DATA CI_END="5.442412530570031" CI_START="-3.6424125305700303" EFFECT_SIZE="0.9" ESTIMABLE="YES" ESTIMATE="0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 16:49:28 +0100" MODIFIED_BY="[Empty name]" ORDER="125" SE="2.3176" STUDY_ID="STD-Mauerhoff-1986" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.9193342159270932"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="114.00283166494401" CI_END="0.3074160366994728" CI_START="-0.5942863240954839" DF="4" EFFECT_SIZE="-0.1434351436980055" ESTIMABLE="YES" I2="96.49131522297967" ID="CMP-001.02.02" LOG_CI_END="-0.5122734807906443" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 13:43:52 +0200" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="-2.220446049250313E-16" P_Z="0.5329239430274599" STUDIES="5" TAU2="0.24406962922828268" TOTAL_1="0" TOTAL_2="0" WEIGHT="98.91671389565064" Z="0.6235488072085582">
<NAME>Cross-over group</NAME>
<IV_DATA CI_END="-0.784403961700594" CI_START="-1.215596038299406" EFFECT_SIZE="-1.0" ESTIMABLE="YES" ESTIMATE="-1.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-12 16:34:44 +0100" MODIFIED_BY="[Empty name]" ORDER="126" SE="0.11" STUDY_ID="STD-Kitabchi-1987" TOTAL_1="0" TOTAL_2="0" WEIGHT="20.43846702235656"/>
<IV_DATA CI_END="0.5879891953620162" CI_START="-0.5879891953620162" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-04 12:59:47 +0100" MODIFIED_BY="[Empty name]" ORDER="127" SE="0.3" STUDY_ID="STD-Kyllastinen-1985" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.61831092511107"/>
<IV_DATA CI_END="0.2567971187632043" CI_START="-0.05679711876320434" EFFECT_SIZE="0.1" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 16:47:54 +0100" MODIFIED_BY="[Empty name]" ORDER="128" SE="0.08" STUDY_ID="STD-Lindstrom-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="20.91067407513187"/>
<IV_DATA CI_END="0.5567971187632044" CI_START="0.24320288123679568" EFFECT_SIZE="0.4" ESTIMABLE="YES" ESTIMATE="0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 16:48:00 +0100" MODIFIED_BY="[Empty name]" ORDER="129" SE="0.08" STUDY_ID="STD-Schade-1987" TOTAL_1="0" TOTAL_2="0" WEIGHT="20.91067407513187"/>
<IV_DATA CI_END="-0.0628025210821962" CI_START="-0.33719747891780383" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-12-04 12:59:48 +0100" MODIFIED_BY="[Empty name]" ORDER="130" SE="0.07" STUDY_ID="STD-Stenman-1988" TOTAL_1="0" TOTAL_2="0" WEIGHT="21.03858779791928"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="19.19544518830524" CI_END="-0.48842620582724083" CI_START="-1.5581639319303637" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0232950688788023" ESTIMABLE="YES" I2="58.32344641387128" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2016-03-29 12:22:02 +0200" MODIFIED_BY="Bernd Richter" NO="3" P_CHI2="0.013848668488417704" P_Q="0.6831072541126935" P_Z="1.7701496100676857E-4" Q="0.16664930767188588" RANDOM="YES" SCALE="9.46" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.33986794087664596" TOTALS="YES" TOTAL_1="156" TOTAL_2="160" UNITS="%" WEIGHT="100.0" Z="3.7497443188547397">
<NAME>HbA1c (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin+Sulphonylurea</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+sulpho</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="15.266662952304891" CI_END="0.06040753364935836" CI_START="-2.568104769286129" DF="3" EFFECT_SIZE="-1.2538486178183852" ESTIMABLE="YES" I2="80.34934019718386" ID="CMP-001.03.01" MODIFIED="2016-03-29 12:22:01 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0016023870474112245" P_Z="0.061500817641226696" STUDIES="4" TAU2="1.3938845338970869" TOTAL_1="73" TOTAL_2="77" WEIGHT="43.03168758025011" Z="1.8698775959654905">
<NAME>Parallel-group trials</NAME>
<CONT_DATA CI_END="0.5636990666888904" CI_START="-2.46369906668889" EFFECT_SIZE="-0.9499999999999997" ESTIMABLE="YES" MEAN_1="2.08" MEAN_2="3.03" MODIFIED="2016-03-29 12:22:00 +0200" MODIFIED_BY="Bernd Richter" ORDER="45" SD_1="2.63" SD_2="3.51" SE="0.7723096335589609" STUDY_ID="STD-Casner-1988" TOTAL_1="31" TOTAL_2="33" WEIGHT="7.953704671123501"/>
<CONT_DATA CI_END="0.08701045749905045" CI_START="-2.8470104574990507" EFFECT_SIZE="-1.3800000000000001" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="0.08" MODIFIED="2012-12-20 11:58:43 +0100" MODIFIED_BY="[Empty name]" ORDER="4" SD_1="1.56" SD_2="1.95" SE="0.7484884768652087" STUDY_ID="STD-Osei-1984" TOTAL_1="10" TOTAL_2="12" WEIGHT="8.273823847347602"/>
<CONT_DATA CI_END="-1.5241015602292678" CI_START="-4.275898439770733" EFFECT_SIZE="-2.9000000000000004" ESTIMABLE="YES" MEAN_1="-3.2" MEAN_2="-0.3" MODIFIED="2012-12-20 11:59:05 +0100" MODIFIED_BY="[Empty name]" ORDER="5" SD_1="2.36" SD_2="1.35" SE="0.7020018993326632" STUDY_ID="STD-Quatraro-1986" TOTAL_1="15" TOTAL_2="15" WEIGHT="8.943821643925322"/>
<CONT_DATA CI_END="0.44424174030674035" CI_START="-0.6442417403067403" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.35" MEAN_2="-0.25" MODIFIED="2016-03-29 12:22:01 +0200" MODIFIED_BY="Bernd Richter" ORDER="108" SD_1="0.52" SD_2="1.02" SE="0.27767945972459174" STUDY_ID="STD-Schiel-2007" TOTAL_1="17" TOTAL_2="17" WEIGHT="17.860337417853682"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.622275695103831" CI_END="-0.5555792125086996" CI_START="-1.3784438140239093" DF="4" EFFECT_SIZE="-0.9670115132663044" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" MODIFIED="2016-03-29 12:22:02 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.6228823450288775" P_Z="4.092885657229137E-6" STUDIES="5" TAU2="0.0" TOTAL_1="83" TOTAL_2="83" WEIGHT="56.968312419749886" Z="4.606608997756239">
<NAME>Cross-over trials</NAME>
<CONT_DATA CI_END="1.2531321233339578" CI_START="-2.053132123333958" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-1.5" MODIFIED="2013-02-06 17:59:16 +0100" MODIFIED_BY="Bernd Richter" ORDER="60" SD_1="2.0" SD_2="2.13" SE="0.8434502553994119" STUDY_ID="STD-Kitabchi-1987" TOTAL_1="12" TOTAL_2="12" WEIGHT="7.084049511998592"/>
<CONT_DATA CI_END="-0.2029031430016528" CI_START="-3.797096856998347" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="0.6" MODIFIED="2016-03-29 12:22:02 +0200" MODIFIED_BY="Bernd Richter" ORDER="61" SD_1="1.8" SD_2="2.08" SE="0.9169029998375571" STUDY_ID="STD-Kyllastinen-1985" TOTAL_1="9" TOTAL_2="9" WEIGHT="6.308169846613653"/>
<CONT_DATA CI_END="-0.509206305653604" CI_START="-1.8907936943463963" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="0.4" MODIFIED="2013-02-06 17:59:17 +0100" MODIFIED_BY="[Empty name]" ORDER="212" SD_1="1.3" SD_2="1.47" SE="0.35245223881422755" STUDY_ID="STD-Lewitt-1989" TOTAL_1="31" TOTAL_2="31" WEIGHT="16.047070198443947"/>
<CONT_DATA CI_END="0.4410058735391633" CI_START="-1.8410058735391632" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="0.3" MODIFIED="2013-02-06 17:59:17 +0100" MODIFIED_BY="Bernd Richter" ORDER="7" SD_1="1.83" SD_2="1.44" SE="0.582156551109751" STUDY_ID="STD-Schade-1987" TOTAL_1="16" TOTAL_2="16" WEIGHT="10.971679945100185"/>
<CONT_DATA CI_END="-0.15018990961150935" CI_START="-1.4498100903884907" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.1" MODIFIED="2013-02-06 17:59:18 +0100" MODIFIED_BY="Bernd Richter" ORDER="9" SD_1="0.78" SD_2="1.02" SE="0.33154185256163365" STUDY_ID="STD-Stenman-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="16.55734291759351"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="18.671443451141755" CI_END="-0.4745730643522267" CI_START="-1.5848823375400616" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_SIZE="-1.029727700946144" ESTIMABLE="YES" I2="57.15382144431472" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2015-12-04 14:51:22 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.016719057375522928" P_Q="0.6843753790053518" P_Z="2.7751077622505197E-4" Q="0.16524237965564753" RANDOM="YES" SCALE="9.63" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.35989554650075517" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="3.6354361014081946">
<NAME>HbA1c (change from baseline) GIV</NAME>
<GROUP_LABEL_1>Insulin+sulphonyreas</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+sulpho</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="15.266196162820425" CI_END="0.06040122495140077" CI_START="-2.568101780705944" DF="3" EFFECT_SIZE="-1.2538502778772715" ESTIMABLE="YES" I2="80.34873934538942" ID="CMP-001.04.01" LOG_CI_END="-1.2189542536927842" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2015-01-12 17:02:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0016027392821963415" P_Z="0.06149955511871087" STUDIES="4" TAU2="1.3938678190867035" TOTAL_1="0" TOTAL_2="0" WEIGHT="44.875652212369644" Z="1.8698866855816372">
<NAME>Parallel-group trials</NAME>
<IV_DATA CI_END="0.563680185260284" CI_START="-2.4636801852602837" EFFECT_SIZE="-0.95" ESTIMABLE="YES" ESTIMATE="-0.95" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-12 17:02:14 +0100" MODIFIED_BY="[Empty name]" ORDER="121" SE="0.7723" STUDY_ID="STD-Casner-1988" TOTAL_1="0" TOTAL_2="0" WEIGHT="8.389153704464183"/>
<IV_DATA CI_END="0.08703304242823084" CI_START="-2.8470330424282304" EFFECT_SIZE="-1.38" ESTIMABLE="YES" ESTIMATE="-1.38" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 14:28:17 +0100" MODIFIED_BY="[Empty name]" ORDER="123" SE="0.7485" STUDY_ID="STD-Osei-1984" TOTAL_1="0" TOTAL_2="0" WEIGHT="8.719150423528195"/>
<IV_DATA CI_END="-1.5241052828528818" CI_START="-4.275894717147118" EFFECT_SIZE="-2.9" ESTIMABLE="YES" ESTIMATE="-2.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-12 17:02:15 +0100" MODIFIED_BY="[Empty name]" ORDER="124" SE="0.702" STUDY_ID="STD-Quatraro-1986" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.408832316719181"/>
<IV_DATA CI_END="0.4442819985067731" CI_START="-0.644281998506773" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 14:29:12 +0100" MODIFIED_BY="[Empty name]" ORDER="125" SE="0.2777" STUDY_ID="STD-Schiel-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="18.35851576765808"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.2147226143388887" CI_END="-0.5152762738569986" CI_START="-1.4161388596507964" DF="4" EFFECT_SIZE="-0.9657075667538976" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2014-12-15 14:26:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.696334822554829" P_Z="2.6446397050870295E-5" STUDIES="5" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="55.124347787630356" Z="4.202088265809474">
<NAME>Cross-over trials</NAME>
<IV_DATA CI_END="1.40316686577685" CI_START="-2.20316686577685" EFFECT_SIZE="-0.4" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 14:25:13 +0100" MODIFIED_BY="[Empty name]" ORDER="116" SE="0.92" STUDY_ID="STD-Kitabchi-1987" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.650863524151353"/>
<IV_DATA CI_END="-0.05963565530534631" CI_START="-3.940364344694654" EFFECT_SIZE="-2.0" ESTIMABLE="YES" ESTIMATE="-2.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 14:25:23 +0100" MODIFIED_BY="[Empty name]" ORDER="117" SE="0.99" STUDY_ID="STD-Kyllastinen-1985" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.987263965554958"/>
<IV_DATA CI_END="-0.4356140460293788" CI_START="-1.9643859539706212" EFFECT_SIZE="-1.2" ESTIMABLE="YES" ESTIMATE="-1.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 14:25:36 +0100" MODIFIED_BY="[Empty name]" ORDER="118" SE="0.39" STUDY_ID="STD-Lewitt-1989" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.669876631546563"/>
<IV_DATA CI_END="0.5543769501056348" CI_START="-1.9543769501056347" EFFECT_SIZE="-0.7" ESTIMABLE="YES" ESTIMATE="-0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 14:25:48 +0100" MODIFIED_BY="[Empty name]" ORDER="119" SE="0.64" STUDY_ID="STD-Schade-1987" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.426190360752429"/>
<IV_DATA CI_END="-0.09441296556558054" CI_START="-1.5055870344344195" EFFECT_SIZE="-0.8" ESTIMABLE="YES" ESTIMATE="-0.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 14:26:07 +0100" MODIFIED_BY="[Empty name]" ORDER="120" SE="0.36" STUDY_ID="STD-Stenman-1988" TOTAL_1="0" TOTAL_2="0" WEIGHT="16.390153305625056"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="7.204596959392344" CI_END="-1.327037712244157" CI_START="-3.226073000365149" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.276555356304653" ESTIMABLE="YES" I2="30.599865222416078" I2_Q="70.92107032611838" ID="CMP-001.05" MODIFIED="2016-03-29 12:20:48 +0200" MODIFIED_BY="Bernd Richter" NO="5" P_CHI2="0.20586356045802334" P_Q="0.06367755932036434" P_Z="2.611917470130062E-6" Q="3.438916119729776" RANDOM="YES" SCALE="11.04" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.4174343183102255" TOTALS="YES" TOTAL_1="106" TOTAL_2="99" UNITS="mmol/L" WEIGHT="100.00000000000001" Z="4.699192832360457">
<NAME>Fasting glucose (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin+Sulphonylurea</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+sulpho</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.04621049638417868" CI_END="0.614293574255985" CI_START="-2.5592455847840907" DF="1" EFFECT_SIZE="-0.9724760052640529" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" MODIFIED="2016-03-29 12:20:48 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.8297937762859184" P_Z="0.22967601537175097" STUDIES="2" TAU2="0.0" TOTAL_1="39" TOTAL_2="32" WEIGHT="25.57202125113318" Z="1.2011939041101705">
<NAME>Parallel-group trials</NAME>
<CONT_DATA CI_END="2.081613593124877" CI_START="-4.681613593124877" EFFECT_SIZE="-1.3" ESTIMABLE="YES" MEAN_1="-3.0" MEAN_2="-1.7" MODIFIED="2015-12-12 16:29:10 +0100" MODIFIED_BY="[Empty name]" ORDER="46" SD_1="4.96" SD_2="5.28" SE="1.7253447613316435" STUDY_ID="STD-Casner-1988" TOTAL_1="22" TOTAL_2="15" WEIGHT="6.914586520217606"/>
<CONT_DATA CI_END="0.9168712081819921" CI_START="-2.6768712081819923" EFFECT_SIZE="-0.8800000000000001" ESTIMABLE="YES" MEAN_1="-2.02" MEAN_2="-1.14" MODIFIED="2016-03-29 12:20:48 +0200" MODIFIED_BY="Bernd Richter" ORDER="109" SD_1="2.26" SD_2="3.03" SE="0.9167878707749136" STUDY_ID="STD-Schiel-2007" TOTAL_1="17" TOTAL_2="17" WEIGHT="18.657434730915575"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.492808371161716" CI_END="-1.7759232941665655" CI_START="-3.6619047775381137" DF="3" EFFECT_SIZE="-2.7189140358523396" ESTIMABLE="YES" I2="14.109230132135963" ID="CMP-001.05.02" MODIFIED="2012-12-20 12:10:42 +0100" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.3216961738510439" P_Z="1.5938633380448045E-8" STUDIES="4" TAU2="0.13698854289165216" TOTAL_1="67" TOTAL_2="67" WEIGHT="74.42797874886683" Z="5.6511409410069975">
<NAME>Cross-over trials</NAME>
<CONT_DATA CI_END="-1.1230229093571937" CI_START="-8.076977090642806" EFFECT_SIZE="-4.6" ESTIMABLE="YES" MEAN_1="-2.6" MEAN_2="2.0" MODIFIED="2012-06-04 12:06:55 +0200" MODIFIED_BY="Bernd Richter" ORDER="74" SD_1="4.26" SD_2="3.19" SE="1.7740005010646918" STUDY_ID="STD-Kyllastinen-1985" TOTAL_1="9" TOTAL_2="9" WEIGHT="6.584302930381296"/>
<CONT_DATA CI_END="-0.6216289559777446" CI_START="-3.9783710440222553" EFFECT_SIZE="-2.3" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="1.2" MODIFIED="2012-06-04 12:06:55 +0200" MODIFIED_BY="Bernd Richter" ORDER="72" SD_1="2.61" SD_2="3.99" SE="0.8563274923728353" STUDY_ID="STD-Lewitt-1989" TOTAL_1="31" TOTAL_2="31" WEIGHT="20.395579464691345"/>
<CONT_DATA CI_END="-2.016946935839507" CI_START="-4.5830530641604925" EFFECT_SIZE="-3.3" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="0.5" MODIFIED="2012-06-04 12:06:55 +0200" MODIFIED_BY="Bernd Richter" ORDER="10" SD_1="1.76" SD_2="1.43" SE="0.6546309392830946" STUDY_ID="STD-Longnecker-1986" TOTAL_1="12" TOTAL_2="12" WEIGHT="27.742900338114076"/>
<CONT_DATA CI_END="0.023892039293620382" CI_START="-3.4238920392936207" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="0.8" MODIFIED="2012-06-04 12:06:55 +0200" MODIFIED_BY="Bernd Richter" ORDER="18" SD_1="2.09" SD_2="2.69" SE="0.8795529167328895" STUDY_ID="STD-Stenman-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="19.705196015680112"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="9.205782523790118" CI_END="-1.3541865618036633" CI_START="-3.2308974753845447" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="-2.292542018594104" ESTIMABLE="YES" I2="45.68631197751294" I2_Q="72.30309005389367" ID="CMP-001.06" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NO="6" P_CHI2="0.10113241953001972" P_Q="0.057415651188645556" P_Z="1.6804622806991181E-6" Q="3.6105110712560977" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.5943952193888014" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.00000000000001" Z="4.788483678517863">
<NAME>Fasting plasma glucose (change from baseline) [mmol/L] GIV</NAME>
<GROUP_LABEL_1>Insulin + sulphonylureas</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+sulpho</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.07115995699808642" CI_END="0.4384267646143598" CI_START="-2.4832435572540517" DF="1" EFFECT_SIZE="-1.0224083963198458" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="-0.35810294136327875" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NO="1" P_CHI2="0.789655316996319" P_Z="0.17014490081861938" STUDIES="2" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="26.239652471185227" Z="1.371738364372861">
<NAME>Parallel-group</NAME>
<IV_DATA CI_END="1.2087539002112695" CI_START="-3.8087539002112694" EFFECT_SIZE="-1.3" ESTIMABLE="YES" ESTIMATE="-1.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-12 17:03:32 +0100" MODIFIED_BY="[Empty name]" ORDER="136" SE="1.28" STUDY_ID="STD-Casner-1988" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.265726559515283"/>
<IV_DATA CI_END="0.9168949810263217" CI_START="-2.676894981026322" EFFECT_SIZE="-0.88" ESTIMABLE="YES" ESTIMATE="-0.88" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:02:10 +0100" MODIFIED_BY="[Empty name]" ORDER="138" SE="0.9168" STUDY_ID="STD-Schiel-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.973925911669944"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="4.860432324110537" CI_END="-1.7499835900142893" CI_START="-3.7005593483964" DF="3" EFFECT_SIZE="-2.7252714692053446" ESTIMABLE="YES" I2="38.277095534932634" ID="CMP-001.06.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="0.18230705011212978" P_Z="4.33143256314397E-8" STUDIES="4" TAU2="0.3721181305670316" TOTAL_1="0" TOTAL_2="0" WEIGHT="73.76034752881479" Z="5.476776695069198">
<NAME>Cross-over group</NAME>
<IV_DATA CI_END="-1.6600540231899181" CI_START="-7.539945976810081" EFFECT_SIZE="-4.6" ESTIMABLE="YES" ESTIMATE="-4.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:00:45 +0100" MODIFIED_BY="[Empty name]" ORDER="139" SE="1.5" STUDY_ID="STD-Kyllastinen-1985" TOTAL_1="0" TOTAL_2="0" WEIGHT="8.058396747890631"/>
<IV_DATA CI_END="-0.8692262912857602" CI_START="-3.7307737087142394" EFFECT_SIZE="-2.3" ESTIMABLE="YES" ESTIMATE="-2.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:00:52 +0100" MODIFIED_BY="[Empty name]" ORDER="140" SE="0.73" STUDY_ID="STD-Lewitt-1989" TOTAL_1="0" TOTAL_2="0" WEIGHT="20.332974709203384"/>
<IV_DATA CI_END="-2.22201980850297" CI_START="-4.37798019149703" EFFECT_SIZE="-3.3" ESTIMABLE="YES" ESTIMATE="-3.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:00:58 +0100" MODIFIED_BY="[Empty name]" ORDER="141" SE="0.55" STUDY_ID="STD-Longnecker-1986" TOTAL_1="0" TOTAL_2="0" WEIGHT="25.556235210238174"/>
<IV_DATA CI_END="-0.2300270115949592" CI_START="-3.169972988405041" EFFECT_SIZE="-1.7" ESTIMABLE="YES" ESTIMATE="-1.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:01:04 +0100" MODIFIED_BY="[Empty name]" ORDER="142" SE="0.75" STUDY_ID="STD-Stenman-1988" TOTAL_1="0" TOTAL_2="0" WEIGHT="19.812740861482595"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.8855144427423285" CI_END="0.3224951023355077" CI_START="-0.37513660269782323" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.02632075018115776" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2015-12-04 14:54:15 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.9266297732489424" P_Q="0.3959661017768189" P_Z="0.8824265350059869" Q="0.7205423161301667" RANDOM="YES" SCALE="3.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="67" UNITS="mmol/L" WEIGHT="100.0" Z="0.14789385869061267">
<NAME>Total cholesterol (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin+Sulphonylurea</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+sulpho</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0074849717811007" CI_START="-0.4874849717811006" DF="0" EFFECT_SIZE="0.26" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" MODIFIED="2015-01-12 15:17:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4954031785353342" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="12" WEIGHT="21.77647077383255" Z="0.6817403094622305">
<NAME>Parallel-group trials</NAME>
<CONT_DATA CI_END="1.0074849717811007" CI_START="-0.4874849717811006" EFFECT_SIZE="0.26" ESTIMABLE="YES" MEAN_1="0.28" MEAN_2="0.02" MODIFIED="2010-04-06 11:42:49 +0200" MODIFIED_BY="[Empty name]" ORDER="63" SD_1="0.98" SD_2="0.77" SE="0.3813768914516627" STUDY_ID="STD-Osei-1984" TOTAL_1="10" TOTAL_2="12" WEIGHT="21.77647077383255"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.1649721266121617" CI_END="0.28836253370987197" CI_START="-0.5004204017544586" DF="3" EFFECT_SIZE="-0.10602893402229328" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" MODIFIED="2012-06-04 12:09:10 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.9830354562111623" P_Z="0.5982489004545992" STUDIES="4" TAU2="0.0" TOTAL_1="55" TOTAL_2="55" WEIGHT="78.22352922616744" Z="0.5269203545346373">
<NAME>Cross-over trials</NAME>
<CONT_DATA CI_END="0.6083039756931009" CI_START="-0.8083039756931009" EFFECT_SIZE="-0.1" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.1" MODIFIED="2012-06-04 12:09:10 +0200" MODIFIED_BY="Bernd Richter" ORDER="60" SD_1="0.97" SD_2="0.87" SE="0.36138621999185305" STUDY_ID="STD-Groop-1985" TOTAL_1="13" TOTAL_2="13" WEIGHT="24.2523076564777"/>
<CONT_DATA CI_END="1.0442096855617211" CI_START="-1.1642096855617212" EFFECT_SIZE="-0.05999999999999994" ESTIMABLE="YES" MEAN_1="-0.86" MEAN_2="-0.8" MODIFIED="2012-06-04 12:09:10 +0200" MODIFIED_BY="Bernd Richter" ORDER="61" SD_1="1.38" SD_2="1.38" SE="0.5633826408401309" STUDY_ID="STD-Kitabchi-1987" TOTAL_1="12" TOTAL_2="12" WEIGHT="9.979052866843062"/>
<CONT_DATA CI_END="0.618773411604135" CI_START="-0.6987734116041351" EFFECT_SIZE="-0.039999999999999994" ESTIMABLE="YES" MEAN_1="-0.15" MEAN_2="-0.11" MODIFIED="2012-06-04 12:09:10 +0200" MODIFIED_BY="Bernd Richter" ORDER="62" SD_1="0.95" SD_2="0.89" SE="0.33611505966459365" STUDY_ID="STD-Lindstrom-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="28.036274459482954"/>
<CONT_DATA CI_END="0.6132440584586049" CI_START="-1.133244058458605" EFFECT_SIZE="-0.26" ESTIMABLE="YES" MEAN_1="-0.02" MEAN_2="0.24" MODIFIED="2012-06-04 12:09:10 +0200" MODIFIED_BY="Bernd Richter" ORDER="64" SD_1="1.2" SD_2="1.24" SE="0.44554086980507934" STUDY_ID="STD-Stenman-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="15.955894243363721"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="1.033449756158394" CI_END="0.0862229647419191" CI_START="-0.16963658268321785" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="-0.041706808970649385" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-1.0643770481845296" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="8" P_CHI2="0.9046822831798426" P_Q="0.42203524590087804" P_Z="0.522839624781559" Q="0.6446415972867439" RANDOM="YES" SCALE="4.87" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="99.99999999999999" Z="0.6389743460050685">
<NAME>Total cholesterol (change from baseline) [mmol/l] GIV</NAME>
<GROUP_LABEL_1>Insulin+Sulphonylurea</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+sulpho</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="1.0075302637035768" CI_START="-0.48753026370357677" DF="0" EFFECT_SIZE="0.26" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.0032581001352973934" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.585026652029182" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="1" P_CHI2="1.0" P_Z="0.4954293021711933" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.9287729442591406" Z="0.6816990036706869">
<NAME>Parallel-group</NAME>
<IV_DATA CI_END="1.0075302637035768" CI_START="-0.48753026370357677" EFFECT_SIZE="0.26" ESTIMABLE="YES" ESTIMATE="0.26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:11:15 +0100" MODIFIED_BY="[Empty name]" ORDER="150" SE="0.3814" STUDY_ID="STD-Osei-1984" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.9287729442591406"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.3888081588716501" CI_END="0.07903562124948962" CI_START="-0.18065506116323746" DF="3" EFFECT_SIZE="-0.05080971995687391" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="-1.1021771286413498" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="0.9425446501648975" P_Z="0.4431097084423554" STUDIES="4" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="97.07122705574085" Z="0.7669525934070122">
<NAME>Cross-over group</NAME>
<IV_DATA CI_END="0.48798919536201624" CI_START="-0.6879891953620162" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:10:06 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SE="0.3" STUDY_ID="STD-Groop-1985" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.733741866207582"/>
<IV_DATA CI_END="0.8219837930430245" CI_START="-0.9419837930430244" EFFECT_SIZE="-0.06" ESTIMABLE="YES" ESTIMATE="-0.06" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:10:12 +0100" MODIFIED_BY="[Empty name]" ORDER="152" SE="0.45" STUDY_ID="STD-Kitabchi-1987" TOTAL_1="0" TOTAL_2="0" WEIGHT="2.1038852738700364"/>
<IV_DATA CI_END="0.09719747891780381" CI_START="-0.17719747891780382" EFFECT_SIZE="-0.04" ESTIMABLE="YES" ESTIMATE="-0.04" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:10:18 +0100" MODIFIED_BY="[Empty name]" ORDER="153" SE="0.07" STUDY_ID="STD-Lindstrom-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="86.9462791752413"/>
<IV_DATA CI_END="0.4455870344344195" CI_START="-0.9655870344344195" EFFECT_SIZE="-0.26" ESTIMABLE="YES" ESTIMATE="-0.26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:10:24 +0100" MODIFIED_BY="[Empty name]" ORDER="154" SE="0.36" STUDY_ID="STD-Stenman-1988" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.2873207404219325"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="6.04255261607568" CI_END="0.029711421399595248" CI_START="-0.17030530552836154" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.07029694206438315" ESTIMABLE="YES" I2="50.352107948240885" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2015-12-04 14:55:34 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.1095582591618739" P_Q="0.5884732857691968" P_Z="0.1683022556793163" Q="0.2927349661166181" RANDOM="YES" SCALE="4.78" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.004959068184058273" TOTALS="YES" TOTAL_1="53" TOTAL_2="55" UNITS="mmol/L" WEIGHT="100.0" Z="1.3776795249640892">
<NAME>HDL-cholesterol (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin+Sulphonylurea</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin mono</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin+sulpho</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.274919446924289" CI_START="-0.274919446924289" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" MODIFIED="2015-01-12 15:17:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="12" WEIGHT="10.569156286677547" Z="0.0">
<NAME>Parallel-group trials</NAME>
<CONT_DATA CI_END="0.274919446924289" CI_START="-0.274919446924289" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-0.03" MEAN_2="-0.03" MODIFIED="2010-04-06 11:45:19 +0200" MODIFIED_BY="[Empty name]" ORDER="72" SD_1="0.4" SD_2="0.21" SE="0.1402676013910554" STUDY_ID="STD-Osei-1984" TOTAL_1="10" TOTAL_2="12" WEIGHT="10.569156286677547"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.912678285358791" CI_END="0.03640742526284596" CI_START="-0.20182570809447756" DF="2" EFFECT_SIZE="-0.0827091414158158" ESTIMABLE="YES" I2="66.17438149894812" ID="CMP-001.09.02" MODIFIED="2012-06-04 12:13:35 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.0520090687003103" P_Z="0.17354210214219748" STUDIES="3" TAU2="0.007191862649821835" TOTAL_1="43" TOTAL_2="43" WEIGHT="89.43084371332245" Z="1.3609100974555588">
<NAME>Cross-over trials</NAME>
<CONT_DATA CI_END="-0.026986043573999308" CI_START="-0.3730139564260007" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="-0.08" MEAN_2="0.12" MODIFIED="2012-06-04 12:13:35 +0200" MODIFIED_BY="Bernd Richter" ORDER="70" SD_1="0.23" SD_2="0.22" SE="0.08827404880432126" STUDY_ID="STD-Groop-1985" TOTAL_1="13" TOTAL_2="13" WEIGHT="20.41829204459023"/>
<CONT_DATA CI_END="0.09238068493216695" CI_START="-0.07238068493216693" EFFECT_SIZE="0.010000000000000002" ESTIMABLE="YES" MEAN_1="0.04" MEAN_2="0.03" MODIFIED="2012-06-04 12:13:35 +0200" MODIFIED_BY="Bernd Richter" ORDER="74" SD_1="0.12" SD_2="0.11" SE="0.04203173404306164" STUDY_ID="STD-Lindstrom-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="38.71120738366896"/>
<CONT_DATA CI_END="0.0081410190486578" CI_START="-0.2281410190486578" EFFECT_SIZE="-0.11" ESTIMABLE="YES" MEAN_1="-0.06" MEAN_2="0.05" MODIFIED="2012-06-04 12:13:35 +0200" MODIFIED_BY="Bernd Richter" ORDER="73" SD_1="0.16" SD_2="0.17" SE="0.060277137733417085" STUDY_ID="STD-Stenman-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="30.301344285063248"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="5.41917559869184" CI_END="0.047751738156780146" CI_START="-0.1489279709723102" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="-0.05058811640776503" ESTIMABLE="YES" I2="44.641026197339244" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-1.3210108155323916" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="10" P_CHI2="0.14355360849111498" P_Q="0.6591182235969195" P_Z="0.31333580183683496" Q="0.19459649491364323" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0045034271935027684" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.00000000000001" Z="1.0082472324571292">
<NAME>HDL-Cholesterol (change from baseline mmol/L) GIV</NAME>
<GROUP_LABEL_1>Insulin+Sulphonylurea</GROUP_LABEL_1>
<GROUP_LABEL_2>insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin mono</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin+sulpho</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.27498294703096965" CI_START="-0.27498294703096965" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="-0.5606942379515036" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.4081046492434" Z="0.0">
<NAME>Parallel-group</NAME>
<IV_DATA CI_END="0.27498294703096965" CI_START="-0.27498294703096965" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 16:57:03 +0100" MODIFIED_BY="[Empty name]" ORDER="132" SE="0.1403" STUDY_ID="STD-Osei-1984" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.4081046492434"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="5.41867043847242" CI_END="0.05709616019594464" CI_START="-0.1930829855121477" DF="2" EFFECT_SIZE="-0.06799341265810153" ESTIMABLE="YES" I2="63.09057687287915" ID="CMP-001.10.02" LOG_CI_END="-1.243393097739898" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="0.06658124407271682" P_Z="0.28671591374519234" STUDIES="3" TAU2="0.00767301587301587" TOTAL_1="0" TOTAL_2="0" WEIGHT="89.59189535075662" Z="1.06535370579082">
<NAME>Cross-over group</NAME>
<IV_DATA CI_END="0.015596038299405951" CI_START="-0.41559603829940595" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 16:55:40 +0100" MODIFIED_BY="[Empty name]" ORDER="133" SE="0.11" STUDY_ID="STD-Groop-1985" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.16230397624557"/>
<IV_DATA CI_END="0.04919927969080109" CI_START="-0.029199279690801085" EFFECT_SIZE="0.01" ESTIMABLE="YES" ESTIMATE="0.01" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 16:55:47 +0100" MODIFIED_BY="[Empty name]" ORDER="134" SE="0.02" STUDY_ID="STD-Lindstrom-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="51.34086838057355"/>
<IV_DATA CI_END="0.046797118763204346" CI_START="-0.26679711876320433" EFFECT_SIZE="-0.11" ESTIMABLE="YES" ESTIMATE="-0.11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 16:55:55 +0100" MODIFIED_BY="[Empty name]" ORDER="135" SE="0.08" STUDY_ID="STD-Stenman-1988" TOTAL_1="0" TOTAL_2="0" WEIGHT="23.0887229939375"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="33.26963819614342" CI_END="0.28324917554026513" CI_START="-0.2062400770764282" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="0.038504549231918477" ESTIMABLE="YES" I2="87.97702585036325" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-0.5478313455734248" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-1.4144879564758703" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="11" P_CHI2="1.0518776226708937E-6" P_Q="0.6258219884817808" P_Z="0.7578143945326183" Q="0.23776922245878548" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.043573501109273625" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="0.30835214187881804">
<NAME>Triglyceride (change from baseline) [mmol/L] GIV</NAME>
<GROUP_LABEL_1>Insulin+Sulphonylurea</GROUP_LABEL_1>
<GROUP_LABEL_2>insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+sulpho</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.8944271542517834" CI_START="-1.3744271542517834" DF="0" EFFECT_SIZE="-0.24" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="-0.048455024347304476" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="1" P_CHI2="1.0" P_Z="0.6783974072988124" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.118784856223501" Z="0.414651002073255">
<NAME>Parallel-group</NAME>
<IV_DATA CI_END="0.8944271542517834" CI_START="-1.3744271542517834" EFFECT_SIZE="-0.24" ESTIMABLE="YES" ESTIMATE="-0.24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:06:59 +0100" MODIFIED_BY="[Empty name]" ORDER="144" SE="0.5788" STUDY_ID="STD-Osei-1984" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.118784856223501"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="32.75789449938642" CI_END="0.30140710072501753" CI_START="-0.20315352762435615" DF="3" EFFECT_SIZE="0.04912678655033068" ESTIMABLE="YES" I2="90.84190224723939" ID="CMP-001.11.02" LOG_CI_END="-0.5208465205370895" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.3086816427266024" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="3.6225438748704875E-7" P_Z="0.7027093763262059" STUDIES="4" TAU2="0.04459258072367355" TOTAL_1="0" TOTAL_2="0" WEIGHT="95.8812151437765" Z="0.38166565881221676">
<NAME>Cross-over group</NAME>
<IV_DATA CI_END="0.2507917164442125" CI_START="-0.6507917164442125" EFFECT_SIZE="-0.2" ESTIMABLE="YES" ESTIMATE="-0.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:05:49 +0100" MODIFIED_BY="[Empty name]" ORDER="145" SE="0.23" STUDY_ID="STD-Groop-1985" TOTAL_1="0" TOTAL_2="0" WEIGHT="16.163005040101524"/>
<IV_DATA CI_END="0.18718847505281738" CI_START="-1.0671884750528173" EFFECT_SIZE="-0.44" ESTIMABLE="YES" ESTIMATE="-0.44" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:05:56 +0100" MODIFIED_BY="[Empty name]" ORDER="146" SE="0.32" STUDY_ID="STD-Kitabchi-1987" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.682087315958524"/>
<IV_DATA CI_END="0.4083985593816022" CI_START="0.25160144061839784" EFFECT_SIZE="0.33" ESTIMABLE="YES" ESTIMATE="0.33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:06:03 +0100" MODIFIED_BY="[Empty name]" ORDER="147" SE="0.04" STUDY_ID="STD-Lindstrom-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="34.518061393858225"/>
<IV_DATA CI_END="0.11839855938160218" CI_START="-0.03839855938160217" EFFECT_SIZE="0.04" ESTIMABLE="YES" ESTIMATE="0.04" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:06:09 +0100" MODIFIED_BY="[Empty name]" ORDER="148" SE="0.04" STUDY_ID="STD-Stenman-1988" TOTAL_1="0" TOTAL_2="0" WEIGHT="34.518061393858225"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="2.430996326518994" CI_END="0.216338277474172" CI_START="-0.16528891717976635" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="0.025524680147202834" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2015-12-04 14:57:49 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.6570331710667516" P_Q="0.6416377209932216" P_Z="0.7931828949652576" Q="0.21660668762760105" RANDOM="YES" SCALE="3.75" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="67" UNITS="mmol/L" WEIGHT="99.99999999999999" Z="0.26217971101764515">
<NAME>Triglycerides (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin+Sulphonylurea</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+sulpho</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8943575533034298" CI_START="-1.3743575533034298" DF="0" EFFECT_SIZE="-0.24" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" MODIFIED="2015-01-12 15:18:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6783787799792165" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="12" WEIGHT="2.8295586740158694" Z="0.4146764438776456">
<NAME>Parallel-group trials</NAME>
<CONT_DATA CI_END="0.8943575533034298" CI_START="-1.3743575533034298" EFFECT_SIZE="-0.24" ESTIMABLE="YES" MEAN_1="-0.12" MEAN_2="0.12" MODIFIED="2010-04-06 11:46:21 +0200" MODIFIED_BY="[Empty name]" ORDER="91" SD_1="1.64" SD_2="0.89" SE="0.5787644886595352" STUDY_ID="STD-Osei-1984" TOTAL_1="10" TOTAL_2="12" WEIGHT="2.8295586740158694"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.214389638891393" CI_END="0.22682850078355754" CI_START="-0.1603152267387694" DF="3" EFFECT_SIZE="0.03325663702239405" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.02" MODIFIED="2012-06-04 12:15:14 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.529119714833471" P_Z="0.7363190556904797" STUDIES="4" TAU2="0.0" TOTAL_1="55" TOTAL_2="55" WEIGHT="97.17044132598411" Z="0.33673184492988917">
<NAME>Cross-over trials</NAME>
<CONT_DATA CI_END="0.8672359347097569" CI_START="-1.2672359347097568" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.4" MODIFIED="2012-06-04 12:15:14 +0200" MODIFIED_BY="Bernd Richter" ORDER="88" SD_1="1.29" SD_2="1.48" SE="0.5445181356024793" STUDY_ID="STD-Groop-1985" TOTAL_1="13" TOTAL_2="13" WEIGHT="3.196669656337175"/>
<CONT_DATA CI_END="0.393023123209407" CI_START="-1.273023123209407" EFFECT_SIZE="-0.43999999999999995" ESTIMABLE="YES" MEAN_1="-0.47" MEAN_2="-0.03" MODIFIED="2012-06-04 12:15:14 +0200" MODIFIED_BY="Bernd Richter" ORDER="89" SD_1="0.61" SD_2="1.34" SE="0.42501960739084343" STUDY_ID="STD-Kitabchi-1987" TOTAL_1="12" TOTAL_2="12" WEIGHT="5.246920993332871"/>
<CONT_DATA CI_END="0.9213286544916701" CI_START="-0.3013286544916702" EFFECT_SIZE="0.31" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="-0.06" MODIFIED="2012-06-04 12:15:14 +0200" MODIFIED_BY="Bernd Richter" ORDER="90" SD_1="0.97" SD_2="0.72" SE="0.3119081061252924" STUDY_ID="STD-Lindstrom-1999" TOTAL_1="15" TOTAL_2="15" WEIGHT="9.742471250983064"/>
<CONT_DATA CI_END="0.2547032972460589" CI_START="-0.17470329724605888" EFFECT_SIZE="0.039999999999999994" ESTIMABLE="YES" MEAN_1="0.12" MEAN_2="0.08" MODIFIED="2012-06-04 12:15:14 +0200" MODIFIED_BY="Bernd Richter" ORDER="92" SD_1="0.3" SD_2="0.3" SE="0.10954451150103323" STUDY_ID="STD-Stenman-1988" TOTAL_1="15" TOTAL_2="15" WEIGHT="78.98437942533101"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NO="2">
<NAME>Insulin monotherapy versus insulin plus metformin</NAME>
<CONT_OUTCOME CHI2="13.716626677605559" CI_END="-1.0529048835351917" CI_START="-3.190271933772732" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.121588408653962" ESTIMABLE="YES" I2="56.25746664232033" I2_Q="73.01948969087232" ID="CMP-002.01" MODIFIED="2016-03-29 13:40:38 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.032966925153246396" P_Q="0.05420509607156698" P_Z="9.983606269958898E-5" Q="3.7063791178986483" RANDOM="YES" SCALE="11.66" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.058464816374378" TOTALS="YES" TOTAL_1="299" TOTAL_2="316" UNITS="kg" WEIGHT="100.0" Z="3.890989964046913">
<NAME>Weight (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin+Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+metformin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="10.6188896250619" CI_END="-1.2905161450831286" CI_START="-3.6110614084105697" DF="5" EFFECT_SIZE="-2.4507887767468493" ESTIMABLE="YES" I2="52.91409764539432" ID="CMP-002.01.01" MODIFIED="2016-03-29 13:40:38 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.05948246969236104" P_Z="3.4739842452849154E-5" STUDIES="6" TAU2="1.0149425499615106" TOTAL_1="280" TOTAL_2="297" WEIGHT="82.86210457830644" Z="4.139938842865835">
<NAME>Parallel-group trials</NAME>
<CONT_DATA CI_END="0.16917318916831103" CI_START="-5.569173189168311" EFFECT_SIZE="-2.7" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="3.2" MODIFIED="2016-03-29 13:40:35 +0200" MODIFIED_BY="Bernd Richter" ORDER="44" SD_1="5.15" SD_2="4.4" SE="1.463890771361098" STUDY_ID="STD-Avil_x00e9_s-1999" TOTAL_1="21" TOTAL_2="22" WEIGHT="9.28659579826329"/>
<CONT_DATA CI_END="-2.133109574296483" CI_START="-9.066890425703516" EFFECT_SIZE="-5.6" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="0.6" MODIFIED="2016-03-29 13:40:36 +0200" MODIFIED_BY="Bernd Richter" ORDER="101" SD_1="5.0" SD_2="6.13" SE="1.7688541488771763" STUDY_ID="STD-Krawczyk-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="7.100140640739289"/>
<CONT_DATA CI_END="1.1006562408696026" CI_START="-2.820656240869602" EFFECT_SIZE="-0.8599999999999999" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="1.16" MODIFIED="2012-12-30 17:47:03 +0100" MODIFIED_BY="[Empty name]" ORDER="28" SD_1="4.5" SD_2="1.9" SE="1.0003531984949767" STUDY_ID="STD-Relimpio-1998" TOTAL_1="24" TOTAL_2="23" WEIGHT="14.438083928384325"/>
<CONT_DATA CI_END="-2.0642778838536353" CI_START="-5.755722116146365" EFFECT_SIZE="-3.91" ESTIMABLE="YES" MEAN_1="0.49" MEAN_2="4.4" MODIFIED="2012-12-30 17:47:03 +0100" MODIFIED_BY="[Empty name]" ORDER="29" SD_1="2.8" SD_2="4.3" SE="0.9417122614013244" STUDY_ID="STD-Strowig-2002" TOTAL_1="27" TOTAL_2="31" WEIGHT="15.283344650252305"/>
<CONT_DATA CI_END="-0.7436720932500681" CI_START="-2.456327906749932" EFFECT_SIZE="-1.6" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="1.2" MODIFIED="2010-04-06 18:18:20 +0200" MODIFIED_BY="[Empty name]" ORDER="30" SD_1="2.5" SD_2="5.3" SE="0.43691002156393544" STUDY_ID="STD-Wulffel_x00e9_-2002" TOTAL_1="171" TOTAL_2="182" WEIGHT="23.79666647211067"/>
<CONT_DATA CI_END="-0.02096676961678412" CI_START="-4.379033230383216" EFFECT_SIZE="-2.2" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="3.6" MODIFIED="2016-03-29 13:40:38 +0200" MODIFIED_BY="Bernd Richter" ORDER="104" SD_1="3.6" SD_2="3.0" SE="1.1117720772275164" STUDY_ID="STD-Yilmaz-2007" TOTAL_1="17" TOTAL_2="19" WEIGHT="12.957273088556553"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1118434337889012" CI_START="-2.111843433788901" DF="0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" MODIFIED="2012-06-04 12:20:12 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="1.0" P_Z="0.5431952193469421" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="17.137895421693564" Z="0.607988326736189">
<NAME>Cross-over trials</NAME>
<CONT_DATA CI_END="1.1118434337889012" CI_START="-2.111843433788901" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="0.0" MODIFIED="2012-06-04 12:20:12 +0200" MODIFIED_BY="Bernd Richter" ORDER="71" SD_1="3.1" SD_2="1.8" SE="0.8223842103747397" STUDY_ID="STD-Robinson-1998" TOTAL_1="19" TOTAL_2="19" WEIGHT="17.137895421693564"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="13.936293675294825" CI_END="-1.0452803412852174" CI_START="-3.1838560483567506" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_SIZE="-2.114568194820984" ESTIMABLE="YES" I2="56.94694629866812" I2_Q="74.39160720558422" ID="CMP-002.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="0.0303559773438693" P_Q="0.048143552766050646" P_Z="1.0622122485516598E-4" Q="3.9049697809151938" RANDOM="YES" SCALE="11.66" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.0703273555802528" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="3.875923111815631">
<NAME>Weight (change from baseline) [kg] GIV</NAME>
<GROUP_LABEL_1>Insulin+Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Insulin+Metformin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="10.618695560724758" CI_END="-1.2905165831819592" CI_START="-3.6110656906733976" DF="5" EFFECT_SIZE="-2.4507911369276782" ESTIMABLE="YES" I2="52.91323711649254" ID="CMP-002.02.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:42 +0200" MODIFIED_BY="Gudrun Paletta" NO="1" P_CHI2="0.059486885423563396" P_Z="3.474027726933429E-5" STUDIES="6" TAU2="1.0149262090591502" TOTAL_1="0" TOTAL_2="0" WEIGHT="82.43411113484467" Z="4.139935971620841">
<NAME>Parallel-group</NAME>
<IV_DATA CI_END="0.16919127696818537" CI_START="-5.569191276968185" EFFECT_SIZE="-2.7" ESTIMABLE="YES" ESTIMATE="-2.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-16 10:35:11 +0100" MODIFIED_BY="[Empty name]" ORDER="164" SE="1.4639" STUDY_ID="STD-Avil_x00e9_s-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.262701739130613"/>
<IV_DATA CI_END="-2.133019707747098" CI_START="-9.066980292252902" EFFECT_SIZE="-5.6" ESTIMABLE="YES" ESTIMATE="-5.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-16 10:35:12 +0100" MODIFIED_BY="[Empty name]" ORDER="165" SE="1.7689" STUDY_ID="STD-Krawczyk-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="7.087818832574737"/>
<IV_DATA CI_END="1.1007479701338703" CI_START="-2.82074797013387" EFFECT_SIZE="-0.86" ESTIMABLE="YES" ESTIMATE="-0.86" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:22:15 +0100" MODIFIED_BY="[Empty name]" ORDER="166" SE="1.0004" STUDY_ID="STD-Relimpio-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="14.370975420054213"/>
<IV_DATA CI_END="-2.064301915758631" CI_START="-5.755698084241369" EFFECT_SIZE="-3.91" ESTIMABLE="YES" ESTIMATE="-3.91" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:22:37 +0100" MODIFIED_BY="[Empty name]" ORDER="167" SE="0.9417" STUDY_ID="STD-Strowig-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.208074944279966"/>
<IV_DATA CI_END="-0.7436917351544503" CI_START="-2.45630826484555" EFFECT_SIZE="-1.6" ESTIMABLE="YES" ESTIMATE="-1.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:22:58 +0100" MODIFIED_BY="[Empty name]" ORDER="168" SE="0.4369" STUDY_ID="STD-Wulffel_x00e9_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="23.59967573217178"/>
<IV_DATA CI_END="-0.020912041988367935" CI_START="-4.379087958011633" EFFECT_SIZE="-2.2" ESTIMABLE="YES" ESTIMATE="-2.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-16 10:35:12 +0100" MODIFIED_BY="[Empty name]" ORDER="169" SE="1.1118" STUDY_ID="STD-Yilmaz-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="12.904864466633363"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.0483715477866429" CI_START="-2.048371547786643" DF="0" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="0.020515225926858227" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="1.0" P_Z="0.5267915115064378" STUDIES="1" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="17.565888865155333" Z="0.6329113924050632">
<NAME>Cross-over group</NAME>
<IV_DATA CI_END="1.0483715477866429" CI_START="-2.048371547786643" EFFECT_SIZE="-0.5" ESTIMABLE="YES" ESTIMATE="-0.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:24:40 +0100" MODIFIED_BY="[Empty name]" ORDER="170" SE="0.79" STUDY_ID="STD-Robinson-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="17.565888865155333"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="19.2263927502729" CI_END="-0.5111352472095323" CI_START="-1.2033341442701255" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8572346957398289" ESTIMABLE="YES" I2="58.39053064238247" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2016-04-07 12:03:05 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.013694687299646291" P_Q="0.4607718793325689" P_Z="1.2067440651401965E-6" Q="0.5440192148033822" RANDOM="YES" SCALE="6.65" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.1407710829661074" TOTALS="YES" TOTAL_1="341" TOTAL_2="357" UNITS="%" WEIGHT="100.00000000000001" Z="4.854527035749208">
<NAME>HbA1c (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin + Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+Metformin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="12.955398654984705" CI_END="-0.40739899507297145" CI_START="-1.1290710271863154" DF="6" EFFECT_SIZE="-0.7682350111296434" ESTIMABLE="YES" I2="53.68726073364446" ID="CMP-002.03.01" MODIFIED="2016-04-07 12:03:05 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04374973795986514" P_Z="3.0081890989359443E-5" STUDIES="7" TAU2="0.11154731115444066" TOTAL_1="309" TOTAL_2="325" WEIGHT="80.55534195644482" Z="4.172845521164233">
<NAME>Parallel-group trials</NAME>
<CONT_DATA CI_END="-0.1273238789643284" CI_START="-1.6726761210356713" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-1.6" MODIFIED="2013-01-04 11:10:41 +0100" MODIFIED_BY="[Empty name]" ORDER="42" SD_1="1.43" SD_2="1.13" SE="0.39422975479674227" STUDY_ID="STD-Avil_x00e9_s-1999" TOTAL_1="21" TOTAL_2="22" WEIGHT="10.527806782854528"/>
<CONT_DATA CI_END="-0.5847572401842999" CI_START="-2.0152427598157" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-0.4" MODIFIED="2012-12-20 15:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="53" SD_1="1.37" SD_2="1.21" SE="0.3649264810258982" STUDY_ID="STD-Giugliano-1993" TOTAL_1="27" TOTAL_2="23" WEIGHT="11.382727664220681"/>
<CONT_DATA CI_END="0.47284258466369544" CI_START="-1.2728425846636953" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-0.8" MODIFIED="2016-04-07 12:03:04 +0200" MODIFIED_BY="[Empty name]" ORDER="56" SD_1="1.19" SD_2="1.83" SE="0.4453360324723139" STUDY_ID="STD-Hirsch-1999" TOTAL_1="22" TOTAL_2="25" WEIGHT="9.19568121677564"/>
<CONT_DATA CI_END="-0.7962895769148846" CI_START="-3.0037104230851157" EFFECT_SIZE="-1.9000000000000001" ESTIMABLE="YES" MEAN_1="-1.87" MEAN_2="0.03" MODIFIED="2016-04-07 12:03:05 +0200" MODIFIED_BY="[Empty name]" ORDER="19" SD_1="2.16" SD_2="1.68" SE="0.5631279104060292" STUDY_ID="STD-Relimpio-1998" TOTAL_1="24" TOTAL_2="23" WEIGHT="6.81004598540785"/>
<CONT_DATA CI_END="0.6466667632869781" CI_START="-0.6466667632869781" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-1.7" MODIFIED="2016-04-07 12:03:05 +0200" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="1.11" SD_2="1.4" SE="0.329938084774926" STUDY_ID="STD-Strowig-2002" TOTAL_1="27" TOTAL_2="31" WEIGHT="12.491323857785122"/>
<CONT_DATA CI_END="-0.454736040466627" CI_START="-0.8252639595333731" EFFECT_SIZE="-0.64" ESTIMABLE="YES" MEAN_1="-0.91" MEAN_2="-0.27" MODIFIED="2012-01-06 10:01:53 +0100" MODIFIED_BY="[Empty name]" ORDER="21" SD_1="0.93" SD_2="0.84" SE="0.09452416523707143" STUDY_ID="STD-Wulffel_x00e9_-2002" TOTAL_1="171" TOTAL_2="182" WEIGHT="20.82891817109779"/>
<CONT_DATA CI_END="-0.03707541250851465" CI_START="-1.7629245874914852" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-1.1" MODIFIED="2013-01-04 11:10:39 +0100" MODIFIED_BY="[Empty name]" ORDER="102" SD_1="1.2" SD_2="1.44" SE="0.44027573684931165" STUDY_ID="STD-Yilmaz-2007" TOTAL_1="17" TOTAL_2="19" WEIGHT="9.318838278303197"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.62598341484159" CI_END="-0.18564998449120462" CI_START="-2.132001837371144" DF="1" EFFECT_SIZE="-1.1588259109311743" ESTIMABLE="YES" I2="61.91902834008097" ID="CMP-002.03.02" MODIFIED="2013-01-04 11:10:38 +0100" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.1051274040713508" P_Z="0.019603017120114426" STUDIES="2" TAU2="0.3095951417004048" TOTAL_1="32" TOTAL_2="32" WEIGHT="19.444658043555194" Z="2.3338607008966377">
<NAME>Cross-over trials</NAME>
<CONT_DATA CI_END="0.3784731661368749" CI_START="-1.5784731661368752" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.5" MODIFIED="2012-06-04 12:16:54 +0200" MODIFIED_BY="Bernd Richter" ORDER="59" SD_1="1.44" SD_2="1.08" SE="0.4992301766027062" STUDY_ID="STD-Fritsche-2000" TOTAL_1="13" TOTAL_2="13" WEIGHT="7.995377302722008"/>
<CONT_DATA CI_END="-0.8890463390726023" CI_START="-2.3109536609273977" EFFECT_SIZE="-1.6" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="0.5" MODIFIED="2013-01-04 11:10:38 +0100" MODIFIED_BY="Bernd Richter" ORDER="58" SD_1="1.3" SD_2="0.9" SE="0.36273812505500586" STUDY_ID="STD-Robinson-1998" TOTAL_1="19" TOTAL_2="19" WEIGHT="11.449280740833187"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="19.321588074775512" CI_END="-0.5115128889706616" CI_START="-1.20342204217526" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_SIZE="-0.8574674655729608" ESTIMABLE="YES" I2="58.59553588949521" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="4" P_CHI2="0.013231259101450732" P_Q="0.4652089576113291" P_Z="1.1865008861408214E-6" Q="0.5333331890649394" RANDOM="YES" SCALE="4.96" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.14126176371718846" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="4.857878646796525">
<NAME>HbA1c (change from baseline) [%] GIV</NAME>
<GROUP_LABEL_1>Insulin+Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+Metformin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="12.957400990614778" CI_END="-0.40739680570858317" CI_START="-1.1290693079447767" DF="6" EFFECT_SIZE="-0.76823305682668" ESTIMABLE="YES" I2="53.69441754294799" ID="CMP-002.04.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="1" P_CHI2="0.0437174576188788" P_Z="3.008365212247588E-5" STUDIES="7" TAU2="0.11155956466166263" TOTAL_1="0" TOTAL_2="0" WEIGHT="80.32777016054192" Z="4.172832187585852">
<NAME>Parallel-group</NAME>
<IV_DATA CI_END="-0.12738219729431066" CI_START="-1.6726178027056893" EFFECT_SIZE="-0.9" ESTIMABLE="YES" ESTIMATE="-0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-16 10:36:40 +0100" MODIFIED_BY="[Empty name]" ORDER="155" SE="0.3942" STUDY_ID="STD-Avil_x00e9_s-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.50242804566721"/>
<IV_DATA CI_END="-0.5848091420413343" CI_START="-2.015190857958666" EFFECT_SIZE="-1.3" ESTIMABLE="YES" ESTIMATE="-1.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-16 10:36:01 +0100" MODIFIED_BY="[Empty name]" ORDER="156" SE="0.3649" STUDY_ID="STD-Giugliano-1993" TOTAL_1="0" TOTAL_2="0" WEIGHT="11.353664904259057"/>
<IV_DATA CI_END="0.4727719623156861" CI_START="-1.2727719623156861" EFFECT_SIZE="-0.4" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-04-07 12:02:09 +0200" MODIFIED_BY="[Empty name]" ORDER="157" SE="0.4453" STUDY_ID="STD-Hirsch-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.17557553180677"/>
<IV_DATA CI_END="-0.7963442803054952" CI_START="-3.0036557196945046" EFFECT_SIZE="-1.9" ESTIMABLE="YES" ESTIMATE="-1.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-04-07 12:02:10 +0200" MODIFIED_BY="[Empty name]" ORDER="158" SE="0.5631" STUDY_ID="STD-Relimpio-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.797528251865921"/>
<IV_DATA CI_END="0.646592118499764" CI_START="-0.646592118499764" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-04-07 12:02:10 +0200" MODIFIED_BY="[Empty name]" ORDER="159" SE="0.3299" STUDY_ID="STD-Strowig-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="12.457635671290038"/>
<IV_DATA CI_END="-0.4547834034609649" CI_START="-0.8252165965390351" EFFECT_SIZE="-0.64" ESTIMABLE="YES" ESTIMATE="-0.64" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:18:01 +0100" MODIFIED_BY="[Empty name]" ORDER="160" SE="0.0945" STUDY_ID="STD-Wulffel_x00e9_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="20.74412583457871"/>
<IV_DATA CI_END="-0.0370278576070141" CI_START="-1.7629721423929858" EFFECT_SIZE="-0.9" ESTIMABLE="YES" ESTIMATE="-0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-16 10:36:43 +0100" MODIFIED_BY="[Empty name]" ORDER="161" SE="0.4403" STUDY_ID="STD-Yilmaz-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.296811921074207"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="2.7048958615093324" CI_END="-0.18126929586249674" CI_START="-2.1292307041375036" DF="1" EFFECT_SIZE="-1.15525" ESTIMABLE="YES" I2="63.03000000000001" ID="CMP-002.04.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="0.10004068253385501" P_Z="0.02008605979102517" STUDIES="2" TAU2="0.31515000000000015" TOTAL_1="0" TOTAL_2="0" WEIGHT="19.672229839458083" Z="2.324736397262588">
<NAME>Cross-over group</NAME>
<IV_DATA CI_END="0.3603823524246266" CI_START="-1.5603823524246265" EFFECT_SIZE="-0.6" ESTIMABLE="YES" ESTIMATE="-0.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:15:27 +0100" MODIFIED_BY="[Empty name]" ORDER="162" SE="0.49" STUDY_ID="STD-Fritsche-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="8.16967595683926"/>
<IV_DATA CI_END="-0.8944129655655806" CI_START="-2.30558703443442" EFFECT_SIZE="-1.6" ESTIMABLE="YES" ESTIMATE="-1.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-16 10:36:44 +0100" MODIFIED_BY="[Empty name]" ORDER="163" SE="0.36" STUDY_ID="STD-Robinson-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="11.502553882618825"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="10.20041991645693" CI_END="-0.07815829602781962" CI_START="-0.41196923819221387" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.24506376711001673" ESTIMABLE="YES" I2="31.375374177424856" I2_Q="39.43842697877479" ID="CMP-002.05" MODIFIED="2015-12-04 15:01:07 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.1774975587746399" P_Q="0.1987941108197928" P_Z="0.004004924573996124" Q="1.651212064206996" RANDOM="YES" SCALE="3.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.016401902581694005" TOTALS="YES" TOTAL_1="319" TOTAL_2="332" UNITS="mmol/L" WEIGHT="100.0" Z="2.877773594460541">
<NAME>Total cholesterol (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin+Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+Metformin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.1884428538944" CI_END="-0.020521765599791908" CI_START="-0.3752391653529531" DF="5" EFFECT_SIZE="-0.1978804654763725" ESTIMABLE="YES" I2="30.44390695418539" ID="CMP-002.05.01" MODIFIED="2014-10-17 10:41:02 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.20699870160204692" P_Z="0.028761006424720917" STUDIES="6" TAU2="0.014155459371000672" TOTAL_1="287" TOTAL_2="300" WEIGHT="82.67270543520186" Z="2.1867468911736423">
<NAME>Parallel-group trials</NAME>
<CONT_DATA CI_END="0.6739927586937154" CI_START="-0.6339927586937154" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" MEAN_1="-0.51" MEAN_2="-0.53" MODIFIED="2009-12-08 09:57:57 +0100" MODIFIED_BY="[Empty name]" ORDER="52" SD_1="1.32" SD_2="0.79" SE="0.33367590621681154" STUDY_ID="STD-Avil_x00e9_s-1999" TOTAL_1="21" TOTAL_2="22" WEIGHT="5.676921750991993"/>
<CONT_DATA CI_END="0.08996655032119943" CI_START="-0.4499665503211994" EFFECT_SIZE="-0.18" ESTIMABLE="YES" MEAN_1="-0.21" MEAN_2="-0.03" MODIFIED="2009-12-07 22:44:58 +0100" MODIFIED_BY="[Empty name]" ORDER="54" SD_1="0.48" SD_2="0.49" SE="0.1377405668934027" STUDY_ID="STD-Giugliano-1993" TOTAL_1="27" TOTAL_2="23" WEIGHT="20.500114866236178"/>
<CONT_DATA CI_END="-0.23808302847719837" CI_START="-1.1619169715228017" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" MEAN_1="-0.56" MEAN_2="0.14" MODIFIED="2010-04-06 11:52:10 +0200" MODIFIED_BY="[Empty name]" ORDER="55" SD_1="0.89" SD_2="0.72" SE="0.23567625485281557" STUDY_ID="STD-Relimpio-1998" TOTAL_1="24" TOTAL_2="23" WEIGHT="10.079596368975437"/>
<CONT_DATA CI_END="0.5097648792501" CI_START="-0.5097648792501" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.04" MEAN_2="0.04" MODIFIED="2010-04-06 11:52:09 +0200" MODIFIED_BY="[Empty name]" ORDER="57" SD_1="1.02" SD_2="0.95" SE="0.2600889012609723" STUDY_ID="STD-Strowig-2002" TOTAL_1="27" TOTAL_2="31" WEIGHT="8.62813360181944"/>
<CONT_DATA CI_END="-0.06383583106540236" CI_START="-0.3561641689345976" EFFECT_SIZE="-0.21" ESTIMABLE="YES" MEAN_1="-0.25" MEAN_2="-0.04" MODIFIED="2010-04-06 11:52:09 +0200" MODIFIED_BY="[Empty name]" ORDER="58" SD_1="0.65" SD_2="0.75" SE="0.07457492591064016" STUDY_ID="STD-Wulffel_x00e9_-2002" TOTAL_1="171" TOTAL_2="182" WEIGHT="33.01770872055228"/>
<CONT_DATA CI_END="0.9917880102071907" CI_START="-0.4517880102071906" EFFECT_SIZE="0.27" ESTIMABLE="YES" MEAN_1="-0.07" MEAN_2="-0.34" MODIFIED="2010-03-09 11:50:27 +0100" MODIFIED_BY="[Empty name]" ORDER="105" SD_1="0.61" SD_2="1.47" SE="0.3682659558545781" STUDY_ID="STD-Yilmaz-2007" TOTAL_1="17" TOTAL_2="19" WEIGHT="4.77023012662655"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1150662325366034" CI_END="-0.09295180597747421" CI_START="-0.8522864375603644" DF="1" EFFECT_SIZE="-0.4726191217689193" ESTIMABLE="YES" I2="10.319228506709015" ID="CMP-002.05.02" MODIFIED="2012-06-04 12:21:40 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.2909833430217972" P_Z="0.014694951693592452" STUDIES="2" TAU2="0.007847773279352203" TOTAL_1="32" TOTAL_2="32" WEIGHT="17.32729456479813" Z="2.4398109042940814">
<NAME>Cross-over trials</NAME>
<CONT_DATA CI_END="-0.14637661745991581" CI_START="-1.2336233825400842" EFFECT_SIZE="-0.69" ESTIMABLE="YES" MEAN_1="-0.72" MEAN_2="-0.03" MODIFIED="2012-06-04 12:21:40 +0200" MODIFIED_BY="Bernd Richter" ORDER="53" SD_1="0.65" SD_2="0.76" SE="0.2773639652708499" STUDY_ID="STD-Fritsche-2000" TOTAL_1="13" TOTAL_2="13" WEIGHT="7.769825500640887"/>
<CONT_DATA CI_END="0.1779808665728193" CI_START="-0.7779808665728193" EFFECT_SIZE="-0.3" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="0.0" MODIFIED="2012-06-04 12:21:40 +0200" MODIFIED_BY="Bernd Richter" ORDER="56" SD_1="0.7" SD_2="0.8" SE="0.24387227027795988" STUDY_ID="STD-Robinson-1998" TOTAL_1="19" TOTAL_2="19" WEIGHT="9.557469064157244"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="20.84867430425406" CI_END="-0.06981578554514598" CI_START="-0.5038509904387205" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_SIZE="-0.28683338799193325" ESTIMABLE="YES" I2="66.42472371218497" I2_Q="67.79208670579297" ID="CMP-002.06" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="6" P_CHI2="0.004000706052644576" P_Q="0.07806079979989233" P_Z="0.009583789062959865" Q="3.1048270369625635" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.05445908450970271" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="99.99999999999997" Z="2.5904954422563033">
<NAME>Total cholesterol (change from baseline) [mmol/L] GIV</NAME>
<GROUP_LABEL_1>Insulin+Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Insulin+Metformin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Insulin mono</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="7.18714335830972" CI_END="-0.020542366054466965" CI_START="-0.3752173337730006" DF="5" EFFECT_SIZE="-0.19787984991373378" ESTIMABLE="YES" I2="30.431330631257854" ID="CMP-002.06.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="1" P_CHI2="0.20709024901548423" P_Z="0.02874239971988247" STUDIES="6" TAU2="0.014146856672440141" TOTAL_1="0" TOTAL_2="0" WEIGHT="72.15099723081923" Z="2.187001702386244">
<NAME>Parallel-group</NAME>
<IV_DATA CI_END="0.6740399816410161" CI_START="-0.634039981641016" EFFECT_SIZE="0.02" ESTIMABLE="YES" ESTIMATE="0.02" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:28:07 +0100" MODIFIED_BY="[Empty name]" ORDER="171" SE="0.3337" STUDY_ID="STD-Avil_x00e9_s-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="7.393847956404414"/>
<IV_DATA CI_END="0.08988704067116549" CI_START="-0.4498870406711655" EFFECT_SIZE="-0.18" ESTIMABLE="YES" ESTIMATE="-0.18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:28:24 +0100" MODIFIED_BY="[Empty name]" ORDER="172" SE="0.1377" STUDY_ID="STD-Giugliano-1993" TOTAL_1="0" TOTAL_2="0" WEIGHT="16.69848784942119"/>
<IV_DATA CI_END="-0.23803648884390916" CI_START="-1.1619635111560909" EFFECT_SIZE="-0.7" ESTIMABLE="YES" ESTIMATE="-0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:28:52 +0100" MODIFIED_BY="[Empty name]" ORDER="173" SE="0.2357" STUDY_ID="STD-Relimpio-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="11.144163228166862"/>
<IV_DATA CI_END="0.5097866323788681" CI_START="-0.5097866323788681" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:29:12 +0100" MODIFIED_BY="[Empty name]" ORDER="174" SE="0.2601" STUDY_ID="STD-Strowig-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.040113362122128"/>
<IV_DATA CI_END="-0.06378668675331195" CI_START="-0.35621331324668803" EFFECT_SIZE="-0.21" ESTIMABLE="YES" ESTIMATE="-0.21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:29:31 +0100" MODIFIED_BY="[Empty name]" ORDER="175" SE="0.0746" STUDY_ID="STD-Wulffel_x00e9_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="20.425233864493602"/>
<IV_DATA CI_END="0.991854735506102" CI_START="-0.451854735506102" EFFECT_SIZE="0.27" ESTIMABLE="YES" ESTIMATE="0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:30:01 +0100" MODIFIED_BY="[Empty name]" ORDER="176" SE="0.3683" STUDY_ID="STD-Yilmaz-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.449150970211039"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.9512195121951215" CI_END="-0.196810317214626" CI_START="-0.936189682785374" DF="1" EFFECT_SIZE="-0.5665" ESTIMABLE="YES" I2="48.749999999999986" ID="CMP-002.06.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="0.1624557870387986" P_Z="0.002669964525411227" STUDIES="2" TAU2="0.039" TOTAL_1="0" TOTAL_2="0" WEIGHT="27.849002769180746" Z="3.0033826989068144">
<NAME>Cross-over group</NAME>
<IV_DATA CI_END="-0.4648043218551935" CI_START="-0.9351956781448064" EFFECT_SIZE="-0.7" ESTIMABLE="YES" ESTIMATE="-0.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:27:40 +0100" MODIFIED_BY="[Empty name]" ORDER="177" SE="0.12" STUDY_ID="STD-Fritsche-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="17.80461126341973"/>
<IV_DATA CI_END="0.2095906359804141" CI_START="-0.8095906359804141" EFFECT_SIZE="-0.3" ESTIMABLE="YES" ESTIMATE="-0.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:27:47 +0100" MODIFIED_BY="[Empty name]" ORDER="178" SE="0.26" STUDY_ID="STD-Robinson-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.044391505761016"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="12.577718007049084" CI_END="0.04008194807414517" CI_START="-0.05944981755550577" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.0096839347406803" ESTIMABLE="YES" I2="44.34602527996808" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2015-12-04 15:02:15 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.08309060226531828" P_Q="0.9661036398840223" P_Z="0.7029145775971841" Q="0.0018058746075363937" RANDOM="YES" SCALE="1.33" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.00195402314337501" TOTALS="YES" TOTAL_1="319" TOTAL_2="332" UNITS="mmol/L" WEIGHT="100.00000000000001" Z="0.38138906107610226">
<NAME>HDL-cholesterol (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin+Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin mono</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin+Metformin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.662779548327713" CI_END="0.04611561664275932" CI_START="-0.05023485228782091" DF="5" EFFECT_SIZE="-0.0020596178225307927" ESTIMABLE="YES" I2="34.74952569800634" ID="CMP-002.07.01" MODIFIED="2014-10-17 10:41:02 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.17582601537585185" P_Z="0.9332205295346165" STUDIES="6" TAU2="0.0011809205657872066" TOTAL_1="287" TOTAL_2="300" WEIGHT="82.43515432135897" Z="0.0837936088714966">
<NAME>Parallel-group trials</NAME>
<CONT_DATA CI_END="0.29490849746696546" CI_START="-0.27490849746696544" EFFECT_SIZE="0.009999999999999995" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.11" MODIFIED="2009-12-08 10:42:34 +0100" MODIFIED_BY="[Empty name]" ORDER="75" SD_1="0.38" SD_2="0.56" SE="0.14536414939982945" STUDY_ID="STD-Avil_x00e9_s-1999" TOTAL_1="21" TOTAL_2="22" WEIGHT="2.792813253295429"/>
<CONT_DATA CI_END="0.22270160202371533" CI_START="0.017298397976284685" EFFECT_SIZE="0.12000000000000001" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="0.01" MODIFIED="2010-04-06 11:53:04 +0200" MODIFIED_BY="[Empty name]" ORDER="77" SD_1="0.19" SD_2="0.18" SE="0.05239973940021982" STUDY_ID="STD-Giugliano-1993" TOTAL_1="27" TOTAL_2="23" WEIGHT="13.718036295480198"/>
<CONT_DATA CI_END="0.03973753891380169" CI_START="-0.2057375389138017" EFFECT_SIZE="-0.083" ESTIMABLE="YES" MEAN_1="-0.0030" MEAN_2="0.08" MODIFIED="2010-04-06 11:53:31 +0200" MODIFIED_BY="[Empty name]" ORDER="78" SD_1="0.17" SD_2="0.25" SE="0.062622344023635" STUDY_ID="STD-Relimpio-1998" TOTAL_1="24" TOTAL_2="23" WEIGHT="10.972773558247066"/>
<CONT_DATA CI_END="0.054772210211749356" CI_START="-0.11477221021174935" EFFECT_SIZE="-0.03" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.03" MODIFIED="2010-04-06 11:53:30 +0200" MODIFIED_BY="[Empty name]" ORDER="80" SD_1="0.11" SD_2="0.21" SE="0.04325192242328008" STUDY_ID="STD-Strowig-2002" TOTAL_1="27" TOTAL_2="31" WEIGHT="16.85636667647448"/>
<CONT_DATA CI_END="0.02657656688591223" CI_START="-0.04657656688591223" EFFECT_SIZE="-0.01" ESTIMABLE="YES" MEAN_1="-0.01" MEAN_2="0.0" MODIFIED="2010-04-06 11:53:30 +0200" MODIFIED_BY="[Empty name]" ORDER="81" SD_1="0.18" SD_2="0.17" SE="0.018661856633297103" STUDY_ID="STD-Wulffel_x00e9_-2002" TOTAL_1="171" TOTAL_2="182" WEIGHT="28.00319511401001"/>
<CONT_DATA CI_END="0.12051602120888742" CI_START="-0.14051602120888743" EFFECT_SIZE="-0.01" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.01" MODIFIED="2010-03-09 11:51:49 +0100" MODIFIED_BY="[Empty name]" ORDER="106" SD_1="0.25" SD_2="0.12" SE="0.0665910303650379" STUDY_ID="STD-Yilmaz-2007" TOTAL_1="17" TOTAL_2="19" WEIGHT="10.091969423851772"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.544827293378341" CI_END="0.2528725475544333" CI_START="-0.24597594213556065" DF="1" EFFECT_SIZE="0.003448302709436317" ESTIMABLE="YES" I2="71.78988093812136" ID="CMP-002.07.02" MODIFIED="2012-06-04 12:22:42 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.05973153125733088" P_Z="0.9783826861703823" STUDIES="2" TAU2="0.024264979757085036" TOTAL_1="32" TOTAL_2="32" WEIGHT="17.564845678641053" Z="0.027096600502838544">
<NAME>Cross-over trials</NAME>
<CONT_DATA CI_END="0.4112920075839345" CI_START="-0.09129200758393458" EFFECT_SIZE="0.15999999999999998" ESTIMABLE="YES" MEAN_1="-0.05" MEAN_2="-0.21" MODIFIED="2012-06-04 12:22:42 +0200" MODIFIED_BY="Bernd Richter" ORDER="76" SD_1="0.29" SD_2="0.36" SE="0.12821256388693558" STUDY_ID="STD-Fritsche-2000" TOTAL_1="13" TOTAL_2="13" WEIGHT="3.505313295434062"/>
<CONT_DATA CI_END="5.440309502328655E-4" CI_START="-0.20054403095023288" EFFECT_SIZE="-0.1" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.1" MODIFIED="2012-06-04 12:22:42 +0200" MODIFIED_BY="Bernd Richter" ORDER="79" SD_1="0.1" SD_2="0.2" SE="0.051298917604257706" STUDY_ID="STD-Robinson-1998" TOTAL_1="19" TOTAL_2="19" WEIGHT="14.059532383206992"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="20.750175334232008" CI_END="0.0763620074612217" CI_START="-0.04794796813609886" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_SIZE="0.014207019662561413" ESTIMABLE="YES" I2="66.26534529348314" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-1.1171226630720918" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-1.8474970184734831" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="8" P_CHI2="0.004158054441194992" P_Q="0.74661966996438" P_Z="0.654155377030651" Q="0.1043935002187563" RANDOM="YES" SCALE="1.39" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.004577830263465411" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="0.4479969806521779">
<NAME>HDL-cholesterol (change from baseline) [mmol/L]</NAME>
<GROUP_LABEL_1>Insulin+Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin mono</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Insulin+Metformin</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="7.662870058528621" CI_END="0.04615270139246083" CI_START="-0.05025826217526083" DF="5" EFFECT_SIZE="-0.0020527803913999968" ESTIMABLE="YES" I2="34.75029640578206" ID="CMP-002.08.01" LOG_CI_END="-1.3358028739337597" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="1" P_CHI2="0.1758204805037502" P_Z="0.9334833715404693" STUDIES="6" TAU2="0.0011825141635782672" TOTAL_1="0" TOTAL_2="0" WEIGHT="76.63033349675776" Z="0.08346303130738658">
<NAME>Parallel-group</NAME>
<IV_DATA CI_END="0.2949787633521239" CI_START="-0.2749787633521239" EFFECT_SIZE="0.01" ESTIMABLE="YES" ESTIMATE="0.01" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:33:33 +0100" MODIFIED_BY="[Empty name]" ORDER="179" SE="0.1454" STUDY_ID="STD-Avil_x00e9_s-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.9102261430199605"/>
<IV_DATA CI_END="0.22270211278989885" CI_START="0.017297887210101143" EFFECT_SIZE="0.12" ESTIMABLE="YES" ESTIMATE="0.12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:33:50 +0100" MODIFIED_BY="[Empty name]" ORDER="180" SE="0.0524" STUDY_ID="STD-Giugliano-1993" TOTAL_1="0" TOTAL_2="0" WEIGHT="13.73193535989703"/>
<IV_DATA CI_END="0.0396937454322074" CI_START="-0.20569374543220742" EFFECT_SIZE="-0.083" ESTIMABLE="YES" ESTIMATE="-0.083" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:34:14 +0100" MODIFIED_BY="[Empty name]" ORDER="181" SE="0.0626" STUDY_ID="STD-Relimpio-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="11.836167801654247"/>
<IV_DATA CI_END="0.05486644053058434" CI_START="-0.11486644053058434" EFFECT_SIZE="-0.03" ESTIMABLE="YES" ESTIMATE="-0.03" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:39:40 +0100" MODIFIED_BY="[Empty name]" ORDER="182" SE="0.0433" STUDY_ID="STD-Strowig-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.585220495250338"/>
<IV_DATA CI_END="0.026651326510899014" CI_START="-0.04665132651089902" EFFECT_SIZE="-0.01" ESTIMABLE="YES" ESTIMATE="-0.01" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:35:05 +0100" MODIFIED_BY="[Empty name]" ORDER="183" SE="0.0187" STUDY_ID="STD-Wulffel_x00e9_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="20.40926525374688"/>
<IV_DATA CI_END="0.12053360137036763" CI_START="-0.14053360137036763" EFFECT_SIZE="-0.01" ESTIMABLE="YES" ESTIMATE="-0.01" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:35:21 +0100" MODIFIED_BY="[Empty name]" ORDER="184" SE="0.0666" STUDY_ID="STD-Yilmaz-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="11.157518443189307"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="8.191011235955058" CI_END="0.30643844923723035" CI_START="-0.22199400479278592" DF="1" EFFECT_SIZE="0.04222222222222221" ESTIMABLE="YES" I2="87.79149519890261" ID="CMP-002.08.02" LOG_CI_END="-0.5136567441179574" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.3744589128225149" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="0.00420987852095378" P_Z="0.7541243697511542" STUDIES="2" TAU2="0.03199999999999999" TOTAL_1="0" TOTAL_2="0" WEIGHT="23.369666503242247" Z="0.31320572486299875">
<NAME>Cross-over group</NAME>
<IV_DATA CI_END="0.26799819922700274" CI_START="0.0720018007729973" EFFECT_SIZE="0.17" ESTIMABLE="YES" ESTIMATE="0.17" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:32:38 +0100" MODIFIED_BY="[Empty name]" ORDER="185" SE="0.05" STUDY_ID="STD-Fritsche-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="14.20874256046925"/>
<IV_DATA CI_END="0.05679711876320434" CI_START="-0.2567971187632043" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:32:48 +0100" MODIFIED_BY="[Empty name]" ORDER="186" SE="0.08" STUDY_ID="STD-Robinson-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.160923942772996"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="5.939442904329432" CI_END="0.036286080318235506" CI_START="-0.22099871180901437" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09235631574538943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.09" MODIFIED="2015-12-04 15:03:17 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.5468379269845327" P_Q="0.5853613417309795" P_Z="0.15939235181058614" Q="0.2976470936267553" RANDOM="YES" SCALE="3.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="319" TOTAL_2="332" UNITS="mmol/L" WEIGHT="100.00000000000001" Z="1.4071181674527038">
<NAME>Triglycerides (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin+Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+Metformin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.477698245050538" CI_END="0.1054063183448825" CI_START="-0.23655659700503545" DF="5" EFFECT_SIZE="-0.06557513933007648" ESTIMABLE="YES" I2="0.0" ID="CMP-002.09.01" MODIFIED="2014-10-17 10:41:02 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4828729147039712" P_Z="0.452238006008847" STUDIES="6" TAU2="0.0" TOTAL_1="287" TOTAL_2="300" WEIGHT="56.60700930132862" Z="0.75168917797201">
<NAME>Parallel-group trials</NAME>
<CONT_DATA CI_END="1.614721261398055" CI_START="-0.874721261398055" EFFECT_SIZE="0.37" ESTIMABLE="YES" MEAN_1="-0.07" MEAN_2="-0.44" MODIFIED="2009-12-08 12:04:41 +0100" MODIFIED_BY="[Empty name]" ORDER="93" SD_1="1.25" SD_2="2.69" SE="0.6350735376855173" STUDY_ID="STD-Avil_x00e9_s-1999" TOTAL_1="21" TOTAL_2="22" WEIGHT="1.0681297841823894"/>
<CONT_DATA CI_END="0.11989727255403015" CI_START="-0.6398972725540302" EFFECT_SIZE="-0.26" ESTIMABLE="YES" MEAN_1="-0.31" MEAN_2="-0.05" MODIFIED="2009-12-08 12:08:53 +0100" MODIFIED_BY="[Empty name]" ORDER="95" SD_1="0.72" SD_2="0.65" SE="0.19382870070603916" STUDY_ID="STD-Giugliano-1993" TOTAL_1="27" TOTAL_2="23" WEIGHT="11.466632397965348"/>
<CONT_DATA CI_END="0.27766330420934665" CI_START="-0.8376633042093466" EFFECT_SIZE="-0.27999999999999997" ESTIMABLE="YES" MEAN_1="-0.36" MEAN_2="-0.08" MODIFIED="2010-04-06 11:54:16 +0200" MODIFIED_BY="[Empty name]" ORDER="96" SD_1="0.7" SD_2="1.18" SE="0.2845273222406756" STUDY_ID="STD-Relimpio-1998" TOTAL_1="24" TOTAL_2="23" WEIGHT="5.321377950974423"/>
<CONT_DATA CI_END="1.1388038013198285" CI_START="-0.49880380131982843" EFFECT_SIZE="0.32" ESTIMABLE="YES" MEAN_1="0.07" MEAN_2="-0.25" MODIFIED="2010-04-06 11:54:15 +0200" MODIFIED_BY="[Empty name]" ORDER="98" SD_1="1.43" SD_2="1.75" SE="0.41776471801443715" STUDY_ID="STD-Strowig-2002" TOTAL_1="27" TOTAL_2="31" WEIGHT="2.4683602309856134"/>
<CONT_DATA CI_END="0.1788747276929017" CI_START="-0.2588747276929017" EFFECT_SIZE="-0.04" ESTIMABLE="YES" MEAN_1="-0.02" MEAN_2="0.02" MODIFIED="2010-04-06 11:54:15 +0200" MODIFIED_BY="[Empty name]" ORDER="99" SD_1="0.87" SD_2="1.21" SE="0.11167283144963765" STUDY_ID="STD-Wulffel_x00e9_-2002" TOTAL_1="171" TOTAL_2="182" WEIGHT="34.54434827421029"/>
<CONT_DATA CI_END="1.5257513527443014" CI_START="-0.4257513527443012" EFFECT_SIZE="0.55" ESTIMABLE="YES" MEAN_1="-0.19" MEAN_2="-0.74" MODIFIED="2010-03-09 11:53:29 +0100" MODIFIED_BY="[Empty name]" ORDER="107" SD_1="0.75" SD_2="2.02" SE="0.4978414707825773" STUDY_ID="STD-Yilmaz-2007" TOTAL_1="17" TOTAL_2="19" WEIGHT="1.7381606630105466"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2445556376869285" CI_END="0.1611494319828336" CI_START="-0.4993292565442373" DF="1" EFFECT_SIZE="-0.16908991228070186" ESTIMABLE="YES" I2="19.65003654970764" ID="CMP-002.09.02" MODIFIED="2012-06-04 12:23:50 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.2645949596449152" P_Z="0.31559785037667065" STUDIES="2" TAU2="0.02263684210526324" TOTAL_1="32" TOTAL_2="32" WEIGHT="43.3929906986714" Z="1.0035452891244323">
<NAME>Cross-over trials</NAME>
<CONT_DATA CI_END="0.23897418157912298" CI_START="-1.3989741815791232" EFFECT_SIZE="-0.5800000000000001" ESTIMABLE="YES" MEAN_1="-0.52" MEAN_2="0.06" MODIFIED="2012-06-04 12:23:50 +0200" MODIFIED_BY="Bernd Richter" ORDER="94" SD_1="1.23" SD_2="0.87" SE="0.41785164831552357" STUDY_ID="STD-Fritsche-2000" TOTAL_1="13" TOTAL_2="13" WEIGHT="2.4673332972463413"/>
<CONT_DATA CI_END="0.10108806190046576" CI_START="-0.3010880619004657" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="1.0" MODIFIED="2012-06-04 12:23:50 +0200" MODIFIED_BY="Bernd Richter" ORDER="97" SD_1="0.2" SD_2="0.4" SE="0.10259783520851541" STUDY_ID="STD-Robinson-1998" TOTAL_1="19" TOTAL_2="19" WEIGHT="40.925657401425056"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="27.583176665537337" CI_END="0.11128781310930008" CI_START="-0.40632411408929786" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_SIZE="-0.1475181504899989" ESTIMABLE="YES" I2="74.62221235472903" I2_Q="21.609137270373484" ID="CMP-002.10" LOG_CI_END="-0.9535523917225069" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="10" P_CHI2="2.615995970810525E-4" P_Q="0.25870786035799265" P_Z="0.2639216570864853" Q="1.275658878062158" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.07867898232609351" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="99.99999999999999" Z="1.117170014188733">
<NAME>Triglyceride (change from baseline) [mmol/L] GIV</NAME>
<GROUP_LABEL_1>Insulin+Metformin</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+Metformin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="4.478151474836549" CI_END="0.10540184124975872" CI_START="-0.23659913826217877" DF="5" EFFECT_SIZE="-0.06559864850621001" ESTIMABLE="YES" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="-0.9771518024287327" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="1" P_CHI2="0.48281205174927977" P_Z="0.4521262563681413" STUDIES="6" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="60.895294824200604" Z="0.751874972347476">
<NAME>Parallel-group</NAME>
<IV_DATA CI_END="1.6147731265813885" CI_START="-0.8747731265813884" EFFECT_SIZE="0.37" ESTIMABLE="YES" ESTIMATE="0.37" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:43:43 +0100" MODIFIED_BY="[Empty name]" ORDER="187" SE="0.6351" STUDY_ID="STD-Avil_x00e9_s-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="3.6172407490694396"/>
<IV_DATA CI_END="0.1198410202038625" CI_START="-0.6398410202038625" EFFECT_SIZE="-0.26" ESTIMABLE="YES" ESTIMATE="-0.26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:44:01 +0100" MODIFIED_BY="[Empty name]" ORDER="188" SE="0.1938" STUDY_ID="STD-Giugliano-1993" TOTAL_1="0" TOTAL_2="0" WEIGHT="15.000523178023943"/>
<IV_DATA CI_END="0.2776097536016454" CI_START="-0.8376097536016455" EFFECT_SIZE="-0.28" ESTIMABLE="YES" ESTIMATE="-0.28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:44:20 +0100" MODIFIED_BY="[Empty name]" ORDER="189" SE="0.2845" STUDY_ID="STD-Relimpio-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="10.923634466517152"/>
<IV_DATA CI_END="1.1388729527408348" CI_START="-0.4988729527408347" EFFECT_SIZE="0.32" ESTIMABLE="YES" ESTIMATE="0.32" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:44:40 +0100" MODIFIED_BY="[Empty name]" ORDER="190" SE="0.4178" STUDY_ID="STD-Strowig-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="6.885369264665287"/>
<IV_DATA CI_END="0.17892797707312405" CI_START="-0.25892797707312404" EFFECT_SIZE="-0.04" ESTIMABLE="YES" ESTIMATE="-0.04" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:45:00 +0100" MODIFIED_BY="[Empty name]" ORDER="191" SE="0.1117" STUDY_ID="STD-Wulffel_x00e9_-2002" TOTAL_1="0" TOTAL_2="0" WEIGHT="19.127919060648484"/>
<IV_DATA CI_END="1.525670071504039" CI_START="-0.425670071504039" EFFECT_SIZE="0.55" ESTIMABLE="YES" ESTIMATE="0.55" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:45:20 +0100" MODIFIED_BY="[Empty name]" ORDER="192" SE="0.4978" STUDY_ID="STD-Yilmaz-2007" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.340608105276304"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="9.706422018348626" CI_END="0.10702275607983064" CI_START="-0.7931097126015698" DF="1" EFFECT_SIZE="-0.3430434782608696" ESTIMABLE="YES" I2="89.69754253308129" ID="CMP-002.10.02" LOG_CI_END="-0.9705238691452633" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="2" P_CHI2="0.001836275169592172" P_Z="0.1352023886346023" STUDIES="2" TAU2="0.09489999999999997" TOTAL_1="0" TOTAL_2="0" WEIGHT="39.10470517579938" Z="1.4938975893350004">
<NAME>Cross-over group</NAME>
<IV_DATA CI_END="-0.42280252108219624" CI_START="-0.6971974789178039" EFFECT_SIZE="-0.56" ESTIMABLE="YES" ESTIMATE="-0.56" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:43:08 +0100" MODIFIED_BY="[Empty name]" ORDER="193" SE="0.07" STUDY_ID="STD-Fritsche-2000" TOTAL_1="0" TOTAL_2="0" WEIGHT="20.861969112681596"/>
<IV_DATA CI_END="0.15479531799020704" CI_START="-0.354795317990207" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-15 17:43:19 +0100" MODIFIED_BY="[Empty name]" ORDER="194" SE="0.13" STUDY_ID="STD-Robinson-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="18.24273606311779"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2016-07-14 11:26:06 +0200" MODIFIED_BY="Bernd Richter" NO="3">
<NAME>Insulin monotherapy versus insulin plus pioglitazone</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2016-05-02 13:16:06 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="473" TOTAL_2="312" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>HbA1c (change from baseline)</NAME>
<GROUP_LABEL_1>Pioglitazone + insulin</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [PIO + insulin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [insulin mono]</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-0.69" MEAN_2="-0.08" MODIFIED="2016-04-07 15:45:22 +0200" MODIFIED_BY="[Empty name]" ORDER="171" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Mattoo-2005" TOTAL_1="128" TOTAL_2="135" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-0.5" MEAN_2="-0.6" MODIFIED="2016-04-07 15:43:42 +0200" MODIFIED_BY="[Empty name]" ORDER="170" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Mudaliar-2010" TOTAL_1="12" TOTAL_2="13" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="-1.0" MEAN_2="0.0" MODIFIED="2016-04-07 15:42:39 +0200" MODIFIED_BY="[Empty name]" ORDER="172" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Rosenstock-2002" TOTAL_1="333" TOTAL_2="164" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="51.51981918840383" CI_END="3.464628296788184" CI_START="-3.607260037999722" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.07131587060576913" ESTIMABLE="YES" I2="96.11799879831456" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2016-07-14 11:26:06 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="6.4962479839891785E-12" P_Q="1.0" P_Z="0.9684676857249576" Q="0.0" RANDOM="YES" SCALE="15.13" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="9.222371450911119" TOTALS="YES" TOTAL_1="312" TOTAL_2="312" UNITS="mmol/L" WEIGHT="100.0" Z="0.03953018806189005">
<NAME>Fasting glucose (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin + pioglitazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+pioglitazone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.0661811780024888" CI_START="-3.193818821997511" EFFECT_SIZE="-2.13" ESTIMABLE="YES" MEAN_1="-1.45" MEAN_2="0.68" MODIFIED="2012-12-30 12:20:46 +0100" MODIFIED_BY="[Empty name]" ORDER="65" SD_1="3.96" SD_2="4.82" SE="0.5427746787128632" STUDY_ID="STD-Mattoo-2005" TOTAL_1="128" TOTAL_2="135" WEIGHT="34.19917666049421"/>
<CONT_DATA CI_END="1.2703145075608915" CI_START="-3.0503145075608917" EFFECT_SIZE="-0.89" ESTIMABLE="YES" MEAN_1="-1.5" MEAN_2="-0.61" MODIFIED="2011-11-22 17:13:15 +0100" MODIFIED_BY="Marielle JP van Avendonk" ORDER="121" SD_1="2.7" SD_2="2.81" SE="1.1022215329471239" STUDY_ID="STD-Mudaliar-2010" TOTAL_1="12" TOTAL_2="13" WEIGHT="31.18372250428688"/>
<CONT_DATA CI_END="3.5308678374407605" CI_START="1.8691321625592399" EFFECT_SIZE="2.7" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="0.0" MODIFIED="2016-04-07 15:41:17 +0200" MODIFIED_BY="[Empty name]" ORDER="67" SD_1="3.93" SD_2="3.84" SE="0.4239199515881617" STUDY_ID="STD-Rosenstock-2002" TOTAL_1="172" TOTAL_2="164" WEIGHT="34.617100835218906"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.22059980767045764" CI_END="4.596425426228262" CI_START="2.9745810084532054" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="3.7855032173407333" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2016-04-07 15:42:07 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.638583291768436" P_Q="1.0" P_Z="5.725173550973623E-20" Q="0.0" RANDOM="YES" SCALE="16.39" SORT_BY="WEIGHT" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="140" TOTAL_2="148" UNITS="kg" WEIGHT="100.00000000000001" Z="9.149397917621208">
<NAME>Weight (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin+ pioglitazone</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+pioglita</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.774345588256999" CI_START="0.6256544117430018" EFFECT_SIZE="3.2" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="1.7" MODIFIED="2011-11-08 15:48:23 +0100" MODIFIED_BY="Marielle JP van Avendonk" ORDER="122" SD_1="4.5" SD_2="0.7" SE="1.3134657619033347" STUDY_ID="STD-Mudaliar-2010" TOTAL_1="12" TOTAL_2="13" WEIGHT="9.922581947579479"/>
<CONT_DATA CI_END="4.704419654618172" CI_START="2.9955803453818275" EFFECT_SIZE="3.8499999999999996" ESTIMABLE="YES" MEAN_1="4.05" MEAN_2="0.2" MODIFIED="2010-04-06 18:19:18 +0200" MODIFIED_BY="[Empty name]" ORDER="113" SD_1="4.03" SD_2="2.92" SE="0.43593640564710645" STUDY_ID="STD-Mattoo-2005" TOTAL_1="128" TOTAL_2="135" WEIGHT="90.07741805242054"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-12-04 15:09:29 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Insulin monotherapy versus insulin plus alpha-glucosidase inhibitor</NAME>
<CONT_OUTCOME CHI2="0.07857592297020767" CI_END="0.3244810125860533" CI_START="-1.2217605285724515" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.44863975799319916" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2015-12-04 15:06:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7792366408495012" P_Q="1.0" P_Z="0.2553872309424454" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="123" UNITS="kg" WEIGHT="99.99999999999999" Z="1.1373614591166874">
<NAME>Weight (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin + acarbose</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+acarbose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.44461672219781906" CI_START="-1.244616722197819" EFFECT_SIZE="-0.39999999999999997" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="0.7" MODIFIED="2010-02-25 12:14:14 +0100" MODIFIED_BY="Marielle van Avendonk" ORDER="96" SD_1="3.1" SD_2="3.1" SE="0.43093481760891933" STUDY_ID="STD-Coniff-1995" TOTAL_1="103" TOTAL_2="104" WEIGHT="83.78674733560027"/>
<CONT_DATA CI_END="1.2200487951109977" CI_START="-2.620048795110998" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="3.6" MODIFIED="2010-02-25 12:16:00 +0100" MODIFIED_BY="Marielle van Avendonk" ORDER="97" SD_1="2.7" SD_2="3.0" SE="0.9796347332175988" STUDY_ID="STD-Yilmaz-2007" TOTAL_1="15" TOTAL_2="19" WEIGHT="16.213252664399718"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.305449198002156" CI_END="-0.23628917797261056" CI_START="-0.5442781283947895" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.39028365318370006" ESTIMABLE="YES" I2="13.249010139405824" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2015-12-04 15:08:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3157756375791282" P_Q="1.0" P_Z="6.787982122746405E-7" Q="0.0" RANDOM="YES" SCALE="2.12" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.002969662907432714" TOTALS="YES" TOTAL_1="225" TOTAL_2="223" UNITS="%" WEIGHT="99.99999999999997" Z="4.967333425086981">
<NAME>HbA1c (change from baseline)</NAME>
<GROUP_LABEL_1>Insuline + &#945;-glucosidase</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+&#945;-glucos.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.17794994147579268" CI_START="-0.6220500585242071" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-0.57" MEAN_2="-0.17" MODIFIED="2010-02-25 11:56:43 +0100" MODIFIED_BY="Marielle van Avendonk" ORDER="92" SD_1="0.81" SD_2="0.82" SE="0.11329292796995748" STUDY_ID="STD-Coniff-1995" TOTAL_1="103" TOTAL_2="104" WEIGHT="39.058985595946936"/>
<CONT_DATA CI_END="-0.24074380010001314" CI_START="-0.5792561998999868" EFFECT_SIZE="-0.41" ESTIMABLE="YES" MEAN_1="-0.37" MEAN_2="0.04" MODIFIED="2011-11-08 15:56:41 +0100" MODIFIED_BY="Marielle JP van Avendonk" ORDER="123" SD_1="0.68" SD_2="0.56" SE="0.08635679085690254" STUDY_ID="STD-Nemoto-2011" TOTAL_1="107" TOTAL_2="100" WEIGHT="59.20360250771182"/>
<CONT_DATA CI_END="1.663405810405917" CI_START="-0.6634058104059167" EFFECT_SIZE="0.5000000000000001" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="-1.1" MODIFIED="2015-11-18 14:30:41 +0100" MODIFIED_BY="Bernd Richter" ORDER="93" SD_1="1.91" SD_2="1.44" SE="0.5935853003334313" STUDY_ID="STD-Yilmaz-2007" TOTAL_1="15" TOTAL_2="19" WEIGHT="1.7374118963412208"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5152195581844969" CI_END="1.3889316156794056" CI_START="-0.7356586253815647" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3266364951489204" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2015-12-04 15:09:29 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.47288810049669483" P_Q="1.0" P_Z="0.5467392911437927" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="63" UNITS="mmol/L" WEIGHT="100.0" Z="0.6026534003173972">
<NAME>Fasting glucose (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin + acarbose</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+acarbose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.387068214371402" CI_START="-1.387068214371402" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.1" MODIFIED="2010-02-25 12:03:31 +0100" MODIFIED_BY="Marielle van Avendonk" ORDER="94" SD_1="2.96" SD_2="3.32" SE="0.7077008686447399" STUDY_ID="STD-Chiasson-1994" TOTAL_1="35" TOTAL_2="44" WEIGHT="58.65360820899742"/>
<CONT_DATA CI_END="2.4420621405664793" CI_START="-0.8620621405664792" EFFECT_SIZE="0.79" ESTIMABLE="YES" MEAN_1="-1.48" MEAN_2="-2.27" MODIFIED="2010-03-09 14:18:42 +0100" MODIFIED_BY="[Empty name]" ORDER="95" SD_1="3.05" SD_2="1.31" SE="0.8429043357927669" STUDY_ID="STD-Yilmaz-2007" TOTAL_1="15" TOTAL_2="19" WEIGHT="41.34639179100259"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2016-05-19 13:11:23 +0200" MODIFIED_BY="Bernd Richter" NO="5">
<NAME>Insulin monotherapy versus insulin plus DPP-4 inhibitor</NAME>
<CONT_OUTCOME CHI2="1481.4298261574124" CI_END="1.9001926037570496" CI_START="-2.9997172690250142" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5497623326339822" ESTIMABLE="YES" I2="99.93249764637223" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2016-05-19 13:00:40 +0200" MODIFIED_BY="Bernd Richter" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.6600748168350242" Q="0.0" RANDOM="YES" SCALE="3.61" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="3.1228905514491316" TOTALS="YES" TOTAL_1="175" TOTAL_2="187" UNITS="kg" WEIGHT="99.99999999999999" Z="0.43980987405694666">
<NAME>Weight (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin + DPP-4 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Insulin+DPP-4</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7762947327381223" CI_START="0.6237052672618778" EFFECT_SIZE="0.7000000000000001" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="0.6" MODIFIED="2015-01-12 17:42:31 +0100" MODIFIED_BY="[Empty name]" ORDER="115" SD_1="0.3" SD_2="0.3" SE="0.03892659933545993" STUDY_ID="STD-Fonseca-2007" TOTAL_1="114" TOTAL_2="124" WEIGHT="50.0095066946407"/>
<CONT_DATA CI_END="-1.698089091646276" CI_START="-1.901910908353724" EFFECT_SIZE="-1.8" ESTIMABLE="YES" MEAN_1="-0.7" MEAN_2="1.1" MODIFIED="2014-12-01 13:00:50 +0100" MODIFIED_BY="[Empty name]" ORDER="210" SD_1="0.1" SD_2="0.4" SE="0.0519963168494851" STUDY_ID="STD-Hong-2012" TOTAL_1="61" TOTAL_2="63" WEIGHT="49.99049330535929"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.058312594444433805" CI_END="-0.35477245213413855" CI_START="-0.46294208261079484" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4088572673724667" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2016-05-19 13:11:08 +0200" MODIFIED_BY="Bernd Richter" NO="2" P_CHI2="0.8091831113989518" P_Q="1.0" P_Z="1.146698295568879E-49" Q="0.0" RANDOM="YES" SCALE="1.93" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="109" UNITS="" WEIGHT="100.0" Z="14.816460319524412">
<NAME>HbA1c (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin + DPP-4 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+DPP-4</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.05001248605586889" CI_START="-0.6899875139441312" EFFECT_SIZE="-0.37" ESTIMABLE="YES" MEAN_1="-0.65" MEAN_2="-0.28" MODIFIED="2015-01-10 18:33:25 +0100" MODIFIED_BY="[Empty name]" ORDER="212" SD_1="0.9089" SD_2="0.9089" SE="0.16326193566216102" STUDY_ID="STD-Barnett-2013" TOTAL_1="95" TOTAL_2="46" WEIGHT="2.85683156883314"/>
<CONT_DATA CI_END="-0.35512567156899" CI_START="-0.46487432843101006" EFFECT_SIZE="-0.41000000000000003" ESTIMABLE="YES" MEAN_1="-0.63" MEAN_2="-0.22" MODIFIED="2015-01-10 18:32:38 +0100" MODIFIED_BY="[Empty name]" ORDER="209" SD_1="0.19" SD_2="0.11" SE="0.027997620805204442" STUDY_ID="STD-Hong-2012" TOTAL_1="61" TOTAL_2="63" WEIGHT="97.14316843116686"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.03" MODIFIED="2016-05-19 13:11:23 +0200" MODIFIED_BY="Bernd Richter" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.78" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="114" TOTAL_2="124" UNITS="mmol/L" WEIGHT="0.0" Z="0.0">
<NAME>Fasting glucose (change from baseline)</NAME>
<GROUP_LABEL_1>Insulin + DPP-4 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Insulin mono</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours insulin+DPP-4</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours insulin mono</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3799777887372352" CI_START="-1.5799777887372355" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.2" MODIFIED="2014-12-08 15:46:20 +0100" MODIFIED_BY="[Empty name]" ORDER="113" SD_1="3.2031" SD_2="4.4542" SE="0.499997855301003" STUDY_ID="STD-Fonseca-2007" TOTAL_1="114" TOTAL_2="124" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-09-07 10:11:11 +0200" MODIFIED_BY="Gudrun Paletta">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-09-07 10:11:11 +0200" MODIFIED_BY="Gudrun Paletta" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8kAAATUCAYAAABbI0VSAACAAElEQVR42uzdD4QW3////zdJkiSS
lWTFSpIkVpIkkSRrJZKsZL1IkpXkkyRJIkmSRJKsJJIkWUuSrKwlSZK1JEmSWCsrK/PzON/fc5yd
nT9n5rqu/Xu/calrdmau+T/zmHPmzP8iz//+9z8+fPjw4cOHT+BnumGd8OHDhw8fzpV1OJ/6J1YA
AFAulDItAADMrvPT/zixAgAws0/+nMcBAJwr6zq9nFgBAJipJ3/O4wAAzpWEZAAAOPETkgEAnCsJ
yQAAcOInJAMAOFcSkgEA4MRPSAYAcK4kJAMAwImfkAwA4FxJSAYAgBM/IRkAwLmSkAwAACd+QjIA
gHMlIRkAAE78hGQAAOdKQjIw0fDwMNPKNsBCACd+QjLHAnBtAZYX58rpG5IPHDiQOWO9vb3R1q1b
o4ULF7rPzp07oxcvXgSNt+yw//79izZu3Jg5LU+ePIm2bNkSj0/jfv78+azf4Oqx0YWOp16/l+XM
mTPRokWLcn+zr68v3m7mz58frV27tu7TFTK+kGmda9tRPcaZtlyncj4w/Y4TnPjDflvHym3btkUL
FiyIFi9eHB0+fDgaGhqatttJ8vt0PsbO9m2cawuuLWbKfjKblhfnyhkWkru6ujI3ti9fvriTr/3d
/7x79y53vFWGPXfuXOa03L9/P3Vc+jx8+JAT2Qw5kaWNP9ltxYoV49bvkiVLpuREFjKthOT/Teq0
cGIkJBOS/5/+/n53oZ88H+p4+enTpxkRkqfzMZaQzLUF1xbTYz+ZTcuLc+UMCcm/f/+ODh48OO6A
kXT+/HnXfd++fdGvX79cdYddu3a5bgrXecoOqxN+3rSsWrUqDsQqcdZH/1e31atXcyKbIb9X5gSi
7WY6TAcnMkIyIZnlMt1+WzWz9LezZ8/G58Tr16+7bipRngk3U6bz9kZI5tqCawtCMuZoSF66dGm0
bNkyV105a2Pbu3ev6/727du426tXr1y37du35/54mWFHR0ejNWvWuOoUWdNid8zTVoiqzoTsYK9f
v3Z3DlVl23z79i3av39/XIVb///x40dqiFe1Nk2HltvJkyejkZGRcf2o9Fw3BWxcbW1tE6q+5U3L
+/fvXVUglcDrtzQdyeWhZXXq1KmoqanJTYtuEFy4cKHSQSbk90KXkQ2ncWr9WvW/Y8eOxcspWeKR
Nm1pNQWypj903YXOZ9r8ZE2r5kkXohqn1uOJEyfcuglZz2W2k5D1ODAwEG3atMlNi7aHu3fvVp7u
LKHLUI9E7NixI67Opu1UN8WKtoGQYf3h9ftWzVTTpf0zKWR8oftT6LaWVO/xl1lGadte0XGs7PZd
Zv8vs71y4i/+baupNTY2FndTUA69cRyyLZXZ90P6yzvW5x3jyhwzQ7bBMvsR1xZcW3Bt0bhri6Jp
rnV5ld3O0pZr1fN6PddHLef10GVQ9RgwK0OyFoRKk/NW0vLlyyechLUQ1U0HqTxlhtVGre43btzI
nJb29vYJVasfPXoUl1aHHMRbW1ujefPmRUeOHHHddTcxWf1Gn5aWlnEbmDZqTXOyP02T+f79ezzP
/kfd/A0xa1q0M/lVf/TRSTy5PGxZJT8qTShzIgv9vdBlZN3TltPx48frfiILna7Q+Sx7Itu9e3fm
fOat57LbSdF61IFPN7yyHkUoO91ZJ7GQZdjd3Z05HZ2dnbnLNWRYf3hdLPn9aLvzTz6h4wvZn0K3
tTT1HH/ZZZTc9kKOY2W37zL7f5ntlZBc/Nt241jB2Pz9+zfoxnHothS674f2VyUklz1mFm2DZfcj
ri24tuDaojHXFiHTXOvvlt3Oksu16nm93uujlvN66DKoegyYlSE55E6G3alO618n6Dyhw6pxL3VT
Vey8adGK1Iavk7/1o/GoW9GFqvWvjcq/oDh9+nS8MWkj+vPnT3To0CHX7fLly3F/R48edd1UPV2h
/9mzZ+67NlSj6VA33c3RuH7+/BlfyKcd4JLTYsOrCp0NrzuUyeVhy/XDhw/ue09Pj/uuHaDMOg79
vdBlZMNp/r9+/erm7dKlS/FzP2WqzYT0EzpdofNZtoqP7uLZfNpz/bqDF7qeQ7eTomnSza7k+DRt
Wcu0aLrThC5D1QbRd12E2jzbYxR+oxtp81Z22M2bN7sTjb/8VLJQdnwh+1PotpZ3HKzH+Msuo+S2
F3IcK7t9l93/Q7dXQnLxb9tyUxVrLW/dhFbIUzdtd3lCt6XQfT+0vyrH+rLHzKJtsJbjFNcWXFtw
bVH/a4sq0xz6u2W3s+RyrXper/f6qOW8HroMqh4D5mxIzuvur4Cy47RhVZK9cuVKd7dKd63yhlO/
VoXb/6jKQGhITjZmYi0b+s+n6HdsxzOqcqBunz9/zvwN60fVU4waKFM3PU9dNC124v748eO4qi5Z
DU+oRfLHjx8X7sxZ6yP090KXkQ3nj8+q/vk3Rep1IgudrtD5LHsis4OIX0MibT6T67nsdlI0TevW
rZvQGF7a/IVOd94Fdegy1AWnanwotFpr9WlBLE3osP7yU5W3rCqmReML2Z9Ct7U0jRh/6DLK2vby
jmNlt++y+3/o9kpILv7tp0+fTjgf2vIt2qdDt6XQfT+0vyrH+rLHzKJtsB7HKa4tuLbg2qL2a4ta
pjn0d8tuZyGNHobsK/VeH7Wc10OXQdVjACE5pXvoc8B5w3Z0dLjvDx48KBzuv//+c92vXr0aN1Jy
5cqVoCodRc85p338O8pZz0OnjcsXeiAvGt7vrirmfhWO5ubmcc99hy6D0N8LXUZld/Ra+6ll3aXN
Z9kTWZX5rMd2UnU9lt3Hq2ybulNqF5sh1bN8tQybtvxCxxeyP4Vua2nqOf5allHocazq9l3v7ZWQ
HPbbeuuDtiktV1U71M3mkPNz6LZU9jxR9jhU5lhfr2NmrfsR1xZcW3Bt0fhri7I3QGpdn2XOQWXO
6/VaH7Wc10OXQdVjwJwNybqrqu56zil5p0YLMk/IsFkrLe2EZY16+Xc2bIPzq9zU60Tmb8Q2LyHz
m7ZD+FXfqjRMltZdG66eJ7BndVTFotYTWdkDTL129HqfyPzpKrtcG30iq2U7STtB5Y2vkSeytGHt
feu6a6lqTyql0d3NkGmpZVibXz8YhI4vZH8K3dby1GP8tSyj0ONYo0Ny6PZKSK722yrVUv/r16/P
7S90Wyp7nqjHdlNmmwk5t9bzOMW1BdcWXFvU79qilmmuR0gO2c6qntfrvT5qOa+XvYYpewyYsyHZ
qpOoVWrz5s0b102ttOUJGbZMSNaGkKzinbbBlZk/3SUJeR2AvX5Kzz1ksQ2qatUKW17+8HbBk7Ue
VV1CD9RXWQahvxe6jCb7RBY6XVWWayNPZKHbiR34/IbvVK0oZD3a+Op1IgtdhvY8i173ZtS4Sci0
lB3Wr3JkVcB00Vt2fCH7U+i2VqTW8deyfEOPY40OyaHbKyG52m9bY5aqpVWPbSl03w/tr8qxvtZz
az2PU1xbcG3BtUX9ri1q2bZDf7fW7azqeb3e66OW83qVa5gyx4A5G5L1rI61HqcFpo+961jvQc5T
ddisabEH3u/cueM2JgXka9euxQ/GV5k/a8lNzzWrCpbGqercyddU6UF5/4H5ly9fxuO0km3/IX2N
K6tBoaxpsUYS9HyANUiU1lKiVYXQq7ukr68vqGQ/q1GGot8LXUZlD/B5r9oIOSCGTlfofOYts5DX
goQe0EK3EzU84TfKo4u4tEZBbP40juT46nUiC12GdvGp16vYBYNaYgzZBsoOa42laHrUiJe66bUH
ZccXsj+Fbmtp6jn+sssoKeQ41uiQHLq9EpKLf9ueH9OzY6JWTu0c69+czgvJRdtS6L4f2l+V80Gt
59Zaj1NcW3BtwbVFY64tym7bVZZXrdtZ1fN6vddHLef10GVQ9RgwZ0Oyf1fM/+gkoxWZN44yw4ZM
ixrZSKsyoG5akVXmTwe2tCbaNU6VehuVWvmtavvNpxeNS92sUbK8adGGmxxeJe7J/u3mQ/Kj1uvK
LIPQ3wtdRqEHLKs2r8baajmRhU5X6HymCZnWsiey0O3EDrD+RyEw7fUoZV7TUOVEFroM7WAd+uiE
v1xDh037/bTXKoSOL2R/Ct3W8m4W1mP8ZZdRUshxrNEhOXR7JSQX/7a1yZH8qJXTIqHbUui+H9pf
lfNBrefWqsepWkIy1xZcW3BtUbwcQqe5luVV63ZW7/N61fVRy3k9dBlUPQbM2ZAsukutu6xamPbC
dL22KWQcocOGTouCsu7UaVz66P9VGpbwKbDbC7Y1nbormHYXXkHc3k+mHVbDJF8Kru86SNr06dmn
wcHB4GlRv7qro2Ht7mSyf5XIq8l3HSw0LXrptzZgv6pG6DII+b3QZRR6wLp586b7Pf9d2VVOZGXW
Xeh8JoVMa9kTWeh2ouf3dfDU8/bqR8/OZT27qf1CpanaHlT1RrUtqj6vlyV029RrBdSP1oemyap/
Fm0DocPad7srq371b7Jlx9Dxhe5PodtaUj3HX3YZpSk6jjU6JIdur4TksN9WaYC1bqo3RVy4cCGo
RdLQbanM8TOkvyrng1rPrVWPU7WEZK4tuLbg2iLs2iJkmmtZXrVuZ7Wc1+u5Pmo5r5e5xqhyDJj1
IbkeFFbLvEsLQGOoSlLIOwoBtteZHZIBgGM1OFdO85C8YcOGoJIVAPVjz9ep9UHdfVRjNPZqNd01
BNheCckAwLUFOF9NUUgGMPk6OztTnyFRlRq1kAiwvRKSAYBrC3C+IiQDc4aeFVFr8WqkwZ7ZaW9v
5yQGtldCMgBwbQHOV4RkAAAIyQAAcL4iJAMAQEgGAIDzFSEZAABCMgAAhGRCMgAAhGQAAAjJhGQA
AAjJAABwriQkAwBASAYAgHMlIRkAAEIyAACcKwnJAAAQklkBAADOlYRkAAA48ROSAQCcKwnJAABw
4ickAwA4VxKSAQDgxE9IBgBwriQkAwDAiZ+QDADgXElIBgCAEz9BGQDAeZKQDAAAJ3+CMgCAcyQh
GQAALgBqmw4+fPjw4cNnOn1m6HmdkAwAwGwIyQDYpwEQkgEA4IIaAPs0gMkLycPDw9H58+ej9evX
RwsWLIgWLlwYtba2Rjdu3Eg9oJQpcrfvaeNK9lPrbyQ/8+fPjxYtWhRt3749evz4cea8z5s3L+5/
ZGSkcPpmujt37kRr1qxx89vS0hLdvHkzt/9///5FGzduDFoGBw4cyOyv7O8CABfUANinAUx6SH7/
/n20cuXKzKCpgDk6OlpzgFVYHRoamtSQnPw8ePBgwm/fv39/XD/d3d2zOiTfvXs3ddlcu3Ytc5hz
584FLYOurq7M/qr8LgBwQQ2AfRrApIbkP3/+RKtWrXIHiV27dkXv3r1zpYZjY2Mu1CxdutT9TSGp
amD0A9HmzZuDQnI9//7z5884vK1bt27C3/fu3ev+dvDgQfdvW1vbrA7JKsHVvFjJ+r1799z3FStW
pPbf399f+FD+79+/4+WX1V/Z3wUALqgBsE8DmPSQfOXKFXeA2LJlS+rfrZTVDzJVQ/KpU6fcv5cv
X57UkCwK/lad2qcScnXTRzcM7P9///6tHJJD+rV+VIqvknpVcV+8eHF07Nix1OreWTcd6tW6nIbR
NCRp+ah6tGoB5I1bN1OWLVsWPX/+vPSySvtdAOCCGgD7NIApCcnbtm1zB4inT59mhsve3t5xobFq
SNY41q5d60LRx48fJy0kf/v2zYVP/V3PXPtU/dovPW5vb0+tlt2okKxgnAy4x48fn9SQbNWgjxw5
MuFvJ06ciJ8nzxu3boCoNLnMssr7XQDgghoA+zSAKQnJaqDLAmzZ0Bsa0vxuAwMDrpGsDRs2uABe
75Bc9Hn27Nm44SwUq8RcrOR8//79lUNymWWomxRfv351y+LSpUuu25IlSyZtw9B86jf37Nkz7rlz
0c0Rq4ZfZhmE9Jf3uwDABTUA9mkAUxaSq4S/WkKyqBVtfde/kxGSdSNAJcVv374dN4yeu1bVaoV2
KwW1lq7VXX9vdEj2S9SzqoQ30uHDh+Nn0nXDwKp6a3moMTdVo1ZJfL1DctbvAgAX1ADYpwFMaUi2
6r5VSpKr9q8wqJJkhVGVLNczJPusOq9eXfT9+/cJwzx8+DA3XPuvjGpUSK6ybBvxTLK1Xq3wKh0d
HROqndczJGf9LgBwQQ2AfRrAlIbk3bt3p1ZD9inUvnjxom4hWVSCqhJTPaOsgN6oZ5L1vKs9i5y8
EWDv8836qLXmuRKSVWruN6JVy2+UmYbk7wIAF9QA2KcBTGlI1jtq7dnYNHouVS0b6zVJ9QzJolau
/VavGxGSrXVm/e3MmTPjwpmCmUqzf/z4MW4YvTJK3VVN256bnk4huVb2Wi/Np7EbFZrnRoXkkN8F
AC6oAbBPA5jSkKzXHun1TvZsqD0jqxCpRqysOrbCcr1DsrS2ttaldDLv7/aeX796t1rzVjc//Pvs
3cnW6vdsCslWuq5nwnUTQB/dQLBtoOo6KOqv6u8CABfUANinAUxaSJZ3797FjSilfTo7O1NDUGhJ
Y164+vz5c9zCdiPfk9zV1eX+btW7Dx06lPvqqydPnri/69nckHkuGyanMiR/+fIlLtX1P+qm9dGo
kFz1dwGAC2oA7NMAJjUki0qO7927517No9JjBVeV8ur9uFkhqB4hWa5fv97wkKwS8+bmZtfP//3f
/7l5bGpqGvcaKp+6L1u2zPVnrU7PlpAsqjGwc+dOV+Vc63rfvn3R4OBgpWku01+V3wUALqgBsE8D
mPSQDAAAuKAG2KcBEJIBAAAX1AD7NABCMgAA4IIaYJ8GQEgGAABcUAPs0+zTACEZAABwQQ2AfRoA
IRkAAC6oAbBPAyAkAwDABTUA9mkAhGQAALigBsA+DYCQDAAAF9QA2KcBEJIBAOCCGgD7NABCMgAA
XFADYJ8GUJeQvHz58mjfvn3R2bNno6GhodR+1F1/V3/q3z+whHzy+l+wYEG0YsWK6PDhw9HHjx9T
D14hB7Cs37px40bpYULnZ6a4c+dOtGbNmmj+/PlRS0tLdPPmzcJhDhw4UDiv//79izZu3JjZX19f
X7Rt2za3jhcvXuzWcdY2BgBcUANgnwYwLUKyH/4UjPICU62hsqg/hannz5/XNSQvWrQoM5jNhZB8
9+7d1Hm4du1a5jBdXV1B83ru3LnM/vr7+10oT/7ukiVLok+fPrFHAuCCGgD7NIDpHZLXrl3rAqVK
B336rlLA1atXZ4bKMgeiZP8a/+DgYNTR0eH+pt/69u1b3UKyPps3by41zGyikmPN0+PHj933e/fu
ue8qvU/6/ft3dPDgwaAbAgrBef3t3LnTdVcNBK1jfa5fv+66qUQZALigBsA+DWBah+STJ0+6f3t7
e8f9/eXLl6778ePHGxKSfXv27ImDVb1C8qlTp9y/ly9fbkhIDhnG+nn//n20ffv2uPrxsWPHopGR
kaBh61mybaX2SUuXLo2WLVvmSvPzxj06Ouqqb+umSlZ/Gr+6j42Njbshom664QIAXFADYJ8GMK1D
soXhEydOjPu7Vb198eJFw0Pymzdv3N+3bNlSt5D89+9fV0qu0JZ85nmyQ7KCcTLg6ubDZIZkq359
5MiRCX/TDQWVJhfNl7YRe947qz+rau3XTNC6ULeFCxeyRwLgghoA+zSA6R2SFWZUMpgs5VN1XQUe
KwUs+wxvmUBpv+GHqFpDsgwMDETz5s2LNmzYMC601To/ZYO0GrH6+vWrm4ZLly7Fz+hOlv3797vf
VIm9SoOrhH/VNFD3Xbt25fanGx3qrirWml/9XmdnZ2YpNgBwQQ2AfRrAtArJYg10WYmrGljS9/b2
9rqEytBSV4XyeoZkOX/+vPuuf6cqJPsl2XZDwJ/XRtOzwKtWrYrXaV5V77T5VSnzypUrXbVse248
a7k8ffp0wrJbt27dpM8zAHBBDYB9GkDlkNzd3T3u+V0r7bx9+3ZQEC0bZJOsOq5KtOsdkhVKVZKs
EmWVLNdjfmqd7zJVtesZ3K1V6rwGtNLGbY2rPXjwIGge7t+/HzU3N7tQvHv3bhesqW4NgAtqAOzT
AGZMSP7586f7/9atW913tQqt71mlhvUOyVaVV41b1Tski0pyFdj0jLIF8rkYktWYVlG157yaAFWn
Rctf/axfv549EgAX1ADYpwFM/5Asra2trrT1y5cvrrtKX8sE0VpCskob9feLFy82JCSLSsn9Vq+n
e0iulapG6zd0A8SENKDViJD86NEj149KpAGAC2oA7NMAZkRItmd39cyq/j1z5kxDQ7KqQevVSIcO
HXJ/U6j79etXw0Ky3QhIC3azMSSrFWt7FtveV6x16j9rXuWGRlF/eg+z/37moaEh19iXur169Yo9
EgAX1ADYpwHMjJDc39/vvqs0ORloqjR0VaZ/lWz29PSkTl/ouENC3ufPn91v1To/oWFyKkOyagRY
abL/UTcth0aF5CtXrqQuu4MHD7I3AuCCGgD7NICZE5Jl+fLlExrQalRI1jPCes3Uf//9lxraGhGS
Ra8mmgshWfQs8M6dO90zyLo5sG/fvmhwcLDSNJfp7+rVq+6VYvq7WsW+cOHCuFdwAQAX1ADYpwFM
u5AMAAC4oAbYpwEQkgEAABfUAPs0AEIyAADgghoA+zRASGYpAADABTUA9mkAhGQAALigBsA+DYCQ
DAAAF9QA2KcBEJIBAOCCGgD7NABCMgAAXFADYJ8GQEgGAIALagDs0wAIyQAAcEENgH0aACEZAAAu
qAGwTwOoa0hW95BPPQ5CHIhqc+fOnWjNmjXR/Pnzo5aWlujmzZu5/f/79y/auHFj5nIPGV+jtwsA
4IIaAPs0AEIySrt7927qerl27VrmMOfOnctc7qHjy9smlixZwooBwAU1APZpALMzJE/GQYgDUXUq
6dXye/z4sft+7949933FihWp/ff39+fe5Cg7Pt+DBw9cv7du3WLFAOCCGgD7NIC5HZKt/9+/f0e7
du2KFixYEO3fv99V7R0cHIw2bdrkqu9u27Yt+v79+4Thfvz44f6m4bZu3erCXNKTJ0+iHTt2RAsX
LnTjampqirq6uqKRkZG4n9HR0ejUqVPub+pn9erV0YULFyaM69u3b276NC599H9NQ5XlYP28f/8+
2r59u5uHxYsXR8eOHRs3bXnD1rO0XsNoGpK0bFSNetGiRaXGnTU+369fv6KlS5dG69evZ68CwAU1
APZpAIRk63/fvn0Tqula6aR92tvbJwyncOn3o5A5NDQU99fd3Z0ZIjs7O+P+Tpw4kdrP2bNnxwU6
lYwm+9F0JkNtmZCsaU6O8/jx45Makq269JEjRyb8zZbNjRs3gsedN760cT9//py9CgAX1ADYpwHM
3pAcGt78kPz379+46q1Kcw8dOhSNjY3F3VRymxxu8+bNriT358+fcWBWSaxRCai6KSyrdFqs6rBK
Ro1KPNXtw4cP7ntPT8+E6sKnT5+Ow7oC858/f9w0qtvly5crHUj1UUn4169f3fRdunRp0p/PVWm4
fnPPnj2u1NjX29vr/qZS/tDwnzc+n0rl582bF61du5Y9CgAX1ADYpwEQkv3+P3365L4rKFo3Bcdk
t+RwAwMDcTdVW1Y3VZVOUjB++PChC9DWQrMCmrES4gMHDrjnai1Q+xTm1I8CslE1cXXbsmVL5ZD8
8ePHuJvNq24STJbDhw9Hq1atim8AWKm45m3lypWuOrQCbWhIzhpfkkrp1c/169fZowBwQQ2AfRrA
7A7JZYNi2W5p/aQFTJUwWyjOC+yPHj2Kli9fHndvbm6O3r59O278Gm/WePxS6VrmPXQZNuKZZGu9
WiFXOjo63HeV5FdZv8nxJSmA60aFf9MBALigBsA+DYCQXOeQ7FfLVsmwuqkUWI11qTT58+fPmdOp
YGzPQutZ4WfPngWF5Colv9MtJKtqu9/YVq2/kRyfr6+vL36mHAC4oAbAPg2AkFynkGzVtEVVry0Q
G3vWeHh4OO725cuX3OlUNWOrCuwHPJUuJ6tb13ogrRqSa6Uq1PoNlbQbPRPu32QoE5JDxue7ePGi
+1taC+IAwAU1APZpAITkiiF5586dLrSq8S414qVuJ0+enBCS9Roo0fO/ra2tE8ZnVa2tlWUr6VR3
Yy0xq2EqhUGVXF+9erVyiehUhmS1Oq3fOH/+vJsPfc6cOTOhFfHQaSs7PnXT3/ySegDgghoA+zSA
WRuSQ0sgaw3JbW1t48arUOu/t9jCW9F0qEGvtL+rRWuj8frPLftVrd+8eVM66E5lSFZpupX++h91
U3X0stNcdnzWsJf/7msA4IIaAPs0AEJyjSHZXv2koKp/k4FMVaf1miaVKKsflTarka7k+NTf0aNH
XahTY1JNTU0uIOu52mQYVEmyqhBrfGrV+tWrV5WC7lSGZFGpukritWw0P3oN1+DgYKVpLjs+e747
rRVxAOCCGgD7NIBZE5IBAAAX1AD7NABCMgAA4IIaYJ8GQEgGAABcUANgnwYIySwFAAC4oAbAPg2A
kAwAABfUANinARCSAQDgghoA+zQAQjIAAFxQA2CfBkBIBgCAC2oA7NMACMkAAHBBDYB9GgAhGQAA
LqgBsE8DICQDAMAFNQD2aQANCcnDw8PR+fPno/Xr10cLFiyIFi5cGLW2tkY3btxIPaD440t+L3Ng
atTBKWsaiz6NmuZGziv+n4GBgWjnzp1u250/f360ZcuW6Pnz56nroer6B8AFNQD2aQBzICS/f/8+
WrlyZWZw2L59ezQ6OkpIJiRPWx8+fHDhOG2dPn36NGg7WLJkCQsSABfUAPs0gLkekv/8+ROtWrXK
HSR27doVvXv3Lvr37180NjYW3b17N1q6dKn727lz52ZU4CuaxsmeB0JyYx04cMAt3yNHjkQjIyPu
pk5HR4frtmHDhtxhHzx44Pq7desWCxIAF9QA+zSAuR6Sr1y54g4Qqpqa5v79++7vK1asyAx8Wd9V
Qq1SaFXfXrx4cXTs2DEXYPKCY39/f7Rt2zZXXXbZsmXRyZMnxw0jT548iXbs2BFXq21qaoq6uroK
x10lRL9+/dqVMNrySRuuyvQoxJ06dcr1q2FWr14dXbhwIWhlqlrxpk2b3HLVcLqZkTZdX758ifbt
2+emS5+2trZoaGgo/pv6X7duXepvrFmzxv39zZs3wSE/dL3nDVu1lH/RokWuH7/Gw9+/f103Ld8s
v379cjeC9JgBAHBBDbBPAyAku0CarJLqU6lyb2+vCxxlQ7ICUjLoHD9+PHM4Bbi0Ydrb2+N+uru7
M0NUZ2dn3UOynsueN2+eK6FMG67q9Jw4cSJ1mLNnz+auyG/fvsWl+3lB8vv379Hy5csn/F3dfvz4
4fpRzQF1U+hOhvBkCWyZkFy03hsRktNYSFZNiSy2HpLPLgMAF9QA+zSAORqS7TlOPwSHHFBCQrIC
+NevX13QvnTp0oTnPpPDHT161H0/ePCgq+797Nkz910h1VgJp8KpxisqfVY3lSbWOyQrHNvvpA1X
dXpUyqrvepZWenp6JpTYp1Hpsy1blYL+/PnTlXInx69QmuxPpbt+YLXlmwywFhxv375d+kQTst4n
y82bN91vq0G6rBsO2rbWrl3LEQIAF9QA+zQAQnJYWKwlJH/8+DHupsCUrPqaHE5Vh/X98+fPhdOg
IPrw4UNXlXfjxo0TwnS9QvKnT5+Chis7PQrD+q5naR8/fjwuiOdR9WgNp2fHjZX8pi1Lv5RYwyRL
VtVgm6q12+/rX5U2q7S6zI2TMut9Mmi9aR5UEyBrPlRqr2m7fv06RwgAXFAD7NMACMn/j1WNbURJ
ctnhFKSKDlYqEbUQmlclt14huah71el59OjRuOrQzc3N0du3bwuXfdoysiBatCzTAqueg/ar2794
8cJ917PgVU40Icssb9h6VLfWTRYtWy1Tq1qeRjcIdCNDJe0AwAU1wD4NgJDs7N692x0gVPU2i8KV
wlOjQ7ICS9HByloxVhVZNY6l0luFoqkKybVOj4JxS0tL/Cxv3nrIWkZpITmvP1X1Nnp2Wf3ac99q
EVrf1bDXTAzJfX19LiCrGrzmLa8/e70ZAHBBDbBPAyAkx65duxY/R5pGjXbp2dq9e/c2PCTbq6j0
PGsWe5Z3eHg47mYtNU9FSK7H9Pz+/Tuu+usH2DT2DHRaNWp//Ba8i6pbi1q9Vumyqknr3z179lQ+
0VQNyfVw9erV+FVmWqZ5Ll686PoNbVEcALigBtinAcyRkKz3JNvzsSpNtOdJ1XCWXv9k1bEVlhsd
ktVIlt9Y1suXL+N+7JlZC6V67ZJoevXc6VSH5LLTY1WtrVVlK9lU9zzWcJdKQFXV22+QK6vhrmR/
em7a5y9nfV69ejXjQrJVE9+8ebPbdotoWy+qQQEAXFAD7NMA5mBIFpUwWilu0auMGhmS1diStbbt
f1QqmgzS0+WZ5KrTo6Ca1v/p06dzf09ViENeAaVncbNeAaVWnZOsoS+VVFdZXlMdkvWe6jJVtW17
z6uSDQBcUAPs0wDmaEgWlb7du3cv2r9/vys9VlhVieiNGzdKh92qIVlUomrvJlY1b02P3p9sVI32
0KFDrgRXVYNVcqhGsKYqJFedHg2nV14p8Gpem5qaXEBOloKmTYda0tbvaDiFvTt37qRW1dZyU1Vq
dddHz08PDg6mzu+VK1fcONLW90wIydZQWWhItv5DWxUHAC6oAfZpAHMsJGPmGhkZcQd5vcoJAMAF
NQD2aQCE5DnDnoHWs7QqBVWDYWqRWt1U6g4A4IIaAPs0AELynKHnw9OqE6t6/IcPH1hAAMAFNQD2
aQCE5LlDzyyfP3/eNWamUmU9P66WmgnIAMAFNQD2aQCEZAAAuKAGwD4NgJAMAAAX1ADYpwEQkgEA
4IIaAPs0AEIyAABcUANgnwZASAYAgAtqAOzTAAjJAABwQQ2AfRoAIRkAAC6oAbBPA5jskLxq1Sp3
cPjx48e47u/evXPd7TMwMDDu71+/fnXdV65cGR9gig4yef3cuHEj2rJlS7Rw4cJo/vz50YYNG6KL
Fy9Go6OjwQe4tHEPDw+7dwqvX7/evVNY429tbXW/lzWOok9R/5r+RYsWRdu3b48eP35c+BvqX+86
3rt3b/TmzZsZuXFp+9i5c2e8/rQunz9/Xrk/AOCCGgD7NIApCckHDhxwB4dkmLt3714cgvWvvvse
PXrkuh88eLCmkPzz508XlLICZ0tLiwvkVULy+/fv4+lP+yjE+iG8XiE5+Xnw4EGpYV6/fj2jNqwP
Hz640Js2L0+fPi3dHwBwQQ2AfRrAlIXkmzdvuoPDiRMnxnU/dOiQ6/7ff/+5f/Xdd/ToUdfdSmSr
hmQLyCrdffnyZfTv3z/36e3tdaXJ+tvatWtdtzLj/vPnT1xKvmvXLlcyrnGMjY1Fd+/ejZYuXer+
du7cuVLTG/p3hf+uri7393Xr1hUOoxJvW+YK7zOJ3Wg5cuRINDIy4m48dHR0uG5ah2X7AwAuqAGw
TwOYspDc19fnDg5bt24d113BVN2/ffs2IejJ5s2bXXerHlwlJHd3d7vvmzZtiv7+/TuhfwUp/a76
uXXrVqlxX7lyxX1XCE9z//599/cVK1Y0JCSLQrlVpw4ZRsFef1O18DK/4/ej0nOFbI1DVbiPHTvm
lmPIsCGl52lUtVz9+KXyWp/JeQ/tDwC4oAbAPg1gykKygpwCij5WWmvBpbm52X3Xv/PmzXOlsKJ/
9d0fpkpIbmtrK6xq+/Dhw7g0uMy4t23bljtuK61OC+f1CMm6uaCAqr/reeiQYVSarL+pSnLVkKxg
nAy4x48fb2hITmPbkErz69EfAHBBDYB9GsCkhGQ/UNqzsM+ePRv3vLH+1XdrYEnVopOlz6HP5/rT
YIEuL6haiFK/ZUKyPfuaN+6Qg2ZISC76aHkWjXNwcDBqb293f9uzZ0/ladW61DPcuglw6dIl123J
kiWTvrFZNX41mlaP/gCAC2oA7NMAJi0k27Oz169fd9/VqrS+K8CIqjrr++XLl933q1evTniOuUpI
Vml0yIEppDpuVqNatR40q4ZkhXSVlL99+7ZUsFY1aT0/XXVaP378GHdLq+49GT59+uSe+dZz5nk3
KUL7AwAuqAGwTwOY1JCslq31t/3797vvVqJpzxvbc8v79u1z3/VvskXsKtWtQ0p7rSRZz7OWGXdI
KXW9QrJPjYKp28aNG6Pv378HBWvdLND0avlXCch501pmvdSjuvXnz5+j5cuXuyr6ydeKVekPALig
BsA+DWDSQ7JCiv7W1NTkvqt6rv+8sT23vGzZMvdd/al/PwRWCcl6X65fjTsvwKvfMuPevXv3hKrO
SZqvFy9e1DUki1pvtmeRkyG9HiXc0zUk62aKgu+aNWtSbxCU7Q8AuKAGwD4NYEpCsqiVZ/1d1YPT
WoW255YHBgbcvwo5VcOYuX37dvz6H7/FY6NuCpp+1e/QcV+7di1+RjeNGu1S6fTevXvrHpI13QqA
+tuZM2emfUiuB6uCrwbWfv/+XXN/AMAFNQD2aQBTGpJV1Vd/t3fZ6v3IPrWQbI15+VWzawnJKsm1
VzyperKCq/+eZHXT3xQ4rWXt0HHrdUoW/FV93J7V1Xj0+ierjq3fqXdIlv7+/rgqtW4szOaQrNJ4
/YZeC5a3nkL7AwAuqAGwTwOY8pB848aNuMEp/fvo0aNxf9d3/+8qqa01JIuq27a0tGRW8129enX0
5cuXSiFRz/fq1UJZ4+7s7KwUPEP/bg2i6Z3TVu26SmitumwnKyTv2LEjqKp2aH8AwAU1APZpAFMe
ktVIlx9YhoaGxv1drxXy//7q1au6BTlVT1bL2So5tnc26//qphLhWoKkSizv3bvnSr5VeqyQr9aU
dVOg1nBa9HdNuxqm8qtdz8aQrPUVEn5D+wMALqgBsE8DmPKQDAAAuKAG2KcBEJIBAAAX1AD7NABC
MgAA4IIaYJ8GQEgGAABcUANgnwY4BnAQAACAC2oA7NMACMkAAHBBDYB9GgAhGQAALqgBsE8DICQD
AMAFNQD2aQCEZAAAuKAGwD4NgJAMAAAX1ADYpwEQkgEA4IIaAPs0AEIyAABcUANgnwZASAYAgAtq
AOzTAAjJAABwQQ2AfRoAIRkAAC6oAbBPAyAkAwDABTUA9mkAjTgGcCAAAICLaQDs1wC8kMzBAAAA
LqQBsG8D8EKyHRD48OHDhw8fPmEfAIRkALM8JAPgZA0AAOddzrsAIRkAJ2sAAMB5FwAhGeBkDQAA
OO8CICQDnKwBAADnXQCEZICTNQAA4LwLgJAMcLIGAACcdwEQkgFO1gAAgPMuAEIywMkaAABw3gVA
SAY4WQMAAM67AAjJACdrAADAeRcAIRngZA0AADjvAiAkA5ysAQAA510AhGSAkzUAAOC8C4CQDHCy
BgAAnHcBEJIBTtYAAIDzLgBCMsDJmoUAAADnXQCEZACcrAEA4LwLgJAMgJM1AACcdwEQkgFwsgYA
gPMuAEIyAE7WAABw3gVASAbAyRoAAM67AAjJADhZAwDAeRcAIRkAJ2sAADjvAiAkA+BkDQAA510A
hGQAnKwBAOC8C4CQDICTNQAAnHcBEJIBcLIGAIDzLgBCMgBO1gAAcN4FQEgGwMkaAADOuwAIyQA4
WQMAwHkXACEZACdrAAA47wIgJAPgZA0AAOddAIRkAJysAQDgvAuAkAyAkzUAAJx3ARCSAXCyBgCA
8y4AQjIATtYAAHDeBUBIBsDJGgAAzrsACMkAOFkDAMB5l/MuQEgGwMkaAABw3gVASAY4WQMAAM67
AAjJACdrAADnl//x4cOHz7T5EJIBEJIBAJxbAGCaHZc4OgIcMAAAnFcAgOMTIRngYAEA4JwCAByn
CMnAjDxQ8OHDhw8fPrPtuT8AICQDAMBJHmC7BABCMgAAnOQBtksAICQDAMBJHmC7BABCMgAAnOQ5
zYLtEgAIyQAAgDACtksAICQDAADCCNguAYCQDAAACCNgu8QcMzw8zEIAIRkAABBGMHu3y76+vmjb
tm3RggULosWLF0eHDx+OhoaGKvfX29sbbd26NVq4cKH77Ny5M3rx4sWE/sbGxqLz589Hq1atiubP
nx81NzdH165dm5PrZqYcN86cORMtWrSI9QFCMgAAICRjdm6X/f39LqBaMLDPkiVLok+fPpXu78uX
Ly5EJ/vT5927d+N++8CBA6n9zbWgPJNC2VwIkIRkQjIAACAkYw5vlyrl1d/Onj0b/fv3z32uX7/u
uqmkuGx/KhlWt3379kW/fv1yVXN37drlunV1dcX9vX792nXbvHmzC9YaX3d3t+umEmVCMtPKPHKc
IiQDAMBJHpj07dJKfVX12Siwqtvq1atL97d3717X7e3bt3G3V69euW7bt2+Pux05csR1u3LlSuUQ
8/79ezdOq/597NixaGRkZFy/CuAK7Fb1u62tbUIV8TLjy5seBX+VrG/ZsiX+27dv36L9+/fHv6//
//jxozCU5Q2neVL/69atS52eNWvWuL+/efPGfX/y5Em0Y8cONx7VBmhqanI3LPx5C1kGyRL/Ri4T
Ue0FVe/XNC9btiw6efJkTes3bVo0v3o0QPOr39J0JOdvdHQ0OnXqlFtumhZt7xcuXOCgQkgGAACh
F8qhF5HAdLj4tCrUCrzm79+/rptCR9n+li9fPiFMK2Som0KX2bhxYxzKqu5rGl9ynzt+/Hjc3/fv
3+Pp8T/q5oey0PEVTU9ra2s0b948dwNAVJK+YsWKCeNsaWlJDagmZDgrnR8YGBg3Lfqu7hs2bHDf
rXQ+7dPZ2VlqGVQJyVWXiYJu2rS0t7dXXr/JaVHAVmj2h9XNhOT8nThxInX5qVYFCMkAAICQjFl2
8alSNf1NVacVgBVoFZ7UTaVrZfuzEue031fQNgrW6qago9JnfVc16/v37wfvayr5+/r1q5ueS5cu
xc9IG4U760/h7OfPn66UNBl+Q8dXND0KX/5NhNOnT8fBTr//58+f6NChQ67b5cuXM0NyyHDPnj1L
DfEW6G7fvu2+W6mywrJNm0po1c1vgCt0GYQe22pdJkePHnXdDh486G642Pwq5FZdv8lpseH1KIEN
r1Ll5DzaNv3hwwf3vaenx31X2AchGQAAlAjKwEy4+Hz69OmEmzuqxpsMtaH9ZW3/yYCj/1uJZ3K8
qh4csp99/Pgx7mZVv/1pUbXYZGmrGg9TN7WoXXZ8RdPjN2Ama9eudd0VwMzv379dN7/Kb3KZhQ63
cuVKVw3Zgp/+VSnq0qVLXSm/T8H44cOHrvq0leL76yN0GZQNyVWXia27z58/Z/5G2fWbnBa7geDP
s5XE+/NoJd9qaO7x48fjgjYIyQAAgJCMWXjxqdJbleIqDO3evds9M5qsRh3aX15ITqu+3dHR4Rr3
UvC4detW3JhXyH5W1N1+w1cm+Pnd82qKZA2f1hq4fdJKccsOp+di1U03MESv2dJ3PbtrVDpqobjK
PIT2F7qOQuctbd1ljavq+s0b3u/+6NGjcdW6tQ/4z9yDkAwAAAjJmOUXnypZU//r168v3Z+VEPsl
mfZMsoKGsWdB/f5CS29DA51NS1oI8quIT0VIzgtxocOpqrrm0Z7T1Q0HfdeztsZes6USXDXWpdJk
lc5Ox5Dsz1vaukuqdf1mBfGs/hWM9ey0PbutKuAgJAMAAEIy5sDFp0rOrJS3bH9WhVUtWhu1sqxu
annYWCvYKulMBpxkCXbVkGyBJrQ6bujvhPanEsdk1eKQ4UOHEy1ThT3dsNC/e/bsGfd3e55WpfXG
WseeipAcOm9aP+pPz0dnqXX92rbqD283frLmUVXD1WBXMoiDkAwAAKbxSR4os13a85Z61lLUqrC1
nOwH3dD+9Myruqk6tgKFPtaf3qFsbt68Oa4xJf+9y36YriUk+w07KYz7DTtpOhsdkq0RLb3iSL+t
ebx69eqE12FltaZcNJy8fPly3M05f134Idme81YIVCvPtYbkoldj1bpM7BVhtn3482nPBNe6fvVa
J3sWWq1ha/i01q2tqvXz58/d976+vgk1I0BIBgAAhGTMku1S7ylOq/qqVoWr9OeXxPkfhTW/GrBa
LE57Vlb9qTSwHiFZwSfrFUF6nrrRITnr91Xia+8wLjPdyeGMNWClktEkC5v1eiZZzw3ruxoHa+Qy
USNb1gJ68lVR9Vq/CsXJ4XWDJtm/3fhJftRSNwjJAIBpeDLhw4dP+IeLz3QqybOgpRaT1SBUWgu+
of2ptFmllQo+Cr0q6evt7Z3Qn0qZFUD0fLL6VX8qpasaStO6q8RbwUfToY+e0R0cHKw8vjLTI7ox
oFJTBT7No0otk6W9acOHDJe8gXHjxo3UZaxXLGneNR41imbV5KuEZNUA0Lj8d143YpmItgV7t7HC
uYbR+qzX+hX1q9JnDWslysn+tQz1SirdGNC0NDU1uYDsvwschGQAACcSgP2GeQcAQjIAgJMIwP7D
fAMAIRkAwAkEYD9ingGAkAwA4AQCsB8xzwBASAYAcAIB2I+YZwAgJAMAOIEA7EfMMwAQkgEAnEAA
9iPmGQAIyQAATiAA+xHzDACEZAAAJxCA/Yh5BgCOU4RkAOAEArAfMc8AwHGKkAwAnEAAEJLREMPD
w3XpZzbO92z6XRCSAQAz9ARy4MCBzH57e3ujrVu3RgsXLnSfnTt3Ri9evAgab8iwf//+db+d9knO
S95nNq9DAsvULl9C8uzY9qd6fNeuXXPHWjlz5ky0aNGi3PGF9FPW4OCgG3716tVTstzS5mkyJH9X
60HrAxynCMkAwAkkVVdXV+ZF0JcvX6IFCxakhtJ3797ljjd02L6+vppD8pIlSwjJICQTkqft+HRz
UMepX79+ZQ6b7BbST1lXr151w+u4PxXLbaqOZ8nf/fHjR7R06dLgG77gOEVIBoA5cgL5/ft3dPDg
wdzS2PPnz7vu+/btcxd3qq62a9euoIus0GEfPnzouh0+fLj0/D148MANe+vWLUIyCMmE5Gk5vp8/
f0bLli1zAbXsdlfvkLx9+3Y3/Js3b+Z0SJYrV65Ey5cvd+sHHKcIyQDACcTRXXRduD1//jzzwmXv
3r2u+9u3b+Nur169ct10sZUndNiLFy+6bvfu3Ss1bwremof169cHXyC9fv3aleZs2bIl/tu3b9+i
/fv3x1XC9X+VMiT19/dH27Zti+bPn++W28mTJ6ORkZFx/aj0XDcFbFxtbW3R0NBQ8LS8f//eVU9X
Cbx+S9ORXDejo6PRqVOnoqamJjctqjZ54cKFwmUQOlzRfNZjWYb0Z7+jZaLtRctk8eLF0bFjxyYs
99DfDVm+hOTieS5a3nv27HHDv3z5Mu6m7UXdNmzYUHpbKwpYad1D13Wjtx3p7Ox0VX21D/rTmzd/
If2UnQfdqJw3b54LhubJkyfRjh073HBaDzo+6CZm2nrQODXvWgZaFlp/ZY4xRfOUdkwJmb6ibSnr
dzW9Wi9VbtCCkExIBoBZegLRxYxKk/MuPnUxpe5jY2PjLizUTYElT+iwHR0drtvt27fdxZEucnQh
rUCd58SJE244hfzQkNza2uouEo8cORIH7RUrVky4iGppaRl3Eaagq2lO9tfe3h738/3793ie/Y+6
+ResWdOigK0LRH9YXRwm143Nd/Jz9uzZoOWVN1zIfNa6LEP7s+5p03P8+PHS4wtdvoTk/HkOWd4f
P36cEIg3btzoulmwKrOtlQ3Joet6MrYdDav9xA9i9QzJofMg3d3d7m8K7f73tI/14/+mlUL7+6Z/
E7DoGFM0T8ljSuj0FW1LeY/x6Pyj30zezAQhmZAMAJxAMi/27JnitP4VZvOEDmtVsNXNv5DR8FnP
PavkRBc2a9euLTV/uvj69+9f3P306dPxxZQuNv/8+RMdOnTIdbt8+XLc39GjR103VU9X6H/27Jn7
rmkwCm7qptIMjUtV+Oyi0g91WdNiw6txMxtepTXJdWPL9cOHD+57T0+P+64L5ZD1kTdcyHzWuixD
+7Pf0fL8+vWr+61Lly5NeAY9dHyhy5eQnD/PoctbIUbd9EiEPVLhB5sy21rZkBy6ridj2zl37pzr
59GjR4XH3CrPJIfOg6iEWd2178uaNWvcd4VR25d1E0Pd/Eau7Dc3b97sbvj5xzbV7ChzjMmbp+Qx
JXT6qmxLxrbNopuMICQTkgGAkBzU3b8AKTtOf1grAbh//777roshlSqrm6orp9EFjf5+/fr1UvP3
6dOncd0VstXdGtMRla6rm1/lT9UG1e3z58+Zv2H9DAwMxN0U8tVt1apVhdNiF4QqhTMaV3I5WqmR
Wmd9/PjxuIvKPCHDhcxnrcsytD/7HX95aJqTN1lCxxe6fAnJ+fMcurxVs0JBRtudbmro0Qh/mDLb
WtnjVOi6noxtRzd51I9alW5ESA6dB4VH7TdaJ8l9X8FTYVGB10r80wKmf2xT9fNkK9khx5i8eUoe
U0Knr8q2ZPSb6q6bHiAkE5IBgBNIzSFZz4hVHWfRsBaGsl4VsnLlSneR5F8YVpmWZOm1//F/2/rL
k9ZPWqgrmpa04f3uKpHyq3U3NzePe+47S8hwIfNZr2VZ1F/oNlnLOkxbvoTk/HkOXd5ijfelNa5X
ZVsru00UrevJ2HZ0rFM/ycBYr5AcOg9WuqrSVqMSYQudeW8XSJuOtGNbyDGmTGNkodNXy3HL5qPo
nARCMiEZAAjJMQVRdde7jI09V+w3/pKmlmFtmtKqdNsro4oaDqs12Pm/bfMSMr9pF2CqhlglJOf1
r4tPPXdozwbqIjhE3nAh81nrsgztrx4hOe13Q+dntofkovmuEpKT++vdu3fjv6naddH+UiUk54Xf
6bDtZM3nZIRkfx6s+rtKeI1KfNVNpdFqDEultSqNLbPc08Jl3jGmTEgOnb5ajlt55xoQkgnJAEBI
Tu3Xqhn6jWjp1SF5VaHLDmvVrf1GZhSsk1X5jLWGHdKic9H8qaQjWVUxjapLqz89G5vFLgpDq1tn
LS9/eGsAKWs9qlqlVT33g3iRrOFC5rPWZRnaX2hIDh1fleU7F0JyXulhLetPz8aq+q2Wu1ok1v+t
deeq25qFIb8xQD3/mlXdumhdT8a2o9LcRpYkh86DtTjt37S0Z4jV6rVRQ2NZ0+FXh7bq5lntQmQd
Y8qE5NDpq+W4ZWG/qCFKEJIJyQBASI7pGTB13717t7vo0cca2lJVyjyhw1rr1gq9umDRRw3OZDWm
ogZq9LfQktO8+bPWWNWgjar26bf1LtNkSbUalPEbltGrbWycdvHrN9ylcWU1bpM1LWpt3J4jtMZx
0lrQteqM1qq3lawXlc6HDBcyn7Uuy9D+QkNy6PhCl2/efpQVLGfrJ03o8j5z5kzcYNXNmzfd/9WI
VS3bml7tY20RqB8FprQGtELX9WRsO9Zf8nlbGzbklVd5/YTMgzV2lbyxaSFUr1my4K8WprOmwxou
0zJQI17qplctlTnGhMxT2ekrsy0lW/y2kukyNZNASCYkA8AcD8l+aUmy5WldoOaNI3RYXTymvb5D
JSR+CYKxUgM1DFRrSNbFXtprm1TiolJvfxrt2cLka1aKxqVuao27aFp0gZscXhe1yf7t5kPyo1Zu
Q25a5A0XMp+1LsvQ/kJDcuj4QpfvdLwQa9SxoUpJcsjy1ut09F3Pk5p169a5bvaqnSrbmt2I8j8K
acn+Qtf1ZGw7uvmnflRV2GclzGrQLGt+Q/oJmQcr0U2+i97CZegzyf48p73eLuQYEzJPZacvZFtK
+12x1q3L1EwCIZmQDABzPCSLnmHT3XtddCngqqS0t7c3aByhw6qlVJW4qDqlLnb0TlH/4stnz+CF
tupcNH8K7CqF0e9q3CotSntHs0pF7D2euuDSMMl3a+q7LiQ1r/rombqQVm2N+lWJhoa1Uqtk/yqR
1ytPdLGnaVE1Sl2E+lVQ04QOVzSf9ViWIf2VaUwu9HdDlu9cC8lV5rloeVuYslcNifZ7ddu7d2/l
bU3VtRWU1Vq21qGeU81qQCt0XTd621EVYM2fjgU+la5rXH413+T4QvoJmQfdoNA06BiQPCbodVH6
DQ2n0mGV/GeFZKsdo371b7I16ZBjTOg8lZm+kG0p7XdF60XDJG/6gpBMSAYATiB1ocZait7VC7Af
Mc9zjYK9Ql5azRhMHa0PrRf/cRhwnCIkAwAnkLrasGFDagkMwH7EPM9leo5XpapU6Z1etD5UZTz0
VYLgOEVIBgBOIAAIyagTVT1XNXEC2fSgquOqev3ixQsWBscpQjIAcAIBwH7EPE+FGzduuGdsMfX0
VgW1kg6OU4RkAOAEAoD9iHkGwHGKkAwAnEAAsB8xzwA4ThGSAYATCBe6APsR8wyA4xQhGQDAhS7A
fsQ8A+A4RUgGAHChC7AfMc8AOE4RkgEAXOgC7EfMMwCOU4RkAAAXugD7EfMMgOMUIRkAwIUuwH7E
PAPg2ExIBgBwoQuwHzHPADg2E5IBAFzoAuxHzDMAEJIBAFzoAuxHzDMAEJIBAFzoAuxHzDMAEJIB
AFzsAuw/zDsATNPjE0dIAOBkArDfsAwAgOMSIRkAZtdJhQ8fPuEfcOzgw4cPx2ZCMgAAc/SOOAAA
ICQDAEBIBgAAhGQAAAjJAACAkAwAACEZAAAQkgEAICQDAABCMgAAhGQAAEBIBgCAkAwAAAjJAAAQ
kgEAACEZAABCMgAAICQDAEBIBgAAhGQAAAjJAACAkAwAACEZAAAQkgEAICQDAABCMgAAhGQAAEBI
BgCAkAwAAAjJAAAQkgEAACEZAABCMgAAICQDAEBIBgAAhGQAAAjJAACAkAwAACGZhQAAACEZAAAQ
kgEAICQDAABCMgAAhGQAAEBIBgCAkAwAAAjJAAAQkgEAACEZAABCMgAAICQDAEBIBgAAhGQAAAjJ
AACAkAwAACEZAAAQkgEAICQDAABCMgAAhGQAAEBIBgCAkAwAAAjJAACAkAwAACEZAAAQkgEAICQD
AABCMgAAhGQAAEBIBgCAkAwAAAjJAAAQkgEAACEZAABCMgAAICQDAEBIBgAAhGQAAAjJAACAkAwA
ACEZaPw2zYcPHz6z6UNIBgCAkAywPQNAzrGNox0AAIQKgG0ZAMc4QjIAAAQLgO0YAMYf6zjqAQBA
uADYjgFwrCMkAwBAuADYjgGAkAwAAOECYDsGAEIyAACEC4DtGAAIyQAAEC4AtmMAICQDAEC4ANiO
AYCQDAAA4QJgOwYAQjIAAIQLgO24FsPDwzNy3FPxOwAhGQAAEC7Advz/6+vri7Zt2xYtWLAgWrx4
cXT48OFoaGhowvB5nzwa/9atW6OFCxdG8+fPj9auXVtqusdd9Ab8npw5cyZatGhRQ5ZlI8dd9Duh
81/rMDNpu67nvE338YGQDAAAIRlo8Hbc39/vgmsy9C5ZsiT69OlTUEhWv3lWrFhRqv96hORGhpPJ
Cj5pv0NIJiSDkAwAACEZaOB2vHPnTve3s2fPRv/+/XOf69evu24qUc7z4MED19+tW7eCgsKvX79q
DhlzPSQT1AjJICQDAEBIBhq4HauKtf42NjYWd1NQVrfVq1dnjk+Bd+nSpdH69euDQkKyanZWeCgK
xSGhI68q+Ldv36L9+/e7qt/66P8/fvyI/75nzx43zMuXL+Nur1+/dt02bNhQqpq5PHnyJNqxY0dc
1bypqSnq6uqKRkZGJkyvfkel7Fu2bMn8nbTfVW0AVZfX+JctWxadPHkydfxlloOMjo5Gp06dctOs
cWt7uHDhQtD2VutyrjpvoduVvH//3j0GoH1Av6Hpq7qsyowPhGQAAAjJwDTejq2qtYKx+fv3r+um
QJDlxIkTrp/nz5/PmJCsYJ+s+q1PS0tLHLw+fvw4Iaht3LjRdVNgKxOSu7u7M6uod3Z2Tpje1tbW
aN68edGRI0eCQ7KeHddz5Mn+29vbM4cJWQ7+Ok5+VOsgTz2Wc9V5C92uvnz54m5I+OPVzYyqyyp0
fCAkAwBASAam+XZspZaqYq2grNJDBTh1U4lYGpWsKcyFNsBV5tnaeoTkrP5Onz4dhyyFnz9//kSH
Dh1y3S5fvhz3Z/Ov6uQPHz7MDLVF1qxZ4/pTWLabEBa0/Qa5bHwKx/7NipDldvToUff94MGDrjbA
s2fP3Hetn6xhQpeD1TL48OGD+97T0+O+KzTmqddyrjJvodvV8ePH3Xc9bqBp/PnzpysFrrqsQscH
QjIAAIRkYJpvx0+fPp1QSrZu3Tr3r0qZ06gk0YL1TArJCvXJZ6N///7tuulmgfn+/bsLsQqDKh1U
tXJ/mLLBR8FYIfDYsWNxaWla0PMbSgtdbqoCre+fP38OXhahy8FKUA8cOBA9fvx4XIDPU6/lXGXe
Qrcru4GhEm0zMDBQeVmFjg+EZAAACMnADNiO79+/HzU3N7tQvHv3bldSnFfdeuXKlS7khTbE1aiQ
nPcqqrTxp7XibZ/kq5bOnz8f/y3ZMFlo8FFpooXistMautxsnsos/9Dl8OjRo2j58uXx37SNvH37
tnC+67Wcq8xb6LJMG7c9i19lWYWOD4RkAAAIycAM3I7tedG0Rrn0zmP9bfv27aV+OyQkp4WKyQrJ
yVLzu3fvxn9TdeAqIVklsOpPpZFqrEulySoVrWdI1s2KeobktNoDCsZ6Bld/1zPCqvZcNSSXWc5V
5i10u8oK4FWXVej4QEgGAICQDMzA7VgliOq/o6Njwt8uXrzo/hbaynFWULAA5LeqrWdfG1ndWiWh
Ia+i0nOnqgKsKrRq2Vn/17PaZafBnukdHh6Ou6mBp3qG5FWrVrnvX79+DV4WocvBpyrGVs0+61n1
ei/nKvMWul1Z9WhViU7eHKqyrELHB0IyAACEZGCab8f23KmeORW1KLxr1y7X7dWrVxP6VwNG+ltR
aWJR2NPrfPwGwxQe0xo6qjUkp7XWrFf4qCq0fvfq1asTSsbPnDnjuulmwc2bN93/z507lzvuvJCs
10BZaFIL1mVDct4rj6wlbGv0S69Usn7sGeLkMKHLwapaWwvmVotA3fPUazlXmbfQ7UqvtrLnivWq
Jk1nWmvUofMSOj4QkgEAICQD03w7vnLlSmpVUrUonMZK99ToUi0h2VoD9j96B269QrKeF1V/agzK
KLz4z9j61WbfvHkT3yTQdz1LbNSQmbrpb1njTpP2KqcyzySn/U6yXzX2pWfH015RlDVMyHIQNTSW
Nt1q8TlPvZZzlXkL3a4UYpPT2NbWVnlZhY4PhGQAAAjJwAzYjlUyZi0Jq1EuVaXOask47b3KVUKy
qtUq0KhVY5W46pndss8k51HJpMarZ2h9KllUqaDCl+ZFJX9+ibkFG73uyPT29rpue/fuzR13kqoo
63VB6le/tXnz5rgqe8g8pf1OWr8q4bV3LCtYa/4saGYNU7QcbPr1GiaFdI1bVaIVkP2qzFnqsZyr
zFvodiWDg4OuNFj9WQlw1WVVZnwgJAMAQEgG2I4BgJAMAADhAmA7BgBCMgAAhAuA7RgACMkAABAu
ALZjACAkAwBAuADYjgGAkAwAAOECYDsGAEIyAACEC4DtGAAIyQAAEC4AtmMAICQDAMAJF2A7BgBC
MgAAnHA5zYLtGAAIyQAAgHABtmMAICQDAADCBdiOAYCQDAAACBdgOwYAQjIAACBcgO0YAAjJAACA
cAG2YwAgJAMAAMIF2I4BgJAMAAAIF2A7BgBCMgAAIFyA7RgACMkAAIBwAbZjtmMAhGQAAEC4ANiO
ARCSAQAA4QJgOwZASAYAAIQLYKZtx5q2qZ6+5DRMh2marsvs2rVr0YEDB9z///79G09L8pM0NjYW
nT9/Plq1alU0f/78qLm52Y3LaJz+d4CQDAAA4QIgJBOSp/Uye/HiRbRkyZLo169f7ntfX19wSFYI
TuvPgvGPHz+ipUuXut8ACMkAABAuAELyHJ+G6e7nz5/RsmXLoqtXr8bdHj586Jbb4cOHc4d9/fq1
62/z5s3Rly9fon///kXd3d2um0qUzZUrV6Lly5e73wIIyQAAEC4AQrL3/f3799H27dujBQsWRIsX
L46OHTsWjYyMxP2Njo5Gp06dipqamlz13dWrV0cXLlwICr9FJcdVp6loHkOGf/LkSbRjx45o4cKF
br40f11dXeP6s/EpcOrfdevWpf7umjVr3N/fvHnjvn/79i3av3+/G7c++r9KcEN0dnZGixYtcsvd
XLx40Y3/3r17ucMeOXLE9acQnEfj1m8UhW6AkAwAAOECmHMhWSEyWTX3+PHjcX8nTpxIrb579uzZ
hoXkomkqmsei4a10Ne2jkJo2fbt27XL/HxgYGPeb+q7uGzZscN9VRXrFihUTxtvS0lIY9BXG582b
NyG8dnR0uHHcvn072rJliwv1+r1Xr16N62/jxo3xTYIiGqd+a2hoiB0XhGQAAAgXACHZvm/bti36
+vWrq5p76dIl103PwxqVxqrbhw8f3Peenh73XUGwUSG5aJqK5rFoeCv5VVhWP9Lf3++6qYQ1bfqe
PXuWGtbtJoICrJw+fdp9b29vd4H5z58/0aFDh1y3y5cv507/uXPnXH+PHj0a190CusKxH7y1bt69
exf3p1Jrdf/+/Xu0d+9e913VrO/fvz/ht6wKt3+zAyAkAwBAuABm7HYc0ohTSGD9+PFj3E2B0cKY
sVJRNQj1+PHjOFTmjbvWkFw0TUXzGDq8grHCoqpjWymsSlezpm/lypXueWFbBvpXz/aqISy1QC1r
1651w1ijW/L792/XTaXAeRTu1d/g4OC47lYybmFXv6tQrm5tbW1xf5p2K9VObhuqXu779OmT6751
61Z2XBCSAQAgJAMzezvOqiqc9/uhLUsnu6tUU0HQuqtk8u3btw0NyXnjyZvn0OlQg1UWisuMT89i
6/vTp0/dd7UQre8nT56M+0mW9vofv5Q6jZUEp92ISLLw74/TfltVqYeHh10/t27dihvzShtevwkQ
kgEAICQDhOTAQGkUjPVcrT3zq+rHecNYCJuOIdlek6RSXzXWpdLkz58/F45P1ZhVWquq1GLP9epZ
4pCQXFQabiXBZbYDf5yqUq5uVqrtr4e03w4toQcIyQAAEJKBabsd5wXkRoZkUbVhPcNqz8Mmw93Y
2FjcTc8wNyIkhyybou72nLVKW421YF00ParerGCpKt36d8+ePeP+rpL2ZHXrUCoVTitJturWfsNf
CsLqptbGjZ5DVjf/1U5ZJcbWXeMGCMkAABCSgRm9HU9mSLaq1s+fP3ff+/r63Hd1N3pOV92uX7/u
wpcCp551ne4h2Z7TVeBtbW0Nmp6XL1+OW97JFqatIS+99klhVctD7zxWN72WKo9eSaX+9Lywz1q3
VnVvjU8fNQKWbHjr5s2brpteBWX9aZ0kn10WKzkvmiaAkAwAACEZICR73dWoVdrvqBVnoxafk3/X
c7rTNSTb+4TLPpNsVHqr7molO0nvQ/af4farWtt7lLPYM8+q/u1TaE57rZVKrf3ScJXkpz1rnWwF
W6x16+Q7rwFCMgAAhGRgRm7H9Wrduqg/VbE+evSoa8FZ1aqbmppcQParVo+OjrqgrGdiFcj0nG+j
nkmuR0jWPOm1TJpWhVc1aqUGykKn58qVK677jRs3UqdDJekqSVYVZ41frVonS5zT6LVVWsZ6ZjpJ
7z5WSbP+rvHqXcoK5EmaN93Y0LrQb6vFbJX+J+k3ks9TA4RkAAAIyQDbMaYV3WxQuPVLiOtN49Zv
KEwDhGQAAAgXANsxpi01+KXS+kZWg9a4VSW8SuNiACEZAADCBcB2jEnV09Pjqks3IsSqMTE936x3
PAOEZAAACBcA2zFmBD3vrOem600tZavFa4CQDAAA4QJgOwYAQjIAAIQLgO0YAAjJAAAQLgC2YwAg
JAMAQLgA2I4BgJAMAADhAmA7BgBCMgAAhAuA7RgACMkAABAuALZjTJHh4WEWAgjJLA4AAAgXwEzc
jjVt+uj9u0X91PP3psM8N2Kazpw5Ey1atGjazTOi6Nq1a9GBAwfi7wMDA9HOnTujhQsXRvPnz4+2
bNkSPX/+PP67+tUwICQDAEC4AOZgSFawGxoaIiQ3YP4IyVPvxYsX0ZIlS6Jfv3657x8+fHDh2NaN
/3n69Knr58ePH9HSpUvdsCAkAwBAuADmWEjWZ/PmzdM22DYyJDd63ITkqfXz589o2bJl0dWrV+Nu
KiXWOjly5Eg0MjISjY6ORh0dHa7bhg0b4v6uXLkSLV++3I0DhGQAAAgXwBwKyadOnXL/Xr58OSj4
ffnyJdq3b58rjdOnra0tsyQ6b1z2/f3799H27dujBQsWRIsXL46OHTvmwotRiNE0NjU1uaqxq1ev
ji5cuBAURotKjqtOU94Nh7TxadjDhw+78alU88SJE26+fN++fYv2798fL1f9XyWaab/z+vVrNx5V
EzZPnjyJduzYEVch1vLq6uoaN902vEpVNX/qb9OmTdHbt2/jdTtv3rxozZo1E+ZR61jDtrS05K7n
MtORnA/r/vv372jXrl1ueWk5/Pv3LxocHHTTqnFu27Yt+v79e+E219nZ6WpK+Mta3/Ubfre/f/+6
bhq3v92pX603EJIBACBcAHMoJCsgrF271gWSjx8/5oZMBROVriVDobolA11oYFUITY7v+PHjcX8K
lGlVY8+ePduwkFw0TWVD8u7du3PHp9C6YsWKCf0okKaFy9bWVhdmVRoq3d3dqctIHwXF5PCHDh0a
14/m1250WEnr48ePx82jntFVdwXeLGWnIzkf1l03Yfxh9dtaFn639vb23O3NAn9IyLWQvGrVqnHd
VcKscYTcBOJYR0gGAICQDMySkCxqyEhhQNVNVWqXFSIV7PRdJXkKdqqKqhLJohCZF0g1rq9fv7rf
vXTpkuum0kWj8K5uepZUenp63HeFykaF5KJpCpk/v5tKSm18CpnqpmrA5vTp03Hw03L98+dPHGT9
En4bn0Klv55U8qvuCqnWvb+/P37mPDn8xo0bXcl12vp79+5d3I9PpcPq/vLly8xlUHY6kvPhh2QF
1wcPHsQlvFoeY2NjcTeVVOc5d+6c6+/Ro0eF+8LNmzddv+fPnx/X/eHDhxNuyICQDAAA4QKYIdtx
WuldmVCngJAMCsl+VNVZ3xWqjYWqZClcaGD1S68VmJLVXq2EVSWcKt30Q1WjQnLRNJUNyRbwRdV4
k+NTSb5VgzaqcmwBOzm+T58+pU6DAqmCnaqHK+SqX938SA7f19cXd1PV8mQ1agvOr169ct9Vmq3x
KOimLf+q05Gcj2R3W/b66CZDslse3ehQP6qmnUe/pUa6VKqtYJ78m8axdetWDmaEZAAACMnATNqO
s6q45v1+8u8KHypJVpixEJzsR8EuOc6qITI02Kok0K/i3dzcHD9D26iQHBrCQ0NyUb+2XNM+aSWw
SSoRtjCatw3Ydz/opq0/hWN1U1gWK1H1X6OUpux0VF2GIevDWrDOC/WfP39225a2qbTHBWzZFJVa
g5AMAAAhGZiFIVlUgqqwpJJNe07T70cBOiskq1p0I0KyUTC251L1DO2zZ89yh0krcZyJIdkPr1nj
s+eItd5UnVuhVgEwZP6ygqCFXZU02/hV1TlPLdNR75Cctq36VJqugKwq4nmNgIXcAAIhGQAAQjIw
jbbjvIBcNiSLnoH1W732+7GQWs/q1mUCqaog6/nQZCi3QKRnVo2qOM+UkKySzGR16zLrzJ7bHh4e
jrup4aq81ruT689//ZFY6fHRo0fd89haxv7405SdjkaGZGvFOq0kWa+E0t/Ugra2qSx2A0E3ZUBI
BgCAkAzMoO24niFZ9Hxm2jj8hrtUtdZv+EnPnzYiJFtV6+fPn7vvKgG0FrWNGsFSt+vXr7tgo2Cm
50inIiSntUZdND5rwVuvO9Iy1TxYkLMqzyEhWa9fEtUI8NdhcniNU7+jKsa2nNIap9JNESvl9qej
KCSHTkcjQ7I1NJZ87vnFixfxu8H9mypprBQ8ZN451hGSAQAgJAOzOCQrHNgznX4/ClVZr4BSa8mN
CMkK32nzpRahk+Hd/5w8eXJSQ7KVXKoRqLLjy1quCqhv3rwpHJ9aiQ7ZBvzWrf2/q3G0tFJsa/VZ
H4X2ImWno5EhWe/SVj8qEU8LzyH7i5WmJ9/LDUIyAACEZGAGbMe1tm6dpFLZtH70zti2tjZXaqiP
nkMtakG4lkCq6rCq8qvwqSq/TU1NLiD7pYBqMVpBWdWCNU16Hnayn0lWoNRv+1Vzy4xPpd8qSdbN
CYVjtWptrUsXjU/LSK9I0u9rWJWSqsGzrPlTS9EKyup/79697rfTaBlbVfasFrVrmY5GhmTNo6Y9
2dhY3vPfyXFqWI0ja/mAkAwAACEZYDvGDN8ey2yTvb29rv/169fPyPnVjROF4qJnqdNoGA1b9BgB
CMkAABAuALZjzPKQrBJkVb+254nv378/I+dX86CaB1WqS2sYVYEvakwNhGQAAAgXANsxZnlI9qsf
q1r2TNbT0+Oq4ZcJu2rUTNXm1cgXCMkAABAuALZjzFL2HHkRvc5Lz0bv2bMn9x3CM8WNGzfcs9Kh
Ojo63DP5ICQDAEC4ANiOAYCQDAAA4QJgOwYAQjIAAIQLgO0YAAjJAAAQLgC2YwAgJAMAQLgA2I4B
gJAMAADhAmA7BgBCMgAAhAuA7RgACMkAABAuALbj/Gkrmr6QfqZCX19ftHXrVvcu3/nz50dr166d
9styKsY1k7c9ppWQDAAACMlgOyYkB1qxYkU8bfosWbKEkExIJiQTkgEAIFwAbMdzMyTbdP369WvW
BSlCMgjJAACAkAy24xkSkkdHR6NTp05FTU1Nrprz6tWrowsXLkwY7tu3b9H+/ftddWh99P8fP34E
TdeXL1+iffv2xcO2tbVFQ0NDE6bJ/9QyPn+cr1+/dqXSW7Zsif/25MmTaMeOHXHVbs17V1dXNDIy
Ujr0DQwMRJs2bYoWLFjglt3du3cnDFv0Pa97f39/tG3bNjedy5Yti06ePDluOkOXR6PXc9q0502X
1oH6P3DgwLhhnj596rrr7z6tL797yHRmbQNZ6+P9+/fR9u3b3bpcvHhxdOzYsQnLOmR9E5IBAAAh
GWzHMzgknzhxIjWknj17Nu5HpbvJ6tD6tLS0TAgRSd+/f4+WL18+YVh1s1BTJiSHjM8fZ2trazRv
3rzoyJEjrnt3d3fq7+nT2dlZalkqqC1dujRzfLWGZAVKhbXkeNvb20svj0av5+S0F03X2NiYC+vJ
avWHDx92/R08eDDuZv3q8/fv3+DpzNoGstZH2rI+fvx46fVNSAYAAIRksB3P4JCsEjF9//Dhg/ve
09PjviuEmNOnT8fhTAHlz58/0aFDh1y3y5cv5/6eQob6U2mohv3586crrUsGkNCgUXZ8Ckb//v2L
u69Zs8Z1V1i27iqtVbdFixaVmh6VzCanRaWV9QrJR48ejQOjguKzZ8/cdwW+ssuj0es5Oe0h06VS
ZH1Xo22i9aHQrPWgj60fm1aVRJeZzqxtIGt9aFq/fv3q+r106dKEZ+ND1zchGQAAEJLBdtzg0Bta
WlWlHyuRU2B5/PjxuDBh1NJ08nnh379/u25+NeY0qpKq/lRN1bx79851W7VqVemQXHZ8nz59Sh2P
gvHDhw9dldqNGzdOCJ8h07Nu3TrXj37faLrqFZJtXj9//lzz8mj0es6a9rzpevDgwbjSbAvDCrX6
V1WvRX/X9/v375eazqxtIGt9fPz4Me6m5aNuKr0uu74JyQAAgJAMtuNJCshFF+OhIdkPg48ePRpX
Lba5uTl6+/btuGEUFLKmxS99TWPD+tICSGjQqHV8Kv2zUFyminTZaalHSE4bf9Xl0ej1HDLtyelS
1Wn9f8OGDe77f//9576rZFjbaEdHh+uuklt9VxAuM52hy7mW9ZG2vgnJAACAkAy242kSktWAkf6u
kJFGJW/6u/pLUmDSM532bKaq9oaEJz+IpVG4yQoWqgJcNiTXOj6r4qvSSDXWpdJkldRWCcl501I2
JKcNlzb+qsuj0es5ZNrTpmvv3r2um6o5q2GyPXv2uO5qqEvTpyCtcel72emsd0gOXd+EZAAAQEgG
2/EkBuS837fnI+/cuZP699u3b7u/b968OfXvKqmzqq1+kFGpY9XXM1kgq1d161rHZ8/mDg8Px93U
CnOVkGzPN6dNS964LGzpOWOjZ4WT/Wl+LEDWujwavZ6T0x46XapCrW7WsNjNmzdd96tXr7rvupHh
dy8znfUOyaHrm5AM4P9j7/wjtOj+//9HkiSJlZW3JJLklkSSJIncbslKrGQl6yZJkkSS5JZIkuR2
k9ySJJIka90kyUoiSZIVSZKsWMlKMl/P4/O6vmdnz8yc+XHtXrs9Hoy6zp45c368ZuY857zOOQAA
iGTAjidZKGfx119/ub9rBV4JZRtR1r/aqsZW5tWiRIa54N6/f9/91iJKtgqxYQJG2+zIXVmjZyZi
tBhTHv4CTjrXX8BJ84HLiuS66ZlItq2ENA9Vqx9XEcm2kJOun85LXloaMdXvixcvurqUSN+4ceOE
eDY31xaeevDgQSuOzSmOrY92t3Pewl15+dLHCn000NZU/vxhG93Xwln6VytLl81n0yI5tr0RyQAA
AIBIBuy4Q0Sy9sLVKHHeuRItimdIsITiaQVhQ1v2hLbzkWvr48ePc8uRda7CfOETKzTqpmfCs4k5
ydrmqMoWUCYg/UP7H6fjSTCaC316q6Oy9dHudk7nPTZfQi7W+psW+/Kx0ei050NsPpsWybHtjUgG
AAAARDJgx5MolIvQHM4LFy44MWwCS//qt41c+sj1VlsNqfNvI3oSTr4rsNBop0bulJbEiFy7Hz58
GFUO7fer7Xs0iqtD84KHh4dzBUm70lN5tV2QzlM5JMC0qFUVkSy0SrbSUN3JjVgj+EXzo/WRQkJZ
o6SKJ5firLmtGvG1fX61KJXaQOUvWx/tbudQ3mPyJWwagL9llTBX69D2UzH5bFokx7Y3IhkAAAAQ
yYAdA/wfX79+dTYil2qgvRHJAAAAgLgA7Bh+GWx+s1aI1kiw5tdq2yKbLwu0NyIZAAAAEBeAHcMv
Q39/f9AlXi7AWq0aaG9EMgAAACAuADuGXwbN5z116pRbYEqjjNrXt6enB4FMeyOSAQAAAHEB2DEA
ACIZAAAAEBeAHQMAIJIBAAAAcQHYMQAAIhkAAAAQF4AdUwkAgEgGAAAAxAUAdgwAiGQAAABAXABg
xwCASAYAAADEBQB23DSjo6ONxpuMvMzE+gXqDpEMAACAuADAjqeY48ePJ/PmzasUT/XeZN3H5qXp
6xYxNDSUbNy4MZk7d24ye/bsZOXKlcGwqaq3TrsXmypbrD34XLhwIent7W39tn2UlyxZ4tpp6dKl
Lo6huP5vRDIAAAAgLgA7pu6i6i8Ur2mxVycv7WTx4sWta+pYsGBBMGyq6m2miuSyaQ0MDLh2GBkZ
GSeC/Xayw4Txp0+fkoULF7pzEckAAACAuADsGKalSJ6qOvLFVygMkTx1Ivnz589JV1dXcv78+VbY
o0eP3Pnr169P3r17l/z8+TO5fv26C9OIsnHu3Llk0aJFLg1EMgAAACAuADueBO7cuZNs2bKl5Zrb
3d2dHD58OPn69eu4eM+ePUvWrl2bzJkzJ1m2bFly9erVoFD48OFDsmvXLpeeDv1fI2IhgfHixYtk
8+bNLs358+cnBw4caF03PbpWJFbS8ey30tu7d6+7hkbyDh06lIyNjZWqg9i8hMSTrnX06FGXptJW
3Z0+fTqqbSSedu7c2arLHTt2JG/fvs0se9bRrnqLaeu8a3/58iXZtm2bu4bOlVAcHh52dqa62rRp
U/Lx48fS9mrpS4gq7xs2bMgUtrI52Z7EaGy5ytiD6O/vd67Zfv3t27fPnetfN4TO0blqC0QyAAAA
IJIBO24zNnIVOtSx90WD3D6LRJhGLtOuvjqWL18eFDESJ+m4Bw8ebFQk//7775nXiK2DOiJZ4jKU
9okTJ3LTkTjUCGL6PIWZYGunSC6qt9i2zru2PgCk3Yx1vh/W09NT2l4tbN26dcmsWbOcIA21TV9f
n/u9f//+UuUqYw/60KE8pEXumjVrWh+KilA+lYb/gQSRDAAAgLgAwI7bwIoVK1z+JD40iieePn3q
wvxFiTQSqjCN7ElEyPVTo3NpkXDs2LGWsFG8b9++JXv27HFhZ8+enSBilN779+/dtc+cOTNh/mwT
7tbKp11DI44Kk+tr2TqomheNkur3y5cv3e/BwUH3W0IsDwnSdJ1r1D0tVuu4TNept9i2LhLJ379/
T27cuOF+a2RYaWhBKwvTSG7VtpI4tnjp8lpe06P6ZW24iJMnT7p4t27dGheucilcH0O2b9/ufsvN
+tq1axPSuHnzZtSHFUQyAAAA4gIAO24ICQ11xOV6aiNcGrkyVq1a5cKeP3/eCpP7dVooaBXl9FxY
udSa6EoLjFevXrXCJGZMKDUp9kycCrmupq8RWwdV82Kjklqk6fbt2+NEWx5yy9Z5qmdD9a8wrYbc
bpFcVG+xbZ133devX49rex0S5umwqm1l6YfEuf79559/JqRd1oaL0EcOxZMbuY/yq/DVq1dPGJmW
S7mPyqFwrViOSAYAAEBcUAmAHbcRjU6ayMhz05U4SpcjJGIsXuiIGZXNcv2tI/aK4sbWQdW8aATR
d5vWaOGTJ08K08mr86IPCZNRb7FtXee6TbdVOn5obnhdG05jI8bpjyN2HblSa79l/f3vv/9uLeYV
and/VB2RDAAAgLgAwI7bgG1Bo9EzudRqdO7NmzcTBICNetURyTEjxFMhkmProO4WUBLGNt9Wc7Hv
3buXm05encuFu5NFcmikvgmRXLetLPyvv/5yc+xVj+kR3ro2HNOOQtMKFC5387yPIP71iuoVkQwA
AIC4AMCOa2LzZTWSZWihobQAsLmgIddfP55GSatuPTRVIjm2DprYJ1luu5pXmha6IUxQT5W7dVHc
2LZuUiTXbSs/3EZt5Q7tU9eG02j0OTSSrHnICve3dsoaMbZwfVxBJAMAACAuqATAjidBJNscSM0R
1orAaQFgC3dp4Sh16v1FpEIrOWvLHMVR5157w9q5VUVy7GrJoRW0Y0VyUR2UzYthrtb37993v4eG
hlqrVOfhL9yVrnPNxW1SJFept9i2bodIjm2rouua67Y/N7msDRfZg7arCs2Pvnz58rjFxXRcvHjR
hWmrLx8bLS+qV0QyAAAA4gIAO66J7dVaNMdTK/DGbAGlrYlC2xbJTfTx48elRYyNwunaeYTixV4j
tg5i85I+T4I2lK5WUc4jqy4Vpi25mhDJdeottq2bFMmxbRVbBhuZV/ltW63YcsXag+Y9K55cw320
gndofrU+BPgL5Alb3Tp2f21EMgAAAOICADuuiNx/tb2NOuYSAVowSAtNhUSGVhTW3zXHUu6+V65c
CboNy/1Vo3ByGVWaWhH44cOHUSIuHa7RNqVf5GYaihd7jdg6iM1LKH3twysxpbrr7u52AlkiqQjt
i6tRRV1Xh+bkpufQ1hHJdeottq2bFMmxbVWmDEeOHGmtPl6mXLH2oNW61e5++n559BFF85N1HXkN
yNMgjc5VGsoXIhkAAABxQSUAdtyhyM00vXcuAExErvMSwf5c6lh0js71XewRyQAAAIgLAOx4irG5
oFqRWXMn1XHX1jU2dxMAstEiYPIgqOIurXPk/l1lgTREMgAAAOICADtuE/39/cE5oHJHffnyJY0M
UMDg4KBzqy4jdrVwmNy5BwYGpt2zjrc3AAAA4gJgRtux5s+eOnXKbUtk8zB7enoQyAAluHTpkptT
HYu8NbTi9XR81vH2BgAAQFwAYMcAwLMOkQwAAIC4AMCOAQAQyQAAAIgLAOwYAACRDAAAgLgAwI4B
ABDJAAAAiAsA7BgAAJEMAACAuADAjgEAEMkAAACICwDsGAAAkQwAAIC4APg17Fh506H9W4viNHm9
9DF79uxk3rx5yebNm5Pbt28Hzx0dHXV7Nf/2229ur+a5c+cm69atC+Y96zrpI5YLFy4kvb29rd93
7txJNmzY4PKgY+PGjcn9+/dbf1dcnQOASAYAAABEMsA0FMkSqG/fvp0ykZw+bty4Me68Fy9eJP/7
3/8y40tcj42NtUUkDwwMJAsWLEhGRkbc72vXrmWmd/PmTRfn06dPycKFC925AIhkAAAAQCQDTDOR
rGP9+vWTJpJDfP78OTl8+LD7+6pVq1rh3759S5YsWeLCt23bljx//jz5+fNn8uPHj+Tq1atOjOpv
J0+erHTdPJSnrq6u5Pz5860wy4sEsfKhQ/9X2LJly1rxzp07lyxatMilAYBIBgAAAEQywDQSyUeP
HnX/nj17Nkpgvnv3Ltm5c2fL3XjHjh2ZI9FlxKoEp7lf+2JTYXJvDmEju4sXL25cJPf397tRdn+U
WnkLpaUw1YWhc3Tu3r17uQkAkQwAAACIZIDpJJK/f/+erFy50s31ffXqVa7A/PjxoxshTbsaK0xu
xlVF8ocPH5IDBw64v2vesbFp0yYXdvfu3Uxh/d9//7kyNCmS9SFg1qxZE0RuT0/PONdqcevWLRem
Dwc+fX19Lo2YDwgAiGQAAABAJAN23CEiWTx79swJutWrVzvhmSUwDx486H5LvGqertyJNSdYYfpb
zPWKjnv37rXO0eisCfkmyhmL3Ld1jgSwz9evX105LV828q0w/c3H3LBPnDjBjQCIZAAAAEAkA0y2
HZddnCodR6tH67f+zYqjebf6LVFtaJ6wwjRft6pINrftJ0+e1Ba4TYhkG8EeHh4eF/7ly5dk+/bt
E/K/a9euCSL59evX7m9a/RoAkQwAAACIZIBJtOMqqzin/64RZI0ka0TZRHA6TmhObmgucaxY1eJb
CluzZo1z5U4zf/78KRlJtpFif1Rd/Pnnny5ci3nZwl02bzo9km714s9VBkAkAwAAACIZsONpIpKF
5iRL7GqOsoRpOo4EdJZI1pzmKmJ13759rbnIaTH8+++/T3DBTqPr5223VEUkh8optBhXWjxb+bVV
VOjaRR8PABDJAAAAgEgG7HiSBHJZkSy0yrW/6rUfZ/ny5bXdrdNoJegVK1a4vx0/fnzc3y5cuNCa
Ax1Ci3ZJuMoFukmRHBLDJp51xHwksHCNhgMgkgEAAACRDJBMv5FkY926dcE0/IW7tGiXv3CXVqeu
IpLF06dP3d98V2+hfZK1vZP+ppWlbfVt7ZOs7Z/MHVtiuUmRvGXLFneO5hX7WFmvXLni8iAhnCXk
37x548J1DgAiGQAAABDJANNYJEvg+Ss4G9rmKWsLKG3jVFUki8OHD7u/m6u3oZFqjVJnlU/7Gde5
bojTp09P2OrJxLzNy/YPhQ0NDY2La6tbKy0ARDIAAAAgkgGS6bW6dZqLFy8G42jfX61ELfdiHb29
vRNWga5yPY0aL126NOh2rVHbf//9160irdFjCXiNdl+6dKn2dUO8f//ejWqrbGkklDXSbOXX/9Or
cgudqzS05zIAIhkAAAAQyQDY8bRGruUaIR4dHS19rs7RuUUu6ACIZAAAAEBcAHYM04KRkZGku7u7
kru0zpELutIAQCQDAAAA4gIAO54RDA4Ouq2dyohdLWYml/C8bakAEMkAAACAuADsGKYlmve8Z8+e
6Ph9fX1uPjcAIhkAAAAQFwDYMQAgkgEAAABxAYAdAwDPOkQyAAAA4gIAOwYAnnWIZAAAAMQFAHYM
AIBIBgAAQFwAYMcAAIhkAAAAxAUAdgwAgEgGAABAXABgxzAtGR0dJX+0FSIZAAAAcQGAHcfmreio
mmbW75nczp1WzuPHjyfz5s3r2HyG8ver0ulthUgGAABAXAAgkhHJ014kh/LUSfn8VWxjJrQVIhkA
AABxAfBLieR2polIRnghkhHJAAAAgEgGmJEi+d27d8nOnTuTuXPnumPHjh3J27dvS4vkvHTu3Lnj
4vf29o475+7duy5cf/fZsmVLMDymnFl5HRkZSTZv3pzMnj07Wbt2bfLkyZNKdfnhw4dk165drXLq
/58+fRoXZ2xsLDl69GjS3d3trrds2bLk9OnTpeNk5SerjF+/fk327t2bzJkzJ1mwYEFy6NAhdx0f
1anqV3nXdXX9w4cPu3PT6b148cLVmdKbP39+cuDAgXHxivJXt91jbDMvH1++fEm2bdvm8q92+vnz
ZzI8POzaX2XftGlT8vHjx8r3Q1791G2rKvaBSAYAAEBcAGDHNUWyBMKiRYsmdOgV5gu/IpFclM6P
Hz9cR19iwEciQfF2797dCrO4Or5//96YSN6zZ8+4vEnUFAmudFoS2osXL55QzuXLl48TjxI8ITf3
EydOlIpTViT//vvvE+IcPHiwFe/69euZLvj9/f0T0lMd5aVXlL867R5rm3n5kNj1z71w4YJrKz+s
p6en8v2QVz9126qKfSCSAQAAEBcA2HGEUMmbj6xOucI0oiYB+PnzZzcylu6wF4nkmHQ0mqjfQ0ND
7rdG9SSetLCRDv0Wg4ODLp5G8Kp8DMjK65o1a9wocFYZY65x7NixlrBSOb99+9YS32fPnm3F0+ig
wl6+fDmuTBLYZeLEltvCNmzYkLx//97VpUaHFdbV1dWKt2LFChcmsWz1/fTpUxfmLzBl6ak9Lb0z
Z864sLTgLcpf1XaPtc0ikSzBfePGDfdbAlztJUFuYRotrno/FNVPnbaqah+IZAAAAMQFwIy347IL
b5URyXLhVNizZ89aYc+fP3dhS5YsiRbJMemYKLGRMOv079u3z/0rF1yhv+v3tWvXGhXJJtKE3GRt
BLjMNVauXNly3Tbk0muix7DRZgnE27dvt4SgT0ycsiLZBJWQu64JwzQSxjdv3nTuwfp4oHizZs2a
kN6rV69aYcpfVnp5+ava7rG2mZeH169fj8u7DgnTdFjV+6Gofuq0VVX7QCQDAAAgLgBmtB1XWaG6
jLu1OuXpuDGd/fTvmHQ0oqf/r1692v3+888/3W+Nxkqg9fX1uXCNzum3ic8it9VYkeyLjKqCz8oZ
OvyR2Fu3bo1z2126dOmEOdAxccqK5KK4Ghk1UdxE3cbkr0q7l7HNOnVUxY6r2F6VtqpqH4hkAAAA
xAUAIrmGSJYoyRIFcveM7fzHprN9+/bWaJ5cS//44w8XrgWbNL9Tgkpp6XdW+fPKGRodzIvnu9rW
Fckh4SZRY3NgVb579+5VitOUSDbXZ42Iy8VXo8lv3rxpq0iu0u5lbKpJkVz1fmiHSK5qH4hkAAAA
xAXAjLXjqnsdlxHJ1vmu624dm45caRVmixJdvnzZhZ8/f979trmZFh4j8DW/1JALa1Ze5WKdzpuN
bsbWpUbz0u7WRWhk1FyJs8RdTJwmhJfNcx0dHW2FaTXndovkKu0ea1NNiuSq90M7RXJZ+0AkAwAA
IC4AZrQdt1sk+wsVyRXXX6hI81VjO/+x6UicSdxqWxt/zqiNZmrRI/2rBbaK0Iik4l68eNGN9kns
bdy4MTOvyo/ypVWKLV7RSsHptEzkaTshpaXrmtBT+oa5yd6/f9/91nxoWyW5TJy8PIW2bIoVybbF
kubUrlu3ri0i2c9flXaPtakmRXLV+6HoPqnSVlXtA5EMAACAuABAJNcQyRKMWVve+IKlSETFpiPk
aqu/aZEkHxvFW79+fSmB7x9HjhzJXd3aj6uFkYpGhGPLKVfrx48ft+JJUIXaTKtjl4kTQnOfFW/h
woWlhZctltXOOcmh/FVp9zI21ZRIrno/ZIXXaauq9oFIBgAAQFwAzHg7rrq6dSzaK1jb7miUUYfm
rQ4PD+emGbpGTDrin3/+CW7jYy63/lZKeWhFYKWhUUhdT+fnzUnWfFgJZcXVHFmNPMfWvY/O00iy
5jNLHGtV64cPH46LI/fY/fv3O3FkI6gSN75reEycEHJJVhk0P7Ws8NI1tQWSzlfeJUy1QFSTIjmU
v6rtHmtTTYnkqvdDVnjdtqpiH4hkAAAAxAUAdgyNfjQAAEQyAAAA4gIAO0YkAwAiGQAAAHEBgB0j
kgEAkQwAAIC4AMCOfxFsbikAIJIBAAAQFwDYMQAAIhkAAABxAYAdAwAgkgEAABAXANgxAAAiGQAA
AHEBgB0DACCSAQAAEBcA2DEAACIZAAAAcQGAHQMAIJIBAAAQFwDYMQAAIhkAAABxAYAdl+PChQtJ
b29v6/ezZ8+SrVu3JnPnzk1mz56dbNiwIbl//37r74qrcwAAEMkAAACIC4AZZccDAwPJggULkpGR
Eff75cuXThwr7+nj7t27Ls6nT5+ShQsXunMBABDJAAAAiAuAGWHHnz9/Trq6upLz58+3wjRKrHzv
27cv+fr1azI2Npb09fW5sNWrV7finTt3Llm0aJFLAwB41iGSAQAAEMkA096O+/v7k3nz5jkhbOi3
8u2Hff/+3YXJ9drQ3xV37969NDQAzzpEMgAAACIZYHrb8bt375JZs2ZFiVwTyUuWLBkXrhFmpfH2
7VsaG4BnHSIZAAAAkQwwfe345MmTLn+3bt0qjHv58mUX99SpU+PCb9686cJPnDhBYwPwrEMkAwAA
IJIBpq8db9q0yeVveHg4N97r16/dIl3r1q1zI8rpvymNjRs30tgAPOsQyQAAAIhkgOlrx7aC9c+f
PzPjvHnzxi3OtXTpUreidRqdqzSUFgDwrEMkAwAAIJIBpq0day5xXv6GhoacQF6xYkXy8ePH3DL6
C3oBACIZAAAAEMkA086ObRXr0EiytoTS37Zt25Z8+fIlMw0bSZ4/fz6NDcCzDpEMAACASAaYvna8
ZcsWlz/NK/YZGBhw4evXr09+/PiRm4bcsRV38+bNNDYAzzpEMgAAACIZYPra8enTp13+tEJ1SDxn
HT62urXSAgCedYhkAAAARDLAtLXj9+/fu3nJvb2948I1vzhWJOtcpaE9lwGAZx0iGQAAAJEMMK3t
+ODBg04Uj46Olj5X5+jcAwcO0NAAPOsQyQAAAIhkgOlvxyMjI0l3d3cld2mdo9WvlQYA8KxDJAMA
ACCSAWaEHQ8ODiYLFiwoJXY/f/7sVrTWIl8AAIhkAAAAxAXAjLLjS5cuJXv27ImO39fXl1y8eJEG
BgBEMgAAAOICADsGAEAkAwAAIC4AsGMAAEQyAAAA4gIAOwYAQCQDAAAgLgCwYwAARDIAAADiAgA7
BgBAJAMAACAuALBjAABEMgAAAOICADueWkZHR6kEwCYRyQAAAIC4AOx46oXArFmzXF5nz56dfP36
tVT5YsqYjpf+ffz48WTevHmV0p4KhoaGko0bNyZz5851dbZy5UqMfZq0XSwhmyziwoULSW9vb+v3
jx8/klOnTiVLlixxdrJ06VIXx1Bc/zciGQAAABDJgB13ANeuXWuJGh3Xr1+fdJEcSqeThdbixYvH
1dmCBQsw9hkmksuWYWBgwNnByMjIOBHs24kdJow/ffqULFy40J2LSAYAAABEMmDHHcL27dtdPnfv
3u3+3bFjR9tF8nQXVZZfXxDBryuSP3/+nHR1dSXnz59vhT169Midv379+uTdu3fJz58/3QcohWlE
2Th37lyyaNEilwYiGQAAABDJgB1PMWNjY84NVMe3b99a///+/fuEuC9evHAuxnPmzEk2bdrkRsFC
QiImnv87PcqWJ1IkNnbu3OncnHVI0L99+zYobpSPzZs3u3zMnz8/OXDgQJQredE1QiODRUIrJi+T
Ubay15HQ0+johg0bWn+7c+dOsmXLlpareXd3d3L48OFx148VmDFpiWfPniVr16515V22bFly9erV
4DU+fPiQ7Nq1q1U2/V/2V7YOY9vX6O/vd67Zup+Mffv2uXMlgovuQZ27d+9eRDIAAAAgkgE7nmpu
3LgxbvS4p6fH/VZ4WlhJLPnCQeImLSJi41URyR8/fnQjbun4CvOFkIVL+KTjHjx4MLc+Yq5RRSQX
5WUyylblOuvWrXPz1SX4hI2Ehg4JxTIiOTYtCV+5JGfFNTSqn3aD17F8+fKggM+rwzIiWTavOkqL
3DVr1rTEeBF9fX0ujfTHCkQyAAAAIJIBO55kTBRrXrKw+ckagfOReFD41q1bnRiRa6hGi9MiIjZe
lTnJlrZGpy1tjQSmBaKdp3jv3793bq5nzpyJmjtc9hox7R+Tl8koW5XrSBzrGsaKFSta89Yt/OnT
py7MX+Qqpn5i0zp69OiEPGtkO32NY8eOud+yacWTZ8SePXtc2NmzZ0vXYWwbnzx50sW7devWuHCN
ZCtcHyY0pUG/5WZt95rPzZs3XdwTJ04gkgEAAACRDNhxk9cqMwKmlXfl4qoRrC9fvrgwW+la4fp7
WtC8evWqFSYX2PR1YuNVEclys9VvpWc8f/7chWn14PR5fh4khGz17jzKXiO2TYryMhllq3Kd169f
B9ORmJWwk4uyjZjKbsrWT0xaq1atcmHKZ55NaYXx9Dxx2bXCfHfx2DqMLYPEtuINDw+PC7cV41ev
Xj3hvpSbuY/qWeH6oIRIBgAAAEQyYMdtEshFnXwbvco6bt++3Yor8ZBOy4SFHx4br4pIzks7RtzE
iJ6614i9ZjvLlmcDda+jUVwTsnnXiamf2LTK2l7oiBnlrlIGYSPG/oi7nx+5Uuvjk/7+999/txbz
CpVHaSGSAQAAAJEM2PEUieSs7Wns0GrXeUIlVuzFCJAYkWwjcyFxocWXmhDJda9RVSQ3WbY8G6h7
HbMZjdpqgS19aHnz5k0lgRmbVl6eY0VylY8osW0cyp+wufn+Inh5o/6x3gCIZAAAAMQFAHZcQyBn
XV+u1BJF6uCnV//VCJ/CNaplo2PmRu276cpdNcvduiheFZGsBZjquELHiJ6616gqkiejbE1cRzaj
cI2MGlq4qorAjE0rZFOWZz+e5vvGbMvVtEjWKHVoJNm2VvO3dsoaMbZwLSaGSAYAAABEMmDHbRbK
Ie7evev+po58COvgK56wxZM0t1OiWh3/0KrVsfGyfudtI+QvOqV0/UWnNJ+1CSFZ9xpVBdlklK2J
65iwtTm1+gCiFbDriOSitMymlM90nv14hw4dai06pzgSntq32M6tKpKLttYy+07P3758+fK4xc90
XLx4MbgXuY2g+/lEJAMAAAAiGbDjSRTJtuqvieA0Ei42n1JIdKS3DlJHP32N2Hjp3zYap61+suJI
dGdtX6RtgpoQknWvUVUkT0bZmriO7f3bxJzk2LS0OnTMFlBZZZML8+PHj0vXYcgmQ5w+fdrFk7u4
j7w1QnOu9XHAX4RM2PoASguRDAAAAIhkwI7bKJRDaERLbp3d3d0TXET9OF1dXS6exdHqvRrpUiff
RopD14mJl/6tUTfF991NQ2lrH1mJbsXVoXmt6VWF6wrJOteoKpInq2x1r6PVovWBRedJfGoBKm19
VEUkx6YltAK2/q5pAHILv3LlyoR51ELu2hpJljuz0pT9PXz4sFIdhmwyhLaRUr5Uj6EyaoRe85OV
H43gDw0NTYinc5WG8o9IBgAAAEQyYMcAUAq5QOve0oecTkBu7BLB/vzqWHSOzvXd3RHJAAAAgLgA
7BgAgtjc5Xv37jmvBolKTQOw+cedgBYLk2dGFXdpnSM38aIFxxDJAAAAgLgA7BgAkv7+/uBUArlU
v3z5smPyOTg46Nyqy4hdzeGXO/fAwMCMetbx1AMAAEBcAGDHAG1CC2CdOnXKbV9lc4R7eno6SiAb
ly5dcvOsY9GIuFa8nmnPOp56AAAAiAsA7BgAeNYhkgEAABAXANgxAAAiGQAAAHEBgB0DACCSAQAA
EBcA2DEAACIZAAAAcQGAHQMAIJIBAAAQFwDYMQAAIhkAAABxAYAdQwOMjo5SCYBIBgAAAMQFQKfb
sfI2k++zdPliy9tkvRw/fjyZN2/ejKvLmW4rgEgGAABAXAAgkhHJbaiXmVLHiGRAJAMAACAuABDJ
v6gQQiQjkgGRDAAAgLgAQCS3fn/58iXZtm1bMmfOnGTXrrmkGRQAAIAASURBVF3Jz58/k+Hh4WTt
2rXJ7Nmzk02bNiUfP36ccN7IyEiyefNmF0dxnzx5MuGa7969S3bu3JnMnTvXHTt27Ejevn07Ls7Y
2Fhy9OjRpLu726W1bNmy5PTp06XjZJXv06dPrgwq38aNG5OnT58WCqYPHz64urB86/9KJ6Z+Q+nF
1EMWd+7cSbZs2eLOU9lVB4cPH06+fv064dovXrxwbaKyzp8/Pzlw4MC4eGXTU75nzZqVrFixYkK+
lH/FWb58eXQbVa3bqjZQ1zbEs2fPnH0rjq559erVzPQePXqULFiwINmwYUOpti+b76J7L7YtEMkA
AACICwBEcqDDrQ68L+4uXLjghI8f1tPTM+G8PXv2jIsjUeZ3/iWsFy1aNEE8KswXRYcOHZoQR8eJ
EydKxckqn8REXj7T50mALF68eMK1VCdpwRkjkmPrIcT169eD5dbR398/4doqWzrewYMHK6cnent7
3f9v3749Lm+yE4VLYMe2UdW6rWoDdW1Dgn7hwoWZdZZOb926de6jwr59+0q1fdl8F917MXWFSAYA
AEBcACCSc0Ty9+/fkxs3brjfGnlSJ/zHjx+tMI2Apc9bs2aNExGfP39uiQ1fkOn/CtNIncRRVjyN
0Cns5cuX7vfg4KD7LTFVJk5W+davX+8EiX99jbBmnXfs2LHWhwHl+9u3by1Rcvbs2VJ1XKYeQmgE
V/EkbjXCLzTaqTB/gTC7rq7x/v17F/fMmTMuTCObVdMTz58/b7W3j0ajFf7gwYPoNqpTt1VsoK5t
aDQ23XYaJc5KT+LY6rVM25fNd9G9F1NXiGQAAADEBcCMs+O8ka0yIvn169futzr3FiahlQ5Lnzc0
NNQKk5uv73or5OKpMLmrGia4lixZ0gqzkUWNWGq00hcZZeJk5dO/vuVTecs6b+XKlS2XVkMu6Qrz
3WhjRXJsPeQhIXvz5k0n4CSQdK5GLNPXffXqVSvM2k4fPaqmZ5gQe/jwofutUV/Fl7C2tohpozp1
W8UG6trGqlWrXJjay9A5RfdS2bYvm++iey+mrhDJAAAAiAuAGWXHWe6fedePWf05Jsx++x3vkCDT
/9NpheLdunVrnEvq0qVLJ8yxjIkTU77Q9dPxLN+ho2h7p9A1Y+shhEYKTcTGuPsW5adqehLH5p4s
JLBNhJVpozp1W8UG6tpGXtvF1H9s25fNd9G9F1NXiGQAAADEBQAiuWGRHOr4+27ZGmnMiid30DTq
xNtcaM2xvHfvXqk4VfNZRiQXidrQNcvWg4/NB9YIrOb+Spy+efOmskiuk56Ja41cWjpyxy/TRnXq
tooNlBG1ZW04pv5j277pfJe5pxDJAAAAiAuAaW/HeQJ5MkWyxJJhLqSrV69uhVnnvIybsVxvtbhQ
noDMihPjAmuushKJWedp1C3tEly2bXyq1INhc0tHR0dbYVotuapIrpOejR7v37/fzXOWAPTTiWmj
OnUbk76JUs2nNzQvt6pt2BzuUNvF1H9s25fNd9G9V/aeQiQDAAAgkgGmvR13gkiW663cd7XwkbbP
Sa+e6y9apHhZiyOZW+j9+/fdb823tBWAy8TJyufWrVudKFM+tVCTwo4cOZJ5nq0MrK2JlGeN1J0/
f36cu3FRHfsrNcfWQ55I1rZNQnOOtYJyXZFcNT2JPhsNTtdFTBvVqduY9Lu6ulzYxYsXXdr6AGC2
WcU2bOEus3W/7WLqK7bty+a76N6LqStEMgAAAOICAJHcsEhOz23VYkH+CKE68Fnb32hlXkNiIVQO
rYRcJk5WPrUvbZntd7LyLXH4+PHj3HbRvFrF1bZBZeshhFZLjmnrWJFcN73Lly+3/iZx6xPTRnXq
NiZ9E6X+IdFb1Ta0hVOZLaDSxLZ92XwX3XsxdYVIBgAAQFwAzDg7bmp166oiWStgq7Ou0cnt27e7
0a802rtVQkRxdGgu6/Dw8Lg4cgeVC6/EiNxOu7u7XWfedz2NiZOVTxu9kxDTv5qDW1RmlUWjnZrn
qfO08rKt7JyHRKTKqfmfZeshhMqtLZJ0jvKh0U4tylRVJNdNT/VtrsHplZxj2qhO3cakPzY25gSn
3MFVRs27zpvbW2QbQiuBq550TblIX7lyJWpOcZm2L5vvonsvti0QyQAAAIgLAOy4QXEOvx7//fef
a/vffvvtl60DudKrDuQi/Svfe4hkAAAAxAUAdoxI/mXRCKTceW3+8rVr136Jctscbq0KrZFdLVTW
19fXmleNSEYkAwAAIC4AsGNE8i9q1/582F+F/v7+4LQGuYpr9WlEMiIZAAAAcQGAHbfmVsKvg+bi
Shj+8ccfbjGrXwWNoJ86dcqt6m1zzXt6eqZEIHfavYdIBgAAQFwAYMcAAIhkAAAAxAUAdgwAgEgG
AABAXABgxwAAiGQAAADEBQB2DACASAYAAEBcAGDHAACIZAAAAMQFAHYMAIBIBgAAQFwAYMcA05rR
0VEqAZEMAACAuADAjtvH0NBQsnHjRrcv7uzZs5OVK1dmlnWqy5vOQyfkCSaP48ePJ/PmzWvEdprg
woULSW9vb+v3nTt3kg0bNrh7SYfuq/v377f+rrg6B5EMAAAAiGTAjjuYxYsXtwSEjgULFiCSoWPv
t6rt3bStDAwMuHtlZGTE/b527dq4+8g/bt686eJ8+vQpWbhwoTsXkQwAAACIZMCOO1x4WGd/pook
QCQ3ZTufP39Ourq6kvPnz7fClixZ0hLEP3/+dIf+r7Bly5a14p07dy5ZtGiRSwORDAAAAIhkwI4n
mXfv3iU7d+5suX/u2LEjefv27QTh4B+xIsN+v3jxItm8eXMyZ86cZP78+cmBAweSr1+/tuKNjY0l
R48eTbq7u507twTD6dOnowRM0chx1TyVFVLp8JgyiQ8fPiS7du1q1b/+r9HEUNqPHj1yI5Ny1y1z
jTTtyJs+oKg+ld7atWuTJ0+eTEhPrsZbtmxpue3r+ocPHx5X71lljTk/z07LlEX3xKxZs5IVK1ZM
KIPuDcVZvnx5bh339/c7t2/VtaE8Z9mO8uS3j87du3cvIhkAAAAQyYAdTyYfP350I1ZpcaEwExBN
iGSJ0HQaBw8ebMU7dOhQ8DonTpxom0guylNdkRxTJgnLtCu7CbCQcFy3bp0Tb/v27Yu+Roh25G3P
nj3j4ql+/Y8t169fz3Q1lqAsKmvM+Vl2WrYsQnOD9f/bt2+PqzvNF1a4xHnehyflPS1ye3p6xrlW
i1u3brkwfajy6evrc2n4dYhIBgAAAEQyYMdtRqJQ+du0aZMTEnLv1GhgWjDGuqFmCVKl//79e+de
eubMmQnzmjWaq7CXL1+634ODg+63hE27RHJRnuqK5JgyHTt2zIVJPKn+v3371hKbZ8+enZC2BKPy
W+YaIdqRtzVr1rjR2iwb0qiswiR2rQxPnz51Yf5CW1llLXu+T9myiOfPn7fK5aORbIU/ePAgs35P
njzp4kgA+0iQq040amzX0uiywtJeDOaGXfTBA5EMAACAuADAjhtEbrbK37Nnz1phJg40f7Ipkfzq
1atWmASOiQPDRvk0eqeRO18ctUskF+WprkiOKZNWCU/P9f7y5YsL892MLe3Xr1+POz/mGiHakTet
gG7IlT3LJVnCVgJQ7u0SoIqnEdOispY9v05ZDBP7Dx8+bIlcXUuiPK+u9QFG5w0PD48L1zW3b98+
YURbrt9pkazy629a/RqRDAAAAIhkwI4nidAcyZBgrCuSi+JpxM13+166dOmEOa1Ni+S8dPJczJss
k9V/6CgaHY29Roh25M0XjSEb0gizidoq9Vvn/Kr1LHGs3xLLwkZ3/S2dQthIcVpI//nnny5ci3nZ
wl1apCvk6m916M9VRiQDAAAAIhmw4zajUbEskSyX3MkSyYaEmkYfbU7rvXv3cs+xvE61SA7lI6ZM
eeKtzEeKvGvk0a68hQSezfHVqK7m80pwvnnzJrp96pxfpywmzDU6bnm4ceNG6ftKSJBnfVAIufrH
ejcgkgEAABAXANhxQ5hAare7daxIFnJJ1TzMtFA34fHjx49WmObUtkMkxwigonzElEkjuDFba8Xk
LesaRTSVN4nItA2tXr26FWbzoEdHR1thWuAqtn3qnF+nnm30eP/+/U7Iqv39PIQIiWGzHd81POuj
lB+ujxeIZAAAAEAkA3Y8SfgLd8md1V90SXM+J0skm+vv/fv33W/Nb7VVtg3tOauwixcvOgEhgaT5
mpMtkmPzEVMmW2Vac1JV90pPrri+i29e3mKuEaIdeVOY4mlVdKsPf9EpE7naxkloTrhWsC4rkmPP
9+f41q1nfUyy0Wg/fha2uFd6XrXdW1euXHEfWZQPWy1b96CPjZLHXA+RDAAAgLgAwI4bQoImawso
rVQ8WSJZgjzkCqtVidOC3j+OHDky6SI5Nh8xZcqqfwmyx48fF+Yt5hoh2pG39HxhLQ7mj9xqteos
l+eY9ok930ZxFy5c2Fg9X758ufU3iesitOd0eqsnoUXHQq7fCvMXPhM2gh2z7zUiGQAAAHEBgB03
iPZh3bFjhxup06F5l+lVedstkuXyK3dWCRu5o3Z3dzvB5rs0j42NOYEql1flU/NS2zUnOY/YfMSU
SWgkWiOcmr8rsaTVlm015aK8xV6j6nll8qbttCSUVSdawVnnpq+pbZf0d6W1fv361h7BMe0Te74E
reKk3ZTr1LPqxdzss1bd9lFdKH5ogS8JZY002/2m/4cWW9O5SiNdj4hkAAAAxAWVANgxQIfb90y3
8f/++8+V8bfffos+Rx9SJMaL5i+H0Dk615/ygEgGAAAAxAVgxwCI5ClFI8hyGbe5z9euXYs+V+dp
hL6Ku7TOkXt40UJjiGQAAADEBQB2DIBInvSy2ZzrsgwODjq3/DJiVwuLyVV8YGBgWj/reOoBAAAg
LgCwY/glsbm1MxFtg6Y5zH/88Ufy8ePHSmlcunTJzaWOpa+vz62cPt2fdTz1AAAAEBcA2DEA8KxD
JAMAACAuALBjAABEMgAAAOICADsGAEAkAwAAIC4AsGMAAEQyAAAA4gIAOwYAQCQDAAAgLgCwYwAA
RDIAAADiAgA7/uUYHR0lj5QfEMkAAACIC4Bf1Y4/fPiQnD17NtmxY0cyb948ty/smjVrklOnTiVf
vnzpiPrz63BoaCjZuHGjy+fs2bOTlStXTohTlePHj7s66GSmQx6rtGud8jfV/lW5cOFC0tvbOyH8
58+f7l5K501xdQ4iGQAAABDJgB13GI8fP3aCw0RG+li6dGny6dOnjhJTixcvHpfHBQsWNCaSplps
zZQ8trMcofOmsk4GBgacDY6MjEz428mTJ4N50z21cOFCdy4iGQAAABDJgB13EGvXrnX527VrV/L2
7VsXptGvZ8+eJRs2bHB/6+/v70hxFRIliORfUyRPFZ8/f066urqS8+fPT/jb06dPx33MSXPu3Llk
0aJFLg1EMgAAACCSATvuEOSurPz9+PFjwt/ev3/v/jZ//vygQN28ebM7X0L7yZMnE86XG7fEt9yi
dej/oVFpiYlNmza5tCQ4jhw5knz9+jUoikKj3VnCqSjdLPEVSuvOnTvJli1bWi7e3d3dyeHDh4P5
fPTokRtZ1EcGQx8dVE9z5sxJli1blly9ejV4naI6y8tj3seEorZ69+5dsnPnztZ15XpvH03KppeV
t3R4lXrOKn8orTJlevHihSuT2kf2fuDAgVxbMfQBSZ4YY2Nj48L1e8WKFeO8NNIojv6+d+9eRDIA
AADEvWjLdAYBEMnV0Nxe5e/atWul7s09e/aMuz8lLHwBIiGVdovWsXz58nHiQ+fo3HS8np6eWiI5
Jt1YkXz9+vVMd3R/lN3C1q1bl8yaNSvZt29fS/jKtTYrjTJ1VkUkF7XVx48f3YhmOm2FhQR6UXpV
RXJMPceK5LJlCtnKwYMHc+tXIlztHBK5hw4dcmlcunQpt636+vpcGmnxjkgGAAAARDIgkqcIdc41
Wqc8aoRTnXYJ5levXuXem1qMSOJPrqIagUuLimPHjrVEqcTft2/fWuJKi4QZ+/fvd2G7d+92o9n3
7t1zvyUcYsVVKCwm3bzy+WhEUGEScXJFF+ZK6y8gZedKHFs8cfToUReuUW3VherMXNn9a8XWWewz
Mbat9P90/kLxYtOrKpLL1nNe2mXLpHjynNB1z5w505rrnofNN75169a48P/++8+Fb9u2rbC9bt68
6f524sQJRDIAAACUE8oAiOT2fWDSyJqEnEYs0yOYN27cCKavFaYNuapafMNWnPbnDWulbIX5bsgS
5gp78+ZNtHCNEUkx6caKZEOCTaJGrri2YnFIzL9+/XrceatWrXLhz58/b4XJ/Tp9rdg6KyuSi9rK
6kp5MpRXhS1ZsqR0enXcrcvUc0z7x5bJ/ygkoawwuXvnIWGteMPDw+Pa63//+5/zHNCHhKL2kq3o
b/LoQCQDAAAAIhkQyZMgkMveQ5pPK9dWjSjbol6XL1+ecA1/pDQkKmyuc+jwRwUtXhnhGiOSYtKN
FckahTSxlle3WXUdyovVWSjPRXVWViTHtlUof3682PSqiuQ69RzT/nXyGkLznNP1oftGYf7Hpby0
LE9KC5EMAAAAiGRAJHegSPaxUUyNjOV1+EMd/TzB54sUjRC2QyTHpBsrkrWnrcI00qtFpDTKqRHq
WJEcyktZkRwj7GLKEmqrvPxpIauy6eXFy6uvOvUc0/6xZYqt49A18u7BvGsVjVojkgEAAACRDIjk
BgVy3vVt9V3Nx0yTJ4DkZmuYG+vq1atbYdpfOWabJrm+Zl2/jkiOSTdWWEpUKWx0dLQVpkWbYkWy
zbUNuf768WPrrKxILmorc7OPdU0uSs/Eo79i+suXLwvrq049p8PKlqlKHdu9448klxXJdo/5K8gj
kgEAAGDKxQXATLHjKiJZrtX6+2+//ZYMDg62OvwSJ/Y3bcmTvoYWQZJ7rOYz2wrZ/uJDtrqvtjBS
PKWrvWTtXEOLXPmLXT148GCCW28VkRSTbl4d+itwm3jT9kRC81e1gnWsSLaFu6zO/EWk/PixdRbK
Y15ZitrKX+QqnT/NCy6bnrbbUtjFixddGWRLFi9GJMfWc9Y2YVXKVEUk674IzUEvk5aNlPvti0gG
AAAARDJgx1MokiUebAQzdGgBIo0Cpq+RnjuqrYv8EVAJqNAWPHIrffz4cSueBIbN7UwvGpYlMmJE
cky6IWx0UOVOC+6qc5K1HVHMFlCxdRbKY549VG0rhdniU2XSM4HqH9qjuqi+Yus5VP7YuswqUxWR
fPr0aRdHbuFVRbKtbq20EMkAADBlHUUODo6pORDJU/f8K0LuradOnXILdUlYyl1W20JpJDm9f6ul
KTdmiSWN/m3fvt2NFqZRmEZFlaaEnlZofvjw4YR4Wi3Z9haWANI5efvuxojkmHRDaJEylcl3f9Xc
bG3FpHCVY/369W7bn1iRLLRis85TXuTue+XKlQnzY2PrLJTHPFuIaSvVy44dO1wcHZof7K/aXCa9
sbExJ5S1hZLiaH5xzJzk2HoOlT9U92XKVEUkqx7Unkq3qkjWuUoj1CaIZAAAmJadUQDg3vzVys5H
j2aQq7DqUa7J06WtaPuJ6GOABL0/jzoWnaNzffdvRDIAANARBeAepdyI5BmPzbW9d++eG1GVOLKt
gjRqjEievsjNXF4XVdyldY7cv4sWakMkAwAAnVAA7lXKjEieUdgCaOlDLtX+fG9E8vREC97JtbyM
2NVaAHIXHxgYmLHPOiwFAIBOKABwr/4SZbb5nRCPtkLSnG8tGmZzaXt6etoqkNvRVrR9NpcuXXLz
qWORJ4FW/57Jzzp6ZQAAdEIBgHuVMgMAz3dEMgAAnVAA4F6lzAAAiGQAADqhAMC9SpkBABDJAAB0
QgGAe5UyAwAgkgEA6IQCAPcqZQYAQCQDANAJBQDuVcoMAIBIBgCgEzpDGB0dnZZpT8V1gHuVMsN0
fj7xrKROEckAAFC6E9rb2xuM+/37dxceOqqkF2JoaCjZuHFjMnfu3GT27NnJypUrS5Vv3MsnIm/i
+PHjybx589pS5+1Mu+g6seWve05ZhoeH3TWWLVs27e+ndtUVIrkz21r7vE7lvTNd742mnk/T6Znc
Sc/cX61OEckAANB4J/Tw4cOZL20J2LIiOS+9EIsXLx6X7oIFC9ouktstdiajAxS6TqeK5PPnz7tr
yDYQyYjk6SSSJQTevn2LSG7gWTxV9dVp7TQT7AbbRyQDAMzYTuiXL1+S3bt35wrfmzdvuvC9e/cW
XismvbyX7cjISFs6Zr+SSO7U/G7evNld4/Hjx3QMEcnTSiTrWL9+PUKhgXsFkYxIpi+GSAYA6PhO
6MKFC5Ourq7k/v37mS+8v/76y4X/+++/hdeKSS+vI+qfk3V+kSiOuW7eiPiHDx+SXbt2OddvHfr/
p0+fWn//448/3DkPHjxohT169MiFrV69upRLurhz506yZcuWlqt5d3e3G239+vXrhPzqOhpl37Bh
Q+Z1Qtd9+vRpsmnTJpe+2ufIkSPB9MvUgxgbG0uOHj3q8qy05Up9+vTpCWXUvLVZs2YlixYtyixP
mevGlEm8e/cu2blzZyutHTt2TBgRzMvLixcv3DSAOXPmuGspH+m6iq0DRPL0FclqX/179uzZKKEQ
Y3dNPw/8cH2s3LZtm7Nb3T8/f/500x3Wrl3r0pQtf/z4MfP6SkPTZXzu3r3rwvV3H+XVwkPP76zn
k8qjD6/Ko8pw6NAhdy9VvX/z2qXsM7nuc6NMGzZhD+LZs2eufVWfegZdvXq18nPdztPzTx83leb8
+fOTAwcOtK472XWKSAYAgEnthKrzpw5V3ku7r6/Phf/zzz/upaUXtcTgw4cPK6XXySJZI9lp128d
y5cvb3UOXr161RLExpo1a1yYhFuZzsP169czXdn7+/sn5HfdunVObO7bty9aJKsjog5OOn5PT0/m
OTH1INSxDeX9xIkTwXJamULlKXPdmDJJBEiUp+MozO8UZuVFnTp11PxzTRD4dRVbB4jk6SuStS6D
1kmQWND9n/c8irW7pp8HfrjEiH/uhQsX3D2Uda/4/Pjxwz3j01NeJGh1njyF0nF1+GtXxIjk33//
fUKcgwcPVr5/mxLJdZ8bZduwCXuQ8NUH6qJpUbHPVwsPPWOtjSazThHJAAAwpZ3QrJedRiQUro6Q
/4JTh/H58+el04uN206RnBXv2LFjrQ6kOhTfvn1L9uzZM2EUSR0Uhd24caPljl62AyRWrFjh4qkz
pNEeYULbXxDF0lOnweLF1tv+/ftbnVt1au/du+d+qxOSdU5sPcgGFPby5Uv3e3Bw0P1WR8xHoxUK
19/zyhN73ZgyqTOnMI2aKa3Pnz+3XL79znhWXuz8rVu3ts7XqHK6rmLrAJE8fUWy0Eid7Esfx/Lu
wVi7a+fzQCJZolXPJ3t26z7SvWJhGs3LwhZd1HoUQteQaFYedNg1zdY1Khj7LLYwfXB9//69S8vW
sJBHSNX7t+x7Iou6z42ybdiEPZing59n39uo7PPVzlN61kZnzpyZsF7IZNUpIhkAADpSJNvX5GvX
rrU6TBpV9jtHM0Uka7QoPTdaI+PWqTP0ZVydFAkhdRr0Fd8/p+xcLXV8JLblzmaj0iER+/r169L1
Jtc7/X7z5k10XcTWg41KqFN9+/btYMfGRpv8znVWeWKvG1MmiyNxY+ijjsKWLFlSWLfWQfVHDpVW
uq5i6gCR3BllLrtCfzrOqVOn3G/9W3S/FdldO58HFi5btDCJnXRYFiakzRvCxLB5sMj1Wujv/ruh
jEi2j0pCbtYm5qvev02J5LrPjbJt2IQ9rFq1yoX5H61Dz6rY56ud5z/7zG78NprsOkUkAwBAR4nk
EPbCzNv+oRNEcl6nOJR+erTcP9JltQ6zjr///rtS2fVF3To9ZfMaW29WpjL1H1sPt27dGudGt3Tp
0uTJkyfj0rZRXt9NM6s8sdeNKVMoTpmOXt75fnhMHSCSp77MWXaVd/3039X+GkmWQLEOf8z9FrK7
qXoexDyfNApt02rEn3/+6X5r5FFl1xQcoZFB/c6aYlPnuV73/q0qkutet24bVkkr9lkV+3zttDpF
JAMAwLQRyRY/r9PXDpEcevFPlkhOl9VfGEUjL1XKbm6N+sIvl0ONFmh0tMlOsTqxTYrkUJtLFNqc
R3keSBgb5pquUdY6Itm/bkyZQnHMfuQiXUUk58XPqwNE8swQyUKja7aXe3oebhm7m6rnQezzafv2
7a0RaLlBa8FCoXn5sm+VXWXV7zIiKjbvde7fmPdEu54bdduwSlp5ea7yXG9aJNetU0QyAAB0pEg2
d2t/YQ/rHMqNql0i2V6sctc15KLXTndrjQLGbEWlERW52colV6uN6v/+yqyxebD5rFr92dCCUU12
iuXO5rtbxtRFbD34aDTJ3C/9jo+t+iybKSpP7HVjymSCtaq7prlb++fbom1ZbZtVB4jkqS1znkAu
K5KF5m/6q177cWLtbqqeB7HPJ7lQK44tTHf58mUX7u937oc3LZJj67Hqe6Jdz426bVglrdCzyvJc
5bnetEiuW6eIZAAA6EiRbKtba1sbff3VYZ3EvBV864pkjV4o7OLFi+6a6hyEFk6qK5JDqzVroSm5
uum61inUQiPG8ePHXZhcbdVJ1P9PnjyZm3ZeJ8i2VZEI08qeZTvFeVuL2DxCWwxFW1dZnPQc4bL1
YG7G2vJLaKEfW7VU2CIz6bnrWeWJvW5MmfzFYpSWv1iM5vYV5cUEkObqaQVWnR9a3bqoDhDJnVHm
JkWy8O/TrIW78uyunc+DJkSybdumj1z+PFEbybSV37WyctGzOGbro6r1WPY9UfRMrvvcqNuGVdKy
Z5Xymc5zled6WZHc7jpFJAMAQEeKZHWOQltB6Ku0/4W7aZFsL1b/0F64TYlkzcFSPC26ZUgMhbaq
0Ejo48ePXRxtP6TfmitmaOEUhdm+j6G0Q4S2ciozfy10nXRctZ9Wsg1t+5F1Tkw9CHVwQvnWKqrC
RlXTe2xnlSf2ujFlykpLYXkde0MdufT5Evvp+EV1gEiemSJZYtG3wbJ2147nQZMiWdie8GmPIRsZ
XL9+fW66Mc+nss+gdD3Gvidin8l1nxt127BKWlpIMmYLqNjna2wbTVadIpIBAKAjRbJ48eKFG0XT
yII6htozs2jPz7oiWe7L6gBpxEJf1OXeV3ZOch4aAVa6+gDgo5EIfWlXOdV50Eiivye0CSXbzkj8
999/Lkzz+PLSTiP3XG3Bobi6ljqdGp2OLVPoOqG4Gt20vSfVsVH5TNBnnVNUD5Z/bcekTpKNOkkc
muujPh74C/vEtFHMdWPKZB801F6qIx2a4zc8PBydF8XViIfOtRHldPyiOkAkd06Z665unUajl6E4
MXbXjudB0yLZdjFIb11lrtb+tkGhdGOfT1nhMfUY+56IfSbXfW7UbcMqaQl57ejvegbJhfnKlSvB
aR8xz9fYNpqsOkUkAwDAtO+EAgD3KmUGmFrkAp3eexoQyQAAQCcUgHuVMgPMeGzuslbU1yi6pkHZ
WiIaNQZEMgAA0AkF4F6lzAC/DLbNXvqQS7VW+gZEMgAA0AkF4F6lzAC/DFr/4NSpU25BNZsj3NPT
g0BGJAMAAJ1QAO5VygwAgEgGAAA6oQDcq5QZAACRDAAAdEIBuFcpMwAAIhkAAOiEAnCvTqsy5ZWL
5xMAIJIBAICONwD8ciI5ffB8AgBEMgAA0PEGgKh7NUtYztQDAACRDAAAiGSA/2N0dJRKmMH3KiPJ
AACIZAAAOt4zrHOfx9DQULJx48Zk7ty5yezZs5OVK1d2VJ6rjtRVTafovPTv48ePJ/PmzcPYfgGR
PJPL3Akj4pOdhwsXLiS9vb3u/9+/fy/8GKK4OgeA5zsiGQCAjvcM7/guXrx4XIdwwYIFiOQSIhl3
W+5VRPL0y8PAwIB71o2MjLjf+lhYJJI/ffqULFy40J0LgEgGAAA6oTO442txrLM4UzvrTYntThQX
3KuUGZEcz+fPn5Ourq7k/PnzrbCbN2+6a+/duzf33HPnziWLFi1yaQAgkgEAoGM7oXfu3Em2bNnS
chfu7u5ODh8+nHz9+rUVZ2xsLDl69Kj7m+IsW7YsOX369Lh0YuKIDx8+JLt27XLX06H/a4ShbFpN
Xk+8ePHCuU3PmTMn2bRpk4sTK/BCoybv3r1Ldu7c2brujh07krdv3wbPf/TokRuV2bBhQ247xpQl
ZqT22bNnydq1a11ZVW9Xr16NHvHV9VQ/Olf19fTp01LX93+n6051NmvWrGTFihUTyq66U5zly5cj
GCnzpAtPfQTbvHmze9bo3nny5EmhQI15tgrdQ7qnFEfi88iRIxPilLn3i+7R2OdTFv39/W6KhJ7B
xl9//eWu/e+//+aeq3N0bpGYBkAkAwDAlHVCr1+/nukip46QcejQoWCcEydOlIqjjmbaPdmEj98p
nOzrqcMokerHUee2qkj++PGjGy1J/01hfsfWwtetW+fE4b59+zKvFVuWIpGqzrZcHmMWUwr9llDw
48+fP39c57qOSBaat6j/3759e1z5NZdR4RIZCEbKPNkiec+ePaXsPvbZqjSUVjpOT09P5Xu/6B6N
fT6FsA9ZaZHb19fn0vjnn3/cxz4J/tWrVycPHz6ckIbiKo1YUQ6ASAYAgEnthGrETn9Th+7nz58u
TKMOCvMXU9KIhMJevnzpfg8ODrrf6riViXPs2LFWB1Adv2/fvrU6n2fPnp2y6x08eNCFbd261cWT
K6BGYMq4W/tYehrNsfSs46q/pc+VOLb6zyK2LEUiVaPv6bypUxsrbtevX+860n6ZDhw4UEkkh34/
f/7c/V6zZs248ttHiwcPHiAYKfOki2TZoz4wFd3LZZ+t+/fvd2G7d+9Ofvz4kdy7d8/9loiseu8X
3aOxz6cQJ0+edPFu3bo1Lnzbtm0uXOLYF956Tuue9jHXbP+DJgAiGQAAOq4Tqs6bOi7qSKkzmO6k
2SiGRvk0whcSdDFxtPJzev7uly9fXJjvajzZ17MO7atXr1phckmuKpLlwqwwpZEWf0uWLJlw7uvX
rwvbMLYsRSJ01apV7rffcQ2VNeu3Xya5qCtM5W1KJAvrsNsolEbLZI8SF0UfExCMlLkdIlkLU6Xt
3nf9z3pWFD1b7Vnx5s2bxu79ons09vkUQsJa8YaHh8eF22j4tWvX3G/dpxpVVphcuX30vFO4PkQC
IJIBAKDjOqEaQbCOW57rrUYNfPe8pUuXTpiTFxMnPcrgH/7oymRfz+L5qJNXVSTnpae/FXWsQ8SW
pUiExpY1RszGlKlKuhLH5jYqbOTJtptBMFLmyRbJ/seZGLuPfbaG7sem7v2svMY+n0Jo/nK6PrKw
NNNbvFm40gJAJAMAQMd1Qm3+p0YqNNdTYkQjGlniTSJUoyc2z02ugWXi5HX2Qp2zybpeVke1qkjW
SFFWJ1Tuh02L5DIiNS9vVUWy39ltagsoExgaCTM7vXHjBoKRMk+JSC5r97HP1tD92NS9n5XX2OdT
iJj8pusv9GyPEeQAiGQAAJiSTqjN6x0dHW2FaWGWPPEmNz/NJcvrUGXF0Whv2e2SJuN65m7tux/K
9bqqSDbRHutuHUNsWYpEaKislrcYMeu7hpubtoRA0yLZRo81Z1OLqqlz7tspgpEyT6ZI1sea9P2i
hamy7Dj22arngX6/f/++sXu/6B6NfT6F0KhwaCTZ3K39hcS+f/8+wdXbF+Q6BwCRDAAAHSuStVWJ
CUOttJzuyJlb8/37991vzc+z1VDLxLEVqbV9idwR1VnSXpu+a+1UXM8Ws9L8PlvwJmZ16yyR5y+M
o7RiF7nKI7YssQt36Zx03mLErC1upnrSAkEK05Y1dUVyessb68zbKJpfRgQjZZ5skWz3i+zeFvXz
F57KEslFz1Yt2ucv3qeF6dIu3mXv/aJ7NPb5FMKei+l1FGx1a23Dp/zp0KJioQW6bET9V7mnARDJ
AADTrBNqHbSieXPqOIX+rlVXy8RRpy209YiE0OPHj6fseuokpuNpsZmqIjnrugrTCrlVRHJsWYpE
qbZ/qbMFlF8vedtaxf62kSnlKc3ly5db8SUKEIyUeapEcnp+sRYO9Ed2s8Rv0X0msWnzfNPbO1W9
94vu0djnUwiJYMWVp4ePyhHaykqj4GkPEPMSCe1rD4BIBgCAKe+Eyk1ZW4lo1EMdLo06aEGsdEdO
8eT2KiEjt9fu7m4nRrVlSZk4Qi6HGhFRx1DX1Ohtei/Nyb6e0GqtGtlQXdiIclWRLLQHqDqrSk+H
5iimV4QtI5JjyxLjzqwVd9XWqje5V165cqVwvrT9tlEnXV//plflLSuSJYR13ZDrpdrS5kDGrACO
YKTM7RLJcoeWUJatbt++3d2LeXYf+2wV8oKxvdL10Uj3eHoP4TL3ftE9Gvt8CqF6UD5Di+jJJV0j
zfq78qm9lEP7LutcxUnXIQAiGQAA6IRCxyBXZ9lIV1dXR+Xrv//+c/n67bffuFcp85SKZPj/yF1b
ArzKGgE6R+cWuXUDIJIBAICON0waNldSq4Br3qA6rTafUCNVnYBGkOXKanM4be9V7lXKjEieenRv
ynOniru0zpFbd5nFGwEQyQAAQMcb2kp/f39wjqTcI1++fNlRwsTmgnKvUmZEcmcxODjoVp0vI3bl
Bq5pFQMDA1QgIJKpDgAAOqHQOWiU9tSpU25hIJsL3NPT0zECWWietET7H3/84RYa416lzFOFzdmF
iVy6dMnNu45FHisXL16k4oC+GCIZAIBOKABwr1JmAOD5jkgGAKATCgDcq5QZAACRDABAJxQAuFcp
MwAAIhkAgE4oAHCvUmYAAEQyAACdUADgXqXMAACIZAAAOqEAwL1KmQEAEMkAAHRCAYB7lTIDACCS
AQDohAIA9yplBgBAJAMA0AkFAO5VygwAgEgGAKATCgDcq5QZAACRDABAJxQAuFcpMwAAIhkAgE4o
AHCvUmYAAEQyAAAdUQDgHqXsAADtfcbxxAMAoCMKANyb1AEA8GxDJAMAdO7DmoODo7MO4PnEwcHx
6zzfeeoDAABM4tdpAAAA6PD3N1UAAACASAYAAABEMgAAACIZAAAAEMkAAACIZAAAAEAkAwAAIJIB
AAAAkQwAAIBIBgAAAEQyAAAAIhkAAAAQyQAAAIhkAAAAQCQDAAAgkgEAAACRDAAAgEgGAAAARDIA
AAAiGQAAABDJAAAAiGQAAABAJAMAACCSAQAAAJEMAACASAYAAABEMgAAACIZAAAAEMkAAACIZAAA
AEAkAwAAIJIBAAAAkQwAAIBIBgAAAEQyAAAAIhkAAAAQyQAAAIhkAAAAQCQDAAAgkgEAAACRDAAA
gEgGAAAARDIAAAAiGQAAABDJAAAAiGQAAABAJAMAACCSAQAAAJEMAACASAYAAABEMgAAACCSAQAA
EMkAAACASAYAAEAkAwAAACIZAAAAkQwAAACIZAAAAEQyAAAAIJIBAAAQyQAAAIBIBgAAQCQDAABA
tDhOHwAAAIBIBgAAQCQjkgEAABDJAAAACGUEMgAAACIZAAAAEMkAAACIZAAAAEAkAwAAIJIBAAAA
kQwAAIBIBgAAgGKhDAAAAIhkAAAAQCQDAAAgkgE6vbPKwcHBwcHBwTGTDwBAJANEC2QAAAAA+jwA
gEgGjJyXBQAAAND3AQBEMgAvCQAAAKAPBACIZABeEAAAAEAfCAAQyQC8IAAAAADoAwEgkgF4QQAA
AADQBwJAJAPwggAAAACgDwSASAbgBQEAAABAHwgAkQzACwIAAACAPhAAIhmAFwQAAAAAfSAARDIA
L4gsRkdHaWT45WwJuwcAnrv0gQAQyQBteEE8e/Ys2bp1azJ37txk9uzZyYYNG5L79+9PSp5iXlzp
eOnfx48fT+bNm1cp7U4p43S2qybKV9UWmibGloaGhpKNGze27peVK1c2nq+Y9DrZ7ifTjjqtzNP9
nu+Ue7EOoXt0Ol9nOtlLFbsIPcsQyQCIZIApFckvX750L3h7sfnH3bt3p4VIDqWDSEYkN5WPdNji
xYvH3ScLFiyYEpHcyXaPSEYkTyWhe3Q6X2emi+TJsCVEMgAiGaDUC6K3t9f9bd++fcnXr1+TsbGx
pK+vz4WtXr16WnTGOrmzhkieXtcrI05HRkY6Ih+IZEQy+Z/8e3QyrzPT7QWRDIBIBug4kSwXJ/1N
4tj4/v27C5P7WBF37txJtmzZ0nI36+7uTg4fPuwEt8+LFy+cW9qcOXOSTZs2JZ8+fQq+GGPi+b/T
o995L913794lO3fudHnVsWPHjuTt27fBl7XysXnzZpeP+fPnJwcOHJhQppiylxE7jx49ciMRcnc3
Pnz4kOzatauVZ/1fdZLm6dOnrr6Uj66uruTIkSMT8lum/KG8xLSN7Ojo0aOuLpSXZcuWJadPn67U
SYq1mZg6imnXGFsKeVxk5T+27WLLGSpPVl5Vpr1797o01Y6HDh0ad4/ntXMZO4lpR03nWLt2rcuL
7OHq1auV851XFzHnlrlnY54BTd4TsfZSpgyh9i16VpS1oSr1FmMTWRTZZ9Y92vSzN+86ZZ5JVZ/7
Zeo75v0Qa39F93xZ+8+qw6rvEkQyACIZoG0vCBPJS5YsyY13/fr1YEdBR39//7hOje+SqkOdvPRL
MTZeFZH88ePHZNGiRRPiKyzU8VFnIx334MGDpcteRiSvW7cumTVrlhvVFxqdSLvz6Vi+fPm4Do46
iKH89vT0VC5/Oi+xbaOOdKhOTpw4UaqjFXu92DqKadcmRXJsvmLLWVYk//7777n2m9XOZe2kqB3V
8V64cGHmvVI233l1UXRu2Xu26BnQ5D0Ray9ly5Bu35hnRVkbKltvsTYRIsY+q4jkKs/erOuUfSZV
fe7H1ndMm8des4pILrL/rLaq+i5BJAMgkgHa9oK4fPmyi3/q1KnceCtWrHDx1HH7+fNn64u1wvxF
OPTCVpgWB9PL+PPnz270Jf1SjI1XZU6ypa2v6Za2vr5ndfwU7/37965cZ86cmTDfLLbsZUSyOkmW
ljh27FirM6M8f/v2LdmzZ48LO3v2bCve/v37Xdju3buTHz9+JPfu3XO/1fGqWv50XmLbRqMZ+q25
7mJwcND9VgesTEcr9nqxdRTbrjG2FBMnNl+x5YypMz9Mo1JWTo0yKkwjSLHtHGsnRXnSSFA6PeUt
q06L8p1XD0Xnlr1ni2ylyXsi1l7KliHdvjHPirI2VLbeYm0iRF37bPrZG7pO2XPrXruovmPaPPaa
VURyjP2H6rHquwSRDIBIBmjLC+L169fuK7++bmtEOQZ10m7evOncvNasWTPhBWwdu1evXrXC5G6X
fjHGxqsiWuSqpd9Kz3j+/PmEEXM7z8+DOh9Z7udFZS8jdlT3PrZqsj/f7cuXL60ObLpsb968ybxG
2fKn8xLbNjYaobnut2/fHtf5K9PRir1ebB3FtmtTIjk2X7HlLCuSrWMp5LaYVc50O5e1k6I8rVq1
yv1WGjH3dFG+8+oh9tzYe7bIVpq8J2LtpWwZsto371lR1obK1lusTTTxHIt97lR99oauU/bcutcu
qu+YNi9rf2WejzH2H6rHqu8SRDIAIhmg8ReEXqJyW1u6dGnUXCR9xbcOWp6Lm17Y6evby7xKvCqi
JS/tIpEUCo8te1Wx4+c5dPijRqGyZaVVtfyxbXPr1q1x7pCypSdPnpQWyWVtpqiOYtu1KZFcp+1C
5SwrkquUsx33SdV7uon7p+l7tmrZYu6JWHupW4aYZ0VVG2q63trxHGv62Rs6v+4zqelnWpn3Q9E1
q4jkGPsPlaXquwSRDIBIBmj0BaH9HvVC0uiI5n3FYCtj6yu03PE0siGhHfuSrhqvimjRKEtW50pu
XWU7HrFlb5dI9juEobKlqVv+2LYx1JnRfDabMycXv7oiuawYrSLqJkMk+/kqW6/tFsl17CQkdPLS
m2yRXPeerWqjMfdErL3ULUPMs6LdIjnWJtrxHGv62VtWJJf5INnUMy2mzWOvWUUkx9h/XnuVfZcg
kgEQyQCNvSDOnz/v/r5t2zbnYhWLzRkaHR1thWkxmyzXWd9FTi5iVeNVES32km3KjTS27HU6+fpy
HrO9iPKveJqXlkXd8se2jY9sSYuspDuwMXUQe73YOppskRybryr12k6RHGsn1vHWHEdD7rkx7Wjp
TbZIrnvPVrXRmHsi1l7qliHmWdFukRxrE+14jjX97A2dX/eZ1PQzLabNY69ZRyTn2X9Re5V5lyCS
ARDJAI28IAYGBtzf1q9fP67DW0Yka0sS6yBqLnPW4j2a2yQ3brkMhlaBjY2Xt31MVhx/wRel6y/4
onl9VTvcRWWv08m31T21FYfyqxET+6ChvBta+MVfAObBgwetNG0eV93yx7aNucfdv3/f/ZaHgq0+
W6YOYq8XW0dlO/55thQjTmPzFVvOvDqL2XIs1i5j7UQLOCns4sWLrmwSaqFFq6x8SiOd3lSJ5Kr3
bFUbjbknYu2lbhlinhXtFsmxNhGi7nOs6Wdv6Py6z6Smn2kxbR57zSoiOcb+Q8+yqu8SRDIAIhmg
kReE36krux2HvXyLztVLN71th/a2rBov/dv2etaCY1lx1InN2jpEW5JU7Xi0c05yVp7l/vb48eNW
PC38on0tQ9t3NFX+2LZRRzVUH1o9tUwdxF4vto5i2zXGlmJEcmy+YssZIiavZQVNrJ2YWPEP7b0a
2nqtzBZQ7RTJde/ZqjYac0/E2kvdMsQ8K9otkmNtIkTd51jTz97Q+XWfSU0/0+q8H9LXrCKSY+w/
9Cyr+i5BJAMgkgEaeUHkzUUqeqnIBUrbRGh0Q+loNFqLbYTOHR4edl+kFddGXqrGS//WllWKr/lK
eR0I7RepTqzi6tD8Pl2vSoc7tux1OvlCI3T6uq9Ojq6jOnn48OGEePrKbvttqsOhc1Tepsof2zaq
F205os6O8tLd3e06NUVeCnVsJqaOYts1xpZi3Zxj2y62nGli7b6MoIm1E612LKGsrWYUR/Njs+aV
aiVm3R+yB7l+XrlypfJaAHVEct17tqqNxt4TMfbSxHOn6FnRbpEcaxNZ1H2ONfnszTq/zrlNP9Ni
3w+xz6uydhFj/6FnWdV3CSIZAJEMwAsCAKYdcqmM2f8YsAkA+kAAiGQAXhAAMKOwObRakVYjzVpw
qq+vrzX/EbAJbALoAwEgkgF4QQDAL0N/f39wGodcOrUaNmAT2ATQBwJAJAPwggCAXwbNHzx16pRb
JMjmHPb09CCGsAlsAugDASCSAXhBAAAAANAHAkAkA/CCAAAAAKAPBIBIBuAFAQAAAEAfCACRDMAL
AgAAAIA+EAAiGYAXBAAAAAB9IABEMgAvCAAAAAD6QACIZABeEFCF0dFRKmEG1BXtiH0BwPS4t+gD
ASCSAdryghgaGko2btyYzJ07N5k9e3aycuXKzOu062XUdNpTkd7x48eTefPmtTV/7WyDyaRMXXVC
3qZTvXdqXoeHh12+li1b9kvb1696z09l/VSJY7+LjpCAnDVrlvub3qdfv36dUfXdifcW9wcAIhmg
LS+IxYsXj3vpL1iwAJHcpo4YIrnzyxHKGyK5PufPn3f5Onz4MMISkTxjRfK1a9fG/f369eu/XH0j
kgEQyQAz4gVhL72RkZEZ8+LtdJH8q3eYp5tIhvps3rzZ1evjx49pQ+yx40Vy1XbYvn27i7d79273
744dOxDJiGQARDJAp70g3r17l+zcudO5UuvQC/vt27cTXnh5X8azXo72+8WLF64DPGfOnGT+/PnJ
gQMHJriYPX36NNm0aZNzP+vq6kqOHDkyLk5W2jEvaF1f7uK6vq7x6dOnYLwPHz4ku3btatWF/q+4
aWLTC+UrqxyPHj1yI/QbNmzILMedO3eSLVu2tNzeu7u73ahbXj2NjY0lR48edXF1jlxZT58+XcmO
8tKSHcmFcMWKFRPOkz0pT8uXL4/KU569xbSRnffly5dk27Ztrp0U7+fPn86ld+3ate66aruPHz+W
quOidixj03l2kraHorKr/nXeqlWrgumqXUyAlq1X1Yni9/b2jjvn7t27Llx/91H9WXis/ZkL6qJF
i2q3YZGN5NlXzD2WR5l7NOa5WCa9Ju/BMvdbnWdM0/VV5dk8mSJZdaVy6vj27Vvr/9+/f48Wn2Wf
Denz9bFb9ajr6j568uRJ6X5BVn6y7q0m30OIZABEMkDbXxDqXKpTmn6xKcxesE2IZHVo0mkcPHhw
XAcuFKenp6e2SNbLXi9wP13rxPvx1HFIu5Vbp9LviMWmV1Ykr1u3znVw9+3bFyyHXPKy3Pn6+/sz
y3/o0KHgOSdOnChtR0VpSUTp9+3bt8edd+HChXFutEXpZNVVbBtZuDp5fjzlQ3GzbCymjmNFcoxN
59lJ2h5iyi4xqbBnz56NS1O/Fb569epgXovS/vHjh+vYpqdZ7N27tzUiZlhc6/jH2p/Vfbqey7Zh
TD1ltWHsPZZF2Xu06LlY5Z5v6h4sc79VfcY0XV9Vn82TKZJv3LgxbvRYtqvfCo8VyVWeDf75e/bs
GRdP9eoL4Jh+QVZ+su6tJt9DiGQARDJA218Q6mDob/rirhft58+fWy6Pfucj1n0qSzgo/ffv37tR
oDNnzkyY17x///5WZ1ud7Hv37rnfevHWFclWxq1bt7bKqJGGdLxjx461OtyKp6/81pk4e/Zs6fRi
O1EWpg6G6icrro0EqmNp8TRSqTB/kZT0eRpR0e+XL1+634ODg+63OlVlKUrr+fPn7veaNWvGnWcd
1QcPHkTnKVRXsW3kCywJNeuYSrgpvmzMwjRKUreOQ2ExNp1nI2l7iCm7XcO/d/0O6j///BPMa0za
Jr60iJ9Q3nQPq150WF6tLU0ExNqfRr4Urr/XacOyNuIT2/5ZlLWfoudiFXts8h6Mrcuqz5im66uJ
Z3OVOcZl3pMmijUvWdj8ZNl/7Pu1yrPBP1+2oZHnrPd92X5B0bur6fcQIhkAkQzQ9heEXJ7SI0/W
yVqyZEljIvnVq1etML1MrbObzsebN29Kp10Uzzpifh5sZM2PpxW70/Ou5eqpMN+tLTa9siL59evX
UR0udSJv3rzpXA3V2Sn6mGAjDBI5Gl3yOzNliUnLOlMPHz50vzWSofz5QiomnVD5Y9soXadmczrU
yU6H1a3jUFiMTefZSNoeYsv+v//9z7l2W53qX40ALVy4sOXSWcX2TZDayI91cm30SK7XQn/3RUBM
W9vos28jVduwrI2EKGr/ImLtp+i5WNUem7oHY+uy7jOmqfpq4tncTpFsdq6yqR6FTTNQuP7ezmeD
nW8fuoTc0303/Cr9gph3V5PvIUQyACIZoO0vCL2Y038LdT7qiuSieKF8tDPtUOfa4oUOf1QjNr2y
Irkorr7mWwcyr+OW/n3r1q1xrnNLly4NzkGLISYtdcz1N3XUhTq/6fmsMemE6iW2jWLruak6rmrT
ZTrasWXXPD9ftA4MDLjfmg9dlNe8tCWwFc9ctv/888/WvEp18vv6+ly4Rp98ERDT1jYC7rttV23D
OjYS0/55dlHHfpq0x6buwdi6rPqMabq+mn42l41T9Hdrh6wj7SLf9LPBwnyBGnrf1+0XhMKbfA8h
kgEQyQBtf0HYXo2hl6HcoyZLJIfyUSXtPPEb28EKHUUdiDqdrNg6MndXjRpoXqE6XBqljK1zdUhs
LqfmoEmYVKUoLev4apTC8h2ac5eXTlmRXNR5iwmrU8dVbLqpjrBfds0n1LVtnq7Eq35rvmZd27dV
eTWSq9HqP/74w4XLlVftJyGta+l3mbbW/NO0SGiHSC6ykZj2zxNzde/RJtNr4h6Mrcuqz5im66vp
Z3PTItnKm3X4H4na8WzIe2f6Uxbq9gvy6qHJ9xAiGQCRDNC2F4S9rNrtbl0UT9fy3Shj0rYXue+i
pvlOWe7WfhnljpeOpy/bMdtcxabXtEi2OV1yzzNsReOYOhca3TN3WL+zU4W8tGzERPNyNWdQbeXn
OyadUDli26iqwKpTx1VsukxHOLbsQvOB1TmWXepfE7NZ14hN2+ZP2hzny5cvu3B/f2M/PLatbcVb
f4Xfqm1Yx0Zi2z+Luvdok/bYxD1YxuaqPGOarq+mn81NimS9p1RetUN61WmNqCtcQjXPDbnus8Ff
JTz9vjcPkSb6BUX11OR7CJEMgEgGaMsLwl+gQy9qf4EOzQ+bLJFs8xptARAtLpN2DUufo5Es/b54
8aKLo85VaJEWbTthc7PUOVEZQyueWsdfC6gojtK0zr+5LZZJL69+8rZsKuow23Y76vxpVdGiOjcX
t/v377vfmo9mK5WWpUxa6mjZCIdff7HphOoqto3qiuTYOs5rxxibLtMRji278K/lz03NukZs2jZ/
UqLWn4too3+2srAWBYpta1uoKb1XbNU2LGsjfhvGtn+R6Ct7jzZ9zzd1D8bWZdVnTNP11cSzuV0i
2bZLkzdGCPPSsGkS7Xg22PkKUzzVkb0z/VWm6/YLQvdWk+8hRDIAIhmg7S8IvSSztnrwO7rtFsnq
bOsremgLi6xz7EXuH5p3GZrXly6jOuTpeFl1oU6m9pYtm14IzQ9THC2iVPVDQtn5e+rUhOJrRdSy
ncTYtIRGE+3v6rCVTSdUV7FtVFVgxdZxTDvG2HSZjnBs2Q1bfCe0Z25V2xcaldbflH5akCl8/fr1
pdraRpT+/fffRkRybFlCbRjb/llUvUebvuebugdj67LMc6Gd9VXn2dxukWyrTWeJYNuL3Ob2t+PZ
4K9u7cfTolr+KHTdfkHo3qpqI4hkAEQywJS9ILQ/ojoS+qqvQ/OmhoeHS3cg6ohkoS/Ltt+iXrL6
Ku7v3Zg+Z2xszAlljV4p33L1zFqkReXRl3DFs1GGUDyNRuu6EjfqYChuehSuTHqhTqvO0VyssnUk
FzV1tHS+8iYxosVQiupc58nlUh0WGwVUxyS9kmpM/mPTEgozl/j06qcx6YTqKraNqgqs2DqObcci
my7b0Y61T3Hu3DmXzqVLl6KuEZu2tpEKbTNlrtb+ljMxbb1q1apxC33VbcPYsoTaMLb98+6PKvdo
0/d8U/dgbF2WeS60s77qPJvbKZL1XpKdqV6yvEgULu8oxcuKU/fZ4K8OL6GsOtIItr9eQRP9gqx7
q4qNIJIBEMkAvCBgStGCKk3uWfnff/85u/vtt9+oXIApgHsQyn4IoA8EAIhk4AUB4KGFW7JGJcug
kQG57tncQtsvFwAmB+5BQCTTBwJAJAPwgoAO7IjZ3DcA4B4ERDJ9IABEMgAvCPhl0RYhmhenBZ60
Zy8AcA/C1GPzi+kDAQAiGYAXBAAAANAHAgBEMgAvCAAAAAD6QACIZID/1979R2x1P/4D/yOZySSS
ZJKYyczMSDLJjJmZJJFJJvkwSTKJzGRmxszM5G3MzMzMmJnJJGYmMxlJMpNIkiSRZCa5vp7n63U7
97nPdV3n+nH36348uNR17vP7nOuc1/N6vc7rcoMAAFAGAiEZ3CAAAJSBQEgGNwgAAGUgEJLBDQIA
QBkIhGRwgwAAUAYCIRncIAAAlIFASAY3CAAAZSAQksENAgBAGQiEZHCDAABQBgIhGdwgAACUgUBI
BjcJAABlHxCSwc0CAECZB4RkuG83DS8vLy8vLy+vR/kFCMkA8EB/OQcACMkAgJAMAEIyACAkA4CQ
DAAIyQAgJAMAQjIACMkAgJAMAEIyACAkA4CQDAAIyQAgJAMAQjIACMkAgJAMAEIyACAkA4CQDAAI
yQAgJAMAQjIA4O4NAEIyACAkA4CQDAAIyQAgJAMAQjIACMkAgJAMAEIyACAkA4CQDAAIyQAgJAMA
QjIACMkAgJAMAEIyACAkA4CQDAAIyQAgJAMAQjIACMkAgJAMAEIyACAkA4CQDAAIyQAgJAMAQjIA
CMkAgJAMAEIyACAkA4CQDAAIyQAgJAMAQjIACMkAgJAMAEIyACAkA4CQDAAIyQAgJAMAQjIACMkA
gJAMAEKynQAAQjIAICQDgJAMAAjJACAkAwBCMrR9Bry8vLzu50tIBgAhGZz/ABNci1y9AEBIAOc+
4JokJAOAoADOe8C1SUgGAGEBnPeAa5OQDADCAjjvAdcmIRkAhAVw3gOuTUIyAAgL4LwHXJuEZAAQ
FsB5DyAkA4CwAM57ACEZAIQFcN4DCMkAICyA8340N2/efCSWgeNh3wnJACAswEN43mf4oNe9dPjw
4d6SJUvu+TLG3dbmdPdjn3VZrwfZvTjmj+o+H2XfTescF5IBQEiGBR2Sly5d+sgFjbZlCMnW9WHc
jlGWKSQDAEIyTHDef/vtt9X4//vf/xZESJ7WvITkhRuSH9V9JyQDgLAAC/68v379em/ZsmW9Z599
tnMBOtNs3ry5t3jx4t4LL7zQ+/PPP+eMe/Hixd62bdt6jz/+ePXasmVL78KFC3Pm1VYov3z5cm/7
9u0z0+b/V69ebV2XM2fOVOvy2GOP9Z544one3r17e7du3Rq4jLZl/vjjj72XXnqpWl62a+XKlb0D
Bw7MzGtQSM62Llq0qPf000/P2Q/Z5ozz1FNPDd2vv//+e1Wbv3HjxrH2Rdd9mPXN+M8880zr+mQ7
8veTJ0+OvG/GOR79DDuHui63+Ouvv6rzNeOsXbu29+WXX7auyyjLnc/1aFtev+U2z51pneP//vtv
7+DBg9W4mSbr+9577wnJACAkw6N73u/fv78a99ixY51D8s6dO2cV2BMG6iHiypUrvRUrVswp2GdY
CWr9Cv0J4KtWrZrz94TMtsJ8lt0cd9++fSOF5G+++aZvE/Q9e/YMDUaxY8eO6v8//PDDrH32ySef
VMMTRobt1/Xr11dhe/fu3WPti1H24SuvvFINS2BrBrgMf+6558baN+McjzZdzqGuyy1fGuTLoGHP
4o+63Plaj1FDcvPcmdY5Xq4Pzdc777wjJAOAkAyP3nmfAnsK1uvWres8z7yef/75atpr165VtWbN
IJD/Z9imTZuqwNZvvLZgcOjQoWrY1q1bq2lv3749E8o//PDDOdNmGZcuXerdvXu398EHH8x5trrL
M8ml5jRBIvOJU6dOVcPqHSUNCsmnT5+e2Td1qbnL8F9//XXofk3AKcsfZ1+MMt3PP/8853jUQ9Hn
n38+1r4Z53i0GfUcGrbc1IY255da1+b6jHvuTns9Bp0nXc6daZ3jqe3O+7Nnz1bvjx8/Xr3PlzBC
MgAIyfDInfepDcp4n3766Ugh+Y8//pgZlualzebEaZLZrKUsIXL16tUDC/0J7KVJd3Hjxo1qWL0Z
cpn23LlzM8NS+M+wNAsdJSQXCQ3fffdd1UQ2YTfj5EuELiE5Spj67bffqveptc30CSH1ANNvv/79
998T7YtRp3vyySd7y5cvn1m3/Jsa09R0/vfff2Ptm3GOR5tRz6Fhy03T8gzLPIpSa15fn3HP3Wmv
x6ghuXnuTOscLy0S0lIirSQGncdCMgAIyfDQn/cJSSkg18NUl0J6vaDcFgTy/+byuwamMm3ba1CN
V9cg2zYstXklMAxqAjvsfcJx3icsR8JICRijhp9J9kXX6fJsaYb99NNP1ftffvmlev/2229PvG9G
OR5tJjmHBu2Ttvl1HW/Qcqe9HqOG5GHjjnscv//++1nNz9esWdPaB4GQDABCMjz0531qg+uBbpSQ
3FbAT2dARYJ3v/HSfHPckDxOOOoSLMrzxKmBzbPDCbf//PPPyCE5ShBJDXuZb3oPn3ZIHrQvuk6X
529zrNIsO3bt2lW9T8dVk+6bSUPyJOdQ2/BB8+s63qDlTns9ph2SJz2OCcZpLVKeu05zfSEZAIRk
eKTO+/fff78aZ5Seaus9+BalKWrp6ClKYXqc5tapqWo2FR4lWI4Tkstzlzdv3pwZVnqAHjUkl9rj
t956q3oWNaGoPt9RtmXcfdF1ukjPzQnOaSacf1977bVZfx9330wakic5h9qGl2dy2+ZXH2/c5U57
PaYdkic9jpEm++URjfoXBkIyAAjJ8Eic96k9zDij1AiVAnRqn9N8M739vvjii3N6u613fpTx6p0f
5VnI5vzqPTWXjqPyk0WZLrVsH3/88Zxa71FD2aDeoEuAyE/kRAJjegseJySXoFVqc7vU1Pebz7j7
out0kQ7F6jXN5XnqSffNKMejzajn0LDllg6zyrlbn1+/jrtGWe6012PQeTLoXJ72OV6aWpfe70sL
lAwXkgFASIZH6rxPrVjGSZPbUUNy89nGdO5Tr7VMeO73MzrpFbvI87EZno6ihk2b0Fl+t3eUcNC2
jOY46Rm4X/PkcULy0aNHZ/6WcDpuSB53X3SdriidVbX9zvO4+2aU49Gm6znUdbk5z7v89NK4y532
erTpci5P+xzPFwNt46cHdSEZAIRkeKTO+1LTOUpvtaWAnJ+4SVBO7dTrr78+6xnWIr+bnKa8GSev
PBN5/vz5OWEyf8szjnWZX2pB85xz1jM9MjdrOLuGg7ZlNMdJM9L8RFLGy/I2bNhQdVg0bki+c+fO
zLOnzV6HRwnJk+yLLtMVH330UTX9Z599Nudv4+6bUY5HP13Ooa7LjfTsnPXPscmXRF988UVr0+Fx
ljsf69H25cuwc3na53imy6MDCeZZ35UrV1YBOee4kAwAQjIs+PO+6/OkC92JEyeq/fTss8/aGQ+w
NFvOccrPYFmPB/Pa5GoDAPNUoO/alA2EZCF5EqldS7Pz8qzn119/bac8IMozuXkGP60n0oFVevMu
z24vtPUQkgFASFa4R0gWku/pNSfN0Xlw7Nmzp/WekOboZ8+eXXDrISQDgEKrgj1C8hSUZzRpl+dL
E3byM0qjdIjG/Est/5EjR6qex8tzvenh/V4H0wdlPYRkABCShWSEZAAhGQAQklEQBRCSAQAhGee+
nQAIyQCAsADOe0BIBgCEBXDeA0IyAKNclL28vBbWS0EUQEgGQGER8Nl33QOEZAAUFAHXANc+QEgG
QCERcC2wzYCQDIBCIuBaYJsBIRkAhUTAtcA2A0IyAAqJgGuBbQaEZAAUEgHXAtsMCMkAKCQCrgW2
GRCSAVBIBFwLbDMgJAOgkAi4FthmQEgGQCFxiJs3bz4Sy8DxcC149LfZuWv/OVYIyQAP0YX4v//+
q/7W9mq6c+dO78iRI73Vq1f3Fi9e3FuzZk3vk08+uefbcvjw4d6SJUvu+TL67Zcu+74+3bjzmY9z
4mEJTPfimC+U4yEk97djx46+4544caL34osv9h5//PHq9fLLL/d++eWXqZ6707rGPEqfg2leix/1
a2pz+X/88cfMOZt79rp16+Z1HR+mYyUkAzDwQpybaNeQXAqQzde9Dsr34qbbtgwh2boKyY9uQfTA
gQN9j8HFixd7jz32WOv17/Tp01M7rkJyt+ulkNxt+atWrZp1ri5dunRe1/FhOlZCMgADL8Tfffdd
9bc333xz4PS///57Nd6GDRuqAuPdu3d733zzTTUsNcoLISTPZ6FP8BSSheT7s803btzovfHGGwO/
IEwLmgzftm1b7/r161WT0ldeeaUalnD9KF2vfPYfnXUt65Nz1rESkgEY4UL8/vvvV3/76quvBk6/
e/fuaryPPvpoohv15s2bq2ZfL7zwQu/PP/+cM24CeAqipUnjli1behcuXJgzr7ab8eXLl3vbt2+f
mTb/v3r1auu6nDlzplqX1A498cQTvb179/Zu3bo1cBlty/zxxx97L7300kxztpUrV1aF5jKvQSE5
27po0aLe008/PWc/ZJszzlNPPTV0v+YLjNQQbNy4cax90XUfZn0z/jPPPNO6PtmO/P3kyZMj75tx
jsd87JM4depUb9OmTdU6L1++vPf222/PWucu5+mwdcn2phlktjfLyno0t+/ff//tHTx4sNpvWZe1
a9f23nvvPSF5ytu8bNmy6jgfO3as7zn2+uuvV8Pr16zffvutGpbzdtj52O8a0Dw3pnWNmeTcGbS8
/C3LSauiup9++qkanr/XZT714aNuS9drcZfrSPHXX39V95+Mk/3y5Zdfdg53w64N4x6/LseryziD
9l1z+KjXvGHbMcp9c5TrZ5djKiQDMPUL8a5du6q/ff7551VBLTe/5557rioA1j3//PMzN6xxQ/LO
nTtn3URzw6vfGK9cudJbsWLFnJtthpUw0+9GnADebFpWQmZbISbLbo67b9++kW72pSa97bVnz56h
BbooTdh/+OGHWfssTdiH1VKV+axfv74K2/kiY5x9Mco+LLVnKWg2C54ZnnNnnH0zzvGYj32S87Ft
XbZu3TrSeTpoXVJArDd7zKuEifr27d+/v3X/vfPOO0LyFLc5wSO1yf0K9FGOd/plqIeWcu6OG5Kb
58a0rjHjnjvDlpftzz0i529dWiJlnNTIF2XcvNL3xTjbMmpIHnQdKV+U5UuRro8YNb+4HHZtGPf4
dTleXcYZJyR32a4u29H1WI16/Rx2TIVkAOblQlxCTwoy9ZtQvrWtP2uXb3szPDe41KrkfZpZf/31
151DcoJ2CinXrl2rvhlu3uzy/wzLN9oJNf3GayvQHDp0aObGnmlv3749E8o//PDDOdNmGZcuXaqa
jX/wwQczz2sNWkZzWKk5TQEi84l8I59h9c5LBhUaso/LvqkroenXX38dul9TwC7LH2dfjDLdzz//
3FpIKQW4fNkyzr4Z53jMxz556623Zgr7KeSX7U2QGfc8ba5LmT4dP5XpU6vc3MbyDOzZs2er98eP
H6/eJ+wLyfOzzf3Os3Is2sbPtXPUefY7N6Z1jRn33OmyvPLFXvqziIyXz2r+nleZriwztYTTul4O
G2fYdSRfiDQ/u/lyuMv1pcu1Ydzj1+V4dRlnnH3XZbvGPXZtw0a9fg47pkIyAPNyIS7f0pawmxtR
gk69cBO5YZaawua3us0mdv0KiaVQFamRbjYnTvOxZi1lCZHpUXvQjbj02ll/9iq1QxlWb+Zapj13
7tzMsGxzs7A7SgckKSzk2e40Ays17oMKTs33pYBQau9Ts5np6wXOQfv177//nmhfjDrdk08+WTXJ
K+uWf1MLkBqa1BiNs2/GOR7zsU/KOfjPP//0Xcao52lzXUqBs77NpSa+rdOdhJK0NBh0LgjJ8xuS
Bw2vn8+jhuTmuTGta8yk586g5X377bezajBLWCuP5KTpdeTv9XvLtK6Xg8YZdh3JoyLNztbaPnuD
PveDrg3jHr8ux6vLOOPsuy7bNe6xG7S8rtfPYcdUSAbgnl2Iy42o/g1xqWlO8+x0WpNx/ve//810
5tWlkFi/qbfd7Moy2tZlWGBq1oTXX8O+6R63cJFvwEtBYVDTvWHvm882ls7Ums/9dS2Qjbsvuk6X
5+DqheH8DE7e5zm2SffNKMdjPvZJ2znYb17jnKfDpq8P//7772c1S0zLjbbn+IXk+xuS06pm3JA8
bNxxP0fjnjtdlpcvwspjOfF///d/1fu0zkhgyj0iUgOY96Up+7Sul6NcH/pd44Z99rp+7qd1/Loc
ry7jjLPvumzXJNfzUY5Bl+vno9Y5mJAM8BBdiMv49RtWeYayXlPY9VvdtptambZewCy11W3jpanZ
uCF5nBtvl5t9aXaYWso8O5xwm2/jxyn01Z/5LvNNjc20A+GgfdF1ujS5z7Eqz6ylUJz3edZ20n1z
P0JyfdvazsGmSc7TQYXSfuOnIJwWF+X5vDSHFJJHKzhPGpLLMa9f/8ozyQku8xWSJ/0cjXrudF1e
6cgszWDTquS1116rhucxkSwn+yn7LO/n43o57nVk0Gd3nM/9tI7fKMdr0Djj7Lsu2zXJeTjKMehy
/RSSAbgnF+LS3LreeVEKOBmWZlHNQlG+UR4UdAcVHOqdfpXmVaU2IsqNf5zm1vlWvctPXUwzJJdn
xFKzXpQeoEct9JXa4zwfli8kUpCoz3eUbRl3X3SdLtIUP2EvTeHybykkT7pv5iskd922nGel8N/P
JOdplObW9emzHwdtY2rjSvPVekFSSJ69rwfVcE0Skssxq3domF7cm4+lTDskT/o5GvXc6bq8NKHO
+9IXwdGjR6vhH3/88UyHg/Xh075ejnsdafvslc/usHOky7Vh3OM36vHqN844+67Ldk1yHjaHTXr9
FJIBuCcX4tK7dZrQJvTmlY6Mmr1mprBT72gmr08//XSkQmKaEydkpwfL0lFRfRn1Dj0yXr1DjzwD
1ZxfPdiXwlp+1ifTZf1Kga3+Ey2jhrJBvUGXgkN5JjtBJ73VjlPoK4WHUss46Gdlhs1n3H3RdbpI
h2L1MNLsDX3cfTPK8ZiPfVKeqyzneX07y+MCo56nTaXzoDwLnc9Cpm/r3bo0rcxPE0We6e9Sc9n1
WtAvWD6qr0lCco5rhr/66qtVQMmrdHqY31DuMs9hPxU0zWvMuOdO1+UlLOWLvPwMUP3Z6lK7WFoe
paPGaV0vu/ys3rD9WT575V5U/+wOO0e6XBvGPX5djleXccYJrV22a9RjN+hYTXr9FJIBuCcX4hRu
2n5iITVv9W+N0+tl2zNJzV6wBxUSm9OnI5J6zV4CQ7+fhqgXtvIMaYano6hh0yZ0lt/tHeXG27aM
foWLaTxjV/8iIq8EuHEL9OPui67TFaUDlrbfeR5334xyPOZjn+TzUHpyb/5U1Kjnab91SaGwOX2+
aGqOX4JZ85Weuu9Voexhur7NZ01yvaa/ef2rP2bQpsu1ZNrXmHHPna7Li7QeabY4Kl/2tfVVMe62
dNl/XfdnHhUZ9yegulwbxj1+XY5Xl3HGCcldtqvrdnQ5VpNeP4VkAO7ZhTjNoFOTlZqB3Czzm5f1
3yssUnuSG3VqCRIu8k1wvcfqYQXPNOdKUE7BMs232wqX+c3GBIaMk1eehTp//vycMJm/NX+fNPNL
TWG2IeuXmrpmDWfXG2/bMprjZH/kZ4QyXpaXQmE6Vxk3JOeLiPK8VrPX21EK9JPsiy7TFR999FE1
/WeffdZ6royzb0Y5HvOxTyLndPn92hT6Mk3997y7nqeD1iXjpvYk05Ya5bbzK83vU+AstXYpENd/
q1dI7lZwnjQkR3oUznmRcyfHLde/EydODJ1nl2vJtK8x4547XZcX5VcQmj8HV5pa139abZJt6bL/
RglU6aE5y85+SfPeL774ovNjDMOuDeMevy7Hq8s444TkLtvVdTu6nuuTXD+FZADu24X4Xhdg+f9S
4M5+evbZZ+0MHslrgW3mQZOmwTk/0gEZCMkALsRC8gMiNQFpdl6e8Wr+rigIjLaZyZVna9MjdJ63
zSNFpV+O1J6CkAzgQiwkP0DHpv7cNgiMtpnp27NnT+sztXkE4+zZs3YQQjKAC/G9U547ol2ei0sh
LR3hpGMZEBhtM9OXVjvpjTydUpVnZ/N77wIyQjKACzHgWmCbAYRkABdiACEZQEgGQCEREJIBhGQA
FBIB1wLXP0BIBkAhEXAtcP0DhGQAFBIB1wLbDAjJACgkAq4FthkQkgFQSARcC2wzICQDoJAIuBbY
ZkBIBkAhEXAtsM2AkAyAQiLgWmCbASEZAIVEwLXANgNCMgAKioBrgG0HFvg1yRUMQEER8Nm3DwDX
IiEZ4N5dnL28vBbWC9c/Ly+vh/d67CoOAA/Qt9cAwH2+f9sFACAkAwBCMgAIyQCAkAwAQjIAICQD
gJAMAAjJACAkAwBCMgAIyQCAkAwAQjIAICQDgJAMAAjJACAkAwBCMgAIyQCAkAwAQjIAICQDgJAM
AAjJACAkAwBCMgAIyQCAkAwAQjIAICQDgJAMAAjJACAkAwBCMgAIyQCAkAwAQjIAICQDgJAMAAjJ
ACAkAwBCMgAIyQCAkAwAQjIAICQDgJAMAAjJACAkAwBCMgAgJAOAkAwACMkAICQDAEIyAAjJAICQ
DABCMgAgJAOAkAwACMkAICQDAJ3DcfMFAAjJACAkC8kAICQDgKAsIAOAkAwACMkAICQDAEIyAAjJ
AICQDABCMgAwPCgDAEIyACAkA4CQDMxfQdvLy8vLy8vr3rwAIRl4wAMyAODeCwjJ4APqJg0A7sGA
kAy4OQOAezEgJANuzADgXgwIyYAbMwC4FwNCMuDGDADuxYCQDLgxA4B7MSAkA27MAOBeDAjJgBsz
ALgXA0Iy4MYMAO7FgJAMPLw35ps3bzoIOBdwHi/Qz4DPvZAMQjLwUN2Yv/jii97TTz/dW7x4ce+p
p57qHT16tHX6Qa9BDh8+3FuyZEnn9RynEDHudIN88sknvR07doy0n+KPP/7obdq0qffYY4/1nnji
id6bb77Zu3Dhwn055l32SXO8+diXg86F+VxeFznGOdb381ybr3nfj/nd7+M5H9vZfD/KNe1h+AzM
twdlmx+E/Swkg5AMPAQh+csvv2wNvc3QMCggL126dGoFkwclJP/yyy/Vdl2/fn2k/XTq1KkqRLft
o7///nvBh+S2ed/vguvVq1d7y5Ytq465kCwkd/lMTLKND+Jn4H5ci4RkQEgGHtiQnBrR/O2HH36o
3n/11VfV+1WrVg2d57fffluN+7///e++F0ymuYxr1671li9f3vv4449H3k8vv/xyNfydd97p3b17
t3p9+umn1bDUKD8MIflRL6S2+eijj3orVqyojv2DFiYe5fk9TKFuWvthoezDhf7FgJAMCMnwiN2Y
M26aCg+SGtbUvj377LOdCkf9amJ+//33qpZ148aNfQtOP/74Y++ll17qPf7441Ut7cqVK3sHDhzo
3bp1q2+B699//+0dPHiwGjfTrF27tvfee+912v49e/ZUTQMzj1H3U95n+J07d2aGJShnWNahy77K
vt28eXO13i+88ELvzz//7FS47LePU1Namn+/+OKLVW13l+nqMk3mkXXKFwhvv/32rP3f5TgNOxfq
Ll682Nu2bVs1r7y2bNkyp8l6me7MmTPV/irN2/fu3Ttr3bqcCxknx7zLFxn91n/YenTZj11rLNuG
Z/k5vll+lpHj3jbe5cuXe9u3b5/Zt/l/xm3qOr9p7p82eXwhn4Pss1dffbV348aNifbTONeT+vtB
j5pM+hnIeZ9/n3nmmdZ9kcc98veTJ0+OdCybBn0msg6LFi2qltWUz2CWny8Nux7bYduc8fK5y7S5
F+zfv3/OtbfLdnb5nE/zPiEkA0IyLKCQXJoV7969e+B4KchkvGPHjk0UktevX18VyMrymuN98803
fZt5J8z2K/yU9Wu+UsM7SCkgDgtL/fZTaWqdYFz8999/1bAU7rrsq507d85a5xQ66wFx1JCcwuso
82u+z7iZprkvt27dOtJx6hqSr1y5UtXqNsfPsHrBuL49zXH37ds38rmwa9eu6tgPe3683/oPW48u
+3Hc8JfzNgGjPt+EteZ4+QImrR+a65DQUw+JXec3zf3T5vz589WXF/Vp6p+PUffTuNeTLiF5Wp+B
V155pfr/X3/9NWtb8j7Dn3vuuZGO5aDrd7/PRJ7Tr7ecKfJ4SYYn+Hc9tsO2OV98DDovum5nl8/5
tO4TQjIgJMMCCsn5dj7jvfbaawNrUfOtfsLEunXrOi+7X1O7hMx6oGyOW2pOUgAt46U2LsPqHcE0
pys1umfPnq3eHz9+vFMz8nfffbca7/vvvx9rP6VGPH9LE+usb/6eAnKX2vmyDc8//3y1j9P0twTc
eqFx1JC8YcOGKlzW55eanq7B7K233qrev/HGG1UN+c8//1y9zzkw6XFqG5ZtzfvUXqaAPGw/ZLxL
ly5Vy/3ggw/mPCff9Vz47rvvOhWQ++2vYevRZT+OG/7KPktz/7LPUgvcHO/QoUMzwTzj3b59eyZ0
fvjhhyPPb5r7p03ZZwnoWY98gZJa5XH307jnaZflTeszUM6L5hcIJdB9/vnnIx3LNsM+E6dPn565
FtWVL0p+/fXXkY7toG3ONbNMm/CdYWllMeo52+VzPq37hJAMCMmwgEJyak9Xr149UyDpVxuREFGC
4KQhudmZVb/CbgqbCTEJdym4DQsXpeYhNSKpDakH8UFS2Mt0qcEaZz/99NNPc2ol0nQy/6aWuct+
SvPSIs0Y680bxwnJ9RqpMr960+9hASDj5v0///wzdP+NepwGLa++3qXQnv3enO7cuXMzw0rT9vq+
7nou5FzMeAmD44TAYevRZT9OGv7q61BqHuvj5Yut0qS/KM2XyyMPo8xvmvunzZo1a6rxcvyLfD4m
aW49znk6Ssdd0/gMPPnkk1VQLOdq/k1LijzikpYpoxzLNl0+E+WLqd9++616n+tctiOBv4zf9dgO
2uYSUCNfKjan7bqdXbZpWvcJIRkQkmEBheSi1Kb2a3KcAlwKS/VCy7ghedi4qcEqBc1BPz3VfJ+a
4HqT3RS2m8/2tkmT6GZz6VH309dff10trzxDmVrhUZpb15fdtcDZtSDfZX7N96UJ+SDjHqeuy5tk
P3Q9F8oyuh6nUdejy36c5rzL9rSN1/aq13Z2nd80t6FN1/WY7+tJl+VN8zOQ52LzPl+6RXpez/s8
wz7qsWzT5TORcFwe14jS0qL+s3iTXItGPbeHbWeXbZrWfUJIBoRkWIAhOU1B+zUPLrU4peA03yG5
PBuX2oQ0xUtBLTVxXQvJKfCUnqnz3FyaMg6S8N91Xw3aT3WpZcl4XTs5GxbcBo3XNSQPml/zfZd9
Mslx6rK8st71fT1q+OpyLoxS4z/qenTZj6Mcwy4BfJTAUd/urvO7HyF5kv007nnaZXnT/AykWXnO
l/K8enlePs+Kj3osBxn2mSihPy1QyvblVw0elJDctp2Dtmla9wkhGRCS4REPyWm+l7/Vf/pmUEdT
77//fvW3UXoAnaSAVJ4Zu3nz5syw0gNs1+aPaZpXmogPC7Slk6BmTfKo+6kutRUZLwXdLvspBdKi
NDMunfXUw1a9B+00Wey3T+pN2kuT2frz5MP2ZWlanucG+5nkODWHlcJq1+bWo4SvQedCCVUpJM9H
COyyH/sF62HHujSPru+z8uVMfbzSfHlYK5Cu85vvkFya2g5bj677adzztMs2TfMzEOnRPSEw25t/
0wdCXddjOcygz0SpPc6z4XnGOPu5vn33IiSPs539tmla9wkhGRCS4REPyek4K387cuTIzO/6Hj58
eE6vu0WG5W+jfNNe/6mPcUNyflqlFJDTI/awQlhpQld63y414Bk+SOmYpvmsdNf9VJ5xK73Cpkfj
0lttebZv2H5KLX3CeDrbKp0l1TuTyrOK9c7BUhBv61SpvC+dL2V+6cSr2Wxz2L4s2146WUunPc2m
4aMep0HnQr3jruyHrh2OTXoulFq/Ya0kxg2BXfZjc5quxzo/Y1Oe0SydtLX1Rl06f0rncxkn88zv
gTe3u+v85jskl06bsh6pXe23Hl3307jXky7n8TQ/A1E/P9quH12PZZtRro/50qrU5jbnO2pIHuce
0HU7u2zTtO4TQjIgJMMjHpJTmCy1pPVXhrV1MFRqw1Jg7arUzmae4waLUZ/zS5hqGz+F7kHKs4Cp
QRlnP3300Uety02Pxl2/TGg+15jgXa9FKSGy/kro7bdPUiPV5aeU+r3PFwblWe3mT7CMepy6nAtZ
t34/AZXnu0c9h7qeC6XWbFgriXFDYJf92O8Lg2HHOuGhuc/qx33Yvk0IKr+9O8r85jskt/38T/3z
Mep+Gvd60uU8nuZnoCidvbX9ZnHXY9lmlOvj0aNHZ/6ecDpOSJ7kHtB1O7ts07TuE0IyICTDIx6S
IzUeqW1MTUgK8du2bevbu3Pb7wAPk0JW5l1vxtq1gJQmcPm5j0yfZacmtDRfHlSIzXRpIphCWZoI
rly5sir41JtjtklT2Ixf75xm1P2UgmQp3KaTs4SuLvurbEPWIUEgy3n99ddnPYcY6QE2oSDNHzNO
nn8c9ExyqYnN/su/zS8/uoSa1LCU37ROgTe1OvXfE+56nLqeC5l3QlnGzSvHo7mvRzmHupwLWUbz
uc9ph8Bh+7E5TddjHdk/Ob4Zr9QAt42X7ctycw7nWGXctlYOXec3nyG5fCbTAV7WIz//lPfj7qdx
ryddzuNpfwbqX7p99tlnfb/k7HIsm0a5PmZYac7e9dcIJtnmcc/ZLts0rfuEkAwIybAAQjKzpbCd
glj92bt7dYwcp/sjxzrHvN6cmwf7euazcm+cOHGiU8eDuBcDQjK4MT/C0sQzNQqjdE6m4P9wy7FO
k85JO0HCZ+VRkdrUfB7Kc9X5aTvciwEhGdyYF7Djx49XTTfvZWhS8L8/0hw9zUDzW7QIyczex+U5
cNyLASEZ3JipngPMM4b3Snn+lnsrP82VXpF5ePiszL900phngPPTU6N01Ih7MSAkgxszAOBeDAjJ
4MYMALgXA0IyuDEDAO7FgJAMbswAgHsxICSDGzMA4F4MCMngxgwAuBcDQjK4MQMA7sWAkAxuzACA
ezEgJIMbMwDgXgwIyeDGDAC4FwNCMrgxAwDuxYCQDG7MAIB7MSAkgw+omzMAuAcDQjLgJg0A7r2A
kAz0vVl7eXl5eXl53ZsXICQDAPP0BRcAICQDAEIyAAjJAICQDABCMgAgJAOAkAwACMkAICQDAEIy
AAjJAICQDABCMgAgJAOAkAwACMkAICQDAEIyAAjJAICQDABCMgAgJAOAkAwACMkAgLs3AAjJAICQ
DABCMgAgJAOAkAwACMkAICQDAEIyAAjJAICQDABCMgAgJAOAkAwACMkAICQDAEIyAAjJAICQDABC
MgAgJAOAkAwACMkAICQDAEIyAAjJAICQDABCMgAgJAOAkAwACMkAICQDAEIyAAjJAICQDABCMgAg
JAOAkAwACMkA8KiG4+YLABCSAUBIFpIBQEgGAEFZQAYAIRkAEJIBQEgGAIRkABCSAQAhGQCEZABg
eFAGAIRkAEBIBgAhGboWGr28vLy8vLy8vB6tFwjJoFYFAADlPIRkcOEEAEB5DyEZXDABAFDuQ0gG
F0sAAJT7EJLBxRIAAOU+hGRwsQQAQLkPIRlcLAEAUO5DSAYXSwAAlPsQksHFEgAA5T4QknGxBABA
uQ+EZFwsgQfSzZs37QSc+/Pw+ViIny3XE+U+EJJ5aC+WX3zxRe/pp5/uLV68uPfUU0/1jh492jre
jz/+2Nu4cWPv8ccfr14vvvhi79ixY3ZuYz8/CjemTz75pLdjx46Z93/99Vfv5Zdfro57zpOcB23H
/o8//uht2rSp99hjj/WeeOKJ3ptvvtm7cOHCI7V/H5Vj3Obw4cO9JUuWzOv+mvb+q88v52zO3Qfh
WM7ndt6r+T3K53qXc7+5/ZN8PrrMfyHuU9dsIRmEZB7Ii+WXX345cwOpv5oFza+//rp1vLy+++47
O/gRuhn/8ssvvaVLl/auX79evT979mwVjtuO/U8//TQz3alTp6oA3Rwn8/r777+F5AV6/t7LkHz1
6tXesmXLqnNYSBaSJ90f0zx3u8x/Ie5T12whGYRkHsiLZWqO87cffvihev/VV19V71etWjVrvNWr
V88E4rt371av/D/D1q5dawc/Iq5du9Zbvnx57+OPP54Zltq5HOfdu3f3bt261fv33397u3btqoY9
99xzM+OlpjnD3nnnnZlz5NNPP62GpUZZSBaS70XY++ijj3orVqyozuVHaV8+6PNbCOf+tEOyLx4Q
kkFI5iG6WGbcNJetKzWEbeOmlnGY1DKmGW7mkxD29ttvV4Gr7uLFi71t27bNNOfesmXLnKa65QZ7
48aN3iuvvFKt5/bt26tAdv78+d4LL7xQLSPLunLlypzpUju6efPmapyM++eff85Z1zQrf+mll2aa
Fq9cubJ34MCBWetb5vf7779XNaVpftxWAEigPHjwYDWPzCtfKLz33ntzljnKtp85c6bahtKkee/e
vbPWresy2+zZs6dqHpd5FHmf5daH/ffff9WwzL/I+mTYnTt3ZobluHT5IqXr8WkrYHU5Xl3PwcuX
L1fnUzkO+X9qJ9vWIcNL0/I8epD5j3Nc7+XnZtC502wBMOxcH3XZg45hl/0eWf/s66x/9kvGafvM
5Zzt8sVMv3Ub9hnrcmy6fjnQNrzLdk57v017/7TJ4xjlGv3qq69W1/FJ9tMo1+pJzv1B43RZj2Hz
z+co/z7zzDOt+y2PQ+XvJ0+eHOm4Nw26N2QdFi1aVC2rKZ/pLD9fqk9rn2a8fEYzba4r+/fvn3WP
6bqdXe53496XhWQQkhGSZ5Tm16k1rNu6deucptXff/99NSyF5EFyg80NtHnTzDyLBNrU/jTHybD6
TbEMzzKbzcNLrXjb/MuwnTt3zhon61Uv1H/zzTd9m5UnQDbnt379+qpgUfZX82acG3/bvFLbOu62
t+3Lffv2jbTMNqWQ1CVclJCcFgbNL1ISjJvjDfsipevxae7frseryzmYgJ4WFM1xcl61FbpTOBy0
rl2P67383Aw6d4YVapvn+qjL7ve+637P+ZnCdH2cBJO20JKWDlnXYV9I9Fu3YZ+xLsdm3PDXdTvn
Y79Na/+0yZeY5Qu3ts/7qPtp1Gv1JOf+oHG6rEeX+edL3/w//T/U5X291U7X495m2L2htBoqLcuK
3F8zPMF/Wvs0X5IMOoe6bmeX+90492UhGYRkhOQZ+ZY247322mtzvtHNTSk3sPqzqQlFGTbsxvzW
W29V47/xxhtVLePPP/9cvU8htsh8Miy1HLk5pqlkCSH1G2c9JCeAffvttzPrkgJX5l+G1YNZme75
55+vvp3uN//yjX0KPiXspcYow+odkJT5JTDUQ2HzZlxqV/Ncbxw/fnxOc/ZRtz3jXbp0qVruBx98
MPPc7yjLbPPuu+9W4+XLj2HSuVvGPXLkyMyw1DBmWJpYZ91yDqWQ2NYyoV8BeNjxae7frseryzl4
6NChmaCT43D79u2ZQvyHH344Zx02bNhQhcH6uqYmZdTjei8/N8POnUHNI5vn+qjL7ve+634vy0uz
/rK81I62rXN5FGRYobffug3bT12Ozbjhr+t2zsd+m9b+GXQ+J6BnPfIlS2qVx91Po16rJzn3B40z
6nr0m385h5rXhhLoPv/885GOe5th94bTp0/PXIfrypcqv/7669T2ae4XZdqE7wxLi4xRz+8u97tx
7stCMgjJCMkzUoNYnj3OjakeftMs7vXXX5/zzWuC9bCQnKZMGfeff/4ZOk79W/Ryw67XVpbllo6g
SnPevHLDbQ5rTpfmfkWaitWbkNWlkJOCdkJPCgz9CsDNDqmayy3fhOcb+nw7Xw8Z4277uXPnZoaV
ba03e+6yzDYp8GS61PgMkm1O50ipWcwXFUU68WqeH2k+2Fy/QYXxYcenXwF62PHqcg6uW7dupsl3
/bwvBbrmOtSPV1nXerPyrsf1Xn5uhp07gwq1zXN91GX3e991v5cwUt+GUsvWXOesa4YlDI4TAoft
py7HZtLwN2w752O/TWv/tFmzZk01Xs6RIp/3SZpbj3KtnuTcH7YOo6zHoPk/+eSTVVAs1+z8m5YZ
ud6Wa23X496my72hfNH122+/zXxBnu1I4C/jT2OfloAa+UK1OW3X7eyyTePcl4VkEJIRkucoNYr1
Zrf/93//Vw1Lh06lU6Z0kNOlVqzf88zDxhm3IDOocFO/GbbNP7UspYDT9hq1IJda2XqT1BQUm8/Z
TrLt4y6zTWklMKjAkFCQeWeebU2G0wt6/laeOUyt8CjNrYcdn+a2dj1eo5yDba9hNUJt69rluE5r
nad17ozS0c64y+63ncP2+6Dl9Rve9bwbdT91OTbTnHfbds7HfpvWNox6ro6zjGlfq8cNyZOsR3NY
nout/2pAemnP+zzvPupxb9Pl3pBwXB4nidIqo/6TgPNxPRn3/O6yTdO6RwrJICSzwENymg82m8iW
Z8naQsywZnb5FnrY8tvGKfOvr8ekIXlYQbo8k5VvsdMELAWEBMNJC4u5AZdnpvMcV5rWTWPbx13m
OMcptT4pWKRmqt4p2iCpacg8n3322ZEK4/2OT3O8rseryzk4qFA2LHC2rWuX4zqoUD3fn5tJC7Xj
LnuUwvCwLx2GbVvXFgyj7qcux2aUa1CXAH6v9tu9DMmT7KdpX6vHvY9Msh7NYbmu5twqz7aXZ+vz
XPmox32QYfeGEvrTQqZsXx5jelBCctt2Dtqmad0jhWQQkllAITnNuPK3+s+ltHW2lBt1velYvwJx
m9KEuzSHblNuVKM23Ry1cJObfnP+9Z8xKs8q3bx5c2ZY6Xl00sJimorlGcnmPptk28ddZpu2L0KK
tCDI39K5TObZVencLYW9LoXxYcen37Nlw45Xl3OwNAetN+8btK715sel+WoKyqMe1/v1uZm0UDvu
spvvu+730my4vrzyJUy/UJWC73yEwC7Hpl+wrvf+nian/ZpbD9vO+dhv8xmSS/PZYevRdT9N+1o9
bkieZD3ahqWH+ITA7Jv8mz5CxrlODTPo3lBqj/Mceb4EzzGpb9+9CMnjbGe/bZrWPVJIBiGZBRSS
0xlP6YCpNKM+fPjwnJ5ay3NKX3zxRVV4yXilx8s8yzpIWUbp+CedfzSb19Y7AUpg79cZ0qQhOfPM
vNNUuHReU+/cpxR48pMepRCXZ2/HLXiVJl3Hjh2r3pdn8DK8mGTbx11mm9I5S/PZ09LkLx1V1Quu
TeU5r9IzanoALj22lufbhhXGhx2ffgXlYceryzlYOsjJc/ZZhwwvXw6Upof1dSgdIWVds2+azSK7
Htf79bkZ9DkZ9FNGk563/XqaHbbf85Mt5XnE0mFav16aS01effpphsAux6Y5TZ41rXdslyDV1oFW
1+2cj/02nyG5dMSU9UiNab/16Lqfpn2t7nLut40z6noM+2zVz6W2a2fX495mlHtDvgQrtbnN+c7H
9WTc87vLNk3rHikkg5DMAgrJKYCU2uT6K8PqndKkU5K25k8ZVu9sqU1CV71X7PpPORQpvPX7OZk8
1zqtkNx8dizBrv5NdSn8Tus5t4SFtvmkwDiNbR93mW3K83D1n/mqh+dh+6Q8o958pQfgLudnl+PT
L6wMW7dJzsGc4+X3SevrkBqfQT991PW43q/PTdvw0pogn/9h04677Ob7rvs9BeXmePVjUFdqwob9
9um4n+sux6Zfr9X1V75UaXvWtst2zsd+m8+Q3PaTPvXP+6j7adrX6i7nfts4XddjlM9W6Riu7TeL
ux73NqPcG8ovGJS+SMYJyaNs87jnd5dtmtY9UkgGIZkFFJLLN9+pFcs34in45eeV2no4TlBOYMp4
eeX/XTu7SJAuv7OaG2e+HW7+hmnep/BW5p9noZrrMWlITvPIFMwy//TWXX/WK9L0Kj8zkb/nZpwa
wtJkeJyCV+aXJmspJGTbV65cWd2ImzWy4277JMtsyr7J+PUOWmLQs2HN9UlhqhTw0lNrQkqXnkO7
Hp+2be1yvLqeg1lehudzkPml1qtZk1PmXWpOM17+bevpuMtxvV+fm7bhKRhnHvVmyoMC0DjLbptf
l/0emXf2dZZVakb7PSfafJZz2iFw2LFpTpMefBMA03w165/nV/t1oNV1O6e93+YzJJdrTDr0y3rk
55/yftz9NO1rdZdzv22crusxymerfOH42Wef9f1yu8txbxrl3pBhpen7sF9xmMb1ZNzzu8s2Tese
KSSDkMwCC8kLZfvdMIZL4TSFkfrzZ44PD5OcuzmHuzRpx7WZdidOnOjU6SLKfSAk42KpIPbIS5PI
fKs+rJmq48ODKudummlO2rERPvsLUWpT89kpz1XnZ/1Q7gMhGRdLBbEF7/jx41VTx3sZMhwfpiFN
4NO0M53N4drM+MejPDOOch8IybhYPsLKM5N0k2fh8pyd48PDJD81ll6RcW1mPPl5szwDnJ+eSi/k
KPeBkIyLJQAAyn0gJONiCQCAch8IybhYAgCg3AdCMi6WAAAo94GQjIslAADKfSAk42LpVAMAUO4D
IRke2IvlzZs3HRgAACEZhGQezIvlJ5980tuxY8c9WZ/Dhw/3lixZ8sjs2/m4GY063xy7HEMAQLkP
hGSY8GL5yy+/9JYuXdq7fv36Qx0sF3JIvnr1am/ZsmXVsQQAlPtASIYxL5bXrl3rLV++vPfxxx8/
9MHyUQrJ4/joo496K1asqI4pAKDcB0IyjHGx3LNnT9X0+d9//50T/G7cuNF75ZVXeo899lhv+/bt
vbt37/bOnz/fe+GFF3qLFy/ubdq0qXflypVZ87t8+XI17uOPP1698v/Ucjbn3RYuf/zxx95LL71U
TZf5r1y5snfgwIHerVu3Om1nl+nLcs+cOdPbvHlztW1PPPFEb+/evXOWM8r8Ll682Fu0aFHv6aef
nrNeFy5cqMZ56qmnqvfZ1wcPHqzml/muXbu299577w0M312myTg5lm+++aaTHgCU+0BIhlEvliXY
NUNVCWjbtm2bFWjzzGuCXn3Y1q1bZ6ZLc+1Vq1bNCcKZpgTLfiH5m2++mfO38kqQH6br9GVYgnFz
vH379o09v8hzwfn/Dz/8MGvdst8yPAE79u/f3zrfd955p29I7jJN7Nq1qzqmCeYAgHIfCMkwwsXy
3Xffrf72/fff9w3J//33X+/bb7+t3qcGc+fOnb07d+7MDEsta3Ho0KGZ4JzAfPv27Wr8DPvwww/7
BsBIDWyGJZymxjpOnTpVDevSyVfX6cuyUwt+6dKlatwPPvigGpbnssedX5w+fbr6//PPPz9r3VIb
neG//vpr9T6113l/9uzZ6v3x48er9/mCod8+6jJNfPfdd63hGQAQkkFIhiEXywTF/C1NqNtC8t9/
/129T0gswxIsm8OKdevWVe/rHYClyXaGbdy4cWBILhJEE/TS/DlhM+OlZrSrYdOXZZ87d25mWNmW
fAkw7vyKNOHO+99++616nxr0jJ9gXcJ2qW1PzXNqncvwtmNQdJkmcswy3osvvujEBwDlPhCSYZSL
ZWqB87dm4GoLsV2GJWT2a6Lcr/a1SGdTJYS2verTtTXX7jL9oIA+rfklHOd9wnKUmt36z2ul5j4d
bJVp16xZ0/vzzz8Hrk+XaeqBv17DDwAo94GQDB0ulqnh7BIYpxGS67W0bfMqz/OmNjrP7iZc/vPP
P51DcpfpRwnJk8yvhOt0Dlbmk+bpTQm55RnvPCP9888/D13PQdPUp22rFQcAhGQQkmHAxTK1u9Os
SU7tZrO5db/1ac6rPHN78+bNmWHpWKzrTyx1nb5rSJ5kfqX2+K233qqec86XEfX51KU5ep4fzvhZ
5rD1HDRNlJrkBGgAQLkPhGQY4WJZOpQqzx5PGpJLD8z52ac0V05gy+8v15sf16er/5RSCaX52aXI
M8Pr168fOSQPm37UkDzu/FLbW2rW69sepdn0sWPHqvd//PFH9T7D+823yzRRarubywQAhGQQkmHI
xTK/s5u/peZzGiE5v4dcf2623tT65MmTM+OVGuxly5bNDNu9e3ffptpdLvZdp+8akied39GjR2f+
li8K6tIJWNs80zt4v/l2mSZKLXbzN5QBACEZhGQYcrFMT9VpClzvVGqSkBxpkpya5HQclXCcXq1L
T8/1AJma2nqT4DQhzs9FZXim27BhQ9VZVdeQ3HX6riF50vnlZ7LKM9/NmvrMO02x8yVBxlm5cmUV
djPNoPUZNk3kWObvOQ4AgHIfCMkw4sVy3759VQjs98ws4zlx4kS135999tl7tswcwxzL1DoDAMp9
ICTDGBfLdLKVWknNc6cjNbvZp+X55a+//vqeLTvHMM3dh3WcBgAIySAk42I5wPHjx6temIWr6ezr
8spPQd0r6Sgtzdd/+eUXBwEAlPtASIZJL5afffZZ9Qwuk1m9enX1PPZrr73Wu3Llyj1b7q5du3qf
fvqpAwAAyn12AkIyuFgCAKDch5AMLpYAACj3ISSDiyUAAMp9CMngYgkAgHIfQjK4WAIAoNyHkAwu
lgAAKPchJIOLJQAAyn0IyeBiCQCAch9CMrhYAgCg3IeQDC6WAAAoaKGMXAAAHqZJREFU94GQjIsl
AADKfSAk42IJAIByHwjJuFgCAKDcB0IyLpYAACj3gZCMiyUAAMp9ICTjYgkAgHIfCMm4WAIAoNwH
QjIulmO5fPly78MPP+xt2bKlt2TJkt7jjz/ee/7553tHjhzp3bhxY+xtHme7x53uXh3HhXrj27Fj
R+u2l33S7wUAyn0gJMNDdbE8efJkFYz7hZw1a9b0rl69KiQv4JB84MCBvts+KCAvXbrUhx8A5T4Q
kuHhuli+8MIL1fpt3769d+HChWrY3bt3e3/99Vdv48aN1d/27NkjJC/AkJxWBG+88cbINcPffvtt
Ne7//vc/H34AlPtASIaH62K5ePHiav3u3Lkz52+XLl2q/vbEE08MDYrN4f3eX79+vbd58+ZquQno
f/75Z+t8bt261XvzzTd7jz32WFUjuX///t6///47a9yLFy/2tm3bVjUPzyvNxUvQb87vzJkz1XIz
v2zP3r17q2VkHosWLeo9/fTTc7Yp88q0Tz31VKdtHLbtv//+e7Ut+fKhSFP3fEFRtiH/b6u5//HH
H3svvfRSNU723cqVK6sa3mxDkf1z8ODB6m8ZZ+3atb333ntv7LC/bNmy3vLly3vHjh3rPE2Ob6Z7
9tlnffABUO4DIRkevovliy++WK3f119/3XlbJgnJO3funFUzmcBaD7Zl+Kuvvjqn+e6+fftmxrty
5UpvxYoVc8bJsHrIrC+n3/zK87Y//PDDrG365JNPquEJo9MIyevXr68C+e7du2cC5apVq+asV0J5
Pfx+8803fZs012v580VC2zjvvPPOWCE5gbs8k951mrIOCdYAoNwHQjI8dBfLBNTUPGYdU/O4a9eu
KjCfO3duXkJyOgRL7em1a9eqmt1m+C3jpbY1Ndlp+l2eiU2tZpFpMmzTpk1V2Bw2v4xX5vfBBx/M
emb29OnTM+tWl5rbDP/111+nEpITjrP84tChQ9XwrVu3Vttw+/btmS8R0pFakVruDEtYLtOfOnWq
GpbnyYvUkmfY2bNnq/fHjx+v3ieIT+McHnYe57jmS4B169b50AOg3AdCMjwYF8txehhOzWtqDVOD
2azRzPOl0wzJf/zxx8ywNIGuN2euj1eCXqQZcYalCXGRQJ9heXa6KGF39erVc+ZXD/0Jms35lYD9
22+/Ve9Tk5vAlxBagumkIfnvv/+eNV7CZGmCXqTmtnxJ0JRg/N1331VNxRPoM17WsSi10qkZT614
PZDfi5CcGuuM8+mnn/rQA6DcB0Iy3P+L5TR+iifPzaYJb2qUS6deR48enVpIrge3trDadf7lWeq6
SeaXcJz3CcuRMFoCZ9dtHHW8sg1tr3oNcWrJSygedGy///77WU3Q0zN585nv+QzJTz75ZBXa66Ef
AJT7QEiGhzok15VazYSfQWGphNMuIbltunRGNWrwTBjrN780Ox51flGCaGq4y3PK9Zr0UbZp0pBc
D/plXVLznKbnCfD//PNP3/kmGJdWAXkW++eff573kJwWAvUvGQBAuQ+EZLivF8tBAXnQ8stvJOd5
3aa2EFvCab037DSN7hqSE0CL0jz6ueeeGznUlhDYtbl1l9BXao/feuut6nnlbOvNmzeHBvVR90WR
mt5mc+s25Vnj+rqkV+5BxzZfcJTmz/UvDeYrJL///vvV39t60wYA5T4QkuG+XCzHCclpWp2/5yd7
0tFTaQ6dEFb+lg6sinSeVZ47zbgZr/SQ3SUkp6YxzYfzHHSZrt77ctdQW++4K/Ord9yVZ3bHCckl
fJca3mataHOacfdFUXqCzs8+Zf0zj48//njOsktIzs9ARZ6vTk/ZzfmWptalZ+lSu5vh8x2S0/lY
/j6NWmsAUO4DIRkXy/sWkhPOSo1m2yu/eVvvRKuE0/rr7bffHql36/q06WyqXpPaNdQmZPf7Caj0
sjxuSM7z1+VvCaxdgvqo+2LYNiSknzx5cma89Ird5djmy4G2v6cX7VEC7zghObX3+Xt+mgsAlPtA
SIYH5mI5zvPIacZ75MiRqqOuNK1OM+L8LFRqkuu/YRzpaTrhMM2RU8OZZ2RHeSY5zboTlDPt66+/
XtW+dgljbcOzblu2bKnmlVee3T1//vzY84s0nS7NqJu9UTenGXdf1GX7U5Oc/Z5wnF6tSw/bRZpO
56ehsoyMs2HDhqqTruZ8M16aiueLjXIME5DrzcHnKySX2vdp9qgNAMp9ICTjYvlI74OHYT+cOHFi
pvk5AIByH0IyuFguyJCc2tY0+y7P+n799ddOXABAuQ8hGVwsF2ZIrjdPT3NwAADlPoRkcLGcN+W5
4QdVOp7Kc8GvvfaazqcAAOU+hGRwsQQAQLkPIRlcLAEAUO4DIRkXSwAAlPtASMbFEgAA5T4QknGx
BABAuQ+EZFwsAQBQ7gMhGRfLB8XNmzedCACAch8IyfBgXyxXrFjR27ZtW++dd97pXbhwoXWcDM/f
M17GH9Xhw4d7S5YsmTXsjz/+6L344ovVbxMvXry4t27duvt6fO7lMdqxY0en5XUdDwBQ7gMhGRfL
KQfEvBLKBoW1ccNk23SrVq2aNc+lS5cuiJB84MCBTsvrOh4AoNwHQjIulvMQEFOTm9reu3fvzvp7
3j/xxBO9tWvXTjUkl2HXr19fEOfAjRs3em+88cbQLxu6jgcAKPeBkIyL5TyG5Lfffrv698SJE7P+
/uuvv1bD9+3b1xraLl++3Nu+fXvVbDqv/P/q1atz5l+ftjmsPs+LFy9WzbrL/LZs2TKnGXiZ5vff
f69qoDdu3DhreILmK6+80nvssceq9UnQP3/+fO+FF16omnZv2rSpd+XKlb4hvrw/c+ZMb/PmzdV8
8kXB3r17e7du3Rr6BUCbZcuW9ZYvX947duzYwGm6jgcAKPeBkIyL5TyG5BKG9+/fP+vvpdnvL7/8
Mie0pRa42Ww6r6eeemomTI4SkhNc88xz828Z1ha8169f31u0aFFv9+7ds4YnZNen/+STT6p1qg/b
unXr0JCcYNxcl3xZME5IPnjwYBXeh03TdTwAQLkPhGRcLOcxJKe2Nc2t06y6LuEyta/5ezO0HTp0
aCZwJjDfvn27t3PnzmrYhx9+ODBItg0rtdWp6c38rl27VtXkNsNpmTbhuN48vB6S//vvv963335b
vc/6Z73u3LkzMyy11MNCctbj0qVL1TI++OCDqT073TX8CskAoNwHQjIullMKYF2faa2PUzroOnfu
XPX+77//nlXr2pxfnmNuPlecWtAMK02gRwnJ5bnnv/76a2bY6dOnq2GrV6+eM23Wr22eZXg92Cfs
NocNC8llP9SnS+AWkgEAIRkhGR6Ci2VbQB4WtOp//+abb2bVApfa088//7w1tCUw9lte/Sefuobk
Mr+6tnDab5u6LqdrSJ6v0CokA4ByHwjJuFg+BCE5zZvz//x+cWzYsKF6n865Rg3Jw0Jt27A8X9wv
JKfzLCEZAFDuAyEZF8uJA3LXkBylM6z0Mp3hzz33XN9x16xZ0+lnnLqG19K5Vtfm1kIyACAkg5CM
i+VYQblrEDty5MjMc8j59/Dhw33HTU/YeZ+fWUotdGp9P/7442pYOtxqTlf/+aRhHXdlfvWOu/Lz
S0IyAKDcB0IyLpb3NCSfOnWqel+aPv/22299x83PMrX9ZFOaWp88eXJmvDyfnOH5DeBBAbDf/DKs
NPl+0ELyOEFWSAYA5T4QknGxvIfLGrd366IE1XrnW/3GTbPs1CTnJ5USjtOrdT1Yx9GjR6tnivO7
w8MC4IULF3pbtmypxs8rPW6fP3++U3gUkgEAIRmEZFwsAQBQ7gMhGRdLAACU+0BIxsUSAADlPhCS
cbEEAEC5D4RkXCwBAFDuAyEZF0sAAJT7QEjGxRIAAOU+EJJxsQQAQLkPhGRcLAEAUO4DIRkXSwAA
lPtASMbFkrHcvHnTTgAAlPtASMbFcn7WrflavHhx74knnui9/vrrvZMnT7aOP9/r0+/94cOHe0uW
LFmw59IXX3zRe/rpp6tj9NRTT/WOHj3qAwYAyn0gJONiOZ8hufn6/fffH5iQPN/Lf5B9+eWXrcfn
k08+8SEDAOU+EJJxsZyPUFqkSfPOnTurv23evPm+r4+Q3KtqjrPtP/zwQ/X+q6++qt6vWrXKhwwA
lPtASMbFcr5D6e3bt6u/PfbYYwPHv3jxYm/btm29xx9/vHpt2bKld+HChTnz++uvv3ovvPBCNb+1
a9fOqhntN//6+2YNat2PP/7Ye+mll6rlpynyypUrewcOHOjdunWrddp+8+qyLWWaM2fOVF8gZHvS
PH3v3r0zyysuX77c2759+8z88v+rV69OLfw3jw8AoNwHQjIulvMUklObnL8l3PUb/8qVK70VK1bM
CZ0ZVg+DCYvLli0bGlLHCcnffPNN3/nu2bOnc0juui1leIJxc9x9+/bNjHf9+vWqlrc5TmqEm2F6
nJBcvmTYvXu3DxkAKPeBkIyL5XyG5PPnz/e2bt1a/e21117rO35CYd5v2rSpCoXXrl2ralebgfHg
wYNzxtu4cePIzyC3rW86ssqwhOW7d+9Ww06dOlUN69fJV74AKMtPaB1lW8o6ZLxLly5Vy/zggw+q
YUuXLp0Z79ChQ9Ww7MfMLzXzpQn7hx9+ONFxS410OTb//vuvDxkAKPeBkIyL5aDQ269Zcpfx6680
5T19+nTfkJpm03mfptRFxs+w1atXzwx75plnqmH1eWWaaYTkIsH4u+++q5o9P//889V4ixYtmjNe
wm/5e5p/5/0o21LW4dy5czPDEpRLz+DFunXrqmEJyMWNGzeqYQnok3jzzTerdSohvFkzDQAIySAk
s+Avll2eue0yTYJlmhKntrIeattCakJhc/5tgXHQeJOG5HroHbbtaVJdwmtqguvhsuu29Nun/fZN
22taP2P17rvvVvNLaAYAhGQQknGxnFJIHnUZRQJ1v2BZ71Bq0HiThuQdO3ZUwxJ+01lXapP/+eef
OeOmA64nn3yyGpYOuf77779Z8+m6LdMIyfXQPYk7d+7ovAsAhGQQknGxHCUgz2dILj9LNKyJcnlu
uG28SUNyAmKG5TnjIr1U18c9e/bsTKdceS64Tddt6RqS16xZM6e59SRKx2eleXgk6Dc7VwMAhGQQ
knGx7N2fmuR6Z1cJb/XOrvJscFE67srfmuONE5LrzaRLSM7PQEWeFV6/fv2saUvA/L//+7++29Z1
W7qG5P3791fv02w980qt9Mcffzz2b0+nF+tMe+TIkWpeeR0+fHjmuWQAQEgGIRkXy/sckvPTSP1+
Nik/+1TkWeBJfwIq8ixv3mdezfA4aN5datq7bkvXkNxvfmlqffLkyZGPQ2rH2/ZhhqV5OQAgJIOQ
jItlh6A8SugdNSRHnvXNM76p0c0rzwjnJ6Sa0vv0hg0bqmd/03z5iy++GPq8b/P90aNHq/HTsViR
HqPThDrDE0CzjO+//37kkNx1W7qG5BJsU5Oc5tBZt/Rq/dtvv419HFJL/vLLL1frlnlu27atdV8D
AEIyCMm4WD5k0mQ6+2b58uV2BgCg3AdCMi6WC0d5bvjnn3+unqVNJ1u7du2aeWYXAEC5D4RkXCwX
jD179rQ2c06T4fQ8DQCg3AdCMi6WC0Z+zze9MudnlsozxemRWUAGAJT7QEjGxRIAAOU+EJJxsQQA
QLkPhGRcLAEAUO4DIRlcLAEAlPtASAYXSwAA5T4QksHFEgBAuQ+EZHCxhIfSzZs37QQAlPtASMbF
cnZIWLRoUbWuixcv7t26dat1O8bZlnGnm8/j8TAck67r+aBuz3yfL83xxp3u8OHDvSVLljwU15K7
d+/2nn/+eQUwAOU+EJJxsZxvX3/99Ux4yOubb74RkoXkBRGSH5bzId59992Han0BlPtASIaH9mL5
+uuvV+v5xhtvVP9u2bJFSH6Izi/b8+icn/2cOnVq1hdZACj3gZCMi+U8+ffff6sm1nndvn175v//
/fffwDBR3l+/fr23efPmapoXXnih9+eff7ZOlybcb775Zu+xxx7rLV26tLd///5q2XU//vhj76WX
Xuo9/vjj1fxWrlzZO3DgQGvz7zZ//fVXtQ5Zxtq1a3tffvnl0JrDfqGjbXiCyqZNm6p1W758ee/t
t9+es24XL17sbdu2rdqGvPKFw4ULF+bs84MHD1bbl3llXd97772hyz9z5kzvxRdfrLYv63H16tXW
8brsxy7rEJcvX+5t3759Znvy/yx31PBZ3mcbcr5kG5544one3r17Z61X1/Ol3/yzbtk3mS77Kses
33rVQ2dzH3Y5jmW633//vVrHjRs3jrRvuwbezO/pp5+umoULyQDKfSAk42I5z7799ttZtcdbt26t
3md4l9Czc+fOWUEjwaceJsrwV199dU4o2bdv38x4aeLd/Ht57dmzZ+h2JMwtW7as7zwmDcnZpmxb
c77ZX8WVK1d6K1asmDNOhtWDZQJf2zq+8847fZef0JYgVh8/Qbg5Xtf92GUd8gXIqlWr5ozz1FNP
Df3iot9+btuH9fOg6/nSb/4J4F3Ox0EhuetxLMPXr19fPdO/e/fuzvt2lJBc5vfZZ58JyQDKfSAk
42I530ooznPJUZ5PTo1hl9CTjoQSUK9duzYTUNrCTGrZLl26VHU+lFrNDEttbJGasvI8dMaJ0sS0
S8dKqbnLuKlFTLjL+mSZ0wrJb7311kyT9Dt37vR+/vnn6n3CUZHtbq5D2z5JLWeGnT17tnp//Pjx
6n0Cab/ll3m//PLLM/NOTWlzvK77scs6HDp0aOaLgCwzLQ3KlyIffvjhWCE5+6acBx988EE1LOF/
1POl3/w3bNhQBdn6vk9t9SjHv+txLNMmHJd93XXfdnXixIlq2ldeeWWkYA2Ach8IybhY9noDa1Db
JOylOWiC3o0bN6phpafrDM/fh4WLP/74Y2ZYmtKWmsbmeCUwRJqPlp60mxLovvvuuyrYlJ5860G0
n2eeeaYa9/Tp0zPD0vx6WiE5TWbz/p9//um7DmWcLLfI+mTY6tWrZ4aV2tkdO3b0fvjhh1kBq9/y
S/g9d+7cwO3ruh+7rMO6detmmtQXOU9KiB0nJNfXP8tsngddz5d+86/v+3I+5riMcvy7Hscy7d9/
/z1r+i77tovs6yeffLJqIZEvooRkAOU+EJJxsZwwIA8rUCdEDZouBfxh4aIeAAaFnmEhKrV1Jcz1
24ZB25ZlNpdT1mcaIblt/k2D1qG+T77//vtZzXnXrFnT91nuUbevy37sug5lmW2vYbX74+7nccdr
m67L+dg2Xdfj2G9du+zbLnbt2jXn0QchGUC5D4RkXCznMSSnpmvQdGlaPE4oSUdHo4aesi6pvUzz
2gT41Np2Dcnld56nEZLbpmubf9OgdUgT3KYEp9S6l2dn04R71JA+zn7sug6DQnJbK4AHNSQPOh/b
put6HId9vgbt20k/08IygJAMQjIulhMUptukKXUK/AkEzd6KUxuZ4QkXpaZ4UG/FRWmS+txzz40c
espznGnuXaSzqq5hoDRHbmsiOygUlUBUb1qepr7N8dLMNu/znGw/JRANa6Zblya16dBpWABr2740
XZ7Gfuy3DqkBbTa3HvWcvNchud70uTRHzxcGoyyv63Hscm7227dCMoByHwjJuFjex6Dc5qeffqr+
lt9IblN+OznjDQoX6dAooTpBu3QkNaiX5mEhOT9fVAJgeg3uGgZKx11lfeqdLQ0KRekMKu8//fTT
6guBBMq2DrHSOVO9k6Zff/11TpPzeodPzXWodx5VmuIeO3asep/nukvvyf3Ws2xfngUuHVO19W7d
dT92WYfSq3I6ccvysp0ff/zxzH5+EENy6dgs+yideGVYfqpr2HT13rq7Hsd+69pl3076OQdASAYh
GRfLKYfk0ktxCcFNCVn5e56LHBQums+/ptOies1j19BTQui4NWb52Z5xfgKqBKL6K6GqOV5qKFOz
3vZzSEWCWb+fDiodL0WCVts6pjfpfuuZoNacd362a9z92GUd+m1PmlqfPHnygQzJ9X0y6GebivLb
wzl3Rj2O/da1y74dN/AKyQDKfSAk42I5YVBukxrBPCO5cuXKvj3vZnhqWTPeoGd70/w4QTk1mKl9
Tk1sl0J9c3iapSa4Zz4JYakFTAdIo4SC9Oic6dKEOs1iv/jii6HNmNNzcoJyfoYo4+U53rbtjdQI
lt/ETbhKDWv9N3gj7xPUMq+88ozw+fPnZ42Tbc1PSiWYZV45DglQg3oTj8wnNZqZb6lRHnc/dlmH
yPHMduYLgswvy/3tt99GDnP3KiSXWt+sa/5t9kbenO7o0aPVvsp5Pupx7LeuXfetkAyg3AdCMi6W
j9h2Pejblia0zd/XBQBQ7gMhGRfLRz4kl2dx04NwaoLTcVX5CZ3UhAIAKPeBkIyL5YIJyXv27Glt
bp5mwumtGgBAuQ+EZFws5015VvNBkec9jxw5UnWkVZ4x3bp1q4AMACj3gZCMiyUAAMp9ICTjYgkA
gHIfCMm4WAIAoNwHQjIulgAAKPeBkIyLJQAAyn0gJONiCQCAch8IybhY8mi5efOmnQAAyn0gJONi
+SCtW/OV3xhetWpV78033+ydO3eu0zSLFy+ufpf49ddf7508eXKi8bu4e/du7/nnn2/dt2UZ4+6L
Uccbd7rDhw/3lixZ8kCfu1988UXv6aefro5Xfn/66NGjPtAAICQjJMPCCsnNwHzs2LGRpsnr999/
H3v8Lt59992+4fRhCcnjrue98uWXX7Yeq08++cSHGgCEZIRkeLRDcl1qac+fP9/btWtX9bfU+F6+
fHlouEvT4Z07d1Z/27x589jjD3Pq1KlZoW0+98WDON29kprjrN8PP/xQvf/qq6+q92llAAAIyQjJ
sGBCct1rr71W/f2dd97pNM3t27dnaqDHHX+Qf//9t2r+m2bKXWuSy/szZ85UYTzLSvDfu3dv79at
W3PGy7A0Nc94S5cu7e3fv79a7rD5X716tbdp06ZquhdffLEK8/3Wq1k7W3fx4sXetm3beo8//nj1
2rJlS+/ChQut80oNfNZx48aNM/vn4MGDvZUrV1ZNpNeuXdt77733phrsux4rAFDuAyEZHrmQnOeF
8/cSwoZNk9rh/C3hbtzxB0lgzfifffbZyCE5wbgZTvft2zdnvFdffbXTeM33CeD1abK8erjtEpKv
XLnSW7FixZy/Z1hCeHNe69ev7y1atKi3e/fuWfun+ap/yTFuSC7Nr8uyAAAhGSEZFlxITtPrrqE3
TbS3bt1a/S010OOO38+JEyeqcV955ZWB8+0XYlPLe+nSpWqbPvjgg2pYamGb4+ULgTLegQMHqmHL
ly8fOv8NGzZUQfbatWszgTm11cOmq0sYL+t6/fr1WfNqC+oJrFnPIrW8GX727Nnq/fHjx6fSRHr7
9u0zx6leqw4ACMkIyfBAXyzbahEnCcllnDTdHbSMZmdfp0+fHnv8Njdu3Og9+eSTvWXLls08Hz1q
SK731F3Cf9t2lYAZCYT9xmu+/+uvv2aGpWl3hqW58yghOeM355V9k2GrV6+eM+3ff/89a/qE4Qzf
sWNH9SxxPUBPIs3Ps/zMO19s1JupAwBCMkIyPJAXy0FBdNyQ/N9//1V/r/9UUdv80+Q3zYtT49gM
vKOM32/dSydi33777dB179qL9LTG69f5WddwXZfxx5lX8f33389qrr1mzZren3/+ObVzrPQqntAM
AAjJCMmw4EJyaeLcpbfqcZcxbBuGbds4IfZeheRBzdTbpsuXB/3m1bUztEgwLr1T58uIn3/+eSrn
2J07d3TeBQBCMkIyPPgXy64BctQAWzqxev/99+9JSB53+x6EkFxv+pzm0hm2bt26kZZXgm3X5taD
pIl6OuwaN9SmaXumzXPRRWlZ0LWjNQBQ7gMhGe7bxXJaITk1l3mmtvyGccJSOpG6nyF5lPner5D8
8ssvV/spnXelE68Me/vtt4dOV3++t95xV8Jp107AitLU+tixY9X7P/74Y6Z37FGlU7BMe+TIkeqc
yOvw4cMzzyUDAEIyQjI8siG53ys1hukheZLQu1BCcn7PuMvPNhXlt57zJUSR8fv9BFTpsGzQuiZI
tx3HQ4cOjXxM8nvNpTa5/sqwf/75xwcbAIRkhGR48C+W4/ZuXX+lg6g0+/2///u/1jAkJLe/L7W+
2X/5t7nvmtMdPXq0agadZ4br8tvKCdz5W17pqTo/l9Vl29PE+q233qqCbJ5vXrlyZRWQ8yzxOMck
PYKnhjzrkS9Mtm3bNmddAAAhGSEZXCwBAFDuQ0gGF0sAAJT7EJLBxRIAAOU+hGRwsQQAQLkPIRlc
LAEAUO5DSAYXSwAAlPsQksHFEgAA5T6EZHCxBABAuQ+cwbhYAgCg3AdCMi6WAAAo94GQjIslAADK
fSAk42IJAIByHwjJuFgCAKDcB0IyLpYAACj3gZCMiyUAAMp9ICTjYgkAgHIfCMm4YAIAoLwHQjIu
nAAAKOeBkMxDfAH18vLy8vLy8vJ6tF7wqPh/QUYfokLGGqcAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-09-07 09:43:42 +0200" MODIFIED_BY="Gudrun Paletta" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph (blank cells indicate that the particular outcome was not investigated in some studies)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA2UAAAIsCAMAAABFiPFxAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-09-07 09:43:42 +0200" MODIFIED_BY="Gudrun Paletta" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary (blank cells indicate that the study did not report that particular outcome)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArQAAAayCAIAAABfSv6DAACAAElEQVR42uzdvY4TS9v+bUtIiGAC
gtkCtmEiZBFBxD5B6ACJCWcvEJvwCB5CICJDrP+AYIIJzP1kfIz82vh+kZfdbbc/qrqu8nGqtTTL
mN8UVddVdVZ1d9VgQERERLSkCREREdEfMQdERETEHBARERFzQERERMwBERERMQdERETEHBARERFz
QERERMwBERERMQdERETEHBAlC3H7gRIRMQdE8/hWCUREzAERc0BExBwQ8QdERMwB0Rbx7ZkDIiLm
gIiIiJgDIiIiYg6Iuoe4ewpERMwB0aTpaUTRTkTEHBBzwBwQETEHRMwBERFzQLQhxD1zQETEHBAR
ERFzQERERMwBUXtkT+yQSETEHBARERFzQLQhvjd+QkREzAEdU2S7rUBExBwQWScgImIOiIiIiDkg
2ibEG38mIiLmgI7dGfAHRETMARFzQETEHBC1hbhXFYiImAMiIiJiDoiIiIg5IOoY4u4sEBExB0ST
hccP/57DpE6IiJgDYg6afyAiIuaAmAPmgIiIOSD6ty0Q6kREzAHxBERExBwQLZgDsU1ExBwQrQS3
VxmJiJgDosX4VglERMwBERERMQdEa0N8MdZVCBERc0CcQfMPRETEHBBzwBwQETEHJL6ZAyIi5oCo
McQ5AyIi5oCIiIiYAyIiImIOiNZE9qRlk0SVQ0TEHBARERFzQPT/x/fGT4iIiDmgY4pstxVqbEp1
QsQcEB1y5YC0IBExB0TEHBARc0C0GuIWpfkDImIOiCYruyYL9Qq8nUYkYg6IDmkO+AMiIuaAxDdz
QETEHBC1+wOhHriTck+BiDkgIprYxoqIOSAiYg6ImAOifKOLUGcOiIg5IPJAYkWdlGcOiJgDIuaA
iIg5IGIOiIiYA6JcIc4ZBDV2dkgkYg6IiIiIOSAiWttDbfyEiJgDIjqmvsltBSLmgIjIOgERc0CU
dWgR7UREzAEdd2RblK7L4Wk+IuaA6PArBxS9BbUpEXNARMwBc0DEHBClCHG3FWppQRVCxBwQHXje
SUREzAExB0RExBwQ8Qf1dVLuLBAxB0SJxhXRHtTb/T2HSZ0QMQdExBw0/0BEzAERMQfMARFzQHTA
ELcoXYU/0IJEzAGReae2IyLmgIg5oIWW0l5EzAERc0Ar3ZP3TYiYA6KkA4wKCWrviIg5ICIiIuaA
iKilk1rsrVQIEXNAtNeI4o51Tc5g6QciYg6IiDlgDoiYA6LDDS1rPiHmgIiYAzqmyHZboZam5AyI
mAOiVCsHRETEHBARERFzQLQa4m4rBGy4ifdNiJgDokQDzMRG/UREzAFRozngD+K24JpPiIg5IGIO
jqlvcluBiDkgSuoPhHoFKwdExBwQERERc0BEtNpJua1AxBwQJRpaVEi45lv8QQsSMQdEBxta1nxC
gcyBFiRiDoiYAy3IHBAxB0Qp/YFQj+4PtGDgYcbdPeaAqNheSfdE1Jc7J+aAiIiIOWAOiIhSji46
K/6AmAMiIg8k1jLGuKnHHBARMQdEzAEREXNAxBwQhY54MR+tyTiDCpJO6jEHRERENiJjDoiIiJgD
5oAoTIg7toeIOSDmgGjicTaikgy64YY5IGIOyLyTiDkgYg4o2XTT1JOIOSBKNcaokOgrBxSr7dg7
5oDIoEJExBwQFT9rURWVdFLmnbXYdC3IHBCVNaiI9gqGFoqegNqUOSAytJAW1ILEHBARGV2ImAOi
YkcUS5qV9FBasBZ7p/mYAyIiMsZ4IJE5ICIiYg6YA6KiI9uidEVNaVypIxlVCHNARHSYeacNsImY
AyIi5oCIOSAiYg4qHmbcWWAOiMoZVKiyoUWFhLZ3WpA5IOq/SxLbREWZA1nJHBCVNeM09SRiDog5
ININhW879q4yf6D5mAMiIuIJiDkgKjbETTprGWA0Yqy2017MAZGhhVK5Og6vpkZUM8wBEXNAh2xB
0oLEHBAxB0REzAFRihC3nllLC2rEuB5d8zEHREQHHlcmFn7it6BGZA6IiAwtWlALMgdERIYW0oLM
ARFRttFFZxV3mOEMmAOiEnslIiJiDoj+HeXinIiIOSDiEmpqNW0XruEmjs5iDogCeQIxH2uAWf8J
ETEHRFvHt3pgDkgLEnNApGOqsxE1X7zRxW0F5oBIx0Takdhx5oBIx0RExBwQERFtO8xY9WEOiEqI
7InXqIjKyMSJo7OYAyIiokZzwB8wB0REZIxhDpgDotIi222FeltWVUT0BxqOOSAiIiLmgIiIiJgD
ohghnuC2gsXSzC04cbs6bAvKFOaAKo+VuL3SYYcWj1n10oLqWQsSc0ClT+OOuWPS5RlaSAsyB0Qh
XQJzYGghLUjMAfXgCQL5g8MWdREoiTKEnM4qdAvKFOaA6s9womyujoiYA4rUWYscSh1vYoyIOaCy
oyTgboMpymzvxd4DT80QMQdU7srBkf8TAj14ocmIiDkgSj7YuMlCJFOYA5LekzoWeJkDUUdZRxct
yBwQld89pYOrbaJ0dpyYAyIiImIOKNr823SZRB3t3JTqhDmg2sKl8eejGmDcCyfardMg5oCOIsmj
+AP9FBFzQMwBMQexDQ0Rf0DMAUULlzir6EnNgXsKRhTaNk0kC3NAVLOhsSaRxxyoVSLmgEwTJ9Yk
aP2kUz0TMQdU1hwuUTe9eta7Rx1JxdZn8jQoc0BUuTnwFj5RxdafdGek+6BIPkyFyG5iDuhYuulF
oICk1aFlzSfEHBBzQLrpXXzMAT2NHRJFHRUyqSDmgGruplPvRmBcEXVExBxQjp76IGGT+rE+Q4t5
JxExB5Sjd84whJc87/SeAlH37JMpzAGReScREXNAxzcPyDOEi0miWvsN2c0cEH/Qv+0goj5HF7cV
mAM6wlQv3xzYurWCqFMPZhTEHJAe5PBYG7DUYUxVBRFzQEfX9Yc+0skAxiVQxwRXJ8wB1ZzkgRYk
wp336FbIek+gWgK13eIPGo45oGqTPFYHzdBU0EPJvmrMAX/AHBBzUPNceWmDF50pS0rimTkg3fQh
kzxd95GozEn7O53pkl90x7omf6D5mAOqv78ueThMfSrj+p/LrOc6LCkRMQd0dBOL1CsH6ZjyiIiY
A6IEgRhhrswc5KxntxVkNzEHFCzJI76tcNhnDhI5A/doqTKTx0YzB3RESX7YKExa5oO/B5HOJHkg
kZgDYg6IOVgebo98oGUOGu2Xdek6ug7NxxwQf9D/QgJzQMTkEXNAufO88JWDSZr796l7t0W49CQi
5oCOcdkgVhBaI63Gknrwk4g5oHLNQdx6iFUnEZM96SOlbT8QEXNABS0eHHAAyL9DYrq5crqqDmcO
JhE27SZiDuj4YiXBuBWrm05tDrK9+hVryynmgIg5oCNdkIhiDpI+fZ1hh6Wl0gbyBymqgjPoK4NU
BXNA1Js5CHoYdApzINmJiDmgkJOJ8s97rKA2oqwZEBFzQJRwFn7Yw6Cje69AG9EkeqTUtjy9NCI/
yhwQHYU5CPcqYzUNenCabjBQDhJzQGEmBFGmniWPKGa0Of2BmyzMATEHRJGmmwf/FX9XdCuwHcwB
c0DMARUXK8c5kOSc3xu01td2Orgcz9OIKoQ5oJrzPB023X3loIZGhlLoNQNiDohL2KsTSbELXsSF
9BTPSXiagXoxB2KMOaAj9QQHfP7fXcmck7mIPukgtqamJzCCNp+aYQ6otlhJOmIxB9mcQSx/EKvA
FC7GiDmgQoeW1BMLQR7UHHgCg4g5oLKjJPLyYIaiHueuDywprW87txWYAzq6eafCU1xDY02CiDmg
MIO3gJwkfrlfCzIHRMwBHawbzbDtT9Ijm5NOPZPOaI+8BfP4A91gBo/rtgJzQFTE0JIuttPNO0Nv
aRzIHBi6iJgDYg7CmINJ5F0dvYxKxBzQkUVJyjnWIi3K9slJqyIP/OC1wRkQMQdER21oItZJoCWK
dC3oFbu+4o2YAyKdyBGZg2w3WYRKuHjTZMwBHeN0vHB/EG6uPEl/W+GwVeEAa9ohPNQMc0AVzjsP
PiFItHSsY+pxCC/Z3omNXvoNYg7oKMzBJObO/OUPtLS+wlUIEXNAzMERTYbizu8nMXd1JPaOmAM6
sD9I8SLcAW9YhB5oI9oa2UEdY0O0MAdE1iTKncCFW5MQGMwBMQd0RElegTk47EAb+uAlxpGYA+aA
jnfG6eClpUltrEE33JpEBnPgpnie8FAhzAFVPgMov/tI9Ppl5oXuENsnp/63hzvv0a0QYg6IOTii
oWWJEMgcBF3gZWiImAM6Rn+QLggTddNJ54U5t6FMsSYRyHNM0txKYA6IOaDji5Vo9+/TvX45iXaX
OuIjpYnKnPoxF+aAmAOiMAsJypzn2Y5J2Zsctx0wcczPdkgNYg6o9HFLVSRd7Uhd4NQrB+mYYk92
E3NAZc0787yflug+SPmz8LixkdTKMAdcAjEHdPguNdDBS1HuhU8i7/qQx3Yc9pmDRMEcbu0nvydQ
LcwBMQdb9PtRttCp4+G+w/YjGexdiMcCPJCYJzaIOaD6Vw7SPReWdBaebt6ZusB5ZofHOdAyB9n6
DWIOqKRwifn+/QFXpJOudmTuqQufLDIH1XQXXt9gDojMLcL014WvHEzS3L9PPUolWvupI7uJOSDq
eU3CEJ6nm47Vah6LI2IOKMlYVf4onnQLnTwPUZrDMQcV1LPbCswB1R8oQX9XrOE26AHQB99PIv8O
iem8qQ6EmAM6liWEpKNLoBExFjbcK6MRVw48Q0PMAVlLKG7GWcHKQbhl2HDmIPONIW8rWEphDsjK
we7dKHMQNzDSmYOgh0GLE2IOyDqBlQMR4qSJ5LVBxBxQuT1diLfkI76tYBk2jznQ4/XegaQID83K
HJBVCmIODmMOYkVaxNRIejrGwWODmAMimkQ5YTndkYxJT/GOtRNlIHvHHDAHRESphqtJlsdc8uwt
wRwwB8wBEe2e7XEH8ijz+9RvK6yWNpA/CHF+KTEHRMea8wmOR0r01kkFhuawj9mKYWIO6Fi6PORs
884ULiHp0nHQo7HDHW5OxBwQWTk45KK0u7+Z3Uas3TO99MscEFHp2Z6IzBzkaUH/hDaakGMOqJRJ
AHIsctJF6dQTON0Ui5Mznok5oN0nnQdcIUROSq5gGTZDUUuuk79PelawkM4cMAd0FE5/n/hBzkOu
oOvUTcUeY6Kt3pE6JaJDDt66lNQjIhFzQMcyACAnJadelM5zZHPShzCSPtuRohLYDmIOqDhncNhO
EDnbQBs3NtKV+eC/K2l7hXs+P4WtqekJDOaAmANk5uAozMEky5ENsfxBrAITc0AG2qMgZ1iUTrfL
fYaDi1JURcRTGxgaYg6ouAEAOQM5Xt9k6TiLoQlqDgQGc0BEkQYAotRDuDUJ5oCIUk3HC/cHsQaA
0A/KhXsZlTlgDugohhbk1OSlWxWF32V3WyGn7Qh6OoZHHZkDKmtiMUnzaDdyTvIk5uNsiazMkfeE
QWNDOzIHVHP3gRydHDeYDVdig5gDMhwe+xCedFfHv8xD7eqYdKAN2u+lPqeAMyDmgMoaWpAzkM07
K1vwKPzxzET2zg6JzAERBRhaKjAHh12TCLcJUrb9Ig03zAER1T+Hy2AO8pz5m9OTFTXQ5r99Y8Rh
DqiqGWes5UHk1KPU+jHm4GPhYd/dOPgTEqlrPu4TGCnMgfcUmAMiKnQKm7nMhz1pInO12PLZ+M0c
ENHR+YN03UiiGxZJVw7CbUOZutjEHJAZAHK55NTLsIkGlaTvboQbCLNtU016e+aAduw+jvkZ7KDP
jefsVpQ5w+Q+1vMoXAhzQMwB8tGZA8vRq00WqEJi3Rgi5oAK7T4Kf0ELucvUM8S0O928M88bFpOw
5xSEqw32lDmg/juOwk/eQ65jTSLDNtUHr42cuz7EWkQJtHLgVghzQHRE2X7w4TDu9koRzUHQW04M
DXNARMdlDhpRUZboU9++SVrgdGsSgTzHJM2tBOaAOSA6yoRP//59yQvpFRysbLUj2+GlzAERUYnm
gHLau8PuRJn0VMb1P5dZz8wBERm01Ea8NYkMKwfpmAKPOaCeu7xJspfKkFOQIy6k1/RWCHvHHDAH
VHOspJ5bIE8SnyaQs1vJMBjEmtce55pEojKnvpMVcRsr5oCYA+QDdNPpxoBAw22sowpSbx+Uod8I
8ViABxKZAzLQHpc5SDEeZHgFLtzKQdAbFgZa5oA5oOKsOnJmcorhijnINm5lyHTmgDlgDoiOItVT
TzeZg8wG/WgP3U79yEWibayYAyIqekQpf2hxOkZmkxRoIEi3tSUxB1RWTiLX1PfpVaxzMAfMAR1v
xxToCBxk4g86DQYRdtfIYA5s6sUckIGWOaBQ/XWo0y8jrhzIQeaASnHTyGYtVMJwG8UcZH62gzkg
IiLmwGHQzAFzQHRkA8DBuzzkCoaWQOc9xq0N5oCqDpc0PQhyBjJRBWsSMoI5oKLnncixyET1mQP5
whwQc4B8oIT3eGZYctsvCjDMpDmSMWnDHfPqHXNAxtqjIDdm+gG3BUROTaacKwcWJ5gD2stTI4cg
ryfsw0fOQ45rMrKde+lVRuaAiIhNH6TDptsOPKihYQ6IqPKETzQHRc5DTuQS0r1wGPT+vdeFmAPa
K8+RA5GTDgDIGchtnuCAN56O/JxiYg5o3+4j3TYpyHnIhvCI5NTP3zEHxByQbhoZOST5gGsGqwsS
iQYFAw1zQMwBcqFzuMV8T7HWjZyIXMH79xmKakdR5oD69wceDYv+OBvFTUCFJ+aAiIgCW//AQ6Md
EiUGkS4PuVjy36dTw73JkrqeU6xMGBOZA9JNHxHZuxvRyXmWDQ47QObcZbz8MjMHVGesINdB9njm
JPI+B8xBanPAHzAHBc3CmQNk5gC5Y3eRbr0qRRBm2CMy9dKdZw4oX6V3+ZA/QE7nD7y74X2TnPOf
I9+NmDmgvfr9WOeyezIgHJkoYs9DzAFZNkCWj9SPJc0TzyVHeOq3QpgD2iJnPHOAnJqcrstDzjm0
JH3DIkVtuK3AHNBeST6J9r4TssUD0m/0aHbZDuZAkhcWK2nmQ8gZyKTfqK8q2A7mQJITHbjvQ45I
XvwVKco8CXJYlD6TOai56gNFufX5+sjlHyWMbLpCzAHxB8gJyQZa5IrNgVt7zAH1Givu34clT5Id
VIOcmpxtiT7WwUuTf98NCTcNYA4od8IQ5RlakHsZwjMEycFH1sO+fnnwJyT4A+aglHpPkTBEdAz9
Rty+bnKgkyYyVwtzQIETJv8EFDkcmfiDNSEXqK9LunJgWZc5YA726pU8wBWLTJX019Hu3yfdDZaH
Zg5q9gdBX2U0hDMHVPHAoMxiQIWSgZY5IDluRIg6eWMOqIi+w/37OsiOxo5ODjHtTvd8QJ43LCYe
SKRshjTWJhv2EYpOVie1ko9570VbQjEHVIqhQQ5KNtAyB90XOaJsr8QcMAdUTKAk6D6Q85CNtRWQ
k64cJNovMvXei4nqPNzZN8xBtcNtlPUD5NBkm0mHJk/S32VP5A/yeGhjGXNQQ71nGxIMtMhE9fVI
xBxIRf4AmSjLYGAK3lQbnjmgfgbaiHsnWzq2KI2cjRxxId0BV8wBVZ7kVJ8fPWwniJyBnLOXSOGW
skU1c8AcEJGB9ojIS7OLdFOXQMNtthdDmAOiTn1HuhNfkBORDbQVmIMU8/ukJxwGXTmwsssc0NZJ
mG4zE+RJ+vfC3b+vhpxicGUOiDkgA+3RmQOK3lknHAasHBBzQAZa5oDi9dSJl7szvHdT+NsKHhhn
DkrM9nBlRg70ItwkzZ1U5DzkalYpiDmgTrNDIiIi5oCYAyol6rxTEItMxBzwBwWHi8X/aGR3f6OT
iZiDY6r3UN2HOVx95PKdLjIRc0DMAbJFaRLPcpA5oLB9U7qt15GRkYmYg+Ou+rDvMbq7HJFsDmfe
ScQcxJiC6z4oetQhZ8tuD9hGJzMHVI85WF+2fUqOnIesm66A3Ig64GIVcmoyc0AVzi0kuY6JGHRk
5oByVX2QIdwcrg4yERFzYG5xpJ6XNtqOSYLn85HzkA9u+pFzkpkDIirUPjqjEhm5FzJzQBvCLukO
iTwv6aaRkZkD5oCENemmkZGZA+aglm56zSfCmlIlvMczg5NTpDZyHjJzQJ16jRQvLBzcHNhnMDqZ
iIg5CLlywPNS/qizj2EsMhFzQESHznPrKGHJa34Fciwyc0BbTC+iNIE3zkOT04UZcmZyuthATkpm
Dmjr7qN8z+up4+hkqqbfEM9ykDlgDgp107qPiB2TdZTQZPHMHDAHR1P1KXdAkorIyPXZu8UOJNGy
BLKt5JiDatckks47vXEekWygNe8kYg74A9snk4GWOSBiDiJW/RE/DUs9Rp11lFjkdGeyIOchMwdU
89zC+8rRyUREzMFxmYPUntcb59HJRETMgZUDwyFy61KEfQzr2CExXZAgH/nSHXPQd9WHCj5jbU3k
RK9+IacjO2kiOpk5oAptR9IbFsh5yLppZGTmgDk4UmcgrEk3XevQYh0lOpk5oC3mhSFmh1Rf+CEH
epXRExihycwBlTVBTNrleeHQq4xExByQNYnkbgY50dsKiX4jch4yEXNwdGP5JM4OSMhxyY2ZfsCV
WOTUZCLm4Cjqve0H/gA5Kdn9+9BkqmZaWHhsiF3mYMeY9lpgODIR9d6FdvmQOWAOnNtGRHt5R+QQ
5HDPozAHpSS5CiGifQYY5PLJ8UYoFWFu0a+hQWYcyUB7DOZgcbXYMwdUZ/dhFzxk5JxkY210cqAb
ysxB/6P4wSf3zAHy+qUIu+AF3V8PuQIyc0C9hUhqz2sIr4ZsahiLTHp+5kCIFOd5J+7fxycTUQmD
bvk+Uu/DP9LRdUxeV6uGzEYz6MwB/0h0GEuKXA3ZbbJYZOaACpodJlrwQA5HNtAyB8i9m4Mo+58y
B2XN3lLsw1X+c7bIecjG2uhkA2015PKP3GMOeqv0Lh8yB8iTCA+rIuchT9y/D072tgL1H3zMATIR
ldbtMwdUm+2YpHyIEjkPmYjK8QduKxBRWcYxkaFBTkT+i0p0WiByanLUvkKnSd0NL3J0spssEzeG
iJiDoxq8Uz8MZayNSzbQVkM+eKggpyaHW5NgDmjLWPHceGSygTYo2TFU0clWDmj3KCzcTVN9UYcc
9EW4dKtKyPpM5qDnes8zs9e+RETHYNCZA+agN8/rufHoZArdY3jyPy65rX/2zAFNosTExgK7rzyJ
vH2yEw5Dk6mybp85oA19R6IbkyE2/kTOTA7kdJGRayKn65+ZA+rNmRpomQPkooYW5EDkcM+EMQfM
we7xnS5zkFMfum0AmMTcqcKruaHJsYYS5qDXqg81tFBlUefJAM8cEDEHxzK/JzIFPxKyfQxjkZkD
qjP4LNGHJhto45LtNhidzBxQ/+Yg0VvyZgAVzFqMtaHJqiI6mTmg/meHDn1B7jIrQo54OoZ4rikH
yxyCmYNq1yQSbaGTyFwj5yFTHXMJi/9xbys0ZneBac4cMAdS/ei6J4qe3ciTuh4pZQ4ox6neRhTq
4h0TrXYgJyVTZfaOOSCigpzBYWdIyHnIE7s+VEdOvVbBHFTiH4mYA+SO5HQPMiMXPq1nDuqtcfeq
iTlARj6+tR/mgLZbOSDKlvApghA5A9lAW4E5cPASWe1ALoVM9c0rPJ4ZkRwol3U9BY24BydPvNmP
TETleTvmgDbb0km0hceDBzpyHrI5XFzyesg+vwI5DzmcP2AOijAHk1D34Qy00cnu/kYkN/bVB7yf
hZyaPEm8ww1zwBz0Q5444TA42UArB5F7JwcapJiD/v2BsCaWFJmIOSCi3hI+xYiFnIdMoa252wrU
dW4R0kvaBjUsmYiIOThSfxDuDV3kCowjEe2Q3VYOaMPUMOLbCobwcOYg6R4YyBnIVFOf77YC9eBM
k+7eaqyNSPZwX3TyxG2y4GSbIFGF5iDpagdyHrKBtiaysxPjkpkD2jwGTDwpTfGNIzIyck3+gDmo
rZsm6r4sgWwbK+TMZM8cUO7gy7MruHuHoclUU9fhDIuI5GATCSlXx8pB6l3BF39w7zAcmYiIOQhS
9ZY0kXORzeGikx0kFp08ibO9PXNABlpk5NLJ6d6SR85DzmA7mAMqwh+YHcaddxrCJ7Ucm55uTQI5
D5k5oM0WVZ2QtR9kOoYcZA4otzMl2pjwKYIQOSfZ2zfVkEufvuo0qzEHgZwpEe2zJuG9nnDkcBMJ
g0cN/iDcwR5EtM+gNXH7JhqZOaBdBvLC1ySostHFg58eKUXObw7cViBDC7KhBfnwQ4t4riAHy5/O
MQdHsSyhm0ZGrsMcUB3zK+aANg/hkyBHfummkZGZAzpgF+22AvXQMTEHyG0JnyJUkJOS7TYYnZyH
zxwwB735A910aDKZdyLXNL9nDpiDvZypCieqzBkcvN9AzkBmDmjrUVzHhJyhY7JXXWiyeK4pByee
OaDKfIy7ktFPhLNX3STs/nrhjnpHXhMbE28rUC9j+STaexDIE4+UIlPVnTNzQLvMEXVMFLFjQpaD
xBzQ4SeIBwyUnBt/IkckL/6KRL0ecjoyVTYzLL2cGqxHZ7D4ScnmwBJ9dDIREXNwpOZgkv5RGgMt
c0BEdWc3c9B31f97CC+8LYy1/AEV0m9Mkr0HgZyazBxQzW4m9ZaiyLaxorZxxeOZcclRslvXcxSj
uDohYg6QeyfHG0dkXX3dB9Ea4zixwBuQbKCNS15PcPASxTYHXgsMTdZNVzDvtNtgXHIjqtghmDng
D3bs8myRG51sCI9oDqiC/tk+B9QpRCaJd1/XTSMjMwdEzEGkyX3ErYp00xOL0shlkN2AC0dmDqg2
czCxkW18MtXRbyBPbDTCHDAHIpuIDLTMAXNwTFWffjVM+9Ka8EAOenSWsZY/YA6ockODnM046qOj
jyusUmjyoEXMAcV2Bok6QeS+yIZwZOT89m71Z5sg0YYQSeFJDYfIeuo6yKqiPnKKt9mZA7Pw8IYG
OT/ZAm90srG2JnvHHFB4c5BuZQI5G1kfHZ3slNHQ5EnLE0XMAW0IkcJnLVSZJUWORSZiDmjfjqnY
1SriD5CJmAPq0xxMDnfYaLqFbuTU5H9lO3JY8sSrudWRix1/mYO+qz7O8UhEVIj1P/gSBXJfZCsH
lC9E7MxPxBwgMwfMAXPQQ7G9FljBq4zI0fe4NNDGIgfq/JkD/kCSIyNHGlpYpdD2zjMH1FuILALN
WpCRazIHRMwB7dUxJToM2gwg9KzFQMscEDEHzIGOiVil2siJPAdyUnLqF5WZgwq76UmaxX/mgKhW
6x9otQPZygGVMoQf3JbaUCg6mZgDZLaDOTh2c0DUpW+ydOxlVOScU6xEB6oxB8yBWQsystkhVeLO
yy8qc9Br1Ud4ZMnBx9HJBlpk5DLJzAFVOL8v300j57SkyOnIzG4dBn1ih0RiDpCrn1tQ79mNHI7s
mQPqLUTy3LCQ5+HIFnijk4mYAxOCIzI0yKnJFnijk8VzHWTmgOr0ByTGkMvJZZUTkRzFczAHFXbc
PC+RfgO5QLJNkKi38Tvns+4hDA3yGixy9EVpZOaAOaBS0iP1eRDIicj66OhkTrcCMnNAtfmDdLs6
IuchG2vrI1PE/tkzB7SFM036vLSBFtlAyxwQMQfB5veB9sxajBvkWGQLvNHJE/tFxiczB7TdTEIr
EFFf/QZytv7ZbQUSfETEHCCHnBYaP/qu+lBPw1oeREauMruRmQPmwNwCGRnZojRyb+TynQFzwBwg
IyMf7+yQ+hlxI5zdwBz0HyWTOHt3p/O8yBnIBlrmgIg5iDG/z/Aue/meFznb3MICb3QyEXPAHBAR
UY2DbuLN0ZkD5mAdnOcgIjItZA5C+sejPdiDiMqZdyJnIDMH1L8zPaA5sJs9MnK/5NRDC3J0MnNA
PaxJpLs9hoyMbDg8qiHc9sm0RfzFfVUBGRk5D9lAa37PHByXM4gSfJZ5kZH7JU+82BmcnDo2Djjh
ZA6YAyIiij3LOviYwhwwB2YAyMgOXkLORI5yy4k56HmgjeUMJDkyci9ke31GJ4ebcDIH1dqOdM7U
AICMXAg5nfVHPvIJJ3NQoTOwcoCMXCWZKPckU0UwBzusSSAjI/dFntjHMCaZOaA6/QER9Z7a9gyY
2OdgkyX1zAFtiA/tS8QcIBdiDvKc2uCZg6pGcXVCRAZa5BLIhqWek5yIaOdJBXLQnSqYA+rBHFiQ
ICIquedPdMNicQg4zDiizarxB5n39nK+DjJyNjLV0fM7lZG260EKNwdLqMM6X2Rk5B0Mh30M7ZDI
HFg26H/loPGTgyQkMjIyHcmIm6LPP7ihYQ5qMweT7Ie+GACQkZkD2qGLtnJAuf1BTtuR4jYtMjJy
TuuPnI2ceiGBOajEOXpeiYj2XJNAjkJOunKQ5PELWVdNx8F2EDEHyMWSo7ynZvCg3Z1pii1FkZGR
O44BB5/OImcgRzGOzEEpA23EuUW6MiMjI3fxHF47jELOsLJ7WEPDHFTi8ibp39DVTSMj90smytbz
Mwf1mIMMHZOeGhmZP6ACe/5UnkObCZHd/CkyMnI28sQTGGHJ4fZeZA5KGWuTjuJqm6jKSQUyMnNA
2wWfTdmImAPkuodw5oB2NAeTw20Hm+ipYGRkZGPtcZJLDgzmoCc7lv6dghTnhRNRaR0IciBytlNz
mYMapviTZNt3aFyiWjsN5DrIxT4GyxyUkuQlt4JtTJCR+yUbaOsgT3Id6WTlgDmobbUDGRnZWFu3
P4gySDEHRUzHy++YHKCCjNw72a4Pocl5xpSJ7ZNJZ4qMfDxkqmlamGjydqhH0ZkD5qCU1Q5kZGQ6
kv754G+TMQcV+sfUL+GoaqJa+w3kWGTmgLae3xMRbdtvuH0TlJxiH5okr97IOuagqNUOZGRkA219
5IlXGalHf2DfVmTkIyEbwsOZg2BTQUN171PwiAmjm0ZGzkmeuH8fn5xzWGEOKJPn1VMjI/fuD6ia
CWHJu2cyB8xBEasdyMjIRMwBeZWRiPYaA2wmHZEcxR8YP3puxYPvk0VExzM79NhgLPIkwQ6JiW5Y
MAdFmINJ8acyTtIsliIjIxtoj5Bcfs/PHNRjDlI/8EJEpXTZnvyPSc6wQ+KhDI3Bowh/oAmIiEwL
y5kWMgfU55oEMjIyHXN3enDbceByajBDOBFFTHPkWORgkSbleknvpL6PiOrrOpBDkwMtSDAHfab3
4rPNSSPmsIYm0Y4xyMjIBtqKyYvBUP5rLMxBz+YgaRSmiLzD7g2CjIxsrD0Gcp6oO+A/gTnof+Ug
kSdI1B/pppGR+zIHNpOOS2YOqDdzkO4hBt00MnIhKwdUWc/PHJCVA2RkZNLzHz42PHNQSYhkeOEw
wyKbd9mRkZGRd+6WCz9vjzk4Ci+iHoiIiDkgIiIi5oCIiIiYAyIiImIOiIiIiDkgIiIi5qCGOiUi
IipbzEFWc4CMjIyMjByXzBwIEWRkZGRkZOaAOUBGRkZGRmYOmANkZGRkZGTmgDlARkZGRkZmDpgD
ZGRkZGRk5iCiObi5GX//Prq6Gn7+fPf//b/B5eXJt29n4/HTm5vrYsnpamP8azy6HA3fD+/+793B
/wxOXp+cvT17+s/T65/HWOaItREx6uSgHERmDsoyB//3fxefP59Oe43Va9qb/Oc/5wWS09XGxdeL
0zen02hevaZRfv7luMocsTYiRp0clIPIzEFZ5mA6gWjsOBav6XeKIqerjamxbQzoxWv6nSMpc8Ta
iBh1clAOIh+XOSjnX9FWkumsYmPfMb/aZhj5yelqY+p2N8b0/GpzvjWVOWJtRIw6OSgHkaOag/WF
+funS1/b4Z+w+lcat5Ps/uH6wtzcjBfXG1+9Gjx4MLhzZ3Y9fjx49255BfL376veyekadPxr3LYO
1rgydvWj5jJHrI2IUScH5SByVHMwL0mX8uxZ5sbxfr0FWf/hxrJ9/z5a7CDu3ZsV4OXLwYsXsx/u
3++0/JiZnC7JR5ejjjG9ZlmsmjJHrI2IUScH5SByJeZgdRhu+6OtJveNFiS1Obi6GjauMX78OCvk
7dvLn3/7dtY7OV2SD98PG8J3rqawPntbc5kj1kbEqJODchD5iMzBbuN3fnMwf69p6frwYfDw4az+
nz9f/qPLy5PeyemSfP6+TfewPnldc5kj1kbEqJODchA5pDlYMxKv8QQbx++Owbf4dxt/y/oPN1Z3
48Ti0aMZ4cmT5geXeienS/LmgF7USmRXXOaItREx6uSgHESOag5WD5nuYg4aj6buclh1YwEa71l0
+XCHucWtWzPOp08Nfcees5aDkM1arBzUFHVyUA4iH+nKQfcg21gpB/+w7a5k27X//c79yemS3P3O
6LURMerkoBxEjmcOGufxXW4cRHnmYOl55vk1V/fNUjKT0yW5J6Wj10bEqJODchD5iMzBZKetCCZ9
73OwvvvY5x3rA5LTJbl3rKPXRsSok4NyEDnkbYVqZHe2LmS7s0WvDTskykE5WHG/wRzkC+uJfd3/
Lfu6R68NZyvIQTlYK5k5yBrWk/+e23a3/dy2ZwWS09XG1Pk2P3P7Zx3s2efjKnPE2ogYdXJQDiIz
B8WZg0n7ie+NdyILIaerjbaTyBvvkFVf5oi1ETHq5KAcRGYOijMHyMjIyMjIJZOZAyGCjIyMjIzM
HDAHyMjIyMjIzAFzgIyMjIyMzBwwB8jIyMjIyMwBc4CMjIyMjMwclGkOiIiIyhdzYOUAGRkZGRnZ
ygFzgIyMjIyMzBwwB8jIyMjIyMwBc4CMjIyMjMwcMAfIyMjIyMjMAXOAjIyMjIzMHFRrDtpO0Lr+
eV0sOWJtRCxz25l+Nzfl1kbEMiMv6td4fDkavR8O//fu3f8ZDF6fnLw9O/vn6dOf19dHWOZ02Z2u
zClykDnIHdYXXy9O35y2nb19/uW8QHLE2ohY5v/7v4vPn0+nub16TXP+P/8psTYilhl5UV8vLt6c
njaF82A6hn05Pz+qMqfL7nRlTpSDzEHWsJ7az8awW7ym3ymKHLE2IpZ5avMb03vxmn6nqNqIWGbk
RU2nrZvCeTD9zpGUOV12pytzuhxkDvKF9dSTboy8+dXmT/OTI9ZGxDJPvf/GDJ9fbfOA/LURsczI
S3PZbuE8aJvX1lTmdNmdrsxJc7Afc9Bx+8aDxFYjv/FXt5Wn8ZM1JW/8fPxr3LZa1bh+dfXjqndy
uiRX5kXd3IwXVwVfvRo8eDC4c2d2PX48ePdueZ3w9+/+ayNimZEX9Ws8blvlblz3/nF1VXGZ02V3
ujKnzsHezEHqCFtjDhY/afza0s9rStvmPFY/HF2OOkbemsWrzOR0Sa7Mi/r+fbSYxvfuzULu5cvB
ixezH+7f77RImLk2IpYZeVGXo9E24dy86F1NmdNld7oyp87B4szB6qR8/vPSf9dP+rc6W2KjY+jy
1zd+OHw/bAiEuZpi5OztWe/kdEmuzIu6uho2rgR+/Dhj3769/Pm3b/3XRsQyIy/q/XC41aD19uys
4jKny+50ZU6dg2WZg7YRuu3nLisB6/91G1cODmUO5m/FdA++k9cnvZPTJbkyL2r+9tHS9eHD4OHD
Gfv58+U/urzsvzYilhl5UfO36bpfr09OKi5zuuxOV+bUOVjuMwddFvz3NAcbyesdwFbPHDSH3aJW
wqR3crokV+ZFNdr/R49myCdPmh8v6r02IpYZeVGrw9LphnAeVFzmdNmdrsypc7Dc2wpbmYM1fyuR
ObByYOUg6crBrVsz8KdPDRle7MpB4WVGtnJQ/crBAXMwxm2F7isHHf90o0E5uDnwzIEyT7a8d9h2
lfzMQcllRl6UZw7yZHf+Zw4OlYOFmoNtVw62va3Q8RWGbW3Emg+9raDMk25PHc+vubpvadLv2woh
yoy8KG8r5MnubG8rHDwHi3vm4O8n3c3BpOUdh42vNjT+FfscZEhyZV7U0vvK65O8zH0OQpQZeVH2
OciT3dn2OTh4DtohMV+S2yFRme2QaAgvh2yHxDzZbYdE2lzdzlZQ5rY/craCITw/2dkKebLb2Qq0
OWGm/rT5ydg/q1XPPj8rkByxNiKW+c/panfbT1crsTYilhl5aV7b9kT99PPPz54dVZnTZXe6MifK
QeaghyRvOy+88T5WIeSItRGxzG3nsjfeLyykNiKWGXlRv8bjy9Ho/XA4H71en5y8PTubTmQb739X
X+Z02Z2uzClykDnQfSAjIyMjIzMHzAEyMjIyMjJzwBwgIyMjIyMzB8wBMjIyMjIyc8AcICMjIyMj
MwfMATIyMjIyMnMQwBwQERGVL+bAygEyMjIyMrKVA+YAGRkZGRmZOWAOkJGRkZGRmQPmABkZGRkZ
mTlgDpCRkZGRkZkD5gAZGRkZGZk5qNYctJ2gdXNzXSw5XW20nVT287rcMred23b98/oIayNi1MnB
PPEcsczIzEE/5uDP2dun7WdvnxdITlcbXy8u3pyetp1x/uW8xDJffL04fXPaduL7+Zfzo6qNiFEn
B/PEc8QyIzMH/ZiD6QSiseNYvKbfKYqcrjamE+LGgXDxmn6nqDJPzfhgU6Gn3zmS2ogYdXIwTzxH
LDMyc9CPOZjOKjb2HfOrbYaRn5yuNqaz5I1j4fxqmzHnL/PUoQ+6FbrNrddUGxGjTg7mieeIZUYu
whxs3LixlyG8sVTdP1xf3Tc348X1xlevBg8eDO7cmV2PHw/evVtegfz9+6p3crok/zUet62fN66o
/7jqv8zjX+O2tbvG1byrH1cV10bEqJODeeI5YpmRizAHi7+uL3/QON6v/tz9w43V/f37aLGDuHdv
VoCXLwcvXsx+uH+/0/JjZnK6JL8cjTqOhWuW0zOXeXQ5GmxT6MalvGpqI2LUycE88RyxzMj9m4PG
+fq20/T5z1t9c/U3ZjYHV1fDxjXGjx9nBb59e/nzb9/OeienS/L3w+FWw+Hbs/7LPHw/bCjZXE2F
Pnt7VnFtRIw6OZgnniOWGblEc7Db8Lz6hY3fXF+S1OZg/l7T0vXhw+Dhw1kJnz9f/qPLy5Peyela
fP6eXvfr9Un/ZZ6/I9Q9FU9en1RcGxGjTg7mieeIZUYu2hw0fm3j6Nt9IO9oDlbXHg7yzEHjxOLR
oxnkyZPmB5d6J6dr8dXQPf33KaKrX+i9zM1JuLbQFddGxKiTg3niOWKZkUs3B42HTLfdLGgc1Je+
3N0cLNqCbCsHt27NfuOnTw19x56zloOQrRxYOagp6uSglQPkSOZgh0G3+yLBVuYg6W2FtruSbdf+
9zv3J6dLcs8cRK+NiFEnB/PEc8QyI/dvDtYMrusfKdhtzN7htsIky9sK82uu7pulZCanS3JvK0Sv
jYhRJwfzxHPEMiMXYQ4m7ffsVxf2u99W2PjNjrcV8uxzsL772Ocd6wOS0yW5fQ6i10bEqJODeeI5
YpmRSzEHdcvubF3IdkiMXht2SIxeG3ZIRGYOijAHE/u6/1vOVoheG85WiF4bzlZAZg6KMAeT/57b
drf93LZnBZLT1cZ0xtz2rP7088/PSizz1K03Pyf8Z+3u2ednR1UbEaNODuaJ54hlRmYOejMHk/YT
3xvvRBZCTlcbv8bjy9Ho/XA4Hxdfn5y8PTubTpEb76wXUua209Mb7+pVXxsRo04O5onniGVGZg56
MwfIyMjIyMglk5kDIYKMjIyMjMwcMAfIyMjIyMjMAXOAjIyMjIzMHDAHyMjIyMjIzAFzgIyMjIyM
zByUaQ6IiIjKF3Ng5QAZGRkZGdnKAXOAjIyMjIzMHDAHyMjIyMjIzAFzgIyMjIyMzBwwB8jIyMjI
yMwBc4CMjIyMjMwcVGsO2s5tu7m5LpYcsTa0oBbUgpM9zvS7/llumdvOL/15fV1sbcSKOuYgd1j/
OfH9tP3E9/MCyRFrQwtqQS3YhXzx9eL0zel0FFy9pqPj+ZcSy/z14uLN6WlTkQdTr/Dl/LzA2ggX
dcxB1rCeWrnGJly8pt8pihyxNrSgFtSCXcjTCXHjQLh4Tb9TVJn/efp0U5EH0+8UVRsRo445yBfW
U3+3sRXnV5vXy0+OWBtaUAtqwS7k6Sx541g4v9pmzPnL/PXioluRB23rB/lrI2jUHdgcNO7I2Mjv
3ZGsFqCt8G1V1PZPaPz85ma8uPLz6tXgwYPBnTuz6/Hjwbt3y2tBv39f9U5Ol+TKrDa0YL+1Mf41
bls/b1xRv/rRf5l/jcdtdxMa7y/8uLrqvTbiRt0hzcEip+3ncib3axzM35/X/CvW1Fvj59+/jxab
6t692V9/+XLw4sXsh/v3Oy0EZSanS3JlVhtasN/aGF2OOo6Fa5bTM5f5cjTapsjNNxcy10bcqDuY
OWiciC/+sPSLln7uOGXv+GHjb1z905zm4Opq2Lja8/HjjHP79vLn376d9U5Ol+TKrDa0YL+1MXw/
bBj25moaDs/e9l/m98PhVubg7dlZ77URN+oSmoPGcXTND4f9sPELawq8lTlotBfrq2L+hsnS9eHD
4OHDWVGfP1/+o8vLk97J6ZJcmdWGFuy3Nubv6XUfDk9e91/m+VuL3a/XJye910bcqMtkDtaPu9v+
6T4z/o3moM3K7GkOGi3eo0cz7JMnzY+Q9E5Ol+TKrDa0YL+10TwQLmplROy9zKvD9OmGIg96r424
UVeEOWg8W3qrOwj7m4NFB7BajI1rHru5vFu3ZvBPnxpacU//eBBy5jnc0ZZZbWhBKwdHtXIQIury
PXOw1W2F7gsGBzQH3X9jo5vZ7f5Q27X/naf9yemSXJnVhhbstzY8c5CnNuJGXe63FdY/fJD0QYSO
txW6c/Z5W2F+zdV924rM5HRJrsxqQwv2WxveVshTG3GjLvc+B2tuK0wO9wrDPrcV8uxzsL4h93nb
9YDkdEmuzGpDC/ZbG/Y5yFMbcaPODomZwnpidzZlVhta0A6J+5XZDonZoo45yBfWE/u6K7Pa0IIl
1YazFfLUhrMVaHPC/DlB6277CVrPCiRHrA0tqAW1YBfydMbc/Kz+n/XzZ59LLPPXi4u2Nxemn39+
9qzA2ggXdcxB7rCetJ+93XhPqBByxNrQglpQC3Yhj3+NR5ej4fvhfFw8eX1y9vZsOkVuvLNeSJl/
jceXo9H74XDuEl6fnLw9O/vn6dPG5wwKqY1YUccc9BDWyMjIyMjIJZOZAyGCjIyMjIzMHDAHyMjI
yMjIzAFzgIyMjIyMzBwwB8jIyMjIyMwBc4CMjIyMjMwclGkOiIiIyhdzYOUAGRkZGRnZygFzgIyM
jIyMzBwwB8jIyMjIyMwBc4CMjIyMjMwcMAfIyMjIyMjMAXOAjIyMjIzMHFRrDtpO0Lq5uS6WHLE2
Ipa57US4659aUA6mqo2IUZeuzOnIbSdJ/rwuMeqYg9xh/efs7dP2s7fPCyRHrI2IZb74enH65rTt
LPnzL1pQDh6+NiJGXboypyN/vbh4c3raBB5MvcKX8+KijjnIGtZTK9fYhIvX9DtFkSPWRsQyT6cm
jV3S4jX9jhaUgwesjYhRl67M6cj/PH26CTyYfqeoqGMO8oX11N9tbMX51eb18pMj1kbEMk/nKxt7
pfnVNnfRgnJw29qIGHXpypyO/PXioht40LZ+0EvUFWcONu7p2D2k/nIagY2frH5z/YeN5Wz88OZm
vLjy8+rV4MGDwZ07s+vx48G7d8trQb9/X/VOTpfkyvwv7/9r3LaS2bi2efVDC5ZV5oi1ETHq0pU5
HfnXeNx2N6Hx/sKPq1KirixzsDS0HwTVNn6vjvfr/273sjX+6ffvo8WmundvVoCXLwcvXsx+uH+/
00JQZnK6JFfmRY0uRx17pTULm1pQDm5VGxGjLl2Z05EvR6NtwM03F3qJuoLMwfrJ/epMvXFVYPHD
tvn93+/sZg42VlfjF66uho2rPR8/zop3+/by59++nfVOTpfkyryo4fthQycxV1P/cfZWC07k4J61
ETHq0pU5Hfn9cLiVOXh7VkrUFW0ONo7cqwP2mh/W/7qtzMH6ex+Nn8/fMFm6PnwYPHw44zx/vvxH
l5cnvZPTNasyL2r+xlT3junktRYsq8wRayNi1KUrczry/K3F7tfrk1KiLrY5WPPhzuagzXNsvNew
/sNGi/fo0Qz75EnzIyS9k9M1qzL/68PGLmlRK12IFiyqzBFrI2LUpStzOvLq8H+6AVxK1DEHy3Ux
aX+qsWucdXZ5t27N4J8+NbTinrOWg5Azz+GOtszVrBwcbQtGrA0rB1WuHBww6mI8c5DHHOww5Hf/
sO3+UNu1//3O/cnpklyZF1XTMwfH2YIRa8MzB3nI+Z85OFTUxXhbIedthd1MycbqXnqydH7N1X3b
iszkdEmuzIuq4G2FI2/BiLXhbYU85GxvKxw86sLsc9D2tsLBbytstc9B97Beeid1fUPu8471Acnp
klyZF1XBPgdH3oIRa8M+B3nI2fY5OHjU2SExU1hP7M6mzHZIrLfMdkiMXmY7JDIHvZmDiX3dldnZ
CvWW2dkK0cvsbAXmoDdzMPnvCVp320/QelYgOWJtRCzzdO7S/NT0n5XMZ5+1oBw8fG1EjLp0ZU5H
/npx0fbmwvTzz8+KizrmIHdYT9rP3m68J1QIOWJtRCxz21nyjfc4taAcPEhtRIy6dGVOR/41Hl+O
Ru+Hw7lLeH1y8vbs7J+nTxufM+g96piDHsIaGRkZGRm5ZDJzIESQkZGRkZGZA+YAGRkZGRmZOWAO
kJGRkZGRmQPmABkZGRkZmTlgDpCRkZGRkZmDMs0BERFR+WIOrBwgIyMjIyNbOWAOkJGRkZGRmQPm
ABkZGRkZmTlgDpCRkZGRkZkD5gAZGRkZGZk5YA6QkZGRkZGZg2rNQdsJWjc318WSJcyi2s5tu/55
XSxZC8pBOVgrOUXUMQe5w/rP2dun7WdvnxdI1jEt6uLrxemb07YT38+/nBdI1oJyUA7WSk4UdcxB
1rCeWrnGJly8pt8piqxjWtTU5jem9+I1/U5RZC0oB+VgreR0Uccc5Avrqb/b2Irzq83r5SfrmJa8
/8YMn19t84D8ZC0oB+VgreSkUZfQHHTco3G3CNu/zKuExqJ2/3B92W5uxosrP69eDR48GNy5M7se
Px68e7e8FvT791XvZB3Tvxz6r3HbqmDjOuHVj6veyVpQDsrBWsmpoy6tOcg/O9/KuLQB//7c/cON
Zfv+fbTYVPfuzQrw8uXgxYvZD/fvd1oIykzWMS1qdDnqmOFrFgkzk7WgHJSDtZJTR10P5mB12r00
7rbN1NeM0FtN7pdQeczB1dWwcbXn48dZIW/fXv7827ez3sk6pkUN3w8bknmupiQ/e3vWO1kLykE5
WCs5ddTlNgfrh9vFwmz7p1uN3/nNwfwNk6Xrw4fBw4ezf9Tz58t/dHl50jtZx7So+dtH3ZP85PVJ
72QtKAflYK3k1FGX6ZmD7uZg2xF641/pGHwbLcjGtYr11d1o8R49mkGePGl+hKR3so7pXx82pvei
VvK8d7IWlINysFZy6qjrYeVg1TQc3BxsHL8n7Q8kNnISrRzcujWDf/rU0Ip7zloOQtYxWTmofuVA
DsrBmlYODhh1fd5W2GcZf8+hemOlbFvIjX+97f5Q27X//c79yTqmRXnmIDpZDsrByRE8c3CoqCvu
mYP1fxr3mYOlJ0vn11zdt63ITNYxLcrbCtHJclAOTup9W+HgUVfi2wpt9wgmB3pbYf1thTz7HKxv
yH3esT4gWce0KPscRCfLQTk4qXefg4NHXbAdEkMU1e5stZLtkBidLAfloB0S6zEHHbdZDOFg7Ose
nexshehkOSgHayI7WyGSOpygdbf9BK1nBZJ1TEvzgOYnkP+sCj77/KxAshaUg3KwVnKiqGMOekiY
trO3G+8JFULWMf3Lrbecy954v7AQshaUg3KwVnKKqGMOpCIyMjIyMjJzwBwgIyMjIyMzB8wBMjIy
MjIyc8AcICMjIyMjMwfMATIyMjIyMnPAHCAjIyMjIzMHAcwBERFR+WIOrBwgIyMjIyNbOWAOkJGR
kZGRmQPmABkZGRkZmTlgDpCRkZGRkZkD5gAZGRkZGZk5YA6QkZGRkZGZg2rNQdsJWjc318WS09VG
20ll1z+PscwRayNi1MlBOZifHCvqmIPcYf3n7O3T9rO3zwskp6uNi68Xp29O2844P/9yXGWOWBsR
o04OysH85HBRxxxkDeuplWtswsVr+p2iyOlqY2rGG5Nw8Zp+50jKHLE2IkadHJSD+ckRo445yBfW
U3+3sRXnV5vXy09OVxtTh74xD+dXm1uvqcwRayNi1MlBOZifHDTqEpqDjns09jV+r5aq44cb/12N
H97cjBdXfl69Gjx4MLhzZ3Y9fjx49255Lej376veyemSfPxr3LZ217iad/Wj5jJHrI2IUScH5WB+
ctyoS2sOyp/Z//25+4cb/42NH37/Plpsqnv3ZtX+8uXgxYvZD/fvd1oIykxOFwajy1HHPFyzlFdN
mSPWRsSok4NyMD85btT1YA4a5+J/P99nfr/xa2sKuYM5WPMPXP3w6mrYuNrz8eOskLdvL3/+7dtZ
7+R0YTB8P2xIubmaUvHsbc1ljlgbEaNODsrB/OS4UZfbHLSNwavj8Q7z++4z/v3Nwfo6Xf1w/obJ
0vXhw+Dhw9m//fnz5T+6vDzpnZwuDObvCHVPxZPXNZc5Ym1EjDo5KAfzk+NGXaZnDvZc0u/+17f9
x+9QsN3MQaPFe/RoVjlPnjQ/QtI7OaFHbEzCRa1kY8VljlgbEaNODsrB/OS4UVfKykHbF7o8DNj2
i7qcV53NHDS6vFu3ZsX79KmhFff0jwchm7VYOagp6uSgHCxk5SBE1BVtDnZYTuh+W2HNYN/FtWz7
D2+7P9R27X/naX9yujBwvzN6bUSMOjkoByfFPHNQftSVaw4O8sxB97cNU5uDpSdL59dc3betyExO
FwaelI5eGxGjTg7KwUnfbysEirqC3lboclthsuXbCm0+oO15iO6/btt/+NI7qesbcp+3XQ9IThcG
3rGOXhsRo04OysFJ3/scBIo6OyTmc0V2Z1uU3dmi14YdEuWgHKw46piDfGE9sa/7v2Vf9+i14WwF
OSgHa4065iBrWE/+e4LW3fYTtJ4VSE5XG1O33vyc8J+1u2efj6vMEWsjYtTJQTmYnxwu6piD3GE9
aT97u/GeUCHkdLXRdnp641296sscsTYiRp0clIP5ybGijjnoIayRkZGRkZFLJjMHQgQZGRkZGZk5
YA6QkZGRkZGZA+YAGRkZGRmZOWAOkJGRkZGRmQPmABkZGRkZmTko0xwQERGVL+bAygEyMjIyMrKV
A+YAGRkZGRmZOWAOkJGRkZGRmQPmABkZGRkZmTlgDpCRkZGRkZkD5gAZGRkZGZk5qNYctJ36df3z
ek9y29lcNzfXEiZEC6Yja8E8mSIH5WAdPT9zkDusL75enL45bTsv/PzL+c7kP6d6n7af6n2uYyq8
BdORtWCeTJGDcrCanp85yBrWU5PYGByL1/Q7O5CnJrExOBav6Xd0TMW2YDqyFsyTKXJQDtbU8zMH
+cJ66hw3xsf8anORbeSpc9wYH/OrzUXqmPptwXRkLZgnU+SgHKys589kDjbu1/j3w20Ls1vhG0uy
54frizT+NW5bU2pcZbr6cdWRfHMzXlxTevVq8ODB4M6d2fX48eDdu+VVpt+/r3RMO5DTtWA6shbM
kylyUA7W1/PnMweJom2Hwi/+lUZTssOHG4s0uhx1jI81S0yN5O/fR4tBcO/erEFfvhy8eDH74f79
TktMOqYeWzAdWQvmyRQ5KAfr6/n7NAfzD5f+u1ieNbP2VchWk/v85mD4ftgQCnM1hcjZ27OO5Kur
YeM60sePM/bt28uff/t2pmPagZyuBdORtWCeTJGDcrC+nr9nc7A64nYcmJcMxLbjd35zMH93pXuI
nLw+6Uiev7uydH34MHj4cMZ+/nz5jy4vT3RMO5DTtWA6shbMkylyUA7W1/P38MxBx+X9juPubuP3
+q+lMAfNwbGolSjpSG40j48ezZBPnjQ/nKJj2sXLJmvBdGQtmCdT5KAcrK/n7/+2wvqhd42fWA/p
eF51NnOQ2T/eujUDf/rUEB9mLVYOrBwcNlPkoBysr+cv2hx0+dPukPVFqu+Zg7bL/c7dyJ45iE5O
lylyUA7W1/OXaw66P3NwkPG7mrcV5tdc3TfE0DH12ILeVshDTpcpclAO1tfzl2gOdnhbocstidU/
WkVVsM/B+hDxjvXOZPscRCenyxQ5KAfr6/ntkJgvYeyQGJ1sh8ToZDskykE7JDIHxZmDibMV4pOd
rRCd7GwFOVgT2dkKlZiDuYtsfn71z5rSs8/Pdib/OZvrbvvZXM+Op/sI2oLpyFowT6bIQTlYTc/P
HPSQMG2nejfebdqK3Haqd+PdJh1TgS2YjqwF82SKHJSDdfT8zIFUREZGRkZGZg6YA2RkZGRkZOaA
OUBGRkZGRmYOmANkZGRkZGTmgDlARkZGRkZmDpgDZGRkZGRk5iCAOSAiIipfzIGVA2RkZGRkZCsH
zAEyMjIyMjJzwBwgIyMjIyMzB8wBMjIyMjIyc8AcICMjIyMjMwfMATIyMjIyMnNQrTloO5vr+uf1
nuS2s7lubq4lTIgWTEfWgnkyRQ7KwTrIzEHusL74enH65rTtVO/zL+c7k/+c6n3afqr3uY6p8BZM
R9aCeTJFDsrBasjMQdawnlq5xiZcvKbf2YE8nZo0dkmL1/Q7OqZiWzAdWQvmyRQ5KAdrIjMH+cJ6
6u82tuL8avN6beTpfGVjrzS/2uYuOqZ+WzAdWQvmyRQ5KAcr6zcObw4aN2Xc4Vf8/SuJ4m8V21by
jh+u/8eOf43bVn4a14Kuflx1JN/cjBdXMl+9Gjx4MLhzZ3Y9fjx49255bfP37ysd0w7kdC2YjqwF
82SKHJSD9fUbBzYHi6g9sUnXM9bbl0Zfsv7DjSUfXY46tuKahaBG8vfvo8Wu59692T/t5cvBixez
H+7f77SwqWPqsQXTkbVgnkyRg3Kwvn7jkOagcS7ecWT9W4yNf2WpwH//VvfJ/dIvOrgPaPxw+H7Y
0GBzNTXk2duzjuSrq2Hj6uXHjzP27dvLn3/7dqZj2oGcrgXTkbVgnkyRg3Kwvn4jrTnYdi6+WJiO
xmL9X1lTqszmYP6GSfeGPHl90pE8f2Nq6frwYfDw4Yz9/PnyH11enuiYdiCna8F0ZC2YJ1PkoBys
r99IZQ6WJu47LNSvf+Zgz5X/NeagrdiNKxPdw7q5CRe10pYdyY1TlkePZsgnT5ofidIx7UBO14Lp
yFowT6bIQTlYX79RxG2F7uZg9RTqQ5mDxlsbbR+Wv3Jw69YM/OlTQ69k1mLlwMrBYTNFDspBKwd9
moMDPjPY8SbIAT/M/8xB2+V+525kzxxEJ6fLFDkoByeeOdjqzsL6IX/nZw5SrBxU87bC/Jqr+zYs
OqYeW9DbCnnI6TJFDsrBibcVujTqxhcFu6zer7mtMOn8+sNWywN17HOwvmPyjvXOZPscRCenyxQ5
KAcn9jlIrQq2a7RDYq1kOyRGJ9shUQ4iRzIHq48ZVmkOJs5WiE92tkJ0srMV5CByyJWDus3B3Os1
P2X6Z+Xn2ednO5P/nAh3t/1EuGfH030EbcF0ZC2YJ1PkoByshswc9JAwbWdvN94T2orcdpZ84z1O
HVOBLZiOrAXzZIoclIN1kJkDqYiMjIyMjMwcMAfIyMjIyMjMAXOAjIyMjIzMHDAHyMjIyMjIzAFz
gIyMjIyMzBwwB8jIyMjIyMxBAHNARERUvpgDKwfIyMjIyMhWDpgDZGRkZGRk5oA5QEZGRkZGZg6Y
A2RkZGRkZOaAOUBGRkZGRmYOmANkZGRkZGTmoFpz0HaC1vXP6z3JbSfC3dxcFxvW6WojYpkj1kbE
qEtXZjkoB/PHRooyMwe5w/ri68Xpm9O2s7fPv5zvTP5zlvxp+1ny5wUmebraiFjmiLURMerSlVkO
ysH8sZGozMxB1rCeWrnGJly8pt/ZgTy1n41ht3hNv1NUkqerjYhljlgbEaMuXZnloBzMHxvpyswc
5Avrqb/b2Irzq83rtZGnnnRj5M2vNn+aP8nT1UbEMkesjYhRl67MclAO5o+NpC1YkDnYuJtj6uBr
LMD6DxtL2/jh+Ne4beWncS3o6sdVR/LNzXhxterVq8GDB4M7d2bX48eDd++W169+/77qPcnT1UbE
MkesjYhRl67MclAO5o+N1C1YijlYLEOG8jSO96s/t5VqfQkb/3R0OerYimsWghrJ37+PFsPr3r3Z
P+3ly8GLF7Mf7t/vtHiVOcnT1UbEMkesjYhRl67MclAO5o+N1C1YhDlonMQv/rD4v10m93//1pqZ
/c7mYGN1NX5h+H7Y0GBzNTXk2duzjuSrq2HjCtXHjzP27dvLn3/7dtZ7kqerjYhljlgbEaMuXZnl
oBzMHxupW7BQc9A4xd9q/N44lu9jDtbfAWn8fP6GSfeGPHl90pE8fytm6frwYfDw4Yz9/PnyH11e
nvSe5OlqI2KZI9ZGxKhLV2Y5KAfzx0bqFizOHCyNuxsX9re6HdDFHKwuQjQuS6yBN3/Y2ISLWmnL
juRGW/ro0Qz55EnzYy+9J3m62ohY5oi1ETHq0pVZDsrB/LGRugVj3FbIYA4WbUF3TvcPMzvTW7dm
4E+fGiLPrMXKQaJZeOFRl67MclAO5o+No1s56NEc7MDp/mH+e1ptl/udpZW5pmcOSo66dGWWg3Iw
f2wcxTMHk27vBZTzzMEO5iDb07Dza67uW214UrrHMlfwtkKIqEtXZjkoB/PHxlG8rfCvorSP2ZMD
va2w/rbCbr9xY3Vne492ffB5x7rAMlewz0GIqEtXZjkoB/PHxrHsc5AhsHr/7XZIzFMbEctsh8To
ZZaDctAOiczB7r/d2Qp5aiNimZ2tEL3MclAO5o8NZyvUY02mXq/5KdM/Kz/PPj/bmfzn1K+77ad+
7U6OWBsRyxyxNiJGXboyy0E5mD82EpWZOehh3aLt7O3Ge0JbkdvOC2+8j1VCkietjYhljlgbEaMu
XZnloBzMHxspyswc9BDWyMjIyMjIJZOZAyGCjIyMjIzMHDAHyMjIyMjIzAFzgIyMjIyMzBwwB8jI
yMjIyMwBc4CMjIyMjMwclGkOiIiIyhdzYOUAGRkZGRnZygFzgIyMjIyMzBwwB8jIyMjIyMwBc4CM
jIyMjMwcMAfIyMjIyMjMAXOAjIyMjIzMHFRrDtpO0Lr+eV0sOWJtaME8tdF21tzNzTGWOWJtyME8
5FhRxxzkDuuLrxenb07bzt4+/3JeIDlibWjBPLXx55T60/ZT6o+rzBFrQw7mIYeLOuYga1hP7Wdj
2C1e0+8URY5YG1owT21MpyaNXdLiNf3OkZQ5Ym3IwTzkiFHHHOQL66kn3Rh586vNn+YnR6wNLZin
NqbzlY290vxqm7vUVOaItSEH85CDRt2BzcEqqkzn0bhzZPcPN9Zpg7/7NW5brWpcv7r6cdU7OV2S
K3P02ri5GS+uZL56NXjwYHDnzux6/Hjw7t3y2ubv3zWXOWJtyME85LhRd4zmYLFIf3/u/uHfWtsq
rEeXo46Rt2bxKjM5XZIrc/Ta+P59tNj13Ls3y4iXLwcvXsx+uH+/08JmNWWOWBtyMA85btRlNQer
s/D5z0v/XRybN87jV/9W24frC7ytY9jWHAzfDxuCbK6m4Dt7e9Y7OV2SK3P02ri6GjauXn78OCv1
7dvLn3/7VnOZI9aGHMxDjht1+cxB20Db5efuhDUfHsoc7HZbYf5WTPfgO3l90js5XZIrc/TamL8x
tXR9+DB4+HBW6ufPl//o8rLmMkesDTmYhxw36g5vDtpOhNx23X596Xce1DfeX0hkDprDblEr8dc7
OV2SK3P02micsjx6NCvskyfNj0RVXOaItSEH85DjRl3WlYOOjmGy6Wb/zp6jR3Ng3qnM1a8c3Lo1
K/KnTw29UrErBwcpc8TakIM9rhyEiLp+bitsawgO8uH6oqY2B+5YK/PkCJ45aLtKfuZg/zJHrA05
mIccN+r6f+ZgB3Ow/8rBxgcnD24OPOuuzJN631aYX3N134almjJHrA05mIccN+qKeFth29sKe64c
NN7gmNjnIGOSK3P02lh6x3p9x1TmPgcHLHPE2pCDechxo84OiZnCemJ/PWW2Q2K9ZbZDohy0QyLt
GNYTO/Mrs7MV6i2zsxXkYE1RxxxkDeu5P21+MvbPatWzz88KJEesDS2Ypzb+nAh3t/1EuOMqc8Ta
kIN5yOGijjnIHdaT9vPCG+9jFUKOWBtaME9ttJ0l33iPs/oyR6wNOZiHHCvqmIMewhoZGRkZGblk
MnMgRJCRkZGRkZkD5gAZGRkZGZk5YA6QkZGRkZGZA+YAGRkZGRmZOWAOkJGRkZGRmYMyzQEREVH5
Yg6sHCAjIyMjI1s5YA6QkZGRkZGZA+YAGRkZGRmZOWAOkJGRkZGRmQPmABkZGRkZmTlgDpCRkZGR
kZmDas1B2wlaNzfXxZLT1UbbGWjXP4+xzBFrIyJZDsrB/ORf4/HlaPR+OPzfu3f/ZzB4fXLy9uzs
n6dPf16XGHXMQe6w/nP29mn72dvnBZLT1cbF14vTN6dtp6effzmuMkesjYhkOSgH85O/Xly8OT1t
Ag+mXuHLeXFRxxxkDeuplWtswsVr+p2iyOlqY2rGG5Nw8Zp+50jKHLE2IpLloBzMT/7n6dNN4MH0
O0VFHXOQL6yn/m5jK86vNq+Xn5yuNqYOfWMezq82t15TmSPWRkSyHJSD+clfLy66gQdt6we9RF3P
5mD1V//9ZJ9Sdfm7jb96tTa6f7j+t9/cjBdXfl69Gjx4MLhzZ3Y9fjx49255Lej376veyemSfPxr
3LZ217iad/Wj5jJHrI2IZDkoB/OTf43HbXcTGu8v/LgqJerKNQdJO53G8X69QVn/4cbf/v37aLGp
7t2bFeDly8GLF7Mf7t/vtBCUmZwuyUeXo455uGYpr5oyR6yNiGQ5KAfzky9Ho23AzTcXeom6ACsH
8x8W/7dtKr8EafunLQHzmIOrq2Hjas/Hj7NC3r69/Pm3b2e9k9Ml+fD9sCEt5mrKmLO3NZc5Ym1E
JMtBOZif/H443MocvD0rJepimIOOo/XGv7LmV6c2B/M3TJauDx8GDx/Oivr8+fIfXV6e9E5Ol+Tz
d4S6p+LJ65rLHLE2IpLloBzMT56/tdj9en1SStT1bw7aTpDcZzDe+FfWmIO2Mqz/cGN1N1q8R49m
hCdPmh8h6Z2cLsmbk3BRK0lTcZkj1kZEshyUg/nJq8P/6QZwKVEX5rbCqp84rDlYHOyX/nrHD3dw
ebduzTifPjW04p6zloOQzVqsHFS/ciAH5WBNKwcHjLp45mD9Ov8+5mCHmwX7P3PQdu1/v3N/crok
d78zem1EJMtBOTg5gmcODhV1wcxB92cOdr6tMMnytsL8mqv7thWZyemS3JPS0WsjIlkOysFJvW8r
HDzqaritMGl5W2G32wp59jlY35D7vGN9QHK6JPeOdfTaiEiWg3JwUu8+BwePOjsk5uvy7M62KLuz
Ra+NiGQ5KAftkMgcFGcOJvZ1/7fs6x69NiKS5aAczE92tgJtTpg/J2jdbT9B61mB5HS1MXXrzc8J
/1m7e/b5uMocsTYikuWgHMxP/npx0fbmwvTzz8+KizrmoIcur+3s7cZ7QoWQ09VG2+npjXf1qi9z
xNqISJaDcjA/+dd4fDkavR8O5y7h9cnJ27Ozf54+bXzOoPeoYw50psjIyMjIyMwBc4CMjIyMjMwc
MAfIyMjIyMjMAXOAjIyMjIzMHDAHyMjIyMjIzAFzgIyMjIyMzBwEMAdERETlizmwcoCMjIyMjGzl
gDlARkZGRkZmDpgDZGRkZGRk5oA5QEZGRkZGZg6YA2RkZGRkZOaAOUBGRkZGRmYOqjUHbSdo3dxc
F0tOVxttJ5X9vD7GMqsNLZi/NtrOIbz+eYxlRmYO+jEHf87ePm0/e/u8QHK62vh6cfHm9LTtjPMv
58dVZrWhBfPXxsXXi9M3p4OmQk9HmvMvx1VmZOagH3MwncQ3Dt6L1/Q7RZHT1cZ0OtXYjS5e0+8c
SZnVhhbMXxvTyeVgU6Gn3zmSMiMzB/2Yg+nMfuP4Pb/aZvn5yelqYzrH2tiTzq+2+VZNZVYbWjB/
bUxnnINuhW6bfdZUZuTSzcFqYVIUr3HnyLbtJBs/WVNvjZ/f3IwX1/xfvRo8eDC4c2d2PX48ePdu
+S7A799XvZPTJfmv8bht9bVxPfbHVc1lVhtaMH9tjH+N29aiG1enr37UXGZk5mAZ+Pfnxg//VtDG
v76xwN+/jxYH6Xv3ZtiXLwcvXsx+uH+/0y2AzOR0SX45GnXsSdcsxlZTZrWhBfPXxuhyNNim0I1L
09WUGTm8OVidss9/blsG2Bi+683BRkJ3c3B1NWxc5//4cVbO27eXP//27ax3crokfz8cbtWZvj2r
ucxqQwvmr43h+2FDyeZqKvTZ25rLjBzbHLSN36tfaPzTHcxBl+rr+OH83cKl68OHwcOHsxI+f778
R5eXJ72T0yX5/C2v7tfrk5rLrDa0YP7amL/z1n1oOXldc5mRY5iDtjMlu98O2Ljyv/FWQpfq2+rz
xsn9o0ezf92TJ80PD/ZOTpfkq6F7+u8WX/1CxWVWG1owf200DyprC11xmZHrXDkIYQ4a5/e3bs0q
/9OnhvF7z5WDg5DNO807ldnKgZUDKwfHZQ66P2Y4GGxtuFY/bHsyoO3a/5mD/cnpktwda7WhBfut
Dc8cIB+1OWj712187LH7lztW99I7BfNrru4bFmUmp0tyz7qrDS3Yb214WwF5cgxvK7R9c7J2l4JV
VJd9Dtr++vrqXtqNYP0Qvs8+Bwckp0tyb8mrDS3Yb23Y5wB5cuQ7JOb/19khsQvZ/npqQwv2Wxt2
SEQ+OnOwfmbfox1xtsKi7MyvNrRgv7XhbAXk4105KG2t4s/ZiXfbz058ViA5XW1M51ttT3pPP//8
7LjKrDa0YP7amM4+m597/7MW/ezzcZUZmTnozRxM/jwl8P376OpqOB/LLy9Pvn07m07rG58GKISc
rjZ+jceXo9H74XDeq74+OXl7djadYDXel62+zGpDC+avjfGv8ehyNHw/nI8xJ69Pzt6eTaebjXep
qy8zMnPQmzlARkZGRkYumcwcCBFkZGRkZGTmgDlARkZGRkZmDpgDZGRkZGRk5oA5QEZGRkZGZg6Y
A2RkZGRkZOagTHNARERUvpgDKwfIyMjIyMhWDpgDZGRkZGRk5oA5QEZGRkZGZg6YA2RkZGRkZOaA
OUBGRkZGRmYOmANkZGRkZGTmoFpz0HZ24s3NdbHkiLWhBbWgFpzscabf9c9jLHNEcoqoYw5yh/X/
/d/F58+n0/Zbvabt+p//nBdIjlgbWlALasEu5IuvF6dvTqdj1eo1HcPOvxxXmSOSE0Udc5A1rKdW
rrEJF6/pd4oiR6wNLagFtWAX8nTa2jhcLV7T7xxJmSOS00Udc5AvrKf+bmMrzq82r5efHLE2tKAW
1IJdyNO57MYRa361zWtrKnNEctKoy2QOVn/F/JO/n68vQ8cSNn6t7e82Fmm1NlY/3Lj3ZOOHNzfj
xZWfV68GDx4M7tyZXY8fD969W14L+v37qndyuiRXZrWhBfutjfGvcdsqd+O699WPmssckZw66vox
B21eIYU5WPPPbvu7jZaluw9o/PD799FiU927NyvAy5eDFy9mP9y/32khKDM5XZIrs9rQgv3Wxuhy
1HHEWrPoXU2ZI5JTR10P5mD156VZeONkvW1E3/i1jYsWO5uD7msSU11dDRtXez5+nJX29u3lz799
O+udnC7JlVltaMF+a2P4ftgwOM3VNGidva25zBHJqaMutzloG5LXj8dL1mHND+uBHRczupiD9XW6
+uH8DZOl68OHwcOHszI/f778R5eXJ72T0yW5MqsNLdhvbczfpus+aJ28rrnMEcmpoy6rOVgz+V6/
Pr9x5N7qaxttSuMTBlvV6eqHjRbv0aMZ+cmT5kdIeienS3JlVhtasN/aaB6uFrUyblVc5ojk1FGX
zxysX8xve+IvmzloLGTqlYNbt2a/8dOnhlbcc9ZyEHLmOdzRllltaEErB1YODrJycMCoK+KZg60W
CdKZg+63FXZ4fLLt/lDbtf/9zv3J6ZJcmdWGFuy3NjxzEJ2cOup6fluh+wMEHf/K/rcVEpmDpSdL
59dc3betyExOl+TKrDa0YL+14W2F6OTUUVfQPgerPy8N0h3fVtjztsLGfQ52MwdL76Sub8h93rE+
IDldkiuz2tCC/daGfQ6ik1NHnR0SM4X1xO5syqw2tKAdEkstsx0SmYPezMHEvu7KrDa0YEm14WyF
6GRnK1RiDib/PUHrbvsJWs8KJEesDS2oBbVgF/J0Xtv8RP2fVe5nn4+rzBHJiaKOOcgd1pP2s7cb
7wkVQo5YG1pQC2rBLuTxr/HocjR8P5yPXievT87enk0nso33v6svc0RyiqhjDnoIa2RkZGRk5JLJ
zIEQQUZGRkZGZg6YA2RkZGRkZOaAOUBGRkZGRmYOmANkZGRkZGTmgDlARkZGRkZmDso0B0REROWL
ObBygIyMjIyMbOWAOUBGRkZGRmYOmANkZGRkZGTmgDlARkZGRkZmDpgDZGRkZGRk5oA5QEZGRkZG
Zg6qNQdtZ3Nd/7zek9x2NtfNzXWxYa3MakMLToo84XD/HiliC6arjXTkX+Px5Wj0fjj837t3/2cw
eH1y8vbs7J+nT39e705mDnKH9cXXi9M3p22nep9/Od+Z/OdU79P2U73PC0xyZVYbWrDf2kjXI0Vs
wXS1kY789eLizelpE3gw9QpfznckMwdZw3pqEhuDY/GafmcH8tQyN6bK4jX9TlFJrsxqQwv2Wxvp
eqSILZiuNtKR/3n6dBN4MP0Oc1C0OZg6x43xMb/aXGQbeeqjN2bL/Grz1PmTXJnVhhbstzbS9UgR
WzBdbaQjf7246AYetK0f5DYHq8D8/mP9b2zcOXKHDxt/S+OH41/jtjWlxlWmqx9XHck3N+PFFbZX
rwYPHgzu3Jldjx8P3r1bXnP7/fuq9yRXZrWhBfutjXQ9UsQWTFcb6ci/xuO2uwmN9xd+XG3XgjnM
QS8rE+v/zas/d/+wi/NY/XB0OeoYH2uWmBrJ37+PFlPi3r1Zg758OXjxYvbD/fudFtwyJ7kyqw0t
2G9tpOuRIrZgutpIR74cjbYBN99c6NMcrP68OPQu/vaNI/HSl9tOj1j6LR2Nwm6OoXtYD98PG5pr
rqaWPHt71pF8dTVsXFX7+HHGvn17+fNv3856T3JlVhtasN/aSNcjRWzBdLWRjvx+ONzKHLw9264F
05qDxtX4jaZho6VY/V3dv38Qc7D+PKvGz+fvrnQPkZPXJx3J8zd5lq4PHwYPH87Yz58v/9Hl5Unv
Sa7MakML9lsb6XqkiC2YrjbSkedvLXa/Xp9s14IJzUH3Jw+WBuPV/277d9eUofsKx7b3GjZ82Bgc
i1ppzI7kRiv96NEM+eRJ86M6vSe5MqsNLdhvbaTrkSK2YLraSEdeHf5PN4C3a8FU5qBxbN74WN+2
5qD7PYsDmoPN0VDAysGtWzPwp08N2VLsHO5oy6w2tKCVg37r2cpB7tsK2/68lTlYf3+h+5JDHnOQ
/5mDtqvku7/HWWa1oQUnnjnotZ49c9CDOZh0u4W/w2x+vV3ovuSQ57ZCtrcV5tdc3bcH6fep4yMv
s9rQghNvK/Raz95W6MccTFqeAGi8+7Bm6F3ztkL3VYq2vzvZe/OD9dWdbZ+D9QlT5hvnR15mtaEF
J/Y56LWe7XOQyRz0pUL+IXZIVGY7JGpBOyTGakE7JFZrDsr5VzhbQZnVhhZ0tkK4FnS2QrUrByFs
ytRFNj+/+mdN6dnnZzuT/5xUdrf9pLLdyelqQ5nVhhbstzbS9UgRWzBdbaQjf724aHtzYfr552c7
kpmDHtYw2k71brzbtBW57YzzxntvJSS5MqsNLdh7baTrkSK2YLraSEf+NR5fjkbvh8O5S3h9cvL2
7Oyfp08bnzNgDso1B8jIyMjIyCWTmQMhgoyMjIyMzBwwB8jIyMjIyMwBc4CMjIyMjMwcMAfIyMjI
yMjMAXOAjIyMjIzMHJRpDoiIiMoXc2DlABkZGRkZ2coBc4CMjIyMjMwcMAfIyMjIyMjMAXOAjIyM
jIzMHDAHyMjIyMjIzAFzgIyMjIyMzBxUaw7azhO7ubkulpyuNtpOKrv+qcwxOqaIURexzOJZmdvU
dirjz+vdycxB7hD5cxL5aftJ5OcFktPVxsXXi9M3p21nnJ9/UebSh5aIURexzOJZmdv09eLizelp
E3gw9QpfznckMwdZQ2Q6NWnskhav6XeKIqerjallbkyVxWv6HWUudmiJGHURyyyelbntj/55+nQT
eDD9DnNQtDmYzlc29krzq23ukp+crjamPnpjtsyvNk+tzP2SI0ZdxDKLZ2VuI3+9uOgGHrStHxze
HKz+lUbI3w/3+RWJ2rLxn7BaG+s/XP+vXtTNzXhxJfPVq8GDB4M7d2bX48eDd++W1zZ//77qnZwu
Yca/xm0rbI1rblc/lLmsoSVi1EUss3hW5jbyr/G47W5C4/2FH1fb1cZhzEEb4SDmIFErrvknNBa7
7eeOJf/+fbTY9dy7NyvAy5eDFy9mP9y/32lhMzM5XcKMLkcds2XNgpsy90iOGHURyyyelbmNfDka
bQNuvrmQ1hysGUrb/mjjBH3xf5cgXSb3bd9sLNu25mBjdTV+4epq2Lh6+fHjrJC3by9//u3bWe/k
dAkzfD9sCN65muL67K0ylzW0RIy6iGUWz8rcRn4/HG5lDt6ebVcb+5qD9XPr1a/tMAYvOYaOf3fj
WL6POVh/nlXj5/M3ppauDx8GDx/OOM+fL//R5eVJ7+R0CTN/k6d7wpy8VuayhpaIURexzOJZmdvI
87cWu1+vT7arjb3MQduTB+uH8I5z8YMYix3MweoiROOyRJeSL6pxyvLo0Yz85EnzI1G9k9MlTHOq
LGoltJW5qKElYtRFLLN4VuY28urwf7oBvF1t7G4O1izObxzXG0fctjG4+zx+H3PQ+I/azQd0n7Xc
ujX7jZ8+NfRKe64cHIRsBmDloKaoi1hm8azMIVcOdrib0H243WHloPvkfmOlHNwctN3vbLv2f+Zg
f3K6hHHvMPrQEjHqIpZZPCvzJOgzB128wqTzAwR7moOD3FbYH97lSen5NVf3bVgyk9MljKeOow8t
EaMuYpnFszJP4r6tsMOAunpLou1Gw6Tbw4/bPhYwOdA+B91DZOkd6/Ud0z77HByQnC5hvK8cfWiJ
GHURyyyelXkSa5+DXkI8iuyQ2IVsp7PQQ8vEDonxW1AORi9ziTskcga7VYKzFRZlj/TQQ8vE2Qrx
W1AORi+zsxUqMQeT/54Id7f9RLhnBZLT1cbUUzc/zftnhe3ZZ2UuemgJGnURyyyelblNXy8u2t5c
mH7++dmOZOaghyRvO0u+8R5nIeR0tdF2xnnjvTdlLpAcMeoillk8K3Obfo3Hl6PR++Fw7hJen5y8
PTv75+nTxucMmINyzQEyMjIyMnLJZOZAiCAjIyMjIzMHzAEyMjIyMjJzwBwgIyMjIyMzB8wBMjIy
MjIyc8AcICMjIyMjMwdlmgMiIqLyxRxYOUBGRkZGRrZywBwgIyMjIyMzB8wBMjIyMjIyc8AcICMj
IyMjMwfMATIyMjIyMnPAHCAjIyMjIzMH1ZqDthPhbm6uiyWnq422k8qufx5jmSPWRsSok4NyEJk5
KMsc/DlL/rT9LPnzAsnpauPi68Xpm9O2M87PvxxXmSPWRsSok4NyEJk5KMscTCcQjR3H4jX9TlHk
dLUxNbaNAb14Tb9zJGWOWBsRo04OykFk5qAsczCdVWzsO+ZX2wwjPzldbUzd7saYnl9tzremMkes
jYhRJwflIHI8c3CQYvyFrP6w8dc1bifZ/cP1/5Cbm/HieuOrV4MHDwZ37syux48H794tr0D+/n3V
Ozlds45/jdvWwRpXxq5+1FzmiLURMerkoBxEPl5zsMYlrP6z2357499d/+HGf8j376PFDuLevVkB
Xr4cvHgx++H+/U7Lj5nJ6Zp1dDnqGNNrlsWqKXPE2ogYdXJQDiJXZQ6WpultY/P857//XXO2xOI3
s5mDq6th4xrjx4+z4t2+vfz5t29nvZPTNevw/bAhfOdqCuuztzWXOWJtRIw6OSgHkesxB23D/8Y/
3fa2QmpzMH+vaen68GHw8OGs/p8/X/6jy8uT3snpmnX+vk33sD55XXOZI9ZGxKiTg3IQuWZzsLpI
sN4TbGsOlipkde2h7Zvr/yGNE4tHj2aEJ0+aH1zqnZywWRsDelErkV1xmSPWRsSok4NyELkqc7B6
dyCFOVgc7Lvcwmi8N7Ht3OLWrRnn06eGvmPPWctByGYtVg5qijo5KAeR61w5aLyDcEBzcKg7CFvd
lWy79r/fuT85XbO63xm9NiJGnRyUg8iV31bo8nNpzxwsPc88v+bqvllKZnK6ZvWkdPTaiBh1clAO
Ikc1B203ETq+eThpeiCg+5MBOfc5WN997POO9QHJ6ZLcO9bRayNi1MlBOYgc0hxUI7uzdSHbnS16
bdghUQ7KwYr7DeYgX1hP7Ov+b9nXPXptOFtBDsrBWsnMQdawnvz33La77ee2PSuQnK42ps63+Znb
P+tgzz4fV5kj1kbEqJODchCZOSjOHEzaT3xvvBNZCDldbbSdRN54h6z6MkesjYhRJwflIDJzUJw5
QEZGRkZGLpnMHAgRZGRkZGRk5oA5QEZGRkZGZg6YA2RkZGRkZOaAOUBGRkZGRmYOmANkZGRkZGTm
oExzQEREVL6YAysHyMjIyMjIVg6YA2RkZGRkZOaAOUBGRkZGRmYOmANkZGRkZGTmgDlARkZGRkZm
DpgDZGRkZGRk5qBac9B2btvNzXWx5HS10Xae2PXPYyxzxNqIGHVyUNTlJ6er5xRlZg5yh/WfE99P
2098Py+QnK42Lr5enL45bTuJ/PzLcZU5Ym1EjDo5KOryk9PVc6IyMwdZw3pq5RqbcPGafqcocrra
mFrmxlRZvKbfOZIyR6yNiFEnB0VdfnK6ek5XZuYgX1hP/d3GVpxfbV4vPzldbUx99MZsmV9tnrqm
MkesjYhRJwdFXX5yunpOGnUHMAeNf707c/03cwZf43aS3T9cX+abm/Hiys+rV4MHDwZ37syux48H
794trwX9/n3VOzldko9/jdtW2BrX3K5+1FzmiLURMerkoKjLT05Xz6mjLpU5ONRfTxR8jeP96s/d
P9xY5u/fR4tNde/erAAvXw5evJj9cP9+p4WgzOR0ST66HHXMljULbtWUOWJtRIw6OSjq8pPT1XPq
qEu+cjD/oW3yvTrWLn5z8X+Xvrw6d1/9RW3/tNXfm8EcXF0NG1d7Pn6cFfL27eXPv307652cLsmH
74cNiTFXU8Kcva25zBFrI2LUyUFRl5+crp5TR10Oc7A6rK7/052/ufHLa4qd2hzM3zBZuj58GDx8
OCvq8+fLf3R5edI7OV2Sz9/k6Z4wJ69rLnPE2ogYdXJQ1OUnp6vn1FGXaeVg2w+7D8ndv9DRHLS5
mfUfbqyQRov36NGM8ORJ8yMkvZPTJXlzqixqJWcqLnPE2ogYdXJQ1OUnp6vn1FFXkDlYc7MggzlY
f6ejy4c7uLxbt2acT58aWnFPz3sQslmLlYOaok4Oirr85MwrBweMurLMwfrbCqnNwQ43C/Z/5qDt
2v9u2f7kdEnumYPotREx6uSgqMtPzv/MwaGirmdzsNUzB3luK0yyvK0wv+bqvm1FZnK6JPe2QvTa
iBh1clDU5Sdne1vh4FF3GHOwpO53ELrcVmh7uaDtBsSetxXy7HOwviH3eUP3gOR0SW6fg+i1ETHq
5KCoy0/Ots/BwaPODomZwnpid7Z/yw6J0WvDDolyUAv2W8+l75BI3avbvu6LcrZC9NpwtoIc1IL9
1rOzFSoxB5P/nqB1t/0ErWcFktPVxtRTNz/N+2eF7dnn4ypzxNqIGHVyUNTlJ6er50RlZg5yh/Wk
/eztxntChZDT1UbbGeeN996qL3PE2ogYdXJQ1OUnp6vnFGVmDnoIa2RkZGRk5JLJzIEQQUZGRkZG
Zg6YA2RkZGRkZOaAOUBGRkZGRmYOmANkZGRkZGTmgDlARkZGRkZmDso0B0REROWLObBygIyMjIyM
bOWAOUBGRkZGRmYOmANkZGRkZGTmgDlARkZGRkZmDpgDZGRkZGRk5oA5QEZGRkZGZg6qNQdtJ2jd
3FwXS45YG8qsNrRgF/Kv8fhyNHo/HP7v3bv/Mxi8Pjl5e3b2z9OnP6/LrY22Ew6vf14fYT2niGfm
IHeI/Dl7+7T97O3zAskRa0OZ1YYW7EL+enHx5vR0OlatXtMx7Mt5ibVx8fXi9M3poKnQU69w/uX8
qOo5UTwzB1lDZGrlGptw8Zp+pyhyxNpQZrWhBbuQp9PWxuFq8Zp+p6gyP/3n6WBToaffOZJ6ThfP
zEG+EJn6u42tOL/avF5+csTaUGa1oQW7kKdz2Y0j1vxqm9fmL/PF14tBt0K3rR/UVM9J47mrOSjN
QOxfnlVC43aS3T9cX7abm/Hiys+rV4MHDwZ37syux48H794trwX9/n3VOzldSylz9KFFC0ZvwV/j
cdsqd+O694+r/mtj/Gvcdjeh8f7C1Y+rius5dTwfqTloHO9Xf+7+4cayff8+Wmyqe/dmBXj5cvDi
xeyH+/c7LQRlJqdrKWWOPrRowegteDkadRyx1ix6Zy7z6HI02KbQjTcXqqnn1PG8rzlYnUPPf26b
ba+OsltN1jeO5W2FWf23HMQcdK+rq6th42rPx4+zAt++vfz5t29nvZPTJYwyRx9atGD0Fnw/HG41
aL096782hu+HDSWbq6nQZ2/PKq7n1PG8lzlYM0K3DahLf7rmm21/feMPbb9u/b9oW3Ow7W2F+Rsm
S9eHD4OHD2ec58+X/+jy8qR3crqEUeboQ4sWjN6C87fpul+vT/qvjflbi93Nwcnrk4rrOXU8JzEH
ST9sm/1vO8tvMweraw+Nn2x7W6HR4j16NEM9edL8CEnv5HQJo8zRhxYtGL0FV4el03+f5Lv6hd7L
3GwL1ha64npOHc8lmoPVo6a7PDzY8S+u+Re13fjoUuzdXN6tW7Pf+OlTQyvuuXJwEHLmOZwyR185
0IJWDqwc9LtycMB4LnrlYP1Avttf3OqPDmgO2u4PtV37P3OwPzldwihz9KFFC0ZvQc8cRK/n1PGc
2xy0TevTPXOw7W2FSZa3FebXXN23rchMTpcwyhx9aNGC0VvQ2wrR6zl1PG9hDtrW7bu8R9B90X6S
4G2FrW4r5NnnYH1D7rPPwQHJ6RJGmaMPLVowegva5yB6PaeO5x52SKx+Q0Y7JCqzHRK1YPktaIfE
6PVcxA6J+9fa+tn2MZiDibMVlNnZCspcEtnZCtHr2dkKlZiDyX9P0LrbfoLWswLJEWtDmdWGFuxC
ns5r256on37++VmJtXHx9aL5zYU/dxOefX52VPWcKJ6Zgx6SvO3s7cZ7QoWQI9aGMqsNLdiF/Gs8
vhyN3g+H89Hr9cnJ27Oz6US28f53IWUe/xqPLkfD98O5Szh5fXL29uzpP08bnzOovp5TxDNzUFWS
IyMjIyMj709mDoQIMjIy8v/X3hnrNNIsbXgkJETggMBXwDU4QhYRRNwTGzpAgtB3gbiEIzgbAhEZ
4pNZLQ4IzDnZLlj+Z5jzr2bH3TPtsau7q/20Rp/8Dd6Horqq552anm7IkBEHiAPIkCFDhgwZcYA4
gAwZMmTIkBEHiAPIkCFDhgwZcYA4gAwZMmTIkBEHcYoDGo1Go9Hib4gDKgeQIUOGDBkylQPEAWTI
kCFDhow4QBxAhgwZMmTIiAPEAWTIkCFDhow4QBxAhgwZMmTIiAPEAWTIkCFDhow4SFYc2PYTe/v9
Fi1ZozfoQT/esO0IN59vo80avUEOaidLRB3iwHdYj3+O+9/7tp3IL39cRkjW6A160I83vvaS79v3
kt8umzV6gxzUThaKOsSB17DORaIxOKpH/p2oyBq9QQ/68UZ+a2IckqpH/p0tsVmjN8hB7WS5qEMc
+AvrXDm2xkd52FSkf7JGb9CDfryR36+0jkrlYbt3Sclmjd4gB7WTRaMusDhY/tXNxvz56Zo2G1eO
7HDSaIbx5OxjZqspGatM01/T4GS5JMdm7d6Yz2fVSubNTXZ0lO3tFcfpaXZ/X69tfn6mbLNGb5CD
2snSURdeHFR/e6sxGxEHtd+46kl3BVNto8nIMT4aSkyeyXJJjs3avfH+PqoOPQcHReZeX2dXV8WH
w0OnwmYyNmv0BjmonSwddVGLg9rduW3HCPc7fke14X7SPayHD0NDKJTNFCKDu0FwslySY7N2b0yn
Q2P18umpsHp3t37+9TVlmzV6gxzUTpaOuigeKyz/t/XC3O2Of1PioFl5GM+X7664h0jvthecLJfk
2KzdG+UbU7Xj8TE7Pi6svrio/2gySdlmjd4gB7WTpaMuXnHQfAnfiDhofWrQDW4+aQyOaluKkuBk
uSTHZu3eMN6ynJwUxp6dmadEJWyzRm+Qg9rJ0lEXtTgwPkEILg7ao4H7TmzeysrBzk5h8vOzYVSK
tnKwEZs1eoMcTLJysMGo297HCstzFETFAU+ssXmxBXMObEfMcw7Wt1mjN8hB7WTpqIvlVcbmDxsX
B82vUEo8VmCuOzYv0n1boTzK5r4MSzI2a/QGOaidLB118YqDqixYFgrrvK1gfOVhsfbiB83u5i15
bF6ku85B88AU5zoHG7RZozfIQe1k6ahjhURPYb1gfT1sZoXEdG1mhURykBUSaR3DesHK/NjM3grp
2szeCuSgfzJ7KyQiDkoVaZ6/+lVTOn85j5Cs0Rv0oB9vfO0It2/fEW67bNboDXJQO1ko6hAHvsN6
Yd/V2/i0KRKyRm/Qg368YdtL3viMM3mbNXqDHNROlog6xEGAsIYMGTJkyJBjJiMOCBHIkCFDhgwZ
cYA4gAwZMmTIkBEHiAPIkCFDhgwZcYA4gAwZMmTIkBEHiAPIkCFDhgwZcRCnOKDRaDQaLf6GOKBy
ABkyZMiQIVM5QBxAhgwZMmTIiAPEAWTIkCFDhow4QBxAhgwZMmTIiAPEAWTIkCFDhow4QBxAhgwZ
MmTIiINkxYFtB635/C1aspw3bDuVvf3eRps1ekNj1JGDRJ1/b+iKOsSB77D+2nu7b997+zJCspw3
xj/H/e992x7nlz+2y2aN3tAYdeQgUeffG+qiDnHgNaxzKWfswuqRfycqspw3cjFuTMLqkX9nS2zW
6A2NUUcOEnX+vaEx6hAH/sI613etvVgeNq3nnyznjVyht+ZhedjUeko2a/SGxqgjB4k6/95QGnUb
EwfLEIm4WYn5508z/o3GM8vfdD/ZbOR8PqtWfm5usqOjbG+vOE5Ps/v7ei3o83ManCzXZbOPma12
Z6zmTX+lbLNGb2iMOnKQqPPvDb1Rt0lxUOUIFSTcmX++afwnxut9879tPtlq5Pv7qNpVBweFAdfX
2dVV8eHw0KkQ5Jks12WjycgxDxtKecnYrNEbGqOOHCTq/HtDb9R5EgfLt9oNn43frP23+Va+eW+J
KmpNceAe1tPp0FjteXoqzNvdrZ9/fR0EJ8sl+fBhaEi5splScXCXss0avaEx6shBos6/N/RG3YYf
Kyz/d/2b8uWr/koox+L/qkau+lihfMOkdjw+ZsfHBefiov6jyaQXnCyX5OU7Qu6p2LtN2WaN3tAY
deQgUeffG3qjzoc4aK32dyvjC4kDl5pH6zOL5ZNGiXdyUqDOzsxTSIKT5ZLcnITVtpSNCdus0Rsa
o44cJOr8e0Nv1HkSB8sV/oYigcs3Ny4OFn9PYOwgVjqovJ2d4jc+Pxt6cU39uBEydy1UDlKKOnKQ
qIukcqAi6uJ9rNAsCCTEwZqVjG7Ph2zH+k+e1ifzvNOPzSk9/Y056shBom4RzZyD+KNu868yNn9w
PBnwscLCy9sK5VE292UrPJPlkpy3FbR7Q2PUkYNE3SL02wqKos6HODBW7JtPOr7X4PKvVn2s4Ged
g+aOXOdt1w2S5ZKcdQ60e0Nj1JGDRN0i9DoHiqKOFRI9hfWC1dn+bqyQqN0brJBIDrJCYsJRhzjw
F9YL1nX/u7G3gnZvsLcCOZhSD7K3AuIgmDhY/G8HrX37DlrnEZLlvJGrdfM84a/a3fnLdtms0Rsa
o44cJOr8e0Nd1CEOfIf1wr73tvGZUCRkOW/Ydk83PtVL3maN3tAYdeQgUeffG7qiDnEQIKwhQ4YM
GTLkmMmIA0IEMmTIkCFDRhwgDiBDhgwZMmTEAeIAMmTIkCFDRhwgDiBDhgwZMmTEAeIAMmTIkCFD
RhzEKQ5oNBqNRou/IQ6oHECGDBkyZMhUDhAHkCFDhgwZMuIAcQAZMmTIkCEjDhAHkCFDhgwZMuIA
cQAZMmTIkCEjDhAHkCFDhgwZMuIgWXFg2/Xr7ffbmmTb3lzz+RsJo6IH5cj0oJ9MIQf9kD9ms8lo
9DAc/nt//19Zdtvr3Q0G/3z79vvtDfJGyIgD32E9/jnuf+/b9gu//HHZmfy1q3ffvqv3JQNT5D0o
R6YH/WQKOeiH/HM8/t7vmxIly6+OPy4vIa9PRhx4Dev8FtA49FeP/DsdyPmtiXFIqh75dxiYou1B
OTI96CdTyEE/5PyGuC1Rsvw7kNckIw78hXV+X9g6+peH7R7RRs7vV1pHpfKw3bswMIXtQTkyPegn
U8hBP+T8LtktUTLbHTNkBeJg+feuZMmfLy9/6Pzbl73hfrL5r5h9zGwVY2MNefpr6kiez2fVSubN
TXZ0lO3tFcfpaXZ/X69tfn5OGZg6kOV6UI5MD/rJFHLQD/ljNrPVz40V9V/TKeQO5CjEQfVXd7ak
w78yXu8bZEfryVZ7RpOR4+jfUEA2kt/fR9Wh5+Cg+NOur7Orq+LD4aFTYZOBKWAPypHpQT+ZQg76
IU9Go1USxVxOh6xeHNTuzpf3ivjz39qZ1pv75S9vVgcYTw4fhobuKpupJwd3A0fydDo0Vi+fngr2
7m79/OvrgIGpA1muB+XI9KCfTCEH/ZAfhsOVLod3gwHkDuRYHiss/7f5qtzwNMH9ou5fHJRvprlf
AHq3PUdy+cZU7Xh8zI6PC/bFRf1Hk0mPgakDWa4H5cj0oJ9MIQf9kMv39NyP214PcgfytogDx+Cr
lSgaTq4qO/530jj0V9tSZzqSjbcsJycF8uzMPCWKgakDWa4H5cj0oJ9MIQf9kJcveP2WRMkgdyDH
Lg6MG0433987PlawOaXh8cRilemTMVQOdnYK8POzYVTiroXKAZWDzWYKOUjlgMpBgMpBhxJC50t4
h9/u+M/9zzmwHTzv7EZmzoF2slymkIN+yMwM8EOORRwsnCcNdHi+sJCZc9DssbBvK5RH2dyXYWFg
CtiDvK3ghyyXKeSgHzLvFPghRy0OFs5vKzQ/DujwWKF1SQPbI49md3tb56B5YOId685k1jnQTpbL
FHLQD5nVCPyQw4uDVBsrJKZKZoVE7WRWSNROZh1DP2TEge+EYW8F7WT2VtBOZm8F7WR2QPBDRhz4
Tpj8HtE8O/2rYnz+ct6Z/LUj3L59R7jz7Rk+lPagHJke9JMp5KAfcn7HbJurn59/OT+HvD4ZcRAg
YWYfs9FkNHwYlleC3m1vcDfIbwqNz5JXItv2kjc+42RgirAH5cj0oJ9MIQf9kD9ms8lo9DAcltfF
217vbjDIb5GNT9YhIw50iAPIkCFDhgw5ZjLigBCBDBkyZMiQEQeIA8iQIUOGDBlxgDiADBkyZMiQ
EQeIA8iQIUOGDBlxgDiADBkyZMiQEQdxigMajUaj0eJviIvNpmsAADriSURBVAMqB5AhQ4YMGTKV
A8QBZMiQIUOGjDhAHECGDBkyZMiIA8QBZMiQIUOGjDhAHECGDBkyZMiIA8QBZMiQIUOGjDhIVhzY
9m2bz9+iJct5w7YP4dvvbbRZozc0Rh05SA6mRJaIOsSB77D+2vG9b9/x/TJCspw3xj/H/e/9zLQV
eZ4/lz+2y2aN3tAYdeQgOZgSWSjqEAdewzqXcsYurB75d6Iiy3kjl8zGVKke+Xe2xGaN3tAYdeQg
OZgSWS7qEAf+wjrXd629WB42reefLOeNXEe3Zkt52DR1SjZr9IbGqCMHycGUyKJRJysOlsnuv6v5
m39+2s1448qRtuUkjWca/GY8P5/PqpWfm5vs6Cjb2yuO09Ps/r5eC/r8nAYnyyX57GNmq7AZa27T
XynbrNEbGqOOHCQHUyJLR524OKjCV/pdjuJgzbAzioxmm23fbD75/j6qdtXBQYG9vs6urooPh4dO
hSDPZLkkH01GjtnSUHBLxmaN3tAYdeQgOZgSWTrqgomD1ovx8kmXi7rxa81/f6ti2Ig4mE6HxmrP
01Nh8O5u/fzr6yA4WS7Jhw9DQ2KUzZQwg7uUbdboDY1RRw6SgymRpaPOx2OF5f+23r63yoiGDzZO
B3HQ+r/u4qB8w6R2PD5mx8eFhRcX9R9NJr3gZLkkL9/kcU+Y3m3KNmv0hsaoIwfJwZTI0lEXqTho
ve42zzlwnJHQUL3YuDgwSryTk8L5Z2fmKSTByXJJbk6ValvKmYRt1ugNjVFHDpKDKZGlo06HOFje
fLr5sUKE4sCo8nZ2ClOfnw29uOZdy0bI3LVQOUgp6shBcjD5ysEGo06BOFjzsYJj8EmLA9vzIdux
/vPO9ckanx1qtDmlOQcxRx05SA4utmDOwaaiztOrjM0f1jzp8rVWj0iLg9rM0vIom/uyFZ7JcknO
TGnt3tAYdeQgObhI922FjUddMHGwaHwxofWkI9B28V5+ALHwu85Bc0eu8471BslySc471tq9oTHq
yEFycJHuOgcbjzpWSPQU1gtWZ/u7sTqbdm+wQiI5SA6GJSteIRFxUFeRrOteaazrrt0b7K1ADpKD
YcnsrZCIOFj8bwetffsOWucRkuW8kWtq82zerwrb+ct22azRGxqjjhwkB1MiC0Ud4sB3WC/se28b
nwlFQpbzhm2Pc+Ozt+Rt1ugNjVFHDpKDKZElog5xECCsIUOGDBky5JjJiANCBDJkyJAhQ0YcIA4g
Q4YMGTJkxAHiADJkyJAhQ0YcIA4gQ4YMGTJkxAHiADJkyJAhQ0YcxCkOaDQajUaLvyEOqBxAhgwZ
MmTIVA4QB5AhQ4YMGTLiAHEAGTJkyJAhIw4QB5AhQ4YMGTLiAHEAGTJkyJAhIw4QB5AhQ4YMGTLi
IFlxYNtBaz5/i5Ys5w3bTmVvv+O1mR7EZnIwVZs1xoYEGXHgO6y/9t7u2/fevoyQLOeN8c9x/3vf
tsf55Y8YbaYHsZkcTNVmjbEhREYceA3rXMoZu7B65N+JiiznjVzmG9O7euTficpmehCbycFUbdYY
G3JkxIG/sM71XWsvlodN6/kny3kj1/6tGV4etvsA/zbTg9hMDqZqs8bYEI06T+Jg+VdI/FJ3pnHl
SNtykkZss0+XT87ns2rl5+YmOzrK9vaK4/Q0u7+v14I+P6fByXKdMvuY2aqCxjrh9Fd4m+lBbCYH
U7VZY2xIR50/cbB8JQ4lDqpf+/PZeNJoue1ksxnv76NqVx0cFITr6+zqqvhweOhUCPJMluuU0WTk
mOENRULPNtOD2EwOpmqzxtiQjjqvlYPmC/DyT6snW2/0m/+3NQQbFINR1qwqDqbTobHa8/RUGLm7
Wz//+joITpZL8uHD0JDMZTMl+eAuvM30IDaTg6narDE2pKMuvDiwnbR9drn7t6mQVcXBBh8rlG+Y
1I7Hx+z4uPjrLi7qP5pMesHJcklevn3knuS92/A204PYTA6marPG2JCOOt9zDla9zK8qKVYSB62/
ZYPiwCjxTk4K55+dmaeQBCfLJbk5vattKc+D20wPYjM5mKrNGmNDOuoCTEisVRGMe0unJw6MKm9n
p/iTn58NvbimftwImbsWehCbycGtrRxEHhvSUReFOOhw2V5fHDQoAAlxYHs+ZDvWf/K0PlkuyVOa
c7CdPYjN5OBiC+YcxBwb0lEX5lXG1iKBtDhofl9RQhzUZpaWR9ncl63wTJZL8gTeVtjyHsRmcnCR
7tsKKmJDOuqiWOfA9rZC6+flf+XytoLxQcbC7zoHzR25ztuuGyTLJXkC6xxseQ9iMzm4SHedAxWx
IR11rJDoKawXrM72d2OFRO09iM3kICskJhx1iAN/Yb1gXfe/G3sraO9BbCYHU7KZvRUQB8HEweJ/
O2jt23fQOo+QLOeN/D7APAP5qyp4/hKjzfQgNpODqdqsMTaEyIgD32G9sO+9bXwmFAlZzhu2fdmN
zwsjsZkexGZyMFWbNcaGBBlxECCsIUOGDBky5JjJiANCBDJkyJAhQ0YcIA4gQ4YMGTJkxAHiADJk
yJAhQ0YcIA4gQ4YMGTJkxAHiADJkyJAhQ0YcxCkOaDQajUaLvyEOqBxAhgwZMmTIVA4QB5AhQ4YM
GTLiAHEAGTJkyJAhIw4QB5AhQ4YMGTLiAHEAGTJkyJAhIw4QB5AhQ4YMGTLiIFlxYNtP7O3325pk
295c8/lbtGEt5w2NNmv0hsaok7OZHCQH0xj5EQe+w3r8c9z/3rftRH7547Iz+WtX7759V+/LCJNc
zhsabdboDY1RJ2czOUgOJjPyIw68hnUuEo3BUT3y73Qg5yLRGBzVI/9OVEku5w2NNmv0hsaok7OZ
HCQHUxr5EQf+wjpXjq3xUR42FWkj58qxNT7Kw6Yi/Se5nDc02qzRGxqjTs5mcpAcTGzkVyAOWld5
7BZky+eNv6jht7uTF19Pm2w1JWOVafpr6kiez2fVmtLNTXZ0lO3tFcfpaXZ/X68yfX5Ogye5nDc0
2qzRGxqjTs5mcpAcTG/kj10cVG3boJ1GEbD8ueG3N/jNeH40GTnGR0OJyUh+fx9Vg+DgoDDs+jq7
uio+HB46lZg8J7mcNzTarNEbGqNOzmZykBxMb+SPWhwYb+5XvdG3QTyLg+HD0BAKZTOFyOBu4Eie
TofGOtLTU8He3a2ff30dBE9yOW9otFmjNzRGnZzN5CA5mN7Ir1UcuF/LHS/hK4kDo7xodnf57op7
iPRue47k8t2V2vH4mB0fF+yLi/qPJpNe8CSX84ZGmzV6Q2PUydlMDpKD6Y38KYgD9wu8izhYLjzY
nkGsJA7MwVFtS1HiSDaKx5OTAnl2Zp6cEjzJ5byh0WaN3tAYdXI2k4PkYHojf1KPFYzbVK86IdG9
FBFz5WBnpwA/Pxvig7sWKgdCd+GRR52czeQgOZjeyK9YHHQoJ7g7pVkcLEuQCJ882Q6ed8Zmc0pz
DmKOOjmbyUFyML2RX+vbCmHnHHSQHd7mrJZH2dwXxGCmdECbE3hbQUXUydlMDpKD6Y38itc56Py2
QvNjBe3rHDSHCO9YR2hzAuscqIg6OZvJQXIwvZGfFRI9hfWCFRJ9eUOjzayQqN1mcpAcZIVEWsew
XrC3gi9vaLSZvRW020wOkoMpjfyIA69hXapI8/zVr5rS+ct5Z/LX3lz79r25upM1ekOjzRq9oTHq
5GwmB8nBZEZ+xIHvsF7Yd/U2Pm1aiWzb1dv4tCmGJBf1hkabNXpDY9TJ2UwOkoNpjPyIgwBhDRky
ZMiQIcdMRhwQIpAhQ4YMGTLiAHEAGTJkyJAhIw4QB5AhQ4YMGTLiAHEAGTJkyJAhIw4QB5AhQ4YM
GTLiIE5xQKPRaDRa/A1xQOUAMmTIkCFDpnKAOIAMGTJkyJARB4gDyJAhQ4YMGXGAOIAMGTJkyJAR
B4gDyJAhQ4YMGXGAOIAMGTJkyJARB8mKA9veXG+/39Yk2/bmms/fog1rbMYb9OAiyh0O1x+RNNqs
kfwxm01Go4fh8N/7+//Kstte724w+Ofbt99v3cmIA99hPf457n/v23b1vvxx2Zn8tat3376r92WE
SY7NeIMeDOsNuRFJo80ayT/H4+/9vgmc5Vrhx2VHMuLAa1jnItEYHNUj/04Hcn5rYhySqkf+naiS
HJvxBj0Y1htyI5JGmzWS//n2rQ2c5d9BHEQtDnLl2Bof5WFTkTZyfr/SOiqVh+3exX+SYzPeoAfD
ekNuRNJos0byz/HYDZzZ6gchxUHrGo3rFJc2G3xGU91PNts8+5jZakrGKtP019SRPJ/PqpXMm5vs
6Cjb2yuO09Ps/r5e2/z8nAZPcmzGG/RgWG/IjUgabdZI/pjNbE8TjM8Xfk1X60FZcVAld/stQrYZ
r/fLn91Ptto8mowc46OhxGQkv7+PqkPPwUHxp11fZ1dXxYfDQ6fCpuckx2a8QQ+G9YbciKTRZo3k
yWi0Ctj8cCGMODDemjdfX2t35NX/rf7XeO/e+gXbN9cRB+5hPXwYGrqrbKaeHNwNHMnT6dBYvXx6
Kti7u/Xzr6+D4EmOzXiDHgzrDbkRSaPNGskPw+FK4uBusFoPRiQOmk/WRIPxm+439+uLg1UfK5Tv
rriHSO+250gu35iqHY+P2fFxwb64qP9oMukFT3Jsxhv0YFhvyI1IGm3WSC7fWnQ/bnur9WBclYNm
cdD8WxqqESuJg+WChPHMqo8VzMFRbUud6Ug23rKcnBTIszPzlKjgSY7NeIMeDOsNuRFJo80aycuX
/34LeLUejPSxQqs4aPhmN3FQvepLzDnwXDnY2SnAz8+GUSnae7ittRlv0INUDqgcbGPlYJ2Lrvu1
f31xsM7jj4BPnmzPO21HzE9/t9NmvEEPLphzENRm5hx4FQeOV3TH6QWd5xkIzTlYVRx4e1uhPMrm
vgxL2HnjW24z3qAHF7ytENRm3lbwLQ4WpjcObOUEW43B9nJBQzVi4bC+QqrrHDQPTHG+cb7lNuMN
enDBOgdBbWadgwDiYAsbKyRiMysk0oOskKjLZlZIRBwEEwcL9lbAZrxBD8bkDfZW0E5mb4VExEGp
Is3zV79qSucv553JXzvC7dt3hOtOlvMGNuMNejCsN+RGJI02ayT/HI9tby7k51/OO5IRB77DemHf
1dv4tGklsm0veeMzzhiSHJvxBj0Y3BtyI5JGmzWSP2azyWj0MByWKuG217sbDP759s04zwBxEK84
gAwZMmTIkGMmIw4IEciQIUOGDBlxgDiADBkyZMiQEQeIA8iQIUOGDBlxgDiADBkyZMiQEQeIA8iQ
IUOGDBlxEKc4oNFoNBot/oY4oHIAGTJkyJAhUzlAHECGDBkyZMiIA8QBZMiQIUOGjDhAHECGDBky
ZMiIA8QBZMiQIUOGjDhAHECGDBkyZMiIg2TFgW1vrrffb9GSSRh6MCWybe/E+fwtWjI96MfPcjmo
K+oQB77Devxz3P/et+3qffnjMkIyAxM9mBL5v/8dv7z08zF0+cjH1v/85zJCMj3ox89yOagu6hAH
XsM6l5/GsKse+XeiIjMw0YMpkfPbKeMwWj3y70RFpgf9+FkuBzVGHeLAX1jnmrQ18srDpk/9kxmY
6MGUyPk9VutIWh62+y3/ZHrQj5/lclBp1EUkDtyXdXT5qzoEn/H3Lp9sNdJ4cvYxs1WrjPWr6a9p
cDIDEz2YEnk+n1Wrrzc32dFRtrdXHKen2f19vR77+TkNTqYH/fhZLgf1Rl1c4mBTkeciLJZFwPJn
48nWX2Q8OZqMHCOvoXjlmczARA+mRH5/H1WHy4ODYhC4vs6urooPh4dOxVjPZHrQj5/lclBv1KkR
B8Y7eNvFvvzcfGe/vjiw+c14fvgwNARZ2UzBN7gbBCczMNGDKZGn06Gx4vr0VHh6d7d+/vV1EJxM
D/rxs1wO6o06HeKg+cpt/GD8tw2/blVxsOpDjfKtGPfg6932gpMZmOjBlMjlW1614/ExOz4uPH1x
Uf/RZNILTqYH/fhZLgf1Rp2OOQeO4qD5+47iwDbDYCWfGk4aw67aluIvOJmBiR5MiWy8zTo5KRx8
dmaexhWcTA/68bNcDuqNukgrB7ZZgcaSwEbEQVUWUDlgYKIHt+S+c2encPPzs2EkXfMebiNketCP
nz1XDlREXbyPFdwnA25KHLg/Vmj2GE+skyTTg9rJtme0tmP9p7/rk+lBP372P+cg/qjTJw4c5xx0
fqwgJA6Y666dTA9qJ9dmd5dH2dyXjvFMpgf9+Nnb2wqKoi7ltxVWrRw4rnPQTRzwlrx2Mj2onVx7
L7x5MF3njfMNkulBP372ts6BoqhjhUR/CcP6etrJ9KB2Misk0oOskIg4iE4cLFiZXz+ZHtROZm8F
etB/DrK3Aq09YXJ9ap4Z+1WtOn85j5DMwEQPpkT+2sVu376L3XmEZHrQj5/lclBd1CEOAiSMbb9w
43OsSMgMTPRgSuT5fPb+PppOh+WoOpn0Xl8H+Q2W8blsJGR60I+f5XJQV9QhDkhFyJAhQ4YMGXGA
OIAMGTJkyJARB4gDyJAhQ4YMGXGAOIAMGTJkyJARB4gDyJAhQ4YMGXGAOIAMGTJkyJARBwrEAY1G
o9Fo8TfEAZUDyJAhQ4YMmcoB4gAyZMiQIUNGHCAOIEOGDBkyZMQB4gAyZMiQIUNGHCAOIEOGDBky
ZMQB4gAyZMiQIUNGHCQrDmy7fr39fluTbNubaz5/izasP2azyWj0MBz+e3//X1l22+vdDQb/fPv2
+20bbcYb9KB/b2gcN+RGUY1kiR5EHPgO6/HPcf9737Zf+OWPy87kr129+/ZdvS8jTPKf4/H3ft/k
jCwfW39cbpfNeIMe9O8NjeOG3CiqkSzUg4gDr2Gdi0RjcFSP/DsdyLlINAZH9ci/E1WS57dTbc7I
8u9sic14gx707w2N44bcKKqRLNeDiAN/YZ0rx9b4KA+birSRc+XYGh/lYVOR/pM8v8dyc0Zmu99K
yWa8QQ/694bGcUNuFNVIFu1BEXHgvkBjzb41LVnpny9/2Wit+8lmM2YfM1tNyVhlmv6aOpLn81m1
pnRzkx0dZXt7xXF6mt3f16tMn5/T4En+MZvZqq/Geuyvaco24w160L83NI4bcqOoRrJ0D0qJg5Vi
yH/pwni9bxYrzSdb/5zRZOQYHw0lJiP5/X1UDYKDg+JPu77Orq6KD4eHTiUmz0k+GY1WcYa5GJuM
zXiDHvTvDY3jhtwoqpEs3YMBxMHybffydbf8UP2a8Z/YOM0393/+rU9xMHwYGkKhbKYQGdwNHMnT
6dBYR3p6Kti7u/Xzr6+D4En+MByuNJjeDVK2GW/Qg/69oXHckBtFNZKle9C3OHDRBA2yoPWk4/Xb
vzgo311xD5Hebc+RXL67UjseH7Pj44J9cVH/0WTSC57k5Vte7sdtL2Wb8QY96N8bGscNuVFUI1m6
B33POXAXB+tcttcRB61aZNFpzoE5OKptKUocyUbxeHJSIM/OzJNTgif5clL0W5yRss14gx707w2N
44bcKKqRLN2D4pUD21S+brf+cuKgqgCWdYC6ysHOTgF+fjbEB5UD7jvpQXpQ47hB5cBnD/p4rOB+
NQ0rDlY1chH3nAPbwZyD2GzGG/TgIpo5BzGPG8w58NmDIcXBmpUDXXMOvM1ZLY+yuS+IwVz3gDbj
DXpwEfptBRXjBm8r+OzBqN9WaL1Cd3tbofmxgvZ1DppDhHUOIrQZb9CDi9DrHKgYN1jnwGcPal0h
MWabWSHRhcz6eniDHgzrDVZI1E7Wt0Ii4sD2I/ZWqDZW5scb9GBYb7C3gnYyeyukI1xyFWmev/pV
Uzp/Oe9M/tqba9++N1d3spw38vst20zv/PzL+XbZjDfoQf/e0DhuyI2iGslCPYg4CFDVsO3qbXza
tBLZtqu38WlTDEm++HpeOxmNHobDclS97fXuBoP8Bsv4XDZ5m/EGPejfGxrHDblRVCNZogcRBwHC
GjJkyJAhQ46ZjDggRCBDhgwZMmTEAeIAMmTIkCFDRhwgDiBDhgwZMmTEAeIAMmTIkCFDRhwgDiBD
hgwZMmTEQZzigEaj0Wi0+BvigMoBZMiQIUOGTOUAcQAZMmTIkCEjDhAHkCFDhgwZMuIAcQAZMmTI
kCEjDhAHkCFDhgwZMuIAcQAZMmTIkCEjDpIVB7YdtObzt2jJct6w7VT29nsbbdboDY1RRw6SgymR
JaIOceA7rL/23u7b996+jJAs543xz3H/e9+2x/nlj+2yWaM3NEYdOUgOpkQWijrEgdewzqWcsQur
R/6dqMhy3sglszFVqkf+nS2xWaM3NEYdOUgOpkSWizrEgb+wzvVday+Wh03r+SfLeSPX0a3ZUh42
TZ2SzRq9oTHqyEFyMCWyaNRtTBy4L8rYYJNPmbL8u4yWu59s/ivm81m18nNzkx0dZXt7xXF6mt3f
12tBn5/T4GS5JJ99zGwVNmPNbforZZs1ekNj1JGD5GBKZOmo26Q4WCluwpYrjNf75c/uJ1v/tPf3
UbWrDg4KA66vs6ur4sPhoVMhyDNZLslHk5FjtjQU3JKxWaM3NEYdOUgOpkSWjjpP4mD5Vrv8bDxp
+6n7fbztn9d+6lMcTKdDY7Xn6akwcne3fv71dRCcLJfkw4ehITHKZkqYwV3KNmv0hsaoIwfJwZTI
0lHnQxzYLrHLX3D8aTd4s8HS4qB8w6R2PD5mx8eFqRcX9R9NJr3gZLkkL9/kcU+Y3m3KNmv0hsao
IwfJwZTI0lHnY85Bh+tu6z/pAHcUBzZd0lwIaXW3UeKdnBSQszPzFJLgZLkkN6dKtS3lTMI2a/SG
xqgjB8nBlMjSUSdSOVj/prxBW3RWHi6ljuUnDssnN1g52Nkp4M/Phl5c865lI2TuWqgcpBR15CA5
mHzlYINRJ/VYQaJysNIziw7iYJ3f2Pn5kO1Y/3nn+mSNzw412pzSnIOYo44cJAcXWzDnYFNRF1Ic
NM85WEcHrPNYYeHlbYXyKJv7shWeyXJJzkxp7d7QGHXkIDm4SPdthY1HXdRvK7hw3J81OD5W8LPO
QXNHrvOO9QbJcknOO9bavaEx6shBcnCR7joHG486Vkj0FNYLVmf7u7E6m3ZvsEIiOUgOhiXrWCGR
5uJu1nWvNtZ11+4N9lYgB8nBsGT2VkhEHCz+t4PWvn0HrfMIyXLeyDW1eTbvV4Xt/GW7bNboDY1R
Rw6SgymRhaIOceA7rBf2vbeNz4QiIct5w7bHufHZW/I2a/SGxqgjB8nBlMgSUYc4CBDWkCFDhgwZ
csxkxAEhAhkyZMiQISMOEAeQIUOGDBky4gBxABkyZMiQISMOEAeQIUOGDBky4gBxABkyZMiQISMO
4hQHNBqNRqPF3xAHVA4gQ4YMGTJkKgeIA8iQIUOGDBlxgDiADBkyZMiQEQeIA8iQIUOGDBlxgDiA
DBkyZMiQEQeIA8iQIUOGDBlxkKw4sO2gNZ+/RUuW84Ztp7K339tos0ZvaIw6cpAcTIksEXWIA99h
/bX3dt++9/ZlhGQ5b4x/jvvf+7Y9zi9/bJfNGr2hMerIQXIwJbJQ1CEOvIZ1LuWMXVg98u9ERZbz
Ri6ZjalSPfLvbInNGr2hMerIQXIwJbJc1CEO/IV1ru9ae7E8bFrPP1nOG7mObs2W8rBp6pRs1ugN
jVFHDpKDKZFFo85JHLgvuBjkdrzD941/yJonm3/1fD6rVn5ubrKjo2xvrzhOT7P7+3ot6PNzGpws
13Gzj5mtwmasuU1/pWyzRm9ojDpykBxMiSwdda7iwFtMeBAH1R/9+bzmydZf/f4+qnbVwUHh9uvr
7Oqq+HB46FQI8kyW67jRZOSYLQ0Ft2Rs1ugNjVFHDpKDKZGlo24D4mCdG+7yc+s3m/+3erJZATT8
aRvUAcaT0+nQWO15eirM3t2tn399HQQnyyX58GFoSIyymRJmcJeyzRq9oTHqyEFyMCWydNStKw7W
vwtf/kLzP3f8qfH7AcVB+YZJ7Xh8zI6PCw9cXNR/NJn0gpPlkrx8k8c9YXq3Kdus0Rsao44cJAdT
IktH3bpzDlqvqWsW8zv/kz81Ccf46yAOVppzYJR4JyeFM8/OzFNIgpPlktycKtW2lDMJ26zRGxqj
jhwkB1MiS0fdypWD5WK+47MGo7xY6Z+vKg5a/zSf4sCo8nZ2Cgufnw29uOZdy0bI3LVQOUgp6shB
cjD5ysEGo67LY4WVHu13KCc0//OVKgful/BVxYHjhMfW50O2Y/3nneuTNT471GhzSnMOYo46cpAc
XGzBnINNRZ2IOBA9uZE5B61TLDvIoOaf1maWlkfZ3Jet8EyWS3JmSmv3hsaoIwfJwUW6bytsPOqi
eFvB/alEK9zxUYht/oSjzc1LPri8k9rckeu8Y71BslyS8461dm9ojDpykBxcpLvOwcajjhUSPYX1
gtXZ/m6szqbdG6yQSA6Sg2HJ4VdIpG0krBes6/53Y1137d5gbwVykBwMS2ZvhUTEweJ/O2jt23fQ
Oo+QLOeNXFObZ/N+VdjOX7bLZo3e0Bh15CA5mBJZKOoQB77DemHfe9v4TCgSspw3bHucG5+9JW+z
Rm9ojDpykBxMiSwRdYiDAGENGTJkyJAhx0xGHBAikCFDhgwZMuIAcQAZMmTIkCEjDhAHkCFDhgwZ
MuIAcQAZMmTIkCEjDhAHkCFDhgwZMuIgTnFAo9FoNFr8DXFA5QAyZMiQIUOmcoA4gAwZMmTIkBEH
iAPIkCFDhgwZcYA4gAwZMmTIkBEHiAPIkCFDhgwZcYA4gAwZMmTIkBEHyYoD2w5a8/lbtGQ5b9h2
Knv7vY02a/SGxqgjB8nBlMgSUYc48B3WX3tv9+17b19GSJbzxvjnuP+9b9vj/PLHdtms0Rsao44c
JAdTIgtFHeLAa1jnUs7YhdUj/05UZDlv5JLZmCrVI//Oltis0Rsao44cJAdTIstFHeLAX1jn+q61
F8vDpvX8k+W8kevo1mwpD5umTslmjd7QGHXkIDmYElk06nyLA5dVGzvH3Er/avnLRsOWT7auPWk8
OZ/PqpWfm5vs6Cjb2yuO09Ps/r5eC/r8nAYnyyX57GNmq7AZa27TXynbrNEbGqOOHCQHUyJLR51X
cbB83Q0lDowiYPmz8WTrbzSefH8fVbvq4KAw4Po6u7oqPhweOhWCPJPlknw0GTlmS0PBLRmbNXpD
Y9SRg+RgSmTpqItFHCzfndsu4baTRmDDxXt9cWDzm/H8dDo0Vnuengojd3fr519fB8HJckk+fBga
EqNspoQZ3KVss0ZvaIw6cpAcTIksHXUhxUHDxbhqVfOluvmfuF/CVxUHq5Y9yjdMasfjY3Z8XJh9
cVH/0WTSC06W6/TyTR73hOndpmyzRm9ojDpykBxMiSwddVHMOWi+KW8u3Xd7HNBwsbfNMFjJp8sn
jRLv5KQgn52Zp5AEJ8sluTlVqm0pZxK2WaM3NEYdOUgOpkSWjrqQbysYr+XNV/dlbWETB60zH20T
En1WDnZ2it/4/GzoxTXvWjZC5q6FykFKUUcOkoPJVw42GHVRzDlwFAfdTq76jMNFHHR41cL2fMh2
rP+8c32yXJLzvFO7NzRGHTlIDi62YM7BpqIuLnGwzvQCn3MOOoiD2szS8iib+7IVnslySc5Mae3e
0Bh15CA5uEj3bYWNR10s6xw0zEIwvtTgeHKl4r/jOgfdxEHtndTmjlznHesNkuWSnHestXtDY9SR
g+TgIt11DjYedayQ6CmsF6zO9ndjdTbt3mCFRHKQHAxLTmqFxG0WBwvWdf+7sa67dm+wtwI5SA6G
JbO3QiLiYPG/HbT27TtonUdIlvNGrqnNs3m/KmznL9tls0ZvaIw6cpAcTIksFHWIA99hvbDvvW18
JhQJWc4btj3Ojc/ekrdZozc0Rh05SA6mRJaIOsRBgLCGDBkyZMiQYyYjDggRyJAhQ4YMGXGAOIAM
GTJkyJARB4gDyJAhQ4YMGXGAOIAMGTJkyJARB4gDyJAhQ4YMGXEQpzig0Wg0Gi3+hjigcgAZMmTI
kCFTOUAcQIYMGTJkyIgDxAFkyJAhQ4aMOEAcQIYMGTJkyIgDxAFkyJAhQ4aMOEAcQIYMGTJkyIiD
ZMWBbW+ut99v0ZLlvPExm01Go4fh8N/7+//Kstte724w+Ofbt99vb5A3SKYH6cGURiTI1WbblXE+
705GHPhOxfHPcf9737ar9+WPywjJct74OR5/7/dNJmf52Prj8hLyRsj0ID2Y0ogEudr++9/xy0s/
1wTLR64V/vOfjmTEgddUzEWiMTiqR/6dqMhy3shvp9pMzvLvQF6TTA/SgymNSJD/qkbMvhllQfXI
v4M4iFoc5MqxNT7Kw6Yi/ZPlvJHfY7mZnNnutyDTg/Tgto1IkGs1g1ZlUB62+oECceCymqPtL+n2
T5Z/l+PJ1rUnjSdnHzNbTclYZZr+mgYnyw1MH7OZrfpqrMf+mk4hdyDTg/RgSiMS5Gqbz2fVpwk3
N9nRUba3Vxynp9n9ff35wufnalEXhThYvh5vsPK2/E9qV/pVT3YTK6PJyDE+GkpMnslyA9NkNFrF
ZHMxFjI9SA927kGNIxLkant/H1Uv/wcHxaX8+jq7uio+HB46PVxQLA6W79ptJxtu9F1+dQdxYCMb
zw8fhoZQKJspRAZ3g+BkuYHpYThcaTC9GwwgdyDTg/RgSiMS5GqbTofGJwhPTwV7d7d+/vV1taiL
URw0XKSr1jZ8sJ3coDhYtbxRvrviHiK9215wslznlm95uR+3vR7kDmR6kB5MaUSCXG3lW4u14/Ex
Oz4u2BcX9R9NJqtFXdRzDlZ9IrCqOGgoP2xcHJiDo9qWoiQ4WW5gWk6KfovJGeQOZHqQHkxpRIJc
bcaywclJgTw7M09LVCkOWu/mHcXBssiIRBxQOeDukMoBZCoHkEUrBzs7Bfj52aAMVFYObNfddSoH
7s8sOoiDDu9HMOeA58oL5hxAZs4BZOE5B7YjhTkHnWcVuD9WWOcVhm7igLcVqo0Z6X7I9CA9uGDm
f6Lk2tsK5VE296WQFK9z0PxigvGky8QF2xQH98UPVk1F1jmoNt5l90OmB+nBBWsGJEqurXPQLA60
rnOQWGOFRBcyq+D5IdOD9CCrDaZK3ooVErdBHCzYW+Hvxvr5fsj0ID2Y0ogE+a/KBHsrpCEOShVp
nr/6VVM6fzmPkCznjfx+yzbTOz//cn4OeSNkepAeTGlEglyrHxjfXPj/XRk7khEHvlNxYd/V2/i0
KRKynDc+ZrPJaPQwHJaj6m2vdzcY5DdYxueykOlBepARCXKtzeez9/fRdDosVcJk0nt9Hcxm34zz
DBAH8YoDyJAhQ4YMOWYy4oAQgQwZMmTIkBEHiAPIkCFDhgwZcYA4gAwZMmTIkBEHiAPIkCFDhgwZ
cYA4gAwZMmTIkBEHcYoDGo1Go9Hib4gDKgeQIUOGDBkylQPEAWTIkCFDhow4QBxAhgwZMmTIiAPE
AWTIkCFDhow4QBxAhgwZMmTIiAPEAWTIkCFDhow4SFYc2Pbmevv9tibZtjfXfP4WbVjLeUOjzRq9
oTHq5GwmB8nBNEZ+xIHvsB7/HPe/9227el/+uOxM/trVu2/f1fsywiSX84ZGmzV6Q2PUydlMDpKD
yYz8iAOvYZ2LRGNwVI/8Ox3IuUg0Bkf1yL8TVZLLeUOjzRq9oTHq5GwmB8nBlEZ+xIG/sM6VY2t8
lIdNRdrIuXJsjY/ysKlI/0ku5w2NNmv0hsaok7OZHCQHExv5pcSBcXXGqFTIsjHG5STdTzb/mbOP
ma2mZKwyTX9NHcnz+axaU7q5yY6Osr294jg9ze7v61Wmz89p8CSX84ZGmzV6Q2PUydlMDpKD6Y38
IuJg+VIa4c19g5F/PrufbP17R5ORY3w0lJiM5Pf3UTUIDg6KP+36Oru6Kj4cHjqVmDwnuZw3NNqs
0Rsao07OZnKQHExv5PcqDmofqr/aWGPofB9v++e1n/oUB8OHoSEUymYKkcHdwJE8nQ6NdaSnp4K9
u1s///o6CJ7kct7QaLNGb2iMOjmbyUFyML2R34c4MF5fbZ+bT7pfv41fcCxvSIiD8t0V9xDp3fYc
yeW7K7Xj8TE7Pi7YFxf1H00mveBJLucNjTZr9IbGqJOzmRwkB9Mb+cPMObBdX92vyh3+uXt5w1Gs
rCQOzMFRbUtR4kg2iseTkwJ5dmaenBI8yeW8odFmjd7QGHVyNpOD5GB6I7+PtxUcawCOX2iY5LiO
OKgqgOXfqK5ysLNTgJ+fDfHBXQuVA6G78MijTs5mcpAcTG/kDznnYCOl+w2Kg3V+Y4RPnmwHzztj
szmlOQcxR52czeQgOZjeyB+vOFhzzkHnxwoL5W8rlEfZ3BfEYKZ0QJsTeFtBRdTJ2UwOkoPpjfxR
zzlY822Fbo8VtK9z0BwivGMdoc0JrHOgIurkbCYHycH0Rv5IV0hUvWgjKySG9YZGm1khUbvN5CA5
yAqJiIPuxrO3gh9vaLSZvRW020wOkoMpjfzsreBb2eQq0jx/9aumdP5y3pn8tTfXvn1vru5kjd7Q
aLNGb2iMOjmbyUFyMJmRH3EQoOxh29Xb+LRpJbJtV2/j06YYklzUGxpt1ugNjVEnZzM5SA6mMfIj
DgKENWTIkCFDhhwzGXFAiECGDBkyZMiIA8QBZMiQIUOGjDhAHECGDBkyZMiIA8QBZMiQIUOGjDhA
HECGDBkyZMiIgzjFAY1Go9Fo8TfEAZUDyJAhQ4YMmcoB4gAyZMiQIUNGHCAOIEOGDBkyZMQB4gAy
ZMiQIUNGHCAOIEOGDBkyZMQB4gAyZMiQIUNGHCQrDmx7c739fluTbNubaz5/izas5byh0WaN3tAY
dXI2k4PkYBpkxIHvsB7/HPe/9227el/+uOxM/trVu2/f1fsywiSX84ZGmzV6Q2PUydlMDpKDyZAR
B17DOpdyxi6sHvl3OpDzWxPjkFQ98u9EleRy3tBos0ZvaIw6OZvJQXIwJTLiwF9Y5/qutRfLw6b1
bOT8fqV1VCoP272L/ySX84ZGmzV6Q2PUydlMDpKDiY0bUuLAuDpjVCpk2RjjcpLuJ5v/zNnHzFb5
MdaCpr+mjuT5fFatZN7cZEdH2d5ecZyeZvf39drm5+c0eJLLeUOjzRq9oTHq5GwmB8nB9MYNEXGw
fCmNTRwYr/fNBjefbHX3aDJy7MWGQpCR/P4+qg49BwfFn3Z9nV1dFR8OD50Km56TXM4bGm3W6A2N
USdnMzlIDqY3bvgTB7W7bVtdofWky328EbX8U5/iYPgwNHRY2UwdObgbOJKn06Gxevn0VLB3d+vn
X18HwZNczhsabdboDY1RJ2czOUgOpjdu+BAH7hfd5S/YZEEHlGN5Q0gclG+YuHdk77bnSC7fmKod
j4/Z8XHBvrio/2gy6QVPcjlvaLRZozc0Rp2czeQgOZjeuBFmzsH6V+Lmq7LLRIeGZx+1f76ROQfm
Lqy2pb50JBtvWU5OCuTZmXlKVPAkl/OGRps1ekNj1MnZTA6Sg+mNGz7eVrDVA5YfNHQTB46oVqf8
ISRQOdjZKcDPz4ZRibsWKgdCd+GRR52czeQgOUjloEu/Nj8L6FDYX//63eqUjYsD/3MObAfPO2Oz
OaU5BzFHnZzN5CA5uGDOwcbFwZqVg9Z5BpHMOfD2tkJ5lM19GRZmSge0OYG3FVREnZzN5CA5uOBt
BfeuNc45aH1bofNjhfUrB2msc9A8MPGOdYQ2J7DOgYqok7OZHCQHF6xzQOsW1gtWSPTlDY02s0Ki
dpvJQXKQFRJpHcN6wd4Kvryh0Wb2VtBuMzlIDqZERhx4DetS65lnmX5Vfs5fzjuTv3aE27fvCNed
rNEbGm3W6A2NUSdnMzlIDiZDRhz4DuuFfe9t4zOhlci2veSNzzhjSHJRb2i0WaM3NEadnM3kIDmY
BhlxECCsIUOGDBky5JjJiANCBDJkyJAhQ0YcIA4gQ4YMGTJkxAHiADJkyJAhQ0YcIA4gQ4YMGTJk
xAHiADJkyJAhQ0YcxCkOaDQajUaLvyEOqBxAhgwZMmTIVA4QB5AhQ4YMGTLiAHEAGTJkyJAhIw4Q
B5AhQ4YMGTLiAHEAGTJkyJAhIw4QB5AhQ4YMGTLiIFlxYNtB6+33W7RkOW98zGaT0ehhOPz3/v6/
suy217sbDP759u332zbajDfowZRGJEbRarPt2Dmfx0hGHPgO6/HPcf9737b39uWPywjJct74OR5/
7/dNJmf52Prjcrtsxhv0YEojEqNotf33v+OXl35+5V4+8iv6f/4THRlx4DWsc/lpDLvqkX8nKrKc
N/LbqTaTs/w7W2Iz3qAHUxqRGEX/qkbMvhkv3tUj/05UZMSBv7DONWlr5JWHTZ/6J8t5I7/HcjM5
s91vpWQz3qAH/XtD47ihcRTN7+xbr9/lYbvL908OIw6MCzduxAZ3iHHlyDVPNpsx+5jZqlXG+tX0
1zQ4WS7JP2YzW/XVWI/9NU3ZZrxBD/r3hsZxQ+MoOp/PqjX/m5vs6Cjb2yuO09Ps/r7+FODzMzw5
jDhYvspKB1mzDUYDOpxsdfdoMnKMvIbilWeyXJJPRqNVTDYXY5OxGW/Qg/69oXHc0DiKvr+Pqhfp
g4Pignt9nV1dFR8OD50eAXgmRyQOqjfi1f8u36PbLsy1f/XnH7aGr4QOMJ4cPgwNQVY2U/AN7gbB
yXJJ/jAcrjSY3g1Sthlv0IP+vaFx3NA4ik6nQ2Od/+mpYO/u1s+/voYnRyEOjNfjhmuzozgw0sKK
g/KtGPfg6932gpPlerx8y8v9uO2lbDPeoAf9e0PjuKFxFC3fLawdj4/Z8XHBvrio/2gyCU8OIw4W
bXMOmi//NR3QoAkc//gOzxrchc5fJ41hV21L8RecLJfky+nWbzE5ZZvxBj3o3xsaxw2No6jx5v7k
pECenZknDwYnBxMHzTfuqYoDKgfcd+INepDKAZWD/NjZKcDPz4br95qVg42Qo3isEFAc2Cxx5Dhq
DtVPy+SSnCfWeIMeDOsN5hz4IdtmBtiO9eccrE/WKg5WuuO3/XXNZYCVjHF0N28rVBtz3fEGPRjW
G7yt4Idce6egPMrmvmCRZ3Kwxwq2OQfGlwtsywy4fLa9rVB7ltT6u2xfc1ceC9Y5+LvxljzeoAfD
eoN1DvyQa6sRNF/C11nnYIPkYOLAc/P/17FCoguZ9fXwBj0Y1huskOiHzAqJcQmC5kUMQ8kR9lao
Nlbmxxv0YFhvsLeCHzJ7K9DaEybXp+aZsV/VqvOX8wjJct7I77dsM73z8y/n22Uz3qAHUxqRGEVr
d/nG9wv+f+/E6MiIA99hvbDvF258jhUJWc4bH7PZZDR6GA7LUfW217sbDPIbLONz2eRtxhv0YEoj
EqNotc3ns/f30XQ6LK/lk0nv9XWQ39YbZwMEJyMOAoQ1ZMiQIUOGHDMZcUCIQIYMGTJkyIgDxAFk
yJAhQ4aMOEAcQIYMGTJkyIgDxAFkyJAhQ4aMOEAcQIYMGTJkyIiDOMUBjUaj0WjxN8QBlQPIkCFD
hgyZygHiADJkyJAhQ0YcIA4gQ4YMGTJkxAHiADJkyJAhQ0YcIA4gQ4YMGTJkxAHiADJkyJAhQ0Yc
JCsObLt+vf1+W5Ns25trPn+LNqzlvKHRZo3e0Bh1cjaTg+RgGiM/4sB3WI9/jvvf+7b9wi9/XHYm
f+3q3bfv6n0ZYZLLeUOjzRq9oTHq5GwmB8nBZEZ+xIHXsM5FojE4qkf+nQ7kXCQag6N65N+JKsnl
vKHRZo3e0Bh1cjaTg+RgSiN/4uIgyJ9m+6W5cmyNj/KwqUgbOVeOrfFRHjYV6T/J5byh0WaN3tAY
dXI2k4PkYGIjvw9xUOM3/6/tR3/sbDB4JfIyZ82Tzb939jGz1ZSMVabpr6kjeT6fVWtKNzfZ0VG2
t1ccp6fZ/X29yvT5OQ2e5HLe0GizRm9ojDo5m8lBcjC9kd+3OPhzgV9JHCx/WEfGGn/7midbzRhN
Ro7x0VBiMpLf30fVIDg4KDr0+jq7uio+HB46lZg8J7mcNzTarNEbGqNOzmZykBxMb+QPLA5cLsO2
jSKWb9+XKw2tf5qEDjCeHD4MDaFQNlOIDO4GjuTpdGisIz09Fezd3fr519dB8CSX84ZGmzV6Q2PU
ydlMDpKD6Y38nuYcLF/vV7o2d/6+e7FBWhyU7664h0jvtudILt9dqR2Pj9nxccG+uKj/aDLpBU9y
OW9otFmjNzRGnZzN5CA5mN7I71UcuJQQfIqDhqqDC2elOQfm4Ki2pShxJBvF48lJgTw7M09OCZ7k
ct7QaLNGb2iMOjmbyUFyML2RX7E4MD5oaPhpWHHgWT/u7BTg52dDfHDXQuVA6C488qiTs5kcJAfT
G/lTqBw0X9Qdg29VceCoOQI+ebIdPO+MzeaU5hzEHHVyNpOD5GB6I7+/dQ6a77xrN/3SjxXcjWkt
Mzi629uc1fIom/uCGMyUDmhzAm8rqIg6OZvJQXIwvZE/FnGw+HslA8erfre3FWwPHRyXNGh9ZhH2
bdfmEOEd6whtTmCdAxVRJ2czOUgOpjfys3yyp7BesEKiL29otJkVErXbTA6Sg6yQSOsY1gv2VvDl
DY02s7eCdpvJQXIwpZEfceA1rEsVaZ6/+lVTOn8570z+2ptr3743V3eyRm9otFmjNzRGnZzN5CA5
mMzIjzjwHdYL+67exqdNK5Ftu3obnzbFkOSi3tBos0ZvaIw6OZvJQXIwjZEfcRAgrCFDhgwZMuSY
yYgDQgQyZMiQIUNGHCAOIEOGDBkyZMQB4gAyZMiQIUNGHCAOIEOGDBkyZMQB4gAyZMiQIUNGHMQp
Dmg0Go1Gi78hDqgcQIYMGTJkyFQOEAeQIUOGDBky4gBxABkyZMiQISMOEAeQIUOGDBky4gBxABky
ZMiQISMOEAeQIUOGDBky4iBZcWDbm+vt99uaZNveXPP5W7Rhjc14gx5cRLnD4fojkkabNZIlog5x
4Dusxz/H/e99267elz8uO5O/dvXu23f1vowwybEZb9CDYb0hNyJptFkjWSjqEAdewzoXicbgqB75
dzqQc5FoDI7qkX8nqiTHZrxBD4b1htyIpNFmjWS5qEMc+AvrXDm2xkd52FSkjZwrx9b4KA+bivSf
5NiMN+jBsN6QG5E02qyRLBp1IcXB8u8tz/w5Lxp5y3+448nWtSeNJ2cfM1tNyVhlmv6aOpLn81m1
pnRzkx0dZXt7xXF6mt3f16tMn5/T4EmOzXiDHgzrDbkRSaPNGsnSURe4clC76PqJPOMvdT/ZaqHx
5GgycoyPhhKTkfz+PqoGwcFB0aHX19nVVfHh8NCpxOQ5ybEZb9CDYb0hNyJptFkjWTrqYhQHtg9V
U1tv8d33lugsDmxY4/nhw9AQCmUzhcjgbuBInk6HxjrS01PB3t2tn399HQRPcmzGG/RgWG/IjUga
bdZIlo668HMOao8SbOLA9rn1Kt7813UWBy6Co9rKd1fcQ6R323Mkl++u1I7Hx+z4uGBfXNR/NJn0
gic5NuMNejCsN+RGJI02ayRLR10UExJt193Wi7RLVd/xKi4tDszBUW1LUeJINorHk5MCeXZmnpwS
PMmxGW/Qg2G9ITciabRZI1k66tIRB8aHCI5lg/QqBzs7Bfj52RAf0d7Dba3NeIMepHJA5SC2kT8R
cdB6cqUCQ7eKRWxPnmxHzE9/t9NmvEEPLphzENTmlOYcbCrqUhMHxhkJLh6RFgfe5qyWR9ncF8QI
O298y23GG/TggrcVgtqcwNsKG4+61B4rLP5+taF56QLbAgbGL7unRNi3XZtDJM43zrfcZrxBDy5Y
5yCozQmsc7DxqGOFRE9hvWCFRGzGG/QgKyTGajMrJCIOgomDBXsrYDPeoAdj8gZ7K2gns7dCIuKg
VJHm+atfNaXzl/PO5K+9ufbte3N1J8t5A5vxBj0Y1htyI5JGmzWShaIOceA7rBf2Xb2NT5tWItt2
9TY+bYohybEZb9CDwb0hNyJptFkjWSLqEAcBwhoyZMiQIUOOmYw4IEQgQ4YMGTJkxAHiADJkyJAh
Q0YcIA4gQ4YMGTJkxAHiADJkyJAhQ0YcIA4gQ4YMGTJkxEGc4oBGo9FotPgb4oBGo9FoNNoqd7k4
gkaj0Wg0GuKARqPRaDQa4oBGo9FoNBrigEaj0Wg0GuKARqPRaDQa4oBGo9FoNBrigEaj0Wg0mqA4
oNFoNBqNRvvT/g//BX6n9TE+0gAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2014-10-14 14:07:13 +0200" MODIFIED_BY="Gudrun Paletta"/>
<APPENDICES MODIFIED="2016-09-07 10:12:08 +0200" MODIFIED_BY="Gudrun Paletta">
<APPENDIX ID="APP-01" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="1">
<TITLE MODIFIED="2009-12-09 09:10:54 +0100" MODIFIED_BY="Gudrun Paletta">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="1" ROWS="10">
<TR>
<TH>
<P>Cochrane Central Register of Controlled Trials (<B>CENTRAL)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>#1 [mh "Diabetes mellitus"]</P>
<P>#2 diabet*:ti,ab,kw</P>
<P>#3 (IDDM or NIDDM or MODY or T1DM or T2DM or T1D or T2D):ti,ab,kw</P>
<P>#4 ((non and insulin* and depend*) or (noninsulin* and depend*) or (non and insulin?depend*) or noninsulin?depend*):ti,ab,kw</P>
<P>#5 ((insulin* and depend*) or insulin?depend*):ti,ab,kw</P>
<P>#6 {or #1-#5}</P>
<P>#7 [mh "Diabetes insipidus"]</P>
<P>#8 (diabet* and insipidus):ti,ab,kw</P>
<P>#9 #7 or #8</P>
<P>#10 #6 not #9</P>
<P>#11 [mh "Drug Therapy, Combination"]</P>
<P>#12 combin*:ti,ab,kw</P>
<P>#13 #11 or #12</P>
<P>#14 [mh "Sulfonylurea compounds"]</P>
<P>#15 [mh Biguanides]</P>
<P>#16 [mh Acarbose]</P>
<P>#17 [mh Thiazolidinediones]</P>
<P>#18 [mh Tolbutamide]</P>
<P>#19 [mh Metformin]</P>
<P>#20 [mh Chlorpropamide]</P>
<P>#21 [mh "Dipeptidyl-Peptidase IV inhibitors"]</P>
<P>#22 [mh Glyburide]</P>
<P>#23 [mh Tolazamide]</P>
<P>#24 [mh Carbutamide]</P>
<P>#25 [mh Acetohexamide]</P>
<P>#26 [mh Buformin]</P>
<P>#27 [mh Chlorhexidine]</P>
<P>#28 [mh Chloroguanide]</P>
<P>#29 [mh Phenformin]</P>
<P>#30 (biguanid* or sulfonylurea* or sulphonylurea* or acarbos*):ti,ab,kw</P>
<P>#31 (gliglacid* or glimepirid* or glibornurid* or gliguidon* or glisoxepid* or glipizid* or gliburid* or glyburid* or tolazamid*):ti,ab,kw</P>
<P>#32 (tolbutamid* or carbutamid* or chlorpropamid* or acetohexamid* or glibenclamid*):ti,ab,kw</P>
<P>#33 (metformin* or buformin* or chlorhexidin* or chlorguanid or phenformin*):ti,ab,kw</P>
<P>#34 (miglitol* or nateglinid* or repaglinid* or meglitinid* or glucobay):ti,ab,kw</P>
<P>#35 (troglitazone* or rosiglitazon* or pioglitazon* or thiazolidinedion* or glitazon*):ti,ab,kw</P>
<P>#36 (antidiabet* near/3 drug*):ti,ab,kw</P>
<P>#37 (antidiabet* near/3 herb*):ti,ab,kw</P>
<P>#38 (antidiabet* near/3 agent*):ti,ab,kw</P>
<P>#39 (antidiabet* near/3 compound*):ti,ab,kw</P>
<P>#40 (anti and (diabet* near/3 drug*)):ti,ab,kw</P>
<P>#41 (anti and (diabet* near/3 herb*)):ti,ab,kw</P>
<P>#42 (anti and (diabet* near/3 agent*)):ti,ab,kw</P>
<P>#43 (anti and (diabet* near/3 compound*)):ti,ab,kw</P>
<P>#44 (oral near/6 hypoglyc?emic):ti,ab,kw</P>
<P>#45 (oral near/6 antidiabet*):ti,ab,kw</P>
<P>#46 (oral near/6 antihyperglyc?emic):ti,ab,kw</P>
<P>#47 alpha-glucosidase-inhibitor*:ti,ab,kw</P>
<P>#48 (hypoglyc?emic near/3 drug*):ti,ab,kw</P>
<P>#49 (hypoglyc?emic near/3 herb*):ti,ab,kw</P>
<P>#50 (hypoglyc?emic near/3 agent*):ti,ab,kw</P>
<P>#51 (hypoglyc?emic near/3 compound*):ti,ab,kw</P>
<P>#52 (sitagliptin* or vildagliptin*):ti,ab,kw</P>
<P>#53 [mh "Glucagon-Like Peptides"]</P>
<P>#54 (glucagon-like and peptid*):ti,ab,kw</P>
<P>#55 (GLP1 or (GLP and 1)):ti,ab,kw</P>
<P>#56 (DPP-4 or DPP-IV or DPP4 or DPPIV):ti,ab,kw</P>
<P>#57 {or #14-#30}</P>
<P>#58 {or #13-#50}</P>
<P>#59 {or #51-#56}</P>
<P>#60 {or #57-#59}</P>
<P>#61 [mh Insulin]</P>
<P>#62 insulin*:ti,ab,kw</P>
<P>#63 #61 or #62</P>
<P>#64 #10 and #13 and #60 and #63</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>MEDLINE (Ovid SP)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>1. exp Drug therapy combination/<BR/>2. combin*.tw,ot.<BR/>3. 1 or 2<BR/>4. exp Diabetes Mellitus/<BR/>5. diabet$.tw,ot.<BR/>6. (IDDM or NIDDM or MODY or T1DM or T2DM).tw,ot.<BR/>7. (non insulin$ depend$ or noninsulin$ depend$ or non insulin?depend$ or<BR/>noninsulin?depend$).tw,ot.<BR/>8. (insulin$ depend$ or insulin?depend$).tw,ot.<BR/>9. or/4-8<BR/>10. exp Diabetes Insipidus/<BR/>11. diabet$ insipidus.tw,ot.<BR/>12. 10 or 11<BR/>13. 9 not 12<BR/>14. exp Sulfonylurea Compounds/<BR/>15. exp Biguanides/<BR/>16. exp Acarbose/<BR/>17. exp Thiazolidinediones/<BR/>18. exp Tolbutamide/ or exp Metformin/ or exp Chlorpropamide/ or exp Dipeptidyl-Peptidase IV Inhibitors/<BR/>19. exp Glyburide/ or exp Tolazamide/ or exp Carbutamide/ or exp Acetohexamide/<BR/>20. exp Buformin/ or exp Chlorhexidine/ or exp Chloroguanide/ or exp Phenformin/<BR/>21. (biguanid$ or sulfonylurea$ or sulphonylurea$ or acarbos$).tw,ot.<BR/>22. (gliglacide$ or glimepirid$ or glibornurid$ or gliguidon$ or glisoxepid$ or glipizid$ or gliburid$ or glyburid$ or tolazamid$).tw,ot.<BR/>23. (tolbutamid$ or carbutamid$ or chlorpropamid$ or acetohexamid$ or glibenclamid$ or glimepirid$).tw,ot.<BR/>24. (metformin$ or buformin$ or chlorhexidin$ or chlorguanid$ or phenformin$).tw,ot.<BR/>25. (miglitol$ or nateglinid$ or meglitinid$ or glucobay).tw,ot.<BR/>26. (troglitazon$ or rosiglitazon$ or pioglitazon$ or thiazolidinedion$ or glitazon$).tw,ot.<BR/>27. repaglinid$.tw,ot.<BR/>28. ( (antidiabet$ or anti diabet$) adj3 (drug$ or herb$ or agent$ or compound$)).tw,ot.<BR/>29. (oral adj6 (hypoglycemic or antidiabetic or antihyperglycemic)).tw,ot.<BR/>30. alpha-glucosidase-inhibitor$.tw,ot.<BR/>31. (hypoglyc?emic adj3 (drug$ or herb or agent$ or compound$)).tw,ot.<BR/>32. (sitagliptin$ or vildagliptin$).tw,ot.<BR/>33. exp Glucagon-Like Peptide 1/<BR/>34. glucagon-like peptid$ 1.tw,ot.<BR/>35. (GLP1 or GLP 1).tw,ot.<BR/>36. (DPP-4 or DPP-IV or DPP4 or DPPIV).tw,ot.<BR/>37. or/14-36<BR/>38. exp Insulin/<BR/>39. insulin$.tw,ot.<BR/>40. 38 or 39<BR/>41. 3 and 13 and 37 and 40<BR/>42. Meta-analysis.pt.<BR/>43. exp Review/<BR/>44. exp Technology Assessment, Biomedical/<BR/>45. exp Meta-analysis/<BR/>46. exp Meta-analysis as topic/<BR/>47. hta.tw,ot.<BR/>48. (health technology adj6 assessment$).tw,ot.<BR/>49. (meta analy$ or metaanaly$ or meta?analy$).tw,ot.<BR/>50. ( (review$ or search$) adj10 (literature$ or medical database$ or medline or pubmed or embase or cochrane or cinahl or psycinfo or psyclit or healthstar or biosis or current content$ or systemat$)).tw,ot.<BR/>51. or/42-50<BR/>52. randomized controlled trial.pt.<BR/>53. controlled clinical trial.pt.<BR/>54. randomi?ed.ab.<BR/>55. placebo.ab.<BR/>56. drug therapy.fs.<BR/>57. randomly.ab.<BR/>58. trial.ab.<BR/>59. groups.ab.<BR/>60. or/52-59<BR/>61. 51 or 60<BR/>62. 41 and 61<BR/>63. (animals not (animals and humans)).sh.<BR/>64. 62 not 63<BR/>65. (comment or editorial or historical-article).pt.<BR/>66. 64 not 65</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>Embase (Ovid SP)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>1. exp Drug combination/<BR/>2. combin*.tw,ot.<BR/>3. 1 or 2<BR/>4. exp Diabetes Mellitus/<BR/>5. diabet$.tw,ot.<BR/>6. (non insulin* depend* or noninsulin* depend* or non insulin?depend* or noninsulin?depend*).tw,ot.<BR/>7. (insulin* depend* or insulin?depend*).tw,ot.<BR/>8. (IDDM or NIDDM or MODY or T1DM or T2DM or T1d or T2D).tw,ot.<BR/>9. or/4-8<BR/>10. exp Diabetes Insipidus/<BR/>11. diabet* insipidus.tw,ot.<BR/>12. 10 or 11<BR/>13. 9 not 12<BR/>14. exp sulfonylurea derivative/<BR/>15. exp biguanide derivative/<BR/>16. exp acarbose/<BR/>17. exp 2,4 thiazolidinedione derivative/<BR/>18. (biguanid* or sulfonylurea* or sulphonylurea* or acarbos*).tw,ot.<BR/>19. (gliglacide* or glimeprid* or glibornurid* or gliguidon* or glisoxepid* or glipizid* or gliburid* or glyburid* or tolazamid*).tw,ot.<BR/>20. (metformin* or buformin* or chlorhexidin* or chlorguanid* or phenformin*).tw,ot.<BR/>21. (troglitazon* or rosiglitazon* or pioglitazon* or thiazolidinedion* or glitazon*).tw,ot.<BR/>22. (miglitol* or nateglinid* or repaglinid* or meglitinid* or glucobay).tw,ot.<BR/>23. ( (antidiabet* or anti diabet*) adj3 (drug* or herb* or agent* or compound*)).tw,ot.<BR/>24. (oral adj6 (hypoglyc?emic or antidiabetic or antihyperglyc?emic)).tw,ot.<BR/>25. alpha-glucosidase-inhibitor*.tw,ot.<BR/>26. (hypoglyc?emic adj3 (drug* or herb* or agent* or compound*)).tw,ot.<BR/>27. (sitagliptin* or vildagliptin*).tw,ot.<BR/>28. exp glucagon like peptide 1/<BR/>29. glucagon-like peptid* 1.tw,ot.<BR/>30. (GLP 1 or GLP1).tw,ot.<BR/>31. (DPP-4 or DPP-IV or DPP4 or DPPIV).tw,ot.<BR/>32. (biguanid* or sulfonylurea* or sulphonylurea* or acarbos*).tw,ot.<BR/>33. exp glimepiride/<BR/>34. exp glibornuride/<BR/>35. exp glisoxepide/<BR/>36. glibenclamide/ or metformin/ or glipizide/ or tolbutamide/<BR/>37. exp tolazamide/<BR/>38. exp carbutamide/<BR/>39. exp chlorpropamide/<BR/>40. exp acetohexamide/<BR/>41. exp buformin/<BR/>42. (tolbutamid* or carbutamid* or chlorpropamid* or acetohexamid* or glibenclamid* or glimepirid*).tw,ot.<BR/>43. exp chlorhexidine/<BR/>44. proguanil/<BR/>45. exp phenformin/<BR/>46. exp miglitol/<BR/>47. exp nateglinide/<BR/>48. exp meglitinide/<BR/>49. exp troglitazone/<BR/>50. exp rosiglitazone/<BR/>51. exp pioglitazone/<BR/>52. exp 2,4 thiazolidinedione derivative/<BR/>53. exp glitazone derivative/<BR/>54. exp alpha glucosidase inhibitor/<BR/>55. exp sitagliptin/<BR/>56. exp vildagliptin/<BR/>57. or/14-56<BR/>58. exp insulin/<BR/>59. insulin*.tw,ot.<BR/>60. 58 or 59<BR/>61. exp Randomized Controlled Trial/<BR/>62. exp Controlled Clinical Trial/<BR/>63. exp Clinical Trial/<BR/>64. exp Comparative Study/<BR/>65. exp Drug comparison/<BR/>66. exp Randomization/<BR/>67. exp Crossover procedure/<BR/>68. exp Double blind procedure/<BR/>69. exp Single blind procedure/<BR/>70. exp Placebo/<BR/>71. exp Prospective Study/<BR/>72. ( (clinical or control$ or comparativ$ or placebo$ or prospectiv$ or randomi?ed) adj3 (trial$ or stud$)).ab,ti.<BR/>73. (random$ adj6 (allocat$ or assign$ or basis or order$)).ab,ti.<BR/>74. ( (singl$ or doubl$ or trebl$ or tripl$) adj6 (blind$ or mask$)).ab,ti.<BR/>75. (cross over or crossover).ab,ti.<BR/>76. or/61-75<BR/>77. exp meta analysis/<BR/>78. (metaanaly$ or meta analy$ or meta?analy$).ab,ti,ot.<BR/>79. ( (review$ or search$) adj10 (literature$ or medical database$ or medline or pubmed or embase or cochrane or cinahl or psycinfo or psyclit or healthstar or biosis or current content$ or systematic$)).ab,ti,ot.<BR/>80. exp Literature/<BR/>81. exp Biomedical Technology Assessment/<BR/>82. hta.tw,ot.<BR/>83. (health technology adj6 assessment$).tw,ot.<BR/>84. or/77-83<BR/>85. 76 or 84<BR/>86. 3 and 13 and 57 and 60 and 85<BR/>87. (comment or editorial or historical-article).pt.<BR/>88. 86 not 87<BR/>89. limit 88 to human</P>
</TD>
</TR>
<TR>
<TH>
<P>WHO ICTRP (Standard search)</P>
</TH>
</TR>
<TR>
<TD>
<P>diabet* AND insulin monotherapy OR diabet* AND insulin alone</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>ClinicalTrials.gov (Advanced search)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Search Terms: </B>(((diabetes OR diabetic) AND ("type 2" OR "type II")) OR T2D OR T2DM) AND ("insulin monotherapy" OR "insulin alone")</P>
<P>
<B>Study Type: </B>Interventional Studies</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="2">
<TITLE MODIFIED="2015-01-05 13:42:58 +0100" MODIFIED_BY="Gudrun Paletta">Description of interventions</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="3" ROWS="44">
<TR>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>Intervention(s)<BR/>(route, frequency, total dose/day)</P>
</TH>
<TH VALIGN="TOP">
<P>Comparator(s)<BR/>(route, frequency, total dose/day)<BR/>
</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Avilés 1999</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin as before treatment of at least 50 U insulin/day + <B>metformin</B>, oral, 2500 mg/day, 5 tablets of 500 mg daily</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin as before treatment of at least 50 U insulin/day + <B>placebo</B>, 5 tablets daily</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Barnett 2013</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (premixed 67.4%, intermediate 16.8%, long-acting 11.6%, intermediate + long-acting 1.1%, intermediate + premixed 1.1, long-acting + premixed 1.1) 53.6 U (range 30-150) daily dose + <B>saxagliptin</B>, oral, 5 mg daily</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (premixed 54.3%, intermediate 21.7%, long acting 13.0%, intermediate + long-acting 6.5%, intermediate + premixed 4.3, long-acting + premixed 0) 55.3 U (range 30-149) daily dose + <B>placebo</B> daily</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Casner 1988</P>
</TH>
<TD VALIGN="TOP">
<P>NPH insulin twice a day, total of at least 25 U insulin/day + <B>glibenclamide</B>, oral, 3.39 ± 0.22 mg/day</P>
</TD>
<TD VALIGN="TOP">
<P>NPH insulin twice a day, total of at least 25 U insulin/day + <B>placebo</B>, oral, 3.28 ± 0.28 mg/day</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Chiasson 1994</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (type and dose not mentioned) + <B>acarbose</B>, oral, 3 times a day, 50 mg to 200 mg/day</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (type and dose not mentioned) + <B>placebo,</B> oral, 3 times a day</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Coniff 1995</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (type and dose not mentioned) + <B>acarbose</B>, oral, 3 times a day 50 mg to 300 mg/day</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (type and dose not mentioned) + <B>placebo</B>, oral, 3 times a day</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Feinglos 1998</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (regular or NPH: 1 participant; daily, 26 participants; twice a day, 2 participants: 3 times a day, dose not mentioned) + <B>glipizide</B>, oral, 5-40 mg/day, daily or twice a day</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (regular or NPH: 1 participant; daily, 26 participants twice a day, 2 participants 3 times a day, dose not mentioned) + <B>placebo</B>, oral</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Fonseca 2007</P>
</TH>
<TD VALIGN="TOP">
<P>Injectable insulin (type not mentioned) of at least 30 U/day + <B>vildagliptin</B>, oral, 100 mg/day, twice a day 50 mg</P>
</TD>
<TD VALIGN="TOP">
<P>Injectable insulin (type not mentioned) of at least 30 U/day + <B>placebo</B>, oral, twice a day</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Fritsche 2000</P>
</TH>
<TD VALIGN="TOP">
<P>NPH insulin twice a day (dose not mentioned) + <B>metformin</B>, oral, daily 850 mg - 3 times a day</P>
</TD>
<TD VALIGN="TOP">
<P>NPH insulin twice a day (dose not mentioned) + <B>placebo</B>, oral, daily - 3 times a day</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Giugliano 1993</P>
</TH>
<TD VALIGN="TOP">
<P>Regular and lente insulin, mean dose 90 (9 SD) U/day, twice a day + <B>metformin</B>, oral, 850 mg twice daily</P>
</TD>
<TD VALIGN="TOP">
<P>Regular and lente insulin, mean dose 90 (9 SD) U/day, twice a day + <B>placebo</B>, oral, twice daily</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Groop 1985</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (type and dose not mentioned) + <B>glibenclamide</B>, oral, 10 mg/day, twice a day 5 mg</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (type and dose not mentioned) + <B>placebo</B>, oral, twice a day</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Hermann 2001</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (rapid-acting + NPH or premixed) 0.75 (0.28 SD) U/kg/day + <B>metformin</B>, oral, 2 weeks daily 850 mg, thereafter twice a day 850 mg</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (rapid-acting + NPH or premixed) 0.73 (0.23 SD) U/kg/day + <B>placebo</B>, oral, 2 weeks daily, thereafter twice a day</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Hirsch 1999</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (type and dose not mentioned) + <B>metformin</B>, oral, 2.5 gram/day, frequency not stated</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (type and dose not mentioned) + <B>placebo</B>, oral, frequency not stated</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Hong 2012</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (glargine, glargine + rapid-acting, NPH + regular) at least 10 U/day + <B>sitagliptin</B>, oral, 100 mg/day</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Increase insulin</B> (glargine, glargine + rapid-acting, NPH + regular) by &#8805; 10% at random at the start of the intervention and again by &#8805; 10% at 12 weeks if their HbA1c was not within target (&#8804; 7%)</P>
<P>If glargine insulin 20 U daily was used, the dose increased to &#8805; 22 U daily and to &#8805; 24 U daily at 12 weeks. If 20-10 U mixed insulin was used twice a day, the dose was increased to &#8805; 22-11 U twice a day and &#8805; 24-12 U twice a day at 12 weeks</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Kitabchi 1987</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (NPH, dose not mentioned) + <B>tolazamide</B>, oral, 1000 mg/day, twice a day 500 mg</P>
</TD>
<TD VALIGN="TOP">
<P>NPH insulin alone</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Krawczyk 2005</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (type not mentioned) 57.5 (15.8 SD) U + <B>metformin</B> 1500 mg once daily</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin alone (type not mentioned) 59.5 (15.4 SD) U</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Kyllastinen 1985</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (type not mentioned) mean dose 58 (3 SD) U daily + <B>glibenclamide</B>, oral, 10 mg/day, twice a day 5 mg</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (type not mentioned) mean dose 58 (3 SD) U daily + <B>placebo</B>, oral, twice daily</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Lewitt 1989</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (14 participants on daily, 17 on twice a day, 12 mixed, 19 premixed or intermediate-acting insulin) mean dose 47 (21 SD) U + <B>glibenclamide</B>, oral, 15 mg/day, 10 mg in the morning and 5 mg in the evening</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (14 participants on daily, 17 on twice a day, 12 mixed, 19 premixed or intermediate-acting insulin) mean dose 47 (21 SD) U + <B>placebo</B>, oral, twice daily</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Lindström 1999</P>
</TH>
<TD VALIGN="TOP">
<P>Soluble insulin (total dose 100 U/ml 3 times a day) + intermediate-acting insulin (100 U/ml daily) + <B>glibenclamide</B>, oral, 10.5 mg/day, 3 times daily 3.5 mg</P>
</TD>
<TD VALIGN="TOP">
<P>Soluble insulin (total dose 100 U/ml three times a day) + intermediate-acting insulin (100 U/ml daily) +<B> placebo</B>, oral 3 times daily</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Longnecker 1986</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (5 participants daily insulin injection: 1 participant on isophane insulin suspension alone (40 U daily), 4 participants on isophane insulin suspension (48 (8 SD) U) + regular insulin injections (23 (9 SD) U); 6 participants twice a day insulin injections: mean morning dose 38 (6 SD) U (regular, isophane suspension, or both) + mean afternoon dose 25 (7 SD) U (regular, isophane suspension, or both) + <B>tolazamide</B>, oral, 1000 mg, twice daily 250 mg</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (5 participants daily insulin injection: 1 participant on isophane insulin suspension alone (40 U daily), 4 participants on isophane insulin suspension (48 (8 SD) U) + regular insulin injections (23 (9 SD) U); 6 participants DIB insulin injections: mean morning dose 38 (6 SD) U (regular, isophane suspension, or both) + mean afternoon dose 25 (7 SD) U (regular, isophane suspension, or both) + <B>placebo</B>, oral, twice daily</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Mattoo 2005</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (type and dose not mentioned) + <B>pioglitazone</B> 30 mg</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (type and dose not mentioned) + <B>placebo</B>, oral</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Mauerhoff 1986</P>
</TH>
<TD VALIGN="TOP">
<P>Usual insulin (type and dose not mentioned) + Hb420 (galenic form of <B>glibenclamide</B>) 7 mg before breakfast and 3.5 mg before supper</P>
</TD>
<TD VALIGN="TOP">
<P>Usual insulin (type and dose not mentioned) + <B>placebo</B>, oral</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Mezitis 1992</P>
</TH>
<TD VALIGN="TOP">
<P>Biosynthetic human insulin (dose not mentioned) + <B>glibenclamide</B>, oral, twice daily 2 tablets (dose not mentioned)/day</P>
</TD>
<TD VALIGN="TOP">
<P>Biosynthetic human insulin + <B>placebo</B>, oral</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Mudaliar 2010</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (type and dose not mentioned) + <B>pioglitazone</B>, oral, 30 mg for 4 weeks, then titrated to 45 mg</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (type and dose not mentioned) + <B>placebo</B>, oral</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Nemoto 2011</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (type and dose not mentioned) + <B>miglitol</B>, oral, 50 mg 3 times a day</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (type and dose not mentioned) + <B>placebo</B>, oral, 3 times a day</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Osei 1984</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (intermediate-acting insulin alone or in combination with short-acting insulin twice a day (dose not mentioned)) + <B>glibenclamide</B>, oral, 5-20 mg once daily</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (intermediate-acting insulin alone or in combination with short-acting insulin twice a day (dose not mentioned)) + <B>placebo</B>, oral</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Quartraro 1986</P>
</TH>
<TD VALIGN="TOP">
<P>Monocomponent porcine insulin (mean dose 95 (2 SD) U daily) + <B>gliclazide</B> 40-240 mg once daily</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin alone (mono component porcine insulin (mean dose 95 (2 SD) U daily))</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Reich 1987</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (intermediate-acting, dose not mentioned) + <B>glibenclamide,</B> oral, 5-40 mg once daily</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (intermediate-acting, dose not mentioned) + <B>placebo</B>, oral</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Relimpio 1998</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (premixed formulation of soluble and NPH or NPH only, twice a day in 23 participants and 3 times a day in 1 participant) + <B>metformin</B> 1275-2550 mg once daily</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin dose increase (premixed formulation of soluble and NPH or NPH only, twice a day in 22 participants and 3 times a day in 1 participant), <B>insulin increase </B>by 10%</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Robinson 1998</P>
</TH>
<TD VALIGN="TOP">
<P>Trial 1: insulin (type and dose not mentioned) + <B>metformin </B>1000 mg/day increasing to 2000 mg /day<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (type and dose not mentioned) + <B>placebo</B>
</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Rosenstock 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I1: insulin (type and dose not mentioned) + <B>pioglitazone</B> 15 mg once daily</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Insulin (type and dose not mentioned) + <B>placebo</B> once daily</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: insulin (type and dose not mentioned) + <B>pioglitazone</B> 30 mg once daily</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Schade 1987</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (intermediate-acting or short-acting) mean dose at least 28 U/day (daily or twice a day) + <B>glibenclamide</B> 20 mg once daily</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (intermediate-acting or short-acting, mean dose at least 28 U/day, daily or twice a day) + <B>placebo</B>, oral</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Schiel 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I1: insulin glargine (before treatment dose) + <B>glimepiride 3 </B>mg/day</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Insulin alone (75/25 or 70/30 premixed human insulin)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: insulin glargine (before treatment dose) + <B>glimepiride</B> 3 mg/day + <B>metformin </B>1700 mg/day</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Simpson 1990</P>
</TH>
<TD VALIGN="TOP">
<P>Usual insulin soluble + isophane twice a day or soluble + zinc-complexed insulin daily or twice a day) + <B>glipizide</B> 10 mg twice a day</P>
</TD>
<TD VALIGN="TOP">
<P>Usual insulin soluble + isophane twice a day or soluble + zinc-complexed insulin daily or twice a day) + <B>placebo</B>, oral</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Stenman 1988</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (intermediate-acting daily or twice a day or intermediate- and short-acting daily) + <B>glibenclamide</B>, oral, 15 mg once daily</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (intermediate-acting daily or twice a day or intermediate- and short-acting daily) + <B>placeb</B>o, oral</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Strowig 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I1: insulin (type and dose not mentioned) + <B>metformin</B>, oral, 2000 mg once daily</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Insulin alone (type and dose not mentioned)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: insulin (type and dose not mentioned) + <B>troglitazone<SUP>a</SUP>
</B>, oral, 600 mg once daily</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Wulffelé 2002</P>
</TH>
<TD VALIGN="TOP">
<P>Insulin (Actrapid + Insulatard 4 times daily or mixed Actrapid (10%-50%) + Insulatard (90%-50%) twice a day) + <B>metformin</B>, oral, 3 x 850 mg once daily</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin (Actrapid + Insulatard 4 times daily or mixed Actrapid (10%-50%) + Insulatard (90%-50%) twice a day) + <B>placebo</B>, oral</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Yilmaz 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I1: insulin (mixed 30% insulin aspart + 70% NPH insulin twice a day) + <B>acarbose</B>, oral, 300 mg once daily</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Insulin alone (mixed 30% insulin aspart + 70% NPH insulin twice a day)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: insulin (mixed 30% insulin aspart + 70% NPH insulin twice a day) + <B>metformin</B>, oral, 1700 mg once daily</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I3: insulin (mixed 30% insulin aspart + 70% NPH insulin twice a day) + <B>rosiglitazone<SUP>a</SUP>
</B>, oral, 8 mg once daily</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<SUP>a</SUP>off the market</P>
<P>I: intervention; NPH: Neutral Protamine Hagedorn; SD: standard deviation; U: units</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta" NO="3">
<TITLE MODIFIED="2014-10-16 17:02:23 +0200" MODIFIED_BY="Gudrun Paletta">Baseline characteristics (I)</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-26 17:26:41 +0200" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="8" ROWS="92">
<TR>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>Intervention(s) and comparator(s)</P>
</TH>
<TH VALIGN="TOP">
<P>Duration of intervention<BR/>
</P>
</TH>
<TH VALIGN="TOP">
<P>Description of participants</P>
</TH>
<TH VALIGN="TOP">
<P>Country</P>
</TH>
<TH VALIGN="TOP">
<P>Setting</P>
</TH>
<TH VALIGN="TOP">
<P>Ethnic groups<BR/>(%)</P>
</TH>
<TH VALIGN="TOP">
<P>Duration of diabetes<BR/>(mean/range years (SD), or as reported)</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Avilés 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>24 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Participants with poorly controlled type 2 diabetes on insulin therapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD VALIGN="TOP">
<P>White: 49<BR/>African-American: 23<BR/>Hispanic :23<BR/>Other: 5</P>
</TD>
<TD VALIGN="TOP">
<P>9.2 (6.4)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>White: 68<BR/>African-American: 18<BR/>Hispanic: 14<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>10.1 (4.7)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Barnett 2013</P>
</TH>
<TD VALIGN="TOP">
<P>I: saxagliptin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>52 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Inadequately controlled type 2 diabetes individuals with insulin alone (subgroup in the publication)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Canada, Hungary, India, Mexico, Poland, Russia, South Africa, UK </P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Multiple choices possible</P>
</TD>
<TD VALIGN="TOP">
<P>White: 84.2</P>
<P>Black: 6.3</P>
<P>Asian: 7.4</P>
<P>Other: 2.1</P>
</TD>
<TD VALIGN="TOP">
<P>12.1 (6.3)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>White: 76.1</P>
<P>Black: 10.9</P>
<P>Asian: 6.5</P>
<P>Other: 6.5</P>
</TD>
<TD VALIGN="TOP">
<P>10.3 (6.4)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Casner 1988</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>12 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Participants with type 2 diabetes on insulin therapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Hispanic: 84<BR/>Non-Hispanic white: 10<BR/>Non-Hispanic black: 6</P>
</TD>
<TD VALIGN="TOP">
<P>14.3 (0.1)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>Hispanic: 94<BR/>Non-Hispanic white: 6<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>10.9 (0.1)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Chiasson 1994</P>
</TH>
<TD VALIGN="TOP">
<P>I: acarbose</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>12 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Participants with type 2 diabetes (26% pretreated with insulin, only results of this subgroup is used)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Canada</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="5" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>White: 92</P>
</TD>
<TD VALIGN="TOP">
<P>12.9 (0.8 SE)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Coniff 1995</P>
</TH>
<TD VALIGN="TOP">
<P>I: acarbose</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>24 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Insulin pretreated participants with type 2 diabetes</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Canda, USA</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Not stated</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Feinglos 1998</P>
</TH>
<TD VALIGN="TOP">
<P>I: glipizide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Participants with type 2 diabetes taking insulin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care inpatients and outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="5" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>15 (3 - 30)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Fonseca 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I: vildagliptin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>24 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Participants with type 2 diabetes inadequately controlled by insulin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Finland, Germany, Spain, USA</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Black: 15<BR/>White: 70<BR/>Hispanic + Latino: 12<BR/>Other: 3</P>
</TD>
<TD VALIGN="TOP">
<P>14.4 (8.6)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>Black: 11<BR/>White: 72<BR/>Hispanic + Latino: 15<BR/>Other: 2</P>
</TD>
<TD VALIGN="TOP">
<P>14.9 (8.4)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Fritsche 2000</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>10 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Severely obese participants with type 2 diabetes on intensified insulin therapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Germany</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care inpatients and outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="5" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>10 (8)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Giugliano 1993</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>6 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Obese type 2 diabetes on insulin therapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Italy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>11.9 (1.2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>11.5 (1.2)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Groop 1985</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>8 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Poorly controlled participants with type 2 diabetes on insulin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Finland</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="5" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>8 (1)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Hermann 2001</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>12 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Overweight and obese type 2 diabetes participants on insulin therapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Sweden</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>13 (3 - 31)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>13 (4 - 25)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Hirsch 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>5 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Participants with type 2 diabetes and sub optimal insulin therapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Hong 2012</P>
</TH>
<TD VALIGN="TOP">
<P>I: Sitagliptin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>24 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Participants with uncontrolled type 2 diabetes on insulin therapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Korea</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>15.9 (10.5)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin increase</P>
</TD>
<TD VALIGN="TOP">
<P>15.8 (9.9)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Kitabchi 1987</P>
</TH>
<TD VALIGN="TOP">
<P>I: tolazamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Obese insulin-requiring participants with type 2 diabetes</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care inpatients and outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="5" VALIGN="TOP">
<P>all:</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>10 (1)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Krawczyk 2005</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>6 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Obese insulin-requiring participants with type 2 diabetes</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Poland</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>12.2 (4.8)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>11.9 (5.9)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Kyllastinen 1985</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>2 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Elderly participants with type 2 diabetes on insulin therapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Finland</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="5" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>11 (1)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Lewitt 1989</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Insulin-treated type 2 diabetes participants</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Australia</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Lindström 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>3 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Sweden</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="5" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>10.5 (1.2)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Longnecker 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: tolazamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>8 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="5" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>12 (2)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mattoo 2005</P>
</TH>
<TD VALIGN="TOP">
<P>I: pioglitazone</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>6 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Australia, Belgium, Canada, New Zealand, Romania, Spain</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD VALIGN="TOP">
<P>White: 97</P>
</TD>
<TD VALIGN="TOP">
<P>13.6 (6.8)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>White: 97</P>
</TD>
<TD VALIGN="TOP">
<P>13.4 (6.1)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mauerhoff 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>16 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Belgium</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>11 (2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>10 (2)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mezitis 1992</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>20 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mudaliar 2010</P>
</TH>
<TD VALIGN="TOP">
<P>I: pioglitazone</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>12 to 16 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Clinical research centre</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Nemoto 2011</P>
</TH>
<TD VALIGN="TOP">
<P>I: miglitol</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>24 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Japan</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="5" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>15.1 (8.5)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Osei 1984</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>16 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care inpatients and outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>12.3 (1.2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>12.9 (1.6)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Quartraro 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: gliclazide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>12 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Italy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care inpatients and outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>12.1 (1.4 SE)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>11.8 (1.3 SE)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Reich 1987</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>4 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care inpatients and outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>9.0 (3.1)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>9.7 (3.3)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Relimpio 1998</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>4 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Spain</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>15.4 (7.7)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin dose increase</P>
</TD>
<TD VALIGN="TOP">
<P>15.3 (6.0)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Robinson 1998</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>12 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>UK</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Study 1: 15 (7)</P>
<P>Study 2: 14 (6)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Rosenstock 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I1: pioglitazone 15 mg</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>16 weeks</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin ± oral antidiabetic medication. Those participants on insulin + oral antidiabetic medication discontinued the oral drug at the beginning of the screening period. In addition the run-in period for those participants was 6 weeks instead of 3 for the participants on insulin monotherapy.</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>White: 75</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: pioglitazone 30 mg</P>
</TD>
<TD VALIGN="TOP">
<P>White: 73</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C1: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>White: 71</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Schade 1987</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>16 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="5" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>10 (1)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Schiel 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I1: glimepiride</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>16 weeks</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Germany</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>15.3 (8.4)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: glimepiride + metformin</P>
</TD>
<TD VALIGN="TOP">
<P>14.2 (8.0)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C1: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>16.3 (6.7)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Simpson 1990</P>
</TH>
<TD VALIGN="TOP">
<P>I: glipizide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>8 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>UK</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>9 (2 - 18)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>10 (1 - 20)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Stenman 1988</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>4 months</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Finland</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care inpatients and outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" COLSPAN="5" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>9.8 (4.7)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Strowig 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I1: metformin</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>4 months</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>USA</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>White: 52 Afro-American: 15 Hispanic: 30</P>
<P>Other: 4</P>
</TD>
<TD VALIGN="TOP">
<P>7.6 (4.1)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: troglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>White: 57 Afro-American: 17 Hispanic: 27<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>11.6 (6.8)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C1: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>White: 55 Afro-American: 29 Hispanic: 16</P>
</TD>
<TD VALIGN="TOP">
<P>10.5 (7.3)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Wulffelé 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>16 weeks</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>The Netherlands</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>14.0 (8.4)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C1: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>12.0 (8.0)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="4" VALIGN="TOP">
<P>Yilmaz 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I1: acarbose</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>6 months</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>Type 2 diabetes participants on insulin monotherapy</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>Turkey</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>Secondary care outpatients</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>13.9 (7.2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>12.1 (7.7)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I3: rosiglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>12.1 (7.9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C1: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="8" VALIGN="TOP">
<P>- denotes not reported</P>
<P>C: comparator; I: intervention; SD: standard deviation; SE: standard error</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2016-09-07 10:11:47 +0200" MODIFIED_BY="Gudrun Paletta" NO="4">
<TITLE MODIFIED="2014-10-14 12:38:27 +0200" MODIFIED_BY="Gudrun Paletta">Baseline characteristics (II)</TITLE>
<APPENDIX_BODY MODIFIED="2016-09-07 10:11:47 +0200" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="7" ROWS="96">
<TR>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>Intervention(s) and comparator(s)</P>
</TH>
<TH VALIGN="TOP">
<P>Sex<BR/>(female %)</P>
</TH>
<TH VALIGN="TOP">
<P>Age<BR/>(mean years (SD); (range))</P>
</TH>
<TH VALIGN="TOP">
<P>HbA1c<BR/>(mean % (SD); (range))</P>
</TH>
<TH VALIGN="TOP">
<P>
<B>Comedications</B>/Cointerventions<BR/>(%)</P>
</TH>
<TH VALIGN="TOP">
<P>Comorbidities<BR/>(%)</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Avilés 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>71</P>
</TD>
<TD VALIGN="TOP">
<P>53.1 (9.4); (35-69)</P>
</TD>
<TD VALIGN="TOP">
<P>9 (1.4); -</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>55</P>
</TD>
<TD VALIGN="TOP">
<P>54.6 (7.8); (36-70)</P>
</TD>
<TD VALIGN="TOP">
<P>9.1 (1.5); -</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Barnett 2013</P>
</TH>
<TD VALIGN="TOP">
<P>I: saxagliptin</P>
</TD>
<TD VALIGN="TOP">
<P>60</P>
</TD>
<TD VALIGN="TOP">
<P>58.7 (10.0); (29-77)</P>
</TD>
<TD VALIGN="TOP">
<P>8.7 (0.9); (7-11)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>57.8 (10.9); (30-75)</P>
</TD>
<TD VALIGN="TOP">
<P>8.7 (0.8); (7-11)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Casner 1988</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>65</P>
</TD>
<TD VALIGN="TOP">
<P>55.8 (0.1); -</P>
</TD>
<TD VALIGN="TOP">
<P>10.9 (0.5 SE); -</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>79</P>
</TD>
<TD VALIGN="TOP">
<P>60.0 (0.1); -</P>
</TD>
<TD VALIGN="TOP">
<P>11.4 (0.4 SE); -</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Chiasson 1994</P>
</TH>
<TD VALIGN="TOP">
<P>I: acarbose</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>39</P>
</TD>
<TD VALIGN="TOP">
<P>56.6 (0.9); -</P>
</TD>
<TD VALIGN="TOP">
<P>7.7 (0.2 SE); -</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Coniff 1995</P>
</TH>
<TD VALIGN="TOP">
<P>I: acarbose</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>6.4 (0.1 SE); -</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>6.6 (0.1 SE); -</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Feinglos 1998</P>
</TH>
<TD VALIGN="TOP">
<P>I: glipizide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>56 (39 - 68); (39-68)</P>
</TD>
<TD VALIGN="TOP">
<P>12.1 (5.4-21.2);</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Fonseca 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I: vildagliptin</P>
</TD>
<TD VALIGN="TOP">
<P>52</P>
</TD>
<TD VALIGN="TOP">
<P>59.6 (10.3); -</P>
</TD>
<TD VALIGN="TOP">
<P>8.4 (1.0); -</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>45</P>
</TD>
<TD VALIGN="TOP">
<P>58.9 (10.8); -</P>
</TD>
<TD VALIGN="TOP">
<P>8.4 (1.1); -</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Fritsche 2000</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>8.5 (0.4 SE); -</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>8.1 (0.4 SE); -</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>69</P>
</TD>
<TD VALIGN="TOP">
<P>51 (9); -</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Giugliano 1993</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>11.5 (1.2); -</P>
</TD>
<TD VALIGN="TOP">
<P>Antihypertensive drugs (ACE-inhibitor or calcium antagonist): 5</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>11.7 (1.3); -</P>
</TD>
<TD VALIGN="TOP">
<P>Antihypertensive drugs (ACE-inhibitor or calcium antagonist): 4</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>62</P>
</TD>
<TD VALIGN="TOP">
<P>60 (2); -</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Groop 1985</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Antihypertensive drugs (n = 4)</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Background retinopathy and signs of sensory neuropathy (n = 5)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>56 (1); (49-61)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>38</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Hermann 2001</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>56.9 (10.2); -</P>
</TD>
<TD VALIGN="TOP">
<P>9.1 (1.3); -</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Hypertension (n = 10) 27<BR/>Ischaemic heart disease (n = 7) 19<BR/>diabetic nephropathy (n = 1) 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>37</P>
</TD>
<TD VALIGN="TOP">
<P>58.1 (9.7); -</P>
</TD>
<TD VALIGN="TOP">
<P>8.7 (1.0); -</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Hirsch 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>8.6 (0.2 SE); -</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>9.0 (0.4 SE); -</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Hong 2012</P>
</TH>
<TD VALIGN="TOP">
<P>I: sitagliptin</P>
</TD>
<TD VALIGN="TOP">
<P>53.7</P>
</TD>
<TD VALIGN="TOP">
<P>58.8 (14.3); -</P>
</TD>
<TD VALIGN="TOP">
<P>9.2 (1.0); -</P>
</TD>
<TD VALIGN="TOP">
<P>Sulphonylurea: 24.6<BR/>Glinides (short-acting insulin secretagogues): 13.1<BR/>Metformin: 45.9<BR/>Thiazolidinedione: 6.6<BR/>Alpha-glucosidase inhibitor: 31.1<BR/>Glargine only: 47.5<BR/>Glargine plus rapid acting insulin: 23<BR/>NPH plus regular insulin: 29.5</P>
</TD>
<TD VALIGN="TOP">
<P>Retinopathy: 16.4<BR/>Neuropathy: 21.3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin increase</P>
</TD>
<TD VALIGN="TOP">
<P>50.9</P>
</TD>
<TD VALIGN="TOP">
<P>59.6 (13.0); -</P>
</TD>
<TD VALIGN="TOP">
<P>9.2 (1.1); -</P>
</TD>
<TD VALIGN="TOP">
<P>Sulphonylurea: 23.8<BR/>Glinides (short acting insulin secretagogues): 15.9<BR/>Metformin: 41.3<BR/>Thiazolidinedione: 3.2<BR/>Alpha-glucosidase inhibitor: 42.9<BR/>Glargine only: 49.2<BR/>Glargine plus rapid-acting insulin: 17.5<BR/>NPH plus regular insulin: 33.3</P>
</TD>
<TD VALIGN="TOP">
<P>Retinopathy: 14.3<BR/>Neuropathy: 23.8</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Kitabchi 1987</P>
</TH>
<TD VALIGN="TOP">
<P>I: tolazamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>51 (3); (34-66)</P>
</TD>
<TD VALIGN="TOP">
<P>10.7 (0.7 SE); (8.7-15.5)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Krawczyk 2005</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>60</P>
</TD>
<TD VALIGN="TOP">
<P>55.8 (8.1); -</P>
</TD>
<TD VALIGN="TOP">
<P>8.6 (1.9); -</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>40</P>
</TD>
<TD VALIGN="TOP">
<P>58.4 (6.0); -</P>
</TD>
<TD VALIGN="TOP">
<P>8.4 (1.6); -</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Kyllastinen 1985</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>13.8 (0.6 SE); -</P>
</TD>
<TD VALIGN="TOP">
<P>Dose kept constant throughout trial</P>
</TD>
<TD VALIGN="TOP">
<P>Heart failure: 89<BR/>Hypertension: 44<BR/>Hypothyroidism: 11<BR/>Psychiatric illness: 11<BR/>Chronic obstipation: 33<BR/>Retinopathy: 22<BR/>Elevated creatinine: 33</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>13.5 (0.8 SE); -</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>78</P>
</TD>
<TD VALIGN="TOP">
<P>73 (2); (66-80)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Lewitt 1989</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>67 (5); (59-78)</P>
</TD>
<TD VALIGN="TOP">
<P>9.9 (1.3); (7.3-13.3)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Lindström 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>59 (2); (48-71)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Longnecker 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: tolazamide</P>
</TD>
<TD VALIGN="TOP">
<P>92</P>
</TD>
<TD VALIGN="TOP">
<P>62 (2.4); (48-76)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>54 (2.9); (43-65)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>12.7 (0.8); (9-16.3)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mattoo 2005</P>
</TH>
<TD VALIGN="TOP">
<P>I: pioglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>58.8 (7.4); -</P>
</TD>
<TD VALIGN="TOP">
<P>8.9 (0.1 SE); -</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>57</P>
</TD>
<TD VALIGN="TOP">
<P>58.9 (6.9); -</P>
</TD>
<TD VALIGN="TOP">
<P>8.8 (0.1 SE); -</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mauerhoff 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>63</P>
</TD>
<TD VALIGN="TOP">
<P>62 (2); -</P>
</TD>
<TD VALIGN="TOP">
<P>-; -</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>59 (4); -</P>
</TD>
<TD VALIGN="TOP">
<P>-; -</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mezitis 1992</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-; 46-68</P>
</TD>
<TD VALIGN="TOP">
<P>8.7; (4.4-8.2)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-; 46-68</P>
</TD>
<TD VALIGN="TOP">
<P>8.6; (4.4-8.2)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Mudaliar 2010</P>
</TH>
<TD VALIGN="TOP">
<P>I: pioglitazone</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>7.6 (0.3); -</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>7.8 (0.3); -</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>58 (2); -</P>
</TD>
<TD VALIGN="TOP">
<P>-; 7.5-10</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Nemoto 2011</P>
</TH>
<TD VALIGN="TOP">
<P>I: miglitol</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>42</P>
</TD>
<TD VALIGN="TOP">
<P>59.9 (10.7); -</P>
</TD>
<TD VALIGN="TOP">
<P>7.9 (1); -</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Osei 1984</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>60</P>
</TD>
<TD VALIGN="TOP">
<P>58.6 (2.7); -</P>
</TD>
<TD VALIGN="TOP">
<P>10.9 (0.6 SE); -</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>83</P>
</TD>
<TD VALIGN="TOP">
<P>56.3 (1.2); -</P>
</TD>
<TD VALIGN="TOP">
<P>10.4 (0.4 SE); -</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Quartraro 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: gliclazide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>56 (1.9 SE); (39-70)</P>
</TD>
<TD VALIGN="TOP">
<P>12.0 (0.6)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>57 (1.9 SE); (39-70)</P>
</TD>
<TD VALIGN="TOP">
<P>11.8 (0.4)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Reich 1987</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>58.7 (2.8); (39-69)</P>
</TD>
<TD VALIGN="TOP">
<P>8.9 (0.7 SE); (7.2-13.4)</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>56.8 (3.7); (29-69)</P>
</TD>
<TD VALIGN="TOP">
<P>10.0 (1.0 SE); (6.7-12.8)</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Relimpio 1998</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>79</P>
</TD>
<TD VALIGN="TOP">
<P>65.4 (7.9); -</P>
</TD>
<TD VALIGN="TOP">
<P>9.6 (1.4); -</P>
</TD>
<TD VALIGN="TOP">
<P>ACE inhibitors: 42<BR/>Thiazides: 8<BR/>Fibric acid: 8<BR/>HMG-CoA inhibitors: 4</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin dose increase</P>
</TD>
<TD VALIGN="TOP">
<P>65</P>
</TD>
<TD VALIGN="TOP">
<P>66.7 (6.2); -</P>
</TD>
<TD VALIGN="TOP">
<P>9.6 (1.2); -</P>
</TD>
<TD VALIGN="TOP">
<P>ACE inhibitors: 30<BR/>Thiazides: 17<BR/>Fibric acid: 17<BR/>HMG-CoA inhibitors: 22</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Robinson 1998</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>Study 1: 63<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Study 1: 61.3 (7.1); -<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Study 1: 8.9 (1.0 SE); -<BR/>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Trial 1:<BR/>Retinopathy (n = 9) 47<BR/>Neuropathy (n = 6) 32<BR/>Proteinuria (n = 1)<BR/>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Rosenstock 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I1: pioglitazone 15 mg</P>
</TD>
<TD VALIGN="TOP">
<P>54</P>
</TD>
<TD VALIGN="TOP">
<P>56.9 (10.4); (29-75)</P>
</TD>
<TD VALIGN="TOP">
<P>9.8 (0.1 SE); -</P>
</TD>
<TD VALIGN="TOP">
<P>Oral anti-diabetic medication before study: total 12<BR/>evenly distributed among the treatment arms (metformin: 8,</P>
<P>glibenclamide: 2, glipizide: 2)</P>
<P>Lipid-lowering drugs: 28</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: pioglitazone 30 mg</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>57.5 (9.9); (29-75)</P>
</TD>
<TD VALIGN="TOP">
<P>9.8 (0.1 SE); -</P>
</TD>
<TD VALIGN="TOP">
<P>Lipid-lowering drugs: 22</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C1: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>55</P>
</TD>
<TD VALIGN="TOP">
<P>56.8 (3.7); (29-75)</P>
</TD>
<TD VALIGN="TOP">
<P>9.8 (0.1 SE); -</P>
</TD>
<TD VALIGN="TOP">
<P>Lipid-lowering drugs: 21</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Schade 1987</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>51 (3); (35-66)</P>
</TD>
<TD VALIGN="TOP">
<P>10.6 (0.4); -</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Schiel 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I1: glimepiride</P>
</TD>
<TD VALIGN="TOP">
<P>53</P>
</TD>
<TD VALIGN="TOP">
<P>61.7 (10.7); -</P>
</TD>
<TD VALIGN="TOP">
<P>8.2 (0.7); -</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: glimepiride + metformin</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>65.4 (8.5); -</P>
</TD>
<TD VALIGN="TOP">
<P>8.1 (0.9); -</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C1: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>47</P>
</TD>
<TD VALIGN="TOP">
<P>69.8 (6.4); -</P>
</TD>
<TD VALIGN="TOP">
<P>8.1 (0.8); -</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Simpson 1990</P>
</TH>
<TD VALIGN="TOP">
<P>I: glipizide</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>65 (-); (53 - 75)</P>
</TD>
<TD VALIGN="TOP">
<P>10.6 (-); (10-16.4)</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>62 (-); (50 - 78)</P>
</TD>
<TD VALIGN="TOP">
<P>12.0 (-); (7.6-4.9)</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>32</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Stenman 1988</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>58 (6.6); (45-68)</P>
</TD>
<TD VALIGN="TOP">
<P>9.2 (0.2); (9.9-15.8)</P>
</TD>
<TD VALIGN="TOP">
<P>Coronary heart disease (n = 1) 7<BR/>Hypertension (n = 3) 20</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Strowig 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I1: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>51.8 (10.5); -</P>
</TD>
<TD VALIGN="TOP">
<P>8.8 (1.2); -</P>
</TD>
<TD VALIGN="TOP">
<P>Lipid-lowering drugs: 30</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: troglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>57</P>
</TD>
<TD VALIGN="TOP">
<P>51.7 (8.0); -</P>
</TD>
<TD VALIGN="TOP">
<P>8.5 (1.2); -</P>
</TD>
<TD VALIGN="TOP">
<P>Lipid-lowering drugs: 43</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C1: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>52</P>
</TD>
<TD VALIGN="TOP">
<P>54.4 (9.1); -</P>
</TD>
<TD VALIGN="TOP">
<P>8.7 (1.6); -</P>
</TD>
<TD VALIGN="TOP">
<P>Lipid-lowering drugs: 26</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Wulffelé 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>56</P>
</TD>
<TD VALIGN="TOP">
<P>63.2 (9.8); -</P>
</TD>
<TD VALIGN="TOP">
<P>7.9 (1.2); -</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>50</P>
</TD>
<TD VALIGN="TOP">
<P>58.9 (11.1); -</P>
</TD>
<TD VALIGN="TOP">
<P>7.9 (1.2); -</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="4" VALIGN="TOP">
<P>Yilmaz 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I1: acarbose</P>
</TD>
<TD VALIGN="TOP">
<P>53</P>
</TD>
<TD VALIGN="TOP">
<P>62.6 (6.6); (34-80)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>66</P>
</TD>
<TD VALIGN="TOP">
<P>57.7 (8.5); (34-80)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I3: rosiglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>88</P>
</TD>
<TD VALIGN="TOP">
<P>57.6 (8.8); (34-80)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C1: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>63</P>
</TD>
<TD VALIGN="TOP">
<P>61.5 (12.0); (34-80)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>- denotes not reported</P>
<P>C: comparator; HbA1c: glycosylated haemoglobin A1c; I: intervention; NPH: Neutral Protamine Hagedorn; SD: standard deviation; SE: standard error</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2016-09-07 10:11:52 +0200" MODIFIED_BY="Gudrun Paletta" NO="5">
<TITLE MODIFIED="2015-01-06 18:00:27 +0100" MODIFIED_BY="Bernd Richter">Matrix of study endpoints</TITLE>
<APPENDIX_BODY MODIFIED="2016-09-07 10:11:52 +0200" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="4" ROWS="39">
<TR>
<TH VALIGN="TOP">
<P>Characteristic</P>
<P>Study ID</P>
</TH>
<TH VALIGN="TOP">
<P>Primary<SUP>a</SUP> endpoint (s)</P>
</TH>
<TH VALIGN="TOP">
<P>Secondary<SUP>b</SUP> endpoint (s)</P>
</TH>
<TH VALIGN="TOP">
<P>Other<SUP>c</SUP> endpoint (s)</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Avilés 1999</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Glycaemic control, insulin dose requirements, study drug tolerance, body weight, blood pressure, lipid and lipoprotein profiles, C-peptide</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Barnett 2013</P>
</TH>
<TD VALIGN="TOP">
<P>Change in HbA1c from baseline to 52 weeks follow-up</P>
</TD>
<TD VALIGN="TOP">
<P>Mean change from baseline in total daily insulin dose at 52 weeks</P>
</TD>
<TD VALIGN="TOP">
<P>Safety end points including adverse events, hypoglycaemia and weight gain</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Casner 1988</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Fasting blood glucose, HbA1c, C-peptide, glucose tolerance test, side effects, compliance</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Chiasson 1994</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>HbA1c, glucose, C-peptide, lipids, glucose tolerance test, safety, blood count, biochemistry, vitamins/minerals, hypoglycaemia</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Coniff 1995</P>
</TH>
<TD VALIGN="TOP">
<P>HbA1c, insulin requirements</P>
</TD>
<TD VALIGN="TOP">
<P>Glucose tolerance test, postprandial glucose area under the curve</P>
</TD>
<TD VALIGN="TOP">
<P>Lipids, hypoglycaemia</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Feinglos 19987</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Glucose, HbA1c, C-peptide, plasma insulin, lipids</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Fonseca 2007</P>
</TH>
<TD VALIGN="TOP">
<P>HbA1c</P>
</TD>
<TD VALIGN="TOP">
<P>Fasting glucose, insulin dose, insulin injections, lipids, body weight</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Fritsche 2000</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Glucose tolerance test, HbA1c, glucose, C-peptide, insulin dose, lipids</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Giugliano 1993</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Body weight, blood pressure, HbA1c, lipids, glucose profile, safety</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Groop 1985</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Body weight, glucose, HbA1c, lipids, glucose tolerance test, serum free insulin, plasma glucagon, insulin tolerance test, glucose profiles</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Hermann 2001</P>
</TH>
<TD VALIGN="TOP">
<P>HbA1c</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Fasting glucose, body weight, BMI, waist-hip ratio, blood pressure, insulin dose, C-peptide, lipids, biochemistry, adverse events, compliance</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Hong 2012</P>
</TH>
<TD VALIGN="TOP">
<P>Change in HbA1c (from baseline to 24 weeks)</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Proportion of participants achieving HbA1c &lt; 7%, body weight, waist circumference, change in insulin dose, change in C-peptide, safety (AE, SAE, hypoglycaemia, liver/renal function)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Hirsch 1999</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>HbA1c, glucose, body weight, blood pressure, insulin dose, insulin levels, C-peptide, hypoglycaemia</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Kitabchi 1987</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>HbA1c, glucose, body weight, C-peptide, insulin dose, insulin antibodies, chemistry, triglycerides</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Krawczyk 2005</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>HbA1c, glucose, insulin dose, waist-hip ratio, body weight</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Kyllastinen 1985</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Glucose, HbA1c, insulin dose, C-peptide, body weight, biochemistry, lipids</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Lewitt 1989</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>HbA1c, glucose, BMI, C-peptide, insulin dose</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Lindström 1999</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin dose, glucose, HbA1c, plasma insulin, C-peptide, lipoproteins, IGF-1, testosterone, SHBG</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Longnecker 1986</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>HbA1c, glucose, C-peptide, body weight, compliance, side effects</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Mattoo 2005</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>HbA1c, glucose, lipids, CRP, hypoglycaemia, body weight, cardiovascular risk markers</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Mauerhoff 1986</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Glucose, C-peptide, insulin dose, hypoglycaemia</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Mezitis 1992</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin dose, C-peptide, HbA1c, lipids, glucose profiles</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Mudaliar 2010</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>HbA1c, glucose, insulin dose, weight, total body water, extracellular fluid, renal and hormonal measures</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Nemoto 2011</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Meal tolerance test, HbA1c, 1,5 AG, glycoalbumin, hypoglycaemia, safety</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Osei 1984</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Compliance, dietary intake, weight, glucose, HbA1c, tolerance tests</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Quartraro 1986</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Glucose profile, HbA1c, insulin dose, weight, C-peptide</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Reich 1987</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>HbA1c, glucose, chemistry, urinalyses</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Relimpio 1998</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Weight, BMI, blood pressure, HbA1c, lipids, insulin dose, biochemistry, compliance</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Robinson 1998</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Glucose, HbA1c, creatinine, lipids, blood pressure, insulin dose, hypoglycaemia</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Rosenstock 2002</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>HbA1c, glucose, C-peptide, lipids, ECG, chemistry, haematology, vital signs, adverse events</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Schade 1987</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>HbA1c, glucose, insulin dose, C-peptide, free insulin, erythrocyte-glucose binding, compliance</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Schiel 2007</P>
</TH>
<TD VALIGN="TOP">
<P>HbA1c</P>
</TD>
<TD VALIGN="TOP">
<P>Glucose, treatment satisfaction, hypoglycaemia, adverse events</P>
</TD>
<TD VALIGN="TOP">
<P>Blood pressure, creatinine, liver enzymes</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Simpson 1990</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>HbA1c, C-peptide, serum insulin, lipids, glucose, body weight, BMI</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Stenman 1988</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>HbA1c, glucose, body weight, lipids, C-peptide, free insulin</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Strowig 2002</P>
</TH>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>HbA1c, glucose, liver enzymes, body weight, chemistry, C-peptide, lipids, waist-hip ratio</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Wulffelé 2002</P>
</TH>
<TD VALIGN="TOP">
<P>HbA1c, insulin dose</P>
</TD>
<TD VALIGN="TOP">
<P>BMI, body weight, lipids, blood pressure</P>
</TD>
<TD VALIGN="TOP">
<P>Hypoglycaemia</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Yilmaz 2007</P>
</TH>
<TD VALIGN="TOP">
<P>HbA1c</P>
</TD>
<TD VALIGN="TOP">
<P>Insulin dose, body weight, waist-hip ratio, lipids</P>
</TD>
<TD VALIGN="TOP">
<P>Hypoglycaemia, side effects</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<SUP>a,b</SUP>verbatim statement in the publication<BR/>
<SUP>c</SUP>not explicitly stated as primary or secondary endpoint (s) in the publication<BR/>
</P>
<P>- denotes not reported</P>
<P>BMI: body mass index; HbA1c: glycosylated haemoglobin A1c</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2016-09-07 10:11:57 +0200" MODIFIED_BY="Gudrun Paletta" NO="6">
<TITLE MODIFIED="2014-10-15 09:28:02 +0200" MODIFIED_BY="Gudrun Paletta">Adverse events (I)</TITLE>
<APPENDIX_BODY MODIFIED="2016-09-07 10:11:57 +0200" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="9" ROWS="91">
<TR>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>Intervention(s) and<BR/>comparator(s)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants<BR/>included<BR/>in analysis<BR/>(N)</P>
</TH>
<TH VALIGN="TOP">
<P>Deaths<BR/>(N)<BR/>
</P>
</TH>
<TH VALIGN="TOP">
<P>Deaths<BR/>(%)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants with adverse events<BR/>(N)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants with adverse events<BR/>(%)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants with<BR/>severe/serious<BR/>adverse events<BR/>(N)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants with<BR/>severe/serious<BR/>adverse events<BR/>(%)<BR/>
</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Avilés 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Barnett 2013</P>
</TH>
<TD VALIGN="TOP">
<P>I: saxagliptin</P>
</TD>
<TD VALIGN="TOP">
<P>95</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>1.1</P>
</TD>
<TD VALIGN="TOP">
<P>61</P>
</TD>
<TD VALIGN="TOP">
<P>64.2</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>9.5</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>32</P>
</TD>
<TD VALIGN="TOP">
<P>69.6</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>6.5</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Casner 1988</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Chiasson 1994</P>
</TH>
<TD VALIGN="TOP">
<P>I: acarbose</P>
</TD>
<TD VALIGN="TOP">
<P>35</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>2.4</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>2.9</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Coniff 1995</P>
</TH>
<TD VALIGN="TOP">
<P>I: acarbose</P>
</TD>
<TD VALIGN="TOP">
<P>103</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>78</P>
</TD>
<TD VALIGN="TOP">
<P>76</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>104</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>36</P>
</TD>
<TD VALIGN="TOP">
<P>35</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Feinglos 1998</P>
</TH>
<TD VALIGN="TOP">
<P>I: glipizide</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>29</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>69 episodes of hypoglycaemia</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Fonseca 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I: vildagliptin</P>
</TD>
<TD VALIGN="TOP">
<P>144</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>0.7</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>81.3</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>8.3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>152</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>0.7</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>82.9</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>9.2</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Fritsche 2000</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Giugliano 1993</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>7.4</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Groop 1985</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Hermann 2001</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Hong 2012</P>
</TH>
<TD VALIGN="TOP">
<P>I: sitagliptin</P>
</TD>
<TD VALIGN="TOP">
<P>61</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>34.4</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin increase</P>
</TD>
<TD VALIGN="TOP">
<P>63</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>36.5</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Hirsch 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Kitabchi 1987</P>
</TH>
<TD VALIGN="TOP">
<P>I: tolazamide</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: NPH alone</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Krawczyk 2005</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Kyllastinen 1985</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Lewitt 1989</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Lindström 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Longnecker 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: tolazamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mattoo 2005</P>
</TH>
<TD VALIGN="TOP">
<P>I: pioglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>128</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>109</P>
</TD>
<TD VALIGN="TOP">
<P>76.8</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>135</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>0.7</P>
</TD>
<TD VALIGN="TOP">
<P>98</P>
</TD>
<TD VALIGN="TOP">
<P>66.7</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mauerhoff 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>107 episodes</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>25 episodes</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Mezitis 1992</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mudaliar 2010</P>
</TH>
<TD VALIGN="TOP">
<P>I: pioglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Nemoto 2011</P>
</TH>
<TD VALIGN="TOP">
<P>I: miglitol</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>122 episodes</P>
</TD>
<TD VALIGN="TOP">
<P>78.5</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>91 episodes</P>
</TD>
<TD VALIGN="TOP">
<P>76</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Osei 1984</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Quartraro 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: gliclazide</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Reich 1987</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>3 (5 episodes)</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>10 episodes</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Relimpio 1998</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin dose increase</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Robinson 1998</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Rosenstock 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I1: pioglitazone 15 mg</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<BR/>78.4</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: pioglitazone 30 mg</P>
</TD>
<TD VALIGN="TOP">
<P>188</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>187</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>74.3</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Schade 1987</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>37.5</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>6.3</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Schiel 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I1: glimepiride</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: glimepiride + metformin</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>72</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>77</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Simpson 1990</P>
</TH>
<TD VALIGN="TOP">
<P>I: glipizide</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>44.4</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Stenman 1988</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>86.7</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>53.3</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Strowig 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I1: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>6.7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: troglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>3.2</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Wulffelé 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>171</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>0.6</P>
</TD>
<TD VALIGN="TOP">
<P>1 episode per participant per month: 31</P>
<P>2 episodes per participant per month: 12</P>
<P>3 episodes per participant per month: 9</P>
<P>&#8805; 4 episodes per participant per month: 11</P>
</TD>
<TD VALIGN="TOP">
<P>1 episode per participant per month: 18</P>
<P>2 episodes per participant per month: 7</P>
<P>3 episodes per participant per month: 5</P>
<P>&#8805; 4 episodes per participant per month: 6</P>
</TD>
<TD VALIGN="TOP">
<P>8 episodes</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>182</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>1 episode per participant per month: 30</P>
<P>2 episodes per participant per month: 11</P>
<P>3 episodes per participant per month: 11</P>
<P>&#8805; 4 episodes per participant per month: 7</P>
</TD>
<TD VALIGN="TOP">
<P>1 episode per participant per month: 16</P>
<P>2 episodes per participant per month: 6</P>
<P>3 episodes per participant per month: 6</P>
<P>&#8805; 4 episodes per participant per month: 4</P>
</TD>
<TD VALIGN="TOP">
<P>4 episodes</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="4" VALIGN="TOP">
<P>Yilmaz 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I1: acarbose</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>29.4</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I3: rosiglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>15.8</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>- denotes not reported</P>
<P>C: comparator; I: intervention; NPH: Neutral Protamine Hagedorn</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2016-09-07 10:12:03 +0200" MODIFIED_BY="Gudrun Paletta" NO="7">
<TITLE MODIFIED="2014-10-16 15:49:03 +0200" MODIFIED_BY="Gudrun Paletta">Adverse events (II)</TITLE>
<APPENDIX_BODY MODIFIED="2016-09-07 10:12:03 +0200" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="9" ROWS="89">
<TR>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>Intervention(s) and comparator(s)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants included<BR/>in analysis<BR/>(N)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants<BR/>discontinuing<BR/>study due to<BR/>adverse events<BR/>(N)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants<BR/>discontinuing<BR/>study due to<BR/>adverse event<BR/>(%)<BR/>
<BR/>
</P>
</TH>
<TH VALIGN="TOP">
<P>Participants<BR/>hospitalised<BR/>(N)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants<BR/>hospitalised<BR/>(%)<BR/>
</P>
</TH>
<TH VALIGN="TOP">
<P>Participants with<BR/>outpatient treatment<BR/>(N)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants with<BR/>outpatient treatment<BR/>(%)<BR/>
</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Avilés 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Barnett 2013</P>
</TH>
<TD VALIGN="TOP">
<P>I: saxagliptin</P>
</TD>
<TD VALIGN="TOP">
<P>95</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>3.2</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>2.2</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Casner 1988</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Chiasson 1994</P>
</TH>
<TD VALIGN="TOP">
<P>I: acarbose</P>
</TD>
<TD VALIGN="TOP">
<P>35</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Coniff 1995</P>
</TH>
<TD VALIGN="TOP">
<P>I: acarbose</P>
</TD>
<TD VALIGN="TOP">
<P>103</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>104</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Feinglos 1998</P>
</TH>
<TD VALIGN="TOP">
<P>I: glipizide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>29</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Fonseca 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I: vildagliptin</P>
</TD>
<TD VALIGN="TOP">
<P>114</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>6.3</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>124</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0.7</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Fritsche 2000</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Giugliano 1993</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Groop 1985</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Hermann 2001</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Hirsch 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Hong 2012</P>
</TH>
<TD VALIGN="TOP">
<P>I: sitagliptin</P>
</TD>
<TD VALIGN="TOP">
<P>61</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin increase</P>
</TD>
<TD VALIGN="TOP">
<P>63</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Kitabchi 1987</P>
</TH>
<TD VALIGN="TOP">
<P>I: tolazamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: NPH alone</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Krawczyk 2005</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Kyllastinen 1985</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Lewitt 1989</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Lindström 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Longnecker 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: tolazamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mattoo 2005</P>
</TH>
<TD VALIGN="TOP">
<P>I: pioglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>128</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>4.9</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>135</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mauerhoff 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mezitis 1992</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mudaliar 2010</P>
</TH>
<TD VALIGN="TOP">
<P>I: pioglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Nemoto 2011</P>
</TH>
<TD VALIGN="TOP">
<P>I: miglitol</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>6.5</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Osei 1984</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>40</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>8.3</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Quartraro 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: gliclazide</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Reich 1987</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Relimpio 1998</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin dose increase</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Robinson 1998</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Rosenstock 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I1: pioglitazone 15 mg</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>2.6</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: pioglitazone 30 mg</P>
</TD>
<TD VALIGN="TOP">
<P>188</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>3.2</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>187</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>1.6</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Schade 1987</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Schiel 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I1: glimepiride</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: glimepiride + metformin</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>11.1</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Simpson 1990</P>
</TH>
<TD VALIGN="TOP">
<P>I: glipizide</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Stenman 1988</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Strowig 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I1: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>6.7</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: troglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Wulffelé 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>171</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>10.2</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>182</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>3.1</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TH ROWSPAN="4" VALIGN="TOP">
<P>Yilmaz 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I1: acarbose</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I3: rosiglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="9" VALIGN="TOP">
<P>- denotes not reported</P>
<P>C: comparator; I: intervention; NPH: Neutral Protamine Hagedorn</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2016-09-07 10:12:08 +0200" MODIFIED_BY="Gudrun Paletta" NO="8">
<TITLE MODIFIED="2014-10-16 15:59:10 +0200" MODIFIED_BY="Gudrun Paletta">Adverse events (III)</TITLE>
<APPENDIX_BODY MODIFIED="2016-09-07 10:12:08 +0200" MODIFIED_BY="Gudrun Paletta">
<TABLE COLS="10" ROWS="87">
<TR>
<TH VALIGN="TOP">
<P/>
</TH>
<TH VALIGN="TOP">
<P>Intervention(s) and comparator(s)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants included in analysis<BR/>(N)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants with hypoglycaemic episodes<BR/>(N)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants with hypoglycaemic episodes<BR/>(%)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants with nocturnal hypoglycaemic episodes<BR/>(N/%)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants with severe/serious hypoglycaemic episodes<BR/>(N/%)</P>
</TH>
<TH VALIGN="TOP">
<P>Definition of severe/serious hypoglycaemia</P>
</TH>
<TH VALIGN="TOP">
<P>Participants with specific adverse events<BR/>(N)</P>
</TH>
<TH VALIGN="TOP">
<P>Participants with specific adverse events<BR/>(%)</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Avilés 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>21</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>13.6</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>22</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Barnett 2013</P>
</TH>
<TD VALIGN="TOP">
<P>I: saxagliptin</P>
</TD>
<TD VALIGN="TOP">
<P>95</P>
</TD>
<TD VALIGN="TOP">
<P>Reported: 22</P>
<P>Confirmed: 8</P>
</TD>
<TD VALIGN="TOP">
<P>23.2</P>
<P>8.4</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Urine tract infection: 7<BR/>Nasopharyngitis: 6<BR/>Upper resp. tract infection: 6<BR/>Headache: 5<BR/>Bronchitis: 4<BR/>Pharyngitis: 3<BR/>Influenza: 3<BR/>Hypertension: 4<BR/>Pain in extremity: 3</P>
</TD>
<TD VALIGN="TOP">
<P>Urine tract infection: 7.4<BR/>Nasopharyngitis: 6.3<BR/>Upper resp. tract infection: 6.3<BR/>Headache: 5.3<BR/>Bronchitis: 4.2<BR/>Pharyngitis: 3.2<BR/>Influenza: 3.2<BR/>Hypertension: 4.2<BR/>Pain in extremity: 3.2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>46</P>
</TD>
<TD VALIGN="TOP">
<P>Reported: 15</P>
<P>Confirmed: 5</P>
</TD>
<TD VALIGN="TOP">
<P>32.6</P>
<P>10.9</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Urine tract infection: 1<BR/>Nasopharyngitis: 1<BR/>Upper resp. tract infection: 5<BR/>Headache: 1<BR/>Bronchitis: 0<BR/>Pharyngitis: 3<BR/>Influenza: 2<BR/>Hypertension: 4<BR/>Pain in extremity: 2</P>
</TD>
<TD VALIGN="TOP">
<P>Urine tract infection: 2.2</P>
<P>Nasopharyngitis: 2.2<BR/>Upper resp. tract infection: 10.9<BR/>Headache: 2.2<BR/>Bronchitis: 0<BR/>Pharyngitis: 6.5<BR/>Influenza: 4.3<BR/>Hypertension: 8.7<BR/>Pain in extremity: 4.3</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Casner 1988</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>"complains compatible with mild hypoglycaemia were not different between the two groups."</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>33</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Chiasson 1994</P>
</TH>
<TD VALIGN="TOP">
<P>I: acarbose</P>
</TD>
<TD VALIGN="TOP">
<P>35</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>2.4</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>/2.4</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Required correction of hypoglycaemia</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Flatulence: 73.2<BR/>Diarrhoea: 43.6<BR/>Abdominal discomfort: 25.0<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>44</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>6.0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>/6.0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Flatulence: 39.0<BR/>Diarrhoea: 20.3<BR/>Abdominal discomfort: 8.8</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Coniff 1995</P>
</TH>
<TD VALIGN="TOP">
<P>I: acarbose</P>
</TD>
<TD VALIGN="TOP">
<P>103</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Digestive system: 78<BR/>Flatulence: 34</P>
</TD>
<TD VALIGN="TOP">
<P>Digestive system: 76<BR/>Flatulence: 33</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>104</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Digestive system: 36<BR/>Flatulence: 14</P>
</TD>
<TD VALIGN="TOP">
<P>Digestive system: 35<BR/>Flatulence: 13</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Feinglos 1998</P>
</TH>
<TD VALIGN="TOP">
<P>I: glipizide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Requiring assistance from another person</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>29</P>
</TD>
<TD VALIGN="TOP">
<P>69 total episodes, number of participants not mentioned</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>1/</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Fonseca 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I: vildagliptin</P>
</TD>
<TD VALIGN="TOP">
<P>114</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>22.9</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Requiring assistance of another party</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>124</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>29.6</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Fritsche 2000</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Giugliano 1993</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Diarrhoea: 2</P>
</TD>
<TD VALIGN="TOP">
<P>Diarrhoea: 7.4</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Diarrhoea: -</P>
</TD>
<TD VALIGN="TOP">
<P>Diarrhoea: -</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Groop 1985</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Hermann 2001</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Diarrhoea: 6<BR/>Flatulence: 1<BR/>Epigastic pain: 0<BR/>Anorexia: 2<BR/>Constipation: 1<BR/>Sweating: 0<BR/>GI-event: 8</P>
</TD>
<TD VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>Diarrhoea: 1<BR/>Flatulence: 3<BR/>Epigastric pain: 1<BR/>Anorexia: 1<BR/>Constipation: 1<BR/>Sweating: 1<BR/>GI-event: 5</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Hirsch 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Gastro-intestinal side effects: 3</P>
</TD>
<TD VALIGN="TOP">
<P>Gastro-intestinal side effects: 12.0<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>Gastro-intestinal side effects: 0</P>
</TD>
<TD VALIGN="TOP">
<P>Gastro-intestinal side effects: 0</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Hong 2012</P>
</TH>
<TD VALIGN="TOP">
<P>I: sitagliptin</P>
</TD>
<TD VALIGN="TOP">
<P>61</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>8.2</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>1.6</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Any episode requiring assistance from another party with plasma glucose value &lt; 3.0 mmol/L (54 mg/dL)</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin increase</P>
</TD>
<TD VALIGN="TOP">
<P>63</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>17.5</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>4.8</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Kitabchi 1987</P>
</TH>
<TD VALIGN="TOP">
<P>I: tolazamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: NPH alone</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Krawczyk 2005</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>20</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Kyllastinen 1985</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Lewitt 1989</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Lindström 1999</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Longnecker 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: tolazamide</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mattoo 2005</P>
</TH>
<TD VALIGN="TOP">
<P>I: pioglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>128</P>
</TD>
<TD VALIGN="TOP">
<P>109</P>
</TD>
<TD VALIGN="TOP">
<P>63.4</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Requiring assistance</P>
</TD>
<TD VALIGN="TOP">
<P>Oedema: 20<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Oedema: 14.1<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>135</P>
</TD>
<TD VALIGN="TOP">
<P>98</P>
</TD>
<TD VALIGN="TOP">
<P>51.0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Oedema: 5<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Oedema: 3.4</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mauerhoff 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>107 episodes</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>25 episodes</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mezitis 1992</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Mudaliar 2010</P>
</TH>
<TD VALIGN="TOP">
<P>I: pioglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Nemoto 2011</P>
</TH>
<TD VALIGN="TOP">
<P>I: miglitol</P>
</TD>
<TD VALIGN="TOP">
<P>107</P>
</TD>
<TD VALIGN="TOP">
<P>122 episodes</P>
</TD>
<TD VALIGN="TOP">
<P>39.3</P>
</TD>
<TD VALIGN="TOP">
<P>13 episodes</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Flatulence: 20.6<BR/>Diarrhoea: 14.0<BR/>Abdominal distension: 15.0<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>100</P>
</TD>
<TD VALIGN="TOP">
<P>91 episodes</P>
</TD>
<TD VALIGN="TOP">
<P>35.0</P>
</TD>
<TD VALIGN="TOP">
<P>29 episodes</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Flatulence: 12.0<BR/>Diarrhoea: 4.0<BR/>Abdominal distension: 4.0</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Osei 1984</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Quartraro 1986</P>
</TH>
<TD VALIGN="TOP">
<P>I: gliclazide</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Reich 1987</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>3 (5 episodes)</P>
</TD>
<TD VALIGN="TOP">
<P>30.0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>10 episodes</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Relimpio 1998</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin dose increase</P>
</TD>
<TD VALIGN="TOP">
<P>23</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Robinson 1998</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Diarrhoea: 5.0<BR/>Mild abdominal bloating: 5.0<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Diarrhoea: 0<BR/>Mild abdominal bloating: 0</P>
</TD>
</TR>
<TR>
<TD ALIGN="RIGHT" VALIGN="TOP">
<P>all:</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Rosenstock 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I1: pioglitazone 15 mg</P>
</TD>
<TD VALIGN="TOP">
<P>191</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>7.9</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Oedema: 12.6</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: pioglitazone 30 mg</P>
</TD>
<TD VALIGN="TOP">
<P>188</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>15.4</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Oedema: 17.6</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>187</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>4.8</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Oedema: 7.0</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Schade 1987</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
<TD VALIGN="TOP">
<P>37.5</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>16</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>6.3</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Schiel 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I1: glimepiride</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>59</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Need for intravenous glucose or glucagon</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: glimepiride + metformin</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>72</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>Gastrointestinal discomfort: 2</P>
</TD>
<TD VALIGN="TOP">
<P>Gastrointestinal discomfort: 11.1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>77</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Simpson 1990</P>
</TH>
<TD VALIGN="TOP">
<P>I: glipizide</P>
</TD>
<TD VALIGN="TOP">
<P>9</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>44.4</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Stenman 1988</P>
</TH>
<TD VALIGN="TOP">
<P>I: glibenclamide</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>86.7</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>-</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
<TD VALIGN="TOP">
<P>53.3</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Strowig 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I1: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>27</P>
</TD>
<TD VALIGN="TOP">
<P>0.6 episodes per participant per month</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Third party assistance</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Gastrointestinal side effects:<BR/>67<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: troglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>30</P>
</TD>
<TD VALIGN="TOP">
<P>1.7 episodes per participant per month</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Gastrointestinal side effects:36.7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin</P>
</TD>
<TD VALIGN="TOP">
<P>31</P>
</TD>
<TD VALIGN="TOP">
<P>2 episodes per participant per month</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>1/3.2</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Gastrointestinal side effects: 13</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Wulffelé 2002</P>
</TH>
<TD VALIGN="TOP">
<P>I: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>171</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>36.8</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Third party assistance</P>
</TD>
<TD VALIGN="TOP">
<P>Diarrhoea: 9<BR/>Flatulence: 4<BR/>Pruritus: 1<BR/>Headaches: 1<BR/>Pyrosis: 0<BR/>Nausea: 1</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: placebo</P>
</TD>
<TD VALIGN="TOP">
<P>182</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>32.4</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>Diarrhoea: 2<BR/>Flatulence: 1<BR/>Pruritus: 0<BR/>Headaches: 0<BR/>Pyrosis: 1<BR/>Nausea: 0</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="4" VALIGN="TOP">
<P>Yilmaz 2007</P>
</TH>
<TD VALIGN="TOP">
<P>I1: acarbose</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>6.7</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>Unable to treat themselves</P>
</TD>
<TD VALIGN="TOP">
<P>Flatulence and bloating: 2</P>
</TD>
<TD VALIGN="TOP">
<P>Flatulence and bloating: 13.3<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I2: metformin</P>
</TD>
<TD VALIGN="TOP">
<P>17</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>11.8</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>Gastrointestinal side effects: 3</P>
</TD>
<TD VALIGN="TOP">
<P>Gastrointestinal side effects: 17.7<BR/>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>I3: rosiglitazone</P>
</TD>
<TD VALIGN="TOP">
<P>15</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>13.3</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>Pretibial oedema: 1</P>
</TD>
<TD VALIGN="TOP">
<P>Pretibial oedema: 6.7</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>C: insulin alone</P>
</TD>
<TD VALIGN="TOP">
<P>19</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>10.5</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>Pretibial oedema: 1</P>
</TD>
<TD VALIGN="TOP">
<P>Pretibial oedema: 5.3</P>
</TD>
</TR>
<TR>
<TD COLSPAN="10" VALIGN="TOP">
<P>- denotes not reported</P>
<P>C: comparator; I: intervention; NPH: Neutral Protamine Hagedorn</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2014-10-14 14:07:13 +0200" MODIFIED_BY="Gudrun Paletta">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;span&gt;38 &lt;/span&gt;comparisons (29 placebo-controlled) included in quantitative synthesis (meta-analysis)&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Sulphonylureas: 17&lt;/li&gt;&lt;li&gt;Metformin: 11&lt;/li&gt;&lt;li&gt;Pioglitazone: 3&lt;/li&gt;&lt;li&gt;Alpha-glucosidase inhibitors: 4&lt;/li&gt;&lt;li&gt;DPP-4inhibitors: 3&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="629">
<FLOWCHARTBOX TEXT="&lt;p&gt;37 trials (39 publications) included in qualitative synthesis&lt;/p&gt;" WIDTH="474">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;span&gt;56 potentially relevant records&lt;/span&gt;&lt;/p&gt;" WIDTH="250">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 additional records identified through handsearching of reference lists of included trials, systematic reviews/meta-analyses and HTA reports&lt;/p&gt;" WIDTH="568">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;span&gt;151 &lt;/span&gt;full-text articles/records assessed for eligibility&lt;/p&gt;" WIDTH="226">
<FLOWCHARTBOX TEXT="&lt;p&gt;10,057 records screened&lt;/p&gt;" WIDTH="201">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;span&gt;10,048&lt;/span&gt; records identified through database searching&lt;/p&gt;&lt;p&gt;CENTRAL: n = 3413&lt;br&gt;MEDLINE: n = 3149&lt;br&gt;Embase: n = 3437&lt;br&gt;ClinicalTrials.gov: n = 27&lt;br&gt;WHO ICTRP: n = 22&lt;br&gt;&lt;/p&gt;" WIDTH="458"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;9 additional records identified through other sources&lt;/p&gt;" WIDTH="419"/>
<OUT TEXT="&lt;p&gt;9906 non-relevant records excluded (title/abstract)&lt;/p&gt;" WIDTH="289"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;97 full-text articles excluded&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Insulin-naive (56)&lt;/li&gt;&lt;li&gt;No insulin therapy arm (2)&lt;/li&gt;&lt;li&gt;Use of oral glucose lowering agent that is off the market (6)&lt;/li&gt;&lt;li&gt;No RCT (8)&lt;/li&gt;&lt;li&gt;Follow-up less than two months (2)&lt;/li&gt;&lt;li&gt;Addition of non-oral agent (6)&lt;/li&gt;&lt;li&gt;Impossible to analyse subgroups of insulin-users separately (8)&lt;/li&gt;&lt;li&gt;Specific target population (4)&lt;/li&gt;&lt;li&gt;No arm without oral agent or placebo (5)&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="306"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;7 potentially relevant ongoing trials&lt;/p&gt;&lt;p&gt;10 trials awaiting classification&lt;/p&gt;" WIDTH="286"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>